OA18098A - Bicyclic-Fused Heteroaryl or Aryl Compounds and their use as IRAK4 Inhibitors - Google Patents
Bicyclic-Fused Heteroaryl or Aryl Compounds and their use as IRAK4 Inhibitors Download PDFInfo
- Publication number
- OA18098A OA18098A OA1201600374 OA18098A OA 18098 A OA18098 A OA 18098A OA 1201600374 OA1201600374 OA 1201600374 OA 18098 A OA18098 A OA 18098A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- methoxy
- fluoro
- alkyl
- optionally substituted
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims description 159
- 239000003112 inhibitor Substances 0.000 title claims description 148
- 125000003118 aryl group Chemical group 0.000 title claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 title claims description 21
- 102100016185 IRAK4 Human genes 0.000 title description 14
- 101700044314 IRAK4 Proteins 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 509
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- -1 CrCealkyl Chemical group 0.000 claims description 165
- 239000000203 mixture Substances 0.000 claims description 164
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 104
- 201000010099 disease Diseases 0.000 claims description 97
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 93
- 229910052736 halogen Inorganic materials 0.000 claims description 92
- 150000002367 halogens Chemical class 0.000 claims description 83
- 229910052805 deuterium Inorganic materials 0.000 claims description 82
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 81
- 239000003795 chemical substances by application Substances 0.000 claims description 79
- 125000000217 alkyl group Chemical group 0.000 claims description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 239000001257 hydrogen Substances 0.000 claims description 74
- 125000001153 fluoro group Chemical group F* 0.000 claims description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 58
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 46
- 230000000051 modifying Effects 0.000 claims description 44
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 37
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000005842 heteroatoms Chemical group 0.000 claims description 34
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 32
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 29
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims description 29
- 150000002431 hydrogen Chemical group 0.000 claims description 29
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 27
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 26
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 22
- 230000003042 antagnostic Effects 0.000 claims description 21
- 239000005557 antagonist Substances 0.000 claims description 21
- 229910052801 chlorine Inorganic materials 0.000 claims description 21
- 229910052731 fluorine Inorganic materials 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 17
- 125000004429 atoms Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 15
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 208000002193 Pain Diseases 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims description 11
- 102000002689 toll-like receptors Human genes 0.000 claims description 11
- 108020000411 toll-like receptors Proteins 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 206010003816 Autoimmune disease Diseases 0.000 claims description 9
- 229940079593 drugs Drugs 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 239000002464 receptor antagonist Substances 0.000 claims description 9
- 102000007399 Nuclear hormone receptors Human genes 0.000 claims description 8
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims description 8
- 108091000081 Phosphotransferases Proteins 0.000 claims description 8
- 210000003491 Skin Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000001684 chronic Effects 0.000 claims description 8
- 201000004624 dermatitis Diseases 0.000 claims description 8
- 200000000018 inflammatory disease Diseases 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 201000004681 psoriasis Diseases 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 7
- 208000006673 Asthma Diseases 0.000 claims description 7
- 208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 claims description 7
- 206010022114 Injury Diseases 0.000 claims description 7
- 208000008466 Metabolic Disease Diseases 0.000 claims description 7
- 206010038436 Renal failure acute Diseases 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 230000000626 neurodegenerative Effects 0.000 claims description 7
- 208000003432 Bone Disease Diseases 0.000 claims description 6
- 208000009856 Lung Disease Diseases 0.000 claims description 6
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 6
- 206010028302 Muscle disease Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 230000000271 cardiovascular Effects 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 231100000406 dermatitis Toxicity 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000002314 neuroinflammatory Effects 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 102100018955 IL1A Human genes 0.000 claims description 5
- 101700063385 IRAK1 Proteins 0.000 claims description 5
- 102100016182 IRAK1 Human genes 0.000 claims description 5
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 5
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 5
- 229960001940 Sulfasalazine Drugs 0.000 claims description 5
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 5
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 5
- 239000003613 bile acid Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 5
- 230000002496 gastric Effects 0.000 claims description 5
- 102000006495 integrins Human genes 0.000 claims description 5
- 108010044426 integrins Proteins 0.000 claims description 5
- 230000001404 mediated Effects 0.000 claims description 5
- 230000002685 pulmonary Effects 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims description 4
- 206010003645 Atopy Diseases 0.000 claims description 4
- 229960002170 Azathioprine Drugs 0.000 claims description 4
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 4
- 206010064913 Bronchial disease Diseases 0.000 claims description 4
- 206010006482 Bronchospasm Diseases 0.000 claims description 4
- 102100006400 CSF2 Human genes 0.000 claims description 4
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 4
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 4
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims description 4
- 206010061835 Diabetic nephropathy Diseases 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000009883 Joint Disease Diseases 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 4
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims description 4
- 206010067621 Oral disease Diseases 0.000 claims description 4
- 102100009493 TNFSF13B Human genes 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 230000003176 fibrotic Effects 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 201000002406 genetic disease Diseases 0.000 claims description 4
- 201000002138 hematopoietic system disease Diseases 0.000 claims description 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 230000002519 immonomodulatory Effects 0.000 claims description 4
- 201000009673 liver disease Diseases 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 201000010770 muscular disease Diseases 0.000 claims description 4
- 230000000414 obstructive Effects 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 200000000020 tissue injury Diseases 0.000 claims description 4
- DREIJXJRTLTGJC-JQCLMNFQSA-N 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C([C@H]1CC(O)(C2)C3)C2C[C@H]3C1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-JQCLMNFQSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 108010059013 Chaperonin 10 Proteins 0.000 claims description 3
- 102100009020 FFAR2 Human genes 0.000 claims description 3
- 101700017313 FFAR2 Proteins 0.000 claims description 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims description 3
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims description 3
- 229960004171 Hydroxychloroquine Drugs 0.000 claims description 3
- 108010050904 Interferons Proteins 0.000 claims description 3
- 102000014150 Interferons Human genes 0.000 claims description 3
- 229940047124 Interferons Drugs 0.000 claims description 3
- 102100010123 SLC22A12 Human genes 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 229960004963 mesalazine Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 125000004430 oxygen atoms Chemical group O* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 claims description 2
- ISOCDPQFIXDIMS-HSZRJFAPSA-N (2R)-N-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1NCCC1)NC(C=C1)=CC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 ISOCDPQFIXDIMS-HSZRJFAPSA-N 0.000 claims description 2
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 2
- LTPQFVPQTZSJGS-UHFFFAOYSA-N 1$l^{4},3,5$l^{4},7-tetrathia-2,4,6,8-tetrazacycloocta-1,4,5,8-tetraene Chemical group [N]1S[N]S[N]S[N]S1 LTPQFVPQTZSJGS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 claims description 2
- 229940005497 ANTICHOLINERGIC AGENTS Drugs 0.000 claims description 2
- 229940033495 ANTIMALARIALS Drugs 0.000 claims description 2
- 108010007562 Adalimumab Proteins 0.000 claims description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N Astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004754 Astemizole Drugs 0.000 claims description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 2
- JCINBYQJBYJGDM-UHFFFAOYSA-N BMS-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 claims description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N Baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 claims description 2
- 229950000971 Baricitinib Drugs 0.000 claims description 2
- 102000001805 Bromodomains Human genes 0.000 claims description 2
- 108050009021 Bromodomains Proteins 0.000 claims description 2
- 101700020617 CD22 Proteins 0.000 claims description 2
- 102100000189 CD22 Human genes 0.000 claims description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims description 2
- 102000003902 Cathepsin C Human genes 0.000 claims description 2
- 108090000267 Cathepsin C Proteins 0.000 claims description 2
- 229950006295 Cerdulatinib Drugs 0.000 claims description 2
- 108010070202 Certolizumab Pegol Proteins 0.000 claims description 2
- 229940107080 Chlorpheniramine Drugs 0.000 claims description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims description 2
- 229960001334 Corticosteroids Drugs 0.000 claims description 2
- 229950008830 Decernotinib Drugs 0.000 claims description 2
- SOYKEARSMXGVTM-HNNXBMFYSA-N Dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 claims description 2
- 102000004073 Dopamine D3 Receptors Human genes 0.000 claims description 2
- 108090000525 Dopamine D3 Receptors Proteins 0.000 claims description 2
- 108030006933 EC 3.3.2.10 Proteins 0.000 claims description 2
- 102100017900 EPHX2 Human genes 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N Fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 108010001517 Galectin 3 Proteins 0.000 claims description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 2
- 101710039212 ICOSLG Proteins 0.000 claims description 2
- 102100014733 ICOSLG Human genes 0.000 claims description 2
- 102100008982 IL17A Human genes 0.000 claims description 2
- 101710003110 IL17A Proteins 0.000 claims description 2
- 102100004545 IL17RA Human genes 0.000 claims description 2
- 101710035970 IL17RA Proteins 0.000 claims description 2
- 108010034143 Inflammasomes Proteins 0.000 claims description 2
- 108010053490 Infliximab Proteins 0.000 claims description 2
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 2
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 2
- 102000013462 Interleukin-12 Human genes 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000017761 Interleukin-33 Human genes 0.000 claims description 2
- 108010067003 Interleukin-33 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 229960005435 Ixekizumab Drugs 0.000 claims description 2
- 102100019517 JAK1 Human genes 0.000 claims description 2
- 101700034277 JAK1 Proteins 0.000 claims description 2
- 102100019516 JAK2 Human genes 0.000 claims description 2
- 101700016050 JAK2 Proteins 0.000 claims description 2
- 102100019518 JAK3 Human genes 0.000 claims description 2
- 101700007593 JAK3 Proteins 0.000 claims description 2
- 102000015617 Janus Kinases Human genes 0.000 claims description 2
- 108010024121 Janus Kinases Proteins 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 102100005440 LINGO1 Human genes 0.000 claims description 2
- 101710030766 LINGO1 Proteins 0.000 claims description 2
- 229960003088 Loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- RIJLVEAXPNLDTC-UHFFFAOYSA-N N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims description 2
- 101710031938 NFE2L2 Proteins 0.000 claims description 2
- 102100017234 NFE2L2 Human genes 0.000 claims description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 2
- 102100007288 PTGDR2 Human genes 0.000 claims description 2
- 101710013017 PTGDR2 Proteins 0.000 claims description 2
- 229950005157 Peficitinib Drugs 0.000 claims description 2
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 2
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 2
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 claims description 2
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 claims description 2
- 108091008002 RAR-related orphan receptors Proteins 0.000 claims description 2
- 101710019755 SLC22A12 Proteins 0.000 claims description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims description 2
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims description 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 2
- 102100016864 TYK2 Human genes 0.000 claims description 2
- 101700057652 TYK2 Proteins 0.000 claims description 2
- 239000004012 Tofacitinib Substances 0.000 claims description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Trioxopurine Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 2
- 229940116269 Uric Acid Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000003510 anti-fibrotic Effects 0.000 claims description 2
- 230000003110 anti-inflammatory Effects 0.000 claims description 2
- 230000000078 anti-malarial Effects 0.000 claims description 2
- 230000000111 anti-oxidant Effects 0.000 claims description 2
- 239000003793 antidiarrheal agent Substances 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims description 2
- 229960004574 azelastine Drugs 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 108010011709 brodalumab Proteins 0.000 claims description 2
- 229960003735 brodalumab Drugs 0.000 claims description 2
- 229960004649 calcipotriene Drugs 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 102000009410 chemokine receptors Human genes 0.000 claims description 2
- 108050000299 chemokine receptors Proteins 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- FHEPZBIUHGLJMP-UHFFFAOYSA-N cyclohexene Chemical group [CH]1CCCC=C1 FHEPZBIUHGLJMP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000002308 endothelin receptor antagonist Substances 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229960003592 fexofenadine Drugs 0.000 claims description 2
- 108010086781 golimumab Proteins 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 2
- 108010063443 ixekizumab Proteins 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 230000002475 laxative Effects 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N levocetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 2
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 2
- 229960000060 monoclonal antibodies Drugs 0.000 claims description 2
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 229940094443 oxytocics Prostaglandins Drugs 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001350 tofacitinib Drugs 0.000 claims description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims description 2
- 102000038112 transient receptor (TC 1.A.4) family Human genes 0.000 claims description 2
- 108091007157 transient receptor (TC 1.A.4) family Proteins 0.000 claims description 2
- 102000009310 vitamin D receptors Human genes 0.000 claims description 2
- 108050000156 vitamin D receptors Proteins 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 8
- XLVZUOZTEPGARX-QMTHXVAHSA-N C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N XLVZUOZTEPGARX-QMTHXVAHSA-N 0.000 claims 3
- JKDGKIBAOAFRPJ-PSOPSSQASA-N C(C)[C@H]1[C@H](NC([C@@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N JKDGKIBAOAFRPJ-PSOPSSQASA-N 0.000 claims 3
- JKDGKIBAOAFRPJ-ZBINZKHDSA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N JKDGKIBAOAFRPJ-ZBINZKHDSA-N 0.000 claims 3
- IHJCFNPEFTUBKU-HBUWYVDXSA-N C(C)[C@]1([C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)O Chemical compound C(C)[C@]1([C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)O IHJCFNPEFTUBKU-HBUWYVDXSA-N 0.000 claims 3
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 claims 3
- GJQPRSMDPCTEMC-ZBINZKHDSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CCF Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CCF GJQPRSMDPCTEMC-ZBINZKHDSA-N 0.000 claims 3
- 102000008986 Janus Human genes 0.000 claims 3
- 108050000950 Janus Proteins 0.000 claims 3
- 206010038444 Renal failure chronic Diseases 0.000 claims 3
- 201000000522 chronic kidney disease Diseases 0.000 claims 3
- MBJVWMQHKCGMLZ-UHFFFAOYSA-N isoquinoline-6-carboxamide Chemical compound C1=NC=CC2=CC(C(=O)N)=CC=C21 MBJVWMQHKCGMLZ-UHFFFAOYSA-N 0.000 claims 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 3
- MHHACKDUQOCUIG-PSOPSSQASA-N C(C)[C@H]1[C@H](NC([C@@H]1O)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@@H]1O)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N MHHACKDUQOCUIG-PSOPSSQASA-N 0.000 claims 2
- ZGZOLSHTQPEGHS-ZDUSSCGKSA-N CC=1NC=C(N1)C1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC(C)C)OC[C@H]1NC(CC1)=O Chemical compound CC=1NC=C(N1)C1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC(C)C)OC[C@H]1NC(CC1)=O ZGZOLSHTQPEGHS-ZDUSSCGKSA-N 0.000 claims 2
- 102100020540 CCN2 Human genes 0.000 claims 2
- ZMKZEHYXGVIWQY-DLQLIWNFSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C)C(=O)N ZMKZEHYXGVIWQY-DLQLIWNFSA-N 0.000 claims 2
- WEQZHAWTKXIXHT-BXUZGUMPSA-N FCC[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound FCC[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N WEQZHAWTKXIXHT-BXUZGUMPSA-N 0.000 claims 2
- QPIGZYPYOSJOSX-OUCADQQQSA-N F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF Chemical compound F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF QPIGZYPYOSJOSX-OUCADQQQSA-N 0.000 claims 2
- QPIGZYPYOSJOSX-SCRDCRAPSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF QPIGZYPYOSJOSX-SCRDCRAPSA-N 0.000 claims 2
- WILOOZXKTPWZNF-GUTXKFCHSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC WILOOZXKTPWZNF-GUTXKFCHSA-N 0.000 claims 2
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 108010012129 Angiotensin Receptors Proteins 0.000 claims 1
- 102000018984 Angiotensin Receptors Human genes 0.000 claims 1
- 101700008793 BNP Proteins 0.000 claims 1
- 101700018247 BPP Proteins 0.000 claims 1
- 101700071361 BPP4 Proteins 0.000 claims 1
- 101700034740 BPP8 Proteins 0.000 claims 1
- VRLHHQZOWDRYDA-QMTHXVAHSA-N C(=C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(=C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N VRLHHQZOWDRYDA-QMTHXVAHSA-N 0.000 claims 1
- FRASMIHUUNJXMA-BBATYDOGSA-N C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@@](C1)(CF)F)=O)C(=O)N Chemical compound C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@@](C1)(CF)F)=O)C(=O)N FRASMIHUUNJXMA-BBATYDOGSA-N 0.000 claims 1
- QDMZVHDGJRSZRO-RJIBLYRGSA-N C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@H]([C@H]1C)F)=O)C(=O)N Chemical compound C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@H]([C@H]1C)F)=O)C(=O)N QDMZVHDGJRSZRO-RJIBLYRGSA-N 0.000 claims 1
- BXXTYLVWACWIJR-PEYYIBSZSA-N C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@H]([C@H]1CC)F)=O)C(=O)N Chemical compound C(C)OC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@H]([C@H]1CC)F)=O)C(=O)N BXXTYLVWACWIJR-PEYYIBSZSA-N 0.000 claims 1
- XLVZUOZTEPGARX-IINYFYTJSA-N C(C)[C@@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N XLVZUOZTEPGARX-IINYFYTJSA-N 0.000 claims 1
- PNIPCMCVTHCINC-RBZFPXEDSA-N C(C)[C@@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)F Chemical compound C(C)[C@@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)F PNIPCMCVTHCINC-RBZFPXEDSA-N 0.000 claims 1
- HKSVMAFVZDOEGB-VOJFVSQTSA-N C(C)[C@@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)F Chemical compound C(C)[C@@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)F HKSVMAFVZDOEGB-VOJFVSQTSA-N 0.000 claims 1
- YARKEZPLUUXNIB-JSGCOSHPSA-N C(C)[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N Chemical compound C(C)[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N YARKEZPLUUXNIB-JSGCOSHPSA-N 0.000 claims 1
- BVBOCJKRSRRBLS-LSDHHAIUSA-N C(C)[C@H]1[C@H](NC(C1(F)F)=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC(C1(F)F)=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N BVBOCJKRSRRBLS-LSDHHAIUSA-N 0.000 claims 1
- QHXVLUKBUNSIRG-QWHCGFSZSA-N C(C)[C@H]1[C@H](NC(C1(F)F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC(C1(F)F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N QHXVLUKBUNSIRG-QWHCGFSZSA-N 0.000 claims 1
- HGLXDUOSNPAYOE-YMTOWFKASA-N C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=C(C2=CC(=C(C=C12)OC)C(=O)N)F Chemical compound C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=C(C2=CC(=C(C=C12)OC)C(=O)N)F HGLXDUOSNPAYOE-YMTOWFKASA-N 0.000 claims 1
- WOLAYXHNEYUWRD-BXKDBHETSA-N C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C(=C12)F)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C(=C12)F)OC)C(=O)N WOLAYXHNEYUWRD-BXKDBHETSA-N 0.000 claims 1
- MLTLXPWKQFSFEP-SGIREYDYSA-N C(C)[C@H]1[C@H](NC([C@@H]1OC)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@@H]1OC)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N MLTLXPWKQFSFEP-SGIREYDYSA-N 0.000 claims 1
- RYWRPPWLZYBMGL-ZXCZTKLOSA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=C(C2=CC(=C(C=C12)OC)C(=O)N)F Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=C(C2=CC(=C(C=C12)OC)C(=O)N)F RYWRPPWLZYBMGL-ZXCZTKLOSA-N 0.000 claims 1
- RQQOGNCLMIWAND-NDMJEZRESA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C(=C12)F)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C(=C12)F)OC)C(=O)N RQQOGNCLMIWAND-NDMJEZRESA-N 0.000 claims 1
- KTRDMGFSBRMURY-MJEQTWJJSA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N KTRDMGFSBRMURY-MJEQTWJJSA-N 0.000 claims 1
- NGEKUXCUYOCHMU-PELMWDNLSA-N C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=NC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=NC2=CC(=C(C=C12)OC)C(=O)N NGEKUXCUYOCHMU-PELMWDNLSA-N 0.000 claims 1
- OBCZPEMGLVYTTR-OHNRDTAOSA-N C(C)[C@]12[C@H](NC([C@@H]2C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C(C)[C@]12[C@H](NC([C@@H]2C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N OBCZPEMGLVYTTR-OHNRDTAOSA-N 0.000 claims 1
- UENJZPVHFBYGTR-SWLSCSKDSA-N C1(CC1)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C1(CC1)[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N UENJZPVHFBYGTR-SWLSCSKDSA-N 0.000 claims 1
- QZNQXYJCBAWXDZ-VNQPRFMTSA-N C1(CC1)[C@H]1[C@H](NC([C@@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C1(CC1)[C@H]1[C@H](NC([C@@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N QZNQXYJCBAWXDZ-VNQPRFMTSA-N 0.000 claims 1
- QZNQXYJCBAWXDZ-KBMXLJTQSA-N C1(CC1)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound C1(CC1)[C@H]1[C@H](NC([C@H]1F)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N QZNQXYJCBAWXDZ-KBMXLJTQSA-N 0.000 claims 1
- LAWIFKHGIHTEBT-ZDUSSCGKSA-N CN1C=NC(=C1)C1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC(C)C)OC[C@H]1NC(CC1)=O Chemical compound CN1C=NC(=C1)C1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC(C)C)OC[C@H]1NC(CC1)=O LAWIFKHGIHTEBT-ZDUSSCGKSA-N 0.000 claims 1
- VWQQJXDPFPNVPO-CQSZACIVSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1C2(CC2)CC(N1)=O)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1C2(CC2)CC(N1)=O)C(=O)N VWQQJXDPFPNVPO-CQSZACIVSA-N 0.000 claims 1
- IBGVSCFSCZLCQV-DMDPSCGWSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@H]2C[C@H]2C(N1)=O)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@H]2C[C@H]2C(N1)=O)C(=O)N IBGVSCFSCZLCQV-DMDPSCGWSA-N 0.000 claims 1
- SKBLRVFKJJMRBG-WRSAYESZSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@]2(C[C@H]2C(N1)=O)C)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@@H]1[C@]2(C[C@H]2C(N1)=O)C)C(=O)N SKBLRVFKJJMRBG-WRSAYESZSA-N 0.000 claims 1
- SIANUOWPRWUGIU-NOZJJQNGSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC(C[C@H]1C)=O)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC(C[C@H]1C)=O)C(=O)N SIANUOWPRWUGIU-NOZJJQNGSA-N 0.000 claims 1
- NOLFQBKTECYKHP-IUODEOHRSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC(C[C@H]1CCC)=O)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC(C[C@H]1CCC)=O)C(=O)N NOLFQBKTECYKHP-IUODEOHRSA-N 0.000 claims 1
- LKUUSPGGPIEIDJ-JBCWJZNQSA-N COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@@H]([C@H]1C)OC)=O)C(=O)N Chemical compound COC1=C(C=C2C=CN=C(C2=C1)OC[C@H]1NC([C@@H]([C@H]1C)OC)=O)C(=O)N LKUUSPGGPIEIDJ-JBCWJZNQSA-N 0.000 claims 1
- FQIYJJQOVGCZSS-NSHDSACASA-N FC1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)F Chemical compound FC1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)F FQIYJJQOVGCZSS-NSHDSACASA-N 0.000 claims 1
- FZMWZJONXBBKKS-VIFPVBQESA-N FC1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)F Chemical compound FC1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)F FZMWZJONXBBKKS-VIFPVBQESA-N 0.000 claims 1
- DPLSVKKFWKZSCR-QWHCGFSZSA-N FC1([C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC)F Chemical compound FC1([C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC)F DPLSVKKFWKZSCR-QWHCGFSZSA-N 0.000 claims 1
- CBIBANNRIBFXOC-UHSUQZSYSA-N FC1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C Chemical compound FC1=CN=C(C2=CC(=C(C=C12)C(=O)N)OC)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C CBIBANNRIBFXOC-UHSUQZSYSA-N 0.000 claims 1
- YCQBDXWYBMSWHV-BKQLOGFTSA-N FC1[C@H]2C(N[C@@H]([C@@H]12)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O Chemical compound FC1[C@H]2C(N[C@@H]([C@@H]12)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O YCQBDXWYBMSWHV-BKQLOGFTSA-N 0.000 claims 1
- AALYFKUEMJRFCK-CUIDPCAOSA-N FC=1C(=C(C=C2C=CN=C(C12)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C)C(=O)N)OC Chemical compound FC=1C(=C(C=C2C=CN=C(C12)OC[C@@H]1[C@H]2C([C@H]2C(N1)=O)C)C(=O)N)OC AALYFKUEMJRFCK-CUIDPCAOSA-N 0.000 claims 1
- BFSOMDDTZJFJAH-GXFFZTMASA-N FC[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound FC[C@H]1[C@H](NC(C1)=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N BFSOMDDTZJFJAH-GXFFZTMASA-N 0.000 claims 1
- RTMWPFFNYPLNFU-DRZCJDIDSA-N F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)C Chemical compound F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)C RTMWPFFNYPLNFU-DRZCJDIDSA-N 0.000 claims 1
- GISRWBROCYNDME-REAQECSSSA-N F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-REAQECSSSA-N 0.000 claims 1
- WILOOZXKTPWZNF-GZBFAFLISA-N F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC Chemical compound F[C@@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)COC WILOOZXKTPWZNF-GZBFAFLISA-N 0.000 claims 1
- HZQCEPIGYULEEA-QFSBIZTOSA-N F[C@@]12C(N[C@@H]([C@H]2C1)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O Chemical compound F[C@@]12C(N[C@@H]([C@H]2C1)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O HZQCEPIGYULEEA-QFSBIZTOSA-N 0.000 claims 1
- HHDLSOFOGDLPLR-VFVRVIDISA-N F[C@@]12C(N[C@@H]([C@H]2CC1)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O Chemical compound F[C@@]12C(N[C@@H]([C@H]2CC1)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)=O HHDLSOFOGDLPLR-VFVRVIDISA-N 0.000 claims 1
- LJSQXZZXHDYJEY-FZMZJTMJSA-N F[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N Chemical compound F[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N LJSQXZZXHDYJEY-FZMZJTMJSA-N 0.000 claims 1
- REOZKMNWRPKFGC-CABZTGNLSA-N F[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N Chemical compound F[C@H]1C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N REOZKMNWRPKFGC-CABZTGNLSA-N 0.000 claims 1
- HFPPHWYNALOJGU-XABDRZNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=CC=NC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=CC=NC2=CC(=C(C=C12)OC)C(=O)N)C HFPPHWYNALOJGU-XABDRZNLSA-N 0.000 claims 1
- RTMWPFFNYPLNFU-JJMVLAAESA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)C RTMWPFFNYPLNFU-JJMVLAAESA-N 0.000 claims 1
- QHTMZRQSFYHYNT-BTDLBPIBSA-N F[C@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C QHTMZRQSFYHYNT-BTDLBPIBSA-N 0.000 claims 1
- UTOJZIDAEIGHGD-DYZYQPBXSA-N F[C@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF Chemical compound F[C@]1(C[C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)CF UTOJZIDAEIGHGD-DYZYQPBXSA-N 0.000 claims 1
- 102000000802 Galectin 3 Human genes 0.000 claims 1
- 101700071069 NDP Proteins 0.000 claims 1
- HBPASFIWJQTOJM-STQMWFEESA-N O=C1[C@@H](C[C@H](N1)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)CC(F)(F)F Chemical compound O=C1[C@@H](C[C@H](N1)COC1=NC=CC2=CC(=C(C=C12)OC(C)C)C(=O)N)CC(F)(F)F HBPASFIWJQTOJM-STQMWFEESA-N 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 101700050776 SIRT1 Proteins 0.000 claims 1
- 102100007214 SIRT1 Human genes 0.000 claims 1
- 101710038526 TNFRSF1A Proteins 0.000 claims 1
- 102100003095 TNFRSF1A Human genes 0.000 claims 1
- 101710004889 Vejaci Proteins 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 229940075420 xanthine Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 68
- 230000002194 synthesizing Effects 0.000 abstract description 67
- 238000003786 synthesis reaction Methods 0.000 abstract description 66
- 239000011780 sodium chloride Substances 0.000 abstract description 33
- 150000003839 salts Chemical class 0.000 abstract description 31
- 239000000543 intermediate Substances 0.000 abstract description 13
- 230000000875 corresponding Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 92
- 239000000243 solution Substances 0.000 description 67
- 229910001868 water Inorganic materials 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 238000005160 1H NMR spectroscopy Methods 0.000 description 52
- 235000019439 ethyl acetate Nutrition 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 45
- 239000002904 solvent Substances 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 239000007832 Na2SO4 Substances 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000012267 brine Substances 0.000 description 24
- 239000002244 precipitate Substances 0.000 description 24
- 239000012039 electrophile Substances 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 17
- 230000002829 reduced Effects 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 238000007792 addition Methods 0.000 description 16
- 239000002585 base Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 101710043203 P23p89 Proteins 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 229940002612 prodrugs Drugs 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 230000001396 anti-anti-diuretic Effects 0.000 description 10
- 239000002934 diuretic Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000003472 antidiabetic agent Substances 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 9
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 102000001253 Protein Kinases Human genes 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- DCSWGUBEMVRKQO-UHFFFAOYSA-N isoquinoline-6-carbonitrile Chemical compound C1=NC=CC2=CC(C#N)=CC=C21 DCSWGUBEMVRKQO-UHFFFAOYSA-N 0.000 description 8
- KFSLWBXXFJQRDL-UHFFFAOYSA-N peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 210000001772 Blood Platelets Anatomy 0.000 description 7
- 150000007854 aminals Chemical group 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000002027 dichloromethane extract Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000008079 hexane Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 150000003951 lactams Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 201000010874 syndrome Diseases 0.000 description 7
- 206010003246 Arthritis Diseases 0.000 description 6
- 229940030606 DIURETICS Drugs 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000002024 ethyl acetate extract Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 5
- 229940022663 Acetate Drugs 0.000 description 5
- 108010058207 Anistreplase Proteins 0.000 description 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 5
- 229960003009 Clopidogrel Drugs 0.000 description 5
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 5
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 5
- 229940093915 Gynecological Organic acids Drugs 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- 239000000908 ammonium hydroxide Substances 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 230000001430 anti-depressive Effects 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 125000004104 aryloxy group Chemical group 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 230000002354 daily Effects 0.000 description 5
- 239000003527 fibrinolytic agent Substances 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000699 topical Effects 0.000 description 5
- 229960002070 torsemide Drugs 0.000 description 5
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 4
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- 208000008787 Cardiovascular Disease Diseases 0.000 description 4
- 229960002155 Chlorothiazide Drugs 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N Furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
- 229960003883 Furosemide Drugs 0.000 description 4
- 101700042506 HIRUD Proteins 0.000 description 4
- 229940006607 Hirudin Drugs 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000003734 Kidney Anatomy 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 208000010125 Myocardial Infarction Diseases 0.000 description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 4
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 229960005356 Urokinase Drugs 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 4
- 230000001882 diuretic Effects 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- GALFBPQYWHBOPA-UHFFFAOYSA-N methyl 4-iodo-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(I)C(OC)=C1 GALFBPQYWHBOPA-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229960002702 piroxicam Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 229960000187 tissue plasminogen activator Drugs 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-Bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 3
- UABBBWVTEWIIMN-UHFFFAOYSA-N 3-hydroxy-4-iodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C(O)=C1 UABBBWVTEWIIMN-UHFFFAOYSA-N 0.000 description 3
- 229960000983 Anistreplase Drugs 0.000 description 3
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 3
- 101700035485 C170 Proteins 0.000 description 3
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 3
- 102100005862 CCR2 Human genes 0.000 description 3
- 108060001122 CRTISO Proteins 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- JIVPVXMEBJLZRO-UHFFFAOYSA-N Chlortalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 3
- 229940107084 Chlorthalidone Drugs 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 101710042131 GCG Proteins 0.000 description 3
- 102100003818 GCG Human genes 0.000 description 3
- 102100011903 HSPE1 Human genes 0.000 description 3
- 108060003344 HTR1A Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 102100017336 NLRP3 Human genes 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 206010053643 Neurodegenerative disease Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010038683 Respiratory disease Diseases 0.000 description 3
- 206010039083 Rhinitis Diseases 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 3
- 229960000894 Sulindac Drugs 0.000 description 3
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 3
- 229960005001 Ticlopidine Drugs 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- 208000001756 Virus Disease Diseases 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000002429 anti-coagulation Effects 0.000 description 3
- 230000000702 anti-platelet Effects 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 201000001320 atherosclerosis Diseases 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 229960001523 chlortalidone Drugs 0.000 description 3
- 238000005888 cyclopropanation reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 3
- 229960001519 exenatide Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002949 hemolytic Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001771 impaired Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000002171 loop diuretic Substances 0.000 description 3
- 229960003646 lysine Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 201000009251 multiple myeloma Diseases 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 230000000926 neurological Effects 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 101710035540 plaa2 Proteins 0.000 description 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 125000001425 triazolyl group Chemical group 0.000 description 3
- 229960001722 verapamil Drugs 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N water-d2 Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- SYOKIDBDQMKNDQ-HHUWHTLVSA-N (2S)-1-[2-[[(5S,7R)-3-hydroxy-1-adamantyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C[C@H](C2)CC(C1)(C1)O)C21NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-HHUWHTLVSA-N 0.000 description 2
- VWVKUNOPTJGDOB-BDHVOXNPSA-N (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol Chemical compound C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 VWVKUNOPTJGDOB-BDHVOXNPSA-N 0.000 description 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZXNMIUJDTOMBPV-UHFFFAOYSA-N 2-chloroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCCl)C=C1 ZXNMIUJDTOMBPV-UHFFFAOYSA-N 0.000 description 2
- OAVGBZOFDPFGPJ-UHFFFAOYSA-N 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione Chemical compound C1CN(C)CCN1C1=NC(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C(C=CC=C2)C2=N1 OAVGBZOFDPFGPJ-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N 4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N 4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 description 2
- CYLWJCABXYDINA-UHFFFAOYSA-N 6-chloro-2-methyl-1,1-dioxo-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1lambda^{6},2,4-benzothiadiazine-7-sulfonamide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 2
- 108010004463 Abciximab Proteins 0.000 description 2
- 229960000583 Acetic Acid Drugs 0.000 description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N Alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 2
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- FLZQKRKHLSUHOR-UHFFFAOYSA-N Alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 description 2
- 206010001897 Alzheimer's disease Diseases 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N Amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 2
- 108010022043 Antineutrophil Cytoplasmic Antibodies Proteins 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N Antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 description 2
- 229960003515 Bendroflumethiazide Drugs 0.000 description 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N Benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- FJVIXIKVROWMSG-UHFFFAOYSA-N BrC1=CN=C(C2=CC(=C(C=C12)C#N)OC(C)C)Cl Chemical compound BrC1=CN=C(C2=CC(=C(C=C12)C#N)OC(C)C)Cl FJVIXIKVROWMSG-UHFFFAOYSA-N 0.000 description 2
- YFVJDPUKCRTRHY-UHFFFAOYSA-N BrC=1C=C2C=CN=C(C2=CC1OC(F)(F)F)Cl Chemical compound BrC=1C=C2C=CN=C(C2=CC1OC(F)(F)F)Cl YFVJDPUKCRTRHY-UHFFFAOYSA-N 0.000 description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 2
- PUADFYSRNNTHIY-UHFFFAOYSA-N C(C)(C)OC1=C(C=2C(C=CNC2C=C1)=O)C(=O)OC Chemical compound C(C)(C)OC1=C(C=2C(C=CNC2C=C1)=O)C(=O)OC PUADFYSRNNTHIY-UHFFFAOYSA-N 0.000 description 2
- 239000008001 CAPS buffer Substances 0.000 description 2
- 229940097217 CARDIAC GLYCOSIDES Drugs 0.000 description 2
- 101700043583 CCR5 Proteins 0.000 description 2
- 102100012080 CCR5 Human genes 0.000 description 2
- OGWAVGNOAMXIIM-VTAHJYCESA-N CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O OGWAVGNOAMXIIM-VTAHJYCESA-N 0.000 description 2
- 101700046984 CDK20 Proteins 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960003677 Chloroquine Drugs 0.000 description 2
- 229920001268 Cholestyramine Polymers 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N Cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- JZGYPIQSXGOEQY-UHFFFAOYSA-N ClC1=CC=NC2=CC(=C(C=C12)OC(C)C)C#N Chemical compound ClC1=CC=NC2=CC(=C(C=C12)OC(C)C)C#N JZGYPIQSXGOEQY-UHFFFAOYSA-N 0.000 description 2
- VENAHGCLRRWAAE-UHFFFAOYSA-N ClC1=CC=NC2=CC(=C(C=C12)OC(C)C)C(=O)N Chemical compound ClC1=CC=NC2=CC(=C(C=C12)OC(C)C)C(=O)N VENAHGCLRRWAAE-UHFFFAOYSA-N 0.000 description 2
- QCCORLOIERGOLP-UHFFFAOYSA-N ClC=1C=NC2=CC(=C(C=C2C1Cl)OC)C#N Chemical compound ClC=1C=NC2=CC(=C(C=C2C1Cl)OC)C#N QCCORLOIERGOLP-UHFFFAOYSA-N 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N Co-phenotrope Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- 206010009839 Coeliac disease Diseases 0.000 description 2
- 206010057668 Cognitive disease Diseases 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Natural products C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- 210000004351 Coronary Vessels Anatomy 0.000 description 2
- 206010011401 Crohn's disease Diseases 0.000 description 2
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 2
- QGJUIPDUBHWZPV-YQBUGCKMSA-N DB07465 Chemical compound C([C@@H](C1)C2)[C@@H](C3)C[C@@]1(O)C[C@]23[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-YQBUGCKMSA-N 0.000 description 2
- 206010052337 Diastolic dysfunction Diseases 0.000 description 2
- CURUTKGFNZGFSE-UHFFFAOYSA-N Dicycloverine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- OEHFRZLKGRKFAS-UHFFFAOYSA-N Droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 229950003693 Dutogliptin Drugs 0.000 description 2
- 102000010909 EC 1.4.3.4 Human genes 0.000 description 2
- 108010062431 EC 1.4.3.4 Proteins 0.000 description 2
- 108010000775 EC 2.3.3.10 Proteins 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Enoxaparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- GLGOPUHVAZCPRB-LROMGURASA-N Eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 2
- 229960004468 Eptifibatide Drugs 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N Etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960002541 Ethacrynic Acid Drugs 0.000 description 2
- 108010074860 Factor Xa Proteins 0.000 description 2
- 206010016207 Familial mediterranean fever Diseases 0.000 description 2
- 229960004580 GLIBENCLAMIDE Drugs 0.000 description 2
- 102100016463 GPBAR1 Human genes 0.000 description 2
- 101710045222 GPBAR1 Proteins 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 208000007565 Gingivitis Diseases 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N Glibenclamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 102100013175 HCAR2 Human genes 0.000 description 2
- 102100009498 HMGB1 Human genes 0.000 description 2
- 101700084087 HMGB1 Proteins 0.000 description 2
- 102100017183 HMGCS1 Human genes 0.000 description 2
- 101710013938 HSPE1 Proteins 0.000 description 2
- 102100002512 HTR1A Human genes 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N Hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 229960003445 Idelalisib Drugs 0.000 description 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N Idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 2
- 229960000905 Indomethacin Drugs 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 208000001083 Kidney Disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 2
- 229960002397 Linagliptin Drugs 0.000 description 2
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N Loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 229960001571 Loperamide Drugs 0.000 description 2
- 102100000541 MARK2 Human genes 0.000 description 2
- 101700064507 MARK2 Proteins 0.000 description 2
- 108090000028 MMP12 Proteins 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 229940103185 Mefenamate Drugs 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229960003194 Meglumine Drugs 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N Meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 229960003105 Metformin Drugs 0.000 description 2
- DVSDBMFJEQPWNO-UHFFFAOYSA-N Methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 2
- 208000008085 Migraine Disorders Diseases 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 101700065330 NLRP3 Proteins 0.000 description 2
- 102100002376 NR3C2 Human genes 0.000 description 2
- 206010029149 Nephropathy Diseases 0.000 description 2
- 206010029151 Nephropathy Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 108009000551 Nephrotic syndrome Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 Nifedipine Drugs 0.000 description 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 2
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- 102100017813 PTPN1 Human genes 0.000 description 2
- 241000282322 Panthera Species 0.000 description 2
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M Potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 206010061920 Psychotic disease Diseases 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N Pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N Quinazolinone Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Resveratrol Natural products C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 108010001645 Rituximab Proteins 0.000 description 2
- 102100007015 SERPINE1 Human genes 0.000 description 2
- 101710040671 SLC5A1 Proteins 0.000 description 2
- 102100016744 SLC5A1 Human genes 0.000 description 2
- 101710040722 SLC5A10 Proteins 0.000 description 2
- 101710040674 SLC5A2 Proteins 0.000 description 2
- 102100016749 SLC5A2 Human genes 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229960004937 Saxagliptin Drugs 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N Sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 102000019459 Squalene cyclase Human genes 0.000 description 2
- 108010088324 Squalene cyclase Proteins 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 229960005202 Streptokinase Drugs 0.000 description 2
- 229960003329 Sulfinpyrazone Drugs 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 102100006355 TLR7 Human genes 0.000 description 2
- 101700075266 TLR7 Proteins 0.000 description 2
- 101710040537 TNF Proteins 0.000 description 2
- 101710004627 TNFSF13B Proteins 0.000 description 2
- 102000003623 TRPC6 Human genes 0.000 description 2
- 108010061792 TRPC6 Cation Channel Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- LMJSLTNSBFUCMU-UHFFFAOYSA-N Trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N Triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N Trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229940035504 Tromethamine Drugs 0.000 description 2
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N Xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 229960004733 albiglutide Drugs 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 229960001667 alogliptin Drugs 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 2
- 229960001541 benzthiazide Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 108010036787 canakinumab Proteins 0.000 description 2
- 229960001838 canakinumab Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 239000002368 cardiac glycoside Substances 0.000 description 2
- 229940082638 cardiac stimulant Phosphodiesterase inhibitors Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 description 2
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229960001850 droxicam Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 201000010238 heart disease Diseases 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 229960003313 hydroflumethiazide Drugs 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 201000001431 hyperuricemia Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 229960002137 melagatran Drugs 0.000 description 2
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002107 myocardial Effects 0.000 description 2
- 201000002481 myositis Diseases 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- 101710031992 pRL90232 Proteins 0.000 description 2
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 2
- 201000008838 periodontal disease Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229960002797 pitavastatin Drugs 0.000 description 2
- 101710038852 pkc-3 Proteins 0.000 description 2
- 229960005483 polythiazide Drugs 0.000 description 2
- 229920000046 polythiazide Polymers 0.000 description 2
- 150000003140 primary amides Chemical class 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (NE)-N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 108010033693 saxagliptin Proteins 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 description 2
- 238000000580 st segment Methods 0.000 description 2
- 150000008143 steroidal glycosides Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 201000009594 systemic scleroderma Diseases 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 230000002537 thrombolytic Effects 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin dichloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 229960003425 tirofiban Drugs 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 229950006667 tofogliflozin Drugs 0.000 description 2
- 229960004813 trichlormethiazide Drugs 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 201000006704 ulcerative colitis Diseases 0.000 description 2
- 201000011528 vascular disease Diseases 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 229960001254 vildagliptin Drugs 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- HWBIQJOWCBKZJW-UHFFFAOYSA-N $l^{1}-silanyloxysilicon Chemical compound [Si]O[Si] HWBIQJOWCBKZJW-UHFFFAOYSA-N 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N (1R,3R)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}cyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- CNXNMLQATFFYLX-ICTDYHGOSA-N (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;[2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trime Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CNXNMLQATFFYLX-ICTDYHGOSA-N 0.000 description 1
- DYWNLSQWJMTVGJ-PRCZDLBKSA-N (1S,2R)-2-amino-1-phenylpropan-1-ol;hydron;chloride Chemical compound Cl.C[C@@H](N)[C@@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-PRCZDLBKSA-N 0.000 description 1
- TXTWXQXDMWILOF-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl)azanium;chloride Chemical compound [Cl-].CCOC(=O)C[NH3+] TXTWXQXDMWILOF-UHFFFAOYSA-N 0.000 description 1
- CZCHIEJNWPNBDE-UHFFFAOYSA-N (2-ethyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(O)C(I)=C1 CZCHIEJNWPNBDE-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- ZEYYDOLCHFETHQ-JOCHJYFZSA-N (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid Chemical compound C1([C@@H](C(=O)O)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)CCCC1 ZEYYDOLCHFETHQ-JOCHJYFZSA-N 0.000 description 1
- UEZIBPZHJNOZNX-CDTKKYFSSA-N (2R,3R,4R,5S)-2-(hydroxymethyl)-1-[[(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 UEZIBPZHJNOZNX-CDTKKYFSSA-N 0.000 description 1
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2S)-1-[(2R,4R)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N (2S)-2-(2-benzoylanilino)-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]propanoic acid Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 description 1
- DXRXYJYFADHAPA-AUTRQRHGSA-N (2S)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-aminopropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-methylbutanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N DXRXYJYFADHAPA-AUTRQRHGSA-N 0.000 description 1
- SFVLTCAESLKEHH-WKAQUBQDSA-N (2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](NC(=O)[C@H](N)CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N)=O)CC1=CC=CC=C1 SFVLTCAESLKEHH-WKAQUBQDSA-N 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- XUFXOAAUWZOOIT-WVJZLWNXSA-N (2S,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-WVJZLWNXSA-N 0.000 description 1
- PUTJFIQGLGDLIT-RNDOZLNUSA-N (2S,3S,3aR,5aS,9aS,9bR)-3-[(2S)-2-(furan-3-yl)-2-hydroxyethyl]-2,3a,6,6,9a-pentamethyl-3,4,5,5a,7,8,9,9b-octahydro-1H-cyclopenta[a]naphthalene-2-carbaldehyde Chemical compound C=1([C@@H](O)C[C@H]2[C@@]3(C)[C@@H]([C@]4(CCCC(C)(C)[C@@H]4CC3)C)C[C@]2(C)C=O)C=COC=1 PUTJFIQGLGDLIT-RNDOZLNUSA-N 0.000 description 1
- PMOOKBAYUNEHOF-IKHMJLPLSA-N (2S,3S,4S,5R,6R)-6-[[(4aR,6aR,6bS,8aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,13,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(1R,2R,3S,4R)-2,3,4-trihydroxycyclohexyl]oxyoxane-2-carboxylic acid Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O)OC1CC[C@]2(C)[C@H]3CCC=4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(CC1=4)(C)C)C(O)=O)C(O)=O)[C@@H]1CC[C@@H](O)[C@H](O)[C@H]1O PMOOKBAYUNEHOF-IKHMJLPLSA-N 0.000 description 1
- NPBCMXATLRCCLF-RSSZJYSTSA-N (2S,4R)-4-[(3R,5S,6R,7R,10S,12S,13R,17R)-6-ethyl-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)C1C2C[C@H](O)[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CCC21 NPBCMXATLRCCLF-RSSZJYSTSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2S,4S)-4-cyclohexyl-1-[2-[[(1S)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- MQXRTCVZPIHBLD-TUAOUCFPSA-N (4S)-5-[[(1S)-1-carboxyethyl]amino]-4-[5-[(3R)-dithiolan-3-yl]pentanoylamino]-5-oxopentanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1 MQXRTCVZPIHBLD-TUAOUCFPSA-N 0.000 description 1
- QJLPWVUZFKETMK-LLVKDONJSA-N (5R)-1,5,7,9,11,14-hexahydroxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1C[C@@H](O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-LLVKDONJSA-N 0.000 description 1
- LPAUOXUZGSBGDU-KDFPNGMWSA-N (5Z)-5-[[3-chloro-4-[(2S)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-KDFPNGMWSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- RZKRYCXNAUAHHC-GQCTYLIASA-N (E)-3-(3-bromo-4-propan-2-yloxyphenyl)prop-2-enoic acid Chemical compound CC(C)OC1=CC=C(\C=C\C(O)=O)C=C1Br RZKRYCXNAUAHHC-GQCTYLIASA-N 0.000 description 1
- NKHAVTQWNUWKEO-NSCUHMNNSA-N (E)-4-methoxy-4-oxobut-2-enoic acid Chemical group COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- BPZSYCZIITTYBL-ORAYPTAESA-N (S,S)-formoterol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-ORAYPTAESA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N 1,1-dioxo-6-(trifluoromethyl)-4H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- PYAOPMWCFSVFOT-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d]pyrimidine-4-thione Chemical compound SC1=NC=NC2=C1C=NN2 PYAOPMWCFSVFOT-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- ZUHZNKJIJDAJFD-UHFFFAOYSA-N 1-(2-ethoxyethyl)-5-[ethyl(methyl)amino]-7-[(4-methylpyridin-2-yl)amino]-N-methylsulfonylpyrazolo[4,3-d]pyrimidine-3-carboxamide Chemical compound C=12N(CCOCC)N=C(C(=O)NS(C)(=O)=O)C2=NC(N(C)CC)=NC=1NC1=CC(C)=CC=N1 ZUHZNKJIJDAJFD-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-Naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 description 1
- LNMRSSIMGCDUTP-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NCC=2C(=CC=C(F)C=2)OC=2C=C3C=NN(CCO)C3=CC=2)=CC(C(C)(C)C)=N1 LNMRSSIMGCDUTP-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical group COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Chemical compound OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 description 1
- CGBJSGAELGCMKE-UHFFFAOYSA-N 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamide Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- OHMPXDCOVKOOAN-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)-N-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2F)Cl)=C1C1=CC=NC=N1 OHMPXDCOVKOOAN-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- RUEYEZADQJCKGV-UHFFFAOYSA-N 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid Chemical compound O=C1N(C2CCCCC2)C(=O)C(C(=O)NCC(=O)O)C(=O)N1C1CCCCC1 RUEYEZADQJCKGV-UHFFFAOYSA-N 0.000 description 1
- BZCALJIHZVNMGJ-HSZRJFAPSA-N 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid Chemical compound CC1=CC(OCCCS(C)(=O)=O)=CC(C)=C1C1=CC=CC(COC=2C=C3OC[C@@H](CC(O)=O)C3=CC=2)=C1 BZCALJIHZVNMGJ-HSZRJFAPSA-N 0.000 description 1
- YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
- NFTMKHWBOINJGM-UHFFFAOYSA-N 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole Chemical compound N1=CC(CC)=CN=C1N1CCC(C=2SC=C(COC=3C=CC(=CC=3)N3N=NN=C3)N=2)CC1 NFTMKHWBOINJGM-UHFFFAOYSA-N 0.000 description 1
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 description 1
- YXFNPRHZMOGREC-UHFFFAOYSA-N 2-[4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid Chemical compound N1=C(C(N)=O)C(C)=NC(C)=C1C1=CC=C(C2CCC(CC(O)=O)CC2)C=C1 YXFNPRHZMOGREC-UHFFFAOYSA-N 0.000 description 1
- GXALXAKNHIROPE-UHFFFAOYSA-N 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid Chemical compound C1CC(CC(=O)O)CCC1C1=CC=C(C=2N=CC(NC=3C=NC(=CC=3)C(F)(F)F)=CC=2)C=C1 GXALXAKNHIROPE-UHFFFAOYSA-N 0.000 description 1
- JWYIGNODXSRKGP-UHFFFAOYSA-N 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 JWYIGNODXSRKGP-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- JGRXMPYUTJLTKT-UHFFFAOYSA-N 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Chemical compound C1=C(O)C(C(=O)NCC(=O)O)=NC=C1C1=CC=CC(Cl)=C1 JGRXMPYUTJLTKT-UHFFFAOYSA-N 0.000 description 1
- FGQFOYHRJSUHMR-UHFFFAOYSA-N 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 1
- BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 description 1
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- RZIAABRFQASVSW-UHFFFAOYSA-N 2-oxidoisoquinolin-2-ium Chemical compound C1=CC=CC2=C[N+]([O-])=CC=C21 RZIAABRFQASVSW-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XXBMHUDJYDEMMT-UHFFFAOYSA-N 2-thiomorpholin-2-ylsulfinylthiomorpholine Chemical compound C1NCCSC1S(=O)C1CNCCS1 XXBMHUDJYDEMMT-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- JXGJAHAKCWUIGR-UHFFFAOYSA-N 3,4,5,6-tetradehydropyran Chemical group [CH]1OC#CC#C1 JXGJAHAKCWUIGR-UHFFFAOYSA-N 0.000 description 1
- YELLAPKUWRTITI-UHFFFAOYSA-N 3,5-dihydroxynaphthalene-2-carboxylic acid Chemical compound C1=CC(O)=C2C=C(O)C(C(=O)O)=CC2=C1 YELLAPKUWRTITI-UHFFFAOYSA-N 0.000 description 1
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 1
- VKHVAUKFLBBZFJ-SFHVURJKSA-N 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound N([C@@H](CC)C=1ON=C(C)N=1)C(N1N=C2C)=CC(C)=NC1=C2C1=CC=C(OC)C=C1C VKHVAUKFLBBZFJ-SFHVURJKSA-N 0.000 description 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N 3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
- DFQGDHBGRSTTHX-UHFFFAOYSA-N 3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoic acid Chemical compound C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C(O)=O DFQGDHBGRSTTHX-UHFFFAOYSA-N 0.000 description 1
- FJEJHJINOKKDCW-INIZCTEOSA-N 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2S)-1-methoxypropan-2-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide Chemical compound C=1C(C(=O)NC=2N=CC(C)=NC=2)=CC(O[C@@H](C)COC)=CC=1OC(N=C1)=CN=C1C(=O)N1CCC1 FJEJHJINOKKDCW-INIZCTEOSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- UOTMHAOCAJROQF-UHFFFAOYSA-N 3-bromo-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Br UOTMHAOCAJROQF-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BTLSKPZHRKKBDD-UHFFFAOYSA-N 3-sulfonyloxaziridine Chemical class O=S(=O)=C1NO1 BTLSKPZHRKKBDD-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- KCAJXIDMCNPGHZ-UHFFFAOYSA-N 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide Chemical compound CNC(=O)C1=CC=C(C)C(N2C(C(Br)=C(OCC=3C(=CC(F)=CC=3)F)C=C2C)=O)=C1 KCAJXIDMCNPGHZ-UHFFFAOYSA-N 0.000 description 1
- DGOCVISYYYQFEP-UHFFFAOYSA-N 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione;hydron;chloride Chemical compound Cl.O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 DGOCVISYYYQFEP-UHFFFAOYSA-N 0.000 description 1
- HMMBJOWWRLZEMI-UHFFFAOYSA-N 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1CCCC2=C1C(=O)OC2=O HMMBJOWWRLZEMI-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-UHFFFAOYSA-N 4-Anisaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 description 1
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-Pyridin-4-Yl-1h-[1,2,4]Triazol-3-Yl]-Pyridine-2-Carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
- XJBOCWDQVNIFRU-UHFFFAOYSA-N 4-chloro-6-methoxyquinoline-7-carbonitrile Chemical compound C1=CN=C2C=C(C#N)C(OC)=CC2=C1Cl XJBOCWDQVNIFRU-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JRWROCIMSDXGOZ-UHFFFAOYSA-N 4-tert-butyl-N-[4-chloro-2-(1-oxidopyridin-1-ium-4-carbonyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=C(Cl)C=C1C(=O)C1=CC=[N+]([O-])C=C1 JRWROCIMSDXGOZ-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- IFGWYHGYNVGVRB-UHFFFAOYSA-N 5-(2,4-difluorophenoxy)-N-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)indazole-6-carboxamide Chemical compound CN(C)CCNC(=O)C=1C=C2N(CC(C)C)N=CC2=CC=1OC1=CC=C(F)C=C1F IFGWYHGYNVGVRB-UHFFFAOYSA-N 0.000 description 1
- XPPBBJCBDOEXDN-UHFFFAOYSA-N 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine Chemical compound N1=C2N(CC(C)(C)C)C(N)=NC2=CC=C1C=1N=C(C(C)(C)C)NC=1C1=CC=C(F)C=C1 XPPBBJCBDOEXDN-UHFFFAOYSA-N 0.000 description 1
- AYJRTVVIBJSSKN-UHFFFAOYSA-N 5-[4-[[6-(4-methylsulfonylphenyl)pyridin-3-yl]oxymethyl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(COC=3C=NC(=CC=3)C=3C=CC(=CC=3)S(C)(=O)=O)CC2)=N1 AYJRTVVIBJSSKN-UHFFFAOYSA-N 0.000 description 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
- PPDRLQLKHRZIJC-UHFFFAOYSA-N 5-nitrosalicylic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1O PPDRLQLKHRZIJC-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-DIMETHYL-1-[3-(2,4,5-TRICHLOROPHENOXY)PROPOXY]-1,6-DIHYDRO-1,3,5-TRIAZINE-2,4-DIAMINE Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZIZISTUYLXVKQQ-UHFFFAOYSA-N 6-bromo-7-(trifluoromethoxy)-2H-isoquinolin-1-one Chemical compound C1=C(Br)C(OC(F)(F)F)=CC2=C1C=CNC2=O ZIZISTUYLXVKQQ-UHFFFAOYSA-N 0.000 description 1
- VWNBYMCAENDETE-UHFFFAOYSA-N 6-iodo-7-methoxyisoquinoline Chemical compound N1=CC=C2C=C(I)C(OC)=CC2=C1 VWNBYMCAENDETE-UHFFFAOYSA-N 0.000 description 1
- UHGRYGRGGCTUBV-UHFFFAOYSA-N 7-iodo-6-methoxy-1H-quinolin-4-one Chemical compound N1C=CC(=O)C2=C1C=C(I)C(OC)=C2 UHGRYGRGGCTUBV-UHFFFAOYSA-N 0.000 description 1
- ORVNHOYNEHYKJG-UHFFFAOYSA-N 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC(F)=CC=C1C1=NC(NC(CO)CO)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ORVNHOYNEHYKJG-UHFFFAOYSA-N 0.000 description 1
- AUUKUAHPMHVZJL-NSHDSACASA-N 8-[(3S)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid Chemical compound FC1=CN(C(C(C(O)=O)=CC=2C3CC3)=O)C=2C(C)=C1N1CC[C@H](N)C1 AUUKUAHPMHVZJL-NSHDSACASA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- 229960004308 ACETYLCYSTEINE Drugs 0.000 description 1
- 101700040666 ACKR2 Proteins 0.000 description 1
- 102100016910 ACKR2 Human genes 0.000 description 1
- 101700064578 ACKR3 Proteins 0.000 description 1
- 102100016909 ACKR3 Human genes 0.000 description 1
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 1
- 102100010115 AKR1B1 Human genes 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 108010059766 AMG 139 Proteins 0.000 description 1
- 108091001400 AMG 557 Proteins 0.000 description 1
- 108010013271 AMG 811 Proteins 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 101700018994 ARYL Proteins 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N AZAPROPAZONE Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 108010061171 Abatacept Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229950008347 Abrilumab Drugs 0.000 description 1
- 229960001466 Acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N Acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- ZSLZBFCDCINBPY-ZZSFXRQLSA-N Acetyl-CoA Natural products S(C(=O)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO[P@@](=O)(O[P@](=O)(OC[C@@H]1[C@@H](OP(=O)(O)O)[C@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C ZSLZBFCDCINBPY-ZZSFXRQLSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 208000002552 Acute Disseminated Encephalomyelitis Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010069351 Acute lung injury Diseases 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 229940023808 Albuterol Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- XXROGKLTLUQVRX-UHFFFAOYSA-N Allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 1
- 206010001767 Alopecia universalis Diseases 0.000 description 1
- 206010001843 Alport's syndrome Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N Ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N Amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 Amiodarone Drugs 0.000 description 1
- 229940040386 Amitiza Drugs 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 229960002519 Amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 208000006141 Amyloid angiopathy Diseases 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 206010002425 Angioedemas Diseases 0.000 description 1
- 229950005794 Anrukinzumab Drugs 0.000 description 1
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 1
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 229940091143 Apazone Drugs 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 102000018757 Apolipoprotein L1 Human genes 0.000 description 1
- 108010052469 Apolipoprotein L1 Proteins 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N Apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N Argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229950001019 Arhalofenate Drugs 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010060963 Arterial disease Diseases 0.000 description 1
- 206010058029 Arthrofibrosis Diseases 0.000 description 1
- 229940072224 Asacol Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229950009925 Atacicept Drugs 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N Atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 206010003658 Atrial fibrillation Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229960005207 Auranofin Drugs 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 description 1
- 229940064856 Azulfidine Drugs 0.000 description 1
- 206010073480 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N BAY 38-9456 Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 101700009767 BRD4 Proteins 0.000 description 1
- 102100015500 BRD4 Human genes 0.000 description 1
- 108010020298 BT-061 Proteins 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 229960000794 Baclofen Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 229950010663 Balaglitazone Drugs 0.000 description 1
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical group C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 description 1
- 206010004161 Basedow's disease Diseases 0.000 description 1
- 229940092705 Beclomethasone Drugs 0.000 description 1
- 229950000321 Benralizumab Drugs 0.000 description 1
- 229940090012 Bentyl Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229960002529 Benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N Benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 208000004093 Binge-Eating Disorder Diseases 0.000 description 1
- 206010004939 Bipolar I disease Diseases 0.000 description 1
- 206010004940 Bipolar II disease Diseases 0.000 description 1
- 229950004201 Blisibimod Drugs 0.000 description 1
- 229950011350 Bococizumab Drugs 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- WEHQTFLOWLQDBE-UHFFFAOYSA-N BrC1=C(C=C2C(=CN=CC2=C1)O)OC Chemical compound BrC1=C(C=C2C(=CN=CC2=C1)O)OC WEHQTFLOWLQDBE-UHFFFAOYSA-N 0.000 description 1
- OIQBNNVUEPEWBV-GQCTYLIASA-N BrC=1C=C(C=CC1OC(C)C)/C=C/C(=O)N=[N+]=[N-] Chemical compound BrC=1C=C(C=CC1OC(C)C)/C=C/C(=O)N=[N+]=[N-] OIQBNNVUEPEWBV-GQCTYLIASA-N 0.000 description 1
- JPIAWMRTTKVUPL-UHFFFAOYSA-N BrC=1C=C2C=CNC(C2=CC1OC(C)C)=O Chemical compound BrC=1C=C2C=CNC(C2=CC1OC(C)C)=O JPIAWMRTTKVUPL-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000009973 Brain Hypoxia-Ischemia Diseases 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- CQFNOACVVKSEOJ-VBQPQCOESA-N Bronilide Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O CQFNOACVVKSEOJ-VBQPQCOESA-N 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N Bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 Bupropion Drugs 0.000 description 1
- 206010067184 Burkitt's leukaemia Diseases 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960004301 Butriptyline Drugs 0.000 description 1
- ALELTFCQZDXAMQ-UHFFFAOYSA-N Butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229940084891 Byetta Drugs 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 102100017562 C5AR1 Human genes 0.000 description 1
- 101700049499 C5AR1 Proteins 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 101700076092 CCR1 Proteins 0.000 description 1
- 101700083927 CCR1 Proteins 0.000 description 1
- 102100005860 CCR1 Human genes 0.000 description 1
- 101700024589 CCR4 Proteins 0.000 description 1
- 101700019063 CCR6 Proteins 0.000 description 1
- 101700076302 CCR9 Proteins 0.000 description 1
- 101700026482 CCRL2 Proteins 0.000 description 1
- 102100008147 CCRL2 Human genes 0.000 description 1
- LPAUOXUZGSBGDU-STDDISTJSA-N CHEMBL1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 description 1
- 101710014631 CHURC1 Proteins 0.000 description 1
- 102100017099 CNOT6 Human genes 0.000 description 1
- 101700078818 CNOT6 Proteins 0.000 description 1
- JQKWXIVUADVQRX-UHFFFAOYSA-N COC1=C(C=C2C=CN=CC2=C1)C#[N+][O-] Chemical compound COC1=C(C=C2C=CN=CC2=C1)C#[N+][O-] JQKWXIVUADVQRX-UHFFFAOYSA-N 0.000 description 1
- WEASCGREUWLLAR-UHFFFAOYSA-N COC1=NC=CC2=CC(=CC=C12)C(=O)N Chemical compound COC1=NC=CC2=CC(=CC=C12)C(=O)N WEASCGREUWLLAR-UHFFFAOYSA-N 0.000 description 1
- 102100009791 COL4A5 Human genes 0.000 description 1
- 101710038499 COL4A5 Proteins 0.000 description 1
- 101700060333 CXCR6 Proteins 0.000 description 1
- 102100002068 CXCR6 Human genes 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229950001261 Camiglibose Drugs 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- 102000002666 Carnitine O-Palmitoyltransferase Human genes 0.000 description 1
- 108010018424 Carnitine O-Palmitoyltransferase Proteins 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229960004782 Chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N Chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229960001761 Chlorpropamide Drugs 0.000 description 1
- 208000002849 Chondrocalcinosis Diseases 0.000 description 1
- 206010008874 Chronic fatigue syndrome Diseases 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- KUTCEENANKZBNR-UHFFFAOYSA-N ClC1=CC=NC2=CC(=C(C=C12)OCC)C#N Chemical compound ClC1=CC=NC2=CC(=C(C=C12)OCC)C#N KUTCEENANKZBNR-UHFFFAOYSA-N 0.000 description 1
- XXBRXPWYANWXML-UHFFFAOYSA-N ClC1=CNC2=CC(=C(C=C2C1=O)OC)I Chemical compound ClC1=CNC2=CC(=C(C=C2C1=O)OC)I XXBRXPWYANWXML-UHFFFAOYSA-N 0.000 description 1
- WAGYOSUNFIAHCN-UHFFFAOYSA-N ClC1=NC=CC2=CC(=C(C=C12)OC(C)C)C#N Chemical compound ClC1=NC=CC2=CC(=C(C=C12)OC(C)C)C#N WAGYOSUNFIAHCN-UHFFFAOYSA-N 0.000 description 1
- AKLXWVUWJVQCMG-UHFFFAOYSA-N ClC1=NC=CC2=CC(=C(C=C12)OC)C#N Chemical compound ClC1=NC=CC2=CC(=C(C=C12)OC)C#N AKLXWVUWJVQCMG-UHFFFAOYSA-N 0.000 description 1
- STZCQQVHKCWMAZ-UHFFFAOYSA-N ClC1=NC=CC2=CC(=C(C=C12)OCC)C#N Chemical compound ClC1=NC=CC2=CC(=C(C=C12)OCC)C#N STZCQQVHKCWMAZ-UHFFFAOYSA-N 0.000 description 1
- NDFXNHXHLKJXMQ-UHFFFAOYSA-N ClC1=NC=CC2=CC(=C(C=C12)OCCCl)C#N Chemical compound ClC1=NC=CC2=CC(=C(C=C12)OCCCl)C#N NDFXNHXHLKJXMQ-UHFFFAOYSA-N 0.000 description 1
- BTRBYMHBNYRNBK-UHFFFAOYSA-N ClC1=NC=NC2=CC(=C(C=C12)OC)C#N Chemical compound ClC1=NC=NC2=CC(=C(C=C12)OC)C#N BTRBYMHBNYRNBK-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000010007 Cogan Syndrome Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229950008199 Crisaborole Drugs 0.000 description 1
- 229940009997 Cromolyn Drugs 0.000 description 1
- 208000010342 Crystal Arthropathy Diseases 0.000 description 1
- 206010071503 Crystal nephropathy Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N DCM Dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229960005227 DELAPRIL Drugs 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 102100012353 DPP4 Human genes 0.000 description 1
- 101700039720 DPP4 Proteins 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- 229960004969 Dalteparin Drugs 0.000 description 1
- 229950003518 Danirixin Drugs 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- 229950004456 Darapladib Drugs 0.000 description 1
- QQKNSPHAFATFNQ-UHFFFAOYSA-N Darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 1
- 229950006689 Darglitazone Drugs 0.000 description 1
- 208000007322 Death, Sudden, Cardiac Diseases 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N Delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012256 Delusional disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229960002593 Desoximetasone Drugs 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N Dichlorine monoxide Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 229940120131 Dicyclomine Drugs 0.000 description 1
- 229960002777 Dicycloverine Drugs 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 229950009763 Dilmapimod Drugs 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N Dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N Dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 229950010286 Diolamine Drugs 0.000 description 1
- 229960002768 Dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N Dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 208000010309 Disruptive, Impulse Control, and Conduct Disorders Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine hydrobromide Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229940000011 Dothiepin Drugs 0.000 description 1
- 201000010374 Down syndrome Diseases 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- HKXBNHCUPKIYDM-CGMHZMFXSA-N Doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 229940099198 Dulcolax Drugs 0.000 description 1
- 229950004949 Duvelisib Drugs 0.000 description 1
- 206010058108 Dyslipidaemia Diseases 0.000 description 1
- 108010053754 EC 1.1.1.21 Proteins 0.000 description 1
- 108010093894 EC 1.17.3.2 Proteins 0.000 description 1
- 102000015785 EC 2.3.1.50 Human genes 0.000 description 1
- 108010024814 EC 2.3.1.50 Proteins 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 101700072570 EREG Proteins 0.000 description 1
- 102100019146 EREG Human genes 0.000 description 1
- 101700024131 EXE4 Proteins 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 210000002351 Embryonic Muscle Cell Anatomy 0.000 description 1
- 229950000269 Emiglitate Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N Enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 Enalapril Drugs 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 229950003048 Enavatuzumab Drugs 0.000 description 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 description 1
- MVDXXGIBARMXSA-UHFFFAOYSA-N Englitazone Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(OC(CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-UHFFFAOYSA-N 0.000 description 1
- 229950002375 Englitazone Drugs 0.000 description 1
- 229960000610 Enoxaparin Drugs 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N Epinephrine Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N Eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N Et3N triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 229960000745 Ethylnorepinephrine hydrochloride Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 101710008097 FAP Proteins 0.000 description 1
- 102100009019 FFAR1 Human genes 0.000 description 1
- 102100009022 FFAR3 Human genes 0.000 description 1
- 101700007106 FFAR3 Proteins 0.000 description 1
- 102100009021 FFAR4 Human genes 0.000 description 1
- 101700008340 FFAR4 Proteins 0.000 description 1
- 229950002834 FIBOFLAPON Drugs 0.000 description 1
- 229950003499 FIBRIN Drugs 0.000 description 1
- 206010016072 Factitious disease Diseases 0.000 description 1
- 206010064570 Familial cold autoinflammatory syndrome Diseases 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N Febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229940063190 Flagyl Drugs 0.000 description 1
- 229960003028 Flumethiazide Drugs 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- 229960002464 Fluoxetine Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- SIXHCCPAJIVTOY-UITAMQMPSA-N Flutimide Chemical compound CC(C)CC1=N\C(=C/C(C)C)C(=O)N(O)C1=O SIXHCCPAJIVTOY-UITAMQMPSA-N 0.000 description 1
- 229960004038 Fluvoxamine Drugs 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 208000001914 Fragile X Syndrome Diseases 0.000 description 1
- 108009000484 Fragile X Syndrome Proteins 0.000 description 1
- 229950004003 Fresolimumab Drugs 0.000 description 1
- 102000027721 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 102000025873 GPCR, family 2, glucagon receptor Human genes 0.000 description 1
- 108010063919 GPCR, family 2, glucagon receptor Proteins 0.000 description 1
- 102100004504 GPR119 Human genes 0.000 description 1
- 101710030426 GPR119 Proteins 0.000 description 1
- 102100006989 GPR39 Human genes 0.000 description 1
- 101700029943 GPR39 Proteins 0.000 description 1
- 108010070653 GSK2862277 Proteins 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- 229960003980 Galantamine Drugs 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000009471 Gastroesophageal Reflux Diseases 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N Gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 Gemopatrilat Drugs 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 229950003717 Gevokizumab Drugs 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 229960000346 Gliclazide Drugs 0.000 description 1
- BOVGTQGAOIONJV-UHFFFAOYSA-N Gliclazide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CC2CCCC2C1 BOVGTQGAOIONJV-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N Glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 Gliquidone Drugs 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N Gliquidone Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 206010061989 Glomerulosclerosis Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 229940014653 Glyburide Drugs 0.000 description 1
- 229960002449 Glycine Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 229940015042 Glycopyrrolate Drugs 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010018620 Goodpasture's syndrome Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229950010864 Guselkumab Drugs 0.000 description 1
- 108060003497 HAUS7 Proteins 0.000 description 1
- 102100013174 HCAR1 Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 206010070737 HIV associated nephropathy Diseases 0.000 description 1
- 229940030482 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Drugs 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 208000005100 Herpetic Keratitis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229960002474 Hydralazine Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010020765 Hypersomnia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- BGCBQVUYJNZHIJ-UHFFFAOYSA-N IC1=C(C=C2C(NC=NC2=C1)=O)OC Chemical compound IC1=C(C=C2C(NC=NC2=C1)=O)OC BGCBQVUYJNZHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 102100015966 IL4 Human genes 0.000 description 1
- 101700049319 INS Proteins 0.000 description 1
- 229950003599 IPSAPIRONE Drugs 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 229960004053 Ibutilide Drugs 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 229950004274 Ifetroban Drugs 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Ilacox Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229940095970 Imodium Drugs 0.000 description 1
- 206010061215 Impulse-control disease Diseases 0.000 description 1
- 229940073062 Imuran Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N Indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 Indapamide Drugs 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 229960004461 Interferon beta-1a Drugs 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 206010022568 Intermittent explosive disease Diseases 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 229960001361 Ipratropium Bromide Drugs 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N Ipsapirone Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N Irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010061255 Ischaemia Diseases 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N Ivabradine Chemical group C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 102100019242 KCNA3 Human genes 0.000 description 1
- 101700057850 KCNA3 Proteins 0.000 description 1
- 206010023332 Keratitis Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- 208000008531 Knee Injury Diseases 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 102100011540 LGALS3 Human genes 0.000 description 1
- 102100015591 LOXL2 Human genes 0.000 description 1
- 101700013321 LOXL2 Proteins 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229950010645 Lanoteplase Drugs 0.000 description 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N Laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
- 208000003849 Large Cell Carcinoma Diseases 0.000 description 1
- 210000000867 Larynx Anatomy 0.000 description 1
- 229950002183 Lebrikizumab Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N Leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000001152 Leukemia, Prolymphocytic, B-Cell Diseases 0.000 description 1
- YEESKJGWJFYOOK-IJHYULJSSA-N Leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010065433 Ligament rupture Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229940040461 Lipase Drugs 0.000 description 1
- 206010061227 Lipid metabolism disease Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- 229960002394 Lisinopril Drugs 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 208000000185 Localized Scleroderma Diseases 0.000 description 1
- 229940087973 Lomotil Drugs 0.000 description 1
- 229960004773 Losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N Losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229940060963 Lotronex Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N Lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 1
- 229960000345 Lubiprostone Drugs 0.000 description 1
- 210000004705 Lumbosacral Region Anatomy 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710027724 MAGEC3 Proteins 0.000 description 1
- 101710027718 MAGEE1 Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 101710027479 MAP2K1 Proteins 0.000 description 1
- 102100006473 MAP2K1 Human genes 0.000 description 1
- 102100003436 MAP3K5 Human genes 0.000 description 1
- 101710038965 MAP4K4 Proteins 0.000 description 1
- 102100009763 MAP4K4 Human genes 0.000 description 1
- 102100000918 MAPK14 Human genes 0.000 description 1
- 101700062311 MASP2 Proteins 0.000 description 1
- 102100011108 MASP2 Human genes 0.000 description 1
- 108010051602 MEDI2070 Proteins 0.000 description 1
- 101700028785 MEK1 Proteins 0.000 description 1
- 101700053443 MKK1 Proteins 0.000 description 1
- 101700052154 MPK1 Proteins 0.000 description 1
- 102100014404 MPO Human genes 0.000 description 1
- 101710034456 MT-CO1 Proteins 0.000 description 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 description 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N Macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 208000008585 Mastocytosis Diseases 0.000 description 1
- 229950007254 Mavrilimumab Drugs 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N MeOH methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 229950004994 Meglitinide Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 206010027378 Mental retardation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N Metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 Metoprolol Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 206010027603 Migraine headache Diseases 0.000 description 1
- TZRFSLHOCZEXCC-HIVFKXHNSA-A Mipomersen Chemical compound N1([C@H]2C[C@@H]([C@H](O2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=O)S[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2COP([O-])(=O)S[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(NC(=O)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@H]2O[C@H](C[C@@H]2SP([O-])(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C3=NC=NC(N)=C3N=C2)OCCOC)SP([O-])(=O)OC[C@H]2[C@@H]([C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)SP([O-])(=O)OC[C@H]2[C@H](O)[C@@H]([C@H](O2)N2C(N=C(N)C(C)=C2)=O)OCCOC)N2C(N=C(N)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)C=C(C)C(N)=NC1=O TZRFSLHOCZEXCC-HIVFKXHNSA-A 0.000 description 1
- 229960004778 Mipomersen Drugs 0.000 description 1
- 229940060946 Miralax Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 229950007856 Mofetil Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 201000009262 Mooren's ulcer Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N N,N'-bis[3,5-bis[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N N-(benzenesulfonyl)-N-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N N-(p-Tolylsulfonyl)-N'-butylcarbamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- WDPFJWLDPVQCAJ-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-2-[2-[(4-fluorophenyl)methylsulfanyl]-4-oxo-6,7-dihydro-5H-cyclopenta[d]pyrimidin-1-yl]-N-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1=2CCCC=2C(=O)N=C(SCC=2C=CC(F)=CC=2)N1CC(=O)N(CCN(CC)CC)CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 WDPFJWLDPVQCAJ-UHFFFAOYSA-N 0.000 description 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 description 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N N-[2-[4-(cyclopentylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-methyl-D-aspartate receptors Human genes 0.000 description 1
- 108090001041 N-methyl-D-aspartate receptors Proteins 0.000 description 1
- SAHXZDPTZACVTR-UHFFFAOYSA-N NC1=C(C(=O)OC)C=C(C(=C1)I)OC Chemical compound NC1=C(C(=O)OC)C=C(C(=C1)I)OC SAHXZDPTZACVTR-UHFFFAOYSA-N 0.000 description 1
- 102100000661 NLRP12 Human genes 0.000 description 1
- 101710043086 NLRP12 Proteins 0.000 description 1
- 101700014192 NOCT Proteins 0.000 description 1
- 101700043017 NTRK1 Proteins 0.000 description 1
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 1
- 229960004760 Naphazoline Hydrochloride Drugs 0.000 description 1
- 108010035649 Natalizumab Proteins 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N Neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 229960002362 Neostigmine Drugs 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N Netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 206010058105 Neutrophilic dermatosis Diseases 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 229960002715 Nicotine Drugs 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 108070000019 Nicotinic acid receptor Proteins 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 229960002460 Nitroprusside Drugs 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 229960001158 Nortriptyline Drugs 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N OC(=O)C(N)CCCNC(N)=N Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229950005751 Ocrelizumab Drugs 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- 229950004864 Olamine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229950010006 Olokizumab Drugs 0.000 description 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N Ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M Oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 229960001609 Oxitropium bromide Drugs 0.000 description 1
- 229960005162 Oxymetazoline hydrochloride Drugs 0.000 description 1
- 101700062635 P2RY1 Proteins 0.000 description 1
- 101710037776 P2RY14 Proteins 0.000 description 1
- 102100010468 P2RY14 Human genes 0.000 description 1
- 102100005352 PCSK9 Human genes 0.000 description 1
- 101700000651 PCSK9 Proteins 0.000 description 1
- 101700031366 PDK2 Proteins 0.000 description 1
- 102100014459 PDK2 Human genes 0.000 description 1
- 102100014428 PDK4 Human genes 0.000 description 1
- 101700014996 PDK4 Proteins 0.000 description 1
- 229950008492 PENTOPRIL Drugs 0.000 description 1
- 229940097241 POTASSIUM-SPARING DIURETICS Drugs 0.000 description 1
- 102000024367 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100012041 PRKAA2 Human genes 0.000 description 1
- 101710035826 PRKAA2 Proteins 0.000 description 1
- 101710015127 PRKAB1 Proteins 0.000 description 1
- 101710038828 PRKCA Proteins 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010033675 Panniculitis Diseases 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 229950011485 Pascolizumab Drugs 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 229960001376 Pegloticase Drugs 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N Penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 229950002913 Pexmetinib Drugs 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 229960003733 Phenylephrine Hydrochloride Drugs 0.000 description 1
- 229960002305 Phenylpropanolamine Hydrochloride Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- KVCSJPATKXABRQ-UHFFFAOYSA-N Piboserod Chemical compound C1CN(CCCC)CCC1CNC(=O)C(C1=CC=CC=C11)=C2N1CCCO2 KVCSJPATKXABRQ-UHFFFAOYSA-N 0.000 description 1
- 229950005769 Pilaralisib Drugs 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229960003073 Pirfenidone Drugs 0.000 description 1
- 229950008185 Pitrakinra Drugs 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- 229940072689 Plaquenil Drugs 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229940095638 Pletal Drugs 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229950009275 Ponesimod Drugs 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N Pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960004856 Prazepam Drugs 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 206010065347 Premenstrual pain Diseases 0.000 description 1
- 206010065857 Primary effusion lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N Propadiene Chemical compound C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N Propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N Propargyl bromide Chemical group BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N Prostacyclin Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229960003447 Pseudoephedrine Hydrochloride Drugs 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- 208000002027 Psychomotor Disorders Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- 229940073095 Questran Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N Quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N Quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 description 1
- 101700071234 RBG8 Proteins 0.000 description 1
- 102100000735 RBP4 Human genes 0.000 description 1
- 101710002756 RBP4 Proteins 0.000 description 1
- 101710005817 RORC Proteins 0.000 description 1
- 101700064749 RXRA Proteins 0.000 description 1
- 229950010994 Ralimetinib Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N Ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 229960003401 Ramipril Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010038294 Reiter's syndrome Diseases 0.000 description 1
- 208000009169 Relapsing Polychondritis Diseases 0.000 description 1
- 229940086526 Renin-inhibitors Drugs 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 229940061969 Rheumatrex Drugs 0.000 description 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N Riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N Rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N Roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 Roflumilast Drugs 0.000 description 1
- 229950010316 Rontalizumab Drugs 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 108091006660 SLC22A12 Proteins 0.000 description 1
- 102100006182 SSTR1 Human genes 0.000 description 1
- 102100006137 SSTR2 Human genes 0.000 description 1
- 101710016458 SSTR2 Proteins 0.000 description 1
- 102100000875 SSTR3 Human genes 0.000 description 1
- 101710016457 SSTR3 Proteins 0.000 description 1
- 102100000874 SSTR5 Human genes 0.000 description 1
- 101710016366 SSTR5 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 229960004540 Secukinumab Drugs 0.000 description 1
- DLSWIYLPEUIQAV-CCUURXOWSA-N Semaglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DLSWIYLPEUIQAV-CCUURXOWSA-N 0.000 description 1
- 229950011186 Semaglutide Drugs 0.000 description 1
- 229950011005 Semapimod Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229940063651 Senokot Drugs 0.000 description 1
- 206010040070 Septic shock Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 Sertraline Drugs 0.000 description 1
- 229950010077 Sifalimumab Drugs 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229950009513 Simtuzumab Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229950006094 Sirukumab Drugs 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N Sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010040984 Sleep disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- 229950005814 Sotrastaurin Drugs 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N Spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 description 1
- 102000005782 Squalene Monooxygenase Human genes 0.000 description 1
- 108020003891 Squalene Monooxygenase Proteins 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000004490 Stress Disorders, Traumatic, Acute Diseases 0.000 description 1
- 240000006531 Strophanthus gratus Species 0.000 description 1
- 206010049418 Sudden cardiac death Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- SUVMJBTUFCVSAD-UHFFFAOYSA-N Sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 1
- 229950011082 Suplatast tosilate Drugs 0.000 description 1
- 208000010265 Sweet Syndrome Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000008253 Systolic Heart Failure Diseases 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 101700038204 TGFA Proteins 0.000 description 1
- 108091000182 THR-184 Proteins 0.000 description 1
- 102100012096 TLR2 Human genes 0.000 description 1
- 101700064022 TLR2 Proteins 0.000 description 1
- 102100006354 TLR8 Human genes 0.000 description 1
- 101700071772 TLR8 Proteins 0.000 description 1
- 102100008791 TNFRSF12A Human genes 0.000 description 1
- 102100003472 TRADD Human genes 0.000 description 1
- 101700007105 TRADD Proteins 0.000 description 1
- 102100001147 TRPA1 Human genes 0.000 description 1
- 102000003629 TRPC3 Human genes 0.000 description 1
- 101700005591 TRPC5 Proteins 0.000 description 1
- 102000003621 TRPC5 Human genes 0.000 description 1
- 108010014401 TWEAK Receptor Proteins 0.000 description 1
- 229950010265 Tabalumab Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- CBPNZQVSJQDFBE-HGVVHKDOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CCC2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HGVVHKDOSA-N 0.000 description 1
- 229950001790 Tendamistat Drugs 0.000 description 1
- 229960000216 Tenecteplase Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N Teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- BYJAVTDNIXVSPW-UHFFFAOYSA-N Tetrahydrozoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 1
- 229940021790 Tetrahydrozoline hydrochloride Drugs 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N Tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 108010069102 Thromboxane-A Synthase Proteins 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N Ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229950005515 Tildrakizumab Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229960002277 Tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N Tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229950004176 Topiroxostat Drugs 0.000 description 1
- 210000003437 Trachea Anatomy 0.000 description 1
- 229950000835 Tralokinumab Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- 229950010086 Tregalizumab Drugs 0.000 description 1
- 229960001288 Triamterene Drugs 0.000 description 1
- 229940062627 Tribasic potassium phosphate Drugs 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N Tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triurene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 229950004499 Trodusquemine Drugs 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 206010046736 Urticarias Diseases 0.000 description 1
- 108010077389 Ustekinumab Proteins 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- RNOBTWYQAWEZHH-JGVFFNPUSA-N VI5LR1EU47 Chemical compound C12=CC(C(F)(F)F)=CC=C2[C@]2([H])CNC[C@@]1([H])C2 RNOBTWYQAWEZHH-JGVFFNPUSA-N 0.000 description 1
- 102100001433 VIPR2 Human genes 0.000 description 1
- 101700031564 VIPR2 Proteins 0.000 description 1
- 210000001215 Vagina Anatomy 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N Valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N Varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 229950008314 Veliflapon Drugs 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229950007805 Vercirnon Drugs 0.000 description 1
- 229950005117 Verucerfont Drugs 0.000 description 1
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N Viloxazine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 Viloxazine Drugs 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N Voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 229960005289 Voclosporin Drugs 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010047680 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- 101700009925 WNK1 Proteins 0.000 description 1
- 101700086325 WRN Proteins 0.000 description 1
- 229960005080 Warfarin Drugs 0.000 description 1
- 206010047931 Whipple's disease Diseases 0.000 description 1
- 102100002634 XDH Human genes 0.000 description 1
- 229960001095 Xylometazoline hydrochloride Drugs 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- 229960004764 Zafirlukast Drugs 0.000 description 1
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N Zibotentan Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 description 1
- 229950003684 Zibotentan Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N Ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N Zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- WUJVPODXELZABP-FWJXURDUSA-N [(3R,6R)-6-[(3S,5R,7R,8R,9S,10S,13R,14S,17R)-3-[3-[4-(3-aminopropylamino)butylamino]propylamino]-7-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] hydrogen sulfate Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCNCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 WUJVPODXELZABP-FWJXURDUSA-N 0.000 description 1
- NZDMRJGAFPUTMZ-UHFFFAOYSA-N [1-(3,4-dihydroxyphenyl)-1-hydroxybutan-2-yl]azanium;chloride Chemical compound [Cl-].CCC([NH3+])C(O)C1=CC=C(O)C(O)=C1 NZDMRJGAFPUTMZ-UHFFFAOYSA-N 0.000 description 1
- AKLXWVUWJVQCMG-FIBGUPNXSA-N [2H]C([2H])([2H])OC1=CC2=C(C=CN=C2Cl)C=C1C#N Chemical compound [2H]C([2H])([2H])OC1=CC2=C(C=CN=C2Cl)C=C1C#N AKLXWVUWJVQCMG-FIBGUPNXSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- HGMSJMJPXGGEBP-UHFFFAOYSA-N [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium Chemical compound C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 HGMSJMJPXGGEBP-UHFFFAOYSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 108091003897 abrilumab Proteins 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 201000004625 acrodermatitis Diseases 0.000 description 1
- 229920002877 acrylic styrene acrylonitrile Polymers 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 201000005913 acute stress disease Diseases 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000002404 acyltransferase inhibitor Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005038 alkynylalkyl group Chemical group 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229960003550 alosetron Drugs 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229940051880 analgesics and antipyretics Pyrazolones Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 108091021984 anrukinzumab Proteins 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-M anthranilate Chemical compound NC1=CC=CC=C1C([O-])=O RWZYAGGXGHYGMB-UHFFFAOYSA-M 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001078 anti-cholinergic Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 230000002921 anti-spasmodic Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 200000000007 arterial disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003143 atherosclerotic Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 201000006647 atypical hemolytic-uremic syndrome Diseases 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 201000002055 autistic disease Diseases 0.000 description 1
- 235000020127 ayran Nutrition 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 229950001786 azimilide Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 108010051561 belimumab Proteins 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 108010055391 benralizumab Proteins 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229960004411 benziodarone Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical compound C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 108010072948 bococizumab Proteins 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000005586 carbonic acid group Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 230000002612 cardiopulmonary Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 201000003963 colon carcinoma Diseases 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 201000009929 conduct disease Diseases 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical group OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-M cyclohexylsulfamate Chemical compound [O-]S(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-M 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000593 degrading Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 230000003210 demyelinating Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N deuterated methanol Substances [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 230000003205 diastolic Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- VXIHRIQNJCRFQX-UHFFFAOYSA-K disodium aurothiomalate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S[Au])C([O-])=O VXIHRIQNJCRFQX-UHFFFAOYSA-K 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 229960000413 doxercalciferol Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 108010005794 dulaglutide Proteins 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 201000006180 eating disease Diseases 0.000 description 1
- 108010063231 eculizumab Proteins 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 108010088118 enavatuzumab Proteins 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 201000009273 endometriosis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- FFLYUXVZEPLMCL-UHFFFAOYSA-N ethylchloranuidyl formate Chemical compound CC[Cl-]OC=O FFLYUXVZEPLMCL-UHFFFAOYSA-N 0.000 description 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 102000003973 fibroblast growth factor 21 Human genes 0.000 description 1
- 108090000376 fibroblast growth factor 21 Proteins 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 201000005160 follicular thyroid carcinoma Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 108010073818 fresolimumab Proteins 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 201000006860 gastroesophageal reflux disease Diseases 0.000 description 1
- 201000006529 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 108010072141 gevokizumab Proteins 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229950008402 glisentide Drugs 0.000 description 1
- 229950005319 glisolamide Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035780 glucosuria Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 108010020157 guselkumab Proteins 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 230000003400 hallucinatory Effects 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 101710011541 hrg-7 Proteins 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-O hydron;thiourea Chemical class NC(N)=[SH+] UMGDCJDMYOKAJW-UHFFFAOYSA-O 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001631 hypertensive Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- LHLMOSXCXGLMMN-VVQPYUEFSA-M ipratropium bromide Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 LHLMOSXCXGLMMN-VVQPYUEFSA-M 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229960003825 ivabradine Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010051044 lanoteplase Proteins 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- 108010010776 lebrikizumab Proteins 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960003838 lesinurad Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 102000004882 lipase Human genes 0.000 description 1
- 108090001060 lipase Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 229960001039 macitentan Drugs 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108010089383 mavrilimumab Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 108010062313 mepolizumab Proteins 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229940072739 mesalamine Drugs 0.000 description 1
- 229940054556 metaproterenol Drugs 0.000 description 1
- RLXWGEUQYNIHRM-UHFFFAOYSA-N methanetriolate Chemical compound [O-]C([O-])[O-] RLXWGEUQYNIHRM-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- UUBFELFUKFJSRD-UHFFFAOYSA-N methyl 2-hydroxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1O UUBFELFUKFJSRD-UHFFFAOYSA-N 0.000 description 1
- KUZAUIMZCSWJPG-UHFFFAOYSA-N methyl 5-amino-2-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC(N)=CC=C1OC(C)C KUZAUIMZCSWJPG-UHFFFAOYSA-N 0.000 description 1
- QWDADDKGBBZBAC-UHFFFAOYSA-N methyl 5-nitro-2-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1OC(C)C QWDADDKGBBZBAC-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical group Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 229920002784 mipomersen Polymers 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 229940005650 monomethyl fumarate Drugs 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 201000008895 mood disease Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001016 myotrophic Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000001338 necrotic Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229930015196 nicotine Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- ASPOIVQEUUCDQT-UHFFFAOYSA-N nitroprusside Chemical compound O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N ASPOIVQEUUCDQT-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 1
- 108010030900 ocrelizumab Proteins 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 108010082216 olokizumab Proteins 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- QMLWSAXEQSBAAQ-UHFFFAOYSA-N oxetan-3-ol Chemical group OC1COC1 QMLWSAXEQSBAAQ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 201000008743 palmoplantar keratosis Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000000505 pernicious Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 108010010907 pitrakinra Proteins 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 200000000002 platelet activation Diseases 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 201000008839 post-traumatic stress disease Diseases 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- WPDCHTSXOPUOII-UHFFFAOYSA-N propan-2-yl 4-[5-methoxy-6-[(2-methyl-6-methylsulfonylpyridin-3-yl)amino]pyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound N1=CN=C(OC2CCN(CC2)C(=O)OC(C)C)C(OC)=C1NC1=CC=C(S(C)(=O)=O)N=C1C WPDCHTSXOPUOII-UHFFFAOYSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl N-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- BWVDUDRBWILROL-UHFFFAOYSA-N propan-2-yl benzenecarboperoxoate Chemical compound CC(C)OOC(=O)C1=CC=CC=C1 BWVDUDRBWILROL-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 229960000577 quinethazone Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 108010069061 reslizumab Proteins 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000529 riociguat Drugs 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- 108010024190 rontalizumab Proteins 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 108010073863 saruplase Proteins 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000000978 schizoaffective disease Diseases 0.000 description 1
- 201000000261 schizophreniform disease Diseases 0.000 description 1
- 230000001932 seasonal Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 108010040425 secukinumab Proteins 0.000 description 1
- 150000003962 selenoxides Chemical class 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- RGYQPQARIQKJKH-UHFFFAOYSA-N setanaxib Chemical compound CN(C)C1=CC=CC(C2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2C)=C1 RGYQPQARIQKJKH-UHFFFAOYSA-N 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 108010037957 sifalimumab Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 108010056973 siltuximab Proteins 0.000 description 1
- 108010074113 simtuzumab Proteins 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 108010012416 sirukumab Proteins 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960001315 sodium aurothiomalate Drugs 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- PFYAMVWLZDZJOQ-UHFFFAOYSA-M sodium;2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)F PFYAMVWLZDZJOQ-UHFFFAOYSA-M 0.000 description 1
- MHSYOMOOZBKVFH-UHFFFAOYSA-M sodium;hydrogen carbonate;sodium Chemical compound [Na].[Na+].OC([O-])=O MHSYOMOOZBKVFH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 108010082379 somatostatin receptor type 1 Proteins 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 229950002009 sparsentan Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 108010019261 squalene epoxidase-cyclase Proteins 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical class [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical class [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229950001956 suplatast Drugs 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002889 sympathetic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 108010029352 tabalumab Proteins 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229960000337 tetryzoline Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 108010042345 tildrakizumab Proteins 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 229960001787 tisopurine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 108010078548 tocilizumab Proteins 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 108010037465 tralokinumab Proteins 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 108010025519 tregalizumab Proteins 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 201000005539 vernal conjunctivitis Diseases 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N α-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
Abstract
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula la,
Description
BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS
FIELD OF THE INVENTION
This invention pertains to compounds useful for the treatment of autoimmune and inflammatory diseases associated with lnterleukin-1 Receptor Associated Kinase (IRAK) and more particularly compounds that modulate the function of IRAK4.
BACKGROUND OFTHE INVENTION
Protein kinases are families of enzymes that catalyze the phosphorylation of spécifie 10 residues in proteins, broadly classified in tyrosine and serine/threonine kinases. Inappropriate activity arising from dysrégulation of certain kinases by a variety of mechanisms is believed to underlie the causes of many diseases, including but not limited to, cancer, cardiovascular diseases, allergies, asthma, respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, and neurological and neurodegenerative 15 diseases. As such, potent and sélective inhibitors of kinases are sought as potential treatments for a variety of human diseases.
There is considérable interest in targeting the innate immune System in the treatment of autoimmune diseases and stérile inflammation. Receptors of the innate immune System provide the first line of defense against bacterial and viral insults. These receptors recognize 20 bacterial and viral products as well as pro-inflammatory cytokines and thereby initiate a signaling cascade that ultimately results in the up-regulation of inflammatory cytokines such as TNFa, IL6, and interferons. Recently it has become apparent that self-generated ligands such as nucleic acids and products of inflammation such as high-mobility group protein B1 (HMGB1) and Advanced Glycated End-products (AGE) are ligands for Toll-like receptors (TLRs) which 25 are key receptors of the innate immune System (O’Neili 2003, Kanzler et al 2007, Wagner 2006). This demonstrates the rôle of TLRs in the initiation and perpétuation of inflammation due to autoimmunity.
lnterleukin-1 receptor associated kinase 4 (IRAK4) is a ubiquitously expressed serine/threonine kinase involved in the régulation of innate immunity (Suzuki & Saito 2006).
IRAK4 is responsible for initiating signaling from TLRs and members of the IL-1/18 receptor family. Kinase-inactive knock-ins and targeted délétions of IRAK4 in mice were reported to cause réductions in TLR and IL-1 induced pro-inflammatory cytokines (Kawagoe et al 2007; Fraczek et al. 2008; Kim et al. 2007). IRAK4 kinase-dead knock-in mice hâve also been shown to be résistant to induced joint inflammation in the antigen-induced-arthritis (AIA) and sérum transfer-induced (K/BxN) arthritis models (Koziczak-Holbro 2009). Likewise, humans déficient in IRAK4 also appear to display the inability to respond to challenge by Toll ligands and IL-1 (Hernandez & Bastian 2006). However, the immunodeficient phenotype of IRAK4-null individuals is narrowly restricted to challenge by gram positive bacteria, but not gram négative bacteria, viruses or fungi. This gram positive sensitivity also lessens with âge, implying redundant or compensating mechanisms for innate immunity in the absence of IRAK4 (Lavine et al 2007).
These data indicate that inhibitors of IRAK4 kinase activity should hâve therapeutic value in treating cytokine driven autoimmune diseases while having minimal immunosuppressive side effects. Additional recent studies suggest that targeting IRAK4 may be useful in other inflammatory pathologies such as atherosclerosis and diffuse large B-cell lymphoma (Rekhter et al 2008; Ngo et al 2011). Therefore, inhibitors of IRAK4 kinase activity are potential therapeutics for a wide variety of diseases including but not limited to autoimmunity, inflammation, cardiovascular diseases, cancer, and metabolic diseases. See the following references for additional information: N. Suzuki and T. Saito, Trends in Immunology, 2006, 27, 566. T. Kawagoe, S. Sato, A. Jung, M. Yamamoto, K. Matsui, H. Kato, S. Uematsu, O. Takeuchi and S. Akira, Journal of Experimental Medicine, 2007, 204, 1013. J. Fraczek, T. W. Kim, H. Xiao, J. Yao, Q. Wen, Y. Li, J.-L. Casanova, J. Pryjma and X. Li, Journal of Biological Chemistry, 2008, 283, 31697. T. W. Kim, K. Staschke, K. Bulek, J. Yao, K. Peters, K.-H. Oh, Y. Vandenburg, H. Xiao, W. Qian, T. Hamilton, B. Min, G. Sen, R. Gilmour and X. Li, Journal of Experimental Medicine, 2007, 204, 1025. M. Koziczak-Holbro, A. Littlewood-Evans,
B. Pollinger, J. Kovarik, J. Dawson, G. Zenke, C. Burkhart, M. Muller and H. Gram, Arthritis & Rheumatism, 2009, 60, 1661. M. Hernandez and J. F. Bastian, Current Allergy and Asthma Reports, 2006, 6, 468. E. Lavine, R. Somech, J. Y. Zhang, A. Puel, X. Bossuyt, C. Picard, J. L. Casanova and C. M. Roifman, Journal of Allergy and Clinical Immunology, 2007, 120, 948. M. Rekhter, K. Staschke, T. Estridge, P. Rutherford, N. Jackson, D. Gifford-Moore, P. Foxworthy,
C. Reidy, X.-d. Huang, M. Kalbfleisch, K. Hui, M.-S. Kuo, R. Gilmour and C. J. Vlahos, Biochemical and Biophysical Research Communications, 2008, 367, 642. O'Neill, L. A. (2003). Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol 3(4): 396. Kanzler, H et al. (2007) “Therapeutic targeting of innate immunity with toll-like receptor agonists and antagoniste.” Nature Medicine 13:552. Wagner, H. (2006) “Endogenous TLR ligands and autoimmunity” Advances in Immunol 91: 159. Ngo, V. N. et al. (2011) “Oncogenically active MyD88 mutations in human lymphoma” Nature 470:115.
SUMMARY OF THE INVENTION
The invention provides for compounds of the Formula la,
la wherein
X and X’ are each independently CR8, N or-N+-0_; Y is independently N, -N+-O'or
CR8’; provided that at least one of X, X’ or Y is neither N nor -N+-0‘ and that no more than one of X, X’ or Y is -N+-0';
R1 is C-i-Cealkyl; C2-Cealkenyl; C2-Cealkynyl; -(CR3aR3b)m-(3- to 7-membered cycloalkyl); -(CR3aR3b)m-(3- to 7-membered heterocycloalkyl) having one to three 10 heteroatoms; -(CR3aR3b)m-(5- to 10-membered heteroaryl), having one to three heteroatoms;
or -(CR3aR3b)m-Ce-Ci2aryl; wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five halogen, deuterium, -OR5, -SR5, NR11aR11b, cyano, Ci-Cealkyl, C3-C6cycloalkyl or -Ci-C6alkoxy;
R2 is -(CR3aR3b)m-(3- to 10-membered cycloalkyl); -(CR3aR3b)m-(3- to 10-membered heterocycloalkyl) having one to three heteroatoms; -(CR3aR3b)m-(5- to 10 membered heteroaryl) having one to three heteroatoms; or -(CR3aR3b)m-C6-Ci2aryl; wherein said cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five R4; and wherein, if the heteroatom on said heterocycloalkyl and heteroaryl is N, said N is optionally substituted with R4’; or R2 is Ci-C6alkyl, wherein said alkyl is optionally substituted with NH2, OH or cyano;
R3a and R3b for each occurrence are independently hydrogen or Ci-Csalkyl;
R4 for each occurrence is independently a bond, deuterium, halogen, cyano, C1Cealkyl, C2-C6alkenyl, oxo, -OR5, -SR5, -S(O)R9, -S(O)2R9, -NR11aR11b, -C(O)R1°, (CR3aR3b)n-(3- to 7- membered cycloalkyl), -(CR3aR3b)n-(4- to 10- membered 25 heterocycloalkyl), having one to three heteroatoms, -(CR3aR3b)n-(5- to 10 membered heteroaryl), having one to three heteroatoms, or-(CR3aR3b)n- Ce-C^aryl wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is each optionally and independently substituted with one to five deuterium, halogen, OR5, -SR5, -NR11aR11b, cyano, Ci-Cealkyl, C3-C6cycloalkyl or C-i-Cealkoxy; or two R4 taken together with the respective carbons to
which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano or CrC6alkyl or CiCealkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, 5 deuterium, -OR5, -SR5, -NR11aR11b or cyano; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with R4';
R4' is independently Ci-C6alkyl, C2-C6alkenyl, -C(O)R10, -S(O)2R9, -(CR3aR3b)n-(3- to 7- membered cycloalkyl), -(CR3aR3b)n-(4- to 10- membered heterocycloalkyl) or C(O)(CH2)tCN; wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally 10 and independently substituted with one to five deuterium, halogen, OH, cyano or CiCsalkoxy; or R4 and R4’ taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, CrCealkyl or Ci-Cealkoxy, wherein the alkyl or 15 alkoxy is optionally substituted with halogen, deuterium, -OR5, -SR5, -NR11aR11b, or cyano;
R5 is independently hydrogen or Ci-C6alkyl, wherein said alkyl is optionally substituted with halogen, deuterium, Ci-C6alkoxy, Ci-C6alkylthiolyl, -NR11aR11b, cyano, CrC6alkyl or Cs-Cecycloalkyl; or two R5 taken together with the oxygen atoms to which they are bonded form a 5- or 6-membered heterocycloalkyl;
R6 is -C(O)NHR7, CO2R7 or cyano;
R7 is hydrogen or C-i-Csalkyl;
each R8 is independently hydrogen, halogen, cyano, -OR5, -SR5, -NR11aR11b, Ci-Cealkyl, C3-C6cycloalkyl, 3- to 10-membered heterocycloalkyl or 5- to 6-membered heteroaryl or aryl, wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is 25 optionally substituted with one to three halogen, -NR11aR11b, -OR5, -SR5, cyano, C1-C3 alkyl, C(O)R10 or oxo;
R8' is hydrogen, deuterium, halogen, cyano, -OR5, -SR5 or NR11aNR11b;
R9 is -(CR3aR3b)p-(Ci-C3alkyl), -(CR3aR3b)p-(4- to 6- membered cycloalkyl), -(CR3aR3b)p-(4- to 6- membered heterocycloalkyl) or -(CR3aR3b)p-(C5-C9aryl), 30 wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl is each optionally substituted with fluoro or Ci-C3alkyI;
R10 is Ci-C6alkyl, wherein said alkyl is optionally substituted with deuterium, halogen,
OH, Ci-Cealkoxy or cyano;
R11a and R11b are each independently hydrogen or Ci-Cealkyl, wherein said alkyl is optionally substituted with deuterium, C-i-Cealkoxy or cyano; and if C2-C6alkyl, said alkyl is optionally substituted with deuterium, Ci~C6alkoxy, cyano, halogen or OH;
m is independently 0,1, 2 or 3;
n is independently 0,1, 2 or 3;
p is independently 0 or 1; and t is 1, 2 or 3;
or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
The invention also provides for pharmaceutical compositions comprising the compounds, methods of using the compounds, combination thérapies utilizing the compounds and other therapeutic agents and methods of preparing the compounds. The invention also provides for intermediates useful in the préparation of the compounds of the invention.
In particular, novel bicyclic kinase enzyme inhibitor compounds of Formula I of the présent invention possess a therapeutic rôle of inhibiting IRAK4 useful in the area of diseases and/or disorders that include, but are not limited to, cancers, allergie diseases, autoimmune diseases, inflammatory diseases and/or disorders and/or conditions associated with inflammation and pain, proliférative diseases, hematopoietic disorders, hematological malignancies, bone disorders, rénal disease, fibrosis diseases and/or disorders, metabolic disorders, muscle diseases and/or disorders, respiratory diseases, pulmonary disorders, genetic development diseases, neurological and neurodegenerative diseases and/or disorders, chronic inflammatory demyelinating neuropathies, cardiovascular, vascular or heart diseases, ophthalmic/ocular diseases, wound repair, infection and viral diseases. Therefore, inhibition of IRAK4 would hâve the potential for multiple therapeutic indications over a wide range of unmet needs.
DESCRIPTION OF FIGURES
Figure 1: Mean change in ear swelling (pm) from baseline ear measurements on day 5.
Mice treated with Example 296 (PO BID daily X 5 days) and P40 Ab (IP day 1, 4) had significantly reduced ear swelling on the final day compared to Vehicle (p value and %).
Figure 2: Figure 2. Delta paw volume in rat collagen-induced arthritis model using
Example 26.
DETAILED DESCRIPTION OF THE INVENTION
The présent invention may be understood more readily by reference to the following detailed description of exemplary embodiments of the invention and the examples included therein. It is to be understood that this invention is not limited to spécifie methods of synthesis, 5 which may of course vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
Ail patents, patent applications and references referred to herein are hereby incorporated by reference in their entirety.
Other features and advantages of this invention will be apparent from this spécification and the appendent daims which describe the invention. There are many features of this invention that are not necessarily fully captured by the daims. It is understood, however, that ail such novel subject matter is part of the invention.
Définitions
Unless otherwise defined herein, scientific and technical terms used in connection with the présent invention hâve the meaning commonly understood by those of ordinary skill in the art. As used in the spécification and the appended daims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictâtes otherwise.
The term “about” refers to a relative term denoting an approximation of plus or minus 20 10% of the nominal value it refers, in one embodiment, to plus or minus 5%, in another embodiment, to plus or minus 2%. For the field of this disclosure, this level of approximation is appropriate unless the value is specifically stated require a tighter range.
The term alkyl” refers to a linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms. In one embodiment from one to six carbon atoms; and in 25 another embodiment from one to four carbon atoms; and in another embodiment one to three carbon atoms. Non-limiting examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isoamyl, hexyl and the like. As appropriate, an alkyl may be optionally substituted at each carbon as defined in the daims. Typical substitution includes, but is not limited to, fluoro, 30 chloro, OH, cyano, alkyl (optionally substituted), cycloalkyl and the like.
In some instances, the number of carbon atoms in a hydrocarbon substituent (i.e., alkyl, cycloalkyl, etc.) is indicated by the prefix “Cx-Cy-” or “Cx.y”, wherein x is the minimum and y is the maximum number of carbon atoms in the substituent. Thus, for example, “Ci-C6-alkyl” or “C1-6 alkyl” refers to an alkyl substituent containing from 1 to 6 carbon atoms. Illustrating further,
C3-C6-cycloalkyl or C3-6-cycloalkyl refers to saturated cycloalkyl containing from 3 to 6 carbon ring atoms.
Unless otherwise indicated, alkylene, by itself or as part of another term, refers to a saturated, branched or straight chain or cyclic hydrocarbon diradical of the stated number of 5 carbon atoms, typically 1-6 carbon atoms, and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane. Typical alkylene radicals include, but are not limited to methylene (-CH2-), 1,2-ethylene (-CH2CH2-), 2,2-dimethylene, 1,3-propylene (-CH2CH2CH2-), 2-methylpropylene, 1,4-butylene (-CH2CH2CH2CH2-), and the like; optionally substituted, as appropriate, by 1 to 5 suitable 10 substituents as defined above such as fluoro, chloro, deuteron, cyano, trifluoromethyl, (Ci-C6)alkoxy, (Ce-Cio)aryloxy, trifluoromethoxy, difluoromethoxy or (Ci-Ce)alkyl. When the compounds of the invention contain a C2-6alkenyl group, the compound may exist as the pure E (entgegen) form, the pure Z (zusammen) form, or any mixture thereof.
“Alkylidene” or “alkenyl” refers to a divalent group formed from an alkane by removal of 15 two hydrogen atoms from the same carbon atom, the free valencies of which are part of a double bond, optionally substituted as described herein. The term alkylidene also includes “aliénés” wherein on carbon atom has double bonds with each of its two adjacent carbon centers, such as, for example, propadiene. As appropriate, an alkenyl may be optionally substituted at each carbon as defined in the daims, optionally substituted, as appropriate, by 1 20 to 5 suitable substituents as defined above and herein such as fluoro, chloro, deutero, cyano, trifluoromethyl, (CrCeJalkoxy, (Ce-Ciojaryloxy, trifluoromethoxy, difluoromethoxy or (C-i-Cejalkyl.
Alkynyl refers to an aliphatic hydrocarbon having at least one carbon-carbon triple bond, including straight chain, branched chain or cyclic groups having at least one carboncarbon triple bond, optionally substituted as described herein. Preferably, it is a lower alkynyl 25 having 2 to 6 carbon atoms. For example, as used herein, the term C2-6alkynyl” is used herein to mean a straight or branched hydrocarbon chain alkynyl radical as defined above having 2 to 6 carbon atoms and one triple bond. As appropriate, an alkynyl may be optionally substituted at each carbon as defined in the daims. Typical substitution includes, but is not limited to, optionally substituted, as appropriate, by 1 to 5 suitable substituents as defined above and 30 herein, such as fluoro, chloro, deutero, cyano, trifluoromethyl, (Ci-C6)alkoxy, (Cs-Cio)aryloxy, trifluoromethoxy, difluoromethoxy or (C-i-Cejalkyl.
The term “cycloalkyl” refers to a nonaromatic ring containing 3 to 10 carbons that is fully hydrogenated consisting of mono-, bi- or tricyclic rings. Accordingly, a cycloalkyl may be a single ring, which typically contains from 3 to 7 ring atoms. Examples include, but are not 35 limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Alternative^, 2 or 3 rings may be
fused together, such as bicyclodecanyl and decalinyl. The term “cycloalkyl” also includes bridged bicycloalkyl Systems such as, but not limited to, bicyclo[2.2.1]heptane and bicyclo[1.1.1]pentane. The cycloalkyl group may be optionally substituted as described herein, as appropriate, by 1 to 5 suitable substituents as defined above such as fluoro, chloro, deutero, cyano, trifluoromethyl, (C-i-CeJalkoxy, (C6-C-io)aryloxy, trifluoromethoxy, difluoromethoxy or (Ci-Ce)alkyl.
The term “heterocycloalkyl” means a monovalent saturated moiety, consisting of one to three rings, incorporating one, two, three or four heteroatoms (selected from N, O or S) and three to 10 carbon atoms. The heterocycloalkyl may be optionally substituted as defined herein.
Examples of heterocycloalkyl moieties include, but are not limited to, optionally substituted piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolylidinyl, benzothiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorphilinylsulfone, dihydroquinolinyl, tetrahydroquinolinyl, tetrahydrisoquinolinyl, and the like. Heterocycloalkyls may be optionally substituted, as appropriate, by 1 to 5 suitable substituents as defined herein such as fluoro, chloro, deutero, cyano, trifluoromethyl, (C-i-C6)alkoxy, (C6-Cio)aryloxy, trifluoromethoxy, difluoromethoxy or (Ci-Cejalkyl.
Unless otherwise indicated, the term heteroalkyl, by itself or in combination with another term, means, unless otherwise stated, a saturated, straight or branched chain hydrocarbon radical consisting of the stated number of carbon atoms and from one to three heteroatoms selected from the group consisting of O, N and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be 25 quaternized. The heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. The heteroatom S may be placed at any position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molécule. Up to two heteroatoms may be consecutive.
Unless otherwise indicated, the term heteroalkylene by itself or as part of another substituent means a divalent group derived from heteroalkyl (as defined above). For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini.
The term “alkoxy” and “alkyloxy”, which may be used interchangeably, refers to a moiety of the formula -OR, wherein R is a straight chain saturated alkyl or branched chain saturated alkyl moiety, as defined herein, bonded through an oxygen atom. The alkoxy group may be optionally substituted as defined herein. Non-limiting examples of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy and the like.
The term aryl” means a carbocyclic aromatic System containing one or two rings wherein such rings may be fused. If the rings are fused, one of the rings must be fully unsaturated and the fused ring(s) may be fully saturated, partially unsaturated or fully unsaturated. The term fused means that a second ring is présent (i.e., attached or formed) by having two adjacent atoms in common (i.e., shared) with the first ring. The term fused is équivalent to the term condensed. The aryl group may be optionally substituted as defined herein. The term aryl embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, benzo[b][1,4]oxazin-3(4H)-onyl, 2,3-dihydro-1 H indenyl and 1,2,3,4-tetrahydronaphthalenyl. Aryls may be optionally substituted, as appropriate, by 1 to 5 suitable substituents as defined above such as fluoro, chloro, deutero, cyano, trifluoromethyl, (Ci-C6)alkoxy, (Cs-Ciojaryloxy, trifluoromethoxy, difluoromethoxy or (Ci-C6)alkyl.
The term “heteroaryl” refers to an aromatic ring structure containing from 5 to 6 ring atoms in which at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; and 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl. In a group that has a heteroaryl substituent, the ring atom of the heteroaryl substituent that is bound to the group may be one of the heteroatoms, or it may be a ring carbon atom. Similarly, if the heteroaryl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to one of the heteroatoms, or it may be bound to a ring carbon atom. The term “heteroaryl” also includes pyridyl A/-oxides and groups containing a pyridine /V-oxide ring.
Further examples include furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1/-/)-onyl, pyridazin-2(1/-/)-onyl, pyrimidin-2(1H)-onyl, pyrazin-2(1/-/)-onyl, imidazo[1,2-a]pyridinyl, tetrahydroquinolinyl, cyclopenta[c]pyridinyl, pyrazolo[1,5-a]pyridinyl, 5,6,7,8-tetrahydroisoquinolinyl, 5,6,7,86,7-dihydro-5/7-cyclopenta[b]pyridinyl,
1,4,5,6-tetrahydrocyclopenta[c]pyrazolyl, tetrahydrocyclopenta[c]pyrazolyl, 5,6-dihydro-4/-/-pyrrolo[1,2-b]pyrazolyl,
6,7-dihydro-5H2,4,5,66,7-dihydro-5Hpyrrolo[1,2-b][1,2,4]triazoly 1, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a] pyridinyl, 4,5,6,7tetrahydropyrazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydro-1/7-indazolyl and 4,5,6,7-tetrahydro-2/-/indazolyl. The heteroaryl can be optionally substituted, as appropriate, by 1 to 5 suitable substituents as defined herein such as fluoro, chloro, deutero, cyano, trifluoromethyl, (CiCejalkoxy, (C6-Cio)aryloxy, trifluoromethoxy, difluoromethoxy or (Ci-Cejalkyl.
Examples of single-ring heteroaryls and heterocycloalkyls include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, isopyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, dithiolyl, oxathiolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiaoxadiazolyl, oxathiazolyl, oxadiazolyl (including oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, or
1.3.4- oxadiazolyl), pyranyl (including 1,2-pyranyl or 1,4-pyranyl), dihydropyranyl, pyridinyl, piperidinyl, diazinyl (including pyridazinyl, pyrimidinyl, piperazinyl, triazinyl (including s-triazinyl, as-triazinyl and v-triazinyl), oxazinyl (including 2F/-1,2-oxazinyl, 6F/-1,3-oxazinyl, or 2H-
1.4- oxazinyl), isoxazinyl (including o-isoxazinyl or p-isoxazinyl), oxazolidinyl, isoxazolidinyl, oxathiazinyl (including 1,2,5-oxathiazinyl or 1,2,6-oxathiazinyl), oxadiazinyl (including 2H-
1.2.4- oxadiazinyl or2/7-1,2,5-oxadiazinyl), and morpholinyl.
The term “heteroaryl” also includes fused ring Systems having one or two rings wherein such rings may be fused, wherein fused is as defined above. It is to be understood that if a carbocyclic or heterocyclic moiety may be bonded or otherwise attached to a designated substrate through differing ring atoms without denoting a spécifie point of attachment, then ail possible points are intended, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term “pyridyl” means 2-, 3- or 4-pyridyl, the term “thienyl” means 2- or 3-thienyl, and so forth.
In some instances, the number of atoms in a cyclic substituent containing one or more heteroatoms (i.e., heteroaryl or heterocycloalkyl) is indicated by the prefix “x- to y-membered”, wherein x is the minimum and y is the maximum number of atoms forming the cyclic moiety of the substituent. Thus, for example, “5- to 6-membered heteroaryl” refers to a heteroaryl containing from 5 to 6 atoms, including one or more heteroatoms, in the cyclic moiety of the heteroaryl. The heteroatoms for this invention are selected from nitrogen, oxygen and sulfur.
Compounds of the présent invention may contain basic nitrogen atoms (e.g. alkyl amines or heterocycles such as pyridine etc.) which may be converted to N-oxides by treatment with an oxidizing agent (e.g. MCPBA and/or hydrogen peroxides) to afford other compounds of this invention. Thus, ail nitrogen-containing compounds that may converted to N-oxide (N->O or -N+-O-) dérivatives are part of the invention.
One skilled in the art would appreciate that métabolites may be formed as part of the natural biochemical process of degrading and eliminating the compounds. For example, some compounds of the invention may naturally form an N-oxide, as depicted below in the compound
of Formula If or in other areas of the compound of Formula la. Métabolites such as these or others formed as part of the natural biochemical process are within the scope of the invention.
Ilf llf
If substituents are described as “independently” having more than one variable, each instance of a substituent is selected independent of the other from the list of variables available. Each substituent therefore may be identical to or different from the other substituent(s).
“Patient” or “subject” refers to warm-blooded animais such as, for example, guinea pigs, mice, rats^gerbils, cats, rabbits, dogs, cattle, goats, sheep, horses, monkeys, chimpanzees, and humans.
The term “pharmaceutically acceptable” means the substance or composition must be compatible, chemically and/or toxicologically, with the other ingrédients comprising a formulation, and/or the mammal being treated therewith.
The term “therapeutically effective amount” means an amount of a compound of the présent invention that (i) treats or prevents the particular disease, condition, or disorder, (ii) 15 atténuâtes, améliorâtes, or éliminâtes one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
The term treating, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, delaying the progression of, delaying the onset of, or 20 preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term treatment, as used herein, unless otherwise indicated, refers to the act of treating as treating is defined immediately above. The term “treating” also includes adjuvant and neo-adjuvant treatment of a subject. For the avoidance of doubt, reference herein to “treatment” includes reference to curative, palliative and prophylactic 25 treatment, and to the administration of a médicament for use in such treatment.
As used herein, the terms “Formula I”, “Formula la”, Formula lla-Ilg”, “Formula III” and “Formula fila” may be hereinafter referred to as a “compound(s) of the invention,” “the présent invention,” and collectively the “compound of Formula I.” Accordingly, the term “compound of
Formula I” includes the compounds of Formula la, lla-llg, III and Ilia. Such terms are also defined to include ail forms of the compound of Formula I, including hydrates, solvatés, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, tautomers and métabolites thereof. For example, the compounds of the invention, or pharmaceutically acceptable salts 5 thereof, may exist in unsolvated and solvated forms. When the solvent orwater is tightly bound, the complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, nonstoichiometry will be the norm.
The compounds of the invention hâve asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line (------), a solid wedge ( ), or a dotted wedge (.......ul|i). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers (e.g., spécifie enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid 15 or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of Formula I may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ali possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the 20 compounds of Formula I can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of Formula I and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is présent.
Stereoisomers of Formula I include cis and trans isomers, optical isomers such as R and
S enantiomers, diastereomers, géométrie isomers, rotational isomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition salts wherein the counterion is optically active, 30 for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.
The compounds of the invention may exhibit the phenomenon of tautomerism. For example, the compound exemplified by 173 may exist in several tautomeric forms, including the pyrrolidin-2-one form, Example 173a, and the 5-hydroxy-3,4-dihydro-2H-pyrrol form, Example 173b. Ail such tautomeric forms are included within the scope of the compounds of the Formula 35 I and the scope of the invention. One of ordinary skill in the art would appreciate and recognize
that many of the Examples described herein may exhibit tautomerism and are within the scope of the compound of Formula I, la, lla-llg, III and Ilia. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, the présent invention includes ail tautomers of the compounds of 5 the invention and salts thereof. Examples of tautomers are described by Examples 173a and 173b.
Example 173a
Example 173b
When any racemate crystallizes, crystals of two different types are possible. The frrst type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The compounds of this invention may be used in the form of salts derived from inorganic or organic acids. Depending on the particular compound, a sait of the compound may be advantageous due to one or more of the salt’s physical properties, such as enhanced pharmaceutical stability in differing températures and humidities, or a désirable solubility in water or oil. In some instances, a sait of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
Where a sait is intended to be administered to a patient (as opposed to, for example, being used in an in vitro context), the sait preferably is pharmaceutically acceptable. The term pharmaceutically acceptable sait refers to a sait prepared by combining a compound of Formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the présent invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are nontoxic “pharmaceutically acceptable salts.” Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention, which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
Suitable pharmaceutically acceptable acid addition salts of the compounds of the présent invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
Spécifie examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartrate, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilate, stéarate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, 15 toluenesulfonate, 2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenate, β-hydroxybutyrate, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycérophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali métal salts, e.g., sodium or potassium salts; alkaline earth métal salts, e.g., calcium or magnésium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, Λ/,Λ/’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine. Basic 30 nitrogen-containing groups may be quaternized with agents such as lower alkyl (C-i-C6) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
In one embodiment, hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
Also within the scope of the présent invention are so-called “prodrugs” of the compound of the invention. Thus, certain dérivatives of the compound of the invention that may hâve little 5 or no pharmacological activity themselves can, when administered into or onto the body, be converted into the compound of the invention having the desired activity, for example, by hydrolytic cleavage. Such dérivatives are referred to as “prodrugs.” Further information on the use of prodrugs may be found in “Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T. Higuchi and V. Stella) and “Bioreversible Carriers in Drug Design,” 10 Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association). Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities présent in the compounds of any of Formula I with certain moieties known to those skilled in the art as “pro-moieties” as described, for example, in “Design of Prodrugs” by H. Bundgaard (Elsevier, 1985).
The présent invention also includes isotopically labeled compounds, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the présent invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 11C, 14C, 15N, 18O, 17O, 32P, 35S, 18F, and 36CI, respectively. Compounds of the présent invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the présent invention, for example those into which radioactive isotopes such as 25 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays.
Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be 30 preferred in some circumstances. Compounds of the invention as claimed in the daims may specifically define substitution with deutero or deuterium. The absence of the term deuteron, deuteron or deuterium, ail of which are used interchangeably, in a substitution group shall not be implied to exclude deutero.
Isotopically labeled compounds of Formula I of this invention and prodrugs thereof can 35 generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the
Examples and Préparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
Ail patents and publications identified herein are incorporated herein by reference in their entirety and for ail purposes.
Compounds of the Invention
In one embodiment, as described above and more fully herein, the invention is directed to a compound of Formula la,
la wherein
X and X’ are each independently CR8, N or -N+-O’; Y is independently N, -N+-O' or CR8’; provided that at least one of X, X’ or Y is neither N nor -N+-O‘ and that no more than one of X, X’ or Y is -N+-O_; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In one aspect, the invention provides for compounds of Formula la wherein X is N, X’ is
CR8 and Y is CR8’; X is N, X’ is N and Y is CR8’; X is N, X’ is CR8 and Y is N; X is CR8, X’ and Y are N; X and X’ are CR8 and Y is N; X is CR8 and Y is CR8’ and X’ is N; X and X’ are CR8 and Y is CR8’; or a pharmaceutically acceptable sait of said compound or a tautomer of said sait. In another aspect, R6 is -C(O)NHR7, -CO2R7 or cyano; and R7 is hydrogen; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
The invention also provides for a compound of Formula lia, llb, Ile, lld, Ile, llf or llg,
lia llb
Ile
lld
Ile llf
Iig wherein R1 is C-i-Csalkyl; C2-C6alkenyl; C2-Csalkynyl; -(CR3aR3b)m-(3- to 7-membered cycloalkyl); or -(CR3aR3b)m-(3- to 7-membered heterocycloalkyl) having one to three heteroatoms; wherein said alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl is optionally substituted with one to five halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, Ci-Cealkyl, C3-C6cycloalkyl or -Ci-C6alkoxy;
R2 is -(CR3aR3b)m-(3- to 7-membered cycloalkyl), wherein said cycloalkyl is optionally substituted with one to four R4; -(CR3aR3b)m-(3- to 7-membered heterocycloalkyl) having one 10 to three heteroatoms, wherein said heterocycloalkyl is optionally substituted at a carbon atom with one to five R4 and wherein, if the heteroatom is N, said N is optionally substituted with R4'; or R2 is Ci-C6alkyl, wherein said alkyl is optionally substituted with NH2, cyano or halogen
R3a and R3b are each independently hydrogen or Ci-C3alkyl;
R4 for each occurrence is independently and optionally halogen, cyano, C-i-Csalkyl,
C2-C6alkenyl, oxo, -OR5, -SR5,-S(O)R9, -S(O)2R9, -C(O)R10, -(CR3aR3b)n-(3- to 7- membered cycloalkyl) or -(CR3aR3b)n-(4- to 7- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, -OR5, -SR5, -NR11aR11b, cyano, C-i-C6alkyl, C3-C6cycloalkyl, CiCealkoxy or NR11aR11b; or two R4taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano or C-i-Cealkyl or C-i-Cealkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, -OR5, -NR11aR11b, or cyano ; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with R4';
R4' is independently Ci-C6alkyl, C2-C6alkenyl, -S(O)R9, -S(O)2R9, -C(O)R10, C(O)(CH2)tCN; wherein said alkyl is optionally substituted with NH2, cyano or halogen (CR3aR3b)n-(3- to 7- membered cycloalkyl), or (CR3aR3b)n-(4- to 10- membered heterocycloalkyl), wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano or C-i-C6alkoxy; or R4 and R4’ taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, C-i-Cealkyl or Ci-Csalkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, -OR5, -SR5, -NR11aR11fa or cyano;
R5 is hydrogen or C-i-Cealkyl, wherein said alkyl is optionally substituted with halogen;
R6 is -C(O)NHR7 or cyano;
R7 is hydrogen or Ci-C6alkyl;
R8 is independently hydrogen, halogen, cyano, -NR11aR11b, Ci-Cealkyl, 5- to 6membered heteroaryl or 5- to 6- membered aryl, wherein said alkyl or heteroaryl or aryl is optionally substituted with one to three halogen, -NR11aR11b, C1-C3 alkyl or oxo;
R8' is hydrogen, deuterium, halogen, cyano, -OR5 or NR11aNR11b;
R9 is -(CR3aR3b)P-(Ci-C3alkyl), -(CR3aR3b)P-(4- to 6- membered cycloalkyl), -(CR3aR3b)p-(4- to 6- membered heterocycloalkyl) or -(CR3aR3b)p-(Cs-C9aryl), wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl is each optionally substituted with fluoro or Ci-C3alkyl;
R10 is Ci-C6alkyl, wherein said alkyl is optionally substituted with fluoro or cyano;
R11a and R11b are each independently hydrogen or C-i-Cealkyl, wherein said alkyl is optionally substituted with OH;
m is independently 0,1 or 2; n is independently 0 or 1;
p is independently 0 or 1 ; and t is 0, 1, 2 or 3;
or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In one aspect of the invention, R1 is Ci-C4alkyl; C2-C4alkenyl; C2-C4alkynyl; (CR3aR3b)m-(3- to 6-membered cycloalkyl); or -(CR3aR3b)m-(3- to 5-membered heterocycloalkyl) having one to three heteroatoms; wherein said alkyl, alkenyl, alkynyl, 10 cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, C-i-Cealkyl, Cs-Cscycloalkyl or CrCealkoxy; R3a and R3b are each independently hydrogen or Ci-C3alkyl; R6 is -C(O)NHR7 or cyano; R7 is hydrogen; and m is independently 0 or 1.
In another aspect, the invention provides for compounds wherein R1 is fluoromethyl;
difluoromethyl; trifluoromethyl; methyl, ethyl, propyl or isopropyl, each optionally substituted with one to three fluoro or deuterium; aliéné, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, oxetane or tetrahydrofuran, each of which is optionally substituted with fluoro or C1-C3 alkyl.
In another aspect, R2 is selected from pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, piperidin-2-onyl, octahydro-1/7-pyrrolo[3,4-c]pyridinyl, oxazolidinyl, oxazolidin-2-onyl, 1,3oxazinan-2-onyl, imidazolidinyl, imidazolidin-2-onyl, morpholinyl, morpholin-3-onyl, thiazyl, isothiazyl, isothiazolidine-1,1-dioxidyl, 1,2-thiazinane 1,1-dioxidyl, hexahydrocyclopenta/b/pyrrol-2(1 F/)-onyl, octahydrocyclopenta[c]pyrrolyl, azetidinyl, hexahydro-1H-indol-2(3H)-onyl, octahydro-1/7-isoindolyl, azepanyl, tetrahydrofuranyl, 1,325 dioxolanyl, oxetanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-azepanyl, 1,4oxazepanyl, tetrahydro-2H-pyranyl, 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolyl, cyclohex-2-enyl, or 1,2,3,4-tetrahydroisoquinolinyl; wherein said alkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one to four R4.
In another aspect, the cycloalkyl and heterocycloalkyl of R2 is optionally substituted 30 with one to four R4; or two R4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three F, Cl, OH, cyano, Ci-C3alkyl (optionally substituted with OH, F or Cl), Ci-C3fluoroalkyl or Ci-C6alkoxy; Rq is independently hydrogen, deuterium or Ci-C3alkyl, wherein said alkyl is optionally 35 substituted with halogen; R3a and R3b for each occurrence are independently hydrogen or
Ci-C3alkyl; R4 for each occurrence is independently and optionally halogen; Ci-C3alkyl; C2-C4alkenyl; oxo; -OR5; -C(O)R10; -(CR3aR3b)n-(3- to 5-membered cycloalkyl); or (CR3aR3b)n-(4- to 7- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano, Ci-Cealkoxy or -NR11aR11b; or two R4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three halogen, OH, methyl, ethyl, propyl, Ci-C3fluoroalkyl, Ci-Cshydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the respective carbons to which each are bonded form a 4- to
6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one to three fluoro, Ci-C3alkyl, or C-i-Csfluoroalkyl; R5 is hydrogen, methyl or ethyl; R9 is phenyl; R10 is Ci-Cealkyl, wherein said alkyl is optionally substituted with fluoro or cyano; and R11a and R11b are each independently H or Ci-C6alkyl; or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait.
In another aspect, R4 is selected from F, Cl, OH; CrCsalkyl, optionally substituted with one to five deuterium, Cl, F, OH, CrC3alkyl, Ci-C3alkoxy; or two R4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three Cl, F, OH, methyl, ethyl, propyl, Ci-C3fluoroalkyl, Ci-C3hydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the respective carbons to which each are bonded form a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one to three fluoro, Ci-C3alkyl, C-t-Csfluoroalkyl, -C(O)(CH2)tCN; or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait.
In another embodiment, the invention is directed to a compound of Formula III wherein
III
X and X’ are each independently CR8 or N; Y is independently N or CR8’; provided that at least one of X, X’ or Y is not N;
R1 is CrC6alkyl or Ci-C6cycloalkyl, wherein said alkyl or cycloalkyl is optionally substituted with deuterium, halogen, OH, cyano, Ci-C3alkyl, Cs-Cecycloalkyl, C-i-Cealkoxy or
Ci-Cealkylthiolyl;
R3a and R3b are each independently hydrogen or Ci-Csalkyl;
R4 for each occurrence (one, two, three, four or five) is independently and optionally halogen, Ci-C6alkyl, C2-C6alkenyl -OR5, -(CR3aR3b)n-(3- to 6- membered cycloalkyl) or -(CR3aR3b)n-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, CN, -C(O)(CH2)tCN or -C-i-Cealkoxy; -NR11aR11b; two R4takentogetherwith the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three F, Cl, OH, methyl, ethyl, propyl, Ci-C3fluoroalkyl, Ci-C3difluoroalkyl, Ci-C3trifluoroalkyl,
Ci-C3hydroxyalkyl, methoxy or ethoxy;
R5 is hydrogen or Ci-C6alkyl, wherein said alkyl is optionally substituted with fluoro;
R8 is independently hydrogen, halogen, cyano, -NR11aR11b, Ci-Cealkyl, 5- to 6membered heteroaryl or aryl, wherein said alkyl or heteroaryl or aryl is optionally substituted with one, two or three halogen, -NR11aR11b, C1-C3 alkyl or oxo;
R8’ is hydrogen, deuterium, halogen or cyano;
R10 is C-i-Cealkyl, wherein said alkyl is optionally substituted with fluoro or cyano;
R11a and R11b are each independently hydrogen or Ci-Csalkyl, wherein said alkyl is optionally substituted with OH;
n is independently 0 or 1 ; and tis1,2or3;
or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In one aspect, theinvention is directed to compounds whereinn Y is N; X and X’ are CR8. In another aspect, X and X’ are each CR8 and Y is CR8'· In another aspect, X and Y are N and 30 X’ is CR8. In another aspect, X is N, X’ is CR8 and Y is CR8’.
In another aspect, R1 is Ci-C3alkyl, wherein said alkyl is optionally substituted with one to three deuterium, F, Cl or CrC3alkoxy; and R3a and R3b are each independently hydrogen or methyl. In another aspect, R4 for each occurrence is independently and optionally F; Cl; OH; or Ci-C3alkyl, optionally substituted with one to five deuterium, Cl, F, OH, Ci-C3alkyl, or C-i35 C3alkoxy; or two R4 taken together with the carbons to which they are bonded form a
cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three Cl, F, OH, methyl, ethyl, propyl, C-i-Cshaloalkyl, C-iC3dihaloalkyl, CrCstrihaloalkyl, C-i-Cahydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the carbons to which they are bonded form a 4- to 6-membered heterocycloalkyl, wherein 5 said heterocycloalkyl is optionally substituted with one to three fluoro, Ci-C3alkyl,
Ci-C3fluoroalkyl or -C(O)(CHz)tCN.
In still another aspect, R1 is methyl, ethyl, propyl or isopropyl wherein each of said R1 moieties are optionally substituted with deuterium, fluoro or methoxy; R4 is independently and optionally selected from fluoro, OH, methyl, ethyl, vinyl, propyl, wherein said methyl, ethyl, vinyl 10 or propyl are optionally substituted with one, two or three fluoro, OH or methoxy; or two R4taken together with the carbons to which they are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three Cl, F, OH, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxymethyl, propyl, CrC3haloalkyl, Ci-C3dihaloalkyl, Ci-C3trihaloalkyl, Ci-C3hydroxyalkyl, 15 methoxy, or ethoxy; and R8 is independently hydrogen, halogen or Ci-C6alkyl, wherein said alkyl is optionally substituted with fluoro.
In another embodiment, the invention is directed to a compound of Formula Ilia,
wherein
X and X’ are each independently CR8 or N; Y is independently N or CR8'; provided that at least one of X, X’ or Y is not N;
R1 is C-i-C6alkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, Ci-C3alkyl, Cs-Cecycloalkyl or Ci-Cealkoxy;
R3a and R3b are each independently hydrogen or Ci-Csalkyl;
R4a and R4b are each independently hydrogen, deuterium, fluoro, OH, -OR5, methyl, ethyl, vinyl, cyclopropyl or propyl, optionally substituted with one to five deuterium, fluoro, methoxy or OH;
R4c and R4d for each occurrence are independently and optionally halogen, OH, deuterium, Ci-C6alkyl, C2-C6alkenyl, -OR5, -(CR3aR3b)n-(3- to 6- membered cycloalkyl), or -(CR3aR3b)n-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally and independently substituted with one to five 5 deuterium, halogen, OH, cyano, or Ci-Csalkoxy; NH2; or R4c and R4dtaken together with the carbons to which they are bonded form a 4- to 7-membered heterocycloalkyl or a 3- to 7membered cycloalkyl, wherein said heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, Ci-Csalkyl or Ci-C3fluoroalkyl; or
R4a and R4c taken together with the carbon to which they are bonded form a 4- to 710 membered heterocycloalkyl or a 3- to 7-membered cycloalkyl, wherein said heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, Ci-C3alkyl or Ci-C3fluoroalkyl;
R5 is hydrogen or Ci-Cealkyl, wherein said alkyl is optionally substituted with fluoro;
R8 is hydrogen, halogen or C-i-C6alkyl, wherein said alkyl is optionally substituted with halogen;
R8’ is hydrogen, deuterium, halogen or cyano; and n is independently 0 or 1;
or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In one aspect, the invention provides R8is hydrogen, methyl or fluoro; R1 is methyl, ethyl, isopropyl or propyl, optionally substituted with deuterium; R4a is hydrogen; methyl, ethyl or propyl, optionally substituted with deuterium, fluoro, methoxy; R4b is hydrogen or fluoro; R4c is hydrogen or OH; R4d is hydrogen, fluoro, methoxy or OH; or methyl, optionally substituted with 1, 2 or 3 fluoro; or ethyl, optionally substituted with 1, 2, or 3 fluoro; or R4c and R4d or alternative^ R4a and R4c taken together with the carbons to which they are bonded form a 25 cyclopropyl, optionally substituted with one to three fluoro, Ci-C3alkyl or Ci-C3fluoroalkyl; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In another embodiment, the invention is directed to the compounds described in Tables 1 or 3; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
In another embodiment, the invention is directed to the intermediate compounds described in Table 2; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait
In another embodiment, the invention is directed to a synthetic process and préparation of the intermediate compounds described in Table 2, as detailed in the Schemes and the 35 préparation section described herein. In another aspect, the invention is directed to a synthetic
process and préparation of the compounds of Tables 1 or 3, as detailed in the Schemes and the préparation section described herein.
IRAK4 Indications
The compounds of the invention are also useful in treating and/or preventing a disease or condition mediated by or otherwise associated with an IRAK enzyme; the method comprising administering to a subject in need thereof an effective amount of a compound of the invention.
The disease may be, but not limited to, one of the following classes: auto-immune diseases, inflammatory diseases, allergie diseases, metabolic diseases, infection-based 10 diseases, trauma or tissue-injury based diseases, fibrotic diseases, genetic diseases, diseases driven by over-activity of IL1 pathways, cardiovascular diseases, vascular diseases, heart diseases, neurological diseases, neurodegenerative diseases, respiratory diseases, pulmonary diseases, airways diseases, rénal diseases, skin and/ or dermatological diseases, liver diseases, gastrointestinal diseases, oral diseases, pain and sensory diseases, hematopoietic 15 diseases, joint diseases, muscle diseases, bone diseases, and ophthalmic and/or ocular diseases.
Spécifie autoimmune diseases include, but are not limited to: rheumatoid arthritis, osteoarthritis, psoriasis, allergie dermatitis, systemic lupus erythematosus (and resulting complications), Sjôgren's syndrome, multiple sclerosis, asthma, glomerular nephritis, irritable 20 bowel syndrome, inflammatory bowel disease, Crohn's disease, ankylosing spondylitis, Behçet's disease, lupus nephritis, scleroderma, systemic scleroderma, type 1 or juvénile on-set diabètes, alopecia universalis, acute disseminated encephalomyelitis, Addison's disease, antiphospholipid antibody syndrome, atrophie gastritis of pernicious anémia, autoimmune alopecia, autoimmune hemolytic anémia, autoimmune hepatitis, autoimmune encephalomyelitis, autoimmune 25 thrombocytopenia, Bullous pemphigoid, Chagas disease, Celiac disease, chronic hepatitis, Cogan’s syndrome, dermatomyositis, endometriosis, Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome, Hashimoto's disease (or Hashimoto’s thyroiditis), hemolytic anémia, hidradentitis suppurativa, idiopathic thrombocytopenia purpura, interstitial cystitis, membranous glomerulopathy, morphea, mystenia gravis, narcolepsy, pemphigus, pernicous 30 anémia, polyarteritis nodosa, polymyositis, primary biliary cirrhosis, Reiter’s syndrome, schizophrenia, symphathetic opthalmia, systemic sclerosis, temporal arteritis, thyroiditis, vasculitis, vitiglio, vulvodynia, Wegner's granulomatosis, palmoplantar keratoderma, systemiconset Juvénile Idiopathic Arthritis (SJIA), or an indication listed in a separate category herein.
Spécifie inflammatory diseases include, but are not limited to: chronic obstructive 35 pulmonary diseases, airway hyper-responsiveness, cystic fibrosis, acute respiratory distress
syndrome, sinusitis, rhinitis, gingivitis, atherosclerosis, chronic prostatitis, glomerular nephritis, ulcerative colitis, uveitis, periodontal disease, or an indication listed in a separate category herein.
Spécifie pain conditions include, but are not limited to: inflammatory pain, surgical pain, viscéral pain, dental pain, premenstrual pain, central pain, pain due to burns, migraine or cluster headaches, nerve injury, interstitial cystitis, cancer pain, viral, parasitic or bacterial infection, post-traumatic injury, pain associated with irritable bowel syndrome, goût, pain associated with any of the other indications listed within this spécification, or an indication listed in a separate category herein.
Spécifie respiratory, airway and pulmonary conditions include, but are not limited to:
asthma (which may encompass chronic, late, bronchial, allergie, intrinsic, extrinsic or dust), chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, cystic fibrosis, interstitial lung disease, acute lung injury, sarcoidosis, allergie rhinitis, chronic cough, bronchitis, récurrent airway obstruction, emphysema, or bronchospasm, 15 or an indication listed in a separate disease category herein.
Spécifie gastrointestinal (Gl) disorders include, but are not limited to: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), biliary colic and other biliary disorders, rénal colic, diarrhea-dominant IBS, pain associated with Gl distension, ulcerative colitis, Crohn's Disease, irritable bowel syndrome, Celiac disease, proctitis, éosinophilie gastroenteritis, 20 mastocytosis, or an indication listed in a separate disease category herein.
Spécifie allergie diseases include, but are not limited to: anaphylaxis, allergie rhinitis, allergie dermatitis, allergie urticaria, angioedema, allergie asthma, allergie reactions to: food, drugs, insect bites, pollen; or an indication listed in a separate disease category herein.
Spécifie infection-based diseases include, but are not limited to: sepsis, septic shock, 25 viral diseases, malaria, Lyme disease, ocular infections, conjunctivitis, Whipple Disease, or an indication listed in a separate disease category herein.
Spécifie trauma and tissue injury-based conditions include, but are not limited to: Rénal glomerular damage, reperfusion injury (for example to heart, kidney, lung), spinal cord injury, tissue scarring, tissue adhesion, tissue repair, transplant rejection (for examples to heart, lung, 30 bone marrow, cartilage, cornea, kidney, limb, liver, muscle, myoblast, pancréas, pancreatic islet, skin, nerve, small intestine, trachea), hypersensitivities, or an indication listed in a separate disease category herein.
Spécifie fibrotic diseases include, but are not limited to: Idiopathic pulmonary fibrosis, liver fibrosis, rénal fibrosis, or an indication listed in a separate disease category herein.
Spécifie diseases considered to be driven by over-activity of IL1 pathways include, but are not limited to: Cryopyrin-associated periodic syndromes, myositis, and indications included in the following review article: C. A. Dinarello, A. Simon and J. W. M. van der Meer, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nat Rev Drug Discov, 2012, 11(8), 633-652, http://dx.doi.org/10.1038/nrd3800 and supplementary information contained therein, or an indication listed in a separate disease category herein.
Spécifie ophthalmic/ ocular diseases include, but are not limited to: uveitis, age-related macular degeneration, diabetic macular edema, keratoconjuctivitis, uveitis associated with
Behçet’s disease, vernal conjunctivitis, ketatitis, lens-induced uveitis, herpetic keratitis, conical keratitis, corneal épithélial dystrophy, ocular pemphigus, Mooren’s ulcer, Scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca, phlyctenule, iridocyclitis, sympathetic ophthalmia, allergie conjunctivitis, ocular neovascularization, dry eye syndrome, or an indication listed in a separate disease category herein.
Spécifie joint, muscle and bone disorders include, but are not limited to: osteoarthritis, osteoporosis, rheumatoid arthritis, juvénile arthritis, psoriatic arthritis, erosive osteoarthritis of the hand, arthrofibrosis/traumatic knee injury, anterior cruciate knee ligament tear, relapsing polychondritis, récurrent multifocal osteomyelitis, Majeed Syndrome, ankylosing spondylitis, goût of the lumbar spine, antisynthetase syndrome, idiopathic inflammatory myopathies, articular chondrocalcinosis, systemic-onset Juvénile Idiopathic Arthritis (SJIA), goût and pyrophosphate crystal arthritis, or an indication listed in a separate disease category herein.
Spécifie skin/ dermatological diseases include, but are not limited to: psoriasis, atopie dermatitis, cutaneous lupus, acné, dermatomyositis, eczema, pruritus, scleroderma, Sweet Syndrome/neutrophilic dermatosis, neutrophilie panniculitis, acrodermatitis (form of pustular psoriasis), or an indication listed in a separate disease category herein.
Spécifie rénal diseases include, but are not limited to: acute kidney injury (AKI) (sepsisAKI, coronary artery bypass graft-AKI, cardiac surgery-AKI, non-cardiac surgery-AKI, transplant surgery-AKI cisplatin-AKI, contrast/imaging agent induced-AKI), glomerulonephritis, IgA nephropathy, crescentic GN, lupus nephritis, HIV associated nephropathy, membraneous nephropathy, C3 glomerulopathy, Dense deposit disease, ANCA vasculitis, diabetic nephropathy, hemolytic-uremic syndrome, atypical Hemolytic-uremic syndrome, nephrotic syndrome, nephritic syndrome, hypertensive nephrosclerosis, ApoL1 nephropathy, focal segmentai glomerulosclerosis, Alport syndrome, Fanconi, syndrome, crystal nephropathy, nephrolithiasis, nephrotic syndrome, rénal transplant rejection, amyloidosis, glomerulonephritis in SJIA, or an indication listed in a separate disease category herein.
Spécifie genetic diseases include, but are not limited to: Familial Mediterranean fever (FMF), CAPS (FCAS, Muckle-Wells Syndrome, NOMID/CINCA), male hypoinfertility in CAPS, NLRP12 Autoinflammatory Syndrome, or an indication listed in a separate disease category herein.
Spécifie hematopoietic diseases include, but are not limited to: hemolytic anémia, or an indication listed in a separate disease category herein.
Spécifie liver diseases include, but are not limited to: liver fibrosis, liver cirrhosis, nonalcoholic steatohepatitis (NASH), or an indication listed in a separate disease category herein.
Spécifie oral diseases include, but are not limited to: gingivitis, periodontal disease or an indication listed in a separate disease category herein.
Spécifie metabolic diseases include, but are not limited to: Type 2 diabètes (and resulting complications), goût and hyperuricemia, metabolic syndrome, insulin résistance, obesity, or an indication listed in a separate disease category herein.
Compounds of the current invention are also useful in the treatment of a proliférative disease selected from a benign or malignant tumor, solid tumor, carcinoma of the brain, kidney, liver, adrenal gland, bladder, breast, stomach, gastric tumors, ovaries, colon, rectum, prostate, pancréas, lung, vagina, cervix, testis, genitourinary tract, esophagus, larynx, skin, bone or thyroid, sarcoma, glioblastomas, neuroblastomas, multiple myeloma, gastrointestinal cancer, especially colon carcinoma or colorectal adenoma, a tumor of the neck and head, an epidermal hyperproliferation, psoriasis, prostate hyperplasia, a neoplasia, a neoplasia of épithélial character, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, nonsmall-cell lung carcinoma, lymphomas, Hodgkins and Non-Hodgkins, a mammary carcinoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, smoldering of indolent multiple myeloma, or hematological malignancies (including leukemia, diffuse large B-cell lymphoma (DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, plasmacytoma, intravascular large B-cell lymphoma), or an indication listed in a separate disease category herein.
Cardiovascular conditions include, but are not limited to coronary heart disease, acute coronary syndrome, ischaemic heart disease, first or récurrent myocardial infarction, secondary myocardial infarction, non-ST segment élévation myocardial infarction, or ST segment élévation 35 myocardial infarction, ischémie sudden death, transient ischémie attack, peripheral occlusive
arterial disease, angina, atherosclerosis, hypertension, heart failure (such as congestive heart failure), diastolic dysfunction (such as left ventricular diastolic dysfunction, diastolic heart failure, and impaired diastolic filling), systolic dysfunction (such as systolic heart failure with reduced éjection fraction), vasculitis, ANCA vasculitis, post-myocardial infarction cardiac remodeling 5 atrial fibrillation, arrhythmia (ventricular), ischemia, hypertrophie cardiomyopathy, sudden cardiac death, myocardial and vascular fibrosis, impaired arterial compliance, myocardial necrotic lésions, vascular damage, left ventricular hypertrophy, decreased éjection fraction, cardiac lésions, vascular wall hypertrophy, endothélial thickening, fibrinoid necrosis of coronary arteries, adverse remodeling, stroke, and the like, or an indication listed in a separate disease 10 category herein. Also, included are venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary arterial thrombosis, cérébral arterial thrombosis, cérébral embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from (a) prosthetic valves or other implants, (b) indwelling cathéters, (c) stents, (d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which blood is exposed to an artificial surface that promûtes thrombosis. It is noted that thrombosis includes occlusion (e.g., after a bypass) and reocclusion (e.g., during or after percutaneous transluminal coronary angioplasty).
Cardiovascular complications of type 2 diabètes are associated with inflammation, accordingly, the compounds of the présent invention may be used to treat diabètes and diabetic complications such as macrovascular disease, hyperglycemia, metabolic syndrome, impaired glucose tolérance, hyperuricemia, glucosuria, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, obesity, dyslipidemia, hypertension, hyperinsulinemia, and insulin résistance syndrome, or an indication listed in a separate disease category herein.
Linkage of innate immunity and inflammation to disease has been demonstrated in neuroinflammatory and neurodegenerative conditions. Therefore, the compounds of the 25 présent invention are particularly indicated for use in the treatment of neuroinflammatory and neurodegenerative conditions (i.e., disorders or diseases) in mammals including humans such as multiple sclerosis, migraine; epilepsy; Alzheimer’s disease; Parkinson’s disease; brain injury; stroke; cerebrovascular diseases (including cérébral arteriosclerosis, cérébral amyloid angiopathy, hereditary cérébral hemorrhage, and brain hypoxia-ischemia); cognitive disorders 30 (including amnesia, senile dementia, HIV associated dementia, Alzheimer’s associated dementia, Huntington’s associated dementia, Lewy body dementia, vascular dementia, drug related dementia, delirium, and mild cognitive impairment); mental deficiency (including Down syndrome and fragile X syndrome); sleep disorders (including hypersomnia, circadian rhythm sleep disorder, insomnia, parasomnia, and sleep deprivation) and psychiatrie disorders (such as 35 anxiety (including acute stress disorder, generalized anxiety disorder, social anxiety disorder, parue disorder, post-traumatic stress disorder and obsessive-compulsive disorder); factitious disorder (including acute hallucinatory mania); impulse control disorders (including compulsive gambling and intermittent explosive disorder); mood disorders (including bipolar I disorder, bipolar II disorder, mania, mixed affective state, major dépréssion, chronic dépréssion, seasonal dépréssion, psychotic dépréssion, and postpartum dépréssion); psychomotor disorder; psychotic disorders (including schizophrenia, schizoaffective disorder, schizophreniform, and delusional disorder); drug dependence (including narcotic dependence, alcoholism, amphétamine dependence, cocaïne addiction, nicotine dependence, and drug withdrawal syndrome); eating disorders (including anorexia, bulimia, binge eating disorder, hyperphagia, and pagophagia); and pédiatrie psychiatrie disorders (including attention déficit disorder, attention deficit/hyperactive disorder, conduct disorder, and autism), myotrophic latéral sclerosis, chronic fatigue syndrome, or an indication listed in a separate disease category herein.
Typically, a compound of the invention is administered in an amount effective to treat a condition as described herein. The compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the médicinal arts.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, by which the compound enters the blood stream directly from the mouth.
In another embodiment, the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internai organ. Suitable means for parentéral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subeutaneous. Suitable devices for parentéral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
In another embodiment, the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. In another embodiment, the compounds of the invention can also be administered intranasally or by inhalation. In another embodiment, the compounds of the invention may be administered rectally or vaginally. In another embodiment, the compounds of the invention may also be administered directly to the eye or ear.
The dosage regimen for the compounds and/or compositions containmg the compounds is based on a variety of factors, including the type, âge, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions. In one embodiment, the total daily dose of a compound of the invention (administered in single or divided doses) is typically from about 0.01 to about 100 mg/kg. In another embodiment, the total daily dose of the compound of the invention is from about 0.1 to about 50 mg/kg, and in another embodiment, from about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per kg body weight). In one embodiment, dosing is from 0.01 to 10 mg/kg/day. In another embodiment, dosing is from 0.1 to 1.0 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
For oral administration, the compositions may be provided in the form of tablets containing from about 0.01 mg to about 500 mg of the active ingrédient, or in another embodiment, from about 1 mg to about 100 mg of active ingrédient. Intravenously, doses may range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
Suitable subjects according to the présent invention include mammalian subjects. Mammals according to the présent invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
In another embodiment, the invention comprises the use of one or more compounds of the invention for the préparation of a médicament for the treatment of the conditions recited herein.
For the treatment of the conditions referred to above, the compound of the invention can be administered as compound per se. Alternatively, pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
In another embodiment, the présent invention comprises pharmaceutical compositions. Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier. The carrier can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds. A compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be présent.
The compounds of the présent invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and compositions, for example, may be administered orally, rectally, parenterally, or topically.
Oral administration of a solid dose form may be, for example, presented in discrète units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the présent invention. In another embodiment, the oral administration may be in a powder or granule form. In another embodiment, the oral dose form is sub-lingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of Formula I are ordinarily combined with one or more adjuvants. Such capsules or tablets may contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
In another embodiment, oral administration may be in a liquid dose form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable émulsions, solutions, suspensions, syrups, and élixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
In another embodiment, the présent invention comprises a parentéral dose form. Parentéral administration includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion. Injectable préparations (e.g., stérile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents.
In another embodiment, the présent invention comprises a topical dose form. Topical administration includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. A topical formulation may include a compound that enhances absorption or pénétration of the active ingrédient through the skin or other affected areas. When the compounds of this invention are administered by a transdermal device, administration will be accomplished using a patch either of the réservoir and porous membrane type or of a
solid matrix variety. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, minerai oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Pénétration enhancers may be incorporated; see, for example, J. Pharm. Sci., 88(10), 955-958, by Finnin and Morgan (October 1999).
Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aurai administration may be in the form of drops of a micronized suspension or solution in isotonie, pH-adjusted, stérile saline. Other formulations suitable for ocular and aurai administration include ointments, biodégradable (e.g., absorbable gel sponges, collagen) and non-biodegradable (e.g., silicone) implants, wafers, lenses and particulate or vesicular Systems, such as niosomes or liposomes. A polymer such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aérosol spray présentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aérosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
In another embodiment, the présent invention comprises a rectal dose form. Such rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Other carrier materials and modes of administration known in the pharmaceutical art may also be used. Pharmaceutical compositions of the invention may be prepared by any of
the well-known techniques of pharmacy, such as effective formulation and administration procedures. The above considérations in regard to effective formulations and administration procedures are well known in the art and are described in standard textbooks. Formulation of drugs is discussed in, for example, Hoover, John E., Remington’s Pharmaceutical Sciences, 5 Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
The compounds of the présent invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states. The compound(s) 10 of the présent invention and other therapeutic agent(s) may be may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially.
Two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time 15 but at different anatomie sites or using different routes of administration.
The phrases concurrent administration,” “co-administration,” “simultaneous administration,” and “administered simultaneously” mean that the compounds are administered in combination.
The présent invention includes the use of a combination of an IRAK inhibitor compound 20 as provided in the compound of Formula I and one or more additional pharmaceutically active agent(s). If a combination of active agents is administered, then they may be administered sequentially or simultaneously, in separate dosage forms or combined in a single dosage form. Accordingly, the présent invention also includes pharmaceutical compositions comprising an amount of: (a) a first agent comprising a compound of Formula I or a pharmaceutically 25 acceptable sait of the compound; (b) a second pharmaceutically active agent; and (c) a pharmaceutically acceptable carrier, vehicle or diluent.
The compounds of the présent invention can be administered alone or in combination with one or more additional therapeutic agents. By administered in combination or combination therapy it is meant that a compound of the présent invention and one or more 30 additional therapeutic agents are administered concurrently to the mammal being treated.
When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Thus, the methods of prévention and treatment described herein include use of 35 combination agents.
The combination agents are administered to a mammal, including a human, in a therapeutically effective amount. By therapeutically effective amoiint it is meant an amount of a compound of the présent invention that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to treat the desired disease/condition e.g., inflammatory condition such as systemic lupus erythematosus. See also, T. Koutsokeras and T. Healy, Systemic lupus erythematosus and lupus nephritis, Nat Rev Drug Discov, 2014, 13(3), 173-174, for therapeutic agents useful treating lupus.
In particular, it is contemplated that the compounds of the invention may be administered with the following therapeutic agents:
Non-steroidal anti-inflammatory drugs (NSAIDs), including but not limited to, nonselective COX1/2 inhibitors such as piroxicam, naproxen, flubiprofen, fenoprofen, ketoprofen, ibuprofen, etodolac (Lodine), mefanamic acid, sulindac, apazone, pyrazolones (such as phenylbutazone), salicylates (such as aspirin); sélective COX2 inhibitors such as: celecoxib, rofecoxib, etoricoxib, valdecoxib, meloxicam;
Immunomodulatory and/ or anti-inflammatory agents, including but not limited to, methotrexate, leflunomide, ciclesonide chloroquine, hydroxychloroquine, d-penicillamine, auranofin, sulfasalazine, sodium aurothiomalate, cyclosporine, azathioprine, cromolyn, hydroxycarbamide, retinoids, fumarates (such as monomethyl and dimethyl fumarate), glatiramer acetate, mitoxantrone, teriflunomide, suplatast tosilate, mycophenolate mofetil and cyclophosphamide, laquinimod, voclosporin, PUR-118, AMG 357, AMG 811, BCT197;
Antimalarials, including but not limited to, hydroxychloroquine (Plaquenil) and chloroquine (Aralen),cyclophosphamide (Cytoxan), methotrexate (Rheumatrex), azathioprine (Imuran), mesalamine (Asacol) and sulfasalazine (Azulfidine):
Antibiotics, including but not limited to, Flagyl or ciprofloxacin;
Anti-TNFa agents, including but not limited to, infliximab, adalimumab, certolizumab pegol, golimumab and etanercept;
Anti-CD20 agents, including but not limited to, rituximab, ocrelizumab, ofatumumab and PF-05280586;
Antidiarrheals, such as diphenoxylate (Lomotil) and loperamide (Imodium);
Bile acid binding agents, such as cholestyramine, alosetron (Lotronex) and ubiprostone (Amitiza);
Laxatives, such as Milk of Magnesia, polyethylene glycol (MiraLax), Dulcolax, Correctol and Senokot, and anticholinergics or antispasmodics such as dicyclomine (Bentyl);
T lymphocyte activation inhibitors, including but not limited to, abatacept:
Anti-IL1 treatments, including but not limited to, anakinra, rilonacept, canakinumab, gevokizumab, MABp! and MEDI-8968;
Glucocorticoid receptor modulators that may be dosed orally, by inhalation, by injection, topically, rectally, by ocular delivery, including but not limited to, betamethasone, prednisone, 5 hydrocortisone, prednisolone, flunisolide, triamcinoline acetonide, beclomethasone, dipropionate, budesonide, fluticasone propionate, ciclesonide, mometasone furoate, fluocinonide, desoximetasone, méthylprednisolone or PF-04171327;
Aminosalicyic acid dérivatives, including but not limited to, sulfasalazine and mesalazine;
Anti-cc4 integrin agents, including but not limited to, natalizumab;
ai- or a2-adrenergic agonist agents including but not limited to: propylhexidrine, phenylephrine, phenylpropanolamine, pseudoephedrine or naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride or ethylnorepinephrine hydrochloride;
β-adrenergic agonists, including but not limited to, metaproterenol, isoprotenerol, isoprénaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, botolterol mesylate, pirbuterol;
Anticholinergic agents, including but not limited to, ipratropium bromide, tiotropium bromide, oxitropium bromide, aclindinium bromide, glycopyrrolate, pirenzipine ortelenzepine;
Inhaled long acting beta-agonists, long acting muscarinic antagonists and long acting 20 corticosteroids, including but not limited, to those included in the following reference: Y.
Mushtaq, The COPD pipeline, Nat Rev Drug Discov, 2014, 13(4), 253-254.
http://dx.doi.Org/10.1038/nrd425;
Leukotriene pathway modulators, including but not limited to, 5-LO Inhibitors (such as zileuton), FLAP antagonists (such as veliflapon, fiboflapon), LTD4 antagonists (such as 25 montelukast, zafirlukast or pranlukast;
H1 receptor antagonists, including but not limited to, cetirizine, loratidine, desloratidine, fexofenadine, astemizole, azelastine or chlorpheniramine;
PDE4 inhibitors, including but not limited to, apremilast, roflumilast or AN2728;
Vitamin D receptor modulators, including but not limited to, paricalcitol;
Nrf2 pathway activators, including but not limited to, fumarates, sulfurophane and bardoxolone methyl;
Modulators of the RAR-related orphan receptor (ROR) family, in particular RORg;
Modulator and/ or antagonists of the chemokine receptors, including but not limited to, CCR2 antagonists (such as CCX140, BMS-741672, PF-4634817, CCX-872, NOX-E36),
CCR2/5 antagomsts (such as PF-4634817), CCR9 (such as vercirnon, CCX507), CCR1 modulators, CCR4 modulators, CCR5 modulators, CCR6 modulators, CXCR6 modulators, CXCR7 modulators) and CXCR2 modulators (such as danirixin, AZD5069);
Prostaglandins, including but not limited to, prostacyclin;
PDE5 inhibitors, including but not limited to, sildenafil, PF-489791, vardenafil and tadalafil;
Endothelin receptor antagonists, including but not limited to, bosentan, ambrisentan, sparsentan, atrasentan, zibotentan and macitentan;
Soluble guanylate cyclase activators, including but not limited to, riociguat;
Interferons, including but not limited to, interferon beta-1a interferon beta-1b;
Sphingosine 1-phosphate receptor modulators, including but not limited to, fingolimod, ponesimod;
Inhibitors of the complément pathway, including but not limited to, C5aR antagonists (such as CCX168, ΡΜΧ-53, NN8210), C5 inhibitors (such as eculizumab), inhibitors of complément factors B and D, inhibitors of MASP2 (such as OMS-721) and ARC-1905;
Inhibitors of Janus kinases (one of more of JAK1, JAK2, JAK3, TYK2), including but not limited to, decernotinib, cerdulatinib, JTE-052, ruxolitinib, tofacitnib, Baricitinib, Peficitinib, GLPG-0634, INCB-47986, INCB-039110, PF-04965842, XL-019, ABT-494, R-348, GSK2586184, AC-410, BMS-911543 and PF-06263276;
Inhibitors of other anti-inflammatory or immunomodulatory kinases, including but not limited to, spleen tyrosine kinase (SYK) inhibitors, p38 MAP kinase inhibitors (such as PF3715455, PH-797804, AZD-7624, AKP-001, UR-13870, FX-005, semapimod, pexmetinib, ARRY-797, RV-568, dilmapimod, ralimetinib), PI3K inhibitors (such as GSK-2126458, pilaralisib, GSK-2269557), PI3Kg and/ or PI3Kd inhibitors (such as CAL-101/GS-1101, duvelisib), JNK inhibitors, ERK1 and/ or 2 inhibitors, IKKb inhibitors, BTK inhibitors, ITK inhibitors, ASK1 inhibitors (such as GS-4997), PKC inhibitors (such as sotrastaurin), TrkA antagonists (such as CT-327), MEK1 inhibitors (such as E6201);
Antioxidants, including but not limited to, myeloperoxidase inhibitors (such as AZD3241), ΝΟΧ4 and other ΝΟΧ enzymes (such as GKT-137831) and N-acetyl cysteine;
Inhibitors of IL5, including but not limited to, mepolizumab, reslizumab and benralizumab;
Inhibitors of IL4, including but not limited to, pascolizumab, altrakincept and pitrakinra;
Inhibitors of IL13, including but not limited to, tralokinumab, anrukinzumab and lebrikizumab;
Anti-IL6 agents, including but not limited to, tocilizumab, olokizumab, siltuximab, PF4236921 and sirukumab;
Inhibitors/Antagonists of IL17/IL17R, including but not limited to, secukinumab, RG7624, brodalumab and ixekizumab;
Antagonists of IL12 and/or IL23, including but not limited to, tildrakizumab, guselkumab,
MEDI2070 and AMG 139;
Inhibitors of IL33, including but not limited to, AMG 282;
Inhibitors of IL9, including but not limited to, MEDI-528;
Inhibitors of GM-CSF, including but not limited to, MT203;
Anti CD4 agents, including but not limited to, tregalizumab and rigerimod;
CRTH2 antagonists, including but not limited to, AZD-1981;
Inhibitors of B lymphocyte stimulator (BLYS; also known as BAFF), a protein that is often increased in patients with SLE, including but not limited to, belimumab, tabalumab, blisibimod, and atacicept;
CD22-specific monoclonal antibodies, including but not limited to, epratuzumab;
Inhibitors of interferon-α, including but not limited to, sifalimumab and rontalizumab; Inhibitor of type I interferon receptors, including but not limited to, MEDI-546;
FcyRIIB agonists, including but not limited to, SM-101;
Modified and/or recombinant versions of Heat Shock Protein 10 (Hsp10, also known as 20 Chaperonin 10 or EPF), including but not limited to, INV-103;
Inhibitors of the TNF superfamily receptor 12A (TWEAK receptor), including but not limited to, BIIB-023, enavatuzumab, and RG-7212;
Inhibitors of xanthine oxidase, including but not limited to, allopurinol, benzbromarone, febuxostat, topiroxostat, tisopurine and inositols;
Inhibitors of URAT1 (also known as SLC22A12), including but not limited to, lesinurad,
RDEA 3170, UR1102 and levotofispam;
Additional treatments for goût and/ or lowering of uric acid levels, including but not limited to, colchicines, pegloticase, benziodarone, isobrominidione, BCX4208 and arhalofenate;
Inhibitors of toll-like receptors (TLRs), including but not limited to, one or more of TLR7, 30 TLR8, TLR9 (such as IMO-8400, IMO-3100, DV-1179), TLR2 and/ or TLR 4 (such as VB-201, OPN-305);
Agonists of TLRs, including but not limited to, TLR7 (such as GSK2245035, AZD8848), TLR9 (such as AZD1419);
Activators S1RT1, including but not limited to, SRT2104;
A3 receptor agonists, including but not limited to, CF101 ;
Other agents of use of the treatment of psoriasis, including but not limited to, IDP-118, LAS41004, LEO 80185, LEO 90100, PH-10, WBI-1001, CNT01959, BT-061, cimzîa, ustekinumab, MK-3222/SCH 900222, ACT-128800, AEB071, alitretinoin, ASP015K, Apo805K1, BMS-582949, FP187, hectoral (doxercalciferol), LEO 22811, Ly3009104 (INCB28050), 5 calcipotriene foam (STF 115469), tofacitinib (CP-690,550), M518101 and CycloPsorb™;
Antifibrotic agents, including but not limited to: pirfenidone, inhibitors of LOXL2 (such as Simtuzumab), FT-011, modulators of epiregulin and/ or TGFa (such as LY-3016859), modulators of TGFp (such as LY-2382770, fresolimumab);
Prolyl hydroxylase inhibitors, including but not limited to, GSK1278863, FG-2216, ASP10 1517/FG-4592, AKB-6548, JTZ-951, BAY-85-3934 and DS-1093;
Inhibitors of granulocyte macrophage colony-stimulating factor, including but not limited to, GSK3196165 (MOR103), PD-0360324 and mavrilimumab;
Inhibitors of MAdCAM and/ or α4β7 integrin, including but not limited to, PF-00547659 and MEDI7183 (abrilumab);
Inhibitors of connective tissue growth factor (CTGF), including but not limited to, PF06473871; Inhibitors of cathepsin C, including but not limited to, GSK2793660;
Inhibitors of soluble epoxide hydrolase, including but not limited to, GSK2269557;
Inhibitors of the TNFR1 associated death domain protein, including but not limited to, GSK2862277;
Anti-CD19 agents, including but not limited to, MEDI-551 and AMG 729;
Anti-B7RP1 agents/ inhibitors of ICOS ligand, including but not limited to, MEDI5872 and AMG-557;
Inhibitors of thymie stromal lymphoprotein, including but not limited to, AMG157;
Inhibitors of IL2, including but not limited to, daclizumab;
Inhibitors of Leucine rich repeat neuronal protein 6A, including but not limited to, AntiLingo (Biogen);
Inhibitors of integrins, including but not limited to, alpha-V/beta-6 (STX-100) and alphaV/beta-3 (VPI-2690B);
Anti-CD40L agents, including but not limited to, CDP-7657;
Modulators of the dopamine D3 receptor, including but not limited to, ABT-614;
Inhibitors and/ or modulators of galectin-3, including but not limited to, GCS-100 and GR-MD-02;
Agents for treating diabetic nephropathy, including but not limited to, DA-9801 and ASP8232;
Agents for treating acute kidney injury, including but not limited to, THR-184, TRC160334, NX-001, EA-230, ABT-719, CMX-2043, BB-3 and MTP-131;
Modulators of inflammasomes, including but not limited to, inhibitors of NLRP3;
Modulators of bromodomains, including but not limited to, BRD4;
Modulators of GPR43; and
Inhibitors of TRP channels, including but not limited to, TRPA1, TRPC3, TRPC5, TRPC6 and TRPC6.
Additional therapeutic agents include anti-coagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, thrombolytic or fibrinolytic agents, anti-arrhythmic agents, anti-hypertensive agents, calcium channel blockers (L-type and T-type), cardiac glycosides, diuretics, mineralocorticoid receptor antagoniste, NO donating agents such as organonitrates, NO promoting agents such as phosphodiesterase inhibitors, cholesterol/lipid lowering agents and lipid profile thérapies, anti-diabetic agents, anti-depressants, antiinflammatory agents (stéroïdal and non-steroidal), anti-osteoporosis agents, hormone replacement thérapies, oral contraceptives, anti-obesity agents, anti-anxiety agents, antiproliférative agents, anti-tumor agents, anti-ulcer and gastroesophageal reflux disease agents, growth hormone and/or growth hormone secretagogues, thyroid mimetics (including thyroid hormone receptor antagonist), anti-infective agents, anti-viral agents, anti-bacterial agents, and anti-fungal agents.
Agents used in an ICU setting are included, for example, dobutamine, dopamine, epinephrine, nitroglycerin, nitroprusside, etc.
Combination agents useful for treating vasculitis are included, for example, azathioprine, cyclophosphamide, mycophenolate, mofetil, rituximab, etc.
In another embodiment, the présent invention provides a combination wherein the second agent is at least one agent selected from a factor Xa inhibitor, an anti-coagulant agent, an anti-platelet agent, a thrombin inhibiting agent, a thrombolytic agent, and a fibrinolytic agent. Exemplary factor Xa inhibitors include apixaban and rivaroxaban. Examples of suitable anticoagulants for use in combination with the compounds of the présent invention include heparins (e.g., unfractioned and low molecular weight heparins such as enoxaparin and dalteparin).
In another embodiment the second agent is at least one agent selected from warfarin, unfractionated heparin, low molecular weight heparin, synthetic pentasaccharide, hirudin, argatrobanas, aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, ticlopidine, clopidogrel, tirofiban, eptifibatide, abciximab, melagatran, disulfatohirudin, tissue plasminogen activator, modified tissue plasminogen activator, anistreplase, urokinase, and streptokinase.
In another embodiment, the agent is at least one anti-platelet agent. Especially preferred anti-platelet agents are aspirin and clopidogrel. The term anti-platelet agents (or platelet inhibitory agents), as used herein, dénotés agents that inhibit platelet function, for example by inhibiting the aggregation, adhesion or granular sécrétion of platelets. Agents 5 include, but are not limited to, the various known non-steroidal anti-inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, piroxicam, and pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) and COX-2 inhibitors such as celecoxib or piroxicam are preferred. Other suitable platelet inhibitory agents include llb/llla 10 antagonists (e.g., tirofiban, eptifibatide, and abciximab), thromboxane-A2-receptor antagonists (e.g., ifetroban), thromboxane-A2-synthetase inhibitors, PDE-III inhibitors (e.g., Pletal, dipyridamole), and pharmaceutically acceptable salts or prodrugs thereof.
The term anti-platelet agents (or platelet inhibitory agents), as used herein, is also intended to include ADP (adenosine diphosphate) receptor antagonists, preferably antagonists 15 of the purinergic receptors P2Y1 and P2Yl2> w'th P2Y12 being even more preferred. Preferred
P2Y12 receptor antagonists include ticagrelor, prasugrel, ticlopidine and clopidogrel, including pharmaceutically acceptable salts or prodrugs thereof. Clopidogrel is an even more preferred agent. Ticlopidine and clopidogrel are also preferred compounds since they are known to be gentle on the gastro-intestinal tract in use.
The term thrombin inhibitors (or anti-thrombin agents), as used herein, dénotés inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the granular sécrétion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the présent compounds. Such inhibitors include, but are not limited to, boroarginine dérivatives, boropeptides, heparins, hirudin, argatroban, and melagatran, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine dérivatives and boropeptides include N-acetyl and peptide dérivatives of boronic acid, such as C-terminal alpha-aminoboronic acid dérivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable dérivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. The term thrombolytics or fibrinolytic agents (or thrombolytics or fibrinolytics), as used herein, dénoté agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator (natural or recombinant) and modified forms thereof, anistreplase,
urokinase, streptokinase, tenecteplase (TNK), lanoteplase (nPA), factor VIla inhibitors, PAI-1 inhibitors (i.e., inactivators of tissue plasminogen activator inhibitors), alpha2-antiplasmin inhibitors, and anisoylated plasminogen streptokinase activator complex, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, 5 refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in EP 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to dénoté both dual and single chain urokinase, the latter also being referred to herein as prourokinase. Examples of suitable anti-arrythmic agents include: Class I agents (such as propafenone); Class II agents (such as metoprolol, atenolol, 10 carvadiol and propranolol); Class III agents (such as sotalol, dofetilide, amiodarone, azimilide and ibutilide); Class IV agents (such as ditiazem and verapamil); K+ channel openers such as lAch inhibitors, and l«ur inhibitors (e.g., compounds such as those disclosed in W001/40231).
The compounds of the présent invention may be used in combination with antihypertensive agents and such antihypertensive activity is readily determined by those skilled 15 in the art according to standard assays (e.g., blood pressure measurements). Examples of suitable anti-hypertensive agents include: alpha adrenergic blockers; beta adrenergic blockers; calcium channel blockers (e.g., diltiazem, verapamil, nifedipine and amlodipine); vasodilators (e.g., hydralazine), diruetics (e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, 20 polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, torsemide, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolactone); renin inhibitors; ACE inhibitors (e.g., captopril, zofenopril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, ramipril, lisinopril); AT-1 receptor antagonists (e.g., losartan, irbesartan, valsartan); ET receptor antagonists (e.g., sitaxsentan, atrsentan and compounds disclosed in U.S. Patent 25 Nos. 5,612,359 and 6,043,265); Dual ET/AII antagonist (e.g., compounds disclosed in WO 00/01389); neutral endopeptidase (NEP) inhibitors; vasopepsidase inhibitors (dual NEP-ACE inhibitors) (e.g., gemopatrilat and nitrates). An exemplary antianginal agent is ivabradine.
Examples of suitable calcium channel blockers (L-type or T-type) include diltiazem, verapamil, nifedipine and amlodipine and mybefradil. Examples of suitable cardiac glycosides 30 include digitalis and ouabain.
In one embodiment, a compound of the invention may be co-administered with one or more diuretics. Examples of suitable diuretics include (a) loop diuretics such as furosemide (such as LASIX™), torsemide (such as DEMADEX™), bemetanide (such as BUMEX™), and ethacrynic acid (such as EDECRIN™); (b) thiazide-type diuretics such as chlorothiazide (such
as DIURIL™, ESIDRIX™ or HYDRODIURIL™), hydrochlorothiazide (such as MICROZIDE™ or ORETIC™), benzthiazide, hydroflumethiazide (such as SALURON™), bendroflumethiazide, methychlorthiazide, polythiazide, trichlormethiazide, and indapamide (such as LOZOL™); (c) phthalimidine-type diuretics such as chlorthalidone (such as HYGROTON™), and metolazone (such as ZAROXOLYN™); (d) quinazoline-type diuretics such as quinethazone; and (e) potassium-sparing diuretics such as triamterene (such as DYRENIUM™), and amiloride (such as MIDAMOR™ or MODURETIC™). In another embodiment, a compound of the invention may be co-administered with a loop diuretic. In still another embodiment, the loop diuretic is selected from furosemide and torsemide. In still another embodiment, one or more compounds of the 10 invention may be co-administered with furosemide. In still another embodiment, one or more compounds of the invention may be co-administered with torsemide which may optionally be a controlled or modified release form of torsemide.
In another embodiment, a compound of the invention may be co-administered with a thiazide-type diuretic. In still another embodiment, the thiazide-type diuretic is selected from the 15 group consisting of chlorothiazide and hydrochlorothiazide. In still another embodiment, one or more compounds of the invention may be co-administered with chlorothiazide. In still another embodiment, one or more compounds of the invention may be co-administered with hydrochlorothiazide. In another embodiment, one or more compounds of the invention may be co-administered with a phthalimidine-type diuretic. In still another embodiment, the 20 phthalimidine-type diuretic is chlorthalidone.
Examples of suitable combination mineralocorticoid receptor antagonists include sprionolactone and eplerenone. Examples of suitable combination phosphodiesterase inhibitors include: PDE III inhibitors (such as cilostazol); and PDE V inhibitors (such as sildenafil).
The compounds of the présent invention may be used in combination with cholestérol modulating agents (including cholestérol lowering agents) such as a lipase inhibitor, an HMGCoA reductase inhibitor, an HMG-CoA synthase inhibitor, an HMG-CoA reductase gene expression inhibitor, an HMG-CoA synthase gene expression inhibitor, an MTP/Apo B sécrétion inhibitor, a CETP inhibitor, a bile acid absorption inhibitor, a cholestérol absorption inhibitor, a cholestérol synthesis inhibitor, a squalene synthetase inhibitor, a squalene epoxidase inhibitor, a squalene cyclase inhibitor, a combined squalene epoxidase/squalene cyclase inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid séquestrant or an agent such as mipomersen..
Examples of suitable cholesterol/lipid lowering agents and lipid profile thérapies include: HMG-CoA reductase inhibitors (e.g., pravastatin, lovastatin, atorvastatin, simvastatin, 35 fluvastatin, NK-104 (a.k.a. itavastatin, or nisvastatin or nisbastatin) and ZD-4522 (a.k.a.
rosuvastatin, or atavastatin or visastatin)); squalene synthetase inhibitors; fibrates; bile acid séquestrants (such as questran); ACAT inhibitors; MTP inhibitors; lipooxygenase inhibitors; cholestérol absorption inhibitors; and cholesteryl ester transfer protein inhibitors.
Anti-inflammatory agents also include sPLA2 and lpPLA2 inhibitors (such as darapladib), 5 LO inhibitors (such as atrelueton) and IL-1 and IL-1 r antagonists (such as canakinumab).
Other atherosclerotic agents include agents that modulate the action of PCSK9, for example, called bococizumab.
Cardiovascular complications of type 2 diabètes are associated with deleterious levels of MPO, accordingly, the compounds of the présent invention may be used in combination with anti-diabetic agents, particularly type 2 anti-diabetic agents. Examples of suitable anti-diabetic agents include (e.g. insulins, metfomin, DPPIV inhibitors, GLP-1 agonists, analogues and mimetics, SGLT1 and SGLT2 inhibitors) Suitable anti-diabetic agents include an acetyl-CoA carboxylase- (ACC) inhibitor such as those described in WO2009144554, W02003072197, W02009144555 and W02008065508, a diacylglycérol O-acyltransferase 1 (DGAT-1) inhibitor, such as those described in W009016462 or WO2010086820, AZD7687 or LCQ908, diacylglycérol O-acyltransferase 2 (DGAT-2) inhibitor, monoacylglycerol O-acyltransferase inhibitors, a phosphodiesterase (PDE)-10 inhibitor, an AMPK activator, a sulfonylurea (e.g., acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, and tolbutamide), a meglitinide, an aamylase inhibitor (e.g., tendamistat, trestatin and AL-3688), an α-glucoside hydrolase inhibitor (e.g., acarbose), an α-glucosidase inhibitor (e.g., adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, and salbostatin), a PPARy agonist (e.g., balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone and rosiglitazone), a PPAR α/γ agonist (e.g., CLX-0940, GW-1536, GW-1929, GW-2433, KRP-297, L-796449, LR-90, MK-0767 and SB-219994), a biguanide (e.g., metformin), a glucagon-like peptide 1 (GLP-1) modulator such as an agonist (e.g., exendin-3 and exendin-4), liraglutide, albiglutide, exenatide (Byetta®), albiglutide, lixisenatide, dulaglutide, semaglutide, NN-9924,TTP-054, a protein tyrosine phosphatase-1 B (PTP-1B) inhibitor (e.g., trodusquemine, hyrtiosal extract, and compounds disclosed by Zhang, S., et al., Drug Discovery Today, 12(9/10), 373-381 (2007)), SIRT-1 inhibitor (e.g., resveratrol, GSK2245840 or GSK184072), a dipeptidyl peptidease IV (DPP-IV) inhibitor (e.g., those in W02005116014, sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin and saxagliptin), an insulin secreatagogue, a fatty acid oxidation inhibitor, an A2 antagonist, a cjun amino-terminal kinase (JNK) inhibitor, glucokinase activators (GKa) such as those described in WO2010103437, WO2010103438, W02010013161, W02007122482, TTP-399, TTP-355, TTP-547, AZD1656, ARRY403, MK-0599, TAK-329, AZD5658 or GKM-001, insulin, an insulin
mimetic, a glycogen phosphorylase inhibitor (e.g. GSK1362885), a VPAC2 receptor agonist, SGLT2 inhibitors, such as those described in E.C. Chao et al. Nature Reviews Drug Discovery
9, 551-559 (July 2010) including dapagliflozin, canagliflozin, empagliflozin, tofogliflozin (CSG452), ASP-1941, THR1474, TS-071, ISIS388626 and LX4211 as well as those in
WO2010023594, a glucagon receptor modulator such as those described in Demong, D.E. et al.
Annual Reports in Médicinal Chemistry 2008, 43, 119-137, GPR119 modulators, particularly agonists, such as those described in W02010140092, WO2010128425, W02010128414,
WO2010106457, Jones, R.M. et al. in Médicinal Chemistry 2009, 44, 149-170 (e.g. MBX-2982, GSK1292263, APD597 and PSN821), FGF21 dérivatives or analogs such as those described in 10 Kharitonenkov, A. et al. et al., Current Opinion in Investigational Drugs 2009, 10(4)359-364,
TGR5 (also termed GPBAR1) receptor modulators, particularly agonists, such as those described in Zhong, M., Current Topics in Médicinal Chemistry, 2010, 10(4), 386-396 and INT777, GPR40 agonists, such as those described in Médina, J.C., Annual Reports in Médicinal Chemistry, 2008, 43, 75-85, including but not limited to TAK-875, GPR120 modulators, 15 particularly agonists, high affinity nicotinic acid receptor (HM74A) activators, and SGLT1 inhibitors, such as GSK1614235. A further représentative listing of anti-diabetic agents that can be combined with the compounds of the présent invention can be found, for example, at page 28, line 35 through page 30, line 19 of WO2011005611. Preferred anti-diabetic agents are metformin and DPP-IV inhibitors (e.g., sitagliptin, vildagliptin, alogliptin, dutogliptin, linagliptin 20 and saxagliptin). Other antidiabetic agents could include inhibitors or modulators of carnitine palmitoyl transferase enzymes, inhibitors of fructose 1,6-diphosphatase, inhibitors of aldose reductase, mineralocorticoid receptor inhibitors, inhibitors of TORC2, inhibitors of CCR2 and/or CCR5, inhibitors of PKC isoforms (e.g. PKCa, PKCp, PKCy), inhibitors of fatty acid synthetase, inhibitors of serine palmitoyl transferase, modulators of GPR81, GPR39, GPR43, GPR41, 25 GPR105, Kv1.3, retinol binding protein 4, glucocorticoid receptor, somatostain receptors (e.g.
SSTR1, SSTR2, SSTR3 and SSTR5), inhibitors or modulators of PDHK2 or PDHK4, inhibitors of MAP4K4, modulators of IL1 family including ILIbeta, modulators of RXRalpha. In addition suitable anti-diabetic agents include mechanisms listed by Carpino, P.A., Goodwin, B. Expert Opin. Ther. Pat, 2010, 20(12), 1627-51.
Those skilled in the art will recognize that the compounds of this invention may also be used in conjunction with other cardiovascular or cerebrovascular treatments including PCI, stenting, drug eluting stents, stem cell therapy and medical devices such as implanted pacemakers, defibrillators, or cardiac resynchronization therapy.
The compounds of the présent invention may be used in combination with neuroinflammatory and neurodegenerative agents in mammals. Examples of additional neuroinflammatory and neurodegenerative agents include antidepressants, antipsychotics, antipain agents, anti-Alzheimer’s agents, and anti-anxiety agents. Examples of particular classes of 5 antidepressants that can be used in combination with the compounds of the invention include norepinephrine reuptake inhibitors, sélective serotonin reuptake inhibitors (SSRIs), NK-1 receptor antagonists, monoamine oxidase inhibitors (MAOIs), réversible inhibitors of monoamine oxidase (RIMAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), corticotropin releasing factor (CRF) antagonists, and atypical antidepressants. Suitable norepinephrine reuptake inhibitors include tertiary amine tricyclics and secondary amine tricyclics. Examples of suitable tertiary amine tricyclics and secondary amine tricyclics include amitriptyline, clomipramine, doxepin, imipramine, trimipramine, dothiepin, butriptyline, nortriptyline, protriptyline, amoxapine, desipramine and maprotiline. Examples of suitable SSRIs include fluoxetine, fluvoxamine, paroxetine, and sertraline. Examples of monoamine oxidase inhibitors include isocarboxazid, phenelzine, and tranylcyclopramine. Examples of suitable réversible inhibitors of monoamine oxidase include moclobemide. Examples of suitable SNRIs of use in the présent invention include venlafaxine. Examples of suitable atypical antidepressants include bupropion, lithium, trazodone and viloxazine. Examples of anti-Alzheimer’s agents include NMDA receptor antagonists such as memantine; and cholinestérase inhibitors such as donepezil and galantamine. Examples of suitable classes of anti-anxiety agents that can be used in combination with the compounds of the invention include benzodiazépines and serotonin 1A receptor (5-HT1A) agonists, and CRF antagonists. Suitable benzodiazépines include alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, lorazépam, oxazepam, and prazepam. Suitable 5-HT1A receptor agonists include buspirone and ipsapirone. Suitable CRF antagonists include verucerfont. Suitable atypical antipsychotics include paliperidone, ziprasidone, rispéridone, aripiprazole, olanzapine, and quetiapine. Suitable nicotine acétylcholine agonists include CP-601927 and varenicline. Anti-pain agents include pregabalin, gabapentin, clonidine, neostigmine, baclofen, midazolam, ketamine and ziconotide.
The présent invention further comprises kits that are suitable for use in performing the methods of treatment described above. In one embodiment, the kit contains a first dosage form comprising one or more of the compounds of the présent invention and a container for the dosage, in quantifies sufficient to carry out the methods of the présent invention.
In another embodiment, the kit of the présent invention comprises one or more 35 compounds of the invention.
The présent invention further comprises intermediate compounds useful in the synthesis ofthe compounds ofthe invention, including salts and/or tautomers thereof.
General Synthetic Schemes
The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of 10 Organic Synthetic Methods, Vol. I-XII (published by Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
During any ofthe following synthetic sequences it may be necessary and/or désirable to protect sensitive or reactive groups on any of the molécules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, 15 Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M.
Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
Compounds of Formula I, or their pharmaceutically acceptable salts, can be prepared 20 according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of 25 représentation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended daims. Additionally, one skilled in the art will recognize that in many cases, these compounds will be mixtures and enantiomers that may be separated at various stages of the synthetic schemes using conventional techniques, such as, but not limited to, crystallization, 30 normal-phase chromatography, reversed phase chromatography and chiral chromatography, to afford single enantiomers. The schemes are représentative of methods useful in synthesizing the compounds ofthe présent invention. They are notto constrain the scope ofthe invention in any way.
Scheme 1
Further | |
steps n | (R8)y ? zk A |
R1 x | |
(optional) R®x | -4 o ^<X>'(R8)y |
Scheme 1 illustrâtes a method for preparing compounds of Formula la. A compound of Formula A, in which Lv is a displaceable leaving group (such as chloro or fluoro, for example) is treated with a compound of Formula B (for example, see Scheme 9, or as commercially available) to furnish a product of Formula la. The reaction is typically carried out in the presence of a suitable base such as césium carbonate, potassium tert-butoxide, sodium hydride or potassium hexamethyldisilazide in a suitable solvent or solvent mixture, such as THF or dimethylformamide. The compounds of Formula A may be prepared as described in the subséquent schemes. The compounds of formula R2-OH may be obtained from commercial vendors, or prepared by methods reported in the chemical literature, or may be prepared as described in the subséquent schemes.
If desired, further transformations may be effected upon the compound of Formula la. For example, the compound of Formula la wherein R6 = CN may be subjected to a nitrile hydrolysis reaction to provide a compound of Formula la in which R6 = CONH2. The reaction may be carried out in a variety of ways known to one skilled in the art, for example by the use of acids or bases, optionally in the presence of an oxidant such as hydrogen peroxide, or by using chemical or enzymatic catalysts. In other cases, the compound of Formula la may be further treated with reagents, such as acids, to cleave protecting groups, such as tbutoxycarbonyl groups, and/or with other reagents to derivatize functional groups such as carboxyl, amino, or hydroxyl groups.
B
Scheme 2
la
Further steps (optional)
Scheme 2 illustrâtes another method for the préparation of compounds of Formula la, particularly suited to those instances in which X and Y in the compound of Formula A are both carbon. This method provides for the alkylation of a compound of Formula A with a compound
of Formula B (wherein the R120- group is either hydroxyl or a sulfonate ester such as ptoluenesulfonate or methanesulfonate; for example, see Scheme 9, or as commercially available), using methods known to those skilled in the art, to furnish a product of Formula la. For example, this reaction may be carried out by treating a compound of Formula A with a 5 compound of Formula B (R12 = H) in the presence of triphenylphosphine and an azodicarboxylate ester (“Mitsunobu reaction”) in a suitable solvent such as THF. Alternatively, the alkylation of a compound of Formula A may be effected using a compound of Formula B (R120 = TsO or other sulfonate ester) in the presence of a base such as césium carbonate, in a suitable solvent such as THF or dimethylformamide.
If desired, further transformations may be effected upon the compound of Formula la.
For example, the compound of Formula la wherein R6 = CN may be subjected to a nitrile hydrolysis reaction to provide a compound of Formula la in which R6 = CONH2. The reaction may be carried out in variety of ways known to one skilled in the art, for example by the use of acids or bases, optionally in the presence of an oxidant such as hydrogen peroxide, or by using chemical or enzymatic catalysts. In other cases, the compound of Formula la may be further treated with reagents, such as acids, to cleave protecting groups, such as tbutoxycarbonyl groups, and/or with other reagents to derivatize functional groups such as carboxyl, amino, or hydroxyl groups.
Scheme 3
Scheme 3 illustrâtes a method for the préparation of compounds of Formula A, wherein Y = N and X = CH, as illustrated above. An acid of Formula Ci is treated with an alkylating agent, for example, iodomethane (R1 = methyl), and a base, such as K2CO3, in a suitable solvent such as DMF. The resulting ester of Formula Cii is then reduced to a compound of Formula Ciii by treatment with a suitable reducing agent, such as NaBH4, in a solvent such as THF. The alcohol of Formula Ciii is oxidized to an aldéhyde of Formula Civ using methods known to those skilled in the art, such as treatment with pyridinium chlorochromate or 10 manganèse dioxide. The isoquinoline ring is formed from the aldéhyde of Formula Civ by reaction with an aminoacetaldehyde acetal followed by treatment with boron trifluoride etherate, as described in Synthetic Communications 1999, 29 (9), p. 1617. The resulting isoquinoline of Formula Cv is cyanated, using methods known to those skilled in the art, such as treatment with copper(l) cyanide in a solvent such as DMF or pyridine, to afford a nitrile of 15 Formula Cvi. Oxidation with a suitable oxidizing agent, such as hydrogen peroxide or a peracid such as m-chloroperbenzoic acid or peracetic acid, yields an isoquinoline N-oxide of Formula Cvii. This may be halogenated by methods known to those skilled in the art, frequently by treatment with phosphorus oxychloride with or without an additional solvent, to afford the intermediate of Formula A ( Lv = Cl).
Scheme 4
N
Scheme 4 illustrâtes a method for the préparation of compounds of Formula A wherein and X = CH. An aldéhyde of Formula Cviii is treated with an alkylating agent, for
Y = example, 2-bromopropane (R1 = isopropyl), and a base such as K2CO3 in a suitable solvent such as DMF or DMSO. The aldéhyde of Formula Cix is then subjected to Knoevenagel condensation with malonic acid, typically in the presence of pyridine and piperidine, to afford an acid of Formula Cx. The acid may be converted to an acyl azide of Formula Cxi by a variety of means known to one skilled in the art, for example by sequential treatment with a chloroformate ester followed by reaction with sodium azide. Upon exposure to heat, the acyl azide may undergo Curtius reaction to ultimately afford a compound of Formula Cxii. The Curtius reaction may be effected in a suitable solvent, for example diphenyl ether, at a température typically in excess of 200 °C. The compound of Formula Cxii is cyanated, using methods known to those skilled in the art, such as treatment with zinc cyanide under palladium catalysis, to afford a compound of Formula Cxiii. This may be halogenated by methods known to those skilled in the art, frequently by treatment with phosphorus oxychloride with or without an additional solvent, to afford the intermediate of Formula A (Y = N, X = CH, Lv = Cl).
Scheme 5 illustrâtes a method for the préparation of compounds of Formula A wherein
X and Y = N. An ester of Formula Cxiv is nitrated with nitric acid to afford a compound of
Formula Cxv, which may then be reduced to an amine of Formula Cxvi by methods known to those skilled in the art, for example by treatment with tin(ll) chloride in acid solution. Subséquent treatment with formamide or similar reagents may be used to effect formation of a quinazolinone of Formula Cxvii. The resulting quinazolinone of Formula Cxvii is cyanated, 10 using methods known to those skilled in the art, such as treatment with zinc cyanide and a palladium catalyst such as tetra(kis)triphenylphosphine palladium(O), in a solvent such as THF to afford a nitrile of Formula Cxviii. This may be halogenated by methods known to those skilled in the art, frequently by treatment with phosphorus oxychloride with or without an additional solvent, to afford the intermediate of Formula A (Lv = Cl).
Scheme 6
Cxxii Cxxiii
Cxxiv
Scheme 6 illustrâtes a method for the préparation of compounds of Formula A. A nitrobenzoate ester of Formula Cxix is reduced by methods known to those skilled in the art, for example by hydrogen in the presence of a palladium catalyst in a solvent such as éthanol, to an amine of Formula Cxx. This amine is condensed with a malonic acid dérivative such as Meldrum’s acid in the presence of a trialkyl orthoformate, such as triethyl orthoformate, in a 10 suitable solvent such as éthanol to afford a compound of Formula Cxxi. Thermal cyclization is effected by heating a compound of Formula Cxxi to a température typically in excess of 200 °C, and typically in a solvent such as diphenyl ether or Dowtherm A, to afford a quinolone of Formula Cxxii, in some cases accompanied by the regioisomer of Formula Cxxiii. Séparation of these isomers may be accomplished by sélective saponification with an alkali, for example 15 lithium hydroxide, in a solvent such as aqueous THF to afford the desired quinolone of Formula Cxxiv. This compound may be halogenated by methods known to those skilled in the art, frequently by treatment with phosphorus oxychloride with or without an additional solvent. The carboxylic acid may then be converted to the carboxamide by methods known to those skilled in the art; for example, by treatment with an excess of ammonia in a reaction 20 compatible solvent such as 1,4-dioxane affords the intermediate of Formula A.
Scheme 7
OH | OH hoY^A | |
HO. | ιΎί | |
HCkJ | ||
0 | OMe | |
Cxxv | Cxxvi |
Cxxvii
Cxxviii
OH
OH
Cxxix
Cxxx A
Scheme 7 illustrâtes a method for the préparation of compounds of Formula A wherein X and Y are both carbon. A naphthol of Formula Cxxv may be subjected to Fischer estérification to afford a compound of Formula Cxxvi. The distal hydroxyl group may be masked using a suitable protecting group (PG), for example, by forming a silyl ether using standard conditions known to one skilled in the art, for example with t-butyldiphenylsilyl chloride and imidazole, in a suitable solvent such as 1,2-dichloroethane, to provide a compound of Formula Cxxvii. Alkylation of the proximal hydroxyl group may be carried out 10 with an alcohol R1-OH in the presence of triphenylphosphine and an azodicarboxylate ester (“Mitsunobu reaction”) in a suitable solvent such as THF to furnish a compound of Formula Cxxviii, which may be saponified by an alkali to afford a compound of Formula Cxxix. Conversion to the primary amide may be accomplished using standard methods known to one skilled in the art, for example by way of conversion to an acyl chloride using a reagent such as 15 oxalyl chloride to afford a compound of Formula Cxxx, which may be converted to the primary amide of Formula A, by methods known to those skilled in the art; for example, by exposure to an excess of ammonia, typically in the presence of a suitable solvent such as THF, water, or a mixture of solvents.
Scheme 8
A
Scheme 8 illustrâtes a method for the préparation of additional compounds of Formula
A. In this method, a compound of Formula A is dealkylated to remove the R1 alkyl group to afford a compound of Formula Ai. Dealkylation may be effected by standard methods known to one skilled in the art, for example by the use of anhydrous aluminum chloride or boron tribromide in a solvent such as DCM, and may be most advantageously effected when R6 = CN. Subséquent alkylation of the OH group may be effected to install a new R1 group to afford a new compound of Formula A, using methods known to one skilled in the art, for example by 10 treatment with an alcohol R1-OH in the presence of triphenylphosphine and an azodicarboxylate ester (“Mitsunobu reaction”) in a suitable solvent such as THF, or by treatment with an alkylating agent such as an alkyl chloride, bromide, or iodide (R1-CI, R1-Br, or R1-l) and a base such as Κ2ΟΟ3ίη a suitable solvent such as THF or DMF.
Scheme 9
O
Cxxxii
Scheme 9 illustrâtes a method for the préparation of certain compounds of Formula B of the 20 type R2-OH as employed in Schemes 1 and 2. Compounds of Formula Cxxxi are well known in the chemical literature, particularly those compounds in which Ra and Rb are both methyl, and in which Ra is (substituted)phenyl and Rb is H. In this method, the compound of Formula Cxxxi is treated with a suitable base, frequently lithium hexamethyldisilazide or lithium diisopropylamide, in a suitable solvent such as THF, ether, MTBE or 2-methylTHF using 25 conditions well-established in the chemical literature. The mixture may then be treated with an electrophile to install the electrophile Ei on the lactam ring. Suitable electrophiles are well known to those skilled in the art and include, but are not limited to, halogenating agents such as electrophilic halogen species, alkylating agents such as alkyl halides, carbonyl compounds such as aldéhydes, ketones, or esters, oxidizing agents such as molecular oxygen or sulfonyloxaziridines, aminating agents such as sulfonyl azides, and sulfur containing electrophiles such as disulfides, thiocyanates, sulfinates, and sulfonyl halides. The resulting substituted lactam of Formula Cxxxii may be subjected to this process a second time to install another electrophile on the lactam ring, designated in the scheme by E2. It will be recognized by one skilled in the art that the electrophiles Ei and E2 may themselves be subjected to further chemical transformations. It will also be recognized that the introduction of the electrophiles Ei and E2 may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. Finally, treatment with an acid is commonly used to remove the aminal protecting group containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized that the electrophiles Ei and E2 will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 10
Scheme 10 illustrâtes a method for the préparation of certain compounds of the type R2-OH as employed in Schemes 1 and 2. In this method, the compound of Formula Cxxxi is oxidized to the olefin compound of Formula Cxxxiv using methods that are known in the chemical literature. This is frequently accomplished by the élimination reaction of a sulfoxide or selenoxide, or it may be carried out by treatment with a suitable base such as lithium diisopropylamide and chlorotrimethylsilane followed by oxidation of the resulting silyl ketene aminal with a palladium sait and a carbonate ester of allyl alcohol, in a transformation known to one skilled in the art as the Saegusa -Tsuji oxidation. The olefin of Formula Cxxxiv may be converted to a compound of Formula Cxxxv using methods that are known in the chemical literature, frequently by treatement with an organometallic reagent such as methyllithium (Rc = methyl) or ethylmagnesium chloride (Rc = ethyl) in the presence of chlorotrimethylsilane and a
copper compound. The compound of Formula Cxxxv may then be treated with an electrophile, designated in Scheme 10 by Ei, to install the electrophile Ei on the lactam ring as described previously in Scheme 9. Likewise, the resulting compound of Formula Cxxxvi may be subjected to this process a second time to install another electrophile on the lactam ring, 5 designated in Scheme 10 by E2. It will be recognized by one skilled in the art that the electrophiles E1 and E2, and the Rc group, may themselves be subjected to further chemical transformations. It will also be recognized that the introduction of the Rc group and the electrophiles E1 and E2 may generate a mixture of stereoisomers, which may be separated into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is 10 commonly used to remove the aminal protecting group containing Ra and Rb to afford the R2OH compound of Formula B. It will also be recognized that the Rc group and the electrophiles
E1 and E2 will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 11
Cxxxiv
O
Cxxxviii
Scheme 11 illustrâtes a method for the préparation of certain compounds of the type
R2-OH as employed in Schemes 1 and 2. In this method, the olefin compound of Formula Cxxxiv is subjected to cyclopropanation using methods that are known in the chemical literature, frequently by treatment with an appropriately substituted sulfonium sait and a 20 suitable base. It will be recognized by one skilled in the art that the Ra and Re groups may be subjected to further chemical transformations. It will also be recognized that the introduction of the cyclopropane ring containing the Ra and Re groups may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is commonly used to remove the 25 aminal protecting group containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized that the cyclopropane ring containing the Rd and Re groups will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 12
Scheme 12 illustrâtes a method for the préparation of certain compounds of the type R2-OH as employed in Schemes 1 and 2. In this method, the olefin of Formula Cxxxix bearing suitable protecting groups PGi and PG2, wherein PG1 is, for example, a carbamate such as tbutyl carbamate and PG2, for example, is a trialkylsilyl such as TBDMS, may be converted to a compound of Formula Cx! using methods that are known in the chemical literature. This is frequently accomplished by treatment with an organometallic reagent such as methyllithium (Rc = methyl) or ethylmagnesium chloride (Rc = ethyl) in the presence of chlorotrimethylsilane 10 and a copper compound. The compound of Formula Cxl may then be treated with an electrophile (Et), to install the electrophile E1 on the lactam ring as described previously in Scheme 9. Likewise, the resulting compound of Formula Cxli may be subjected to this process a second time to install another electrophile (E2). It will be recognized by one skilled in the art that the electrophiles E1 and E2, and the Rc group, may themselves be subjected to further 15 chemical transformations. It will also be recognized that the introduction of the Rc group and the electrophiles E1 and E2 may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is commonly used to remove the aminal protecting group containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized that the Rc 20 group and the electrophiles E1 and E2 will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 13
O
Cxxxi
Scheme 13 illustrâtes a method for the préparation of certain compounds of the type R2-0H as employed in Schemes 1 and 2. In this method, the compound of Formula Cxxxi is treated with a suitable base, followed by an electrophile (E-ι), to install the electrophile Ei on 5 the lactam ring, as described previously in Scheme 9. The compound of Formula Cxliii is oxidized to an olefin compound of Formula Cxliv using methods that are known in the chemical literature, as described previously in Scheme 10. The olefin compound of Formula Cxliv is subjected to cyclopropanation, as described previously in Scheme 11. It will be recognized by one skilled in the art that the Ei, Rd and Re groups may be subjected to further 10 chemical transformations. It will also be recognized that the introduction of the cyclopropane ring containing the Ei, Rd and Re groups may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is commonly used to remove the aminal protecting group containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized 15 that the cyclopropane ring containing the E-ι, Rd and Re groups will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 14
Scheme 14 illustrâtes a method for the préparation of certain compounds of the type R2-OH as employed in Schemes 1 and 2. In this method, the olefin compound of Formula Cxxxi is converted to a compound of Formula Cxxxv using methods that are known in the chemical literature as described previously in Scheme 10. The compound of Formula Cxxxv is oxidized to an olefin compound of Formula Cxlvi using methods that are known in the chemical literature as described previously in Scheme 10. The olefin compound of Formula Cxxxv is subjected to cyclopropanation as described previously in Scheme 11. It will be recognized by one skilled in the art that the Rc, Rd and Re groups may be subjected to further chemical transformations. It will also be recognized that the introduction of the cyclopropane ring containing the Rc, Rd and Re groups may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is commonly used to remove the aminal protecting group containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized that the cyclopropane ring containing the Ro, Rd and Re groups will ultimately afford the substituents R4 in the compound of Formula la.
Scheme 15
Ο
Cxlviii
Scheme 15 illustrâtes a method for the préparation of certain compounds of the type
R2-OH as employed in Schemes 1 and 2. In this method, the olefin of Formula Cxxxi may be converted to a compound of Formula Cxlviii using methods that are known in the chemical literature, frequently by treatment with an olefin reagent such as ethylene or propylene under irradiation by ultraviolet light in a suitable solvent such as acetone. It will be recognized by one 10 skilled in the art that the Rf, Rg, Rh and R, groups may be subjected to further chemical transformations. It will also be recognized that the introduction of the cyclobutane ring containing the Rf, Rg, Rh and R, groups may generate a mixture of stereoisomers, which may be separated by known methods into discrète stereoisomerically pure compounds. As in Scheme 9, treatment with an acid is commonly used to remove the aminal protecting group 15 containing Ra and Rb to afford the R2-OH compound of Formula B. It will also be recognized that the cyclobutane ring containing the Rf, Rg, Rh and R, groups will ultimately afford the substituents R4 in the compound of Formula la.
Experimental Procedures and Workinq Examples
The following illustrate the synthesis of various compounds of the présent invention.
Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.
It will be understood that the intermediate compounds of the invention depicted above 25 are not limited to the particular enantiomer shown, but also include ail stereoisomers and mixtures thereof. It will also be understood that compounds of Formula la can include intermediates of compounds of Formula la.
Experimental Procedures
Expérimente were generally carried out under inert atmosphère (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate (generally Sure-Seal™ products from the Aldrich Chemical Company, Milwaukee, Wisconsin). Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic résonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed.
For synthèses referencing procedures in other Examples or Methods, reaction conditions (length of reaction and température) may vary. In general, reactions were followed by thin layer chromatography and / or liquid chromatography-mass spectrometry, and subjected to work-up when appropriate. It will be recognized by one skilled in the art that purifications may vary between experiments: in general, sorbents, solvents and the solvent ratios used for eluants/gradients were chosen to provide appropriate RfS or rétention times. It will also be recognized by one skilled in the art that HPLC purifications may be effected in a variety of ways, including the use of normal stationary phases, reverse stationary phases, chiral stationary phases, and supercritical eluants. The appropriate choices of conditions for chromatographie and HPLC purifications will be discerned by one skilled in the art.
The following Préparations describe the préparation of certain intermediates used in the Methods and Examples that follow. The following Préparations, Methods and Examples are intended to illustrate particular embodiments of the invention and préparations thereto and are not intended to limit the spécification, including the daims, in any manner. Unless noted otherwise, ali reactants were obtained commercially.
Unless indicated otherwise, the following abbreviations hâve the indicated meanings:
APCI - atmospheric pressure chemical ionization br. - broad peaks °C - degree Celsius
CDCI3 - deuterated chloroform
CD3OD- deuterated methanol d - doublet peak dd - double doublet peak
D2O - deuterium oxide dmso-de - perdeuterated dimethyl sulfoxide dt - double triplet peak g - gram(s)
H (e.g., 1 H, 2 H) - hydrogen(s) hr - hour(s)
LC - liquid chromatography m - multiplet
M - molarity mg - milligram(s)
MHz - mégahertz min - minute(s) mL - milliliter(s) mmol - millimole(s) mp - melting point
MS - mass spectrum
NMR - nuclear magnetic résonance pH - négative logarithm of hydronium ion concentration psi - pounds per square inch q - quartet peak s - singlet peak t - triplet peak td - triple doublet peak pL - microliter
Unless indicated otherwise, the following chemical formulas and acronyms hâve the indicated meanings:
AcOH - glacial acetic acid
BF3-Et2O - boron trifluoride etherate
BHT - 2,6-dit-t-butyl-4-methylphenol
CHCI3 - chloroform
DAST - (diethylamino)sulfur trifluoride
DCM - dichloromethane
DMAP - (4-dimethylamino)pyridine
DMF - dimethylformamide
DMSO - dimethylsulfoxide
EDCI - N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride
Et3N - triethylamine
EtOAc - ethyl acetate
EtOH - éthanol
HCl - hydrochloric acid
HNO3 - nitric acid
H2SO4 - sulfuric acid
H3PO4 - phosphoric acid
LDA- lithium diisopropylamide
MeCN - acetonitrile
MeOH - methanol
MgSCU - anhydrous magnésium sulfate
K2CO3 - potassium carbonate
K3PO4 - anhydrous tribasic potassium phosphate
KOH - potassium hydroxide
MTBE - methyl t-butyl ether
Na2CO3 - sodium carbonate
Na2SO4 - anhydrous sodium sulfate
NaBH4 - sodium borohydride
NaHCO3 - sodium bicarbonate
NaOH - sodium hydroxide
NFSI - N-fluoro(bisbenzenesulfonyl)imide, CAS 133745-75-2
NH4CI - ammonium chloride
POCI3 - phosphorus oxychloride
TFA - trifluoroacetic acid
THF - tetrahydrofuran
TMSCI - chlorotrimethylsilane
PREPARATIONS
Préparation 1:1-chloro-7-methoxvisoquinoline-6-carbonitrile (P1)
Step 1. Synthesis of methyl 4-iodo-3-methoxybenzoate (CAS 35387-92-9, C1).
To a solution of 3-hydroxy-4-iodobenzoic acid (CAS 58123-77-6, C12) (10800 g, 40.9 moles) in DMF (65 L) was added K2CO3 (25398 g, 184 moles), followed by the slow addition of dimethyl sulfate (11352 g, 90 moles). This mixture was heated to about 50 °C for over night. The reaction mixture was cooled to about 25 °C, diluted with EtOAc (50 L) and filtered through a plug of Celite®. The solid was thoroughly washed with EtOAc (10 L X 3). The combined EtOAc filtrâtes 10 were poured into water. After stirring for about 30 min, the EtOAc layer was separated and it was further washed sequentially with water, 1 M NaOH and brine. The EtOAc layer was separated, dried over Na2SO4, filtered and concentrated to provide the title compound C1. Yield: 11750 g (98%).
Step 2. Synthesis of (4-iodo-3-methoxyphenv0methanol (CAS 244257-61-2, C2),
To a solution of compound C1 (11750 g, 40.2 moles) in THF (35 L) was added NaBH4 (7645 g, 201.09 moles) and refluxed. While refluxing, MeOH (25 L) was slowly added into the reaction mixture at a rate of about 1 L per hour. After completion of the reaction, it was poured into a solution of cold dilute HCl. Once the excess of NaBH4 was quenched, the solution was filtered and extracted with EtOAc (2.5 L X 3). The combined EtOAc extracts were washed sequentially 20 with water, brine and dried over Na2SO4. The solvent was evaporated under reduced pressure and the resulting crude material was treated with MTBE. The resulting solid was filtered and filtrate was washed with water, brine, dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure to provide the title compound C2. Yield: 9900 g (93%). Step 3. Synthesis of 4-iodo-3-methoxybenzaldehvde (CAS 121404-83-9, C3).
To a solution of compound C2 (9900 g, 34.5 moles) in CHCI3 (186 L), was added manganèse dioxide (18000 g, 207 moles) and the resulting mixture was refluxed for about 16 h. The mixture was cooled to about 25 °C and filtered through a Celite pad, which was then washed thoroughly with CHCh. The CHCI3 was evaporated under reduced pressure to provide the title compound C3. Yield: 9330 g (95%). 1H NMR (400 MHz, CDCb): δ 9.95 (s, 1 H), 7.99 (d, 1 H), 7.14 (dd, 1
H), 3.95 (s, 3 H).
Step 3. Synthesis of 6-iodo-7-methoxyisoquinoline (CAS 244257-63-4, C4).
To a solution of compound C3 (9300 g, 35 moles) in toluene (60 L) was added amino acetaldehyde dimethyl acetal (5590 g, 53 moles) and the mixture was refluxed for about 4 h, while removing the liberated water by the use of a Dean - Stark water separator. The reaction 35 mixture was cooled to about 0 °C, after which trifluoroacetic anhydride (22305 g, 106 moles)
followed by BF3-Et2O (15080 g, 106 moles) were added, keeping internai température below 5 °C. The reaction mixture was stirred at about 25 °C for about 16 h and quenched by pouring into a mixture of ice and ammonium hydroxide. The product was extracted with EtOAc (10 L X 3), and the combined EtOAc extracts were washed sequentially with water and brine. The 5 combined EtOAc extracts were dried over Na2SO4, filtered, and concentrated to afford a dark tan colored residue. This was treated with a mixture of MTBE and hexane (1:1 v/v, 30 L), followed by 6 M HCl (9 L), with stirring. The precipitated solid was filtered and washed with MTBE. The solid was suspended in EtOAc (5 L) and made alkaline with ammonium hydroxide. The EtOAc layer was separated, washed with brine, dried over Na2SO4, filtered, and 10 concentrated to afford crude compound C4 as a brown solid. HPLC (230 nm) showed it to be about 83% pure.
The crude material (1000 g) was taken in AcOH (2.5 L) and stirred for about 90 min at about 25 °C. The solid was filtered and washed with AcOH (500 mL). The filtrate was neutralized with saturated aqueous Na2CO3 solution. The resulting precipitated solid was filtered, washed with water (4 L), and oven dried at about 70 - 75 °C for about 5 h to afford about 780 g of pure C4. Similarly, the remaining crude C4 (4 kg) was purified to provide the title compound C4. Yield: 4300 g (42%). 1H NMR (400 MHz, CDCIs): δ 9.15 (s, 1 H), 8.45 (d, 1 H), 8.35 (s, 1 H), 7.45 (d, 1 H), 7.15 (s, 1 H) 4.00 (s, 3 H).
Step 4. Synthesis of 7-methoxvisoquinoline-6-carbonitrile (C5).
To a solution of compound C4 (4300 g , 15 moles) in DMSO (39 L) was added copper(l) cyanide (2954 g, 33 moles) and the mixture was heated to about 120 °C for about 3 h. The reaction mixture was quenched by pouring into a mixture of ice and ammonium hydroxide (40 L) and filtered. The filtrate was extracted with EtOAc (10 L X 2). While stirring, the solid residue was again treated with ammonium hydroxide solution (10 L) and EtOAc (10 L). After filtration, the precipitated material was repeatedly washed with a mixture of MeOH and CHCI3 (1:9, v/v) several times and the combined extracts were washed with brine. The extracts were dried over
Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude material was triturated with hexane to provide the title compound C5. Yield: 2250 g (87%). 1H NMR (400 MHz, CDCIs): δ 9.25 (br. s, 1 H), 8.55 (br. s, 1 H), 8.15 (s, 1 H), 7.60 (d, 1 H), 7.30 (s, 1 H), 4.05 30 (s, 3 H).
Step 5. Synthesis of 7-methoxyisoquinoline-6-carbonitrile N-oxide (C6).
To a solution of compound C5 (500 g, 2.7 moles) in DCM (5 L) was slowly added 30% peracetic acid (413 g, 5.4 moles, 2 équivalents) at about 40 - 45 °C over about 4 h. The resulting mixture was stirred at same température for about 16 h. At this stage, 50% of starting material was
consumed, and for further conversion another 2 équivalents of peracetic acid was added. The reaction mixture was heated at about 40 - 45 °C and monitored by TLC. After approximately another 8 h, a trace of starting material still remained. An additional 0.5 équivalent of peracetic acid was added and the reaction was continued for about 5 h. The heterogeneous reaction 5 mass was cooled to about 25 °C and filtered. The resulting solid was washed with water (2 L X
3) and subsequently titurated with acetone (2 L). Upon drying, 250 g of compound C6 was obtained.
The DCM layer resulting from the filtration was washed with saturated aqueous NaHCC>3 solution (15 L). The resulting aqueous layer was back-extracted with DCM (1.5 L X 2) and the 10 combined DCM layers were washed with brine. Upon concentration, 150 g of compound C6 was obtained.
The acidic water layer from the original filtration was made alkaline with saturated aqueous Na2CC>3 solution (5 L) and extracted with DCM (1 L X 2). The DCM layer was dried over Na2SO4, filtered, and concentrated to give 30 g of compound C6. The batches of 15 compound C6 were combined to provide the title compound C6. Yield: 430 g (80%). 1H NMR (400 MHz, CDCb): δ 8.85 (br. s., 1 H), 8.05 - 8.18 (m, 2 H), 7.71 (d, 1 H), 7.12 (s, 1 H), 4.08 (s, 3 H).
Step 5. Synthesis of 1-chloro-7-methoxyisoquinoline-6-carbonitrile (P1),
To a suspension of compound C6 (700 g, 3.5 moles) in DCM (14 L) was added phosphoryl 20 chloride (333.5 ml_, 3.5 moles) dropwise over a period of about 1 h. After the addition was completed, the reaction mixture was a homogeneous solution and was stirred at about 25 °C overnight. After completion of the reaction, the mixture was poured into ice water (5 L) and the resulting solid was filtered. The solid was washed with saturated aqueous NaHCO3 solution (1 L X 2), followed by water. Upon drying, 360 g of compound P1 with 93% HPLC purity was 25 obtained.
The DCM layer resulting from the filtration was separated. The aqueous layer resulting from the filtration was extracted with DCM (1 L X 2). The combined DCM solutions were washed with saturated aqueous NaHCO3 solution, followed sequentially by water and brine. The DCM solution was dried over Na2SO4, filtered, and concentrated to provide 300 g of compound P1 30 with 75% HPLC purity. This material was taken in a mixture of AcOH (900 mL) and EtOAc (1200 mL) mixture, then heated to about 70 - 75 °C for about 30 min. The solid was filtered while the mixture was still hot (about 70 °C). The solid was further washed with EtOAc (300 mL), followed by hexane (350 mL) and dried to afford 200 g of compound P1 with 95% HPLC purity.
The P1 with 93% HPLC purity (360 g, 93%) was further purified by tituration with a mixture of EtOAc and MTBE (1:1, v/v) and filtered. Upon drying, 300 g of compound P1 was recovered. The batches of P1 were combined to provide the title compound P1. Yield: 500 g (65%). 1H
NMR (400 MHz, CDCI3): δ 8.30 (d, 1 H), 8.18 (s, 1 H), 7.65 (s, 1 H), 7.58 (d, 1 H), 7.15 (s, 3 H).
Préparation 2: 1-chloro-7-isopropoxyisoquinoline-6-carbonitrile (P2)
Step 1. Synthesis of 3-bromo-4-isopropoxvbenzaldehyde (CAS 191602-84-3, C7).
A mixture of 3-bromo-4-hydroxybenzaldehyde (1500 g, 7.5 mol) and K2CO3 (1290 g, 9.3 mol) in anhydrous DMSO (15 L) was treated with 2-bromopropane (1010 g, 8.2 mol) and stirred at about 55 °C for overnight. An additional 200 g (1.6 mol) of 2-bromopropane was added and the reaction was continued for approximately an additional 4 h. The reaction was cooled to about 30 °C and EtOAc (22.5 L) and water (22.5 L) were added. The EtOAc phase was separated and the aqueous phase was back - extracted with EtOAc (2 X 7.5 L). The combined EtOAc phases were washed with water (2 x 15 L) followed by brine (15 L), dried over Na2SO4, filtered, and concentrated to provide the title compound C7. Yield: 1800 g (99%). 1H NMR (400 MHz, CDCI3) δ 9.82 (s, 1 H), 8.07 - 8.08 (d, 1 H), 7.76 - 7.79 (d, 1 H), 6.98 (d, 1 H), 4.67 - 4.74 (m, 1 H), 1.42 -1.44 (d, 6H).
Step 2. Synthesis of (E)-3-(3-bromo-4-isopropoxyphenvl)acrvlic acid (CAS 1344851-82-6, C8).
Compound C7 (1800 g, 7.4 mol) in anhydrous pyridine (7.56 L) was treated with malonic acid (1002 g, 9.6 mmol) and piperidine (316 g, 3.7 mmol) and heated to reflux for about 2 h. The solvent was removed by distillation under reduced pressure. This was treated with cold water (37.8 L) and stirred for about 0.5 h, then acidified to adjust pH to about 4.0 with AcOH (about 300 mL). The suspension was vigorously stirred for about 1 hour to break up ail solids and then the product was collected by filtration, washed with water (3.6 L) and dried under vacuum to provide the title compound C8. Yield: 2014 g (95%). 1H NMR (400 MHz, dmso-d6) δ 7.94 - 7.95 (d, 1 H) 7.64 - 7.67 (dd, 1 H), 7.48 - 7.52 (d, 1 H), 7.14 - 7.16 (d, 1 H), 6.43 - 6.47 (d, 1 H), 4.71 4.77 (m, 1 H), 1.29-1.31 (d, 6 H).
Step 3. Synthesis of (E)-3-(3-bromo-4-isopropoxyphenvl)acryloyl azide (C9).
To a stirred solution of compound C8 (1000 g, 3.5 mol) in acetone (17.5 L), EtsN (355 g, 3.5 mol) was added and the mixture was cooled to about -5 °C. Ethyl chloroformate (495 g, 4.56 mol) was added dropwise, maintaining the température at about -5 °C. After completion of the
addition, the mixture was stirred for approximately an additional 1 h at about -5 °C. A solution of sodium azide (342 g, 5.3 mol) in water (1264 mL) was added slowly at about -5 °C. After the addition of sodium azide solution was complété, the reaction mixture was slowly warmed to about 25 °C and stirred for about 0.5 h. The reaction mass was quenched by addition to water (50 L) and stirring for about 30 minutes at about 25 °C. The precipitate was filtered, washed with water (2 L) and dried to provide the title compound C9. Yield: 978 g (90%). 1H NMR (300 MHz, dmso-de) δ 8.07 - 8.08 (d, 1 H), 7.74 - 7.77 (dd, 1 H), 7.60 (s, 1 H), 7.16 - 7.20 (d, 1 H), 6.60 6.66 (d, 1 H), 4.74 - 4.82 (m, 1 H), 1.29 - 1.32 (d, 6 H).
Step 4. Synthesis of 6-bromo-7-isopropoxyisoquinolin-1(2H)-one (C10).
To a mixture of diphenyl ether (8 L) and tri n-butyl amine (328 g, 1.77 mol) pre-heated to about 230 °C, compound C9 (550 g,1.77 mol) dissolved in diphenyl ether (2.5 L) was added while the température was maintained at about 230 °C. After the addition was completed, stirring and heating were continued for about 0.5 h. The reaction mixture was cooled to about 25 °C and added slowly to hexane (27.5 L). The resulting slurry was cooled to about 0 °C and stirred for about 0.5 h. The crude precipitate was filtered the precipitate was washed with cold hexane (5.5 L). The wet cake was dried under vacuum to afford 310 g of crude C10.
This reaction was repeated three more times to afford 1064 g of crude C10. This was dissolved in THF (5.3 L) at reflux and cooled to about 0 °C. The slurry was stirred for about 0.5 h and then filtered and the filter cake was dried under vacuum to afford 574 g of C10. The filtrate was 20 concentrated and purified by chromatography to afford an additional 181 g to provide the title compound C1Ô. Yield: 755 g (46%). 1H NMR (300 MHz, CDCI3) δ 8.24 - 8.26 (d, 1 H), 8.16 (s, 1 H), 7.65 (s, 1 H), 7.55 - 7.56 (d, 1 H), 4.85 - 4.91 (m, 1 H), 1.51-1.52 (d, 6 H).
Step 5. Synthesis of 7-isopropoxv-1-oxo-1,2-dihvdroisoquinoline-6-carbonitrile (C11).
Compound C10 (490 g, 1.74 mol) and zinc cyanide (265 g, 2.25 mol) were added to dry DMF 25 (9.8 L) and stirred well for about 5 min at 25 °C. The reaction mixture was degassed with nitrogen for about 20 minutes, after which tetra(kis)triphenylphosphinepalladium (0) (120 g, 0.104 mol) was added and the reaction mixture was stirred for about 5 min at about 25 °C before being heated to about 100 °C. The mixture was maintained for about 16 hours at about 100 °C. The reaction mixture was cooled to about 25 °C, diluted with EtOAc (4.9 L), and stirred 30 for about 0.5 h.The mixture was filtered through celite, which was washed with EtOAc (1 L). The combined filtrate was concentrated at at pressure of about 10 torr at about 75 °C. Water (4.9 L) was added to the residue and the mixture was stirred for about 0.5 h. The precipitate was filtered, washed with water (1 L) and dried under vacuum at about 60 °C. The precipitate was stirred for about 0.5 h with MTBE (4.9 L) and filtered. This process was repeated twice more,
after which the filter cake was washed with MTBE (0.5 L) and dried under vacuum at about 60 °C to provide the title compound C11. Yield: 390 g (98%) 1H NMR (400 MHz, CDCI3) δ 8.24 8.26 (d, 1 H), 8.16 (s, 1 H), 7.65 (s, 1 H), 7.54 - 7.56 (d, 1 H), 4.85 - 4.99 (m, 1 H), 1.51 - 1.52 (d, 6 H).
Step 6. Synthesis of 1-chloro-7-isopropoxvisoquinoline-6-carbonitrile (P2).
Compound C11 (390 g, 1.7 mol) and POCI3 (10.97 kg, 71.5 mol) were stirred for about 5 min at about 25 °C, then heated to about 100 °C and maintained at about 100 °C for about 0.5 h. The reaction mixture was cooled to about 25 °C and concentrated under reduced pressure at about 60 °C. The residue was quenched with ice (7.8 kg), then neutralized with 25% K2CO3 solution 10 (7.8 L) with stirring until the mixture was about pH = 7. The solution was extracted with DCM (3 x 5 L), and the combined extracts were washed with 10% NaHCO3 solution (2 x 3.9 L). The DCM was separated, dried over Na2SO4, filtered, and concentrated. n-Heptane (3.9 L) was added to the residue and the mixture was stirred for about 0.5 h at about 25 °C. The precipitate was filtered and the filter cake was washed with n-heptane (390 mL) and dried under vacuum at 15 about 60 °C to provide the title compound P2. Yield: 338 g (80%) 1H NMR (300 MHz, dmso-de) δ 8.73 (s, 1 H), 8.29 - 8.31 (d, 1 H), 7.89 - 7.91 (d, 1 H), 7.67 (s, 1 H), 5.02 - 5.06 (m, 1 H), 1.41 -1.43 (d, 6 H).
Préparation 3: 4-chloro-6-methoxvquinazoline-7-carbonitrile (P3)
Step 1. Synthesis of 3-hydroxv-4-iodobenzoic acid (CAS 58123-77-6, C12).
To a stirred solution of 3-hydroxybenzoic acid (25 g, 181 mmol) in water (180 mL) were added 1 M aqueous NaOH (188 mL) and sodium iodide (28.1 g, 188 mmol), followed by slow addition aqueous sodium hypochlorite solution (0.9 M, 209 mL). The mixture was stirred at about 25 °C for about 2 h, then cooled in ice and acidified with concentrated HCl to pH = 3. A sufficient 25 quantity of 10% ascorbic acid solution was added to afford a colorless mixture. The remaining precipitate was filtered, washed with water, and dissolved in EtOAc. The EtOAc solution was washed with brine, dried over Na2SO4, filtered and concentrated to provide the title compound C12. Yield: 34 g (71%) 1H NMR (400 MHz, dmso-d6) δ 12.98 (br s, 1 H), 10.65 (s, 1 H), 7.78 (dd, 1 H), 7.32 (d, 1 H), 7.11 (dd, 1 H).
Step 2. Synthesis of methyl 4-iodo-3-methoxybenzoate (CAS 35387-92-9, C13).
To a stirred solution of compound C12 (84 g, 318 mmol) in DMF (300 mL) at about 0 °C was added K2CO3 (177 g, 1273 mmol) followed by methyl iodide (79.3 mL, 1273 mmol). The mixture was stirred at about 25 °C for about 16 h, then diluted with EtOAc (2 L) and washed with water (600 mL x 2), followed by brine (100 mL x 2). The EtOAc was dried over Na2SO4, filtered and
concentrated to provide the title compound C13. Yield: 84 g (90%) 1H NMR (400 MHz, CDCh) δ 7.84 (d, 1 H), 7.44 (d, 1 H), 7.36 (dd, 1 H), 3.93 (s, 3 H), 3.91 (s, 3 H).
Step 3. Synthesis of methyl 4-iodo-5-methoxv-2-nitrobenzoate (C14).
A stirred solution of compound C13 (10 g, 38 mmol) in AcOH (92 ml_) was treated with 70% concentrated HNO3 (11.9 ml_) with cooling in an about 25 °C water bath, after which acetic anhydride (46 ml_) was added. The mixture then placed in a pre-heated oil bath at about 70 °C.
After about 2 h, the reaction mixture was cooled to about 25 °C, diluted with 1 M NaOH solution (200 ml_), and extracted with EtOAc (200 mL x 2). The combined extracts were washed with NaHCC>3, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by 10 column chromatography to provide the title compound C14. Yield: 10 g (78%) 1H NMR (400
MHz, dmso-d6) δ 8.50 (s, 1 H), 7.32 (s, 1 H), 4.01 (s, 3 H), 3.84 (s, 3 H).
Step 4. Synthesis of methyl 2-amino-4-iodo-5-methoxybenzoate (C15).
To a stirred solution of compound C14 (19 g, 56 mmol) in MeOH (300 mL) was added a solution of stannous chloride dihydrate (40.7 g, 180 mmol) in 120 mL of 6 M HCl. The mixture was 15 stirred at about 25 °C for about 16 h, then concentrated. The residue was stirred with a saturated aqueous solution of potassium fluoride and extracted twice with EtOAc. The combined extracts were dried over Na2SO4, filtered and concentrated. The residue was triturated with a mixture of DCM and hexane to provide the title compound C15. Yield: 14 g (81%) 1H NMR (400 MHz, dmso-ds) δ 7.35 (s, 1 H), 7.14 (s, 1 H), 3.79 (s, 3 H), 3.68 (s, 3 H).
Step 5. Synthesis of 7-iodo-6-methoxyquinazolin-4(3H)-one (C16).
A stirred solution of compound C15 (17 g, 55 mmol) in formamide (170 mL) was heated at about
160 °C for about 18 h. The reaction mixture was cooled to about 25 °C, diluted with water (170 mL), and stirred at about 10 °C for about 30 minutes. The precipitate was filtered, washed with water followed by diethyl ether, and dried under vacuum to provide the title compound C15.
Yield: 12 g (71%) 1H NMR (400 MHz, dmso-d6) δ 8.14 (s, 1 H), 7.99 (s, 1 H), 7.44 (s, 1 H), 7.16 (brs, 1 H), 3.93 (s, 3 H).
Step 6. Synthesis of 6-methoxv-4-oxo-3,4-dihydroquinazoline-7-carbonitrile (C17),
A stirred solution of compound C16 (16 g, 53 mmol) in dimethyl acetamide (80 mL) was degassed with argon for about 15 minutes, after which zinc cyanide (6.22 g, 53 mmol) was 30 added, followed by TMEDA (2.38 mL, 16 mmol), tris(dibenzylideneacetone)dipalladium(0) (4.85 g, 5.3 mmol) and Xantphos (3.06 g, 5.3 mmol). The mixture was heated at about 80 °C for about 5 h under argon, then cooled to about 25 °C, diluted with diethyl ether (1 L), and filtered. The precipitate was dissolved in a mixture of MeOH and DCM (1/4, v/v) and filtered through Celite®. The filtrate was concentrated and the residue was purified by column chromatography to
provide the title compound C17. Yield: 5.4 g (50%) 1H NMR (400 MHz, dmso-d6) δ 12.47 (br. s,
H), 8.17 (s, 1 H), 8.09 (s, 1 H), 7.69 (s, 1 H), 4.02 (s, 3 H).
Step 7. Synthesis of 4-chloro-6-methoxyquinazoline-7-carbonitrile (P3).
A mixture of compound C17 (10 g, 49.8 mmol) and POCI3 (250 mL) was heated at about 100 °C for about 16 h, then cooled to about 25 °C and concentrated. The residue was diluted with EtOAc and the ethyla acetate solution was washed with water, saturated aqueous NaHCO3 solution, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography to provide the title compound P3. Yield: 2.8g (27%) 1H NMR (400 MHz, dmso-de) δ 9.11 (s, 1 H), 8.75 (s, 1 H), 7.66 (s, 1 H), 4.14 (s, 3 H).
Préparation 4: 4-chloro-6-isopropoxyquinoline-7-carboxamide (P4)
Step 1. Synthesis of methyl 2-hydroxy-5-nitrobenzoate (C18).
Concentrated H2SC>4 (150 mL) was added slowly to a solution of 2-hydroxy-5-nitrobenzoic acid (1000 g, 5.4 mol) in dry MeOH (5 L). Afterthe addition was complété, the mixture was heated to reflux for about 24 h. After completion of the reaction, the mixture was filtered and the precipitate was reserved. The filtrate was concentrated to afford a solid residue. This residue and the previous precipitate were dissolved in EtOAc and washed with water twice. The EtOAc 20 was then washed with brine, dried over Na2SO4, filtered, and concentrated to provide the title compound C18. Yield: 900 g (84%) 1H NMR (300 MHz, CDCI3) δ 11.42 (s, 1 H), 8.80 - 8.79 (d, 1 H), 8.31 - 8.35 (dd, 1 H), 7.07 - 7.10 (d, 1 H), 4.04 (s, 3 H).
Step 2. Synthesis of methyl 2-isopropoxy-5-nitrobenzoate (C19).
Compound C18 (900 g, 4.56 mol), triphenylphosphine (1.33 kg, 5.02 mol) and 2-propanol (3.8 25 kg, 5.02 mol) were dissolved in dry THF (18 L) and cooled to about 5 °C. Di-isopropylazodicarboxylate (1.01 kg, 5.02 mol) was added, and the reaction was allowed to warm to about 25 °C and was stirred overnight. The mixture was concentrated under reduced pressure and the residue treated with EtOAc (5 L). The undissolved solids that remained were removed by filtration, and the filtrate was evaporated. The residue was purified by column chromatography 30 to provide the title compound C19. Yield: 760 g (70%) 1H NMR (300 MHz, CDCI3) δ 8.60 (d, 1
H), 8.29 - 8.34 (dd, 1 H), 7.01 (d, 1 H), 4.73 - 4.77 (m, 1 H), 3.90 (s, 3 H), 1.33 (d, 6 H).
Step 3. Synthesis of methyl 5-amino-2-isopropoxybenzoate (C20).
A solution of compound C19 (760 g, 3.17 mol) in EtOH (12 L) was treated with palladium on carbon (76 g) and this mixture was stirred for about 1 h at about 25 °C under an atmosphère of hydrogen at about 50 psig. After completion of the reaction, the mixture was filtered through celite and filter cake was washed with additional EtOH. The filtrate was evaporated to provide the title compound C20. Yield: 600 g (60%). 1H NMR (400 MHz, dmso-d6) δ 6.83 - 6.85 (d, 1 H),
6.76 - 6.79 (dd, 1 H), 4.31 - 4.37 (m, 1 H), 3.86 (s, 3 H), 2.80 - 3.60 (br. s, 2 H), 1.29 - 1.31 (d, 6 H).
Step 4. Synthesis of methyl 5-(((2,2-dimethvl-4,6-dioxo-1,3-dioxan-5-vlidene)methyl)amino)-210 isopropoxybenzoate (C21).
A mixture of compound C20 (600 g, 2.88 mol), Meldrum’s acid (640 g, 3.44 mol), and triethyl orthoformate (560 g, 3.44 mol) in EtOH (7 L) was heated at reflux overnight. The mixture was cooled to about 20 °C and the resulting precipitate was collected by filtration to provide the title compound C21. Yield: 620 g (60%) 1H NMR (300 MHz, CDCI3) δ 11.07 - 11.17 (br. d, 1 H), 8.53 15 - 8.58 (d, 1 H), 7.69 - 7.70 (d, 1 H), 7.29 - 7.33 (dd, 1 H), 7.02 - 7.05 (d, 1 H), 4.55 - 4.62 (m, 1
H), 2.91 (s, 3 H), 1.75 (d, 6 H), 1.38 -1.40 (d, 6 H).
Step 5. Synthesis of methyl 6-isopropoxv-4-oxo-1,4-dihvdroquinoline-7-carboxvlate (C22).
Compound C21 (20 g, 55 mmol) was added in portions to pre-heated Dowtherm A (480 mL) at about 240 °C. Heating and stirring at that température were continued for approximately an 20 additional 5 minutes after completion of the addition. The mixture was cooled to about 20 °C and purified by column chromatography to give 6.2 g of a mixture of compound C22 and methyl 6-isopropoxy-4-oxo-1,4-dihydroquinoline-5-carboxylate. This procedure was repeated 29 times more with same scale to provide a mixture of the title compound C22 and and methyl 6isopropoxy-4-oxo-1,4-dihydroquinoline-5-carboxylate. Yield: 311 g (72%) 1H NMR (400 MHz, 25 dmso-d6) δ 11.90 (s, 2 H), 7.94 - 7.92 (d , 1 H), 7.87 - 7.86 (d, 1 H), 7.83 (s, 1 H), 7.62 - 7.54 (m,
H), 6.01 - 6.02 (d, 1 H), 5.93 - 5.91 (d, 1 H), 4.72 - 4.66 (m, 1 H), 4.62 -4.56 (m, 1 H), 3.85 (s,
H), 3.76 (s, 3 H), 1.29 - 1.31 (d, 6 H), 1.20 - 1.22 (d, 6 H).
Step 6. Synthesis of 6-isopropoxv-4-oxo-1,4-dihvdroquinoline-7-carboxylic acid (C23).
The mixture of compound C22 and and methyl 6-isopropoxy-4-oxo-1,4-dihydroquinoline-530 carboxylate (311 g, 1.19 mol) was added to THF (1.55 L) and water (1.55 L). Lithium hydroxide monohydrate (199 g, 4760 mmol) was added and the mixture was stirred at about 25 °C overnight. The reaction mixture was diluted with water and extracted with EtOAc 4 times until the methyl 6-isopropoxy-4-oxo-1,4-dihydroquinoline-5-carboxylate was absent from the aqueous phase. The aqueous layer was adjusted to about pH = 1 by the addition of 1 M HCl and the
aqueous layer was extracted with EtOAc twice. The combined EtOAc extracts were dried over Na2SO4, filtered, and concentrated to provide the title compound C23. Yield: 129 g (44%) 1H
NMR (400 MHz, dmso-d6) δ 11.6 - 13.0 (br. s, 1 H), 8.04 - 8.06 (d, 1 H), 7.84 (s, 1 H), 7.60 (s, 1 H), 6.20 - 6.22 (d, 1 H), 4.69 - 4.73 (m, 1 H), 1.30 - 1.32 (d, 6 H).
Step 7. Synthesis of 4-chloro-6-isopropoxyquinoline-7-carboxamide (P4).
A mixture of compound C23 (129 g, 520 mmol) and POCh (2 L) was heated under reflux for about 6 h. The mixture was concentrated under reduced pressure to give a dark oil, which was immediately treated with 10 L of a saturated solution of ammonia gas in dioxane at about 0 °C.
The mixture was then stirred at about 25 °C overnight. The reaction mixture was filtered and the 10 filtrate was concentrated. The residue was diluted with DCM (1 L) and washed with water. The
DCM extract was concentrated to obtain a solid residue which was purified by trituration with diethyl etherto provide the title compound P4. Yield: 55 g (40%) 1H NMR (300 MHz, dmso-d6) δ 8.90 (s, 1 H), 8.71 - 8.72 (d, 1 H), 7.80 (br. s, 1 H), 7.50 (s, 1 H), 4.90 (m, 1 H), 1.47 (d, 6 H).
Préparation 5: 5-hydroxy-3-methoxv-2-naphthamide (P5)
Step 1. Synthesis of methyl 3,5-dihydroxv-2-naphthoate (¢24).
A solution of 3,5-dihydroxy-2-naphthoic acid (2.2 kg, 10.8 mol) in anhydrous MeOH (16 L) was cooled to below 25 °C, after which thionyl chloride (2.56 kg, 21.5 mol) was then added over a period of about 3 h. After the addition, the mixture was stirred at about 25 °C overnight. An 20 additional 500 g of thionyl chloride was added slowly and the mixture was stirred for approximately another 16 hours until the reaction was complété. The reaction mixture was concentrated to dryness and the residue was taken up in cold water. The resulting suspension was adjusted to about pH = 8 with aqueous NaHCC>3. The precipitate was filtered, washed with water (0.5 L x 3) and dried under vacuum to provide the title compound C24. Yield: 2.25 kg 25 (96%) 1H NMR (400 MHz, dmso-d6) δ 10.19 (s, 1 H), 10.18 (s, 1 H), 8.37 (s, 1 H), 7.49 (s, 1 H),
7.39 - 7.42 (d, 1 H), 7.14 - 7.18 (t, 1 H), 6.88 - 6.90 (d, 1 H), 3.95 (s, 3 H).
Step 2. Synthesis of methyl 5-((tert-butvldiphenvlsilvl)oxv)-3-hydroxv-2-naphthoate (C25).
To a solution of compound C24 (500 g, 2.3 mol) in 1,2-dichloroethane (7.5 L) was added imidazole (233 g, 3.4 mol). After the addition, the mixture was heated to about 45 °C and stirred 30 for about 45 minutes before t-butyldiphenylsilyl chloride (453 g, 2.7 mol) was added dropwise.
The mixture was then heated to about 65 °C and held at that température for about two hours.
Water (3 L) was added to the mixture and the dichloroethane layer was separated. The aqueous phase was extracted with DCM (1 L x 2). The combined DCM extracts were washed with water (2 L x 2) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. Cold
MeOH was added to the residue and stirred for about 10 minutes. The precipitate was filtered, washed with cold MeOH, and dried under vacuum to provide the title compound C25. Yield: 900 g (86%) This process was repeated to préparé additional compound C25. 1H NMR (300 MHz, dmso-de) δ 10.35 (s, 1 H), 8.42 (s, 1 H), 7.77 (s, 1 H), 7.69 - 7.72 (t, 4 H), 7.52 (m, 7 H), 6.90 5 6.96 (t, 1 H), 6.37 - 6.41 (d, 1 H), 3.97 (s, 3 H), 1.13 (s, 9 H).
Step 3. Synthesis of methyl 5-((tert-butvldiphenvlsilvl)oxv)-3-methoxy-2-naphthoate (C26).
Triphenylphosphine (1.15 kg, 4.4 mol) was dissolved in THF (13 L) and treated with diisopropylazodicarboxylate (885 g, 4.4 mol) with stirring and cooling to maintain the température below about 25 °C. After the addition was complété, the mixture was stirred for 10 about 10 minutes. Methanol (876 mL, 21.9 mol) was then added into the mixture over a period of about 1 h with cooling to maintain the température approximately below 25 °C. Compound
C25 (1.0 kg, 2.2 mol) was added into the mixture in portions. The resulting solution was heated to about 80 °C for about 1 h. The mixture was then cooled to about 25 °C and concentrated to dryness. The residue was purified by column chromatography, after which it was heated under reflux with a 3/1 mixture of EtOH and petroleum ether for about 1 h to provide the title compound C26. Yield: 500 g (49%) This process was repeated to préparé additional compound C26. 1H NMR (300 MHz, dmso-de) δ 8.24 (s, 1 H), 7.61 - 7.77 (m, 5 H), 7.42 - 7.52 (m, 7 H), 7.01 - 7.06 (t, 1 H), 6.50 - 6.53 (d, 1 H), 3.97 (s, 3 H), 3.86 (s, 3 H), 1.13 (s, 9 H).
Step 4. Synthesis of 5-hydroxv-3-methoxy-2-naphthoic acid (C27).
Compound C26 (1.33 kg, 2.8 mol) and lithium hydroxide monohydrate (475 g, 11.3 mol) were added to a mixture of THF (3 L), MeOH (500 mL) and water (3 L). The mixture was stirred at about 25 °C overnight, after which the mixture was diluted with EtOAc (4 L) and water (2 L). The aqueous phase was separated and the EtOAc phase was extracted with water (2 L x 2). The combined aqueous phases were extracted with EtOAc (2 L x 2) and then acidified to about pH =
3 with concentrated HCl. The precipitate was filtered, washed with water (1 L x 3), and dried in vacuum to provide the title compound C27. Yield: 533 g (86%).
This process was repeated to préparé additional compound C27. 1H NMR (400 MHz, dmso-d6) δ 12.80 (br. s, 1 H), 10.16 (s, 1 H), 8.12 (s, 1 H), 7.50 (s, 1 H), 7.37 (d, 1 H), 7.15 - 7.24 (m, 1 H), 6.92 (dd, 1 H), 3.90 (s, 3 H).
Step 5. Synthesis of 5-hydroxv-3-methoxv-2-naphthamide (P5).
A suspension of compound C27 (80 g, 360 mmol) in a mixture of DMF (15 mL) and dry THF (2 L) was treated with oxalyl chloride (64 mL) at about 25 °C. The resulting suspension was stirred for about 1 h, then it was concentrated to dryness and the residue was suspended in 2 L of dry THF and cooled in ice. Concentrated ammonium hydroxide (220 mL) was added over a period
of about five to ten minutes. The resulting mixture was then stirred at about 25 °C for approximately another twenty minutes. Saturated aqueous NaHCC>3 (100 mL) was added and the THF was evaporated under reduced pressure. Water (1 L) was added and the precipitate was filtered, washed with water, and dried under vacuum. The resulting solid was suspended in 5 EtOAc and heated under reflux for about 2 h. The solid was filtered, washed with EtOAc, and dried to provide the title compound P5. Yield: 51 g (65%) By répétition of these steps a total of
1.0 kg of P5 was prepared. 1H NMR (400 MHz, dmso-d6) δ 10.19 (s, 1 H), 8.21 (s, 1 H), 7.80 7.81 (br. s, 1 H), 7.60 - 7.61 (br. s, 1 H), 7.51 (s, 1 H), 7.38 - 7.41 (d, 2 H), 7.19 - 7.20 (t, 1 H), 6.97-6.99 (d, 1 H), 3.96 (s, 3 H).
Synthesis of 5-hydroxv-3-isopropoxv-2-naphthamide (P6).
This compound was prepared in the same manner as compound P5, substituting 2-propanol for 15 MeOH in the reaction of compound C25 in Step 3, to provide the title compound P6. 1H NMR (400 MHz, dmso-d6) δ 9.00 - 10.8 (br. s, 1 H), 8.28 (s, 1 H), 7.69 (s, 1 H), 7.61 (s, 1 H), 7.55 (s, 1 H), 7.35 - 7.37 (d, 1 H), 7.16 - 7.20 (t, 1 H), 6.90 - 6.91 (d, 1 H), 4.80 - 4.86 (m, 1 H), 1.39 1.41 (d,1 H).
Préparation 6:1-chloro-7-ethoxyisoquinoline-6-carbonitrile (P7)
Step 1. Synthesis of 1-chloro-7-hvdroxvisoquinoline-6-carbonitrile (C28). To a stirred solution of compound P2 (10.0 g, 40.6 mmol) in 250 mL of DCM was added anhydrous aluminum chloride (16.3 g, 122 mmol). The reaction mixture was heated under reflux for about 4 h. The supernatant liquid was was removed by décantation and ice was added to the residue remaining in the flask, which was broken up manually to afford a light yellow suspension. This solid was filtered and washed with water, dried, and was washed with ether to provide the title compound C28. Yield: 8.1 g (97%) 1H NMR (400 MHz, dmso-d6) δ 11.95 (s, 1 H), 8.65 (s, 1 H), 8.22 (d, 1 H), 7.84 (d, 1 H), 7.69 (s, 1 H).
Step 2. Synthesis of 1-chloro-7-ethoxyisoquinoline-6-carbonitrile (P7). To a stirred solution of compound C28 (9.0 g, 44.1 mmol) in 190 mL of DMF was added potassium t-butoxide (6.9 g, 61.8 mmol) at 0 °C. After about 15 minutes, iodoethane (8.8 mL, 110 mmol) was added. The reaction mixture was allowed to warm to about 25 °C and was stirred for about 4 h. The reaction mixture was diluted with water and the resulting precipitate was filtered and dried. The precipitate was then triturated with a mixture of MeOH and diethyl ether (9/1, v/v) to provide the title compound P7. Yield: 7.6 g (83%) Ή NMR (400 MHz, dmso-d6) δ 8.72 (s, 1 H), 8.31 (d, 1 H), 7.90 (d, 1 H), 7.62 (s, 1 H), 7.62 (s, 1 H), 4.37 (q, 2 H), 1.47 (t, 3 H).
Synthesis of 1-chloro-7-(prop-2-vn-1-vloxv)isoquinoline-6-carbonitrile (P8).
This compound was prepared in the same manner as compound P7, substituting 3-bromoprop1-yne for iodoethane in the reaction of compound C28 in Step 2, to provide the title compound P8.1H NMR (400 MHz, dmso-d6) δ 8.78 (s, 1 H), 8.34 (d, 1 H), 7.93 (d, 1 H), 7.84 (s, 1 H), 5.25 (s, 2 H), 3.79 (s, 1 H).
Synthesis of 1-chloro-7-methoxy-d3-isoquinoline-6-carbonitrile (P9).
CD, ci
N
This compound was prepared in the same manner as compound P7, substituting methyl-d3 4methylbenzenesulfonate for iodoethane in the reaction of compound C28 in Step 2, to provide the title compound P9.1H NMR (400 MHz, dmso-d6): δ 8.73 (s, 1 H), 8.31 (d, 1 H), 7.91 (d, 1 H), 7.63 (s, 1 H).
Synthesis of 1-chloro-7-(2-methoxyethoxv)isoquinoline-6-carbonitrile (P10).
This compound was prepared in the same manner as compound P7, substituting 1-bromo-2methoxyethane for iodoethane in the reaction of compound C28 in Step 2, to provide the title compound P10. 1H NMR (400 MHz, CDCb) δ 8.28 (d, 1 H), 8.16 (s, 1 H), 7.70 (s, 1 H), 7.56 (d, 1 H), 4.40 (t, 2 H), 3.90 (t, 2 H), 3.51 (s, 3 H).
Préparation 7; 1-chloro-7-(cvclopropvlmethoxy)isoquinoline-6-carbonitrile (P11)
Step 1. Synthesis of 1-chloro-7-(cvclopropvlmethoxv)isoquinoline-6-carbonitrile (P11).
A solution of triphenylphosphine (0.78 g, 3.0 mmol) in THF (8 mL) was treated with diisopropylazodicarboxylate (0.61 g, 3 mmol). After about 5 minutes, cyclopropylmethanol (0.29 g, 4.0 mmol) was added, followed by compound C28 (0.41 g, 2.0 mmol). The mixture was heated for about 1.5 h, then cooled and concentrated. The residue was triturated with MeOH and filtered to provide the title compound P11. 1H NMR (400 MHz, dmso-de) δ 8.75 (s, 1 H), 8.31 (d, 1 H), 7.91 (d, 1 H), 7.64 (s, 1 H), 4.20 (d, 1 H), 1.35 (m, 1 H), 0.65 (d, 2 H), 0.46 (d, 2 H).
Synthesis of 1-chloro-7-tert-butoxvisoquinoline-6-carbonitrile (P12).
This compound was prepared in the same manner as compound P11, substituting 2-methyl-2ropanol for cyclopropylmethanol in the reaction of compound C28 in Step 1, to provide the title compound P12. 1H NMR (400 MHz, CDCIa) δ 8.29 (d, 1 H), 8.17 (s, 1 H), 7.97 (s, 1 H), 7.58 (d, 1 H), 1.63 (s, 9 H)
Synthesis of 1-chloro-7-cvclobutoxyisoquinoline-6-carbonitrile (P13).
This compound was prepared in the same manner as compound P11, substituting cyclobutanol for cyclopropylmethanol in the reaction of compound C28 in Step 1, to provide the title compound P13. 1H NMR (400 MHz, dmso-d6) δ 8.75 (s, 1 H), 8.31 (d, 1 H), 7.91 (d, 1 H), 7.50 (s, 1 H), 5.10 (quin, 1 H), 2.60 - 2.56 (m, 2 H), 2.26 - 2.18 (m, 2 H), 1.93 - 1.83 (m, 1 H), 1.83 1.73 (m, 1 H).
Synthesis of 1-chloro-7-(oxetan-3-vloxv)isoquinoline-6-carbonitrile (P14).
This compound was prepared in the same manner as compound P11, substituting oxetan-3-ol for cyclopropylmethanol in the reaction of compound C28 in Step 1, to provide the title compound P14. 1H NMR (400 MHz, dmso-d6) δ 8.81 (s, 1 H), 8.35 (d, 1 H), 7.94 (d, 1 H), 7.27 (s, 1 H), 5.63 - 5.81 (m, 1 H), 5.06 (t, 1 H), 4.69 (m, 2 H).
Préparation 8: 4-chloro-6-isopropoxyquinoline-7-carbonitrile (P15)
Step 1. Synthesis of 4-chloro-6-isopropoxyquinoline-7-carbonitrile (P15)
Phosphores oxychloride (28.2 mL, 303 mmol) was added drop wise with stirring to a solution of compound P4 (20 g, 75.8 mmol), pyridine (91 mL, 1.13 mol) and imidazole (10.3 g, 151.5 mmol) in DCM (300 mL). The mixture was stirred at about 25 °C for about 30 minutes. The reaction mixture was then cooled in ice and quenched with cold water (100 mL), added slowly enough to maintain the température to approximately below 5 °C. Stirring was continued for approximately another 20 minutes with cooling. The mixture was then poured into 1 M HCl (500 mL) and separated. The aqueous phase was extracted with DCM. The combined DCM extracts were washed with 1 M HCl, water, Na2CO3 solution, brine, dried over Na2SO4, filtered and concentrated to provide the title compound P15. Yield: 12 g (64%) 1H NMR: (400 MHz, CDCL) δ 8.70 (d, 1 H), 8.41 (s, 1 H), 7.54 (d, 1 H), 7.52 (s, 1 H), 4.85 (quin, 1 H), 1.50 (d, 6 H).
Préparation 9: 4-chloro-6-methoxvquinoline-7-carbonitrile (P16)
Step 1. Synthesis of 4-chloro-6-hvdroxyquinoline-7-carbonitrile (C29)
To a stirred solution of compound P15 (12.0 g, 48.6 mmol) in 180 mL of DCM was added anhydrous aluminum chloride (20.6 g, 155 mmol). The reaction mixture was heated under reflux overnight. The solvent was evaporated under reduced pressure, and the residue was stirred with 0.1 M HCl (400 mL) at 25 °C for 2 h. The remaining solid was filtered, washed with water, MeOH, and dried to provide the title compound C29. Yield: 9.6 g (96%) 1H NMR: (400 MHz, dmso-d6) δ 11.82 (s, 1 H), 8.74 (d, 1 H); 8.56 (s, 1 H), 7.81 (d, 1 H), 7.60 (s, 1 H).
Step 2. Synthesis of 4-chloro-6-methoxyquinoline-7-carbonitrile (P16)
To a stirred solution of compound C29 (9.6 g, 46.9 mmol) in DMF (190 mL) was added potassium t-butoxide (6.8 g, 61 mmol) at 0 °C. After about 15 minutes, iodomethane (7.3 mL, 117 mmol) was added. The reaction mixture was allowed to warm to about 25 °C and was stirred for about 2 h. The reaction mixture was diluted with water and the resulting precipitate was filtered and dried. This solid was washed with water, hexane, and dried under vacuum to provide the title compound P15. Yield: 8.1 g (79%) 1H NMR: (400 MHz, CDCI3) δ 8.73 (d, 1 H), 8.41 (s, 1 H), 7.56 (d, 1 H); 7.52 (s, 1 H), 4.09 (s, 3 H).
Synthesis of 4-chloro-6-ethoxyquinoline-7-carbonitrile (P17).
This compound was prepared in the same manner as compound P16, substituting iodoethane for iodomethane in the reaction of compound C30 in Step 3, to provide the title compound P17. 1H NMR: (400 MHz, dmso-d6) δ 8.72 (s, 1 H), 8.31 (d, 1 H), 7.89 (d, 1 H), 7.62 (s, 1 H), 4.38 (q, 2 H), 1.46 (t, 3 H).
Préparation 10:1-chloro-7-(difluoromethoxv)isoquinoline-6-carbonitrile (P18)
Step 1. Synthesis of 1-chloro-7-(difluoromethoxv)isoquinoline-6-carbonitrile (P18).
A solution of compound C27 (164 mg, 0.8 mmol) in DMF (2 ml_) was treated with sodium difluoroacetate (95 mg, 0.8 mmol) and césium carbonate (285 mg, 0.9 mmol). The mixture was heated at about 60 °C for about 1 h. The mixture was diluted with 25 mL of water and 25 mL of EtOAc, and the EtOAc was separated, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography to provide the title compound P18. Yield 133 mg (65%). 1H NMR: (400 MHz, dmso-d6) δ 8.93 (s, 1 H), 8.48 (d, 1 H), 8.07 (d, 1 H), 8.02 (dd, 1 H), 7.70 (t, 1 H).
Préparation 11: 6-bromo-1-chloro-7-(trifluoromethoxy)isoquinoline (P19)
Step 1. Synthesis of 6-bromo-1-chloro-7-(trifluoromethoxy)isoquinoline (P19). A suspension of 6-bromo-7-(trifluoromethoxy)isoquinolin-1(2H)-one (CAS 1445564-99-7, 410 mg, 1.3 mmol) in 6 mL of POCI3 was heated under reflux for about 40 minutes. The mixture was cooled in ice and then poured into ice water with vigorous stirring. After the ice had melted, the mixture was extracted with EtOAc (100 mL). The EtOAc was separated and stirred with saturated aqueous NaHCO3 solution (100 mL) until no bubbling occured. The EtOAc was separated, washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica chromatography to provide the title compound P19. Yield 130 mg (31%) 1H NMR (400 MHz, CDCI3) δ 8.36 (d, 1 H), 8.24 (d, 1 H), 8.22 (s, 1 H), 7.56 (d, 1 H).
Préparation 12:1-Chloro-7-cvclopropoxyisoquinoline-6-carbonitrile (P21)
Step 1. Synthesis of 1-chloro-7-(2-chloroethoxy)isoquinoline-6-carbonitrile (C166).
A mixture of compound C28 (2.4 g, 11.8 mmol), 2-chloroethanol-1-(4-methylbenzenesulfonate) (CAS 80-41-1, 5.5 g, 23.5 mmol), Triton-405 (6.63 g, 11.8 mmol) and césium carbonate (4.58 g, 14.1 mmol) in 96 mL of THF was heated for about 8 h at about 65 °C. The mixture was diluted with water and extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C166. Yield: 2.0 g (64%). LCMS: MH+ = 267.0.
Step 2, Synthesis of 1-chloro-7-(vinvloxv)isoquinoline-6-carbonitrile (C167).
A solution of compound C166 (1.4 g, 5.3 mmol) in THF (50 mL) was treated with a solution of potassium t-butoxide (1.2 g, 10.6 mmol) in 15 mL of THF at about -20 °C, after which the mixture was warmed to about 25 °C and stirred for about 1 h Saturated aqueous NH4CI was added and the mixture was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C167. Yield: 1.1g (90%). LCMS: MH+ = 230.9. Step 3. Synthesis of 1-Chloro-7-cvclopropoxyisoquinoline-6-carbonitrile (P21).
A solution of compound C167 (220 mg, 0.9 mmol) in 50 mL of DCM was treated sequentially at about 0 °C with ethereal diazomethane (150 mL), followed by palladium(ll) acetate (25 mg). The mixture was stirred overnight at about 25 °C, then the mixture was filtered and concentrated. The residue was purified by chromatography to provide the title compound P21. Yield: 30 mg (13%). 1H NMR (400 MHz, dmso-d6) δ 8.22 - 8.21 (d, 1 H), 8.09 (s, 1 H), 7.98 (s, 1 H), 7.51 7.50 (d, 1 H), 3.99 - 3.95 (m, 1 H), 0.97 -0.88 (m, 4 H).
Préparation 13: 3,4-dichloro-6-methoxyquinoline-7-carbonitrile (P22) I î'
CL /k ^Cl
Step 1. Synthesis of 3-chloro-7-iodo-6-methoxyquinolin-4(1H)-one (C168).
A solution of 7-iodo-6-methoxyquinolin-4(1 H)-one (CAS 1300031-68-8, 2.0 g, 6.6 mmol) and Nchlorosuccinimide (976 mg, 7.3 mmol) in AcOH (20 mL) was heated at about 35 °C for about 18 h. It was filtered and the precipitate was dried to provide the title compound C168. Yield: 1.4 g (63%). 1H NMR (400 MHz, dmso-d6) δ 12.25 (br. s, 1 H), 8.35 (s, 1 H), 8.11 (s, 1 H), 7.47 (s, 1 H), 3.91 (s, 3 H).
Step 2, Synthesis of 3,4-dichloro-6-methoxyquinoline-7-carbonitrile (P22).
A mixture of compound C168 (2.6 g, 7.7 mmol) and cuprous cyanide (1.31 g, 15.5 mmol) in pyridine (26 mL) was heated at about 120 °C for about 16 h. The mixture was cooled to about
°C, filtered, and the filtrate was concentrated. The residue was suspended in toluene and concentrated, then treated with POCI3 (15 mL, 160 mmol) and triethylamine hydrochloride (1.47 g, 10.7 mmol). The mixture was heated at reflux for about 3 h, then cooled to about 25 °C and concentrated. The residue was stirred with aqueous NaHCO3. The resulting precipitate was 5 filtered, washed with n-hexane, and dried under vacuum. The dry solid was suspended in a
9/1 ratio of MeOH/DCM and solid NaHCO3 was added. This mixture was stirred for about 5 h, filtered and the filtrate was concentrated. The residue was triturated with diethyl ether and dried under vacuum to provide the title compound P22. Yield: 1.5 g (56%). 1H NMR (400 MHz, dmsod6) δ 8.98 (s, 1 H), 8.71 (s, 1 H), 7.60 (s, 1 H), 4.11 (s, 3 H).
Préparation 14: 4-bromo-1-chloro-7-isopropoxyisoquinoline-6-carbonitrile (P23)
Step 1. Synthesis of 7-isopropoxv-1-oxo-1,2-dihvdroisoquinoline-6-carbonitrile (C169).
A solution of compound P2 (10.0 g, 40 mmol) and hydrogen chloride in 1,4-dioxane (4 M, 100 15 mL) in water (100 mL) was heated in a sealed tube at about 120 °C for about 18 h. The mixture was cooled to about 25 °C and diluted with water. The precipitate was filtered, washed with water, and dried to provide the title compound C169. Yield: 7.5 g (81%). 1H NMR (300 MHz, dmso-ds) δ 11.5 (br. s, 1 H), 8.21 (s, 1 H), 7.77 (s, 1 H), 7.12 - 7.16 (t, 1 H), 6.53 - 6.56 (d, 1 H), 4.85 - 4.93 (m, 1 H), 1.35 - 1.37 (d, 6 H).
Step 2, Synthesis of 4-bromo-7-isopropoxv-1-oxo-1,2-dihydroisoquinoline-6-carbonitrile (C170).
A solution of N-bromosuccinimide (14 g, 78 mmol) in acetonitrile (150 mL) was added drop wise to a suspension of compound C169 (15 g, 65 mmol) in acetonitrile (1.38 L) at about 25 °C and stirred for about 24 h to afford a yellow suspension. The reaction mixture was concentrated to half volume. The precipitate was filtered, washed with diethyl ether and dried to provide the title 25 compound C170. Yield: 13.0 g (65%). 1H NMR (400 MHz, dmso-d6) δ 11.8 (br. s, 1 H), 8.08 (s,
H), 7.84 (s, 1 H), 7.52 - 7.53 (d, 1 H), 4.92 - 4.98 (m, 1 H), 1.36 - 1.38 (d, 6 H).
Step 3. Synthesis of 4-bromo-1-chloro-7-isopropoxyisoquinoline-6-carbonitrile (P23).
A suspension of compound C170 (10.0 g, 32 mmol) in POCI3 (120 mL) was heated at reflux for about 1.5 h. The mixture was concentrated and the residue was dissolved in DCM. The DCM extract was washed with K2CO3, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound P23. Yield: 9 g (85%). 1H
NMR (400 MHz, CDCI3) δ 8.49 (s, 1 H), 8.42 (s, 1 H), 7.65 (s, 1 H), 4.87 - 4.93 (m, 1 H), 1.52 1.53 (d, 6H).
Préparation 15: 4-hvdroxv-6-methoxvisoquinoline-7-carbonitrile (P24) i OH
Step 1. Synthesis of ethyl 2-((3-bromo-4-methoxvbenzyl)amino)acetate (C173).
To a solution of glycine ethyl ester hydrochloride (17 g, 126 mmol) and EtaN (25.2 g, 252 mmol) in DCM (100 mL) and MeOH (100 mL) was added sodium triacetoxyborohydride (53.1 g, 252 mmol) at about 0 °C. The mixture was stirred for about 30 min before 3-bromo-410 methoxybenzaldehyde (26.8 g, 126 mmol) was added, then the mixture allowed to warm up to about 25 °C for about 18 h. Water (200 mL) and saturated aqueous NH4CI (100 mL) were added and the mixture was extracted with DCM. The combined DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C173. Yield: 15 g (45%). 1H NMR (400 MHz, dmso-d6) δ 7.52 (d, 1 H), 7.26 (dd, 1 H), 7.05 (d, 1 H), 4.08 (q, 2 H), 3.82 (s, 3 H), 3.64 (s, 2 H), 3.27 (s, 2 H), 2.67 (br. s., 1 H), 1.19 (t, 3 H).
Step 2. Synthesis of ethyl 2-(N-(3-bromo-4-methoxvbenzvl)-4-methvlphenylsulfonamido)acetate (C174).
To a solution of compound C173 (18 g, 60 mmol) and pyridine (24 g, 298 mmol) in THF (400 mL) was added tosyl chloride (11.4 g, 60 mmol) at 0 °C. The mixture was stirred for about 16 h at about 25 °C, then acidified to about pH 3 with concentrated HCl and extracted with DCM (3 x 300 mL). The combined DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C174. Yield: 17 g (63%). 1H NMR (400 MHz, CDCh) δ 7.68 (d, 2 H), 7.26 (d, 2 H), 7.19 (s, 1 H), 7.11 (dd, 1 H), 6.76 (d, 1 H), 4.33 (s, 2 H), 3.94 (q, 2 H), 3.83 (s, 2 H), 3.81 (s, 3 H), 2.37 (s, 3 H), 1.08 (t, 3 H).
Step 3. Synthesis of 2-(N-(3-bromo-4-methoxvbenzvl)-4-methvlphenylsulfonamido)acetic acid (C175). To a solution of compound C174 (17 g, 37 mmol) in THF (100 mL) and MeOH (100 mL) was added a solution of lithium hydroxide (1.7 g, 74 mmol) in water (100 mL) at about 25 °C.
The mixture was stirred for about 4 h, then the mixture was partially concentrated to remove THF and MeOH. The remaining solution was acidified to about pH 3 with concentrated HCl and extracted with DCM (3 x 100 mL). The combined DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated to provide the title compound C175. Yield: 15 g (94%). 1H NMR (400 MHz, CDCI3) δ 7.75 (d, 2 H), 7.33 (d, 2 H), 7.27 (s, 1 H), 7.17 (d, 1 H), 6.83 (d, 1 H), 4.38 (s, 2 H), 3.93 (s, 2 H), 3.88 (s, 3 H), 2.43 (s, 3 H).
Step 4. Synthesis of 7-bromo-6-methoxv-2-tosvl-2,3-dihydroisoquinolin-4(1H)-one (C176).
To a solution of compound C1175 (4.27 g, 10 mmol) in DCM (120 mL) were added 2 drops of DMF followed by oxalyl chloride (6.3 g, 50 mmol) at about 25 °C. After about 2 h, the mixture was evaporated. The residue was dissolved in DCM (100 mL) and cooled to about -78 °C. Anhydrous aluminum chloride (3.32 g, 25 mmol) was added in portions. The mixtue was stirred for about 40 min at about -78 °C, then stirred for about 2 h at about 0 °C. Water was added, and the DCM was separated washed with brine, dried over Na2SC>4, filtered and concentrated. The residue was triturated with a mixture of MeOH (7.5 mL) and EtOAc (7.5 mL). The precipitate was collected by filtration and dried to provide the title compound C176. Yield: 1.9 g (46%). 1H NMR (400 MHz, CDCb) δ 7.63 (d, 2 H), 7.47 (s, 1 H), 7.31 (s, 1 H), 7.27 (d, 2 H), 4.43 (s, 2 H), 3.99 (s, 2 H), 3.89 (s, 3 H), 2.39 (s, 3 H).
Step 5. Synthesis of 7-bromo-6-methoxyisoquinolin-4-ol (C177).
A mixture of compound C176 (1.9 g, 4.6 mmol) and NaHCO3 (1.54 g, 18.5 mmol) in EtOH (50 mL) was heated at reflux for about 2 h, then cooled to about 25 °C and concentrated. The residue was treated with EtOAc and water. The EtOAc was separated and the aqueous phase was extracted with additional EtOAc. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C177. Yield: 300 mg (26%). Ή NMR (400 MHz, dmso-de) δ 10.50 (br. s., 1 H), 8.67 (s, 1 H), 8.39 (s, 1 H), 8.03 (s, 1 H), 7.47 (s, 1 H), 4.01 (s, 3 H).
Step 6. Synthesis of 4-hvdroxv-6-methoxyisoquinoline-7-carbonitrile (P24).
A mixture of compound C177 (100 mg, 0.39 mmol), zinc cyanide (231 mg, 2 mmol) and tetrakis(triphenylphosphine)palladium (0) ( 45 mg, 0.04 mmol) in 5 mL of DMF was stirred for about 10 min at about 25 °C, then heated at about 140 °C for about 6 h. The mixture was cooled, concentrated, the residue was treated with water, and extracted with EtOAc. The EtOAc extract was washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound P24. Yield: 65 mg (82%).
1H NMR (400 MHz, dmso-d6) δ 10.74 (s, 1 H), 8.78 (s, 1 H), 8.71 (s, 1 H), 8.13 (s, 1 H), 7.53 (s, 1 H), 4.06 (s, 3 H).
Préparation 16: 8-fluoro-5-hvdroxv-3-methoxy-2-naphthamide (P25)
Step 1. Synthesis of methyl 5-hydroxv-3-methoxy-2-naphthoate (C178)
A solution of compound C26 (40 g, 85 mmol) in THF (150 ml_) was treated with tetra-nbutylammonium fluoride (31 g, 119 mmol) and stirred for 30 min at 25 °C. The reaction mixture was neutralized with AcOH before being diluted with water and EtOAc. The EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C178. Yield: 16.50 g (89%). 1H NMR (400 MHz, dmso-de) δ 10.19 (s, 1 H), 8.21 (s, 1 H), 7.53 (s, 1 H), 7.39 - 7.42 (d, 1 H), 7.19 - 7.22 (t, 1 H), 6.96 (d, 1 H), 3.92 (s, 3 H), 3.85 (s, 3 H).
Step 2. Synthesis of methyl 8-fluoro-5-hvdroxv-3-methoxy-2-naphthoate (C179)
A solution of SelectFluor (3.18 g, 8.6 mmol) in DMF (10 mL) was added slowly to a solution of compound C178 (2.00 g, 8.6 mmol) in DMF (20 mL) at about 0 °C. After stirring overnight, the mixture was diluted with brine and extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C179. Yield: 90 mg (4%). 1H NMR (400 MHz, CDCI3) δ 8.49 (s, 1 H), 7.52 (d, 1 H), 6.86 (dd, 1 H), 6.77 (dd, 1 H), 3.98 (s, 3 H), 4.02 (s, 3 H). 19F NMR (400 MHz, CDCh) δ-130.68.
Step 3. Synthesis of 8-fluoro-5-hvdroxv-3-methoxy-2-naphthamide (P25)
A solution of compound C179 (90 mg, 0.36 mmol) in THF (4 mL) and water (2.5 mL) was treated with lithium hydroxide (88 mg, 3.6 mmol) at about 20 °C. After stirring overnight, the mixture was acidified with 1 M HCl and concentrated to dryness. The residue was stirred in DCM (5 mL) and treated with oxalyl chloride solution (2 M, 0.27mL) along with a catalytic amount of DMF. After about 1 h at about 20 °C, the mixture was filtered and concentrated to dryness. The residue was taken up in THF (2mL) and treated with ammonia in dioxane solution (0.5 M, 1 mL) at about 20 °C. After about 1 h, the mixture was filtered and concentrated. The residue was purified by chromatography to provide the title compound P25. Yield 27 mg (32%). 1H NMR (400 MHz, dmso-de) δ 10.17 (br. s., 1 H), 8.32 (s, 1 H), 7.81 (br. s., 1 H), 7.66 (br. s„ 1 H), 7.53 (s, 1 H), 7.00 (dd, 1 H), 6.82 (dd, 1 H), 3.98 (s, 3 H). 19F NMR (400 MHz, dmso-de) δ 134.39.
Préparation 17: (S)-3,3-dimethvl-1,7a-dihvdropyrrolo[1,2-c1oxazol-5(3H)-one (P20)
Step 1. Synthesis of (S)-3,3-dimethvl-5-(trimethvlsilvloxv)-1,3,7,7a-tetrahydropyrrolo[1,2cloxazole (C30) A solution of diisopropylamine (147 mL, 1.05 mol) in dry THF (875 mL) was
cooled to about -25 °C and treated with n-butyllithium (2.5 M in hexanes, 387 mL, 970 mmol). The mixture was stirred at about -20 °C for about 30 minutes, then cooled to about -70 °C. A solution of (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1H)-one (CAS 99208-71-6, 125 g, 806 mmol) in THF (163 mL) was added, maintaining the température approximately below -60 °C. After the addition was completed, the mixture was stirred for approximately an additional 5 minutes before the addition of TMSCI (132 mL, 1.05 mol) at -60 °C. The mixture was then allowed to warm to about -10 °C before being concentrated under reduced pressure. The residue was stirred with dry hexanes (1 L) and concentrated, then again stirred with dry hexanes (1 L) and concentrated. The residue was stirred with dry hexanes (1 L), filtered, and concentrated under reduced pressure to provide the title compound C30 which was carried on to Step 2 without further purification. 1H NMR (400 MHz, CDCI3) δ 4.16 (m, 1 H), 4.00 (dd, 1 H), 3.75 (dd, 1 H), 3.56 (dd, 1 H), 2.54 (m, 1 H), 2.31 (dd, 1 H), 1.49 (s, 3 H), 1.36 (s, 3 H), 0.24 (s, 9 H).
Step 2. Synthesis of (SI-S.S-dimethvl-Ua-dihvdropvrrolon^-cloxazol-SQHj-one (P20) The crude compound C30 from Step 1 was dissolved in THF (915 mL) and treated with allyl methyl carbonate (104 mL, 911 mmol) and palladium(ll) acetate (9.0 g, 40 mmol). The mixture was heated to about 65 C until gas évolution ceased, and was then heated for approximately an additional 1 h after gas évolution ceased. The mixture was then cooled to about 25 °C and concentrated under reduced pressure. The residue was purified by column chromatography to provide the title compound P20. Yield: 90 g (73%) Ή NMR (400 MHz, CDCb) δ 7.07 (dd, 1 H) 6.09 (dd, 1 H) 4.60-4.71 (m, 1 H)4.13(dd, 1 H) 3.33 (dd, 1 H) 1.67 (s, 3 H) 1.56 (s, 3 H).
Préparation 18: (5S)-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L1)
Step 1. Synthesis of (7aS)-3,3,6-trimethvltetrahvdropyrroloi1,2-c1oxazol-5(3H)-one (C31). To a solution of (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1H)-one (CAS 99208-71-6, 3.0 g, mmol) in 50 mL of THF was added LDA (2 M, 12.1 mL, 20 mmol) at about -78 °C. The reaction mixture was stirred for about 30 minutes, then iodomethane (3.03 g, 21 mmol) was added. The reaction mixture was maintained for about 10 minutes at about -78 °C, then allowed to warm to about 25 °C for about 1 h. The reaction was quenched by addition to EtOAc (10 mL) and water (10 mL). The EtOAc was separated and the aqueous phase was extracted with additional EtOAc (50 mL x 2). The combined EtOAc extracts were washed with brine, dried over
Na2SC>4, filtered and concentrated to provide the title compound C31. Yield 3.1 g (92%). 1H NMR (400 MHz, CDCI3) δ 4.11 (m, 2 H), 3.42 (m, 1 H), 2.87 (dt, 1 H), 2.38 (m, 1 H), 1.65 (s, 3 H), 1.46 (s, 3 H), 1.36 (m, 2 H), 1.20 (s, 1.5 H), 1.19 (s, 1.5 H).
Step 2 Synthesis of (5S)-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L1). A solution of compound C31 (58 mg, 0.34 mmol) in MeOH (1.1 mL) was treated with 4-toluenesulfonic acid (1.4 mg, 7 pmol). The resulting mixture was stirred at 60 °C for about 4 h, The mixture was concentrated under vacuum to provide the title compound L1. Yield 38 mg (86%) 1H NMR (400 MHz, CDCI3) δ 3.70 - 3.83 (m, 2 H), 3.39 - 3.49 (m, 1 H), 2.51 - 2.64 (m, 1 H), 2.30 - 2.42 (m, 1 H), 1.34 - 1.46 (m, 1 H), 1.23 (s, 1.5 H), 1.21 (s, 1.5 H).
Synthesis of (5S)-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L2).
O
This compound was prepared in the same manner as compound L1, substituting NFSI for iodomethane in Step 1.1H NMR (400 MHz, CD3OD) δ 5.24 - 5.11 (m, 1 H), 3.83 - 3.32 (m, 3 H),
2.68- 1.88 (m, 2H).
Synthesis of (3R,5R)-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L3)
This compound was prepared in the same manner as compound L1, substituting (R)-3,3dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1H)-one (CAS 103630-36-0, Chemical
Communications, 2011, 47, 10037 - 10039) for (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol5(1H)-one (CAS 99208-71-6), and NFSI for iodomethane, in Step 1, followed by séparation of the diastereomeric products. 1H NMR (400 MHz, CDCI3) δ 4.96 - 5.16 (m, 1 H), 3.64 - 3.72 (m,
H), 3.41 - 3.49 (m, 1 H), 2.53 - 2.63 (m, 1 H), 1.85 - 2.02 (m, 1 H). Synthesis of (5S)-3-ethvl-5-(hvdroxymethvl)pvrrolidin-2-one (L4).
This compound was prepared in the same manner as compound L1, substituting bromoethane.for iodomethane in Step 1. 1H NMR (400 MHz, CDCI3) δ 4.03 - 4.17 (m, 2 H),
3.37 - 3.47 (m, 1 H), 2.69 - 2.83 (m, 1 H), 2.51 - 2.65 (m, 1 H), 2.37 (s, 1 H), 1.86 - 1.96 (m, 1
H), 1.33-1.44 (m, 1 H), 1.02 (t, 1 H), 0.95 (t, 3 H).
Synthesis of (5S)-5-(hvdroxvmethvl)-3-(methoxvmethvl)pyrrolidin-2-one (L5).
This compound was prepared in the same manner as compound L1, substituting chloro(methoxy)methane for iodomethane in Step 1. 1H NMR (400 MHz, CDCh) δ 3.63 - 3.84 (m, 2 H), 3.46 - 3.63 (m, 2 H), 3.38 (s, 3 H), 2.64 - 2.75 (m, 1 H), 2.17 - 2.39 (m, 2 H), 1.75 2.05 (m, 1 H).
Synthesis of (3R,5S)-5-(hvdroxvmethvl)-3-(2-hvdroxvpropan-2-vl)pyrrolidin-2-one (L11).
This compound was prepared in the same manner as compound L1, substituting acetone.for iodomethane in Step 1. 1H NMR (400 MHz, CDCI3) δ 6.27 - 6.42 (m, 1 H), 3.62 - 3.77 (m, 2 H),
3.50 - 3.59 (m, 1 H), 2.59 - 2.72 (m, 1 H), 1.92 - 2.04 (m, 2 H), 1.23 (s, 6 H). Synthesis of (5S)-3-((benzvloxv)methvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L12).
This compound was prepared in the same manner as compound L1, substituting CAS 3587-608 (“benzyloxymethyl chloride”) for iodomethane in Step 1. 1H NMR (400 MHz, CDCI3) δ 7.27 7.41 (m, 5 H), 6.58 (br. s., 1 H), 4.46 - 4.63 (m, 2 H), 3.61 - 3.85 (m, 4 H), 3.41 - 3.53 (m, 1 H), 2.66 - 2.80 (m, 1 H), 2.30 (m, 1 H), 1.98 (s, 1 H).
Synthesis of (3S,5S)-3-hvdroxv-5-(hvdroxvmethv0pyrrolidin-2-one (L13).
This compound was prepared in the same manner as compound L1, substituting CAS 10437231-8 for iodomethane in Step 1. 1H NMR (400 MHz, dmso-cfe) δ 4.41 (dd, 1 H), 4.07 (dd, 1 H),
3.82 - 3.93 (m, 1 H), 3.34 - 3.42 (m, 1 H), 2.41 - 2.49 (m, 1 H), 1.45 - 1.53 (m, 1 H).
Synthesis of (3R,5S)-3-hydroxv-5-(hvdroxvmethvl)pyrrolidin-2-one (L14),
O
This compound was prepared in the same manner as compound L1, substituting CAS 12718405-8 for iodomethane in Step 1. 1H NMR (400 MHz, dmso-cfe) δ 5.79 (d, 1 H), 4.22 - 4.32 (m, 1 H), 4.16 (td, 1 H), 4.01 (dd, 1 H), 3.32 - 3.36 (m, 1 H), 3.17 (d, 1 H), 1.84- 1.95 (m, 2 H).
Synthesis of (3S,5S)-5-(hvdroxvmethvl)-3-(2,2,2-trifluoroethvl)pyrrolidin-2-one (L15) and (3R,5S)-5-(hvdroxvmethvl)-3-(2,2,2-trifluoroethvl)pyrrolidin-2-one (L16).
These compounds were prepared in the same manner as compound L1, substituting 1,1,1 trifluoro-2-iodoethane, added slowly, for iodomethane in Step 1, followed by séparation of the diastereomeric products by silica gel chromatography prior to Step 2. Application of Step 2 to the individual diastereomers provided the title compounds L15 and L16. L15: 1H NMR (400 MHz,
CDCIa) δ 6.48 (br. s., 1 H), 3.67 - 3.79 (m, 2 H), 3.52 - 3.62 (m, 1 H), 2.74 - 2.91 (m, 2 H), 2.28 (dd, 1 H), 1.99 - 2.15 (m, 2 H). L16: 1H NMR (400 MHz, CDCI3) δ 6.12 (br. s., 1 H) 3.77 - 3.86 (m, 2 H) 3.43 - 3.52 (m, 1 H) 2.83 - 2.98 (m, 1 H) 2.71 - 2.82 (m, 1 H) 2.45 - 2.56 (m, 1 H) 1.99 2.15 (m, 1 H) 1.89 (dd, 1 H) 1.51 - 1.58 (m, 1 H).
Synthesis of (5S)-5-(hydroxvmethvl)-3-(4-hvdroxytetrahvdro-2H-pvran-4-vl)pyrrolidin-2-one (L20L
This compound was prepared in the same manner as compound L1, substituting tetrahydro-4/-/pyran-4-one (CAS 29943-42-8) for iodomethane in Step 1. 1H NMR (400 MHz, CD3CN) δ 4.30 (d, 1 H), 3.60 - 3.77 (m, 4 H), 3.51 - 3.60 (m, 1 H), 3.43 - 3.51 (m, 1 H), 3.34 - 3.42 (m, 1 H), 2.93 (t, 1 H), 2.51 (t, 1 H), 1.98 - 2.08 (m, 1 H), 1.86 - 1.94 (m, 2 H), 1.80 (ddd, 1 H), 1.58 - 1.69 (m, 1 H), 1.41 - 1.52 (m, 1 H), 1.24 (dd, 1 H).
Synthesis of (5S)-5-(hvdroxvmethvl)-3-(3-hvdroxvoxetan-3-vl)pyrrolidin-2-one (1.22).
This compound was prepared in the same manner as compound L1, substituting CAS 6704-310 (oxetane-3-one) for iodomethane in Step 1 to provide (6S,7aS)-6-(3-hydroxyoxetan-3-yl)-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C81), which was used in Step 2. 1H NMR (400 MHz, dmso-de) δ 5.82 (d, 1 H), 4.70 - 4.80 (m, 2 H), 4.46 (d, 1 H), 4.36 - 4.44 (m, 2 H), 3.42 (dd, 1 H), 3.27 - 3.31 (m, 1 H), 2.80 - 2.91 (m, 1 H), 1.83 - 1.98 (m, 2 H).
Synthesis of (5S)-3-benzyl-5-(hvdroxvmethvl)pyrrolidin-2-one (L28).
This compound was prepared in the same manner as compound L1, substituting benzyl bromide for iodomethane in Step 1. 1H NMR (400 MHz, dmso-cfe) δ 7.64 (s, 1 H), 7.31 (t, 2 H) , 7.24 (m, 3 H) , 4.74 (t, 1 H) ,3.16 (q, 2 H) , 3.02 (dd, 1 H) , 2.64 (m, 2 H) , 2.54 ( s, 1 H) , 1.82 (m, 2 H).
Synthesis of (3R,5S)-3-fluoro-5-(hvdroxvmethvl)-3-(tetrahvdro-2H-pvran-4-vl)pyrrolidin-2-one (L31),
This compound was prepared in the same manner as compound L1, substituting compound C49 for compound C30 and NFSI for iodomethane in Step 1. 1H NMR (400 MHz, CDCI3) δ 4.03 (dd, 1 H), 3.98 (d, 1 H), 3.73 (d, 1 H), 3.66 - 3.64 (m, 1 H), 3.58 - 3.55 (m, 1 H), 3.47 - 3.38 (m, 2 H), 2.51 - 2.40 (m, 1 H), 2.32 - 2.26 (m, 2 H), 1.91 (ddd, 1 H), 1.80 (d, 1 H), 1.56 - 1.36 (m, 2 H).
Préparation 19: (3S.5S)-3-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L7)
Step 1. Synthesis of (7aS)-6-ethvl-3,3-dimethvltetrahvdropvrrolo|1,2-c1oxazol-5(3H)-one (C32).
To a solution of (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1 H)-one (CAS 99208-71-6, 1.0 g, 6.4 mmol) in 30 mL of THF was added LDA (2 M, 4.0 mL, 8.0 mmol) at about-78 °C. The reaction mixture was stirred for about 30 minutes, then bromoethane (0.80 g, 7.2 mmol) was added. The reaction mixture was maintained for about 10 minutes at about -78 °C, then allowed to warm to about 25 °C for about 25 minutes. The reaction was quenched by addition to EtOAc 10 (10 mL) and water (10 mL). The EtOAc was separated and the aqueous phase was extracted with additional EtOAc (50 mL x 2). The combined EtOAc extracts were washed with brine, dried over Na2SO4, filtered and concentrated to provide the title compound C32. Yield 0.80 g (68%) 1H
NMR (400 MHz, CDCI3) δ 4.04 - 4.18 (m, 2 H), 3.35 - 3.49 (m, 1 H), 2.71 - 2.84 (m, 1 H), 2.50 2.65 (m, 1 H), 2.13 - 2.38 (m, 1 H), 1.77 - 1.96 (m, 1 H), 1.68 (s, 1 H), 1.64 (s, 2 H), 1.47 (s, 3 15 H), 1.35 - 1.44 (m, 1 H), 1.02 (t, 1 H), 0.94 (t, 2 H).
Step 2. Synthesis of (6S,7aS)-6-ethvl-6-fluoro-3,3-dimethvltetrahvdropvrrolo[1,2-c1oxazol-5(3H)one (C33) and (6R,7aS)-6-ethvl-6-fluoro-3,3-dimethvltetrahvdropvrrolori,2-c1oxazol-5(3H)-one (C34). To a solution of compound C32 (0.80 g, 4.4 mmol) in 5 mL of THF was added LDA (2
M, 2.8 mL, 5.6 mmol) at about -78 °C. The reaction mixture was stirred for about 30 minutes, then treated with a solution of N-fluoroobis(benzenesulfonyl)imide (NFSI) (1.65 g, 5.3 mmol) in mL of THF. The reaction mixture was maintained for about 10 minutes at about -78 °C, then allowed to warm to about 25 °C for about 1 h. The reaction was quenched by addition to EtOAc (10 mL) and water (10 mL). The EtOAc was separated and the aqueous phase was extracted with additional EtOAc (50 mL x 2). The combined EtOAc extracts were washed with brine, dried 25 over Na2SO4, filtered and concentrated. The residue was dissolved in DCM (20 mL) and filtered.
The filtrate was concentrated and the residue was separated by column chromatography to provide the title compounds C33 (Yield: 180 mg, 20%) and C34 (Yield: 403 mg, 45%).
C33:1H NMR (400 MHz, CDCI3) δ 4.17 (dd, 1 H), 3.84 - 3.95 (m, 1 H), 3.47 (dd, 1 H), 2.54 (ddd, 1 H), 1.95 - 2.11 (m, 2 H), 1.78 - 1.95 (m, 1 H), 1.72 (s, 3 H), 1.49 (s, 3 H), 1.07 (t, 3 H).
C34:1H NMR (400 MHz, CDCI3) δ 4.29 - 4.40 (m, 1 H), 4.17 (dd, 1 H), 3.34 - 3.43 (m, 1 H), 2.42 (ddd, 1 H), 1.98-2.11 (m, 1 H), 1.76- 1.83 (m, 1 H), 1.71 (ddd, 1 H), 1.65 (s, 3 H), 1.53 (s, 3 H), 1.01 (t, 3H).
Step 3; Synthesis of (3S,5S)-3-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L7).
A solution of compound C33 (180 mg, 0.9 mmol) in MeOH (5 mL) was treated with 4toluenesulfonic acid (23 mg, 135 pmol). The resulting mixture was stirred at about 70 °C for about 4 h, The mixture was concentrated under vacuum to provide the title compound L7. Yield 150 mg (100%). 1H NMR (400 MHz, CDCIs) δ 3.75 (dd, 1 H), 3.69 (dd, 1 H), 3.56 (dd, 1 H), 2.31 -2.44 (m, 1 H), 1.96 - 2.12 (m, 2 H), 1.68-1.85 (m, 1 H), 1.03 (t, 3 H).
Synthesis of (S)-3,3-difluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L6)
O
This compound was prepared in the same manner as compound L7, substituting NFSI.for bromoethane in Step 1. 1H NMR (400 MHz, CDCIs) δ 4.07 - 4.18 (m, 1 H), 3.78 - 3.92 (m, 1 H), 2.72 - 2.83 (m, 1 H), 2.04 - 2.18 (m, 1 H).
Synthesis of (3R,5S)-3-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L8).
This compound was prepared in the same manner as compound L7, substituting compound C34.for compound C33 in Step 3. 1H NMR (400 MHz, CDCIs) δ 3.90 - 4.01 (m, 1 H), 3.81 (dd, 1 H), 3.46 (dd, 1 H), 2.29 - 2.47 (m, 1 H), 2.00 - 2.11 (m, 1 H), 1.83 - 2.00 (m, 1 H), 1.64 - 1.83 (m, 1 H), 1.02 (t, 3 H).
Synthesis of (3R,5S)-3-fluoro-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L9) and (3S,5S)-3fluoro-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L10).
These compounds were prepared in the same manner as compounds L7 and L8, substituting iodomethane for bromoethane in Step 1, followed by séparation of the diastereomeric products by chromatography priorto Step 2. L9:1H NMR (400 MHz, CDCb) δ 3.77 - 3.83 (m, 1 H), 3.69 3.77 (m, 1 H), 3.53 - 3.62 (m, 1 H), 2.42 - 2.60 (m, 2 H), 1.53 - 1.64 (m, 3 H).
L10:1H NMR (400 MHz, CDCI3) δ 3.73 - 3.80 (m, 1 H), 3.70 (td, 1 H), 3.55 - 3.63 (m, 1 H), 2.26 - 2.40 (m, 1 H), 2.07 - 2.22 (m, 1 H), 1.59 (d, 3 H).
Synthesis of (3S,5S)-3-((benzvloxv)methvl)-3-fluoro-5-(hvdroxvmethyl)pyrrolidin-2-one (L17) and (3R,5S)-3-((benzvloxv)methvl)-3-fluoro-5-(hvdroxymethvl)pyrrolidin-2-one (L18).
These compounds were prepared in the same manner as compounds L7 and L8, substituting NFSI.for bromoethane in Step 1 and benzyloxymethyl chloride (CAS 3587-60-8) for NFSI in Step 2, followed by séparation of the diastereomeric products by chromatography. The individual diastereomers were then subjected to Step 3. L17: 1H NMR (400 MHz, CDCI3) δ 7.27 - 7.42 (m, 5 H), 6.40 - 6.55 (m, 1 H), 4.60 (s, 2 H), 3.88 - 4.00 (m, 1 H), 3.69 - 3.85 (m, 3 H), 3.46 (dd, 1 H), 2.35 - 2.56 (m, 1 H), 2.16 - 2.33 (m, 1 H). L18:1H NMR (400 MHz, CDCb) δ 7.70 (br. s., 1 H), 7.24 - 7.39 (m, 5 H), 4.52 - 4.63 (m, 2 H), 3.63 - 3.86 (m, 4 H), 3.48 (br. s., 1 H), 2.61 (d, 1 H), 1.95-2.13 (m, 1 H).
Synthesis of (3R,5S)-3-fluoro-5-(hvdroxvmethvl)-3-(2-hvdroxvpropan-2-vl)pyrrolidin-2-one (L19).
This compound was prepared in the same manner as compound L7, substituting NFSI.for bromoethane in Step 1 and acetone for NFSI in Step 2,1H NMR (400 MHz, CDCb) δ 3.45 - 3.42 (m, 1 H), 3.27 (s, 1 H), 2.57 - 2.49 (m, 1 H), 1.98 - 1.90 (m, H), 1.86 - 1.83 (m, 3 H), 1.32 1.31 (m, 3 H).
Synthesis of (5S)-3-hvdroxv-5-(hvdroxvmethvl)-3-(2,2.2-trifluoroethvl)pyrrolidin-2-one (L21).
This compound was prepared in the same manner as compound L7, substituting 1,1,1-trifluoro2-iodoethane, added slowly, for bromoethane in Step 1 and CAS 104372-31-8 for NFSI in Step 2. LCMS: Rt = 1.128 min (213.7, MIT); 1.258 (213.7, MH+).
Synthesis of (5S)-3-fluoro-5-(hvdroxvmethvl)-3-(2,2,2-trifluoroethyl)pyrrolidin-2-one (L26).
This compound was prepared in the same manner as compound L7, substituting (3R,7aS)-3-(4methoxyphenyl)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 170885-05-9) for (S)-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(1H)-one (CAS 99208-71-6) and 1,1,1-trifluoro-2iodoethane, added slowly, for bromoethane in Step 1. 1H NMR (400 MHz, CD3OD) δ 3.57 3.53 (m, 1 H), 3.46 - 3.38 (m, 2 H), 2.93 - 2.80 (m, 1 H), 2.70 - 2.35 (m, 2 H), 2.27 - 2.10 (m, 1 H).
Préparation 20: (3S,5S)-3-fluoro-3-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L23).
Step 1. Synthesis of (7aS)-methyl 3,3-dimethvl-5-oxohexahvdropyrrolof1,2-cloxazole-6carboxylate (C35).
To a solution of (S)-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 99208-71-6, 7.0 g, 45 mmol) in THF (70 mL) was added LDA (2.0 M, 56.4 mL, 113 mmol) dropwise at about -78 °C. The reaction mixture was stirred for about 30 min before being treated with dimethyl carbonate (10.2 g, 113 mmol) in one portion. The mixture was stirred for approximately another 10 min at about -78 °C and was then warmed to about 25 °C and stirred for about 1 h.
Saturated aqueous potassium dihydrogen phosphate was added and the mixture was extracted with EtOAc. The extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C35. Yield: 6.8 g (71%). 1H NMR (400 MHz, CDCb) δ 4.43 - 4.53 (m, 1 H, minor diastereomer), 4.16 - 4.25 (m, 1 H, major .
diastereomer), 4.08 - 4.16 (m, 1 H, both diastereomers), 3.85 (dd, 1 H, major diastereomer),
3.81 (s, 3 H, major diastereomer), 3.79 (s, 3 H, minor diastereomer), 3.64 (d, 1 H, minor diastereomer), 3.53 - 3.60 (m, 1 H, major diastereomer), 3.43 - 3.51 (m, 1 H, minor diastereomer), 2.49 - 2.57 (m, 1 H, minor diastereomer), 2.34 - 2.44 (m, 1 H, major diastereomer), 2.22 - 2.33 (m, 1 H, major diastereomer), 1.98 (dt, 1 Hm minor diastereomer),
1.68 (s, 3 H, minor diastereomer), 1.67 (s, 3 H, major diastereomer), 1.48 (s, 3 H, both diastereomers).
Step 2, Synthesis of (7aS)-methyl 6-fluoro-3,3-dimethvl-5-oxohexahvdropvrrolo[1,2-c1oxazole-6carboxylate (C36).
A solution of compound C35 (6.8 g, 32 mmol) in THF (128 mL) was treated with DBU (5.8 g, 38 15 mmol). The mixture was stirred for about 15 min at about 25 °C, then cooled to about 0 °C and treated with NFSI (12.1 g, 38 mmol). It was kept at about 0 °C for about 15 min, then warmed to about 25 °C for about 3 h. The mixture was concentrated, and the residue was diluted with EtOAc and washed with 10% aqueous K2CO3. The mixture was separated and the aqueous layer was extracted with EtOAc. The combined extracts were dried over Na2SO4 filtered and 20 concentrated. The residue was purified by chromatography to provide the title compound C36.
Yield: 5.0 g (68%). 1H NMR (400 MHz, CDCb) δ 4.37 - 4.33 (m, 1 H), 4.13 - 4.10 (m, 1 H), 3.83 (s, 3 H), 3.51 - 3.43 (m, 1 H), 2.49 - 2.42 (m, 2 H), 1.61 (s, 3 H), 1.46 (s, 3 H).
Step 3. Synthesis of (6R,7aS)-6-fluoro-6-(hvdroxvmethvl)-3,3-dimethvltetrahvdropyrrolo[1,2c1oxazol-5(3H)-one (C37) and (6S,7aS)-6-fluoro-6-(hvdroxvmethvl)-3,3-dimethyltetrahvdro25 pyrroloH ,2-c1oxazol-5(3H)-one (C38).
A solution of compound C36 (6.0 g, 26 mmol) in EtOH (100 mL) at about 0 °C was treated with NaBH4 (1.7 g, 44 mmol) added in one portion. The mixture was stirred at about 0 °C for about
1.5 h before being treated with 1 M HCl and then concentrated. The residue was purified by chromatography to provide the title compounds C37 (Yield: 1.8 g, 34%) and C38 (Yield: 400 mg,
8%). C37: 1H NMR (400 MHz, CDCb) δ 4.19 (dd, 1 H), 3.80 - 4.06 (m, 3 H), 3.46 - 3.54 (m, 1 H), 2.79 (ddd, 1 H), 2.10 (dd, 1 H), 1.97 - 2.08 (m, 1 H), 1.72 (s, 3 H), 1.50 (s, 3 H). C38: 1H NMR (400 MHz, CDCb) δ 4.36 - 4.45 (m, 1 H), 4.19 (dd, 1 H), 3.93 - 4.04 (m, 1 H), 3.78 - 3.88 (m, 1 H), 3.39 - 3.49 (m, 1 H), 2.49 (dd, 1 H), 2.40 (ddd, 1 H), 1.97-2.14 (m, 1 H), 1.67 (s, 3 H), 1.54 (s, 3 H).
Step 4. Synthesis of (6S.7aS)-6-fluoro-6-(fluoromethvl)-3,3-dimethvltetrahvdropyrrolo[1.2c1oxazol-5(3H)-one (C39).
A solution of compound C37 (1.5 g, 7.4 mmol) in CHCI3 (30 mL) and pyridine (3.0 mL, 37 mmol) was cooled to about -78 °C and treated with DAST (2.1 mL, 16 mmol). The mixture was allowed to warm to about 25 °C and stirred for about 18 h, and then was heated at about 45 °C for about 2 h. The mixture was cooled to about -78 °C and quenched by the addition of MeOH. The mixture was allowed to warm to about 25 °C, stirred for about 30 min and and concentrated. The residue was purified by chromatography to provide the title compound C39. Yield: 450 mg (30%). 1H NMR (400 MHz, CDCI3) δ 4.68 - 4.62 (m, 1 H), 4.58 - 4.51 (m, 1 H); 4.19 (dd, 1 H), 4.03 - 3.95 (m, 1 H), 3.49 (t, 1 H), 2.84 - 2.79 (m, 1 H), 2.14 - 2.03 (m, 1 H), 1.70 (s, 3 H), 1.52 (s, 3 H).
Step 5. Synthesis of (3S,5S)-3-fluoro-3-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L23).
To a stirred solution of compound C39 (450 mg, 2.2 mmol) in 50.4 mL of acetonitrile and 5.6 mL of water was added 4-toluenesulfonic acid (19 mg, 0.11 mmol). The reaction mixture was stirred at about 25 °C for about 16 h and then heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L23. Yield: 260 mg (72%). 1H NMR (400 MHz, CDCh) δ 6.47 (br s, 1 H), 4.73 - 4.65 (m, 1 H), 4.62 - 4.51 (m, 1 H), 3.80 - 3.74 (m, 1 H), 3.58 (br s, 1 H), 2.72 - 2.62 (m, 1 H), 2.16 - 2.07 (m,1 H), 2.03 - 2.00 (m, 1 H).
Synthesis of (3R,5S)-3-fluoro-3-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L24).
O,
HN
HO
This compound was prepared in the same manner as compound L23, substituting C38 for C37 in step 4.1H NMR (400 MHz, CD3OD) δ 4.67 (dd, 1 H), 4.63 (d, 1 H), 3.82 - 3.90 (m, 1 H), 3.62 (dd, 1 H), 3.48 (dd, 1 H), 2.27 - 2.52 (m, 2 H).
Préparation 21 : (5S)-5-(hydroxvmethvl)-3-methoxvpvrrolidin-2-one (L25)
O. ,0
HN
HO
Step 1. Synthesis of (3R,7aS)-6-hvdroxv-3-(4-methoxvphenvl)tetrahydropvrrolo[1,2-c1oxazol5(3H)-one (C40). To a solution of (3R,7aS)-3-(4-methoxyphenyl)tetrahydropyrrolo[1,2-c]oxazol5(3H)-one (CAS 170885-05-9, 1.0 g, 4.3 mmol) in THF (20 mL) was added LDA (2.0 M, 3.0 mL) at about -78 °C The mixture was stirred at about -78 °C for about 0.5 h, then a solution of (1 R)-(5 )-10-camphorsulfonyl)oxaziridine (CAS 104372-31-8, 1.0 g, 4.7 mmol) in THF (10 mL) was added dropwise at about -78 °C. The mixture was stirred at about -78 °C for about 10 min and then at about 25 °C for about 1.5 h. 10 mL of EtOAc and 10 mL of water were added the mixture was concentrated. The residue was diluted with water and extracted with EtOAc. The EtOAc extracts were washed with brine, dried over MgSÛ4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C40. Yield: 450 mg (42%). LCMS: m/z, 250.1 (M+1), rétention time: 0.748 min
Step 2. Synthesis of (3R,7aS)-6-methoxv-3-(4-methoxyphenvl)tetrahvdropvrrolo[1,2-cloxazol5(3H)-one (C41). A mixture of compound C40 (468 mg, 1.8 mmol), silver (I) oxide (232 mg, 1.0 mmol) and iodomethane (710 mg, 5.0 mmol) in acetonitrile (20 mL) was stirred about 25 °C for 15 about 6 h. Additional silver (I) oxide (464 mg, 2.0 mmol) and iodomethane (710 mg, 5.0 mmol) were added and after about 18 h, the mixture was filtered and concentrated to provide the title compound C41 which was used without further purification. Yield: 370mg (75%). LCMS: m/z, 263.9 (M+1), rétention time: 0.883 min
Step 3. Synthesis of (5S)-5-(hvdroxymethvl)-3-methoxvpvrrolidin-2-one (L25). A solution of 20 compound C41 (430 mg, 1.6 mmol) in AcOH (8 mL) and water (2 mL) was stirred at about 75 °C for about 30 min. The mixture was concentrated, MeOH was added, and the resulting mixture was again concentrated. The residue was purified by chromatography to provide the title compound L25. Yield: 204 mg (86%). 1H NMR (400 MHz, CD3OD) δ 6.19 (br. s, 1 H) 3.89 - 3.86 (m, 1 H), 3.68 - 3.65 (m, 2 H), 3.49 - 3.43 (m, 4 H), 2.45 - 2.42 (m, 1 H), 2.30 - 2.00 (m, 1 H), 25 1.68 - 1.64 (m, 1 H).
Préparation 22: (S)-6-(hydroxvmethyl)-5-azaspiror2.41heptan-4-one (L27)
Step 1. Synthesis of (S)-3',3l-dimethvldihvdro-TH-spiro|'cvclopropane-1.6'-pyrrolori,2-cloxazoll30 5'(3'H)-one (C42). A solution of (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1 H)-one (CAS
99208-71-6, 233 mg, 1.5 mmol) in THF (10 mL) was treated with LDA (2.0 M, 1.6 mL) at about 78 °C. A solution of 1,3,2-dioxathiolane 2,2-dioxide (CAS 1072-53-3, 242 mg,1.9 mmol) in THF (10 mL) was added at a rate to maintain the internai temp at about less than -65 °C. The mixture was stirred at about -78 °C for about 10 min then warmed to about -20 °C. The mixture was stirred for about 45 min and gradually warmed to about -3 °C before being re-cooled to about -78 °C. LDA (2.0 M, 1.95 mmol) was added and the mixture was stirred for about 10 min at about -78 °C, then slowly warmed to about 25 °C and kept for about 8 h. The mixture was treated with half - saturated aqueous NH4CI and extracted with EtOAc. The EtOAc extracts were washed with saturated aqueous NH4CI, dried over MgSO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C42. Yield: 120 mg (44%). 1H NMR (400 MHz, CDCI3) δ 4.29 - 4.21 (m, 1 H), 4.08 - 4.05 (m, 1 H), 3.43 - 3.38 (m, 1
H), 2.04 - 1.99 (m, 1 H), 1.94 - 1.90 (m, 1 H), 1.61 (s, 3 H), 1.45 (s, 3 H), 1.19 - 1.14 (m, 1 H),
1.25- 1.17 (m,1 H),1.16- 1.14 (m, 1 H), 0.95 - 0.94 (m,1 H), 0.93 - 0.90 (m,1 H).
Step 2. Synthesis of (S)-6-(hydroxvmethvl)-5-azaspiro|2.41heptan-4-one (L27). To a stirred solution of compound C42 (120 mg, 0.66 mmol) in 4.5 mL of acetonitrile and 0.5 mL of water was added 4-toluenesulfonic acid (12 mg, 0.06 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C and concentrated to provide the title compound L27 which was used in the next step without further purification.
Yield: 105 mg. 1H NMR (400 MHz, CD3OD) δ 3.82 - 3.82 (m,1 H), 3.80 - 3.50 (m,1 H), 2.33 2.30 (m,1 H), 1.98 - 1.94 (m,1 H), 1.04 - 1.02 (m, 2 H), 0.81 - 0.80 (m, 2 H).
Préparation 23 (3R,5S)-3-fluoro-3-(2-fluoroethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L29)
Step 1. Synthesis of (7aS)-6-allvl-3,3-dimethvltetrahvdropyrrolori,2-c1oxazol-5(3H)-one (C43).
To a stirred solution of (S)-3,3-dimethyltetra-hydropyrrolo[1,2-c]oxazol-5(1 H)-one (CAS 9920825 71-6, 10 g, 64.5 mmol) in THF (160 mL) at -78 °C was added LDA (2 M, 40.3 mL) and the mixture was stirred for about 0.5 h. Allyl bromide (6.2 mL, 71 mmol) was added and mixture was stirred for about 10 min at about -78 °C, then allowed to warm to about 25 °C and stirred for about 1 h. It was quenched with EtOAc-water (1:1, 60 mL) and separated. The aqueous phase was extracted with EtOAc, and the combined EtOAc extracts dried over Na2SO4 filtered and 30 concentrated. The residue was purified by chromatography to provide the title compound L29.
Yield: 8.85 g (70%). 1H NMR (400 MHz, CDCI3) δ 5.78 - 5.71 (m, 1 H), 5.14 - 5.02 (m, 2 H), 4.13
- 4.03 (m, 2 H), 3.40 - 3.36 (m, 1 H), 2.90 - 2.72 (m, 1 H), 2.63 - 2.42 (m, 1 H), 2.35 - 2.15 (m, 2 H), 1.95- 1.87 (m, 1 H), 1.64 (s, 3 H), 1.44 (s, 3 H).
Step 2. Synthesis of (6S.7aS)-6-allvl-6-fluoro-3,3-dimethvltetrahvdropvrrolo|1,2-cloxazol-5(3H)one (C44a), To a stirred solution of L29 (5.0 g, 25.6 mmol) in THF (80 mL) at -78 °C was added
LDA (2 M, 16.0 mL). After about 0.5 h, a solution of NFSI (8.89 g, 28.2 mmol) in THF (20 mL) was added and the mixture was stirred for about 10 min at about -78 °C. Th reaction mixture was warmed to about 25 °C for about 1 h. The mixture was quenched with EtOAc - water (1:1). The aqueous phase was extracted with EtOAc, and the combined EtOAc extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide 10 the title compound C44a. Yield: 1.9 g (35%). There was also obtained the diastereomer C44b.
Yield: 1.1 g (20%). C44a: Ή NMR (400 MHz, CDCI3) δ 5.78 - 5.68 (m, 1 H), 5.19 - 5.15 (m, 2 H), 4.30 - 4.25 (m, 1 H), 4.11 (dd, 1 H), 3.33 (t, 1 H), 2.72 - 2.65 (m, 1 H), 2.55 - 2.47 (m, 1 H), 2.37 - 2.27 (m, 1 H), 1.85 - 1.70 (m, 1 H), 1.59 (s, 3 H), 1.48 (s, 3 H). C44b: 1H NMR (400 MHz, CDCIs) δ 5.85 - 5.76 (m, 1 H), 5.29 - 5.23 (m, 2 H), 4.14 (dd, 1 H), 3.89 - 3.81 (m, 1 H), 3.44 (t, 1
H), 2.75 - 2.67 (m, 1 H), 2.62 - 2.51 (m, 2 H), 2.06 - 1.95 (m, 1 H), 1.54 (s, 3 H), 1.47 (s, 3 H).
Step 3. Synthesis of (6R,7aS)-6-fluoro-6-(2-hvdroxvethvl)-3,3-dimethvltetrahvdropyrrolo[1,2cloxazol-5(3H)-one (C45). A stream of ozonized oxygen was bubbled through a solution of compound C44a (500 mg, 1.4 mmol) in DCM (20 mL) at about -78 °C for about 15 min. A stream of argon was passed through the mixture for about 15 min, then the mixture was treated 20 with dimethyl sulfide (5 mL) at about -78 °C and stirred for about 1 h at about -78 °C. The reaction mixture was evaporated to dryness and the residue was dissolved in THF (18 mL) and water (2 mL). NaBH4 (183 mg, 4.6 mmol) was added and the mixture was stirred at about 25 °C for about 2 h. The mixture was treated with with saturated aqueous NH4CI solution and extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4 filtered and 25 concentrated to provide the title compound C45 as a colorless liquid which was carried on without further purification. Yield: 370 mg (71%). 1H NMR (400 MHz, dmso-d6) δ 4.61 (t, 1 H), 4.11 - 4.08 (m, 1 H), 4.00 - 3.94 (m, 1 H), 3.62 - 3.52 (m, 2 H), 3.47 (t, 1 H), 2.74 - 2.69 (m, 1 H), 2.05 - 1.91 (m, 3 H), 1.56 (s, 3 H), 1.36 (s, 3 H).
Step 4. Synthesis of (6R,7aS)-6-fluoro-6-(2-fluoroethvl)-3,3-dimethvltetrahvdropyrrolo[1,230 c1oxazol-5(3H)-one (C46). To a solution of compound C45 (370 mg, 1.7 mmol) in CHCh (15 mL) was added pyridine (0.69 mL, 8.5 mmol) followed by DAST (0.4 mL, 3.07 mmol) at about 78 °C. The mixture was warmed to about 25 °C and stirred for about 18 h. The mixture was then cooled to about -78 °C and quenched by the slow addition of MeOH. After about 30 min at about -78 °C, the mixture was warmed to about 25 °C and stirred for about 30 min before being
100 evaporated to dryness. The residue was purified by chromatography to provide the title compound C46. Yield: 120 mg (32%). 1H NMR (400 MHz, CDCI3) δ 4.80 - 4.53 (m, 2 H), 4.17 4.14 (m, 1 H), 3.96 - 3.91 (m, 1 H), 3.46 (t, 1 H), 2.76 - 2.71 (m, 1 H), 2.34 - 2.19 (m, 2 H), 2.09 1.98 (m, 1 H), 1.68 (s, 3 H), 1.44 (s, 3 H).
Step 5. Synthesis of (3R,5S)-3-fluoro-3-(2-fluoroethvl)-5-(hvdroxymethvl)pvrrolidin-2-one (L29).
To a stirred solution of compound C46 (130 mg, 0.62 mmol) in 5 mL of acetonitrile and 0.5 mL of water was added 4-toluenesulfonic acid (11 mg, 0.06 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L29. Yield: 170 mg (83%). 1H NMR (400 MHz, CDCb) δ 6.86 (br. s., 1 H), 4.52 - 4.96 (m, 2 H), 3.72 - 3.90 (m, 2 H), 3.55 - 3.72 (m, 1 H), 2.53 - 2.73 (m, 1 H), 2.31 - 2.51 (m, 1 H), 2.05 - 2.31 (m, 2 H).
Préparation 24: (3R,5S)-5-(hvdroxvmethvl)-3-(tetrahvdro-2H-pyran-4-vl)pvrrolidin-2-one (L30)
Step 1. Synthesis of (6S,7aS)-6-(4-hvdroxvtetrahvdro-2H-pyran-4-vl)-3,3-dimethvltetrahvdropyrrolo-1,2-cloxazol-5(3H)-one (C47). A stirred solution of (S)-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 99208-71-6, 10.0 g, 64 mmol) in THF (200 mL) was cooled to about -78 °C and LDA (2 M, 80 mL, 160 mmol) was added. The mixture was stirred at about -78 °C for about 30 min before tetrahydro-4H-pyran-4-one (CAS 29943-428, 15 mL, 160 mmol) in THF (50 mL) was added. The mixture was allowed to warm to about 25 °C and stirred for about 2 h before the reaction was quenched with EtOAc-water (1:1). The EtOAc was separated and the aqueous layer was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C47. Yield: 12 g (74%). 1H NMR (400 MHz, dmso-cfe) δ 4.14 (m, 1 H), 3.97 - 4.07 (m, 3 H), 3.34 - 3.42 (m, 3 H), 2.59 - 2.63 (m, 1 H), 1.99 - 2.05 (m, 2 H), 1.44 - 1.67 (m, 10 H).
Step 2. Synthesis of (S)-6-(dihvdro-2H-pvran-4(3H)-vlidene)-3,3-dimethyltetrahvdropvrrolo[1.2c1oxazol-5(3H)-one (C48). Triethylamine (38 mL, 274 mmol) was added to a stirred solution of compound C47 (7.0 g, 27 mmol) in DCM (150 mL). The resulting mixture was cooled to about 0 °C and methanesulfonyl chloride (10.6 mL, 137 mmol) was added. The reaction mixture was warmed to about 25 °C and stirred for about 16 h before being diluted with DCM and water. The
101
DCM was separated and the aqueous layer was extracted with DCM. The combined DCM extracts were washed with brine, dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C48. Yield 1.0 g (16%). 1H NMR (400 MHz, dmso-de) δ 5.61 (dd, 1 H), 4.22 - 4.27 (m, 1 H), 4.14 - 4.15 (m, 2 H), 4.05 - 4.08 (dd, 1 H), 3.79 - 3.81 (m, 2 H), 3.40 - 3.45 (m, 1 H), 3.25 (d, 1 H), 2.15 - 2.20 (m , 2 H), 2.10 (ddd, 1 H), 1.92 - 2.04 (m, 1 H), 1.65 (s, 3 H), 1.45 (s, 3 H).
Step 3. Synthesis of (6R,7aS)-3,3-dimethvl-6-(tetrahvdro-2H-pyran-4-vl)tetrahvdroDvrrolo|'1,2c1oxazol-5(3H)-one (C49). To a stirred solution of compound C48 (1.1 g, 4.6 mmol) in EtOAc (50 mL) was added platinum dioxide (105 mg, 0.46 mmol). The reaction mixture was shaken under about 50 psi of hydrogen at about 25 °C for about 4 h. The mixture was filtered and the solids were washed with EtOAc. The filtrate was concentrated and the residue was purified by chromatography to provide the title compound C49. Yield 0.75 g (68%) 1H NMR (400 MHz, dmso-ds) δ 4.14 (m, 1 H), 4.04 - 4.07 (dd, 1 H), 3.96 - 4.00 (m, 2 H), 3.34 - 3.42 (m, 3 H), 2.59 - 2.62 (m, 1 H), 1.98 - 2.05 (m, 2 H), 1.83 - 1.89 (m, 1 H), 1.65 - 1.66 (m, 3 H), 1.44 - 1.61 (m, 7 H).
Step 4. Synthesis of (3R,5S)-5-(hvdroxvmethvl)-3-(tetrahvdro-2H-pvran-4-vl)pyrrolidin-2-one (L30). A solution of compound C49 (300 mg, 1.25 mmol) in acetonitrile (5 mL) and water (0.5 mL) was treated with 4-toluenesulfonic acid (11.9 mg, 0.06 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L30. Yield 225 mg (90%). 1H NMR (400 MHz, CDCI3) δ 6.69 (s, 1 H), 3.97 (d, 2 H), 3.65 (m, 2 H), 3.47 - 3.36 (m, 3 H), 3.07 (m, 1 H), 2.48 - 2.43 (m, 1 H), 1.99 - 2.07 (m, 2 H), 1.82 - 1.88 (m, 1 H), 1.63 - 1.66 (m, 1 H), 1.41-1.49 (m, 3 H).
Préparation 25: (3R,5S)-3-(3-fluorooxetan-3-vl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L32)
HO
Step 1. Synthesis of (6R,7aS)-6-(3-fluorooxetan-3-vl)-3,3-dimethvltetrahvdropyrrolo[1,2c1oxazol-5(3H)-one (C50). DAST (0.41 mL, 2.9 mmol) was added dropwise to a solution of compound C81 (0.51 g, 2.2 mmol) in DCM (20 mL) at about -78 °C. After about 2 h, the reaction température was raised to about 0 °C and quenched with 50 mL of about pH 7 phosphate buffer and allowed to warm to about 25 °C. The DCM was separated and the aqueous layer was extracted twice with DCM. The combined DCM layers were washed with NaHCO3, brine, dried over Na2SC>4 filtered and concentrated. The residue was purified by chromatography to afford a sample of compound C50 (0.47 g) which was contaminated with an olefinic by-product. To remove this olefin, the sample was dissolved in EtOH (15 mL), treated with Pearlman's catalyst(170 mg), and hydrogenated at 40 psi for about 2 h. The mixture was filtered and 5 concentrated. The residue was purified by chromatography to provide the title compound C50.
Yield 0.14 g (36%) 1H NMR (400 MHz, CDCI3) δ 4.93 - 5.09 (m, 2 H) 4.74 - 4.87 (m, 1 H) 4.53 4.65 (m, 1 H) 4.16 - 4.25 (m, 1 H) 4.10 - 4.15 (m, 1 H) 3.52 - 3.67 (m, 1 H) 3.47 (t, 1 H) 2.32 (ddd, 1 H) 1.75 (td, 1 H) 1.65 (s, 3 H) 1.48 (s, 3 H). There was also obtained in Step 1 (6S,7aS)-3,3-dimethyl-6-(oxetan-3-yl)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C51). 1H NMR 10 (400 MHz, CDCI3) δ 4.93 (dd, 1 H), 4.79 (dd, 1 H), 4.60 - 4.68 (m, 1 H), 4.40 (t, 1 H), 4.13 - 4.22 (m, 1 H), 4.06 - 4.13 (m, 3 H), 3.39 - 3.47 (m, 1 H), 3.16 - 3.35 (m, 2 H), 2.37 (ddd, 1 H), 1.60 (s, 3 H), 1.46 - 1.56 (m, 1 H), 1.44 (s, 3 H).
Step 2. Synthesis of (3R,5S)-3-(3-fluorooxetan-3-vl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L32),
Compound C50 (130 mg, 0.56 mmol) was dissolved in 18 mL of acetonitrile and 2 mL of water 15 and treated with 4-toluenesulfonic acid (5 mg, 0.03 mmol). The resulting mixture was stirred at about 25 °C for about 18 h, with additional stirring atabout 95 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L32. Yield 68 mg (64%). This was used without further characterization.
Préparation 26: (3R,5S)-3-fluoro-5-(hvdroxvmethvl)-3-(methoxvmethvl)pyrrolidin-2-one (L33)
Step 1. Synthesis of (6R,7aS)-6-fluoro-6-(methoxvmethvl)-3.3-dimethvltetrahvdropyrrolo[1.2cloxazol-5(3H)-one (C52). Lithium hexamethyldisilazide (1 M, 1.3 mL) was added to a solution 25 of compound C37 (180 mg, 0.89 mmol) in THF (6 mL) at about 0 °C. After about 0 minutes, iodomethane (0.55 mL, 8.8 mmol) was added. The mixture was allowed to warm to about 25 °C and was stirred for about 12 h. Additional lithium hexamethyldisilazide and iodomethane were added, and the mixture was stirred for approximately another 12 h. The reaction was then treated with water and EtOAc. The EtOAc was separated, and the aqueous phase was 30 extracted with EtOAc. The combined EtOAc extracts were dried over Na2SÜ4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C52.
103
Yield: 116 mg (60%). 1H NMR (400 MHz, CDCI3) δ 4.17 (dd, 1 H), 3.99 (dd, 1 H), 3.64 - 3.78 (m, 2 H), 3.40 - 3.52 (m, 4 H), 2.78 (ddd, 1 H), 1.94 - 2.11 (m, 1 H), 1.72 (s, 3 H), 1.49 (s, 3 H).
Step 2. Synthesis of (3R.5S)-3-fluoro-5-(hvdroxvmethvl)-3-(methoxvmethvl)pyrrolidin-2-one (L33). Compound C52 (116 mg, 0.53 mmol) was dissolved in 18 mL of acetonitrile and 2 mL of water and treated with 4-toluenesulfonic acid (5 mg, 0.03 mmol). The resulting mixture was stirred at about 25 °C for about 18 h, with additional stirring at about 95 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L33. Yield: 89 mg (94%). This was used without further characterization.
Préparation 27: (3R,5S)-5-(hvdroxvmethvl)-3-(oxetan-3-vl)pyrrolidin-2-one (L34)
Step 1, Synthesis of (3R,5S)-5-(hvdroxvmethvl)-3-(oxetan-3-vl)pvrrolidin-2-one (L34).
To a stirred solution of compound C51 (130 mg, 0.62 mmol) in 8 mL of acetonitrile and 0.5 mL of water was added 4-toluenesulfonic acid (6 mg, 0.03 mmol). The reaction mixture was heated at about 90 °C for about 6 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L34. Yield: 35 mg (33%). 1H NMR (400 MHz, CDCI3) δ 6.04 (bs, 1 H), 4.91 (t, 1 H), 4.80 (t, 1 H), 4.69 (t, 1 H), 4.46 (t, 1 H), 3.75 - 3.80 (m, 2 H), 3.42 - 3.47 (m, 1 H), 3.20 - 3.26 (m, 1 H), 2.89 - 2.96 (m, 1 H), 2.33 - 2.40 (m, 2 H).
Préparation 28: (4R,5S)-5-(hvdroxvmethvl)-4-methylpvrrolidin-2-one (L36)
O
Step 1. Synthesis of (7R,7aS)-3,3,7-trimethvltetrahvdropyrrolon.2-c1oxazol-5(3H)-one (C53).
A suspension of cuprous bromide - dimethyl sulfide complex (11.9 g, 57 mmol) in ether (100 mL) was cooled to about -10 °C and a solution of methyllithium (1.6 M, 71.4 mL, 114 mmol) was added slowly. The mixture was then cooled to about -73 °C and TMSCI (7.18 mL, 57 mmol) was added slowly. After the addition was complété, the mixture was maintained for about 15 min before compound P20 (3.50 g, 23 mmol) in THF (10 mL) was added slowly. The mixture was maintained for approximately another additional 75 min at about -78 °C before being allowed to warm to about 0 °C. The mixture was maintained at about 0 °C for about 45 min before being
104 treated with a mixture of saturated aqueous NH4CI and ammonium hydroxide. The ethereal layer was separated and the aqueous phase was extracted twice with EtOAc. The combined extracts were dried over MgSO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C53. Yield: 2.27 g (59%). 1H NMR (400 MHz, CDCI3) δ 4.32 (dt, 1 H), 3.89 (dd, 1 H), 3.66 - 3.77 (m, 1 H), 2.99 (dd, 1 H), 2.42 - 2.56 (m, 1 H), 2.13 (dd, 1 H), 1.65 (s, 3 H), 1.47 (s, 3 H), 1.02 (d, 3 H).
Step 2, Synthesis of (4R.5S)-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L36).
To a stirred solution of compound C53 (1.00 g, 5.9 mmol) in 18 mL of acetonitrile and 2 mL of water was added 4-toluenesulfonic acid (8 mg, 0.04 mmol). The reaction mixture was heated at about 95 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L36. Yield: 0.67 g (88%). 1H NMR (400 MHz, CD3OD) δ 3.53 - 3.71 (m, 3 H), 2.57 - 2.74 (m, 1 H), 2.36 (dd, 1 H), 2.10 (dd, 1 H), 1.11 (d, 3 H).
Synthesis of (4S,5S)-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L35),
O
HO
This compound was prepared in the same manner as compound L36, substituting (S)-tert-butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1 H-pyrrole-1-carboxylate (CAS 8165827-7) for P20 in Step 1 to afford (2S,3S)-tert-butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-3methyl-5-oxopyrrolidine-1-carboxylate (C78), which was used in Step 2. 1H NMR (400 MHz, CD3OD) δ 3.60 (dd, 1 H), 3.48 (dd, 1 H), 3.27 (d, 1 H), 2.55 (dd, 1 H), 2.32 - 2.22 (m, 1 H), 1.95 (dd, 1 H), 1.15 (d, 3 H).
Synthesis of (4S,5S)-4-ethvl-5-(hvdroxvmethyl)pvrrolidin-2-one (L46).
O
HO
This compound was prepared in the same manner as compound L36, substituting CAS 17088507-1 for P20, and ethylmagnesium bromide for methyllithium, in Step 1, to afford (3R,7S,7aS)-7ethyl-3-(4-methoxyphenyl)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C63), which was used in
105 step 2. 1H NMR (400 MHz, CDCb) δ 3.66 -3.64 (m, 1 H), 3.42 - 3.35 (m, 2 H), 2.49 - 2.42 (m, 1 H), 2.01 - 1.92 (m, 2 H), 1.54 - 1.47 (m,‘ 1 H), 1.39 -1.32 (m, 1 H), 0.88 - 0.84 (m, 3 H).
Synthesis of (4R,5S)-4-ethvl-5-(hvdroxvmethvl)pyrrolidin-2-one (L47).
This compound was prepared in the same manner as compound L36, substituting ethylmagnesium bromide for methyllithium in Step 1, to afford (7R,7aS)-7-ethyl-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C54), which was used in Step 2. 1H NMR (400 MHz, CDCb) δ 4.34 (dt, 1 H), 3.90 (dd, 1 H), 3.72 (dd, 1 H), 2.91 (dd, 1 H), 2.31 (dd, 1 H), 2.25 (m, 1 H), 1.65 (s, 3 H), 1.52 (d, 1 H), 1.48 (s, 3 H), 1.27 - 1.38 (m, 1 H), 0.92 (t, 3 H).
Synthesis of (4S.5S)-5-(hvdroxvmethvl)-4-vinvlpyrrolidin-2-one (L50)
This compound was prepared in the same manner as compound L36, substituting vinylmagnesium bromide for methyllithium in Step 1, to afford (7S,7aS)-3,3-dimethyl-7vinyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C55), which was used in Step 2.
1H NMR (400 MHz, CDCb) δ 6.84 (br. s., 1 H), 5.88 (ddd, 1 H), 5.18 (d, 1 H), 5.15 (d, 1 H), 3.75 (td, 1 H), 3.63 - 3.71 (m, 1 H), 3.54 - 3.63 (m, 1 H), 3.16 - 3.29 (m, 2 H), 2.33 - 2.48 (m, 2 H).
Synthesis of (4R,5S)-5-(hvdroxvmethvl)-4-vinvlpyrrolidin-2-one (L51)
This compound was prepared in the same manner as compound L36, substituting CAS 17088507-1 for P20, and vinylmagnesium bromide for methyllithium, in Step 1. 1H NMR (400 MHz, CDCb) δ 6.61 (br. s., 1 H), 5.74 - 5.91 (m, 1 H), 5.06 - 5.20 (m, 2 H), 3.80 (d, 1 H), 3.46 - 3.62 (m, 2 H), 2.70 - 2.87 (m, 1 H), 2.56 (dd, 1 H), 2.30 (dd, 2 H).
Synthesis of (4S,5S)-4-cvclopropvl-5-(hvdroxvmethvl)pyrrolidin-2-one (L58).
This compound was prepared in the same manner as compound L36, substituting cyclopropylmagnesium bromide for methyllithium in Step 1, to afford (7S,7aS)-7-cyclopropyl3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C56), which was used in Step 2.1H NMR 5 (400 MHz, CDaOD) δ 3.80 (d, 2 H), 3.64 (dt, 1 H), 2.23 - 2.42 (m, 2 H), 1.69 - 1.87 (m, 1 H), 0.89 (dtd, 1 H), 0.52 (dd, 2 H), 0.04 - 0.23 (m, 2 H).
Synthesis of (4R,5S)-5-(hvdroxvmethvl)-4-propylpvrrolidin-2-one (L59)
This compound was prepared in the same manner as compound L36, substituting propylmagnesium bromide for methyllithium in Step 1, to afford (7R,7aS)-3,3-dimethyl-7propyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C57), which was used in Step 2. 1H NMR (400 MHz, dmso-de) δ 7.46 (br. s, 1 H), 4.63 (t, 1 H), 3.44 - 3.36 (m, 3 H), 2.37 - 2.31 (m, 1 H), 2.07 - 2.01 (dd, 1 H), 1.95 - 1.89 (dd, 1 H), 1.48 - 1.41 (m, 1 H), 1.39 - 1.20 (m, 3 H), 0.86 (t, H).
Préparation 29: (3R,4S.5S)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L37)
Step 1. Synthesis of (6R,7S,7aS)-6-fluoro-3,3,7-trimethvltetrahvdropvrrolof1,2-c1oxazol-5(3H)one (C58). A solution of compound C53 (0.93 g, 5.5 mmol) in THF (22 mL) was cooled to about
-78 °C and treated with LDA (2.0 M, 3.44 mL, 6.88 mmol). The mixture was maintainedat about
-78 °C for about 25 min before being treated with NFSI (2.23 g, 6.8 mmol) in THF (8 mL). After stirring at about -78 °C for another approximate 5 min, the mixture was warmed to about 25 °C for about 1 h. Ethyl acetate and water were added, and the mixture was concentrated under reduced pressure to remove the THF présent. The mixture was extracted twice with EtOAc, and the combined extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C58. Yield: 0.56 g (55%). 1H NMR
107 (400 MHz, CDCh) δ 4.58 - 4.77 (m, 1 H), 4.54 (dtd, 1 H), 3.96 (dd, 1 H), 3.68 (dd, 1 H), 2.53 2.73 (m, 1 H), 1.66 (s, 3 H), 1.53 (s, 3 H), 1.05 (d, 3 H). 19F NMR (376 MHz, CDCh) δ -184.92.
There was also obtained (6S,7S,7aS)-6-fluoro-3,3,7-trimethyltetrahydropyrrolo[1,2-c]oxazol5(3H)-one (C59). Yield: 0.11 g (11%). 1H NMR (400 MHz, CDCh) δ 5.25 (dd, 1 H), 3.95 - 4.10 5 (m, 2 H), 3.71 - 3.82 (m, 1 H), 2.86 - 3.03 (m, 1 H), 1.68 (s, 3 H), 1.49 (s, 3 H), 1.01 (dd, 3 H).
19F NMR (376 MHz, CDCh) δ -202.08.
Step 2. Synthesis of (3R,4S,5S)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L37).
To a stirred solution of compound C58 (590 mg, 3.1 mmol) in 18 mL of acetonitrile and 2 mL of water was added 4-toluenesulfonic acid (27 mg, 0.16 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L37. Yield: 451 mg (97%). 1H NMR (400 MHz, CDCh) δ 6.94 (br. s., 1 H), 4.94 (dd, 1 H), 3.66 - 3.77 (m, 2 H), 3.60
- 3.66 (m, 1 H), 2.93 (t, 1 H), 2.61 - 2.81 (m, 1 H), 1.29 (d, 3 H). 19F NMR (376 MHz, CDCh) δ 194.85.
Synthesis of (3S,4S,5S)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L38).
This compound was prepared in the same manner as compound L37, substituting compound C59 for compound C58 in Step 2. 1H NMR (400 MHz, CDCh) δ 6.63 (br. s., 1 H), 4.86 (dd, 1 H), 3.72 - 3.83 (m, 2 H), 3.60 - 3.68 (m, 1 H), 2.67 - 2.80 (m, 1 H), 1.96 (br. s., 1 H) ,1.10 (dd, 3 H).
19F NMR (376 MHz, CDCh) δ -201.74.
Synthesis of (4R,5S)-5-(hvdroxvmethvl)-3,4-dimethylpvrrolidin-2-one (L48).
„v ho3a
This compound was prepared in the same manner as compound L37, substituting iodomethane for NFSI in Step 1, to afford (7R,7aS)-3,3,6,7-tetramethyltetrahydropyrroIo[1,2-c]oxazol-5(3H)25 one (C60), which was used in Step 2. 1H NMR (400 MHz, CD3OD) δ 3.75 - 3.50 (m, 3 H), 2.70 -2.58 (m, 1 H), 2.29-2.15 (m, 1 H), 1.21 - 1.05 (overlapping d, 6 H).
Synthesis of (3S,4S,5S)-4-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L54).
This compound was prepared in the same manner as compound L37, substituting compound 30 C54 for compound C53 in Step 1, to afford (6S,7S,7aS)-7-ethyl-6-fluoro-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C61), which was used in Step 2. 1H NMR (400 MHz, CDCh) δ 7.59 (br. s„ 1 H), 4.80 (dd, 1 H), 3.69 - 3.83 (m, 2 H), 3.52 - 3.64 (m, 1 H),
108
3.48 (br. s, 1 H), 2.27 - 2.52 (m, 1 H), 1.57 - 1.73 (m, 1 H), 1.49 (dt, 1 H), 1.04 (t, 3 H). 19F NMR (376 MHz, CDCb) δ -198.72. There was also obtained in Step 1 (6R,7S,7aS)-7-ethyl-6-fluoro3,3-dimethyltetrahydro-pyrro)o[1,2-c]oxazol-5(3H)-one (C62). 1H NMR (400 MHz, CD3CN) δ
4.78 (dd, 1 H), 4.40 (dt, 1 H), 3.93 (dd, 1 H), 3.56 (dd, 1 H), 2.30 - 2.46 (m, 1 H), 1.56 (s, 3 H),
1.52 (ddd, 1 H), 1.42 (s, 3 H), 1.35-1.48 (m, 1 H), 0.97 (t, 3 H).
Synthesis of (3R,4S,5S)-4-ethvl-3-fluoro-5-(hvdroxymethvl)pyrrolidin-2-one (L55),
O
This compound was prepared in the same manner as compound L37, substituting compound C62 for compound C58 in Step 2. 1H NMR (400 MHz, dmso-d6) δ 8.05 (br. s, 1 H), 4.88 (dd, 1
H), 3.48 - 3.46 (m, 1 H), 3.41 - 3.38 (m, 2 H), 2.32 - 2.23 (m, 1 H), 1.62 - 1.55 (m, 2 H), 0.95 (t, 3 H). 19F NMR (376 MHz, CDCh) δ -189.64.
Synthesis of (3R,4R,5S)-4-ethyl-3-fluoro-5-(hvdroxymethyl)pyrrolidin-2-one (L57),
O
This compound was prepared in the same manner as compound L37, substituting compound C63 for compound C53 in Step 1, to afford (3R,6R,7R,7aS)-7-ethyl-6-fluoro-3-(4-methoxyphenyl)tetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C64), which was used in Step 2. 1H NMR (400 MHz, CDCI3) δ 4.92 (dd, 1 H), 3.83 - 3.80 (m, 1 H), 3.56 - 3.48 m, 2 H), 2.17 - 2.10 (m, 1 H), 1.76 - 1.70 (m, 1 H), 1.52 - 1.46 (m, 1 H), 0.99 (t, 1 H).
Synthesis of (3S,4R,5S)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L90),
O
This compound was prepared in the same manner as compound L37, substituting compound
C78 for compound C53 in Step 1. Ή NMR (400 MHz, CDCb) δ 6.82 (br. s., 1 H), 4.73 (dd, 1 H),
3.87 (dd, 1 H), 3.56 (dd, 1 H), 3.28 - 3.37 (m, 1 H), 2.24 - 2.37 (m, 1 H), 1.21 (d, 3 H).
Synthesis of (3S.4S,5S)-4-cvclopropvl-3-fluoro-5-(hydroxvmethvl)pyrrolidin-2-one (L119).
109
This compound was prepared in the same manner as compound L37, substituting compound C56 for compound C53 in Step 1, to afford (6S,7S,7aS)-7-cyclopropyl-6-fluoro-3,3dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C162), which was used in Step 2. 1H NMR (400 MHz, CD3OD) δ 4.85 (dd, 1 H), 3.94 (dd, 1 H), 3.70 - 3.79 (m, 1 H), 3.60 - 3.70 (m, 1 H), 1.74 - 1.94 (m, 1 H), 0.78 - 0.94 (m, 1 H), 0.53 - 0.70 (m, 2 H), 0.23 - 0.37 (m, 2 H). There was also obtained in Step 1 (6R,7S,7aS)-7-cyclopropyl-6-fluoro-3,3-dimethyltetrahydro-pyrrolo[1,2c]oxazol-5(3H)-one (C163). 1H NMR (400 MHz, CDCI3) δ 4.91 (d, 1 H), 4.44 - 4.57 (m, 1 H), 3.94 - 4.09 (m, 2 H), 1.70 - 1.76 (m, 1 H), 1.67 (s, 3 H), 1.54 (s, 3 H), 0.55 - 0.73 (m, 3 H), 0.29 - 0.38 (m, 1 H), 0.17-0.27 (m, 1 H)
Synthesis of (3R,4S.5S)-4-cvclopropvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L120).
This compound was prepared in the same manner as compound L37, substituting compound C163 for compound C58 in Step 2. 1H NMR (400 MHz, CD3OD) δ 5.13 (dd, 1 H), 3.86 (dd, 1 H),
3.58 - 3.72 (m, 2 H), 1.71 - 1.92 (m, 1 H), 1.08 (dtd, 1 H), 0.51 - 0.70 (m, 2 H), 0.37 (dq, 1 H), 0.14 - 0.26 (m, 1 H).
Préparation 30: (4S,5S)-4-ethvl-3,3-difluoro-5-(hvdroxymethvl)pyrrolidin-2-one (L40)
O
Step 1. Synthesis of (7S,7aS)-7-ethvl-6,6-difluoro-3,3-dimethvltetrahvdropvrrolo(1,2-cloxazol5(3H)-one (C65). A solution of compound C62 (0.80 g, 4.0 mmol) in THF (30 mL) was was treated with LDA (2 M, 4.97 mL, 9.94 mmol) slowly at about -78 °C. The mixture was kept at about -78 °C for about 45 min before the addition of a solution of NFSl (1.63 g, 5.17 mmol) in THF (10 mL). The mixture was maintained at about -78 °C for about 15 min after the completion of the addition, then was warmed to about 25 °C for about 2 h. Water and EtOAc were added
110 and the EtOAc was separated. The aqueous phase was extracted with EtOAc, and the combined EtOAc extracts were washed with water, brine, dried over Na2SÜ4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C65. Yield: 350 mg (40%). 1H NMR (400 MHz, dmso-d6) δ 4.24 (dd, 1 H), 4.09 (dd, 1 H), 3.57 (m, 1 H), 2.80 - 2.76 (m, 1 H), 1.56 (s, 3 H), 1.53 - 1.38 (m, 2 H), 1.42 (s, 3 H), 0.92 (t, 3 H).
Step 2. Synthesis of (4S,5S)-4-ethvl-3.3-difluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L40),
To a stirred solution of compound C65 (350 mg, 1.91 mmol) in 14 mL of acetonitrile and 1.6 mL of water was added 4-toluenesulfonic acid (18 mg, 0.09 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L40. Yield: 260 mg (76%). Ή NMR (400 MHz, CDCI3) δ 6.59 (br. s, 1 H), 3.78 - 3.75 (m, 2 H), 3.53 - 3.51 (m, 1 H), 2.65 - 2.52 (m 1 H), 1.89 (br. s, 1 H), 1.79 - 1.69 (m, 1 H), 1.52 - 1.45 (m, 1 H), 1.08 (t, 3 H).
Synthesis of (4S,5S)-3,3-difluoro-5-(hvdroxvmethvl)-4-methvlpvrrolidin-2-one (L39)
O
HO
This compound was prepared in the same manner as compound L40, substituting compound C58 for compound C62 in Step 1. Ή NMR (400 MHz, CDCI3) δ 3.76 - 3.48 (m, 2 H), 3.29 - 2.71 (m, 1 H), 2.69 - 2.60 (m, 1 H), 1.18 - 1.06 (d, 3 H).
Synthesis of (3R,4S,5S)-3-((benzvloxv)methvl)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2one(L41)
HO
O
This compound was prepared in the same manner as compound L40, substituting compound C58 for compound C62, and benzyloxymethyl chloride (CAS 3587-60-8) for NFSI, in Step 1 to afford a (6R,7S,7aS)-6-((benzyloxy)methyl)-6-fluoro-3,3,7-trimethyltetrahydro-pyrrolo[1,2c]oxazol-5(3H)-one (C66), which was used in Step 2. 1H NMR (400 MHz, CDCI3) δ 7.21 - 7.41 (m, 5 H), 4.57 (d, 2 H), 3.47 - 3.86 (m, 5 H), 2.71 - 2.93 (m, 1 H), 1.04 (d, 3 H). There was also obtained in Step 1 (6S,7S,7aS)-6-((benzyloxy)methyl)-6-fluoro-3,3,7trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C67). 1H NMR (400 MHz, CDCI3) δ 7.28
111
7.40 (m, 5 H), 4.68 (d, 1 H), 4.53 (d, 1 H), 4.45 - 4.51 (m, 1 H), 3.95 (dd, 1 H), 3.88 (dd, 1 H),
3.59 - 3.74 (m, 2 H), 2.72-2.85 (m, 1 H), 1.61 (s, 3 H), 1.51 (s, 3 H), 0.99 (d, 3 H)
Synthesis of (3S.4S,5S)-3-((benzvloxv)methvl)-3-fluoro-5-(hvdroxvmethvl)-4-methylpyrrolidin-2one (L42),
This compound was prepared in the same manner as compound L40, substituting compound C67 for compound C65 in Step 2. 1H NMR (400 MHz, CDCI3) δ 7.28 - 7.45 (m, 5 H), 6.85 (br. s., 1 H), 4.60 (s, 2 H), 3.87 - 3.99 (m, 1 H), 3.65 - 3.86 (m, 3 H), 3.44 (dd, 1 H), 2.32 - 2.55 (m, 1 H), 2.20-2.33 (m, 1 H).
Synthesis of (3R,4S,5S)-3-fluoro-5-(hvdroxvmethvl)-3,4-dimethvlpyrrolidin-2-one (L44)
O
This compound was prepared in the same manner as compound L40, substituting compound C60 for compound C62 in Step 1, to afford (6R,7S,7aS)-6-fluoro-3,3,6,7tetramethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C68), which was used in Step 2.1H NMR (400 MHz, CD3OD) δ 4.90 - 4.78 (m, 2 H), 3.74 - 3.59 (m, 1 H), 2.81 - 2.66 (m, 1 H), 1.42 (dd, 3 H), (1.04 (d, 3 H). There was also obtained in Step 1 (6S,7S,7aS)-6-fluoro-3,3,6,7tetramethyltetrahydro-pyrrolo[1,2-c]oxazol-5(3H)-one (C69).
Synthesis of (3S,4S,5S)-3-fluoro-5-(hvdroxvmethyl)-3,4-dimethvlpvrrolidin-2-one (L45)
O
This compound was prepared in the same manner as compound L40, substituting compound C69 for compound C65 in Step 2. 1H NMR (400 MHz, CD3OD) δ 3.59 - 3.56 (m, 2 H), 3.46 3.44 (m, 1 H), 2.41 - 2.22 (m, 1 H), 1.48 - 1.39 (m, 3 H), 1.10 - 1.01 (m, 3 H).
Préparation 31 (4S,5S)-4-((benzvloxv)methvD-5-(hvdroxymethvl)pvrrolidin-2-one (L43)
112
Step 1. Synthesis of (3R,7R,7aS)-3-(4-methoxvphenvl)-7-(2-methvlprop-1-en-1-vl)tetrahvdropyrrolofl ,2-cloxazol-5(3H)-one (C70). To a solution of cuprous bromide dimethyl sulfide (6.24 g, 30.2 mmol) in THF (120 mL) was slowly added 2-methyl-1-propenylmagnesium bromide (0.5 5 M, 121 60.5 mmol) at about -15 °C. After about 15 min, the mixture was cooled to about -78 °C.
A solution of CAS 170885-07-1 (1.4 g, 6.0 mmol) and TMSCI (1.3 g, 12.1 mmol) in THF (25 mL) was added over about 15 min. After about 1 h, aqueous NH4CI was added to the mixture and it was allowed to warm to about 25 °C. Ethyl acetate was added and the EtOAc was separated, dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C70. Yield: 1.1 g (64.0%). 1H NMR (400 MHz, dmso-de) δ 7.30 (d, 2
H), 6.92 (d, 2 H), 6.05 (s, 1 H), 5.27 (dt, 1 H), 4.13 (dd, 1 H), 3.87 - 3.94 (m, 1 H), 3.74 (s, 3 H),
3.59 - 3.65 (m, 1 H), 3.15 - 3.25 (m, 1 H), 2.55 - 2.65 (m, 1 H), 2.46 - 2.52 (s, 1 H), 1.67 (d, 3 H), 1.61 (d, 3H).
Step 2. Synthesis of (3R,7S.7aS)-7-(hvdroxvmethvl)-3-(4-methoxvphenvl)tetrahvdropyrrolon,215 c1oxazol-5(3H)-one (C71). A solution of compound C70 (1.1 g, 3.8 mmol) in DCM (20 mL) was treated with ozone at about -78 °C. Once excess ozone was présent, methyl sulfide (5 mL) was added slowly. The mixture was stirred at about -78 °C for about 1 hour before being evaporated to dryness. The residue was dissolved in 9 mL of THF and 1 mL of water and treated with NaBH4 (307 mg, 7.6 mmol). The mixture was stirred for about 2 h at about 25 °C before being 20 treated with aqueous NH4CI and EtOAc. The EtOAc extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C71. Yield: 460 mg (46%). 1H NMR (400 MHz, dmso-d6) δ 7.29 (d, 2 H), 6.93 (d, 2 H), 6.03 (s, 1
H), 4.87 (t, 1 H), 4.15 (dd, 1 H), 3.89 - 3.97 (m, 1 H), 3.75 (s, 3 H), 3.40 - 3.55 (m, 3 H), 2.39 2.55 (m, 3 H).
Step 3. Synthesis of (4S,5S)-4-((benzyloxv)methvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L43).
A solution of compound C71 (220 mg, 0.84 mmol) in DMF (4.2 mL) was cooled to about 0 °C and treated with sodium hydride (60%, 40 mg, 1.0 mmol) followed by (bromomethyl)benzene (0.11 mL, 0.92 mmol). The mixture was kept for about 1 h at about 0 °C before being diluted with water. The mixture was extracted with EtOAc. The extracts were dried over Na2SO4 filtered 30 and concentrated. The residue was subjected to treatment with 4-toIuenesulfonic acid in acetonitrile and water to provide the title compound L43. Yield: 100 mg (51%). 1H NMR (400
113
MHz, dmso-de) δ 7.52 (s, 1 H), 7.26 - 7.39 (m, 5 H), 4.77 (t, 1 H), 4.48 (s, 2 H), 3.35 - 3.46 (m, 3 H), 3.26 - 3.35 (m, 2 H), 2.33 - 2.42 (m, 1 H), 2.24 - 2.33 (m, 1 H), 1.85 - 1.95 (m, 1 H).
Préparation 32: (4S,5S)-4-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L49)
O
HO
Step 1. Synthesis of (3R,7S,7aS)-7-(fluoromethvl)-3-(4-methoxvphenvl)tetrahvdropyrrolori,2c1oxazol-5(3H)-one (C72). A solution of compound C71 (460 mg, 1.75 mmol) and 2,6-lutidine (468mg, 4.37 mmol) in DCM at about 0 °C was treated with DAST (563 mg, 3.5 mmol). The mixture was stirred at about 25 °C for about 5 h before being quenched with saturated aqueous NaHCO3 and extracted with DCM. The combined DCM extracts dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C72. Yield: 410 mg (88%). LCMS: m/z, 265.3 (M+1), rétention time: 1.602 min.
Step 2. Synthesis of (4S,5S)-4-(fluoromethvl)-5-(hvdroxymethvl)pvrrolidin-2-one (L49). To a stirred solution of compound C71 (100 mg, 0.38 mmol) in 9 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (3 mg, 0.02 mmol). The reaction mixture was heated at about 90 °C until the solvent was evaporated. Additional acetonitrile and water were added and the operation was repeated several more times. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L49. Yield: 50 mg (90%). 1H NMR (400 MHz, CD3OD) δ 4.53 - 4.51 (m, 1 H), 4.41 - 4.40 (m, 1 H), 3.66 - 3.53 (m, 3 H), 2.65 - 2.54 (m, 2 H), 2.21 - 2.16 (m, 1 H).
Préparation 33: (3S,4S,5S)-4-(fluoromethvl)-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L52)
O
HO
Step 1. Synthesis of (3R,7S,7aS)-7-(fluoromethvl)-3-(4-methoxvphenvl)-6-methvltetrahydropyrroloH ,2-c1oxazol-5(3H)-one (C73). To a solution of compound C73 (160 mg, 0.61 mmol) in THF (3 mL) at about -78 °C was added LDA (2 M, 0.38 mL). The mixture was stirred for about 0.5 h before iodomethane (107 mg, 0.76 mmol) was added. The mixture was maintained for about 10 min at about -78 °C before it was warmed to about 25 °C and stirred for about 1 h. EtOAc and water were added and the mixture was extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by
chromatography to provide the title compound C73. Yield: 140 mg (82%). LCMS: m/z, 279 (M+1), rétention time: 1.244 min
Step 2. Synthesis of (3S,4S,5S)-4-(fluoromethvl)-5-(hvdroxvmethvl)-3-methvlpyrrolidin-2-one (L52). A solution of compound C73 (140 mg, 0.5 mmol) in 6.5 mL of AcOH and 3.5 mL of water 5 was heated to about 90 °C for about 40 min before being evaporated to dryness. The residue was dissolved in 25mL of MeOH and concentrated. The residue was purified by chromatography to provide the title compound L52. Yield: 70 mg (87%). 1H NMR (400 MHz, CDsOD) δ 4.62 - 4.51 (d, 2 H), 3.71 - 3.68 (m, 1 H), 3.54 (m, 2 H), 2.41 - 2.39 (m, 1 H), 2.23 2.10 (m, 1 H), 1.25 (s, 3 H).
Préparation 34: (3R,4R,5R)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L53)
O
HO—
Step 1. Synthesis of (7aR)-3,3-dimethyl-6-(phenvlselanv0tetrahvdropvrrolori ,2-cloxazol-5(3H)one (C74). LDA (2 M, 41.9 mL) was added to a solution of (R)-3,3-dimethyltetra15 hydropyrrolo[1,2-c]oxazol-5(1H)-one (CAS 103630-36-0, 10 g, 64.4 mmol) in THF (130 mL) at about-78 °C. After about 30 min, diphenyl diselenide (24.13 g, 77.3 mmol) in THF (125 mL) was added. The mixture was kept at about -78 °C for about 30 min before being warmed to about 25 °C for about 1 h. Ethyl acetate and water were added, and the mixture was partially concentrated before being extracted with EtOAc. The combined EtOAc extracts were dried over 20 Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C74. Yield: 12.0 g (60%). 1H NMR (400 MHz, CDCI3) δ 7.72 - 7.64 (m, 2 H), 7.38 - 7.27 (m, 3 H), 4.27 (dd, 1 H), 4.12 - 4.07 (m, 1 H), 3.98 - 3.92 (m, 2 H), 3.72 - 3.64 (m, 1 H), 3.31 (t, 1 H), 3.13 (t, 1 H), 2.59 - 2.53 (m, 1 H), 2.33 (dd, 2 H), 1.84- 1.75 (m, 1 H), 1.62 and 1.56 (s, 3 H), 1.59 (s, 3 H), 1.44 and 1.28 (s, 3 H).
Step 2. Synthesis of (R)-3,3-dimethyl-1,7a-dihvdropyrroloi1,2-cloxazol-5(3H)-one (C75).
A solution of compound C74 (12.0 g, 38.7 mmol) in DCM (150 mL) and pyridine (6.8 mL) at about 0 °C was treated with 30% hydrogen peroxide solution (17.86 mL, 128 mmol). The mixture was kept at about 0 °C for about 30 min before being warmed slowly to about 25 °C. After about 3 h, the mixture was diluted with DCM (100 mL) and washed with saturated aqueous 30 NaHCOs solution. The DCM extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C75.
115
Yield: 4.0 g (68%). 1H NMR (400 MHz, CDCI3) δ 7.06 (dd, 1 H), 6.09 (dd, 1 H), 4.66 - 4.62 (m, 1 H), 4.12 (dd, 1 H), 3.33 (dd, 1 H), 1.67 (s, 3 H), 1.55 (s, 3 H).
Step 3. Synthesis of (7S,7aR)-3.3,7-trimethyltetrahvdropvrrolof1,2-c1oxazol-5(3H)-one (C76).
Methyllithium (1.6 M, 34.7 mL) was added to a suspension of cuprous bromide - dimethylsulfide 5 complex (5.7g, 27.8 mmol) in diethyl ether (40 mL) at about -10 °C. After the addition was complété, the solution was cooled to about -78 °C. After about 10 min, TMSCI (3.5 mL, 27.7 mmol) was added, followed by a solution of compound C75 (1.7 g, 11.1 mmol) in THF (28 mL).
The mixture was stirred at about -78 °C for about 2 h. then was allowed to warm to about 20 °C for about 1 h. A mixture of aqueous NH4CI and ammonium hydroxide was added with stirring, 10 after which the mixture was diluted with EtOAc. The EtOAc was separated and the aqueous phase was extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C76. Yield: 1.75 g (93%). 1H NMR (400 MHz, CDCI3) δ 4.33 - 4.28 (m, 1 H), 3.86 (dd, 1 H), 3.71 (t, 1 H), 2.97 (dd, 1 H), 2.50 - 2.43 (m, 1 H), 2.11 (d, 1 H), 1.63 (s, 15 3H), 1.45 (s, 3 H), 1.01 (d, 3 H).
Step 4. Synthesis of (6R,7R,7aR)-6-fluoro-3,3,7-trimethvltetrahvdropyrrolo[1,2-c1oxazol-5(3H)one (C77). LDA (1.8 M, 7.03 mL) was added to a -78 °C solution of compound C76 (1.427 g, 8.4 mmol) in THF (27 mL). After about 1 h, a solution of NFSI (3.43 g, 10.5 mmol) in THF (8 mL) was added. After about 5 min, the mixture was allowed to warm to about 25 °C. After about 3 h, 20 EtOAc and water were added, and the mixture was partially concentrated before being extracted with EtOAc. The combined EtOAc extracts were dried over MgSO4, filtered, and concentrated. The residue was dissolved in DCM and filtered. The filtrate was concentrated and the residue was purified by chromatography to provide the title compound C77. Yield: 282 mg (18%). 1H NMR (400 MHz, CD3CN) δ 5.27 (dd, 1 H), 3.99 - 4.08 (m, 1 H), 3.95 (dd, 1 H), 3.72 (t, 25 1 H), 2.94 (quind, 1 H), 1.58 (s, 3 H), 1.39 (s, 3 H), 0.90 (dd, 3 H).
Step 5. Synthesis (3R,4R.5R)-3-fluoro-5-(hvdroxvmethvl)-4-methvlpyrrolidin-2-one (L53).
To a stirred solution of compound C77 (280 mg, 1.5 mmol) in 9 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (15 mg 0.07 mmol). The reaction mixture was heated at about 90 °C for about 1.5 h. The reaction mixture was cooled to about 25 °C, concentrated, and 30 the residue was purified by chromatography to provide the title compound L53. Yield: 169 mg (77%). 1H NMR (400 MHz, CD3CN) δ 6.56 (br. s, 1 H), 4.83 (dd, 1 H), 3.52 - 3.67 (m, 2 H), 3.37
- 3.50 (m, 1 H), 2.83 - 2.94 (m, 1 H), 2.63 - 2.80 (m, 1 H), 0.98 (dd, 3 H).
Préparation 35: (3S,4S,5S)-4-ethvl-d5-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L56).
Step 1, Synthesis of (7R.7aS)-7-ethvl-d5-3.3-dimethvltetrahvdropyrrolo[1.2-c1oxazol-5(3H)-one (C79), A solution of perdeuteroethylmagnesium bromide was prepared from 11.06 g (97 mmol) of ethyl-d5 bromide and magnésium métal (2.73 g, 112 mmol) in 80 mL of THF. A portion of this 5 solution (43.5 mL) was added to a suspension of cuprous bromide - dimethyl sulfide complex (6.78 g, 32.6 mmol) complex in THF (40 mL) at about -10 °C. The mixture was stirred at about 10 °C for about 10 min before being cooled to about -78 °C. Chlorotrimethylsilane (3.55 g, 32.6 mmol) was added. After about 15 min, compound P20 (2.0 g, 13.1 mmol) in THF (20 mL) was added. The mixture was kept at about -78 °C for about 30 min before being warmed to about 25 10 °C for about 18 h. A mixture of aqueous NH4CI and ammonium hydroxide was added with stirring, after which the mixture was diluted with EtOAc and filtered. The EtOAc was separated and the aqueous phase was extracted with EtOAc. The combined EtOAc extracts were washed with NaHCO3, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C79. Yield: 850 mg (35%). 1H NMR (400 MHz, 15 CDCh) δ 4.34 (dt, 1 H), 3.90 (dd, 1 H), 3.68 - 3.75 (m, 1 H), 2.91 (dd, 1 H), 2.31 (dd, 1 H), 2.24 (t, 1 H), 1.65 (s, 3 H), 1.48 (s, 3 H).
Step 2. Synthesis of (6S,7S,7aS)-7-ethvl-6-fluoro-3,3-dimethvltetrahydropvrrolori,2-c|oxazol5(3H)-one (C80). A solution of compound C79 (512 mg, 2.7 mmol) in 2-methylTHF (12.5 mL) was treated at about -78 °C with lithium hexamethyldisilazide (1 M, 3.0 mL) and the mixture was 20 kept for about 45 min at about -78 °C before being added into an approximate -78 °C solution of
NSFI (1.12 g, 3.54 mmol) in 2-methylTHF (12.5 mL). The mixture was kept at about -78 °C for about 30 min, then water (10 mL) and EtOAc (10 mL) were added. The EtOAc was separated and the aqueous phase was extracted with EtOAc (10 mL). The combined EtOAc extracts were washed with sodium iodide solution, sodium thiosulfate solution, NaOH solution, brine, dried 25 over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C80. Yield: 94 mg (17%). 1H NMR (400 MHz, CD3CN) δ 5.26 (dd, 1 H), 3.95 - 4.08 (m, 2 H), 3.61 - 3.71 (m, 1 H), 2.62 - 2.75 (m, 1 H), 1.58 (s, 3 H), 1.40 (s, 3 H).
Step 3. Synthesis of (3S,4S,5S)-4-ethyl-d5-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L56).
To a stirred solution of compound C80 (94 mg, 0.46 mmol) in 18 mL of acetonitrile and 2 mL of 30 water was added 4-toluenesulfonic acid (4 mg, 0.02 mmol). The reaction mixture was heated at about 90 °C for about 4 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L56. Yield: 51 mg
117 (67%). 1Η NMR (400 MHz, CD3CN) δ 6.76 (br. s., 1 H), 4.73 (dd, 1 H), 3.57 - 3.67 (m, 2 H), 3.32 - 3.42 (m, 1 H), 2.85 (t, 1 H), 2.40 (dt, 1 H).
Préparation 36: (4R.5S)-5-(hvdroxvmethvl)-4-(methoxvmethvl)pyrrolidin-2-one (L60)
O
HO
Step 1, Synthesis of (7R,7aS)-7-(hvdroxvmethvl)-3,3-dimethvltetrahvdropyrrolo[1,2-cloxazol5(3H)-one (C82). A stream of ozonized oxygen was bubbled through a solution of compound C55 (1.95 g, 10.8 mmol) in DCM (49 mL) and MeOH (16 mL) at about -78 °C for about 2 h. Dimethyl sulfide (10 mL) was added at about -78 °C, followed NaBH4 (2.44 g, 64.6 mmol) at the same température. After about 30 min, the reaction was warmed to about 0 °C and stirred for about 2 h. Ethyl acetate was added, and the mixture was washed with water, then brine. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C82. Yield: 1.2 g (60%). 1H NMR (400 MHz, CDCh) δ 4.40 - 4.34 (m, 1 H), 3.97 (dd, 1 H), 3.86 (dd, 1 H), 3.72 - 3.62 (m, 2 H), 2.94 (dd, 1 H), 2.58 - 2.53 (m, 1 H), 2.25 (d, 1 H), 1.64 (s, 3 H), 1.45 (s, 3 H).
Step 2. Synthesis of (7R,7aS)-7-(methoxvmethvl)-3.3-dimethvltetrahvdropvrrolo|1,2-c1oxazol5(3H)-one (C83). To a stirred solution of compound C55 (1.4 g, 7.5 mmol) in THF (40 mL) was added freshly prepared silver(l) oxide (17.48 g, 75.7 mmol), followed by iodomethane (5.37 g, 37.8 mmol). The mixture was heated at about 70 °C for about 16 h. The mixture was then cooled to about 25 °C, filtered and concentrated. The residue was purified by chromatography to provide the title compound C83. Yield: 1.1 g (73%). 1H NMR (400 MHz, CDCh) δ 4.36 - 4.30 (m, 1 H), 3.92 (dd, 1 H), 3.68 (dd, 1 H), 3.39 - 3.25 (m, 2 H), 3.30 (s, 3 H), 2.93 (dd, 1 H), 2.61 2.53 (m, 1 H), 2.22 (dd, 1 H), 1.62 (s, 3 H), 1.46 (s, 3 H).
Step 3. Synthesis of (4R,5S)-5-(hvdroxvmethvl)-4-(methoxvmethvl)pyrrolidin-2-one (L60),
To a stirred solution of compound C83 (200 mg, 1.0 mmol) in 18.8 mL of acetonitrile and 2.1 mL of water was added 4-toluenesulfonic acid (9 mg, 0.05 mmol). The reaction mixture was heated to reflux for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L60. Yield: 150 mg (93%). 1H NMR (400 MHz, dmso-d6) δ 3.49 - 3.34 (m, 5 H), 3.32 (s, 3 H), 3.23 (s, 3 H), 2.73 2.60 (m, 1 H), 2.09 - 1.95 (m, 2 H).
Préparation 37: (4R,5S)-3-fluoro-5-(hvdroxvmethvl)-4-(methoxvmethvl)pyrrolidin-2-one (L61)
118
Step 1, Synthesis of (7R,7aS)-6-fluoro-7-(methoxvmethvl)-3,3-dimethvltetrahvdropvrrolori.2cloxazol-5(3H)-one (C84), A solution of compound C83 (250 mg, 1.3 mmol) in THF (10 mL) was treated with lithium hexamethyldisilazide (1 M, 2.13 mL) at -78 °C and kept for about 30 min before the addition of a solution of NFSI (436 mg, 1.4 mmol) in THF (10 mL). The mixture was maintained for about 30 min at about -78 °C and then was allowed to warm to about 25 °C for about 1 h. Water and EtOAc were added and the phases were separated. The EtOAc extract EtOAc extracts were washed with sodium iodide solution, sodium thiosulfate solution, NaOH solution, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C84. Yield: 90 mg (33%). 1H NMR (400 MHz,
CDCIa) δ 4.88 (d, 1 H), 4.51 - 4.46 (m, 1 H), 3.96 (dd, 1 H), 3.70 (dd, 1 H), 3.49 - 3.44 (m, 2 H),
3.31 (s, 3 H), 2.74 - 2.63 (m, 1 H), 1.63 (s, 3 H), 1.46 (s, 3 H). There was also obtained (7R,7aS)-6,6-difluoro-7-(methoxymethyl)-3,3-dimethyltetrahydro-pyrrolo[1,2-c]oxazol-5(3H)-one (C85). Yield 45 mg (15%). 1H NMR (400 MHz, CDCI3) δ 4.24 - 4.19 (m, 1 H), 4.08 (dd, 1 H),
3.79 (dd, 1 H), 3.55 (dd, 1 H), 3.48 (dd, 1 H), 3.30 (s, 3 H), 2.94 - 2.85 (m, 1 H), 1.65 (s, 3 H), 15 1.53 (s, 3 H).
Step 2. Synthesis of (7R,7aS)-6-fluoro-7-(methoxvmethvl)-3,3-dimethvltetrahvdropyrrolo[1,2cloxazol-5(3H)-one (C86). A solution of compound C84 (125 mg, 0.575 mmol) in THF (10 mL) was treated with potassium hexamethyldisilazide (1 M, 0.115 mL) at about 0 °C. After about 5 min, the mixture was allowed to warm to about 25 °C for about 2 h. Aqueous sodium dihydrogen 20 phosphate was added and the mixture was extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to provide the title compound C86. Yield: 115 mg (92%). Ή NMR (400 MHz, CDCI3) δ 5.28 (dd, 1 H, diastereomer
1) , 4.89 (d, 1 H, diastereomer 2), 4.51 - 4.47 (m, 1 H, diastereomer 2), 4.07 - 4.01 (m, 2 H, diastereomer 1), 3.96 (dd, 1 H, diastereomer 2), 3.83 - 3.78 (m, 1 H, diastereomer 1), 3.70 (dd,
1 H, diastereomer 2), 3.57 - 3.53 (m, 1 H, diastereomer 1), 3.49 - 3.44 (m, 2 H, diastereomer
2) , 3.47 - 3.43 (m, 1 H, diastereomer 1), 3.31 (s, 3 H, diastereomer 2), 3.30 (s, 3 H, diastereomer 1), 3.04 - 3.00 (m, 1 H, diastereomer 1), 2.74 - 2.63 (m, 1 H, diastereomer 2),
1.67 (s, 3 H, diastereomer 1), 1.63 (s, 3 H, diastereomer 2), 1.49 (s, 3 H, diastereomer 1), 1.46 (s, 3 H, diastereomer 2).
Step 3. Synthesis of (4R,5S)-3-fluoro-5-(hvdroxvmethvl)-4-(methoxvmethvl)pyrrolidin-2-one (L61). To a stirred solution of compound C86 (130 mg, 0.6 mmol) in 10 mL of acetonitrile and
0.6 mL of water was added 4-toluenesulfonic acid (6 mg, 0.03 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound
119
L61. Yield: 80 mg (76%). 1H NMR (400 MHz, CDCb) δ 5.12 (dd, 1 H, diastereomer 1), 4.94 (dd,
H, diastereomer 2), 3.85 - 3.54 (m, 10 H, diastereomers 1 and 2), 3.42 (s, 3 H, diastereomer 1), 3.37 (s, 3 H, diastereomer 2), 2.95 - 2.84 (m, 2 H, diastereomers 1 and 2).
Synthesis of (4R,5S)-3,3-difluoro-5-(hvdroxvmethvl)-4-(methoxvmethvl)pyrrolidin-2-one (L63)
O
This compound was prepared in the same manner as compound L61, substituting compound
C85 for compound C86 in Step 3. 1H NMR (400 MHz, CDCI3) δ 3.88 - 3.81 (m, 2 H), 3.75 3.71 (m, 1 H), 3.66 - 3.61 (m, 2 H), 3.39 (s, 3 H), 3.05 - 2.95 (m, 1 H).
Préparation 38: (3S,4S,5S)-4-ethvl-5-(hvdroxvmethvl)-3-methoxvpyrrolidin-2-one (L66)
Step 1. Synthesis of (7S.7aS)-7-ethvl-6-hvdroxv-3,3-dimethvltetrahvdropyrroloi1,2-c1oxazol5(3H)-one (C87). A solution of compound C54 (1.0 g, 5.5 mmol) in THF (25 mL) was treated with LDA (3.4 mL, 6.8 mmol) at about -78 °C. The mixture was kept for about 20 min and then treated with a solution of (1R)-(-)-(10-camphorsulfonyl)oxaziridine (CAS 104372-31-8, 1.50 g, 6.5 mmol) in THF (5 mL). After about 30 min, the mixture was allowed to warm to about 25 °C for about 30 min. Methanol (2 mL) was added and the mixture was concentrated. The residue was purified by chromatography to provide the title compound C87. Yield: 800 mg (73%). This was used in the next step without further characterization.
Step 2. Synthesis of (6S,7S,7aS)-7-ethvl-6-methoxv-3,3-dimethvltetrahvdropyrrolori.2-c1oxazol5(3H)-one (C88). To a stirred solution of compound C87 (800 mg, 4.0 mmol) in THF (50 mL) was added freshly prepared silver(l) oxide (9.3 g, 40.2 mmol), followed by iodomethane (1.25 ml, 20.1 mmol). The mixture was heated at about 75 °C for about 16 h. The mixture was then cooled to about 25 °C, filtered and concentrated. The residue was purified by chromatography to provide the title compound C88. Yield: 180 mg (21%). 1H NMR (400 MHz, CDCh) δ 4.09 (d, 1 H), 4.04 - 3.96 (m, 2 H), 3.70 - 3.66 (m, 1 H), 3.55 (s, 3 H), 2.52 - 2.50 (m, 1 H), 1.69 - 1.64 (m, 1 H), 1.62 (s, 3 H), 1.48 - 1.41 (m, 1 H), 1.47 (s, 3 H), 0.90 (t, 3 H). There was also obtained (6R,7S,7aS)-7-ethyl-6-methoxy-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C89). Yield: 375 mg (44%). 1H NMR (400 MHz, CDCI3) δ 4.44 - 4.40 (m, 1 H), 3.92 - 3.89 (m,
120
H), 3.66 (s, 1 H), 3.64-3.59 (m, 1 H), 3.53 (s, 3 H), 2.17 - 2.12 (m, 1 H), 1.62 (s, 3 H), 1.501.41 (m, 1 H), 1.48 (s, 3 H), 1.38 - 1.30 (m, 1 H), 0.97 (t, 3 H).
Step 3. Synthesis of (3S.4S,5S)-4-ethvl-5-(hvdroxvmethvl)~3-methoxvpyrrolidin-2-one (L66).
To a stirred solution of compound C88 (180 mg, 0.8 mmol) in 9 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (7 mg, 0.04 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L66. Yield: 75 mg (51%). 1H NMR (400 MHz, CDCb) δ 6.09 (br, 1 H), 3.68 - 3.64 (m, 2 H), 3.61 (s, 3 H), 3.57 (d, 1 H), 3.48 (br. s, 1 H), 2.84 (br. s, 1 H), 2.42 - 2.30 (m, 1 H), 1.64 - 1.58 (m, 1 H), 1.47 - 1.33 (m, 1 H), 0.97 (t, 3 H).
Synthesis of (3R14S,5S)-4-ethvl-5-(hvdroxvmethvl)-3-methoxvpyrrolidin-2-one (L67).
This compound was prepared in the same manner as compound L66, substituting compound C89 for compound C88 in Step 3. 1H NMR (400 MHz, CDCb) δ 6.10 (br. s, 1 H), 3.75 - 3.70 (m, 2H), 3.63 (s, 3 H), 3.62-3.60 (m, 2 H), 2.35-2.27 (m, 1 H), 2.12 (br. s, 1 H), 1.73-1.64 (m, 1 H), 1.61 - 1.52 (m, 1 H), 1.00 (t, 3 H).
Synthesis of (3S,4S,5S)-5-(hvdroxvmethvl)-3-methoxv-4-methvlpyrrolidin-2-one (L64).
This compound was prepared in the same manner as compound L66, substituting compound C53 for compound C54 in Step 1 to afford (7S,7aS)-6-hydroxy-3,3,7-trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C90). Application of Step 2 to compound C90 afforded (6S,7S,7aS)-6-methoxy-3,3,7-trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C91) and (6R,7S,7aS)-6-methoxy-3,3,7-trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one (C92).
Application of Step 3 to compound C91 afforded the title compound L64. 1H NMR (400 MHz, CDCb) δ 3.65 - 3.62 (m, 4 H), 3.59 (s, 3 H), 3.48 (br. s, 1 H), 2.69 - 2.64 (m, 1 H), 1.01 (d, 3 H).
Synthesis of (3R,4S,5S)-5-(hvdroxvmethvl)-3-methoxv-4-methvlpyrrolidin-2-one (L65).
121
HO
This compound was prepared in the same manner as compound L64, substituting compound C92 for compound C91 in Step 3. 1H NMR (400 MHz, CDCIs) δ 6.37 (br. s, 1 H), 3.74 - 3.64 (m, 3 H), 3.63 (s, 3 H), 3.58 - 3.55 (m, 1 H), 2.53 -2.47 (m, 1 H), 2.45 (br. s, 1 H), 1.20 (d, 3 H).
Synthesis of (4S.5S)-3-(benzvloxv)-4-ethvl-5-(hvdroxvmethvl)pvrrolidin-2-one (L68),
This compound was prepared in the same manner as compound L66, substituting (bromomethyl)benzene for iodomethane in Step 2 and using the resulting mixture of diastereomers in Step 3. 1H NMR (400 MHz, CDCI3) δ 7.39 - 7.26 (m, 5 H, both diastereomers), 6.27 (br. s, 1 H, both diastereomers), 5.15 (d, 1 H, diastereomer 1), 5.01 (d, 1 H, diastereomer 2), 4.71 (d, 1 H, both diastereomers), 3.93 (d, 1 H, diastereomer 1), 3.78 (d, 1 H, diastereomer 2), 3.69 - 3.60 (m, 3 H, both diastereomers), 2.40 - 2.32 (m, 1 H, both diastereomers), 1.69 - 1.63 (m, 1 H, both diastereomers), 1.54 - 1.40 (m, 1 H, both diastereomers), 0.98 (t, 3 H, diastereomer 1), 0.92 (t, 3 H, diastereomer 2).
Préparation 39: tert-butyl ((4S,5S)-4-ethvl-5-(hvdroxvmethvl)-2-oxopyrrolidin-3-vl)carbamate (L7ÇQ
Step 1, Synthesis of (7S,7aS)-6-azido-7-ethvl-3.3-dimethvltetrahvdropyrrolo[1,2-c1oxazol-5(3H)one (C93). LDA (2.0 M, 1.7 mL) was added to a solution of compound C54 (500 mg, 2.7 mmol) in THF (20 mL) at about -78 °C. After about 30 minutes at about -78 °C, a 10% solution 2,4,6triisopropylbenzenesulfonyl azide (CAS 36982-84-0, 2.0 mL, 0.66 mmol) was added. After stirring at about -78 °C for about 10 min, the solution was allowed to warm to about 25 °C for about 1 h. Aqueous NH4CI solution was added and the mixture was extracted with EtOAc. The EtOAc extracts were dried over NazSCU, filtered and concentrated. The residue was purified by
122
chromatography to provide the title compound C93. Yield: 500 mg (82%). 1H NMR (400 MHz,
CDCh) δ 4.43 (d, 1 H), 4.13 - 4.08 (m, 1 H), 4.00- 3.97 (m, 1 H), 3.70 - 3.65 (m 1 H), 2.49 2.47 (m, 1 H), 1.65 (s, 3 H), 1.75 - 1.42 (m, 2 H), 1.47 (s, 3 H), 0.90 (t, 3 H).
Step 2. Synthesis of (7R,7aS)-6-amino-7-ethvl-3,3-dimethvltetrahvdropvrroloi1,2-c1oxazol5 5(3H)-one (C94), To a solution of compound C93 (500 mg, 2.2 mmol) in MeOH (30 mL) was added palladium on carbon (100 mg) and the mixture was stirred under a hydrogen atmosphère (1 atm) for about 16 h. The mixture was filtered and the filtrate was concentrated to provide the title compound C94. Yield: 380 mg (86%). This was used in the next step without further characterization.
Step 3. Synthesis of (4R,5S)-3-amino-4-ethvl-5-(hvdroxymethvl)pvrrolidin-2-one (C95). To a stirred solution of compound C94 (380 mg, 1.9 mmol) in 27 mL of acetonitrile and 3 mL of water was added 4-toiuenesulfonic acid (0.40 g, 2.3 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C and concentrated to provide the title compound C95. Yield: 300 mg (47%). 1H NMR (400 MHz, dmso-de) δ 7.47 (d, 2
H), 7.11 (d, 2 H), 4.13-4.10 (m, 1 H), 3.71 -3.56 (m, 2 H), 3.46-3.43 (m, 1 H), 2.07 (s, 3 H),
2.06 - 1.91 (m, 1 H), 1.50 - 1.47 (m, 1 H), 1.39 - 1.35 (m, 1 H), 0.92 (t, 3 H).
Step 4. Synthesis of tert-butyl ((4S,5S)-4-ethvl-5-(hvdroxvmethvl)-2-oxopyrrolidin-3vDcarbamate (L70). To a solution of compound C95 (300 mg, 1.9 mmol) and Et3N (0.78 mL, 5.7 mmol) in THF (10 mL) and water (10 mL) was added di-t-butyl dicarbonate (0.83 mL, 3.8 mmol).
The mixture was kept at about 25 °C for about 16 h. The reaction mixture was concentrated and the residue was purified by chromatography to provide the title compound L70. Yield: 280 mg (ca. 100%). Ή NMR (400 MHz, dmso-d6) δ 7.76 (br. s, 1 H), 6.37 (d, 1 H), 5.44 (t, 1 H), 4.07 3.93 (m, 1 H), 3.48 - 3.43 (m, 2 H), 3.37 (br. m, 1 H), 2.36 - 2.33 (m, 1 H), 1.55 - 1.45 (m, 1 H), 1.37 (s, 9 H), 1.33 - 1.28 (m, 1 H), 0.83 (t, 3 H).
Préparation 40: (1R,4S,5S.6S)-4-(hvdroxymethvl)-6-methvl-3-azabicvcloF3.1 .Olhexan-2-one (L74)
Step 1. Synthesis of (3R,5aR,6S,6aS,6bS)-3-(4-methoxvphenvl)-6-methvltetrahydro-1Hcvclopropai3,41pyrrolo[1,2-cloxazol-5(3H)-one (C96). To a stirred suspension of 30 ethyldiphenylsulfonium tetrafluoroborate (CAS 893-69-6, 31.36 g, 104 mmol) in THF (200 mL) was added LDA (2 M, 65 mL, 130 mmol) slowly at about -78 °C. The reaction mixture was kept at about -78 °C for about 1.5 h, at which point a solution of (3R,7aS)-3-(4-methoxyphenyl)-1,7adihydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 170885-07-1, 12.0 g, 51.9 mmol) in THF (90 mL) was added slowly. The reaction mixture was maintained at about -78 °C for about 1.5 h and 35 then allowed to warm to about 25 °C. It was stirred for about 1.5 h at about 25 °C before being
123 quenched with EtOAc and NaHCOs solution. The EtOAc was separated, and the aqueous phase was back extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C96. Yield 6.5 g (48%). 1H NMR (400 MHz, CDCb): δ 7.27 (d, 2 H), 6.84 (d, 2 H), 6.23 (s, 1 H), 4.14 (dd, 1 H), 3.88 (dd, 1 H), 3.78 (s, 3 H), 3.38 (dd, 1 H), 1.88 - 1.86 (m, 1 H), 1.79 - 1.77 (m, 1 H), 1.51 - 1.47 (m, 1 H), 1.14 (d, 3 H). There was also obtained (3R,5aR,6R,6aS,6bS)-3-(4-methoxyphenyl)-6-methyltetrahydro-1H-cyclopropa[3,4]pyrrolo[1,2c]oxazol-5(3H)-one (C97). Yield: 1.5 g (11%). 1H NMR (400 MHz, CDCb): δ 7.29 (d, 2 H), 6.85 (d, 2 H), 6.26 (s, 1 H), 4.20 (t, 1 H), 3.78 (s, 3 H), 3.70 (t, 1 H), 3.53 (dd, 1 H), 2.12 - 2.06 (m, 2 H), 1.61 - 1.55 (m, 1 H), 1.26 (d, 3 H).
Step 2, Synthesis of (1R,4S,5S.6S)-4-(hvdroxvmethvl)-6-methyl-3-azabicyclor3.1.01hexan-2-one (L74), To a stirred solution of compound C96 (1.7 g, 6.6 mmol) in 45 mL of acetonitrile and 5 mL of water was added 4-toluenesulfonic acid (64 mg, 0.33 mmol). The reaction mixture was heated at about 90 °C for about 45 min. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L74. Yield: 0.83 g (90%). 1H NMR (400 MHz, CD3OD) δ 3.40 - 3.59 (m, 3 H), 1.71 (dd, 1 H), 1.57 (dt, 1 H), 1.13 (d, 3 H), 1.02 (dd, 1 H).
Synthesis of (1 R,4S,5S,6R)-4-(hvdroxvmethvl)-6-methvl-3-azabicvclof3.1 .OIhexan-2-one (L75).
This compound was prepared in the same manner as compound L74, substituting compound C97 for compound C96 in Step 2. 1H NMR (400 MHz, CD3CN) δ 6.12 (br. s., 1 H), 3.45 - 3.54 (m, 2 H), 3.35 (br. s, 1 H), 3.26 - 3.33 (m, 1 H), 1.69 - 1.80 (m, 2 H), 1.23 - 1.39 (m, 1 H), 1.02 (d, 3 H).
Synthesis of (1 R,4S,5S)-4-(hvdroxymethvl)-3-azabicvclof3.1 .QIhexan-2-one (L72).
O
This compound was prepared in the same manner as compound L74, substituting (3R,5aR,6aS,6bS)-3-(4-methoxyphenyl)tetrahydro-1H-cyclopropa[3,4]pyrrolo[1,2-c]oxazol18098
124
5(3H)-one (CAS 187742-05-8) for compound C96 in Step 2. 1H NMR (400 MHz, CD3OD) δ 3.47 -3.61 (m, 3 H), 1.97 (ddd, 1 H), 1.75-1.86 (m, 1 H), 1.19 (td, 1 H), 0.59-0.68 (m, 1 H).
Synthesis of (1S,4S,5R)-4-(hvdroxvmethvl)-6,6-dimethvl-3-azabicvcloi3.1.01hexan-2-one (L73),
This compound was prepared in the same manner as compound L74, substituting (1methyl)ethyldiphenylsulfonium tetrafluoroborate (CAS 40447-58-3) for CAS 893-69-6 in Step 1. 1H NMR (400 MHz, CDCI3) δ 7.04 (br. s., 1 H), 3.88 (br. s., 1 H), 3.61 - 3.70 (m, 1 H), 3.48 - 3.61 (m, 1 H), 3.44 (d, 1 H), 1.70 (d, 1 H), 1.51 (d, 1 H), 1.10 (s, 3 H), 1.10 (s, 3 H).
Synthesis of (1 R,4S,5S,6S)-6-ethvl-4-(hydroxvmethvl)-3-azabicvclo[3.1,01hexan-2-one (L76).
This compound was prepared in the same manner as compound L74, substituting propyldiphenylsulfonium tetrafluoroborate (CAS 14264-05-2) for CAS 893-69-6 in Step 1 to afford (3R,5aR,6S,6aS,6bS)-6-ethyl-3-(4-methoxyphenyl)tetrahydro-1H-cyclopropa[3,4]pyrrolo[1,2-c]oxazol-5(3H)-one (C98), which was used in Step 2. 1H NMR (400 MHz, CDCI3) δ 6.56 (br. s., 1 H), 3.63 - 3.69 (m, 1 H), 3.62 (d, 1 H), 3.49 - 3.56 (m, 1 H), 3.48 (br. s, 1 H), 1.63 (ddd, 1 H), 1.55 (ddd, 1 H), 1.29 - 1.39 (m, 2 H), 0.99 (t, 3 H), 0.95 - 1.05 (m, 1 H). There was also obtained in Step 1 (3R,5aR,6R,6aS,6bS)-6-ethyl-3-(4-methoxyphenyl)-tetrahydro-1Hcyclopropa[3,4]pyrrolo[1,2-c]oxazol-5(3H)-one (C99). 1H NMR (400 MHz, CDCI3) δ 7.30 (d, 2 H), 6.88 (d, 2 H), 6.28 (s, 1 H), 4.22 (dd, 1 H), 3.81 (s, 3 H), 3.73 (dd, 1 H), 3.53 (dd, 1 H), 2.14 (d, 2 H), 1.57- 1.67 (m, 2 H), 1.51 (dd, 1 H), 1.08 (t, 3 H).
Synthesis of (1 R,4S,5S,6R)-6-ethvl-4-(hvdroxvmethvl)-3-azabicyclor3.1 .OIhexan-2-one (L77).
125
This compound was prepared in the same manner as compound L74, substituting compound C99 for compound C96 in Step 2. 1H NMR (400 MHz, CDCI3) δ 6.99 (br. s, 1 H), 4.41 (br. s., 1
H), 3.68 (dd, 1 H), 3.57 (dd, 1 H), 3.40 - 3.48 (m, 1 H), 1.95 (ddt, 1 H), 1.71-1.77 (m, 1 H), 1.34 - 1.43 (m, 2 H), 1.19 - 1.29 (m, 1 H), 1.02 (t, 3 H).
Préparation 41 : (1 S,4S,5R,6S)-6-(fluoromethvl)-4-(hvdroxvmethyl)-3-azabicvclo[3.1 .OIhexan-2one(L79)
Step 1. Synthesis of (3R,5aS,6S,6aR,6bS)-ethyl 3-(4-methoxyphenvl)-5-oxohexahvdro-1Hcvclopropai3.41pyrrolori ,2-cloxazole-6-carboxylate (C100). (Carbethoxymethyl)dimethyl10 Isulfonium bromide (CAS 5187-82-6, 15 g, 64.9 mmol) was dissolved in CHCh (130 mL). A saturated aqueous K2CO3 solution (61 mL) was added slowly with vigorous stirring, followed by aqueous NaOH solution (50%, 5.7 mL). Stirring was continued for about 30 min. The CHCh layer was separated and the aqueous phase was extracted with additional CHCI3. The combined CHCI3 extracts were dried over K2CO3, filtered and concentrated to afford a clear 15 yellow colored liquid (9.58 g). This was dissolved in DMSO (100 mL). A solution of CAS 170885-07-1 (6.17 g, 26.7 mmol) in DMSO (33 mL) was added. The mixture was kept for 3 days at about 25 °C. Ethyl acetate (500 mL) was added and the mixture was washed with brine (3 x 200 mL). The combined brine washes were extracted with EtOAc and the combined EtOAc extracts were dried over MgSO4, filtered and concentrated. The residue was purified by 20 chromatography to provide the title compound C100. Yield: 4.0 g (47%). 1H NMR (400 MHz,
CDCIs) δ 7.27 (d, 2 H), 6.86 (d, 2 H), 6.24 (s, 1 H), 4.19 - 4.24 (m, 1 H), 4.13 - 4.19 (m, 2 H), 3.96 (dd, 1 H), 3.79 (s, 3 H), 3.46 (dd, 1 H), 2.61 (dd, 1 H), 2.50 (ddd, 1 H), 2.24 (t, 1 H), 1.27 (t, 3 H). There was also obtained (3R,5aS,6R,6aR,6bS)-ethyl 3-(4-methoxyphenyl)-5oxohexahydro-1H-cyclopropa[3,4]pyrrolo[1,2-c]oxazole-6-carboxylate (C101). Yield: 4.33 g 25 (51%). 1H NMR (400 MHz, CDCI3) δ 7.25 (d, 2 H), 6.84 (d, 2 H), 6.26 (s, 1 H), 4.20 (dd, 1 H),
4.08 - 4.15 (m, 1 H), 4.08 (q, 2 H), 3.78 (s, 3 H), 3.46 (dd, 1 H), 2.37 - 2.45 (m, 3 H), 1.10 (t, 3 H).
Step 2. Synthesis of (3R,5aS,6S,6aS,6bS)-6-(hvdroxymethvl)-3-(4-methoxvphenvl)tetrahvdro1 H-cvclopropaf3,4lpvrroloi1,2-c]oxazol-5(3H)-one (C102). Lithium triethylborohydride (1 M, 30 22.1 mL) was slowly added to a solution of compound C100 (1.80 g, 5.7 mmol) in THF (5.3 mL) at -78 °C. The mixture was kept at about -78 °C for an additional about 1 h before the slow addition of saturated aqueous NaHCO3 solution (4.0 mL). The mixture was allowed to warm to
about 0 °C, after which aqueous hydrogen peroxide solution (30%, 3.0 mL) was added dropwise to control the ensuing exothermic reaction. The mixture was then kept for about 20 min at about 0 °C. The THF was evaporated under educed pressure and water (10 mL) was added. The mixture was extracted with DCM and the combined DCM extracts were dried over Na2SC>4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C102. Yield: 900 mg (58%). 1H NMR (400 MHz, CDCI3) δ 7.28 (d, 1 H), 6.86 (d, 2
H), 6.24 (s, 1 H), 4.17 (dd, 1 H), 3.92 (dd, 1 H), 3.79 (s, 3 H), 3.61 (d, 2 H), 3.42 (dd, 1 H), 2.36 (br. s., 1 H), 2.14 (dd, 1 H), 2.00 - 2.06 (m, 1 H), 1.73 -1.81 (m, 1 H). There was also obtained
400 mg (25%) of the aldéhyde.C108. In a similar manner, treatment of compound C101 with 10 lithium triethylborohydride afforded C104. 1H NMR (400 MHz, CDCh) δ 7.29 (d, 2 H), 6.87 (d, 2
H), 6.27 (s, 1 H), 4.24 (dd, 1 H), 3.97 (dd, 1 H), 3.81 - 3.88 (m, 2 H), 3.80 (s, 3 H), 3.53 (dd, 1 H), 2.21 - 2.32 (m, 2 H), 1.81-1.94 (m, 2 H).
Step 3. Synthesis of (3R,5aS,6S,6aR,6bS)-6-(fluoromethvl)-3-(4-methoxyphenvl)tetrahvdro-1Hcvclopropai3.41pyrrolo[1,2-c1oxazol-5(3H)-one (C103). A solution of compound C102 (200 mg
0.73 mmol) in DCM (3.6 mL) was treated with EtsN (1.1 mL 7.3 mmol) followed by XtalFIuor-E (249 mg 1.1 mmol) and triethylamine trihydrofluoride (0.24 mL 1.4 mmol) in a polyethylene vial at about 25 °C. The mixture was kept for 3 days at about 25 °C. Three additional experiments were prepared similarly. Aqueous NaHCO3 (4 mL) was added to each vial with stiring. After about 20 min, the experiments were poured into aqueous NaHCO3 and extracted with DCM.
The combined DCM extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C103. Yield: 421 mg (52%). 1H
NMR (400 MHz, CD3CN) δ 7.27 (d, 2 H), 6.90 (d, 2 H), 6.06 (s, 1 H), 4.39 (ddd, 1 H), 4.20 - 4.34 (m, 1 H), 4.17 (dd, 1 H), 3.97 (dd, 1 H), 3.77 (s, 3 H), 3.38 (dd, 1 H), 2.25 - 2.32 (m, 1 H), 1.99 2.04 (m, 1 H), 1.90 (dt, 1 H).
Step______4.______Synthesis______of______(1S,4S,5R,6S)-6-(fluoromethvl)-4-(hvdroxvmethyl)-3azabicvcloi3.1 .Olhexan-2-one (L79). To a stirred solution of compound C103 (421 mg, 1.5 mmol) in 18 mL of acetonitrile and 2 mL of water was added 4-toluenesulfonic acid (15 mg, 0.08 mmol). The reaction mixture was heated at about 85 °C for about 1.5 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L79. Yield: 209 mg (87%). 1H NMR (400 MHz, CD3OD) δ 4.43 (ddd,
H), 4.31 (ddd, 1 H), 3.51 - 3.66 (m, 3 H), 2.04 (ddd, 1 H), 1.93 (m, 1 H), 1.49 (qt, 1 H).
Synthesis of (1S,4S,5R,6R)-6-(fluoromethyl)-4-(hvdroxvmethvl)-3-azabicyclor3.1 .Olhexan-2-one (L78).
This compound was prepared in the same manner as compound L79, substituting compound
C101 for compound C100 in Step 2. 1H NMR (400 MHz, CDCI3) δ 4.40 (ddd, 1 H), 4.28 (ddd, 1 H), 3.69 (s, 2 H), 3.53 - 3.61 (m, 1 H), 1.89 (m, 2 H), 1.45 - 1.55 (m, 1 H).
Préparation 42: (1 R,4S,5S)-6-(2-fluoroethvl)-4-(hvdroxvmethyl)-3-azabicvclo[3.1 .OIhexan-2-one
Step 1, Synthesis of (3-fluoropropyl)diphenvlsulfonium tetrafluoroborate (C105). A mixture of 1iodo-3-fluoropropane (CAS 462-40-8, 8.80 g, 46.8 mmol), diphenyl sulfide (23.5 mL, 140 mmol) 15 and silver(l) tetrafluoroborate (9.11 g, 46.8 mmol) in DCM (100 mL) was heated at about 38 °C for about 19 h. The mixture was diluted with DCM (100 mL), filtered, and the filtrate was concentrated to about 50 mL volume. After filtration, the filtrate was diluted with ethyl ether (100 mL). The white precipitate was separated from the liquid by décantation, and the precipitate was washed with two additional portions of DCM - ethyl ether, then dried under reduced pressure to provide the title compound C105. Yield: 10.0 g (53%). 1H NMR (400 MHz, CDCI3) δ 7.92 - 8.00 (m, 4 H), 7.64 - 7.78 (m, 6 H), 4.66 (dt, 2 H), 4.31 (t, 2 H), 2.21 (dtt, 2 H).
Step 2. Synthesis of (3R,5aR,6aS,6bS)-6-(2-fluoroethvl)-3-(4-methoxyphenvl)tetrahvdro-1Hcvclopropaf3.41pvrrolof1,2-c1oxazol-5(3H)-one (C106). A solution of compound C105 (578 mg,
1.7 mmol) in THF (15 mL) was treated with tert-butyllithium solution (1.7 M, 1.32 mL) at about 25 78 °C. The mixture was kept for about 30 min at about -78 °C, then a solution of CAS 17088507-1 (200 mg, 0.87 mmol) in THF (5 mL) was added. After about 3 h at about -78 °C, aqueous NH4CI solution was added and the mixture was extracted with EtOAc. The combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C106. Yield: 170 mg (67%). 1H NMR (400 MHz,
CD3CN) δ 7.27 (d, 2 H, diastereomer 1), 7.26 (d, 2 H, diastereomer 2), 6.90 (d, 2 H,
128
diastereomer 1), 6.89 (d, 2 H, diastereomer 2), 6.07 (s, 1 H, diastereomer 1), 6.06 (s, 1H, diastereomer 2), 4.60 (q, 2 H, diastereomer 1), 4.48 (q, 2 H, diastereomer 2), 4.24 (dd, 1H, diastereomer 2), 4.20 (dd, 1 H, diastereomer 1), 4.13 (dd, 1 H, diastereomer 2), 3.92 (dd, 1H, diastereomer 1), 3.78 (s, 3 H, diastereomer 1), 3.77 (s, 3 H, diastereomer 2), 3.48 (dd, 1H, diastereomer 1 ), 3.34 (dd, 1 H, diastereomer 2).
Step 3. Synthesis of (1R.4S.5S)-6-(2-fluoroethvl)-4-(hvdroxvmethyl)-3-azabicvclo[3.1.0lhexan-2one (L80), To a stirred solution of compound C106 (250 mg, 0.86 mmol) in 6 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (8 mg, 0.04 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L80. Yield: 140 mg (94%). 1H NMR (400 MHz, CD3CN) δ 4.39 - 4.64 (m, 2 H), 3.31 - 3.56 (m, 2 H), 3.07 - 3.30 (m, 1 H), 2.21 - 2.35 (m, 2 H), 0.96 - 1.89 (m, 3 H).
Préparation 43: (1S,4S,5S,6S)-4-(hvdroxvmethvl)-6-(methoxvmethyl)-3-azabicvclo[3.1.01hexan15
2-one (L81)
Step 1. Synthesis of (3R,5aS,6S,6aS,6bS)-6-(methoxvmethvl)-3-(4-methoxyphenvl)tetrahvdro1H-cyclopropa[3,41pyrrolori ,2-c1oxazol-5(3H)-one (C107). To a stirred solution of compound C102 (400 mg, 1.46 mmol) in THF (10 mL) was added freshly prepared silver(l) oxide (1.68 g, 20 7.27 mmol), followed by iodomethane (0.46 ml, 7.27 mmol). The mixture was heated at about °C for about 16 h. The mixture was then cooled to about 25 °C, filtered and concentrated. The residue was purified by chromatography to provide the title compound C107. Yield: 180 mg (43%). 1H NMR (400 MHz, CDCI3) δ 7.26 (d, 2 H), 6.84 (d, 2 H), 4.15 (dd, 1 H), 3.92 (dd, 1 H), 3.78 (s, 3 H), 3.48 (dd, 1 H), 3.40 (dd, 1 H), 3.33 (s, 3 H), 3.21 (dd, 1 H), 2.13 - 2.11 (m, 1 H), 25 1.99 - 1.97 (m, 1 H), 1.78 - 1.75 (m, 1 H).
Step 2. Synthesis of (1S,4S,5S,6S)-4-(hvdroxvmethvl)-6-(methoxvmethvl)-3-azabicvclo[3.1.01hexan-2-one (L81). To a stirred solution of compound C107 (100 mg, 0.35 mmol) in 3.6 mL of acetonitrile and 0.4 mL of water was added 4-toluenesulfonic acid (3 mg, 0.02 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L81. Yield: 45 mg (76%). Ή NMR (400 MHz, CDCI3) δ 6.16 (br. s, 1 H), 3.68 (m, 2 H), 3.56 (m, 1 H), 3.48 (m, 1 H), 3.33 (s, 3 H), 3.17 (m, 1 H), 1.82 (m, 2 H), 1.37 (m, 1 H).
129
Synthesis of (1S,4S,5S,6R)-4-(hvdroxvmethvl)-6-(methoxvmethyl)-3-azabicvclo[3.1 .OIhexan-2one (L82).
This compound was prepared in the same manner as compound L81, substituting compound C104 for compound C102 in Step 1. 1H NMR (400 MHz, CDCh) δ 6.42 (br. s, 1 H), 3.73 - 3.68 (m, 1 H), 3.61 - 3.57 (m, 3 H), 3.42 - 3.38 (m, 1 H), 3.35 (s, 3 H), 3.18 (br. m, 1 H), 2.08 - 2.04 (m, 1 H), 1.92 - 1.88 (m, 1 H), 1.68 - 1.62 (m, 1 H).
Synthesis of (1 S,4S,5S,6S)-6-((benzvloxv)methvl)-4-(hvdroxvmethvl)-3-azabicycloi3.1 .Olhexan2-one (L85).
This compound was prepared in the same manner as compound L81, substituting (bromomethyl)benzene for iodomethane in Step 1. 1H NMR (400 MHz, CDCI3) δ 7.36 - 7.27 (m,
H), 5.67 (br. s, 1 H), 4.49 (dd, 2 H), 3.67 - 3.54 (m 4 H), 3.30 - 3.24 (m, 1 H), 1.85 - 1.76 (br.
m, 2 H), 1.37-1.32 (br. m, 1 H).
Synthesis of (1S,4S,5S,6R)-6-((benzvloxv)methvl)-4-(hvdroxymethvl)-3-azabicvclo[3.1 .Olhexan2-one (L86).
This compound was prepared in the same manner as compound L81, substituting compound C104 for compound C102, and (bromomethyl)benzene for iodomethane, in Step 1. 1H NMR (400 MHz, CDCI3) δ 7.35 - 7.27 (m, 5 H), 5.96 (br. s, 1 H), 4.56 (d, 1 H), 4.48 (d, 1 H), 3.73 3.64 (m, 2 H), 3.60 - 3.55 (m, 2 H), 3.47 - 3.43 (m, 1 H), 2.06 - 2.00 (m, 1 H), 1.96 - 1.88 (m, 1 H), 1.72-1.64 (m, 1 H).
Préparation 44: (1S,4S,5R,6S)-6-(difluoromethvl)-4-(hvdroxvmethvl)-3-azabicyclof3.1 .Olhexan2-one (L84)
Step 1, Synthesis of (3R,5aS,6S,6aS,6bS)-3-(4-methoxvphenyl)-5-oxohexahvdro-1Hcvclopropa-r3,41pyrrolori ,2-cloxazole-6-carbaldehyde (C108), A solution of compound C102 (9.20 g, 33 mmol) in DCM (167 mL) and water (1 mL) was treated with Dess Martin periodinane (28.3 g, 67 mmol) and stirred at about 25 °C for about 2 h. at which time saturated aqueous
NaHCC>3 solution (200 mL) was added and stirring continued for about 30 min. The DCM was separated and the aqueous phase was extracted with additional DCM. The combined DCM extracts were dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C108. Yield: 5.50 g (60%). 1H NMR (400 MHz, 10 CD3OD) δ 9.40 (d, 1 H), 7.32 (d, 2 H), 6.93 (d, 2 H), 6.17 (s, 1 H), 4.29 (dd, 1 H), 4.12 (dd, 1 H),
3.83 (s, 3 H), 3.53 (dd, 1 H), 2.89 (dd, 1 H), 2.64 (ddd, 1 H), 2.59 (q, 1 H).
Step 2. Synthesis of (3R,5aS,6S,6aR,6bS)-6-(difluoromethvl)-3-(4-methoxyphenvl)tetrahvdro1H-cyclopropar3,4lpvrrolo[1,2-c]oxazol-5(3H)-one (C109). A solution of compound C108 (4.0 g,
14.6 mmol) in 1,2-dichloroethane (16.3 mL) and pyridine (24.1 mL), and a solution of DAST (7.7 15 mL, 58 mmol) in 1,2-dichloroethane (33 mL) were prepared. A VaporTec Flow Reactor fitted with 10 mL loops was used for the experiment. A 10 mL portion of the solution of compound
C108 was added to first loop. A 10 mL portion of the solution of DAST was added to the second loop. Both loops were co-injected into the heating coils at a rate 0.2 mL/minute at about 90 °C.
Upon exiting the reactor coil, the eluate was passed through a calcium carbonate plug. Upon 20 completion of the passage, the eluate was diluted with 50 mL of DCM and washed with saturated aqueous NaHCO3. The DCM was separated and the aqueous phase was extracted with additional DCM. The combined DCM extracts were dried over MgSÛ4, filtered and concentrated. The experiment was repeated three additional times and the combined residues were purified by chromatography to provide the title compound C109. Yield: 2.39 g (55%). 1H
NMR (400 MHz, CDCI3) δ 7.29 (d, 2 H), 6.87 (d, 2 H), 6.27 (s, 1 H), 5.87 (td, 1 H), 4.25 (dd, 1
H), 3.98 (dd, 1 H), 3.81 (s, 3 H), 3.47 (dd, 1 H), 2.42 (dd, 1 H), 2.30 (dd, 1 H), 1.92 - 2.02 (m, 1 H). 19F NMR (376 MHz, CDCI3) δ -117.50, -120.09.
Step 3. Synthesis of (1S,4S,5R,6S)-6-(difluoromethyl)-4-(hvdroxvmethvl)-3azabicvclot3.1 .Olhexan-2-one (L84). To a stirred solution of compound C109 (2.39 g, 8.0 mmol) 30 in 87 mL of acetonitrile and 14 mL of water was added 4-toluenesulfonic acid (80 mg, 0.4 mmol). The reaction mixture was heated at about 85 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide
131 the title compound L84. Yield: 1.41 g (99%). 1H NMR (400 MHz, CDCh) δ 6.74 (br. s., 1 H), 5.83 (td, 1 H), 3.67 - 3.76 (m, 2 H), 3.55 - 3.63 (m, 1 H), 2.03 - 2.14 (m, 2 H), 1.50 - 1.61 (m, 1 H). 19F NMR (376 MHz, CDCI3) δ -116.67, -118.70.
Préparation 45: (1 R,4S,5S,6S)-6-fluoro-4-(hydroxvnnethvl)-3-azabicvclor3.1.01hexan-2-one (L83)
O
HO
Step 1. Synthesis of (3R,5aR,6S,6aS,6bS)-6-fluoro-3-(4-methoxyphenvl)tetrahvdro-1Hcvclopropai3.41pyrrolo[1,2-c1oxazol-5(3H)-one (C110). A solution of CAS 170885-07-1 (242 mg, 1.0 mmol) and /V-[(fluoromethyl)oxidophenyl-À4-sulfanylidene]-4-methylbenzenesulfonamide (CAS 1097193-08-2, 513 mg, 1.6 mmol) in THF (10 mL) was treated with lithium hexamethyldisilazide (1 M, 1.3 mL) at about -78 °C. The mixture was stirred at about -78 °C for about 10 min, then was allowed to warm to about 25 °C for about 3 h. Aqueous NH4CI solution was added and the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried over MgSÜ4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C110. Yield: 192 mg (70%). 1H NMR (400 MHz, CD3CN) δ 7.22 - 7.32 (m, 2 H), 6.85 - 6.95 (m, 2 H), 6.05 (s, 1 H), 4.88 (dd, 1 H), 4.17 (dd, 1 H), 3.94 (dd, 1 H), 3.77 (s, 3 H), 3.40 (dd, 1 H), 2.61 (ddd, 1 H), 2.38 (dd, 1 H).
19F NMR (376 MHz, CD3CN) δ -201.68.
Step 2. Synthesis of (1R,4S.5S,6S)-6-fluoro-4-(hvdroxvmethvl)-3-azabicyclo[3.1.01hexan-2-one (L83). To a stirred solution of compound C110 (1.10 g, 4.2 mmol) in 54 mL of acetonitrile and 6 mL of water was added 4-toluenesulfonic acid (40 mg, 0.21 mmol). The reaction mixture was stirred for about 6 h, then concentrated. The residue was purified by chromatography to provide the title compound L83. Yield: 534 g (88%). 1H NMR (400 MHz, CDCI3) δ 5.72 (br. s., 1 H), 4.41 - 4.63 (m, 1 H), 3.67 - 3.76 (m, 2 H), 3.55 - 3.65 (m, 1 H), 2.33 (dd, 1 H), 2.18 (dd, 1 H). 19F NMR (376 MHz, CDCI3) δ -205.65.
Préparation 46: (1 R,4S,5S,6R)-6-fluoro-4-(hvdroxvmethvl)-3-azabicycloi3.1 .OIhexan-2-one (L87)
132
Step 1, Synthesis of 4-methvl-/V-r(S)-(fluoromethvl)oxidophenyl-X4-sulfanvlidene1benzenesulfonamide (C111). A solution of CAS 170885-07-1 (330 mg, 1.4 mmol) and 4-methyl-A/-[(R)methyloxidophenyl-X4-sulfanylidene]benzenesulfonamide (CAS 49620-56-6, 701 mg, 2.1 mmol) in THF (15 mL) was treated with lithium hexamethyldisilazide (1 M, 1.9 mL) at about -78 °C. The mixture was stirred at about -78 °C for about 10 min, then was allowed to warm to about 25 °C for about 3 h. Aqueous NH4CI solution was added and the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried over MgSOzj, filtered and concentrated. The residue was purified by chromatography to provide the title compound C111. Yield: 60 mg (16%). This was used in the next step without further characterization.
Step 2. Synthesis of (1R,4S,5S,6R)-6-fluoro-4-(hvdroxvmethvl)-3-azabicyclo[3.1.01hexan-2-one (L87). To a stirred solution of compound C111 (60 mg, 0.23 mmol) in 9 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (6 mg, 0.03 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L87. Yield: 25 mg (75%). This was used in the next step without further characterization.
Préparation 47 (1R,4S,5S,6S)-6-fluoro-4-(hvdroxvmethvl)-6-methvl-3-azabicvclof3.1.01hexan-2-one (L88)
Step 1. Synthesis of (3R.5aR,6S,6aS,6bS)-6-fluoro-3-(4-methoxvphenvl)-6-methyltetrahvdro1 H-cvclopropar3,4]pvrrolof1,2-c]oxazol-5(3H)-one (C112). A solution of CAS 170885-07-1 (430 mg, 1.9 mmol) and 4-methyl-/V-[(R)- [(1S)-1-fluoroethyl]-oxidophenyl-X4-sulfanylidene]benzenesulfonamide (CAS 1422176-84-8, 952 mg, 2.8 mmol) in THF (19 mL) was treated with lithium hexamethyldisilazide (1 M, 2.4 mL) at -78 °C. The mixture was stirred at about -78 °C for about 10 min, then was allowed to warm to about 25 °C for about 3 h. Aqueous NH4CI solution was added and the mixture was extracted twice with EtOAc. The combined EtOAc extracts were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C112. Yield: 200 mg (39%). 1H NMR (400 MHz,
133
CDCb) δ 7.26 (d, 2 H), 6.88 (d, 2 H), 6.24 (s, 1 H), 4.25 (dd, 1 H), 3.81 (s, 3 H), 3.76 - 3.84 (m, 1 H), 3.50 - 3.57 (m, 1 H), 2.39 - 2.54 (m, 2 H), 1.56 (s, 3 H). 19F NMR (376 MHz, CDCb) δ 157.20. There was also obtained (3R,5aR,6R,6aS,6bS)-6-fluoro-3-(4-methoxyphenyl)-6methyltetra-hydro-1H-cyclopropa[3,4]pyrrolo[1,2-c]oxazol-5(3H)-one (C113). It was used in the next step without further characterization.
Step 2. Synthesis of (1R,4S,5S,6S)-6-fluoro-4-(hydroxvmethvl)-6-methvl-3azabicvclo[3.1 .Olhexan-2-one (L88). To a stirred solution of compound C112 (211 mg, 0.76 mmol) in 9 mL of acetonitrile and 1 mL of water was added 4-toluenesuifonic acid (7 mg, 0.04 mmol). The reaction mixture was heated at about 90 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L88. Yield: 110 mg (91%). 1H NMR (400 MHz, CDCb) δ 6.20 (br. s., 1 H), 3.69 - 3.78 (m, 1 H), 3.54 - 3.68 (m, 2 H), 2.68 (s, 1 H), 2.32 (dd, 1 H), 2.11 (dd, 1 H), 1.67 (s, 3 H). 19F NMR (376 MHz, CDCb) δ-161.43.
Synthesis of (1 R,4S,5S,6R)-6-fluoro-4-(hvdroxymethvl)-6-methvl-3-azabicvclor3.1 .Olhexan-2one (L89).
This compound was prepared in the same manner as compound L88, substituting compound C113 for compound C112 in Step 2. It was used in the next step without further characterization.
Préparation 48: (1R,4S,5S)-4-(hvdroxvmethvl)-1-methvl-3-azabicyclo[3.1.01hexan-2-one (L91)
Step 1. Synthesis of (3R,5aR,6aS,6bS)-3-(4-methoxyphenvl)-5a-methvltetrahvdro-1Hcvclopropa[3.41-pyrrolori ,2-c1oxazol-5(3H)-one (C114). LDA (2 M, 0.31 mL) was added very slowly to a solution of (3R,5aR,6aS,6bS)-3-(4-methoxyphenyl)tetrahydro-1Hcyclopropa[3,4]pyrrolo[1,2-c]oxazol-5(3H)-one (CAS 187742-05-8, 150 mg, 0.61 mmol) and iodomethane (0.20 mL, 3 mmol) in THF (3 mL) at about -78 °C. After about 1 h, an additional 0.31 mL of LDA and 0.2 mL of iodomethane were added. The mixture was warmed to about -20 °C over about 45 min, and allowed to warm to about 25 °C for about 1.5 h. The mixture was
poured into NaHCO3 solution and was extracted twice with EtOAc. The combined EtOAc extracts were dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C114. Yield: 31 mg (20%). 1H NMR (400 MHz, CD3CN) δ 7.27 (d, 2 H), 6.89 (d, 2 H), 6.07 (s, 1 H), 4.13 (dd, 1 H), 3.81 (dd, 1 H), 3.77 (s, 3 H),
3.31 (dd, 1 H), 2.06 (dd, 1 H), 1.30 (s, 3 H), 1.08 -1.18 (m, 2 H).
Step 2. Synthesis of (1R,4S,5S)-4-(hvdroxvmethvl)-1-methvl-3-azabicvclof3.1.01hexan-2-one (L91). To a stirred solution of compound C114 (41 mg, 0.16 mmol) in 2 mL of acetonitrile and 0.2 mL of water was added 4-toluenesulfonic acid (2 mg, 0.008 mmol). The reaction mixture was heated at about 90 °C for about 45 min. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L91. Yield: 21 mg (93%). 1H NMR (400 MHz, CD3OD) δ 3.46 - 3.55 (m, 2 H), 3.43 (q, 1 H), 1.75 (dd, 1 H), 1.28 (s, 3 H), 0.98 (dd, 1 H), 0.68 (t, 1 H).
Préparation 49 (1S,4S,5R,6S)-1-fluoro-4-(hvdroxvmethvl)-6-methvl-3-azabicvcloF3.1.0]hexan-2-one (L92)
Step 1. Synthesis of (3R,7aS)-6-fluoro-3-(4-methoxvphenvl)tetrahvdropvrrolof112-cloxazol5(3H)-one (C115), To a solution of (3R,7aS)-3-(4-methoxyphenyl)tetrahydropyrrolo[1,2c]oxazol-5(3H)-one (CAS 170885-05-9, 16.0 g, 68.59 mmol) in THF (160 mL) was added LDA 20 (2 M, 48 mL) at about -78 °C, and stirred for about 30 min. A solution of NFSI (22.68 g, 72 mmol) in THF (80 mL) was added at about -78 °C. After about 30 min at about -78 °C, the mixture was allowed to warm to about 25 °C for about 30 min. EtOAc and water were added and the phases seprated. The aqueous phase was extracted with EtOAc. The combined EtOAc extractes were washed with brine, dried over Na2SO4, filtered and concentrated. The residue 25 was purified by chromatography to provide the title compound C115. Yield: 12.4 g (72%). 1H
NMR (400 MHz, CDCIs) δ 7.36 (d, 2 H), 6.88 (d, 2 H), 6.22 (s, 1 H), 5.14 (dd, 1 H), 4.40-4.29 (m, 2 H), 3.79 (s, 1 H), 3.46 (dd, 1 H), 2.62 - 2.51 (m 1 H), 2.23 - 2.07 (m 1 H).
Step 2. Synthesis of (3R,7aS)-6-fluoro-3-(4-methoxvphenvl)-6-(phenvlselanvl)tetrahvdropyrrolo[1,2-c1oxazol-5(3H)-one (C116). To a stirred solution of compound C115 (12.4 g, 49 mmol) in 30 THF (130 mL) was added LDA (2 M, 35 mL) at about -78 °C and stirred for about 30 min before a solution of diphenyl diselenide (16.96 g, 54 mmol) in THF (70 mL) was added. The mixture was kept at about -78 °C for about 30 min, then allowed to warm to about 25 °C for about 30
min. EtOAc and water were added and the phases seprated. The aqueous phase was extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C116. Yield: 13 g (65%). This was used in the next step without further characterization.
Step 3. Synthesis of (3R,7aS)-6-fluoro-3-(4-methoxvphenvl)-1,7a-dihvdropvrrolo|1,2-cloxazol5(3H)-one (C117), A solution of compound C116 (13.0 g, 32 mmol) in DCM (260 mL) and pyridine (5.7 mL, 70 mmol) was treated with hydrogen peroxide (30%, 11.9 mL, 106 mmol) at about 0 °C. The mixture was kept at about 0 °C for about 30 min, and allowed to warm to about °C for about 2 h before being diluted with DCM and water. The DCM was separated and the 10 aqueous phase was extracted with DCM. The combined DCM extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C117. Yield: 4.6 g (58%). 1H NMR (400 MHz, CDsCN) δ 7.43 (d, 2 H), 6.96 (d, 2 H), 6.72 (dd, 1 H), 5.91 (s, 1 H), 4.59 (m, 1 H), 4.36 (dd, 1 H), 3.80 (s, 3 H), 3.29 - 3.36 (m, 1 H). 19F NMR (376 MHz, CDsCN) δ-137.11.
Step 4. Synthesis of (3R,5aS,6S,6aR,6bS)-5a-fluoro-3-(4-methoxvphenyl)-6-methvltetrahvdro1 H-cvclopropa[3,4lpyrroloF1,2-c1oxazol-5(3H)-one (C118). To a stirred suspension of ethyldiphenylsulfonium tetrafluoroborate (CAS 893-69-6, 5.31 g, 17 mmol) in DME (62 mL) was added LDA (2 M, 8.0 mL, 16 mmol) slowly at about -55 °C. The reaction mixture was kept at about -55 °C for about 45 min, at which point it was warmed to about -35 °C and a solution of 20 compound C117 (1.99 g, 8.0 mmol) in DME (20 mL) was added. The reaction mixture was maintained at about -30 °C for about 1.5 h, then aqueous NaHCOs and EtOAc were added. The EtOAc was separated and the aqueous phase was extracted with EtOAc. The combined EtOAc extracts were dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C118. Yield: 362 mg (16%). 1H NMR (400 MHz, 25 CDsCN) δ 7.28 (d, 2 H), 6.90 (d, 2 H), 6.12 (s, 1 H), 4.17 (dd, 1 H), 3.78 (s, 3 H), 3.66 - 3.75 (m,
H), 3.45 (dd, 1 H), 2.33 (dd, 1 H), 1.64 (d, 1 H), 1.25 (dd, 3 H). There was also obtained (3R,5aS,6R,6aR,6bS)-5a-fluoro-3-(4-methoxyphenyl)-6-methyltetrahydro-1Hcyclopropa[3,4]pyrrolo[1,2-c]oxazol-5(3H)-one (C119). Yield: 816 mg (37%). 1H NMR (400 MHz, CDsCN) δ 7.30 (d, 2 H), 6.92 (d, 2 H), 6.15 (s, 1 H), 4.20 - 4.24 (m, 1 H), 3.78 (s, 3 H), 30 3.57 - 3.62 (m, 2 H), 2.72 (dd, 1 H), 2.13 - 2.23 (m, 1 H), 1.15 (dd, 3 H).
Step 5. Synthesis of (1S.4S.5R,6S)-1-fluoro-4-(hvdroxvmethvl)-6-methvl-3-azabicvclo[3.1.0lhexan-2-one (L92) To a stirred solution of compound C118 (400 mg, 1.4 mmol) in 18 mL of acetonitrile and 2 mL of water was added 4-toluenesulfonic acid (14 mg, 0.07 mmol). The reaction mixture was kept at about 25 °C for about 12 h, then concentrated and the residue was
136 purified by chromatography to provide the title compound L92. Yield: 181 mg (79%). 1H NMR (400 MHz, CDCb) δ 6.07 (br. s., 1 H), 3.66 - 3.81 (m, 1 H), 3.54 - 3.67 (m, 1 H), 3.36 - 3.50 (m, 1 H), 1.77 - 1.87 (m, 2 H), 1.29 (d, 3 H).
Synthesis of (1 Sl4S,5R.6R)-1-fluoro-4-(hvdroxvmethvl)-6-methvl-3-azabicyclo[3.1 .Olhexan-2one (L93).
This compound was prepared in the same manner as compound L92, substituting compound C119 for compound C118 in Step 5. 1H NMR (400 MHz, CD3OD) δ 3.63 (dd, 2 H), 3.28 (dt, 1 H), 2.38 (dd, 1 H), 1.95 - 2.07 (m, 1 H), 1.07 (dd, 3 H).
Préparation 50: (1R,4S,5S')-4-(hvdroxvmethvl)-5-methvl-3-azabicvclor3.1.01hexan-2-one (L94)
O
Step 1. Synthesis of (3R,7S,7aS)-3-(4-methoxvphenvl)-7-methvltetrahvdropyrrolo[1,2-cloxazol5(3H)-one (C120). A suspension cuprous bromide - dimethyl sulfide complex (2.24 g, 10.8 mmol) in ether (30 mL) was cooled to about -10 °C and a solution of methyllithium (1.6 M, 13.5 mL) was added slowly. The mixture was then cooled to about -78 °C and TMSCI (1.36 mL, 10.8 mmol) was added slowly. After the addition was complété, the mixture was kept for about 15 min before (3R,7aS)-3-(4-methoxyphenyl)-1,7a-dihydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 170885-07-1, 1.00 g, 4.3 mmol) in THF (20 mL) was added slowly. The mixture was kept an additional about 2 h at about -78 °C before being allowed to warm to about 25 °C. The mixture was kept at about 25 °C for about 1 h before being treated with a mixture of saturated aqueous NH4CI and ammonium hydroxide. The ethereal layer was separated and the aqueous phase was extracted twice with EtOAc. The combined extracts were dried over MgSÜ4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C120. Yield: 457 mg (43%). 1H NMR (400 MHz, CDCb) δ 7.36 (d, 2 H), 6.89 (d, 2 H), 6.31 (s, 1 H), 4.20 (dd, 1 H), 3.81 (s, 3 H), 3.77 (q, 1 H), 3.59 (dd, 1 H), 2.61 - 2.72 (m, 1 H), 2.44 - 2.55 (m, 1 H), 2.29 - 2.42 (m, 1 H), 1.23 (d, 3 H).
Step 2. Synthesis of (3R,7R,7aS)-3-(4-methoxvphenvl)-7-methvl-6-(phenvlselanvl)tetrahydropyrroloH ,2-c1oxazol-5(3H)-one (C121), To a stirred solution of compound C120 (450 mg, 1 .8
137 mmol) in THF (10 mL) was added LDA (2 M, 1.18 mL) at about -78 °C and stirred for about 30 min before a solution of phenylselenenyl chloride (462 mg, 2.4 mmol) in THF (5 mL) was added.
The mixture was kept at about -78 °C for about 30 min, then allowed to warm to about 25 °C for about 2 h. EtOAc and water were added and the phases seprated. The aqueous phase was 5 extracted with EtOAc. The combined EtOAc extractes were washed with brine, dried over
Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C121. Yield: 343 mg (47%). This was used in the next step without further characterization.
Step 3. Synthesis of (3R,7aS)-3-(4-methoxvphenvl)-7-methvl-1,7a-dihvdropvrroloi1,2-cloxazol10 5(3H)-one (C122). A solution of compound C121 (343 mg, 0.85 mmol) in DCM (15 mL) and pyridine (0.15 mL) at about 0 °C was treated with 30% hydrogen peroxide solution (0.17 mL, 2.8 mmol). The mixture was kept at about 0 °C for about 30 min before being warmed slowly to about 25 °C. After about 3 h, the mixture was diluted with DCM (10 mL) and washed with saturated aqueous NaHCO3 solution. The DCM extracts were washed with brine, dried over 15 Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C122. Yield: 143 mg (68%). 1H NMR (400 MHz, CDCI3) δ 7.44 (d, 2 H), 6.91 (d, 2 H), 6.18 (s, 1 H), 5.82 (s, 1 H), 4.39 - 4.49 (m, 1 H), 4.21 (s, 1 H), 3.82 (s, 3 H), 3.47 (s, 1 H), 2.09 (d, 3 H).
Step 4. Synthesis of (3R,5aR,6aS,6bS)-3-(4-methoxyphenvl)-6a-methvltetrahvdro-1H20 cvclopropaf3,41pyrrolori ,2-c1oxazol-5(3H)-one (C123). Sodium hexamethyldisilazide (1 M, 0.57 mL) was added to a suspension of trimethylsulfoxonium iodide (128 mg, 0.57 mmol) in DMSO (2 mL) at about 25 °C. The mixture was kept at about 25 °C for about 30 min then heated to about 55 °C for about 30 min. The mixture was cooled to about 25 °C, then a solution of compound C122 (100 mg, 0.41 mmol) in THF (1 mL) was added. After about 18 h, aqueous
NH4CI was added and the mixture was extensively extracted with ethyl ether. The combined ether extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C123. Yield: 55 mg (52%). 1H NMR (400 MHz, CD3CN) δ 7.24 - 7.29 (m, 2 H) 6.86 - 6.92 (m, 2 H) 6.06 (s, 1 H)
4.11-4.16 (m, 1 H) 3.92 (ddd, 1 H) 3.77 (s, 3 H) 3.50 (dd, 1 H) 1.72-1.77 (m, 1 H) 1.30 (s, 3 H) 30 1.19 (s, 1 H) 1.17 (d, 1 H).
Step 5. Synthesis of (1R,4S,5S)-4-(hvdroxvmethvl)-5-methvl-3-azabicvclof3.1.01hexan-2-one (L94), To a stirred solution of compound C123 (200 mg, 0.77 mmol) in 18 mL of acetonitrile and 2 mL of water was added 4-toluenesulfonic acid (7 mg, 0.04 mmol). The reaction mixture was heated at about 95 °C for about 1 h. The reaction mixture was cooled to about 25 °C,
138 concentrated, and the residue was purified by chromatography to provide the title compound L94. Yield: 95 mg (87%). 1H NMR (400 MHz, CDCb) δ 6.04 (br. s„ 1 H) 3.81 (dd, 1 H) 3.62 3.68 (m, 1 H) 3.57 - 3.61 (m, 1 H) 2.12 (br. s., 1 H) 1.62 - 1.68 (m, 1 H) 1.30 (s, 3 H) 0.99 (dd, 1 H) 0.85 - 0.89 (m, 1 H).
Synthesis of (1 R,4S,5S)-5-ethyl-4-(hydroxvmethvl)-3-azabicvclo[3.1 .OIhexan-2-one (L95)
This compound was prepared in the same manner as compound L94, substituting ethylmagnesium chloride for methyllithium in Step 1. It was used in the next step without further characterization.
Préparation 51; (1S,4S,5R)-1-fluoro-4-(hvdroxvmethvl)-3-azabicyclo[3.1.01hexan-2-one (L96)
Step 1. Synthesis of (3R,7R,7aS)-3-phenvl-7-vinvltetrahvdropvrrolof1,2-c1oxazol-5(3H)-one (C124). A suspension cuprous bromide - dimethyl sulfide complex (10.4 g, 50 mmol) in ether (70 mL) was cooled to about -10 °C and a solution of vinylmagnesium bromide (1 M, 100 mL) was added slowly. The mixture was stirred at about -10 °C for about 30 min. The mixture was then cooled to about -78 °C and TMSCI (9.2 mL, 73 mmol) was added slowly. After the addition was complété, the mixture was kept for about 15 min before (3R,7aS)-3-phenyl-1,7adihydropyrrolo[1,2-c]oxazol-5(3H)-one (CAS 134107-65-6, 6.70 g, 33 mmol) in THF (70 mL) was added slowly. The mixture was kept an additional about 4 h at about -78 °C before being treated with a mixture of saturated aqueous NH4CI and ammonium hydroxide. The ethereal layer was separated and the aqueous phase was extracted twice with EtOAc. The combined extracts were dried over MgSÜ4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C124. Yield: 5.53 g (72%). 1H NMR (400 MHz, CDCb) δ 7.42 - 7.47 (m, 2 H), 7.31 - 7.40 (m, 3 H), 6.39 (s, 1 H), 5.88 (ddd, 1 H), 5.12 - 5.20 (m, 2 H), 4.19 (dd, 1 H), 3.96 (q, 1 H), 3.71 (dd, 1 H), 2.95 (dq, 1 H), 2.63 - 2.81 (m, 2 H).
Step 2. Synthesis of (3R,7R,7aS)-6-fluoro-3-phenvl-7-vinvltetrahvdropyrrolori,2-c1oxazol-5(3H)one (C125), A solution of LDA was generated from n-butyllithium (2.5 M, 1.1 mL) and
diisopropylamine (0.73 mL, 5.2 mmol) in THF at about 0 °C for about 1 h. A solution of compound C124 (1.00 g, 4.4 mmol) in THF (40 mL) was treated with the LDA solution at about 78 °C. After about 30 min, a solution of NFSI (1.70 g, 5.2 mmol) in THF (5 mL) was added. The mixture was allowed to warm to about 25 °C for about 16 h. Saturated aqueous NH4CI solution was added and the mixture was extracted with EtOAc (50 mL). The EtOAc extract was washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C125. Yield: 441 mg (41%). 1H NMR (400 MHz, CDCI3) δ 7.33 - 7.50 (m, 5 H), 6.48 (s, 1 H), 5.95 (ddd, 1 H), 5.31 - 5.38 (m, 2 H), 5.22 (dd, 1 H),
4.22 - 4.33 (m, 1 H), 3.75 - 3.86 (m, 2 H), 2.93 - 3.08 (m, 1 H). 19F NMR (376 MHz, CDCI3) δ 10 194.19,-198.01.
Step 3. Synthesis of (3R,7S,7aS)-6-fluoro-7-(hvdroxvmethvl)-3-phenvltetrahvdropyrrolo[1,2c!oxazol-5(3H)-one (C126). A stream of ozonized oxygen was bubbled through a solution of compound C125 (440 mg, 1.8 mmol) in DCM (6 mL) and MeOH (2 mL) at about -78 °C. After a blue color persisted in the mixture, the mixture was treated with dimethyl sulfide (3 mL). NaBH4 15 (202 mg, 5.3 mmol) was added and the mixture was stirred at about -78 °C for about 30 min before being allowed to warm to about 0 °C for about 30 min. The mixture was treated with with saturated aqueous NH4CI solution and extracted with EtOAc. The EtOAc extract was washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C126. Yield: 207 mg (46%). 1H NMR (400 MHz, 20 CDCb) δ 7.31 - 7.50 (m, 5 H), 6.44 (s, 1 H), 5.31 (dd, 1 H), 4.36 (dd, 1 H), 4.04 (dt, 1 H), 3.87 3.97 (m, 2 H), 3.76 (dd, 1 H), 2.49 - 2.69 (m, 1 H), 1.69 (t, 1 H). 19F NMR (376 MHz, CDCI3) δ 193.64.
Step 4. Synthesis of (3R,7R,7aSF7-(bromomethvl)-6-fluoro-3-phenvltetrahvdropvrrolo[1,2c1oxazol-5(3H)-one (C127). A solution of compound C126 (202 mg, 0.8 mL) in DCM was 25 treated with pyridine (0.13 mL, 1.6 mmol) and carbon tetrabromide (323 mg, 1.0 mmol). Triphenylphosphine (258 mg, 1.0 mmol) was slowly added to the mixture. The mixture was kept about 2 h at about 25 °C, then saturated aqueous NaHCO3 was added and the mixture was extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography 30 to provide the title compound C127. Yield: 185 mg (73%). 1H NMR (400 MHz, CDCI3) δ 7.34 7.47 (m, 5 H), 6.45 (s, 1 H), 5.21 (dd, 1 H), 4.41 - 4.49 (m, 1 H), 3.82 - 3.89 (m, 2 H), 3.76 - 3.81 (m, 1 H), 3.56 (dd, 1 H), 2.74 - 2.88 (m, 1 H). 19F NMR (376 MHz, CDCI3) δ -193.19.
Step 5. Synthesis of (3R.5aS,6aR,6bS)-5a-fluoro-3-phenvlteÎrahvdro-1H-cvclopropa[3,4lpyrrolo[1,2-c1oxazol-5(3H)-one (C128). A solution of compound C127 (185 mg, 0.59 mmol) in THF (10
140 mL) was treated with lithium hexamethyldisilazide (1 M, 0.62 mL) at about -78 °C. After about 15 min at about -78 °C, the mixture was allowed to warm to about 0 °C for about 30 min, then an additional portion of lithium hexamethyldisilazide (1 M, 0.31 mL) was added. After approximately another 30 min at about 0 °C, The mixture was treated with with saturated aqueous NH4CI solution and extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C128. Yield: 110 mg (80%). 1H NMR (400 MHz, CDCI3) δ 7.29 - 7.44 (m, 5 H), 6.40 (s, 1 H), 4.26 (dd, 1 H), 3.61 - 3.69 (m, 1 H), 3.53 - 3.60 (m,
H), 2.60 (td, 1 H), 1.90 (ddd, 1 H), 1.44 (dt, 1 H). 19F NMR (376 MHz, CDCI3) δ-208.58.
Step 6. Synthesis of (1S.4S,5R)-1-fluoro-4-(hvdroxvmethvl)-3-azabicyclor3.1.01hexan-2-one (L96). To a stirred solution of compound C128 (110 mg, 0.47 mmol) in 18 mL of acetonitrile and mL of water was added 4-toluenesulfonic acid (5 mg, 0.02 mmol). The reaction mixture was kept at about 25 °C for about 6 h, then heated at about 60 °C for about 6 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L96. Yield 53 mg (77%). It was used in the next step without further characterization.
Préparation 52: (1R.4S.5S)-4-(hvdroxvmethyl)-3-azabicvclo[3.2.0lheptan-2-one (L97)
Step 1. Synthesis of (1S,2S,5R)-tert-butyl 2-(((tert-butvldimethvlsilvl)oxv)methyl)-4-oxo-3azabicvclor3.2.01heptane-3-carboxylate (C129). A solution of (S)-tert-butyl 2-(((tertbutyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1 H-pyrrole-1-carboxylate (CAS 81658-27-7, 1.00 g, 3.1 mmol) in acetone (330 mL) was saturated with ethylene gas and irradiated with ultraviolet light at about -20 °C for about 6 h. A steady flow of ethylene gas was maintained throughout the irradiation. The mixture was then concentrated and the residue was purified by chromatography to provide the title compound C129. Yield: 250 mg (23%). 1H NMR (400 MHz, CDCI3) δ 3.89 (s, 1 H), 3.81 (dd, 1 H), 3.59 (d, 1 H), 3.03 (t, 1 H), 2.88 (q, 1 H), 2.49 - 2.44 (m, 1 H), 2.29 - 2.25 ( m, 1 H), 2.11 - 1.99 (m, 2 H), 1.54 (s, 9 H), 0.84 (s, 9 H), 0.06 (m, 6 H).
Step 2. Synthesis of (1S,2S,5R)-tert-butyl 2-(hvdroxvmethvl)-4-oxo-3-azabicyclo[3.2.01heptane3-carboxylate (C130). A solution of compound C129 (568 mg, 1.6 mmol) in THF (8 mL) was treated with a solution offtetrabutylammonium fluoride (1 M, 3.2 mL) at about 25 °C. After about about 4 h, the mixture was poured into water and extracted with EtOAc. The combined EtOAc
141 extracts were dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C130. Yield: 357 mg (93%). 1H NMR (400 MHz,
CDCb) δ 6.66 (br. s., 1 H), 3.90 - 4.01 (m, 1 H), 3.79 - 3.86 (m, 1 H), 3.61 (t, 1 H), 2.91 - 2.99 (m, 1 H), 2.78 - 2.88 (m, 1 H), 2.41 - 2.52 (m, 1 H), 2.30 - 2.41 (m, 1 H), 2.01 - 2.16 (m, 2 H),
1.46 (s, 9 H).
Step 3. Synthesis of (1R,4S,5S)-4-(hvdroxvmethvl)-3-azabicvclof3.2.0lheptan-2-one (L97).
Compound C130 (357 mg, 1.5 mmol) was dissolved in DCM (1 mL) at about 25 °C. A mixture of
DCM (1 mL) and TFA (1 mL) was added and the mixture was kept at about 25 °C for about 2 h. It was then concentrated to dryness to provide the title compound L97. Yield: 211 mg (100%).
1H NMR (400 MHz, CDCb) δ 5.55 (br. s., 2 H), 4.34 (dd, 1 H), 4.17 (dd, 1 H), 3.82 (t, 1 H), 3.02 3.18 (m, 1 H), 2.82 - 2.99 (m, 1 H), 2.48 - 2.64 (m, 1 H), 2.36 - 2.48 (m, 1 H), 2.02 - 2.26 (m, 2
H).
Préparation 53: (1S,4S,5R)-1-fluoro-4-(hvdroxvmethvl)-3-azabicvclo[3.2.0'|heptan-2-one (L98)
Step 1. Synthesis of (3R,5aS,7aR,7bS)-5a-fluoro-3-(4-methoxyphenvl)hexahvdrocvclobutaf3,41pvrrolof1,2-cloxazol-5(3H)-one (C131). A solution of compound C117 (300 mg, 1.2 mmol) in acetone (450 mL) was saturated with ethylene gas and irradiated with ultraviolet light at about -20 °C for about 6 h. A steady flow of ethylene gas was maintained throughout the 20 irradiation. The mixture was then concentrated and the residue was purified by chromatography to provide the title compound C131. Yield: 170 mg (51%). 1H NMR (400 MHz, CDCb) δ 7.38 (d, 2 H), 6.90 (d, 2 H), 6.37 (s, 1 H), 4.21 (dd, 1 H), 3.81 (s, 3 H), 3.78 - 3.74 (m, 1 H), 3.32 (dd, 1 H), 3.06 - 3.01 (m, 1 H), 2.65 - 2.56 (m, 2 H), 2.49 - 2.42 (m, 1 H), 1.67 - 1.62 (m, 1 H).
Step 2. Synthesis of (1S,4S.5R)-1-fluoro-4-(hvdroxvmethvl)-3-azabicycloi3.2.01heptan-2-one 25 (L98). To a stirred solution of compound C131 (200 mg, 0.72 mmol) in 9 mL of acetonitrile and mL of water was added 4-toluenesulfonic acid (7 mg, 0.04 mmol). The reaction mixture was heated at about 70 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound L98. Yield: 115 (100%). Ή NMR (400 MHz, CDCb) δ 7.84 (br. s., 1 H), 3.55 - 3.71 (m, 2 H), 30 3.39 - 3.55 (m, 2 H), 2.81 - 3.00 (m, 1 H), 2.41 - 2.60 (m, 2 H), 2.18 - 2.34 (m, 1 H), 1.36 - 1.53 (m, 1 H).
Préparation 54: (±)-(1S.5S)-5-(hvdroxvmethyl)-3-azabicvclo[3.1.01hexan-2-one (L100)
Step 1. Synthesis of tert-butyl 1-((benzovloxv)methvl)-3-azabicvclo[3.1.0lhexane-3-carboxylate (C132) A solution of tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (CAS
161152-76-7, 427 mg, 2mmol) in DCM (6.4 mL) was treated with benzoic acid (368 mg, 3 mmol), EDCI hydrochloride (581 mg, 3 mmol), and DMAP (49 mg, 0.4 mmol), and heated to about 40 °C for about 12 h. The mixture was cooled to about 25 °C, diluted with DCM, washed with 1 M HCl and 10% aqueous Na2CO3. The DCM solution was concentrated, and the residue was purified by chromatography to provide the title compound C132, which was used in the next step without further characterization. Yield: 0.57 g (90%).
Step 2. Synthesis of tert-butyl 1-((benzovloxv)methyl)-4-oxo-3-azabicvclo|3.1.0lhexane-3carboxylate (C133) A solution of compound C132 (0.57 g, 1.8 mmol) in EtOAc (20 mL) was treated with a solution of sodium periodate (1.5 g, 7.2 mmol) in water (20 mL) and ruthénium trichloride (21 mg (50%), 0.054 mmol). The mixture was stirred at about 20 °C for about 6 h, 15 then treated with 2-propanol (20 mL) and stirred for about 0.5 h. It was then diluted with water and extracted twice with EtOAc. The combined EtOAc extracts extracts were dried over Na2SO4 filtered and concentrated. The residue was purified by chromatography to provide the title compound C133, which was used in the next step without further characterization. Yield: 0.40 g (60%).
Step 3. Synthesis of (4-oxo-3-azabicvcloi3.1.0lhexan-1-vl)methyl benzoate (C134) A solution of compound C133 (0.40 g, 0.5 mmol) in DCM (2 mL) was treated with TFA (0.5 mL) and stirred at about 25 °C for about 15 minutes. The mixture was concentrated and the residue was redissolved in toluene and again concentrated to provide the title compound C134, which was used in the next step without further characterization.
Step 4, Synthesis of (5-(hvdroxvmethvl)-3-azabicyclo[3.1.01hexan-2-one (L100) Compound C134 (presumed 0.4 mmol) in THF (2 mL) was treated with NaOH (0.3 mL of a 2 M aqueous solution, 0.6 mmol) and stirred at about 25 °C for about 1 h. This solution of compound L100 was used in the next step without further characterization.
Préparation 55: (±)-3-(hvdroxvmethyl)octahvdro-1H-isoindol-1-one (L101)
143
Ο
Step 1. Synthesis of (±)-3-(hvdroxvmethv0octahvdro-1H-isoindol-1-one (L101). Ethyl 3oxooctahydro-1H-isoindole-1-carboxylate (CAS 84385-29-5, 400 mg, 1.9 mmol) was dissolved in THF (9.5 mL) to which lithium borohydride (59 mg, 2.65 mmol) was added. The reaction was stirred at about 25 °C overnight. The mixture was cooled to about 0 °C and 2 M HCl was added dropwise until gas évolution ceased. The solution was neutralized with K2CO3 and filtered. The filtrate was concentrated The residue was purified by chromatography to provide the title compound L101. Yield: 0.26 g (81%). 1H NMR (400 MHz, dmso-d6) δ 4.63 (t, 1 H), 3.42 - 3.50 (m, 1 H), 3.38 - 3.42 (m, 2 H), 2.35 - 2.40 (m, 1 H), 2.23 - 2.30 (m, 1 H), 1.90 - 1.98 (m, 1 H), 1.40 - 1.63 (m, 3 H), 1.27 - 1.40 (m, 1 H), 0.84 - 1.11 (m, 3 H).
Préparation 56: (S)-5-(hvdroxvmethvl)-5-methvlpyrrolidin-2-one (L102)
O
Step 1. Synthesis of (S)-methyl 2-methvl-5-oxopyrrolidine-2-carboxvlate (C135). A solution (S)1-tert-butyl 2-methyl 2-methyl-5-oxopyrrolidine-1,2-dicarboxylate (CAS 1109790-91-1, 1.2 g, 4.7 mmol) in DCM was treated with TFA (0.36 mL, 4.7 mmol) for about 2 h at about 25 °C. The mixture was concentrated to provide the title compound C135. Yield: 1.2 g (100%). 1H NMR (400 MHz, CDCIs) δ 7.78 (br. s„ 1 H), 3.80 (s, 3 H), 2.48 - 2.66 (m, 3 H), 2.02 - 2.15 (m, 1 H), 1.58 (s, 3 H).
Step 2. Synthesis of (S)-5-(hvdroxvmethvl)-5-methvlpyrrolidin-2-one (L102). A solution of compound C135 (1.2 g, 4.7 mmol) in THF (76 mL) was treated with lithium borohydride (218 mg, 9.9 mmol). The reaction was allowed to proceed overnight, after which the solution was cooled to about 0 °C and 2 M HCl was added dropwise until gas évolution ceased. The solution was neutralized with K2CO3 and filtered. The filtrate was concentrated. The residue was purified by chromatography to provide the title compound C136 an oil which crystallized. This was triturated with ether and filtered to provide the title compound L102. Yield: 0.30 g (49%). 1H NMR (400 MHz, dmso-d6) δ 7.43 (br. s., 1 H), 4.83 - 4.87 (m, 1 H), 3.16 - 3.24 (m, 2 H), 2.06 2.21 (m, 2 H), 1.96 (ddd, 1 H), 1.59 (ddd, 1 H), 1.09 (s, 3 H).
Préparation 57: 5-(hvdroxvmethvl)-4-(trifluoromethvl)pyrrolidin-2-one (L104)
Step 1. Synthesis of Diethyl 2-((diphenylmethvlene)amino)-3-(trifluoromethyl)pentanedioate (C136). A mixture of ethyl 2-((diphenylmethylene)amino)acetate (CAS 69555-14-2, 1.9 g, 7 mmol), benzyltriethyl NH4CI (0.3 g, 1.3 mmol), 10% aqueous NaOH (10 mL) and DCM (10 mL) was stirred at about 0 °C for about 15 min. Following the addition of (E)-ethyl 4,4,4-trifluorobut2-enoate (CAS 25597-16-4, 1 mL, 7 mmol) the mixture was stirred vigorously for about 90 min at about 0 °C. The DCM was separated and the aqueous phase was extracted with DCM. The combined DCM extracts were washed with brine, dried over MgSO4, filtered and concentrated to provide the title compound C136. Yield: 2.6 g (85%). 1H NMR (400 MHz, CDCh) δ 7.62 - 7.67 10 (m, 2 H), 7.43 - 7.50 (m, 4 H), 7.31 - 7.38 (m, 2 H), 7.14 - 7.20 (m, 2 H), 4.43 (d, 1 H), 4.13 4.25 (overlapping q, 4 H), 3.62 - 3.74 (m, 1 H), 3.12 (dd, 1 H), 2.81 (dd, 1 H), 1.27 (overlapping t, 6 H).
Step 2. Synthesis of Ethyl 5-oxo-3-(trifluoromethvl)pyrrolidine-2-carboxvlate (C137), A mixture of compound C136 (2.6 g, 6.0 mmol), 10% aqueous citric acid (24 mL, 212 mmol) and THF (17 15 mL) was stirred at about 25 °C for 2 days. The reaction was extracted with EtOAc and the combined EtOAc extracts were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C137. Yield: 1.1 g (85%). 1H NMR (400 MHz, CDCIs) δ 6.72 (br. s., 1 H), 4.28 (q, 2 H), 3.40 (m, 1 H), 2.70 (dd, 1 H), 2.52 (dd, 1 H), 1.33 (t, 3 H).
Step 3. Synthesis of 5-(Hvdroxvmethvl)-4-(trifluoromethvl)pyrrolidin-2-one (L104). To a solution of compound C137 (1.1 g, 5.1 mmol) in THF (25 mL) was added lithium borohydride (0.16 g, 7.1 mmol). The mixture was stirred at about 25 °C overnight. The mixture was cooled to about 0 °C and 2 M HCl was added until gas évolution ceased. The mixture was neutralized with K2CO3 and filtered. The filtrate was concentrated and the residue was purified by chromatography to provide the title compound L104. Yield: 0.44 g (47%). 1H NMR (400 MHz, dmso-d6) δ 7.92 (br.
s., 1 H, diastereomer 1), 6.89 (d, 1 H, diastereomer 2), 5.35 (m, 1 H, diastereomer 2), 5.07 (t, 1
H, diastereomer 1), 3.84 (m, 1 H, diastereomer 2), 3.58 (m, 1 H, diastereomer 1), 3.30 - 3.46 (m, 3 H, mixture of 1 H diastereomer 1 and 2 H diastereomer 2), 3.12 (m, 1 H, diastereomer 1),
2.74 (dd, 1 H, diastereomer 2), 2.59 (dd, 1 H, diastereomer 1), 2.42 (dd, 1 H, diastereomer 2), 30 2.17 (dd, 1 H, diastereomer 1).
Préparation 58: (±)-((1R,6S)-3-benzyl-3-azabicvclor4.1.0lheptan-1-yl)methanol (L105)
Step 1. Synthesis of (±)-((1R,6S)-3-benzvl-3-azabicvclor4.1.0lheptan-1-yl)methanol (L105).
To obtain the desired target material, (1-benzyl-1,2,5,6-tetrahydropyridin-3-yl)methanol (CAS 244267-39-8, 545 mg, 2.7 mmol)) was cyclopropanated as described in Tetrahedron 2003, 59, 5 6363 to provide the title compound L105. Yield: 252 mg (43%). 1H NMR (400 MHz, dmso-de) δ
7.13 - 7.41 (m, 5 H), 4.42 (t, 1 H), 3.32 - 3.49 (m, 2 H), 3.28 (dd, 1 H), 3.08 (dd, 1 H), 2.74 (d, 1
H), 2.21 - 2.39 (m, 2 H), 1.77 - 1.98 (m, 2 H), 1.49 - 1.70 (m, 1 H), 0.69 - 0.85 (m, 1 H), 0.39 0.53 (m, 2 H).
Préparation 59: (S)-4-(hvdroxvmethvl)-1-methvlimidazolidin-2-one (L106)
Step 1, Synthesis of (S)-I-Benzyl 5-methyl 2-oxoimidazolidine-1,5-dicarboxylate (C138).
To a suspension of (S)-3-((benzyloxy)carbonyl)-2-oxoimidazolidine-4-carboxylic acid (CAS 59760-01-9, 3.0 g, 11.4 mmol) in MeOH (40 mL) was added thionyl chloride (0.4 mL, 5.7 mmol) 15 slowly at about 25 °C. The mixture was stirred at about 25 °C overnight before the volatiles where removed under reduced pressure. The residue was dissolved in DCM and the DCM was washed with saturated aqueous NaHCO3. The DCM was dried over MgSCU, filtered and concentrated to provide the title compound C138. Yield: 2.9 g (93%). 1H NMR (400 MHz, dmsode) δ 7.26 - 7.45 (m, 5 H), 5.19 (q, 2 H), 4.78 (dd, Hz, 1 H), 3.66 (s, 3 H), 3.63 - 3.71 (m, 1 H), 20 3.37 (dd, 1 H), 2.71 (s, 3 H).
Step 2. Synthesis of (S)-I-Benzyl 5-methyl 3-methvl-2-oxoimidazolidine-1,5-dicarboxylate (C139). To a solution of compound C138 (0.96 g, 3.5 mmol) in DME (17 mL) was added K2CO3 (0.96 g, 6.9 mmol) followed by iodomethane (0.87 mL, 13.9 mmol). The mixture was heated at about 50 °C for about 19 h. The mixture was then allowed to cool to about 25 °C and diluted with water. The layers were separated and the aqueous phase was extracted three times with EtOAc. The combined DME and EtOAc extracts were washed with half - saturated aqueous NH4CI, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C139. Yield: 0.75 g (74%). 1H NMR (400 MHz, dmso-de) δ 7.31 - 7.44 (m, 5 H), 5.19 (dd, 2 H), 4.78 (dd, 1 H), 3.67 - 3.74 (m, 1 H), 3.37 (dd, 1
H), 3.31 (s, 2 H), 2.71 (s, 3 H).
146
Step 3. Synthesis of (S)-Benzyl 5-(hvdroxvmethvl)-3-methvl-2-oxoimidazolidine-1-carboxylate (C140). NaBHL (119 mg, 3.1 mmol) was added slowly to solution of compound C139 (0.75 g, 2.6 mmol) in EtOH (7 mL) at about 0 °C. The mixture was stirred at about 0 °C for about 2.5 h, at which time after which an additional 119 mg of NaBhk was added. Stirring was continued at about 0 °C for approximately an additional 1.5 h. Hydrochloric acid (10%) was added dropwise to the cooled mixture until the évolution of gas ceased. The mixture was concentrated under reduced pressure and the residue was taken up in EtOAc. The EtOAc extract was washed with saturated aqueous NaHCO3, water, brine, dried over Na2SO4, filtered and concentrated to provide the title compound C140. Yield: 200 mg (30%). 1H NMR (400 MHz, dmso-d6) δ 7.24 7.49 (m, 5 H), 5.10 - 5.28 (m, 2 H), 5.02 (t, 1 H), 4.04 - 4.19 (m, 1 H), 3.42 - 3.60 (m, 2 H), 3.25 (dd, 1 H), 2.71 (s, 3 H).
Step 4. Synthesis of (S)-4-(Hvdroxvmethvl)-1-methylimidazolidin-2-one To a solution of compound C140 (200 mg, 0.74 mmol) in MeOH (19 mL) was added palladium on carbon (25 mg) and the mixture was stirred under a hydrogen atmosphère (1 atm) for about 6 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography to provide the title compound L106. Yield: 61 mg (64%). 1H NMR (400 MHz, dmso-de) δ 3.46 - 3.55 (m, 1 H), 3.31 - 3.38 (m, 2 H), 3.24 - 3.31 (m, 1 H), 3.05 (dd, 1 H), 2.59 (s, 3 H).
Préparation 60:1-benzyl-6-hvdroxv-1-azaspiroi4.4lnonan-2-one (L107)
OH
Step 1. Synthesis of 1-benzvl-1H-pyrrol-2(5H)-one (C141). A mixture of 2,5-dimethoxy-2,5dihydrofuran (12.2 mL, 100 mmol), N-benzylamine (10.9 mL, 100 mmol), conc. HCl (12.5 mL, 150 mmol) and H2O (400 mL) was stirred for about 5 h at about 25 °C. The mixture was neutralized with solid NaHCO3 and extracted with EtOAc. The EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C141. Yield: 5.0 g (29%). 1H NMR (400 MHz, CDCI3) δ 7.26 - 7.38 (m, 5 H), 6.33-6.36 (m, 1 H), 5.29-5.32 (m, 1 H), 4.65 (s, 2 H), 3.14-3.15 (m, 2 H).
Step 2. Synthesis of 1-benzvl-2-((tert-butvldimethvlsilvl)oxv)-1H-pyrrole (C142). To a solution of compound C141 (2.0 g, 12 mmol) and Et3N (3.3 mL, 23 mmol) in anhydrous DCM (20 mL) was added t-butyldimethylsilyl triflate (2.4 mL,12 mmol) at about 25 °C. After about 5 h the reaction
mixture was diluted with EtOAc and H2O. The aqueous phase was separated and extracted with EtOAc. The combined EtOAc extracts were washed with saturated aqueous NaHCO3 and concentrated. The residue was purified by chromatography to provide the title compound C142. Yield: 2.0 g (61%). 1H NMR (400 MHz, CDCI3) δ 7.10 - 7.15 (m, 4 H), 6.90 - 6.93 (m, 1 H), 5 6.03 - 6.04 (m, 1 H), 5.78 - 5.80 (m, 1 H), 5.07 - 5.09 (m, 1 H), 4.76 (s, 2 H), 0.073 (s, 9 H),
0.00 (s, 6 H).
Step 3. Synthesis of 1-benzvl-5-(1-hvdroxycyclobutvl)-1H-pvrrol-2(5H)-one (C143). To a solution of compound C142 (500 mg, 1.7 mmol) in DCM (12 mL) at 25 °C was added 3 A molecular sieves and cyclobutanone (0.21 mL, 2.8 mmol). The resulting mixture was stirred for 10 about 15 min at about 25 °C and was then cooled to about -78 °C. BF3-Et2O (0.32 mL, 370 mg,
2.6 mmol) was added dropwise. The mixture was stirred at about -78 °C for about 2 h then warmed to about 0 °C and quenched with H2O. The DCM was separated, washed with saturated aqueous NaHCO3, and the aqueous phase was extracted with DCM. The DCM extracts were washed with satd. NaHCO3, dried over Na2SO4, filtered and concentrated. The 15 residue was purified by chromatography to provide the title compound C143. Yield: 300 mg (71%). 1H NMR (300 MHz, CDCI3) δ 7.09 - 7.24 (m, 5 H), 6.90 - 6.92 (m, 1 H), 6.23 - 6.25 (m, 1 H), 5.00 (d, 1 H), 4.27 (d, 1 H), 4.05 - 4.06 (m, 1 H), 2.21 - 2.23 (m, 1 H), 1.95 - 2.04 (m, 2 H), 1.82-1.86 (m, 2 H), 1.81 (s, 1 H), 1.42 - 1.49 (m, 1 H).
Step 4. Synthesis of 1-benzvl-1-azaspirof4.41nonane-2,6-dione (C144), To a solution of 20 compound C143 (300 mg, 1.2 mmol) in DCM (20 mL) at 0 °C was added concentrated HCl (0.2 mL, 2.2 mmol). The mixture was stirred at about 0 °C for about 5 h and concentrated to afford compound C144 which was used without purification. 1H NMR (400 MHz, CDCI3) δ 7.06 - 7.30 (m, 5 H), 4.75 (d, 1 H), 3.90 (d, 1 H), 2.37 - 2.59 (m, 2 H), 2.21 - 2.37 (m, 1 H), 1.99 - 2.10 (m, 1 H), 1.83 - 1.99 (m, 3 H), 1.58 - 1.83 (m, 3 H).
Step 5. Synthesis of 1-benzvl-6-hvdroxv-1-azaspirof4.4lnonan-2-one (L107). NaBH4 (38 mg,
0.93 mmol) was added to a solution of compound C144 (150 mg, 0.62 mmol) in MeOH (4 mL). The mixture was stirred at about 25 °C for about 20 min before being diluted with H2O and extracted with EtOAc. The combined EtOAc extracts were washed with water, brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the 30 title compound L107 as a mixture of diastereomers. Yield: 105 mg (70%). It was used in the next step without further characterization.
Préparation 61: (S)-4-(hvdroxymethvl)imidazo)idin-2-one (L108)
148
Step 1. Synthesis of methyl (4S)-2-oxoimidazolidine-4-carboxylate (C145). A suspension of 1benzyl 5-methyl (5S)-2-oxoimidazolidine-1,5-dicarboxylate (CAS 168399-08-4, 325 mg, 1.2 mmol) and 10% Pd/C (33 mg) in MeOH (4.7 mL) was shaken under a hydrogen atmosphère at 5 about 25 °C for about 5.5 h. The mixture was filtered and concentrated to afford the title compound C145. Yield: 163 mg (97%). 1H NMR (400 MHz, dmso-d6) δ 6.73 (s, 1 H), 6.34 (s, 1 H), 4.25 (ddd, 1 H), 3.52 - 3.65 (m, 2 H), 3.32 (2, 3 H).
Step 2. Synthesis of (4S)-4-(hvdroxvmethyl)imidazolidin-2-one (L108). Sodium borohydride (56 mg, 1.4 mmol) was added to a solution of compound C145 (160 mg, 1.1 mmol) at about 0 °C.
The mixture was stirred at about 0 °C for about 3h, and then 10% HCl solution was added dropwise until gas évolution ceased. The mixture was concentrated and the residue was diluted with EtOAc. The EtOAc was washed with saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered and concentrated to provide the title compound L108. Yield: 360 mg (a mixture of desired product and salts). This was used in the next step without purification. 1H NMR (400
MHz, dmso-de) δ 3.53 - 3.61 (m, 1 H), 3.30 - 3.36 (m, 2 H), 3.23 - 3.30 (m, 1 H), 3.04 (dd, 1 H).
Préparation 62: (3S,3aR,6aS)-5-benzvl-3-(hvdroxvmethvl)hexahvdropvrroloi3,4-clpyrrol-1 (2H)one (L109)
Step 1. Synthesis of (SaS.SaR.SbSW-benzyl-S.S-dimethvlhexahvdro-IH-pyrrolorS'^'^^l25 pyrroloM ,2-c1oxazol-5(3H)-one (C146). A solution of compound P20 (100 mg, 0.65 mmol) in
DCM (5 mL) and N-(methoxymethyl)-N-[(trimethylsilyl)methyl]-benzenemethanamine (CAS 93102-05-7, 232 mg, 0.98 mmol) was treated with TFA (0.01 mL, 0.13 mmol) at 0 °C. The mixture was kept at about 25 °C for about 16 h, then heated at about 40 °C for about 4 h, before an additional 232 mg of CAS 93102-05-7 was added. Heating was continued for about 16 h.
The reaction mixture was cooled to about 25 °C, neutralized with Et3N (18 pL, 0.13 mmol), and
149 concentrated. The residue was purified by chromatography to provide the title compound C146.
Yield: 110 mg (59%). 1H NMR (400 MHz, dmso-d6) δ 7.16 - 7.41 (m, 5 H), 3.98 (dd, 1 H), 3.78 3.87 (m, 1 H), 3.59 - 3.68 (m, 1 H), 3.48 - 3.58 (m, 1 H), 3.35 (dd, 1 H), 3.10 (t, 1 H), 2.95 (d, 1 H), 2.79 (d, 1 H), 2.56 - 2.66 (m, 1 H), 2.24 (t, 1 H), 2.18 (dd, 1 H), 1.53 (s, 3 H), 1.33 (s, 3 H).
Step 2. Synthesis of (3S,3aR,6aS)-5-benzvl-3-(hvdroxymethvl)hexahvdropyrrolo[3,4-c|pvrrol1(2H)-one (L109), To a stirred solution of compound C5146 (110 mg, 0.38 mmol) in 6 mL of acetonitrile and 0.6 mL of water was added TFA (36 pL, 0.46 mmol). The reaction mixture was heated at about 60 °C for about 2 h. The reaction mixture was cooled to about 25 °C, concentrated, and the residue was purified by chromatography to provide the title compound 10 L109. Yield: 60 mg (64%). Ή NMR (400 MHz, CD3OD) δ 7.20 - 7.37 (m, 5 H), 3.61 (s, 2 H), 3.46
- 3.55 (m, 2 H), 3.39 - 3.45 (m, 1 H), 2.92 - 3.02 (m, 2 H), 2.66 - 2.78 (m, 2 H), 2.57 (dd, 1 H),
2.45 - 2.53 (m, 1 H).
Préparation 63: 2-((5S)-5-(hvdroxvmethvl)-2-oxopyrrolidin-3-v0acetonitrile (L110)
Stepl: Synthesis of (5S)-tert-butvl 5-(((tert-butoxvcarbonvl)oxv)methvl)-3-(cyanomethvl)-2oxopyrrolidine-1-carboxvlate (C147), LDA solution (2 M, 2.4 mL) was added to a solution of (S)tert-butyl 2-(((tert-butoxycarbonyl)-oxy)methyl)-5-oxopyrrolidine-1-carboxylate (CAS 360782-623, 1.0 g, 3.2 mmol) in THF (20 mL) at about -78 °C. After about 30 min, bromoacetonitrile (0.22 20 mL, 3.2 mmol) was added. The mixture was stirred at about -78 °C for about 20 min, and then saturated aqueous NaHCC>3 (2 mL) was added. The mixture was diluted with H2O and extracted with EtOAc. The combined EtOAc extracts were washed with H2O, brine, dried over MgSÛ4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C147. Yield: 0.86 g (77%). 1H NMR (400 MHz, CDCh) δ 4.50 (dd, 1 H), 4.36 - 4.44 25 (m, 1 H), 4.10 - 4.19 (m, 1 H), 3.08 - 3.22 (m, 1 H), 2.88 (dd, 1 H), 2.60 (dd, 1 H), 2.41 (dd, 1 H),
2.06 - 2.20 (m, 1 H), 1.53 - 1.62 (m, 18 H).
Step 2. Synthesis of 2-((5S)-5-(hvdroxvmethvl)-2-oxopyrrolidin-3-vl)acetonitrile (L110). Concentrated HCl (2 mL) was added to a solution of compound C147 (500 mg, 1.4 mmol) in MeOH (5 mL) and DCM (5 mL). The mixture was stirred at about 25 °C overnight, then 30 concentrated provide the title compound L110. 1H NMR (400 MHz, CD3OD) δ 3.76 - 3.67 (m, 1
H), 3.56 - 3.48 (m, 2 H), 2.90 - 2.87 (m, 1 H), 2.73 - 2.65 (m, 2 H), 2.27 - 2.24 (m, 1 H), 2.12 2.05 (m, 1 H).
Préparation 64: (1S,3aS,6aR)-di-tert-butyl 1-(hvdroxvmethyl)-3-oxotetrahvdropvrrolor3,4clPVrrole-2,5(1H,3H)-dicarboxylate (L111)
Step 1, Synthesis of (1S,3aS,6aR)-tert-butyl 5-benzvl-1-(((tert-butvldimethvlsilvl)oxy)methvl)-3oxohexahvdropvrrolo[3,4-clpyrrole-2(1 H)-carboxylate (C148). A solution of (S)-tert-butyl 2(((tert-butyldimethylsilyl)oxy)methyl)-5-oxo-2,5-dihydro-1H-pyrrole-1-carboxylate (CAS 8165827-7, 3.0 g, 9.2 mmol) and N-(methoxymethyl)-N-[(trimethylsilyl)methyl]-benzenemethanamine (CAS 93102-05-7, 3.27 g, 13.8) in DCM (80 mL) was treated with TFA (208 mg, 1.84 mmol) at 10 about 25 °C and kept for about 18 h. Triethylamine (0.26 mL, 1.84 mmol) was added and mixture was concentrated. The residue was purified by chromatography to provide the title compound C148. Yield: 2.6 g (61%). 1H NMR (400 MHz, dmso-d6) δ 7.27 - 7.34 (m, 2 H), 7.19 7.27 (m, 3 H), 3.87 - 3.91 (m, 1 H), 3.84 (dd, 1 H), 3.65 (d, 1 H), 3.53 (s, 2 H), 2.90 - 2.97 (m, 1 H), 2.82 - 2.89 (m, 1 H), 2.65 - 2.73 (m, 2 H), 2.54 - 2.63 (m, 2 H), 1.45 (s, 9 H), 0.82 (s, 9 H), 15 0.01 (s, 3 H),-0.02 (s, 3 H)
Step 2: Synthesis of (1S,3aS,6aR)-di-tert-butyl 1-(((tert-butvldimethvlsilyl)oxv)methvl)-3oxotetrahvdropvrrolo[3,4-clpyrrole-2,5(1H,3H)-dicarboxvlate (C149). To a solution of compound
C148 (2.2 g, 4.8 mmol) and di-t-butyl dicarbonate (3.1 g, 14.4 mmol) in MeOH (150 mL) was added palladium on carbon (200 mg) and the mixture was stirred under a hydrogen atmosphère 20 (1 atm) for about 18 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography to provide the title compound C149. Yield: 1.12 g (49%). 1H NMR (400 MHz, CD3OD) δ 3.99 - 4.10 (m, 2 H), 3.68 - 3.88 (m, 4 H), 3.45 - 3.55 (m, 1 H), 3.11 (dd, 1 H), 2.87 - 2.99 (m, 1 H), 1.54 (s, 9 H), 1.45 (s, 9 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.06 (s, 3 H).
Step 3. Synthesis of (1S,3aS,6aR)-di-tert-butvl 1-(hvdroxvmethvl)-3-oxotetrahydropvrrolo[3,4clpyrrole-2,5(1H,3H)-dicarboxylate (L111). A solution of compound C149 (1.22 g, 2.6 mmol) in
THF (100 mL) was treated with tetrabutylammonium fluoride (1 M, 3.9 mL) at about 25 °C. After about 2 h, the mixture was concentrated. The residue was purified by chromatography to provide the title compound L111. Yield: 600 mg (65%). 1H NMR (400 MHz, CD3OD) δ 4.18 (dd, 30 1 H), 4.05 (dd, 1 H), 3.69 - 3.82 (m, 2 H), 3.56 - 3.69 (m, 1 H), 3.47 (dd, 1 H), 3.21 (dd, 1 H),
3.08 - 3.17 (m, 1 H), 2.87 - 2.99 (m, 1 H), 1.46 (s, 9 H), 1.46 (s, 9 H)
Préparation 65: (4R,5S)-4-(hvdroxvmethyl)-5-methvloxazolidin-2-one (L112)
O
K
HN O
HO JA
Step 1. Synthesis of (4R,5S)-4-(hvdroxvmethyl)-5-methvloxazolidin-2-one (L112), To a mixture of (4S,5S)-methyl 5-methyl-2-oxooxazolidine-4-carboxylate (CAS 182267-22-7, 165 mg, 1.0 mmol) in EtOH (6 mL) at about 0 °C was added NaBhL (43 mg, 1.1 mmol). After gas évolution ceased, the mixture was stirred at about 25 °C for about 4 h. The mixture was re-cooled to about 0 °C and additional NaBI-fi (35 mg, 0.9 mmol) was added. The mixture was warmed to about 25 °C and after about 2 h, saturated aqueous NH4CI was added and the mixture was stirred overnight. The mixture was filtered and the solids were washed with EtOH. The filtrate was concentrated and the residue was purified by chromatography to provide the title compound L112. Yield: 97 mg (72%). 1H NMR (400 MHz, CDCI3) δ 6.72 (s, 1 H), 4.72 - 4.88 (m, 1 H), 3.99 (br. s., 1 H), 3.74 - 3.86 (m, 1 H), 3.54 - 3.73 (m, 2 H), 1.38 (d, 3 H).
Préparation 66: (1S,4S,5R)-4-(hvdroxvmethvl)-3-azabicvclof3.1.01hexan-2-one (L113)
O
Step 1. Synthesis of (5aS,6aR,6bS)-3,3-dimethvltetrahvdro-1H-cvclopropaf3,4lpyrrolo[1,2cloxazol-5(3H)-one (C150). A solution of compound P20 (1.0 g, 6.5 mmol) in DCM (40 mL) was cooled to 0 °C and a solution of diazomethane (prepared from 6.7 g of N-methyl-N-nitrosurea in 65 mL of diethyl ether) was added. Palladium acetate (72 mg, 0.32 mmol) was added in portions 25 at about 0 °C. The mixture was allowed to warm to about 25 °C for about 16 h. The mixture was filtered and a second portion of diazomethane and palladium acetate were added and stirred over night. The addition of diazomethane and palladium acetate were repeated twice more. The mixture was filtered and the filtrate was concentrated. The residue was purified by HPLC to the title compound C150. Yield: 100 mg (9%). 1H NMR (400 MHz, CD3OD) δ 3.47 - 3.57 (m, 3 H), 30 1.90-1.98 (m, 1 H), 1.75-1.81 (m, 1 H), 1.12-1.19(m, 1 H), 0.58-0.63 (m, 1 H).
Step 2. Synthesis of (1S,4S,5R)-4-(hvdroxvmethvl)-3-azabicyclor3.1.0lhexan-2-one (L113).
To a stirred solution of compound C150 (95 mg, 0.57 mmol) in 5 mL of acetonitrile and 1 mL of water was added 4-toluenesulfonic acid (5 mg, 0.03 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, and 5 the residue was purified by chromatography to provide the title compound L113. Yield: 35 mg (33%). 1H NMR (400 MHz, CD3OD) δ 4.61 (br. s, 1 H), 3.95 (d, 1 H), 3.65 (dd, 1 H), 3.51 (dd, 1
H), 3.34 (dt, 1 H), 2.01 - 2.10 (m, 1 H), 0.98 - 1.05 (m, 1 H), 0.78 - 0.83 (m, 1 H).
Préparation 67: (1S,2S,5R)-tert-butyl 6,6-dichloro-2-(hvdroxvmethyl)-4-oxo-310 azabicyclo|3.1 .Olhexane-3-carboxylate (L114)
Step 1. Synthesis of (1S,2S,5R)-tert-butyl 2-((ïtert-butvldimethvlsilvl)oxv)methyl)-6,6-dichloro-3azabicyclo|3.1 .Olhexane-3-carboxylate (C151). To a stirred solution of (S)-tert-butyl 2-(((tertbutyldimethylsilyl)oxy)methyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (CAS 247200-49-3, 5.0 g,
16 mmol) and benzyltriethyl NH4CI (0.73 g, 3.2 mmol) in CHCL (100 mL) was added 50%
NaOH solution (100 mL). The mixture was stirred at about 25 °C for about 16 h, then diluted with DCM and separated. The aqueous phase was extracted twice with additional DCM. The combined DCM extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C151.
Yield: 3.6 g (57%) as colorless liquid. 1H NMR (400 MHz, CDCh) δ 3.90 - 4.09 (m, 1 H), 3.81 3.89 (m, 1 H), 3.73 - 3.81 (m, 1 H), 3.61 - 3.73 (m, 1 H), 3.57 (dd, 1 H), 2.28 - 2.39 (m, 1 H), 2.22 - 2.29 (m, 1 H), 1.43 (d, 9 H), 0.90 (d, 9 H), 0.03 - 0.10 (m, 6 H)
Step 2. Synthesis of (1S,2S,5R)-tert-butyl 2-(((tert-butvldimethvlsilvl)oxv)methyl)-6,6-dichloro-4oxo-3-azabicyclo[3.1 .OIhexane-3-carboxylate (C152). Sodium periodate (654 mg, 3.0 mmol) was dissolved in water (6.5 mL) and a catalytic amount of hydrated ruthénium dioxide was added. After stirring for 5 min, a solution of compound C151 (400 mg, 1.0 mmol) in EtOAc (6.5 mL) was added. The resulting mixture was stirred vigorously overnight. The phases were separated and the EtOAc phase was washed with sodium bisulfate solution, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C152. Yield: 290 mg (70%). 1H NMR (400 MHz, CDCI3) δ 4.16 - 4.21 (m, 1 H), 3.92 - 3.98 (m, 1 H), 3.85 - 3.91 (m, 1 H), 2.82 (dd, 1 H), 2.56 (d, 1 H), 1.51 (s, 9 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.06 (s, 3 H).
Step 3. Synthesis of (1S,2S,5R)-tert-butyl 6,6-dichloro-2-(hvdroxvmethyl)-4-oxo-3-azabicvcloF3.1.0lhexane-3-carboxylate (L114). Compound C152 (290 mg, 0.7 mmol) in THF (8 mL) was treated with tetrabutylammonium fluoride (1 M, 1.4 mL) at about 25 °C. The mixture was stirred at about 25 °C for about 4 h, then water was added and the mixture was extracted twice with 5 EtOAc (15 mL each). The combined EtOAc extracts were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound L114. Yield: 124 mg (59%). 1H NMR (400 MHz, CDCI3) δ 5.57 (br. s., 1 H), 4.19 4.27 (m, 1 H), 4.08 - 4.15 (m, 1 H), 3.90 (t, 1 H), 2.81 (d, 1 H), 2.55 (d, 1 H), 1.51 (s, 9 H).
Préparation 68: (S)-5-((S)-1-hvdroxvethvl)pyrrolidin-2-one (L115)
Step 1. Synthesis of (S)-5-((S)-1-hvdroxvethvl)pyrrolidin-2-one (L115). A mixture of (S)-5-((S)1-hydroxyethyl)-1-(9-phenyl-9H-fluoren-9-yl)pyrrolidin-2-one (CAS 191406-21-0, 750 mg, 2.0 mmol) and palladium on carbon (350 mg) in MeOH (36 mL) and EtOAc (36 mL) was 15 hydrogenated at about 40 psi for about 30 h at about 25 °C. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography to provide the title compound L115. Yield: 220 mg (84%). Ή NMR (400 MHz, dmso-d6) δ 7.51 (br. s, 1 H), 4.66 (d, 1 H), 3.41-3.45 (m, 1 H), 3.31-3.36 (m, 1 H), 2.08 - 2.13 (m, 2 H), 1.93 - 2.05 (m, 1 H), 1.62 -1.70 (m, 1 H), 0.98 (d, 3 H).
Préparation 69: (4S,5S)-4-(2-fluoroethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L116)
Step 1. Synthesis of (7R,7aS)-7-(2-hvdroxvethvl)-3,3-dimethvltetrahvdropyrrolori,2-cloxazol5(3H)-one (C153). Cyclohexene (4.3 mL, 42 mmol) was added to a solution of borane in THF (1 M, 21.1 mL) at about 0 °C. After 30 min, the mixture was warmed to about 25 °C and stirred 25 approximately 30 min longer. After cooling to about 0 °C, a solution of compound C55 (2.55 g,
14.1 mmol) in DCM (70 mL) was added dropwise over about 15 min. After about 90 minutes at 0 °C, water (40 mL) was added and the mixture was stirred for approximately 30 min at about 0 °C. The mixture was partially concentrated to remove about 50 mL of DCM and THF (20 mL) was added. Sodium perborate tetrahydrate (8.93 g, 56 mmol) was added and the mixture was 30 stirred overnight while being allowed to warm to about 20 °C. The phases were separated and the aqueous phase was extracted 5 times with DCM and 3 times with MTBE. The combined
154
DCM and MTBE extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C153. Yield: 2.04 g (73%). 1H NMR (400 MHz, CDCb) δ 4.38 (dt, 1 H), 3.91 (dd, 1 H), 3.68 - 3.77 (m, 2 H), 3.60 - 3.68 (m, 1 H), 2.94 (dd, 1 H), 2.53-2.65 (m, 1 H), 2.34 (dd, 1 H), 1.71 - 1.82 (m, 1 H), 1.65 (s, 3 H), 1.51 - 1.62 (m,
H), 1.48 (s, 3 H).
Step 2. Synthesis of (7S,7aS)-7-(2-fluoroethvl)-3,3-dimethvltetrahvdropvrroloi1,2-cloxazol5(3H)-one (C154), To a solution of compound C153 (1.43 g, 7.2 mmol) in DCM (36 mL) at about 0 °C were added 2,6-lutidine (2.09 mL, 17.9 mmol), DAST (1.75 mL, 14.4 mmol), and triethylamine trihydrofluoride (1.16 mL, 7.2 mmol). The mixture was stirred overnight while warming to about 20 °C, then was added dropwise into saturated aqueous NaHCCb. The mixture was extracted 4 times with DCM. The combined DCM extracts were dried over Na2SC>4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C154. Yield: 1.06 g (73%). 1H NMR (400 MHz, CD3OD) δ 4.55 - 4.52 (m, 1 H), 4.47 4.40 (m, 2 H), 3.92 (dd, 1 H), 3.78 - 3.73 (m, 1 H), 2.99 (dd, 1 H), 2.66 - 2.58 (m, 1 H), 2.36 (dd, 1 H), 2.01 - 1.86 (m, 1 H), 1.74-1.61 (m, 1 H), 1.60 (s, 3 H), 1.44 (s, 3 H). 19F NMR (376 MHz, CD3OD) δ-221.50.
Step 3. Synthesis of 4S,5S)-4-(2-fluoroethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L116). To a stirred solution of compound C154 (130 mg, 0.65 mmol) in 6.5 mL of acetonitrile and 1.3 mL of water was added TFA (5 uL, 0.07 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C, concentrated, then twice redissolved in acetonitrile and water and concentrated to provide the title compound L116. Yield: 90 mg (86%). 1H NMR (400 MHz, CD3OD) δ 4.63 - 4.51 (m, 1 H), 4.51 - 4.37 (m, 1 H), 3.70 - 3.57 (m,
H), 2.72 (m, 1 H), 2.38 - 2.18 (m, 2 H), 2.14 - 1.95 (m, 1 H), 1.95 - 1.73 (m, 1 H). 19F NMR (376MHz, CD3OD) δ -220.91.
Préparation 70: (4R,5S)-4-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (1-117)
HO
Step 1. Synthesis of (7R,7aS)-7-(1.2-dihvdroxvethvl)-3,3-dimethvltetrahvdropvrrolof1,2-cloxazol5(3H)-one (C155). To a solution of compound C55 (1.50 g, 8.3 mmol) in acetone (30 mL) and H2O (3 mL) was added N-methylmorpholine-N-oxide (1.38 g, 11.8 mmol) followed by osmium tetroxide (31 mg, 0.12 mmol) at about 25 °C. The mixture was stirred at about 25 °C for about 3
155 h, then concentrated. The residue was purified by chromatography to provide the title compound C155 as a mixture of two diastereomers. Yield: 1.47 g (82%).
Step 2. Synthesis of (7R,7aS)-7-(hvdroxvmethvl)-3,3-dimethvltetrahvdropyrrolo[1,2-cloxazol5(3H)-one (C156). To a solution of compound C155 (2.00 g, 9.3 mmol) in MeCN (50 mL) was added water (5 mL) followed by sodium periodate (2.19 g, 10.2 mmol) at about 25 °C. The mixture was stirred at about 25 °C for 1 h, then cooled to about 0 °C and treated with NaBLU (538 mg, 13.9 mmol) and stirred for about 1 h. The mixture was filtered, concentrated, and the residue was taken up in DCM and filtered. The filtrate was concentrated to provide the title compound C156. Yield: 1.69 g (98%). 1H NMR (400 MHz, CD3OD) δ 4.43 (td, 1 H), 3.98 - 3.84 (m, 2 H), 3.63 - 3.48 (m, 2 H), 2.98 (dd, 1 H), 2.59 - 2.49 (m, 1 H), 2.27 (dd, 1 H), 1.59 (s, 3 H), 1.43 (s, 3 H).
Step 3. Synthesis of (7R,7aS)-7-(fluoromethvl)-3,3-dimethvltetrahydropvrrolof1l2-cloxazol5(3H)-one (C157). To a solution of compound C156 (1.70 g, 9.3 mmol) in DCM (20 mL) at about 0 °C were added 2,6-lutidine (2.7 mL, 23 mmol), DAST (2.3 mL, 18.6 mmol), and triethylamine trihydrofluoride (1.5 mL, 9.3 mmol). The mixture was stirred at about 25 °C for about 18 h. The reaction was quenched with saturated aqueous NaHCO3 and extracted with DCM. The combined DCM extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C157. Yield: 800 mg (46%). 1H NMR (400 MHz, CDCI3) δ 4.34 - 4.63 (m, 3 H), 4.01 (dd, 1 H), 3.79 - 3.87 (m, 1 H), 3.03 (ddd, 1 H), 2.72 - 2.85 (m, 1 H), 2.26 (dd, 1 H), 1.67 (s, 3 H), 1.51 (s, 3 H). 19F NMR (376 MHz, CDCI3) δ -218.27.
Step 4. Synthesis of (4R,5S)-4-(fluoromethvl)-5-(hvdroxvmethyl)pyrrolidin-2-one (L117). To a stirred solution of compound C157 (87 mg, 0.46 mmol) in 4 mL of acetonitrile and 1 mL of water was added TFA (0.1 mL, 1.4 mmol). The reaction mixture was heated at about 90 °C for about 1 h. The reaction mixture was cooled to about 25 °C, filtered, concentrated, then redissolved in MeOH and toluene and concentrated. The residue was dissolved in MeOH and toluene and concentrated several more times to provide the title compound L117. Yield: 57 mg (83%). 1H NMR (400 MHz, CD3OD) δ 4.47 - 4.75 (m, 2 H), 3.73 - 3.82 (m, 1 H), 3.58 - 3.73 (m, 2 H), 2.96 (td, 1 H), 2.31 (qd, 2 H). 19F NMR (376 MHz, CD3OD) δ -222.48.
Préparation 71: (3S,4R,5S)-3-fluoro-4-(fluoromethvl)-5-(hvdroxymethvl)pyrrolidin-2-one (L118) Step 1. Synthesis of (6S,7R,7aS)-6-fluoro-7-(fluoromethvl)-3,3-dimethvltetrahvdropyrrolof1,2c]oxazol-5(3H)-one (C158). A solution of compound C157 (730 mg, 3.9 mmol) in THF (20 mL) was slowly treated with LDA (2 M, 2.9 mL) at -78 °C. After 30 min at -78 °C, a pre-cooled (-78
°C) solution of NFSI (1.97 g, 6.2 mmol) in THF (20 mL) was added via cannula. Immediately after the complété addition of NFSI, the reaction was quenched with water at -78 °C and allowed to warm to 25 °C. The solution was diluted with additional water (15 mL) and extracted with MTBE (50 mL). The aqueous phase was again extracted with MTBE (50 mL) and the 5 combined MTBE extracts were dried over Na2SC>4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C158. Yield: 120 mg (15%). 1H NMR (400 MHz, CDCL) δ 5.36 (dd, 1 H), 4.78 - 4.65 (m, 1 H), 4.65 - 4.53 (m, 1 H), 4.17 - 4.04 (m, 2 H), 3.96 - 3.86 (m, 1 H), 3.28 - 3.08 (m, 1 H), 1.69 (s, 3 H), 1.50 (s, 3 H). 19F NMR (376 MHz, CDCL) δ -202.40, -228.51. There was also obtained (6R,7R,7aS)-6-fluoro-7-(fluoromethyl)-3,310 dimethyltetrahydropyrrolo-[1,2-c]oxazol-5(3H)-one (C159). Yield: 540 mg (68%). 1H NMR (400
MHz, CDCL) δ 4.95 (dd, 1 H), 4.65 (d, 1 H), 4.50 - 4.58 (m, 2 H), 4.04 (ddd, 1 H), 3.75 (ddd, 1
H), 2.76 - 2.96 (m, 1 H), 1.65 (s, 3 H), 1.54 (s, 3 H). 19F NMR (376 MHz, CDCI3) δ -187.58, 223.88.
Step 2. Epimerization of (6R,7R,7aS)-6-fluoro-7-(fluoromethvl)-3,3-dimethvltetrahvdropyrrolo15 [1,2-cloxazol-5(3H)-one (C159). LDA (2 M, 0.89 mL) was added to a solution of compound
C159 (240 mg, 1.2 mmol) in toluene (3 mL) at -78 °C. The mixture was stirred for 30 min, after which a -78 °C solution of BHT (517 mg, 2.3 mmol) in toluene (6 mL) was added. Immediately after the addition of BHT, water (2 mL) was added and the mixture was allowed to warm to 20 °C. EtOAc was added and the aqueous phase was extracted again with EtOAc. The combined 20 EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide compound C158. Yield: 113 mg (47%).
Step 3. Synthesis of (3S,4R,5S)-3-fluoro-4-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L118). To a stirred solution of compound C158 (370 mg, 1.8 mmol) in 12 mL of acetonitrile and 3 mL of water was added silica bound 4-toluenesulfonic acid (132 mg, 0.09 mmol). The reaction 25 mixture was heated at 80 °C for 2 h. The reaction mixture was cooled to 25 °C and concentrated to provide the title compound L118. Yield: 250 mg (84%).. 1H NMR (400 MHz, CD3OD) δ 5.03 (dd, 1 H), 4.81 - 4.74 (m, 1 H), 4.74 - 4.61 (m, 1 H), 3.86 - 3.77 (m, 1 H), 3.69 (dd, 1 H), 3.61 (dd, 1 H), 3.15 - 2.94 (m, 1 H). 19F NMR (376 MHz, CD3OD) δ -203.74, -227.31.
Préparation 72: (3S,4S,5S)-3-fluoro-4-(2-fluoroethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L121)
Step 1. Synthesis of (6S,7S,7aS)-6-fluoro-7-(2-fluoroethvl)-3,3-dimethvltetrahvdropyrrolori,2c1oxazol-5(3H)-one (C160). A solution of compound C154 (1.01 g, 5.0 mmol) in THF (25 mL) was slowly treated with LDA (2 M, 3.8 mL) at -78 °C. After 30 min at -78 °C, a pre-cooled (-78 °C) solution of NFSI (2.58 g, 8.0 mmol) in THF (25 mL) was added via cannula. After 20 min,
157 the reaction was quenched with water (4 mL) at -78 °C and allowed to warm to 25 °C. The solution was diluted with additional water (25 mL) and extracted with MTBE (25 mL). The aqueous phase was extracted 3 times with MTBE (20 mL each) and the combined MTBE extracts were dried over Na2SC>4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C160. Yield: 350 mg (32%).1H NMR (400 MHz,
CDCh) δ 5.29 (dd, 1 H), 4.48 - 4.66 (m, 1 H), 4.51 (ddd, 1 H), 4.11 (dt, 1 H), 3.99 - 4.06 (m, 1 H), 3.71 - 3.79 (m, 1 H), 2.98 - 3.08 (m, 1 H), 1.75 - 2.07 (m, 2 H), 1.68 (s, 3 H), 1.49 (s, 3 H). 19F NMR (376 MHz, CDCI3) δ -198.87, -219.80. There was also obtained (6R,7S,7aS)-6-fluoro7-(2-fluoroethyl)-3,3-dimethyltetrahydropyrrolo-[1,2-c]oxazol-5(3H)-one (C161). Yield: 516 mg 10 (47%).. 1H NMR (400 MHz, CDCh) δ 4.83 (dd, 1 H), 4.58 - 4.64 (m, 1 H), 4.44 - 4.53 (m, 2 H),
3.99 (dd, 1 H), 3.57 (dd, 1 H), 2.64 - 2.79 (m, 1 H), 1.72 - 2.01 (m, 2 H), 1.65 (s, 3 H), 1.51 (s, 3 H). 19F NMR (376 MHz, CDCh) δ -185.95, -219.45.
Step 2. Epimerization of (6R.7S,7aS)-6-fluoro-7-(2-fluoroethvl)-3.3-dimethvltetrahvdropyrrolori,2-c1oxazol-5(3H)-one (C161). LDA (2 M, 0.34 mL) was added to a solution of compound
C161 (100 mg, 0.46 mmol) in toluene (2 mL) at about -78 °C. The mixture was stirred for 30 min, after which a about -78 °C solution of BHT (201 mg, 0.91 mmol) in toluene (4 mL) was added. Immediately after the addition of BHT, water (4 mL) was added and the mixture was allowed to warm to about 20 °C. MTBE was added and the phases were separated. The MTBE extract was dried over MgSCU, filtered and concentrated. The residue was purified by 20 chromatography to provide compound C160. Yield: 36 mg (36%).
Step 3. Synthesis of (3S,4S,5S)-3-fluoro-4-(2-fluoroethvl)-5-(hvdroxymethvl)pvrrolidin-2-one (L121). To a stirred solution of compound C160 (460 mg, 0.39 mmol) in 21 mL of acetonitrile and 5 mL of water was added TFA (8 uL, 0.1 mmol). The reaction mixture was heated at 90 °C for 1 h. The reaction mixture was cooled to 25 °C, concentrated, then twice redissolved in 25 acetonitrile and water and concentrated. The residue was triturated with CHCh to provide the title compound L121. Yield: 270 mg (72%). Ή NMR (400 MHz, CD3OD) δ 4.86 (dd, 1 H), 4.62 4.70 (m, 1 H), 4.50 - 4.58 (m, 1 H), 3.71 - 3.82 (m, 2 H), 3.50 - 3.57 (m, 1 H), 2.78 (m, 1 H), 1.95 - 2.10 (m, 2 H). 19F NMR (376 MHz, CD3OD) δ -194.88, -217.30.
Préparation 73: (+)-(3R,4R)-tert-butyl 3-(hvdroxvmethvl)-4-(trifluoromethvl)pyrrolidine-1 carboxylate (L122)
158
Step 1. Synthesis of (±)-(3R,4R)-ethvl 1-benzvl-4-(trifluoromethvl)pyrrolidine-3-carboxvlate (C164), To a solution of ethyl (E)-4,4,4-trifluorocrotonate (CAS 25597-16-4, 6.0 g, 36 mmol) and TFA (0.55 mL, 7 mmol) in DCM (60 mL) at about 0 °C was added N-(methoxymethyl)-N[(trimethylsilyl)methyl]-benzenemethanamine (CAS 93102-05-7, 16.85 g, 71 mmol) over a period of about 20 minutes. The reaction mixture was then heated at reflux for 16 h. It was diluted with DCM (100 mL), washed with saturated aqueous NaHCO3 solution (2 x 100 mL), water (100 mL), and brine (50 mL). The DCM extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C164. Yield: 10.5 g (99%). 1H NMR (400 MHz, dmso-d6) δ 7.23 - 7.34 (m, 5 H), 4.07 - 4.15 (m, 2 H), 3.64 (d, 1 H), 3.54 (d, 1 H), 3.35 - 3.41 (m, 1 H), 3.12 (q, 1 H), 2.81 (t, 2 H), 2.69 - 2.73 (m, 1 H), 2.55-2.59 (m, 1 H), 1.17 (t, 3 H).
Step 2. Synthesis of (±)-(3R,4R)-1-tert-butyl 3-ethyl 4-(trifluoromethvl)pyrrolidine-1,3dicarboxylate (C165). To a solution of compound C164 (2.0 g, 6.6 mmol) and dit-t-butyl dicarbonate (2.3 mL, 9.97 mmol) in EtOH (30 mL) was added palladium hydroxide on carbon (600 mg) and the mixture was stirred under a hydrogen atmosphère (1 atm) for about 16 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography to provide the title compound C165. Yield: 1.8 g (87%). 1H NMR (400 MHz, dmso-de) δ 4.13 (q, 2 H), 3.60 - 3.68 (m, 2 H), 3.43 - 3.59 (m, 2 H), 3.25 - 3.39 (m, 2 H), 1.39 (s, 9 H), 1.19 (t, 1 H).
Step 3. Synthesis of (±)-(3R,4R)-tert-butyl 3-(hvdroxvmethvl)-4-(trifluoromethvl)pyrrolidine-1carboxylate (L122). A solution of compound C165 (1.8 g, 5.8 mmol) in THF (20 mL) was cooled to about 0 °C and lithium borohydride (630 mg, 29 mmol) was added in portions. The mixture was heated under reflux for about 16 hours. It was then cooled to about 25 °C and diluted with
EtOAc (50 mL). The EtOAc extract was washed with water, brine, dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound L122. Yield: 1.3 g (83%). 1H NMR (400 MHz, dmso-d6) δ 4.95 (t, 1 H), 3.55 (br. s, 1 H), 3.33 3.46 (m, 4 H), 3.14 - 3.19 (m, 1 H), 3.02 (br. s, 1 H), 2.44 (br. s, 1 H), 1.39 (s, 9 H).
Préparation 74: (3S,4S15S)-3,4-d2-4-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L123)
Step 1. Synthesis of (S)-7-ethvl-6-fluoro-3,3-dimethvl-1,7a-dihvdropyrrolo[1,2-c1oxazol-5(3H)one (C172). A solution of compound C62 (2.00 g, 9.9 mmol) and diphenyl diselenide (3.32 g, 10.4 mmol) in THF (40 mL) was treated with lithium hexamethyldisilazide (1 M, 10.4 mL) at about 0 °C. The mixture was kept at about 0 °C for about 30 min, then was warmed to about 25 °C for about 3 h. Water and EtOAc were added and the phases were separated. The aqueous phase was extracted with EtOAc, and the combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue was dissolved in DCM (100 mL) and pyridine (5.1 mL, 63 mmol) and was treated with hydrogen peroxide (30%, 4.8 mL, 47 mmol) at about 0 °C. The 10 mixture was stirred at about 0 °C for about 30 min, then allowed to warm to about 25 °C for about 2 h. The mixture was washed with saturated aqueous NaHCO3, 1 M NaOH (twice), water, and brine. The DCM extract was dried over MgSO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C172. Yield: 1.56 g (55%). 1H NMR (400 MHz, CDCb) δ 4.36 (dt, 1 H), 4.21 (dd, 1 H), 3.27 - 3.37 (m, 1 H), 2.31 - 2.50 (m, 2 H), 1.67 15 (s, 3H), 1.57 (s, 3 H), 1.16 (t, 3 H).
Step 2. Synthesis of (3S,4S,5S)-3,4-d2-4-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L123). A solution of compound C172 (1.20 g, 6.0 mmol) in ethanol-di (50 mL) was treated with a rhodium on carbon catalyst (5 mg) and stirred under a deuterium atmosphère at a pressure of 1 atmosphère and a température of about 20 °C for about 2 h. The mixture was filtered and 20 concentrated. The residue was purified by chromatography to provide the title compound L123.
Yield: 250 mg (25%). 1H NMR (400 MHz, CDCI3) δ 7.02 (br. s., 1 H), 3.72 - 3.82 (m, 2 H), 3.55 3.66 (m, 1 H), 2.61 (t, 1 H), 1.59 - 1.71 (m, 1 H), 1.44 - 1.57 (m, 1 H), 1.06 (t, 3 H).
Préparation 75: (3R,4R,5S)-3-fluoro-4-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L124)
Step 1. Synthesis of (3R,4R,5S)-3-fluoro-4-(fluoromethvl)-5-(hvdroxvmethvl)pyrrolidin-2-one (L124). To a stirred solution of compound C159 (70 mg, 0.34 mmol) in 4 mL of acetonitrile and 1 mL of water was added TFA (3 uL, 0.03 mmol). The reaction mixture was heated at 90 °C for 1 h. The reaction mixture was cooled to 25 °C and concentrated to provide the title compound L124. Yield: 69 mg (100%). 1H NMR (400 MHz, CD3OD) δ 5.07 (dd, 1 H) 4.89 - 4.80 (m, 3 H),
4.79 - 4.67 (m, 1 H), 3.76 (td, 1 H), 3.67 - 3.58 (m, 2 H), 3.13 - 2.92 (m, 1 H). 19F NMR (400
MHz, CD3OD) δ -193.07, -226.18.
Préparation 76: 4-(hvdroxymethvl)-5-azaspiror2.41heptan-6-one (L125)
O
Step 1. Synthesis of ethyl 2-cyclopropylideneacetate (C180). To a stirred solution of 1-ethoxy5 1-[(trimethylsilyl)oxy]- cyclopropane (CAS 27374-25-0, 10 g, 57 mmol) in toluene (50 mL) was added (carbethoxymethylene)triphenylphosphorane (CAS 1099-45-2, 26 g, 74 mmol) followed by benzoic acid (0.91 g, 7.5 mmol) at about 25 °C. The mixture was heated overnight at about 90 °C, then cooled and concentrated. The residue was purified by chromatography to provide the title compound C180. Yield: 3.2 g (44%). 1H NMR (400 MHz, CDCb) δ 6.22 (s, 1 H), 4.14 (q, 2 H), 1.40 - 1.46 (m, 2 H), 1.27 (t, 3 H), 1.20 - 1.24 (m, 2 H).
Step 2. Synthesis of ethyl 2-(1-(nitromethvl)cvclopropyl)acetate (C181). A solution of compound C180 (2.3 g, 18 mmol), nitromethane (4.90 mL, 91 mmol) and DBU (2.73 mL, 18 mmol) in MeCN (50mL) was heated overnight at about 60 °C. The mixture was cooled, diluted with EtOAc, and washed with saturated aqueous NH4CI solution. The EtOAc was separated and the 15 aqueous phase was extracted with EtOAc. The combined EtOAc extracts were dried over
Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide the title compound C181. Yield: 1.7 g (50%). 1H NMR (400 MHz, CDCb) δ 4.41 (s, 2 H), 4.15 (q, 2 H), 2.48 (s, 2 H), 1.26 (t, 3 H), 0.80 - 0.83 (m, 2 H), 0.70 - 0.74 (m, 2 H).
Step 3. Synthesis of ethyl 2-(1-(2-hydroxv-1-nitroethvl)cvclopropyl)acetate (C182). A solution of compound C181 (2.5 g, 13 mmol), paraformaldéhyde (0.802 g, 26 mmol) and potassium fluoride (78 mg, 1.3 mmol) in 2-propanol (30 mL) was stirred for about 36 h at about 25 °C and then concentrated. The residue was purified by chromatography to provide the title compound C182. Yield 1.1 g (38%). 1H NMR (400 MHz, CDCb) δ 4.14 (q, 2 H), 4.03 - 4.10 (m, 2 H), 3.92 - 3.96 (m, 1 H), 3.16 - 3.20 (m, 1 H), 2.86 (d, 1 H), 2.23 (d, 1 H), 1.27 (t, 3 H), 0.90 - 0.99 (m, 2 H),
0.79 - 0.83 (m, 1 H), 0.64 - 0.68 (m, 1 H).
Step 4. Synthesis of 4-(hvdroxvmethvl)-5-azaspiroF2.41heptan-6-one (L125) To a solution of compound C182 (600 mg, 2.7 mmol) in EtOH (10 mL) was added platinum dioxide (60 mg) and the mixture was stirred under a hydrogen atmosphère (1 atm) for about 20 h at about 25 °C. The mixture was filtered and the filtrate was heated at about 80 °C for about 24 h, then 30 concentrated. The residue was purified by chromatography to provide the title compound L125.
Yield: 220 mg (56%). 1H NMR (400 MHz, dmso-d6) δ 7.70 (br. s., 1 H), 4.66 (t, 1 H), 3.25 - 3.39 (m, 2 H), 3.08 (t, 1 H), 2.39 (d, 1 H), 1.89 (d, 1 H), 0.73 - 0.86 (m, 1 H), 0.40 - 0.61 (m, 3 H).
Préparation 76: 1-([(2R,3R.4S)-3-ethvl-4-fluoro-3-hvdroxv-5-oxopvrrolidin-2-vl1methoxy}-7methoxvisoquinoline-6-carboxamide
Step 1. Stérile medium was prepared using deionized water containing dextrose (10 g/L), glycerol (20 g/L), Difco Yeast Extract (5 g/L), Nutrisoy flour (5 g/L), NaCI (5 g/L), K2HPO4 (5 g/L), P2000 (1 ml/L), pH adjusted to 7.0 prior to autoclaving to sterilize.
Step 2. Streptomyces spectabilis ATCC 27465 was grown in 25 mL of this medium which had been added to each of three stérile Nalgene flasks (250 mL, baffled, vented closures) on a 2” 10 throw rotary shaker at 30°C, 210 rpm, fortwo days. The contents of each flask were aseptically transferred to each of three stérile 2L Nalgene flasks (baffled, vented closures) containing 400 mL of the same stérile medium then incubated as above. After two days, 16 mL of a solution of 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide in DMSO (5 mg/mL) was added to each flask. Incubation continued as above;
flasks were aseptically sampled every 24 hours. After three days, contents of the flasks were combined and extracted twice with an equal volume of ethyl acetate. The organic phases were combined, dried with anhydrous sodium sulfate then concentrated under vacuum to yield 3.7 g of brown oil.
Step 3. High performance liquid préparative chromatography using a 0.1% trifluoroacetic acid in 20 water with acetonitrile gradient on a Phenomenex Luna phenyl-hexyl column was utilized to isolate compounds from the above préparation. Time based fraction collection was used to collect ail peaks of interest. Each sample was dried and tested by LCMS to confirm rétention time identification and the parent ion of m/z =378 daltons. 1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (Example 196): 1H 25 NMR (600 MHz, dmso-ds) δ 8.85 (s, 1H), 8.17 (s, 1H), 7.91 (d, 1H), 7.85 (br. s, 1H), 7.71 (s,
2H), 7.45 (d, 1H), 4.58 (dd, 1H), 4.48 (d, 1H), 4.30 (dd, 1H), 3.98 (s, 3H), 3.87 (dd, 1H), 1.72 (q, 2H), 1.01 (t, 3H).
The following two examples were also prepared:
162 >
1-{[(3S,4S)-3-ethyl-4-fluoro-2-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide (Example 197), as a mixture of diastereomers: Major diastereomer: 1H NMR (600 MHz, dmso-de) δ 9.25 (s, 1H), 8.18 (s, 1H), 7.92 (d, 1H), 7.6 (s, 1H), 7.72 (s, 1H), 7.6 (s, 1H), 7.54 (s, 1H), 4.96 (dd, 1H ), 4.5 (dd, 2H), 3.98 (s, 3H), 2.47 (m, 5 1H), 1.67 (m, 1H), 0.99 (t, 3H). Minor diastereomer 1H NMR (600 MHz, dmso-d6) δ 9.18 (s, 1H),
8.16 (s, 1H), 7.91 (d, 1H), 7.83 (s, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.44 (s, 1H), 5.14 (dd, 1H ), 4.5 (dd, 2H), 3.92 (s, 3H), 2.39 (m, 1H), 1.58 (m, 1H), 0.99 (t, 3H).
1-{[(2S,3R,4S)-4-fluoro-3-(1-hydroxyethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide (Example 198): 1H NMR (600 MHz, dmso-de) δ 9.0 (s, 1H), 10 8.17 (s, 1H), 7.91 (d, J 1H), 7.86 (br s, 1H), 7.76 (s, 1H), 7.71 (bs, 1H), 7.44 (d, 1H), 4.94 (d,
1H), 4.83 (dd, 1H), 4.60 (dd, 1H), 4.26 (dd, 1H), 4.07 (m, 1H), 3.99 (m, 1H), 3.916 (m, 1H), 2.56 (m, 1H), 1.23 (d, 3H).
METHODS
The Methods set forth hereinbelow are intended only to exemplifÿ various aspects and embodiments of the invention, and are not intended to limit the scope of the claimed invention in any way. It will be apparent to one skilled in the art that the Methods described below may be modified in various ways, for example by changing reaction solvents or volumes, by substituting similar reagents to those described, or by substituting similar catalysts to those described.
A reactant B such as tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (CAS 12385551-6, commercially available, 28 mg, 0.13 mmol) was dissolved in 0.5 mL of DMSO and a reactant A such as 1-chloro-7-isopropoxyisoquinoline-6-carbonitrile (P2) (0.2 M in DMSO, 0.5 mL, 0.10 mmol) was added. The mixture was then treated with potassium tert-butoxide (1 M in
THF, 0.13 mL, 0.13 mmol). The reaction mixture was heated at about 50 °C to about 100 °C for
163 about 2 to 16 hours until the reaction was judged to be complété. The mixture was then cooled to about 25 °C and filtered and the filtrate was concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 2
O
To a solution of a reactant B such as (3S,5S)-3-fluoro-5-(hydroxymethyl)-3-methylpyrrolidin-2-one (L10) (314 mg, 2.1 mmol) in 15 mL of DMF was added sodium hydride (60% in minerai oil, 342 mg, 8.6 mmol) at about 25 °C and the mixture was stirred for about 15 minutes. A reactant A such as 1-chloro-7-methoxyisoquinoline-6-carbonitrile (P1) (513 mg, 2.3 mmol) was added and stirring was continued for about 16 h. The reaction was quenched with EtOAc and water at about 0 °C. The mixture was extracted with EtOAc and the EtOAc was separated, washed with brine, dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 3
A reactant B such as (3R,4S,5S)-5-(hydroxymethyl)-3-methoxy-4-methylpyrrolidin-2-one (L65) (105 mg, 0.66 mmol) and a reactant A such as 1-chloro-7-methoxyisoquinoline-6carbonitrile (P1) (120 mg, 0.55 mmol) were stirred in DMF (15 mL) at about 25 °C. A solution of potassium hexamethyldisilazide (1 M in THF, 1.37 mL) was added dropwise to the reaction mixture. After the addition of potassium hexamethyldisilazide was complété, the reaction was stirred for approximately an additional 50 minutes. The reaction mixture was then poured into a mixture of saturated aqueous NH4CI solution and EtOAc with vigorous stirring. The EtOAc was
164 separated, washed with water, bnne, dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 4
A reactant B such as tert-butyl 4-hydroxypiperidine-1-carboxyiate (CAS 109384-19-2, commercially available, 50 mg, 0.2 mmol), a reactant A such as 4-chloro-6-isopropoxyquinoline-7-carboxamide (P4) (30 mg, 0.1 mmol), and césium carbonate (300 mg, 0.9 mmol) were combined in a small microwave vessel and diluted with 1 mL of DMSO. The vessel was capped and heated in a microwave reactor at about 150 °C for about 15 minutes. The reaction mixture was then diluted with EtOAc and water and the phases were separated. The aqueous phase was extracted three times with EtOAc and the combined EtOAc extracts were dried and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC. Potassium carbonate may be used in place of césium carbonate in some instances.
Method 5
Triphenylphosphine (1.59 g, 5.9 mmol) was added to a suspension of a reactant B such as (4R,5S)-5-(hydroxymethyl)-4-methylpyrrolidin-2-one (L36) (393 mg, 2 mmol) and a reactant A such as 5-hydroxy-3-methoxy-2-naphthamide (P5) (430 mg, 2 mmol) in 10 mL of THF. Diisopropyl azodicarboxylate (0.84 g, 3.9 mmol) was added dropwise. The mixture was stirred at about 20 °C for 6 days and then concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
A solution of a reactant B such as (5S)-5-(hydroxymethyl)-3-methoxypyrrolidin-2-one (L25) (264 mg, 2 mmol) in 15 mL of DCM was treated with p-toluenesulfonyl chloride (760 mg, 4 mmol) and DMAP (512 mg, 4 mmol). The reaction mixture was stirred for about 12 h at about 25 °C. The mixture was washed with water (15mL). The DCM was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography to give 312 mg (52%) of the intermediate p-toluenesulfonate ester of L25.
To a solution of the intermediate p-toluenesulfonate ester of L25 prepared above (166 mg, 0.55 mmol) in dry DMF (5 mL) was added césium carbonate (357 mg, 1.1 mmol) and and a reactant A such as 5-hydroxy-3-methoxy-2-naphthamide (P5) (132 mg, 0.6 mmol). The mixture was stirred for about 2 h at about 65 °C. The DMF was evaporated, and the residue was stirred with EtOAc and the mixture was filtered. The filter cake was washed with water (5 mL x 2). The filter cake was dried under vacuum, treated with EtOAc and filtered. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 7
A solution of a reactant such as tert-butyl 4-(((6-cyano-7-isopropoxyisoquinolin-1yl)oxy)methyl)-piperidine-1-carboxylate (42 mg, 0.10 mmol) in DMSO (1 mL) was treated with powdered K2CO3 (41 mg, 0.30 mmol) followed by 30% hydrogen peroxide solution (0.2 mL, 1.8
166 mmol). The mixture was heated at about 40 °C to 60 °C for about about 15 minutes to 16 hours until the reaction was judged to be complété. The mixture was then cooled to about 25 °C and filtered and the filtrate was concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC. Sodium hydroxide or potassium 5 hydroxide may be substituted for K2CO3 in some cases.
Method 8
A solution of a reactant such as 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-210 yl)methoxy)-7-methoxyisoquinoline-6-carbonitrile (200 mg, 0.5 mmol) in concentrated H2SO4 (1.5 mL) was warmed to about 55 °C for about two hours, then cooled to about 20 °C. The reaction mixture was added dropwise with vigorous stirring to 7.3 mL of ice cold concentrated ammonium hydroxide with cooling in ice. The precipitated solid was filtered and washed with water, heptane, ether, and dried under vacuum. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 9
O
A solution of a reactant such as 1-(((2S,4R)-4-((benzyloxy)methyl)-4-fluoro-520 oxopyrrolidin-2-yl)methoxy)-7-isopropoxyisoquinoline-6-carboxamide (20 mg, 0.44 mmol) in MeOH (0.46 mL) was treated with a palladium on carbon catalyst (5 mg) and stirred under a hydrogen atmosphère at a pressure of about 1 to 5 atmosphères and a température of about 20
167
°C to 65 °C. The mixture was then cooled to about 20 °C and filtered and the filtrate was concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 10
O
A solution of a reactant such as tert-butyl 4-(((6-carbamoyl-7-isopropoxyisoquinolin-1yl)oxy)methyl)piperidine-1-carboxylate (44 mg, 0.1 mmol) in 1.0 to 2.0 mL of a suitable solvent such as DCM was treated with either TFA (0.10 mL) or hydrogen chloride (4 M in dioxane, 0.4 mL). The reaction mixture was was heated at about 30 °C to 40 °C for about 1 to 4 hours until 10 the reaction was judged to be complété. The mixture was then cooled to about 25 °C and concentrated under vacuum and purified using by chromatography or HPLC.
A solution of a reactant such as 7-isopropoxy-1-(piperidin-4-ylmethoxy)isoquinoline-6carboxamide (41 mg, 0.12 mmol) in DMF (1.0 mL) was treated with cyanoacetic acid (11 mg, 0.12 mmol), followed by HATU (47 mg, 0.12 mmol) and Et3N (35 pL, 0.25 mmol). The reaction mixture was was heated at about 30 °C to 50 °C for about 4 to 16 hours until the reaction was
168
judged to be complété. The mixture was then cooled to about 25 °C and concentrated under vacuum and purified by chromatography or HPLC.
Method 12
O
O F
A solution of a reactant such as 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2yl)methoxy)-7-methoxyisoquinoline-6-carboxamide (500 mg, 1.4 mmol) in DMF (15 mL) was treated with SelectFluor® (511 mg, 1.4 mmol) and heated at about 55 °C for about 24 h. The 10 mixture was concentrated, xylene was added, and the mixture was concentrated again. The concentration with xylene was repeated twice more, and the residue was stirred with EtOAc. The precipitated solid was filtered and washed with EtOAc, and the EtOAc filtrâtes were combined, concentrated, and treated with EtOAc and water. The EtOAc was separated, concentrated under vacuum and purified by chromatography or HPLC.
Method 13
A solution of a reactant such as (S)-methyl 3-methoxy-5-((5-oxopyrrolidin-2-yl)methoxy)2-naphthoate (366 mg, 1.1 mmol) in THF (25 mL) and water (25 mL) was treated with lithium hydroxide (272 mg, 11.1 mmol). The resulting mixture was stirred at about 25 °C for about 1 hour, then the mixture was partially concentrated under vacuum to remove the THF. The remaining solution was acidified with 10% aqueous citric acid, an dthe resulting precipitate was
169 collected by filtration, washed with water and dried. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 14
A solution of a reactant such as (S)-methyl 3-methoxy-5-((5-oxopyrrolidin-2-yl)methoxy)2-naphthoate (385 mg, 1.2 mmol) in THF (25 mL) was treated with Et3N (0.26 mL, 1.8 mmol) and heated under reflux. The mixture was cooled to about 25 °C, then BOP reagent (CAS 56602-33-6, 709 mg, 1.6 mmol) was added. The mixture was stirred for about 25 min until almost ail of the BOP reagent had dissolved, then ammonium hydroxide (15 M, 1.5 mL) was added. After about 45 min, the mixture was filtered and the filtrate was concentrated. The residue was treated with water, and the resulting precipitate was collected by filtration, washed with water and dried. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 15
Y | ||
Ό | ||
Y | --- Y cY n JL | |
CL II | ||
H | ||
fY T Br | ||
A solution of a reactant such | as (S)-7-isopropoxy-1-((5-oxopyrrolidin-2-yl)methoxy)- |
isoquinoline-6-carbonitrile (100 mg, 0.3 mmol) in acetonitrile (6.1 mL) was with Nbromosuccinimide (55 mg, 0.3 mmol) was heated at about 60 °C for about 1.5 h. An additional portion of N-bromosuccinimide (30 mg 0.14 mmol) was added. After about 30 min, the mixture
170
was cooled to about 25 °C and diluted with 10 mL of EtOAc. The EtOAc extract was washed with saturated aqueous sodium thiosulfate (10 mL). The aqueous phase was back-extracted with EtOAc (10 mL), and the combined EtOAc extracts were washed with saturated aqueous sodium thiosulfate (15 mL), brine (15 mL), dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 16
A solution of a reactant such as (S)-4-bromo-7-isopropoxy-1-((5-oxopyrrolidin-2yl)methoxy)isoquinoline-6-carbonitrile (54 mg, 0.1 mmol), palladium bis(triphenylphosphine)dichloride (19 mg, 0.03 mmol), potassium methyltrifluoroborate (25 mg, 0.2 mmol), and K2CO3 (55 mg, 0.4 mmol) in acetonitrile (0.75 mL) and water (0.5 mL) was heated in a microwave reactor at about 125 °C for about 30 min. The mixture was diluted with EtOAc (10 mL) and washed brine. The aqueous phase was back-extracted with EtOAc (10 mL) and the combined EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 17
oxooctahydrocyclopenta[b]pyrrol-6-yl)oxy)isoquinoline-6-carboxamide (42 mg, 0.1 mmol) in 3.25 mL of acetonitrile and 0.25 mL of water was treated with molybdenum hexacarbonyl (34 mg,
171
0.13 mmol). The reaction was heated at reflux for about 18 h. The mixture cooled to about 25 °C, diluted with MeOH, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 18
A solution of a reactant such as (±)-1-((1R,6S)-3-azabicyclo[4.1.0]heptan-1-ylmethoxy)7-isopropoxyisoquinoline-6-carboxamide (54 mg, 0.15 mmol) and di-t-butyl dicarbonate (37 mg, 0.17 mmol) in THF (2 mL) and water (2 mL) was stirred for about 45 min at about 25 °C, then diluted with EtOAc and water. The EtOAc was separated, washed with brine, dried over 15 Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 19
O
A solution of a reactant such as (S)-7-isopropoxy-1-((5-oxopyrrolidin-2-yl)methoxy)isoquinoline-6-carboxamide (272 mg, 0.80 mmol) in 1,4-dioxane (20 mL) was treated with 5 mL of cold 50% H2SO4. The mixture was heated at about 55 °C for about 24 h, then cooled to about °C and allowed to remain for about 18 h. The dioxane was separated and the aqueous
172 phase was neutralized to about pH 5 with K2CO3, then extracted repeatedly with EtOAc. The combined dioxane and EtOAc extracts were dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 20
A solution of a reactant such as (S)-5-(((6-bromo-7-(trifluoromethoxy)isoquinolin-1 yl)oxy)methyl)pyrrolidin-2-one (78 mg, 0.19 mmol) and zinc cyanide (46 mg, 0.38 mmol) in DMF (2.5 mL) was treated with tetrakis(triphenylphosphine)palladium (0) (45 mg, 0.04 mmol). The mixture was heated for about 20 min at about 150 °C, then diluted with ice water (35 mL) and filtered. The precipitate was dissolved in DCM, washed with brine, dried over Na2SO4, filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 21
O O
A solution of a reactant such as 1-(((1S,3aS,6aR)-5-benzyl-3-oxooctahydropyrrolo[3,4c]pyrrol-1-yl)methoxy)-7-isopropoxyisoquinoline-6-carboxamide (50 mg, 0.10 mmol), aqueous formaldéhyde solution (37%, 6 mL) in MeOH (50mL) was treated with a palladium on carbon catalyst (5 mg) and stirred under a hydrogen atmosphère at a pressure of 1 atmosphère and a
173 température of about 20 °C for about 2 h. The mixture was filtered and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
Method 22
A solution of a reactant such as (S)-4-bromo-7-isopropoxy-1-((5-oxopyrrolidin-2yl)methoxy)isoquinoline-6-carbonitrile (1.0 g, 2.4 mmol) in 1,4-dioxane (20 mL) was treated with freshly dried potassium acetate (729 mg, 7.4 mmol), bis(pinacolato diboron) (880 mg, 3.5 mmol), and tetrakis(triphenylphosphine)palladium (0) (143 mg, 0.12 mmol). The mixture was heated at about 100 °C for about 16 h. The mixture was cooled to about 25 °C, filtered, and concentrated. The residue may be used directly for subséquent work, or it may be purified by chromatography or HPLC.
EXAMPLES
1-{lï2S.3S,4S)-3-ethvl-4-fluoro-5-oxopvrrolidin-2-vllmethoxy}-7methoxyisoquinoline-6-carboxamide
Step 1. Synthesis of (7R.7aS)-7-ethvl-3.3-dimethvltetrahvdropvrrolof1,2-cloxazol-5(3H)-one (C54).
A suspension of copper bromide dimethyl sulfide complex (833 g, 4.05 mol) in diethyl ether (6 L) was cooled to about -20 to -30 °C, and ethylmagnesium bromide solution (2 M in THF, 4.05 L, 8
174
moles) was added over about 1 hour allowing the température to rise to about -3 °C. After stirring for about 10 min the slurry was cooled to about -70 °C, and TMSCI (382 mL, 3.04 mol) was added drop wise over about 1 h. After about 50 min, compound P20 (310 g, 2.02 mol) in
500 mL of MTBE was added to the mixture drop wise over about 2 hours. The température was maintained at about -72 to -68 °C during the addition. The reaction mixture was stirred at about
-72 °C for about 4 hours, after which time it was warmed up to about -40 °C over about 16 hours. The reaction mixture was quenched with half-saturated aqueous NH4CI (4 L). After a phase séparation, the solvent phase was washed with water, dried over Na2SO4, filtered, and concentrated. The reaction was performed six times in total and the combined crude products 10 were purified by silica chromatography to provide the title compound C54. Yield 1.4 kg (63%, based on 12.1 mol of P20). 1H NMR (400 MHz, CDCh) δ 4.34 (dt, 1 H), 3.90 (dd, 1 H), 3.72 (dd,
H), 2.91 (dd, 1 H), 2.31 (dd, 1 H), 2.25 (m, 1 H), 1.65 (s, 3 H), 1.52 (d, 1 H), 1.48 (s, 3 H), 1.27 -1.38 (m, 1 H), 0.92 (t, 3 H).
Step 2. Synthesis of (6S,7S,7aS)-7-ethvl-6-fluoro-3,3-dimethvltetrahvdropvrrolo[1,2-cloxazol15 5(3H)-one (C61)
A solution of diisopropylamine (184 mL, 1.31 mol) in THF (1.65 L) was cooled to about -20 to 30 °C and treated with n-butyllithium solution (2.5 M in hexanes, 491 mL,1.23 mol) over about minutes, allowing the température to rise to about -20 °C. After stirring for about 10 minutes, the solution was cooled to about -70 °C, and a solution of compound C54 (235 g, 1.17 mol) in
THF (588 mL) was added drop wise over about 30 minutes. The température was maintained at about -70 to -60 °C during the addition, and after stirring for about 30 minutes at this température, a solution of NFSI (387 g, 1.23 mol) in 1.2 L THF was added over about 80 minutes at about -70 to -72 °C. After stirring for about 1 h at about - 70 to -60 °C, the reaction was allowed to warm to about 20 °C overnight. The precipitated solids were filtered and washed with THF (1 L). The filtrate was concentrated to an oily residue. This entire reaction was conducted three times at this scale and once using 500 g of compound C61. The combined crude products were purified by silica chromatography to provide the title compound C61. Yield:
350 g (27% based on 6.6 mol of C54). 1H NMR (400 MHz, CDCh) δ 5.23 (dd, 1 H), 3.97 - 4.11 (m, 2 H), 3.68 - 3.77 (m, 1 H), 2.62 - 2.76 (m, 1 H), 1.69 - 1.79 (m, 1 H), 1.68 (s, 3 H), 1.45 30 1.52 (m, 3 H), 1.28 - 1.42 (m, 1 H), 0.97 (t, 3 H). 19F NMR (376 MHz, CDCh) δ -199.61. There was also obtained (6R,7S,7aS)-7-ethyl-6-fluoro-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol5(3H)-one C62. Yield: 700 g (54% from 6.6 mol of C54). 1H NMR (400 MHz, CD3CN) δ 4.78 (dd, 1 H), 4.40 (dt, 1 H), 3.93 (dd, 1 H), 3.56 (dd, 1 H), 2.30 - 2.46 (m, 1 H), 1.56 (s, 3 H), 1.52 (ddd, 1 H), 1.42 (s, 3 H), 1.35 - 1.48 (m, 1 H), 0.97 (t, 3 H). 19F NMR (376 MHz, CD3CN) δ 185.41.
Step 3. Epimerization of (6R,7S,7aS)-7-ethvl-6-fluoro-3.3-dimethvltetrahvdropyrrolori,2cloxazol-5(3H)-one (C62), To a solution of diisopropylamine (310 g, 3.07 mol) in toluene (4 L) was added n-butyllithium (2.5 M, 1.22 L, 3.05 mol) dropwise at -30 °C. The mixture was maintained at -30 °C for an additional 30 min, then was added dropwise to a solution of compound C62 (556 g, 2.77 mol) in toluene (2 L) at -78 °C over 2 h. After the addition was complété, the mixture was kept at -78 °C for 30 min more before a solution of BHT (1.26 kg, 5.73 mol) in toluene (5 L) was added dropwise over 3 h, keeping the internai température below
-65 °C. After the addition was complété, the mixture was kept at -78 °C for 30 min. The mixture was warmed to 25 °C, water was added, and the toluene was separated. The aqueous layer was extracted with DCM twice, the combined toluene and DCM extracts were dried over Na2SO4, filtered and concentrated. The residue was purified by chromatography to provide compound C61. Yield: 250 g (45%). There was also recovered compound C62. Yield: 150 g (27%).
Step 4. Synthesis of (3S,4S,5S)-4-ethvl-3-fluoro-5-(hvdroxvmethvl)pyrrolidin-2-one (L54).
A solution of compound C61 (90 g, 0.45 mol) in acetonitrile (450 mL) and water (45 mL) was treated with TFA (6.8 mL, 90 mmol). The mixture was warmed to about 65 °C over about 1 h, and held at that température for about 3 h. The mixture was then cooled and about 350 mL of solvent was distilled by rotary évaporation. The residue was diluted with acetonitrile (400 mL) and evaporated to dryness. Isopropyl acetate (250 mL) was added to the residue and the mixture was concentrated again. The residue was diluted with heptane (200 mL) and crystallization was induced by seeding. The precipitate was filtered in two crops to provide the title compound L54. Yield: 46 g (64%). 1H NMR (400 MHz, CDCI3) δ 7.59 (br. s., 1 H), 4.80 (dd,
H), 3.69 - 3.83 (m, 2 H), 3.52 - 3.64 (m, 1 H), 3.48 (br. s, 1 H), 2.27 - 2.52 (m, 1 H), 1.57 - 1.73 (m, 1 H), 1.49 (dt, 1 H), 1.04 (t, 3 H). 19F NMR (376 MHz, CDCI3) δ -198.72.
Step 5. Synthesis of 1-(((2S.3S,4S)-3-ethvl-4-fluoro-5-oxopvrrolidin-2-vl)methoxy)-730 methoxvisoquinoline-6-carbonitrile (C171).
A mixture of compound L54 (8.00 g, 49.6 mmol) and compound P1 (9.87 g, 45.1 mmol) were stirred in DMF (83 mL) and cooled to about -10 °C. A solution of potassium hexamethyldisilazide (1 M in THF, 99 mL, 99 mmol) was added to the reaction mixture over about 45 minutes, maintaining the internai reaction température at about about -10 °C. After the addition of potassium hexamethyldisilazide was complété, the reaction was stirred at about -10 °C for approximately an additional 30 minutes. A solution of 24.9 g of sodium dihydrogen phosphate in 250 mL of water was prepared. The reaction mixture was then poured into 220 mL of this aqueous sodium dihydrogen phosphate solution and 250 mL of EtOAc with vigorous stirring. The reaction flask was rinsed with the remaining 30 mL of the aqueous sodium dihydrogen phosphate solution and the rinse was added to the EtOAc mixture. The EtOAc was separated. The aqueous mixture was extracted three times with EtOAc. The combined EtOAc extracts were dried over MgSO4, filtered and concentrated. Xylene was added to the residue and the mixture was concentrated. Addition of xylene and subséquent évaporation was carried out two more times to provide the title compound C171. Yield: 15.37 g (90%). 1H NMR (400 MHz, dmso-de) δ 8.89 (s, 1 H), 8.50 (s, 1 H), 7.98 (d, 1 H), 7.80 (s, 1 H), 7.41 (d, 1 H), 4.90 (dd, 1 H), 4.56 (dd, 1 H), 4.24 (dd, 1 H), 4.09 (dt, 1 H), 4.03 (s, 3 H), 2.62 (m, 1 H), 1.58 (m, 2 H), 1.02 (t, 3 H). 19F NMR (376 MHz, dmso-d6) δ-199.18.
Step 6. Synthesis of 1-ff(2S.3S.4S)-3-ethvl-4-fluoro-5-oxopvrrolidin-2-vnmethoxy}-720 methoxyisoquinoline-6-carboxamide (Example 296).
A mixture of compound C171 (15.37 g, 44.7 mmol) and methanesulfonic acid (218 mL, 3.36 mol) was heated at about 60 °C with stirring for about 26 hours. The mixture was then cooled to about 25 °C and slowly added to 1 kg of crushed ice with stirring. During the addition, 150 g of additional ice was added so as to ensure that, at the conclusion of the addition, there was still ice remaining in the mixture. Ethyl acetate (1 L) was added. Ammonium hydroxide (274 mL) was then added slowly to the stirring biphasic mixture, along with with another 750 g of ice, until the pH of the mixture rose to about 8. The mixture was then warmed to about 30 °C to dissolve ail of the solids présent. The EtOAc was separated and the aqueous phase was extracted with
EtOAc (4 x 100 mL). The combined EtOAc extracts were washed with brine, dried over MgSO4,
177 filtered and concentrated to provide the title compound. Yield 14.72 g (91%). Recrystallization from EtOH afforded an analytically pure sample, mp 286 °C. 1H NMR (400 MHz, dmso-de) δ
8.86 (s, 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.74 (s, 1 H), 7.69 (br. s., 1 H), 7.43 (d, 1 H), 4.91 (dd, 1 H), 4.54 (dd, 1 H), 4.26 (dd, 1 H), 4.09 (br. s., 1 H), 3.97 (s, 3 H), 2.63 (m, 1
H), 1.60 (m, 2 H), 1.02 (t, 3 H). 19F NMR (H decoupled, 376 MHz, dmso-d6) δ -199.26.
The following compounds of the invention were prepared similarly using the methods described above. The reactants A were prepared as described in this spécification. The reactants B were either known compounds that were commercially available, or known compounds that were 10 prepared as described in the cited references, or compounds prepared as described in this spécification. For those examples characterized by HPLC rétention time, the following HPLC conditions were used:
Method PF-AB01 | Method PF-AB10 | Method PF-CD05 |
Column XbridgeC18 2.1x50mm 5pm | Column XbridgeC18 2.1x50mm 5pm | Column XbridgeC18 2.1x50mm 5μηη |
Température 50 °C | Température 50 °C | Température 50 °C |
Mobile Phase A 0.0375% TFA in water | Mobile Phase A 0.0375% TFA in water | Mobile Phase A 0.05% NH4OH in water |
Mobile Phase B 0.01875% TFA in acetonitrile | Mobile Phase B 0.01875% TFA in acetonitrile | Mobile Phase B 100% acetonitrile |
Gradient - Initial 1% B | Gradient - Initial 10% B | Gradient - Initial 5% B |
Time 0.00 mins 1% B | Time 0.00 mins 10% B | Time 0.00 mins 5% B |
Time 0.60 mins 5% B | Time 0.50 mins 10% B | Time 0.50 mins 5% B |
Time 4.00 mins 100% B | Time 4.00 mins 100% B | Time 3.40 mins 100% B |
Time 4.30 mins 1% B | Time 4.30 mins 10% B | Time 4.20 mins 100% B |
Time 4.70 mins 1% B | Time 4.70 mins 10% B | Time 4.21 mins 5% B |
Flow rate 0.8 ml / min | Flow rate 0.8 ml / min | Time 4.70 mins 5% B |
Injection volume 2 pl | Injection volume 2 pl | Flow rate 0.8 ml / min |
Injection volume 2 μΙ | ||
Agilent 1200 HPLC/1956 MSD/SEDEX 75 ELSD | Agilent 1200 HPLC/1956 MSD/SEDEX 75 ELSD | Agilent 1200 HPLC/1956 MSD/SEDEX 75 ELSD |
lonization Mode API-ES | lonization Mode API-ES | lonization Mode API-ES |
Polarity - Positive | Polarity - Positive | Polarity - Positive |
179
Table 1
Ex. | Structure | Reactant A | Reactant B | Source | Methods | MH+ | Characterization |
1 | À T V-NH 0 | P4 | 95849 -02-8 | commercial | 1 | 316 | Rt = 1.752 min; method PF-AB01 |
2 | Chiral Ύ Ο^·θΙΗ ΗζΝγθΟ 0 | P4 | 140695 -84-7 | commercial | 4,10 | 344 | 1H NMR (400 MHz, CDaOD) δ 8.95 (d, 1 H), 8.53 (s, 1 H), 7.81 (s, 1 H), 7.52 (d, 1 H), 5.08 (dt, 1 H), 4.55 - 4.64 (m, 1 H), 4.43 - 4.55 (m, 1 H), 3.65 - 3.77 (m, 1 H), 3.46 (d, 1 H), 2.95 - 3.10 (m, 2 H), 2.64 (td, 1 H), 2.00 - 2.20 (m, 2 H), 1.82 - 2.00 (m, 1 H), 1.54-1.69 (m, 1 H), 1.51 (d, 6 H) |
3 | Chiral XXOH h2n^AAnj 0 | P4 | 140695- 85-8 | commercial | 4, 10 | 344 | 1H NMR (400 MHz, CDsOD) δ 8.59 (d, 1 H), 8.49 (s, 1 H), 7.89 (s, 1 H), 7.65 (s, 1 H), 7.01 (d, 1 H), 4.91 (dt, 1 H), 4.18 - 4.26 (m, 1 H), 4.09 - 4.18 (m, 1 H), 3.32 - 3.39 (m, 1 H), 3.03 - 3.13 (m, 1 H), 2.56 - 2.72 (m, 2 H), 2.18 - 2.33 (m, 1 H), 1.97 - 2.08 (m, 1 H), 1.77-1.87 (m, 1 H), 1.59 - 1.72 (m, 1 H), 1.50 (d, 6 H), 1.36-1.47 (m, 1 H) |
4 | Y fY^ YH h2n^/nJ 0 | P4 | 123855- 51-6 | commercial | 4,10 | 344 | 1H NMR (600 MHz, dmso-de) δ 8.59 - 8.60 (d, 1 H), 8.26 - 8.32 (m, 1 H), 7.72 (br. s„ 1 H), 7.68 (br. s., 1 H), 6.98 - 6.99 (d, 1 H), 4.81 - 4.85 (dt, 1 H), 4.55 (br. s., 1 H), 3.53 - 3.55 (d, 2 H), 3.41 (br. t., 2 H), 2.78 - 2.82 (t, 2 H), 1.88 -1.90 (d, 2 H), 1.65 (br. s., 1 H), 1.48 -1.55 (m, 2 H), 1.45-1.46 (d, 6H) |
180
5 | H 0 V 0^ h2n^JVLn^ 0 | P4 | 419572- 18-2 | Ref. 1 | 1,10 | 342 | 1H NMR (400 MHz, dmso-dB) δ 8.60 (d, 1 H), 8.21 (s, 1 H), 7.71 (d, 2 H), 7.52 (s, 1 H), 6.99 (d, 1 H), 4.80 (quin, 1 H), 4.20 (d, 2 H), 2.87 (d, 2 H), 2.67 (d, 2 H), 1.50 (m, 2 H), 1.40 (d, 6 H), 1.30 (m, 1 H) |
6 | Y Π1 HzNyUM 0 | P4 | 6246- 06-6 | commercial | 1 | 317 | Rt = 2.039 min; method PF-AB01 |
7 | 'γ^Ό HsNyUy 0 | P4 | 3637- 61-4 | commercial | 1 | 329 | Rt = 2.528 min; method PF-AB10 |
8 | vX HzNyUy 0 | P4 | 7515- 29-9 | commercial | 1 | 329 | Rt = 2.488 min; method PF-AB10 |
9 | vX ΗζΝγΑΑΧ 0 | P4 | 4415- 82-1 | commercial | 1 | 315 | Rt = 2.384 min; method PF-AB10 |
10 | γγΩ 0 | P4 | 15833- 61-1 | commercial | 1 | 331 | Rt = 2.179 min, method PF-AB01 |
11 | Y^Ô ΗζΝγΧΛΧ 0 | P4 | 97- 99-4 | commercial | 1 | 331 | Rt = 2.210 min, method PF-AB01 |
12 | VA00 0 | P4 | 3143- 02-0 | commercial | 1 | 331 | Rt = 2.175 min, method PF-AB01 |
182
13 | 0 | P4 | 38401- 41-1 | commercial | 1 | 329 | Rt = 2.533 min; method PF-AB10 |
14 | ~γ oY\ 0 | P4 | 497- 36-9 | commercial | 1 | 341 | Rt = 2.501 min; method PF-AB10 |
15 | Chiral n ytO H2N. JLxX J Ίι^^Ν 0 | P4 | 22415- 59-4 | commercial | 1 | 331 | Rt = 2.213 min; method PF-AB01 |
16 | H2N. JLJx J Π 0 | P4 | 1632- 68-4 | commercial | 1 | 341 | Rt = 2.496 min; method PF-AB10 |
17 | Y ° ΟγΧ H2NyUNJ 0 | P4 | 695- 04-5 | Ref. 2 | 1 | 339 | Rt = 2.404 min; method PF-AB10 |
18 | Y Ί H2NxAA J π N 0 | P4 | 5464- 28-8 | commercial | 1 | 333 | Rt = 2.097 min; method PF-AB01 |
19 | X Yf H2N- JL Jx JJ Jl^^N 0 | P4 | 61277- 90-5 | commercial | 1 | 341 | Rt = 2.507 min; method PF-AB10 |
184
20 | os V ο\γΝΗ °vyk 0 | P2 | 130658- 13-8 | Ref. 3 | 1,7,10 | 356 | 1H NMR (400 MHz, dmso-de) δ 9.07 (br. s., 2 H), 8.21 (s, 1 H), 7.90 (d, 1 H), 7.73 (br. s., 2 H), 7.57 (s, 1 H), 7.43 (d, 1 H), 5.55 (m, 1 H), 4.92 (dt, 2 H), 3.50 (d, 1 H), 3.22 (m, 3 H), 2.90 (m, 2 H), 2.15 (m, 1 H), 2.07 (d, 1 H), 1.87 (m, 1 H), 1.67 (br. s., 1 H), 1.39 (m, 4 H) |
21 | os V c/t^nh h2n^UAnJ 0 | P4 | 130658- 13-8 | Ref. 3 | 1,10 | 356 | Rt = 2.363 min; method PF-CD05 |
22 | /N v /—N Chiral / \ Y (O Η2Νγθθ 0 | P4 | 199174- 24-8 | commercial | 1, 10, 11 | 397 | 1H NMR (400 MHz, dmso-de) δ 8.67 (d, 1 H), 8.23 (s, 1 H), 7.72 (br. s, 2 H), 7.51 (d, 1 H), 7.02 (s, 1 H), 4.88 (quin, 1 H), 4.23 4.32 (m, 2 H), 3.95 (d, 2 H), 3.38 - 3.78 (m, 4 H), 2.79 - 2.93 (m, 1 H), 2.12-2.23 (m, 1 H), 1.80-2.11 (m 1 H), 1.41 (d, 6 H) |
185
23 | Chiral V °'TT 0 | vN Ç OZ Æ > Λ N | P4 | 138108- 72-2 | commercial | 1,10, 11 | 397 | 1H NMR (400 MHz, dmso-de) δ 8.67 (d, 1 H), 8.23 (s, 1 H), 7.72 (br. s, 2 H), 7.51 (d, 1 H), 7.02 (s, 1 H), 4.88 (quin, 1 H), 4.23 4.32 (m, 2 H), 3.95 (d, 2 H), 3.38 - 3.78 (m, 4 H), 2.79 - 2.93 (m, 1 H), 2.12-2.23 (m, 1 H), 1.80-2.11 (m 1 H), 1.41 (d, 6 H) | |
O | |||||||||
Y | 0 | 15833- | |||||||
24 | I | P2 | commercial | 1,7 | 331 | Rt = 2.767 min; method PF-AB01 | |||
II | Υγ | ^N | 61-1 | ||||||
^zA | γ> | ||||||||
nh2 | |||||||||
Ç | '1 | ||||||||
25 | Y | l | 0 | P2 | 100- | commercial | 1,7 | 345 | Rt = 3.053 min; method PF-AB01 |
]| | Υγ' | ^N | 72-1 | ||||||
Ογΐ | γΑ | ||||||||
nh2 |
186
26 | 0 ehiral Η|ζΛ | P2 | 17342- 08-4 | commercial | 1,7 | 344 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 8.11 (s, 1 H), 7.88 (d, 1 H), 7.72 (br. d, 2 H), 7.64 (s, 1 H), 7.42 (d, 1 H), 4.91 (m, 1 H), 4.47 (dd, 1 H), 4.31 (dd, 1 H), 4.02 (br. s., 1 H), 2.30 (m, 3 H), 1.91 (m, 1 H), 1.39 (d, 6 H) | ||
Y η | (j | ||||||||
ογ nh2 | Ί | ||||||||
27 | Y Cl CKY. nh2 | 0 ^S=o ^NH Y \Y | P2 | 849599- 08-2 | Ref.4 | 1,7 | 394 | Rt = 2.598 min; method PF-AB01 | |
28 | Chiral Y °Y o^J- nh2 | C Y | ^NH Y^N | P2 | 140695- 84-7 | commercial | 1,7, 10 | 344 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.88 (d, 1 H), 7.72 (br. s, 2 H), 7.55 (s, 1 H), 7.38 (d, 1 H), 4.82 (m, 1 H), 4.31 (m, 2 H), 3.32 (br. s„ 1 H), 3.07 (m, 1 H), 2.85 (d, 1 H), 2.41 (m, 2 H), 2.19 (m, 1 H), 2.01 (m, 1 H), 1.85 (m, 1 H), 1.58 (br. s., 1 H), 1.40 (d, 6 H), 1.25 (m, 1 H) |
29 | γ° <Y | P2 | 1217272- 20-2 | Ref. 5 | 1,7 | 360 | Rt = 2.458 min; method PF-AB01 | |
Y °ΥΤ ο^Αγ nh2 | Y 'Y | |||||||
Chiral / | )o | |||||||
30 | Y Ie | Y | 22415- | |||||
Π | P2 | commercial | 1,7 | 331 | Rt = 2.809 min; method PF-AB01 | |||
Ύ^τ | 59-4 | |||||||
ογ1γ | γ | |||||||
NHZ | ||||||||
Chiral / \ ÇN- | ||||||||
31 | 'Y/ Ύ | 34381- | ||||||
P2 | commercial | 1,7 | 344 | Rt = 2.184 min; method PF-AB01 | ||||
'Y | 71-0 | |||||||
NHZ |
32 | Chiral ΗΙψ^ γ % nh2 | P2 | 66673- 40-3 | commercial | 1,7 | 344 | 1H NMR (500 MHz, dmso-de) δ 8.18 (s, 1 H), 8.10 (br. s, 1 H), 7.87 (d, 1 H), 7.76 (br. s., 1 H), 7.70 (br. s., 1 H), 7.63 (s, 1 H), 7.41 (d, 1 H), 4.90 (dt, 1 H), 4.46 (dd, 1 H), 4.31 (dd, 1 H), 3.98 - 4.08 (m, 1 H), 2.15 - 2.36 (m, 3 H), 1.86 - 1.95 (m, 1 H), 1.40 (d, 3H), 1.38 (d, 3H) |
33 | Ύ° 9 γ % °yvk nh2 | P2 | 846057- 27-0 | commercial | 1,7 | 386 | Rt = 2.626 min; method PF-AB01 |
34 | HN—\ X/'O Y y °V^An 0 | P2 | 1428775- 91-0 | Ref. 6 | 1,7, 10 | 360 | Rt = 2.208 min; method PF-AB01 |
189
35 | 0 y—NH Y Y % nh2 | P2 | 7517-99- 9 | commercial | 1,7 | 346 | Rt = 2.319 min; method PF-AB01 |
36 | 9 v % °Y^N nh2 | P2 | 14774- 37-9 | commercial | 1,7 | 345 | Rt = 2.874 min; method PF-AB01 |
37 | _. . . HN^ Chiral ι I Y y S °Yyn θγΛ^Υ nh2 | P2 | 135065- 76-8 | commercial | 1, 7, 10 | 346 | Rt = 2.149 min; method PF-AB01 |
190
38 | /—N H Y A nh2 | P2 | 614730- 97-1 | commercial | 1,7, 10 | 362 | Rt = 2.258 min; method PF-AB01 |
39 | HN^> Y Y % nh2 | P2 | 135065- 69-9 | commercial | 1,7, 10 | 346 | Rt = 2.145 min; method PF-AB01 |
40 | H hnA Y c/ °γγ^Ν 0 | P2 | 161152- 76-7 | Ref.7 | 1, 7, 10 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.87 (d, 1 H), 7.72 (br. s., 2 H), 7.55 (s, 1 H), 7.38 (d, 1 H), 4.81 (dt, 1 H), 4.62 (d, 2 H), 2.95 (d, 1 H), 2.70 - 2.85 (m, 3 H), 1.40 (d, 6 H), 0.68 (d, 2 H), 0.02 (d, 1 H); |
41 | Chiral Çnh Y Y ογίγχ nh2 | P2 | 83435- 58-9 | commercial | 1,7, 10 | 330 | Rt = 2.132 min; method PF-AB01 |
42 | H o Y o/= °YY^N H2NxXX 0 | P2 | 419572- 18-2 | Ref. 8 | 1,7, 10 | 342 | Rt = 2.211 min; method PF-AB01 |
43 | Ω. γ % θγΧ nh2 | P2 | 157634- 00-9 | commercial | 1,7, 10 | 344 | Rt = 2.227 min; method PF-AB01 |
44 | P2 | 40987- 46-0 | Ref. 9 | 1,7 | 360 | Rt = 2.156 min; method PF-AB01 | ||
Y nh2 | X ^Y^N Yyy | |||||||
çr | ||||||||
45 | Y | X | P2 | 7583-53- 1 | commercial | 1,7 | 358 | Rt = 2.259 min; method PF-AB01 |
U./ II | Vy | |||||||
yXy | ||||||||
nh2 | ||||||||
HNY F oy | ||||||||
46 | Y | Cj | P2 | L122 | 1,7,10 | 398 | Rt = 2.349 min; method PF-AB01 | |
°T | ||||||||
H2N>A^ | YY | |||||||
0 |
47 | h Chiral Y 0 c^Jl nh2 | N^i M | P2 | 135065- 71-3 | commercial | 1,7, 10 | 346 | Rt = 2.088 min; method PF-AB01 | ||
Ό YY | ||||||||||
Chiral | c | A H | ||||||||
48 | Y | ^0 | P2 | 140695- | commercial | 1,7, | 10 | 344 | Rt = 2.216 min; method PF-AB01 | |
0 II | Y^N | 85-8 | ||||||||
YY | ||||||||||
nh2 | ||||||||||
Chiral | ς | NH ; | ||||||||
l | Ύ | 199174- | ||||||||
49 | I | P2 | commercial | 1,7, | 10 | 330 | Rt = 2.127 min; method PF-AB01 | |||
CL, π | Y^N | 24-8 | ||||||||
γΧ | YY | |||||||||
nh2 |
50 | Chiral Y CL U nh2 | λ-νη Q | P4 | 199174- 24-8 | commercial | 1,10 | 330 | Rt = 1.824 min; method PF-AB01 | |
Ύ | Ό YY, N | ||||||||
Chiral | Y | ||||||||
51 | Y | -O \n. | P4 | 135065- | Commercia | 1,10 | 346 | Rt= 1.805 min; method PF-AB01 | |
0 | 76-8 | I | |||||||
Y | Yy | Y | |||||||
η2ν^Α | N | ||||||||
0 | |||||||||
n | |||||||||
52 | Y | 0^ | P4 | 1338247- | commercial | 1,10 | 370 | Rt = 1.963 min; method PF-AB01 | |
CL Y | Y, | 76-9 | |||||||
H2N>A | Λ N | ||||||||
0 |
53 | Chiral y V cY 0 | P4 | 135065- 71-3 | commercial | 1, 10 | 346 | Rt =1.812 min; method PF-AB01 |
54 | H 9 V cY ΗζΝγθό 0 | P4 | 614730- 97-1 | commercial | 1,10 | 362 | Rt = 1.887 min; method PF-AB01 |
55 | Y fhf °TrS » 0 | P4 | 1239999- 37-1 | Ref. 10 | 1, 10 | 358 | Rt = 1.963 min; method PF-AB01 |
56 | H 9 0 | Ρ4 | 236406- 21-6 | commercial | 1,10 | 358 | Rt = 2.454 min; method PF-CD05 |
57 | Chiral Y o'^Y ΝΗ η η η ο 0 | Ρ4 | 97859- 49-9 | Ref. 11 | 1,10 | 346 | Rt = 1.887 min; method PF-AB01 |
58 | γ Η,ΙΨ Λ Jx J 0 | Ρ4 | 221298- 00-6 | commercial | 1,10 | 358 | Rt = 1.964 min; method PF-AB01 |
59 | _/^ΝΗ y Γθ ΗΣΝγΥγ 0 | Ρ4 | 4606-65- 9 | commercial | 1 | 344 | Rt = 2.349 min; method PF-CD05 |
60 | N 'V VA H2NyLANJI ° 0 | P4 | 142253- 56-3 | commercial | 1,10, 11 | 383 | 1H NMR (400 MHz, dmso-de) δ 8.66 (d, 1 H), 8.25 (s, 1 H), 7.73 (br. s., 2 H), 7.49 (s, 1 H), 7.07 (d, 1 H), 4.81 (dt, 1 H), 4.37 - 4.47 (m, 2 H), 4.29 - 4.37 (m, 1 H), 4.16 (dd, 1 H), 4.09 (t, 1 H), 3.93 (dd, 1 H), 3.80 (d, 2 H), 3.19 (td, 1 H), 1.40 (d, 2 H), 1.37 (d, 3 H) |
61 | Chiral Y 70 Y <0 0 oysAn nh2 | P2 | 83435- 58-9 | commercial | 1,7,10, 11 | 397 | Rt = 2.637 min; method PF-AB01 |
62 | N II r° 9 Y % °yVn nh2 | P2 | 123855- 51-6 | commercial | 1,7,10, 11 | 411 | Rt = 2.666 min; method PF-AB01 |
63 | Chiral Y °Y nh2 | Y | P2 | 69610- 40-8 | commercial | 1,7,10, 11 | 397 | Rt = 2.638 min; method PF-AB01 | ||
cw..... | 0 N | |||||||||
Chiral | <?Y ‘v'S | |||||||||
64 | Y °ΥΎ | Q> | P2 | 714971- 28-5 | commercial | 1,7,10, 11 | 413 | Rt = 2.522 min; method PF-AB01 | ||
nh2 | ||||||||||
65 | V °yy | 3 | .N Vz -NH | P2 | 168540- 07-6 | commercial | 1,7,10, 11 | 411 | Rt = 2.876 min; method PF-AB01 | |
nh2 |
66 | Chiral Y Y k θΎ^Ύ nh2 | Y 0 ^N | P2 | 199174- 24-8 | commercial | 1,7,10, 11 | 397 | Rt = 2.576 min; method PF-AB01 | |
r | Y | ||||||||
Chiral Y | Y | ||||||||
67 | Y Y Y | =XO Y^N | P2 | 140695- 85-8 | commercial | 1,7,10, 11 | 411 | Rt = 2.755 min; method PF-AB01 | |
ΟγΑγ | |||||||||
nh2 |
68 | ,N /' Chiral ^:0 /—N çXy °Ύ^ι N nh2 | P2 | 1244772- 37-9 | Ref. 12 | 1,7,10, 11, chiral HPLC | 423 | Rt = 2.83 min; method PF-AB01 |
69 | N Y o YT N H 0 0 | P2 | 142253- 56-3 | commercial | 1,7, 10, 11 | 383 | Rt = 2.458 min; method PF-AB01 |
70 | /N (' Chiral \__ >O σ Y \ °Ύ^ί N nh2 | P2 | 138108- 72-2 | commercial | 1,7, 10, 11 | 397 | Rt = 2.577 min; method PF-AB01 |
201
71 | Y θ HzN^UyJ NY 0 | P4 | 130658- 13-8 | Ref. 13 | 1,10, 11 | 423 | 1H NMR (400 MHz, dmso-de) δ 8.71 (d, 2 H), 8.27 (s, 0.5 H, diastereomer 1), 8.25 (s, 0.5 H, diastereomer2), 7.75 (br. s., 2 H), 7.44 (s, 0.5 H, diastereomer 1), 7.32 (s, 0.5 H, diastereomer 1), 7.18 (m, 1 H), 5.10 - 5.25 (m, 1 H), 4.87 (quin, 0.5 H, diastereomer 1), 4.77 (quin, 0.5 H, diastereomer 2), 4.00 (d, 2 H), 3.82 (m, 1 H), 3.65 (m, 1 H), 3.35 (m, 1 H), 3.07 - 3.26 (m, 1 H), 2.80 - 2.97 (m, 1 H), 1.83 - 2.31 (m, 3 H), 1.53 - 1.70 (m, 1 H), 1.33-1.44 (m, 6H) |
72 | H NY V/ mA Y ? °^iYl N 0 | P2 | 1279569- 31-1 | Ref. 14 | 1,7, 10 | 342 | Ή NMR (400 MHz, dmso-d6) δ 8.21 (s, 1 H), 7.91 (d, 1 H), 7.73 (br. s, 2 H), 7.57 (s, 1 H), 7.47 (d, 1 H), 5.49 (d, 1 H), 4.90 (dt, 1 H), 3.01 - 3.12 (m, 1 H), 2.92 (dd, 1 H), 2.73 - 2.80 (m, 1 H), 2.64 - 2.70 (m, 1 H), 2.53 - 2.59 (m, 1 H), 2.14 - 2.23 (m, 1 H), 2.00-2.10 (m, 1 H), 1.77-1.86 (m, 1 H), 1.70-1.77 (m, 1 H), 1.38 (d, 6H) |
73 | /\ /° Chiral <y N—\ Y \—=N Y f °Y1 N nh2 | P2 | 161511- 85-9 | commercial | 1,7,10, 11 | 383 | Rt = 2.518 min; method PF-AB01 |
74 | Chiral Y nh2 | |Y | P2 | 198835- 07-3 | Ref. 15 | 1,7,10, 11 | 409 | Rt = 2.615 min; method PF-AB01 |
75 | Y Chiral Y | Ό Y° -o | P2 | 135065- 76-8 | commercial | 1,7,10, 11 | 413 | Rt = 2.541 min; method PF-AB01 |
0. II | Y/Y | |||||||
O^Jl | νΑγ | |||||||
nh2 | ||||||||
nm N- | ||||||||
76 | L | ΥΓ -ο -ή | P2 | 614730- 97-1 | commercial | 1,7, 10, 11 | 429 | Rt = 2.726 min; method PF-AB01 |
ΎγΥ | ||||||||
nh2 |
77 | 0 A Y 0 nh2 | ckh -0 zya ΎΥ | P2 | 161152- 76-7 | Ref.7 | 1, 7,10, 11 | 409 | Rt = 2.68 min; method PF-AB01 |
Chiral | 0 ÂY Y° | |||||||
78 | Ύ | A | P2 | 135065- 71-3 | commercial | 1,7, 10, 11 | 413 | Rt = 2.542 min; method PF-AB01 |
0, | ||||||||
°v | A^AA | |||||||
nh2 | ||||||||
N | ||||||||
Chiral | ||||||||
79 | Y | \Ah Η'Γ\ ο·^Υ | P2 | 130658- 13-8 | Ref. 13 | 1,7, 10, 11 | 423 | Rt = 2.754 min; method PF-AB01 |
Y | ||||||||
ογΥ^ | γ | |||||||
nh2 |
80 | N | Ρ2 | 1441392- 37-5 | Ref. 16 | 1,7,10, 11 | 425 | Rt = 2.874 min; method PF-AB01 | ||
Y CL 0Υ νη2 | N—A | ||||||||
> ^ΧΧ | ζΥΖ\ | ||||||||
Ν ΐ | |||||||||
Chiral | χ -Ν | 1,7, 10, | |||||||
81 | Y 0^ π | £ ο'Ύ Χν | Ρ2 | 1244772- 37-9 | Ref. 12 | 11, chiral HPLC | 423 | Rt = 2.827 min; method PF-AB01 | |
ΥχΥ | |||||||||
νη2 |
82 | Y ço nh2 | __/ o 0 Y^N | _===N | P2 | 1263506- 20-2 | commercial | 1,7, 10, 11 | 411 | Rt = 2.709 min; method PF-AB01 | |
Chiral | O YNY | |||||||||
83 | Y | c/ | X | P2 | 215917- 99-0 | commercial | 1, | 7,10, 11 | 413 | Rt = 2.521 min; method PF-AB01 |
°Y\Y | xY | |||||||||
nh2 | ||||||||||
N V | o | |||||||||
84 | Y | N—\ UV Ό | P2 | 1428775- 91-0 | Ref. 6 | 1, | 7,10, 11 | 427 | Rt = 2.58 min; method PF-AB01 | |
0.^. | -γΥΝ | |||||||||
O^Jt. | YY | |||||||||
nh2 |
85 | Νκ Μ N—v | P2 | 1349715- 96-3 | commercial | 1,7,10, 11 | 411 | Rt = 2.728 min; method PF-AB01 | |
Y γ nh2 | C..... 0 ΙχΥ | |||||||
/N / | ||||||||
Z | 7=0 N | |||||||
86 | Y Y k | J 0 | P2 | 236406- 21-6 | commercial | 1,7,10, 11 | 425 | Rt = 2.861 min; method PF-AB01 |
Υγ | ||||||||
Y | ||||||||
nh2 |
87 | N II r û Y V 0 | P4 | 419572- 18-2 | Ref. 1 | 1, 10, 11 | 409 | Rt = 2.114 min; method PF-AB01 |
88 | N M N-x k..... % γ νθγΝΗζ O | P4 | 1349715- 96-3 | commercial | 1,10, 11 | 411 | Rt = 2.197 min; method PF-AB01 |
89 | Νχ J o==( Chiral N-\ γ ànr° 0 | P4 | 1244772- 37-9 | Ref. 12 | 1,10, 11, chiral HPLC | 423 | Rt = 2.235 min; method PF-CD05 |
90 | O Chiral ko γ ΟθγΗζ O | P4 | 161152- 76-7 | Ref.7 | 1,10, 11, chiral HPLC | 409 | Rt = 2.149 min; method PF-AB01 |
91 | /N L /N -P % γ ÇOyNH* 0 | P4 | 236406- 21-6 | commercial | 1, 10, 11 | 425 | Rt = 2.254 min; method PF-AB01 |
209
92 | N 4 νά \ -JHiA \ ? | YY yA | Chiral Y ^.0 JL.NH2 0 | P4 | 1244772- 37-9 | Ref. 12 | 1,10, 11 | 423 | Rt = 2.21 min; method PF-AB01 |
X | |||||||||
ο | A | Chiral | |||||||
93 | λ | X | y | P4 | 140695- 84-7 | commercial | 1,10, 11 | 411 | Rt = 2.221 min; method PF-AB01 |
Y^Y | .0 | ||||||||
N | nh2 | ||||||||
0 | |||||||||
94 | s | Y Y0 | P4 | 161152- 76-7 | Ref. 7 | 1,10, 11 | 409 | Rt = 2.136 min; method PF-AB01 | |
lx Y* N | ΥγΝΗ 2 | ||||||||
0 |
95 | nm N-\ CL Y γ 3ύύ° ^ΝΑ3γΝΗ2 0 | P4 | 614730- 97-1 | commercial | 1,10, 11 | 429 | Rt = 2.211 min; method PF-AB01 |
96 | N Μ ΝΥ ÇV y γ ζΟγΝΗζ 0 | P4 | 1428775- 91-0 | Ref. 6 | 1,10, 11 | 427 | Rt = 2.119 min; method PF-AB01 |
97 | 0 Chiral Y γ Αγ 0 | P4 | 140695- 85-8 | commercial | 1, 10, 11 | 411 | Rt = 2.212 min; method PF-AB01 |
98 | YÂ-, | I Chiral Y° % Y ΟθγΝΗζ 0 | P4 | 135065- 76-8 | commercial | 1,10, 11 | 413 | Rt = 2.059 min; method PF-AB01 |
99 | °o; V %i^^YNHz 0 | P4 | 157634- 00-9 | commercial | 1,10, 11 | 411 | Rt = 2.163 min; method PF-AB01 |
100 | N II Y 9 % Y 0θγΝΗ2 0 | P4 | 123855- 51-6 | commercial | 1,10, 11 | 411 | Rt = 2.159 min; method PF-AB01 |
101 | Chiral Y 0 | P P2 | 198835- 07-3 | Ref. 15 | 1,7,10 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.83 - 7.93 (m, 1 H), 7.72 (br. s., 2 H), 7.60 (s, 1 H), 7.38 (d, 1 H), 5.35 - 5.48 (m, 1 H), 4.86 (dt, 1 H), 3.39 (br. s., 1 H), 3.25 (d, 1 H), 2.82 (br. s., 1 H), 2.68-2.80 (m, 1 H), 2.12-2.24 (m, 1 H), 1.58-1.67 (m, 1 H), 1.50 - 1.58 (m, 1 H), 1.40 (d, 6 H), 1.26 -1.37 (m, 1 H) |
102 | Chiral ί< NH Y o*^V 0 | P2 | 198835- 07-3 | Ref. 14 | 1,7,10 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 2 H), 7.62 (s, 1 H), 7.38 (d, 1 H), 5.42 (s, 1 H), 4.77 4.93 (m, 1 H), 3.24 (d, 1 H), 2.81 (br. s., 1 H), 2.69 (dd, 1 H), 2.18 (ddd, 1 H), 1.49 -1.68 (m, 2 H), 1.41 (d, 6 H), 1.29 -1.39 (m, 1 H) |
103 | °Y Chiral \γ % °Ύ^Τ^Ν | P2 | 17342- 08-4 | commercial | 1 | 326 | 1H NMR (500 MHz, CDCb) δ 8.07 (s, 1 H), 7.93 (d, 1 H), 7.54 (s, 1 H), 7.22 (d, 1 H), 6.12 (br. s., 1 H), 4.83 (dt, 1 H), 4.68 (dd, 1 H), 4.43 (dd, 1 H), 4.22 (dd, 1 H), 2.34 - 2.55 (m, 3 H), 1.95 - 2.09 (m, 1 H), 1.49 (dd, 6 H) |
213
104 | V° chiral hn\3 Y Η 2ΝγΐΥ\Α 0 | P2 | 132682- 23-6 | Ref. 17 | 1,7 | 346 | 1H NMR (500 MHz, dmso-de) δ 8.15 (s, 1 H), 7.95 (br. s, 1 H), 7.84 (d, 1 H), 7.69 (br. s., 1 H), 7.67 (br. s., 1 H), 7.59 (s, 1 H), 7.39 (d, 1 H), 4.84 (quin, 1 H), 4.44 - 4.47 (m, 1 H), 4.43 (d, 1 H), 4.35 (dd, 1 H), 4.28 (dd, 1 H), 4.21 (dq, 1 H), 1.36 (d, 3 H), 1.34 (d, 3H) |
105 | 0 Chiral HN.5 Y O °Yf^N o I | P2 | 17342- 08-4 | commercial | 1,15, 16, 7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 8.09 (br. s, 1 H), 7.76 (br. s., 2 H), 7.71 (s, 1 H), 7.67 (s, 1 H), 4.92 (dt, 1 H), 4.42 (dd, 1 H), 4.28 (dd, 1 H), 3.98 - 4.05 (m, 1 H), 2.44 (s, 3 H), 2.15-2.35 (m, 3 H), 1.87-1.94 (m, 1 H), 1.40 (d, 3 H), 1.38 (d, 3 H) |
106 | Chiral J Ί Y 0^ °vS>An 0 | P2 | 128726- 47-6 | commercial | 1, 7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.88 (dd, 1 H), 7.74 (br. s., 1 H), 7.70 (br. s., 2 H), 7.66 (s, 1 H), 7.41 (d, 1 H), 4.89 (dt, 1 H), 4.40 (d, 2 H), 3.78 - 3.86 (m, 1 H), 2.12 - 2.23 (m, 3 H), 1.91 - 2.00 (m, 1 H), 1.81-1.90 (m, 2 H), 1.61 -1.73 (m, 3 H), 1.40 (d, 3 H), 1.38 (d, 3 H) |
214
107 | Ή Y Y °YY^N H2N sJVM 0 | P2 | L1 | 1,7 | 358 | 1H NMR (400 MHz, dmso-de) δ 8.21 (s, 1 H), 7.88 (d, 1 H), 7.74 (br. s, 1 H), 7.71 (br. s, 1 H), 7.69 (s, 1 H), 7.42 (d, 1 H), 4.85 5.00 (m, 1 H), 4.50 - 4.61 (m, 1 H), 4.16 - 4.28 (m, 1 H), 3.89 4.04 (m, 1 H), 2.30 - 2.48 (m, 3 H), 1.36-1.44 (m, 6 H), 1.09 1.13 (m, 3 H) | |
108 | H èjz Y ° °yy^n h2n>iYYY 0 | P2 | 207405- 59-2 | commercial | 1,7, 10, chiral HPLC | 342 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.88 (d, 1 H), 7.71 (br. s, 2 H), 7.53 (s, 1 H), 7.39 (d, 1 H), 5.13 - 5.19 (m, 1 H), 4.85 (dt, 1 H), 3.60 (br. s, 1 H), 2.73 - 2.79 (m, 1 H), 2.51 2.55 (m, 2 H), 1.99 (ddd, 1 H), 1.73 -1.79 (m, 1 H), 1.60 -1.68 (m, 1 H), 1.45-1.51 (m, 1 H), 1.38 (dd, 6 H) |
109 | H /Νλ V'7 lliA Y f °YYN h2nYlyy 0 | P2 | 207405- 59-2 | commercial | 1,7, 10, chiral HPLC | 342 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.88 (d, 1 H), 7.71 (br. s., 2 H), 7.52 (s, 1 H), 7.37 (d, 1 H), 5.07 - 5.11 (m, 1 H), 4.85 (dt, 1 H), 3.45 (br. s, 1 H), 2.66 - 2.73 (m, 1 H), 2.42 - 2.46 (m, 2 H), 1.95 (ddd, 1 H), 1.67 -1.73 (m, 1 H), 1.57 -1.64 (m, 1 H), 1.40 -1.45 (m, 1 H), 1.38 (dd, 6 H) |
215
110 | Chiral ηνΤ^ γ % 0 | P2 | 156088- 46-9 | Ref. 18 | 1,7 | 372 | 1H NMR (500 MHz, dmso-de) δ 8.18 (s, 1 H), 8.13 (s, 1 H), 7.88 (d, 1 H), 7.74 (br. s., 1 H), 7.71 (br. s., 1 H), 7.69 (s, 1 H), 7.41 (d, 1 H), 4.92 (dt, 1 H), 4.57 (dd, 1 H), 4.21 (dd, 1 H), 3.91 - 4.06 (m, 1 H), 2.10 (dd, 1 H), 1.74 (dd, 1 H), 1.39 (t, 6 H), 1.11 (s, 3 H), 1.09 (s, 3 H) |
111 | 0 y—ΝΗ y γ cY °yvk HaN^Jl^kk 0 | P2 | 54320-89- 4 | commercial | 1,7 | 344 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.88 (d, 1 H), 7.72 (br. s., 2 H), 7.59 (s, 1 H), 7.55 (s, 1 H), 7.40 (d, 1 H), 4.87 (dt, 1 H), 4.49 (dd, 1 H), 4.41 (dd, 1 H), 3.50 (dd, 1 H), 3.19 (dd, 1 H), 2.88 - 3.01 (m, 1 H), 2.42 (dd, 1 H), 2.13 (dd, 1 H), 1.39 (d, 3 H), 1.38 (d, 3H) |
112 | <λ F hÇ Y % °Yyk 0 | P2 | L2 | 1,7 | 362 | 1H NMR (500 MHz, dmso-de) δ 8.74 (br. s, 1 H), 8.19 (s, 1 H), 7.88 (d, 1 H), 7.74 (br. s., 1 H), 7.71 (br. s., 1 H), 7.57 (s, 1 H), 7.43 (d, 1 H), 5.28 (dt, 1 H), 4.91 (dt, 1 H), 4.47 (dd, 1 H), 4.34 (dd, 1 H), 4.08 - 4.19 (m, 1 H), 2.30 - 2.48 (m, 2 H), 1.41 (d, 3 H), 1.38 (d, 3H) |
216
113 | γ HN ) Y Y °YV^N 0 | P2 | L4 | 1,7 | 372 | 1H NMR (500 MHz, dmso-de) δ 8.19 (d, 1 H), 8.16 (s, 1 H, diastereomer 1), 8.07 (s, 1 H, diastereomer2), 7.88 (d, 1 H), 7.74 (br. s., 1 H), 7.71 (br. s., 1 H), 7.68 (s, 1 H, diastereomer 1), 7.61 (s, 1 H, diastereomer 2), 7.41 (d, 1 H), 4.90 (dt, 1 H), 4.57 (dd, 1 H, diastereomer 1), 4.46 (dd, 1 H, diastereomer 2), 4.32 (dd, 1 H, diastereomer 1), 4.20 (dd, 1 H, diastereomer 2), 3.97 (td, 1 H), 1.88 - 2.48 (m, 2 H), 1.66 -1.80 (m, 1 H), 1.39 (td, 6 H), 1.24 -1.37 (m, 2 H), 0.92 (td, 3 H) | |
114 | Chiral HNY Y cj h2N^PCyC·^ 0 | P6 | 17342-08- 4 | commercial | 5 | 343 | 1H NMR (500 MHz, dmso-de) δ 8.32 (s, 1 H), 8.02 (s, 1 H), 7.71 (br. s., 1 H), 7.63 (br. s., 1 H), 7.60 (s, 1 H), 7.51 (d, 1 H), 7.29 (t, 1 H), 6.99 (d, 1 H), 4.91 (quin, 1 H), 4.10 (t, 2 H), 4.04 (dd, 1 H), 2.17 - 2.43 (m, 3 H), 1.97 (br. s., 1 H), 1.41 (d, 3 H), 1.39 (d, 3 H) |
115 | Chiral Ηχ Y 0 | P6 | 138108- 72-2 | commercial | 5 | 329 | 1H NMR (500 MHz, dmso-de) δ 8.33 (s, 1 H), 7.70 (br. s., 1 H), 7.65 (br. s., 1 H), 7.55 (s, 1 H), 7.53 (d, 1 H), 7.31 (t, 1 H), 7.02 (d, 1 H), 4.86 (dt, 1 H), 4.19-4.28 (m, 1 H), 4.10 - 4.19 (m, 1 H), 3.21 - 3.54 (m, 4 H), 3.13 (dd, 1 H), 2.90 (dt, 1 H), 2.14 2.27 (m, 1 H), 1.80-1.93 (m, 1 H), 1.41 (d, 6 H) |
217
116 | °^o HN^I Y OJ θγ^γχΧ 0 | P2 | 1073338- 64-3 | Ref.19 | 1,7 | 360 | 1H NMR (500 MHz, dmso-de) δ 8.44 (d, 1 H), 8.19 (s, 1 H), 7.88 (d, 1 H), 7.74 (br. s., 1 H), 7.70 (br. s., 1 H), 7.67 (s, 1 H), 7.42 (d, 1 H), 4.93 (dt, 1 H), 4.48 - 4.56 (m, 1 H), 4.39 - 4.48 (m, 1 H), 4.04 (s, 2 H), 3.86 - 3.96 (m, 3 H), 1.38 (t, 6 H) |
117 | Chiral Τ’) °Ύ^Τ^Ν 0 | P2 | 138108- 72-2 | commercial | 1,7, 10 | 330 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.89 (d, 1 H), 7.73 (br. s., 1 H), 7.71 (br. s., 1 H), 7.56 (s, 1 H), 7.42 (d, 1 H), 4.87 (quin, 1 H), 4.48 - 4.57 (m, 1 H), 4.39 - 4.48 (m, 1 H), 3.35 - 3.52 (m, 2 H), 3.31 (br. s., 1 H), 3.19 - 3.27 (m, 1 H), 3.07 - 3.17 (m, 1 H), 2.89 (dt, 1 H), 2.11 - 2.23 (m, 1 H), 1.78 - 1.90 (m, 1 H), 1.39 (d, 6H) |
118 | °ΧΡ HN—( Y ° °Ύ^ι N 0 | P2 | L101 | Ref. 20 | 1,7 | 398 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 8.03 (br. s, 1 H), 7.90 (d, 1 H), 7.74 (br. s., 1 H), 7.71 (br. s., 1 H), 7.69 (s, 1 H), 7.42 (d, 1 H), 4.93 (dt, 1 H), 4.60 (dd, 1 H), 4.40 (dd, 1 H), 3.92 -4.06 (m, 1 H), 1.98 (d, 1 H), 1.62 (br. s„ 2 H), 1.51 (d, 1 H), 1.40 (t, 6 H), 1.22 (d, 2 H), 1.10 (d, 2 H), 1.01 (br. s., 2 H) |
218
119 | Chiral <3NH Y ko HaNxJVM 0 | P2 | 161511- 85-9 | commercial | 1,7,10 | 316 | 1H NMR (400 MHz, dmso-dB) δ 8.93 (br. s, 1 H), 8.22 (s, 1 H), 7.93 (d, 1 H), 7.70 (br. s, 2 H), 7.65 (s, 1 H), 7.48 (d, 1 H), 4.80 - 4.92 (m, 2 H), 4.68 - 4.79 (m, 2 H), 4.13 - 3.57 (m, 1 H), 3.82 -3.95 (m, 1 H), 1.36-1.45 (m, 6 H), 1.23-1.30 (m, 2 H) |
120 | 0, Chiral ___ HNv> Ÿ °r °Ύ^Ύ^Ν 0 | P13 | 17342-08- 4 | commercial | 1,7 | 356 | 1H NMR (500 MHz, dmso-de) δ 8.16 (s, 1 H), 8.03 (s, 1 H), 7.88 (d, 1 H), 7.77 (br. s., 1 H), 7.70 (br. s., 1 H), 7.38 - 7.45 (m, 2 H), 4.93 (quin, 1 H), 4.42 (dd, 1 H), 4.37 (dd, 1 H), 3.97 - 4.07 (m, 1 H), 2.08-2.38 (m, 6 H), 1.90-1.98 (m, 2 H), 1.85 (q, 1 H), 1.67- 1.80 (m, 1 H) |
121 | 0 Chiral /A HN^ I °Υί N 0 | P1 | 17342- 08-4 | commercial | 1,7 | 316 | 1H NMR (500 MHz, dmso-de) δ 8.16 (s, 1 H), 8.13 (br. s, 1 H), 7.89 (d, 1 H), 7.84 (br. s., 1 H), 7.69 (br. s., 1 H), 7.63 (s, 1 H), 7.42 (d, 1 H), 4.49 (dd, 1 H), 4.29 (dd, 1 H), 4.01 - 4.08 (m, 1 H), 3.99 (s, 3 H), 2.14 - 2.37 (m, 3 H), 1.84-1.96 (m, 1 H) |
219
122 | Ο Chiral HNÇ) > ΐ θγΥ/Υ Η2ΝχΛγΜ 0 | Ρ7 | 17342- 08-4 | commercial | 1,7 | 330 | 1H NMR (500 MHz, dmso-de) δ 8.17 (s, 1 H), 8.12 (s, 1 H), 7.88 (d, 1 H), 7.79 (br. s., 1 H), 7.70 (br. s., 1 H), 7.62 (s, 1 H), 7.41 (d, 1 H), 4.48 (dd, 1 H), 4.26 - 4.35 (m, 2 H), 4.18-4.25 (m, 1 H), 4.03 (br. s., 1 H), 2.12 - 2.38 (m, 3 H), 1.84 -1.94 (m, 1 H), 1.44 (t, 3 H) |
123 | <±> υ^ cr H2N^Jx^A^ 0 | Ρ2 | 1445951- 44-9 | Ref. 21 | 1,7, 10 | 370 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 2 H), 7.52 (s, 1 H), 7.43 (d, 1 H), 4.84 (dt, 1 H), 4.38 - 4.50 (m, 2 H), 3.34 - 3.49 (m, 2 H), 3.18 (d, 1 H), 3.02 (dd, 1 H), 2.62 - 2.72 (m, 1 H), 1.75 -1.95 (m, 4 H), 1.66 -1.75 (m, 1 H), 1.55-1.64 (m, 1 H), 1.40 (d, 6 H) |
124 | CMral Η1Η Y ~° 0 | Ρ2 | L1 | 1,7, chiral HPLC | 358 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 8.07 (br. s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 1 H), 7.71 (br. s., 1 H), 7.61 (s, 1 H), 7.41 (d, 1 H), 4.89 (quin, 1 H), 4.45 (dd, 1 H), 4.33 (dd, 1 H), 3.91 - 4.00 (m, 1 H), 2.54 - 2.59 (m, 1 H), 2.15 - 2.27 (m, 1 H), 1.88 (dt, 1 H), 1.39 (t, 6 H), 1.09 (d, 3 H) |
220
125 | chirai ηνΓ5 Y ό °yvA 0 | P2 | L1 | 1,7, chiral HPLC | 358 | 1H NMR (500 MHz, dmso-de) δ 8.16 (s, 1 H), 8.12 (br. s, 1 H), 7.85 (d, 1 H), 7.71 (br. s., 1 H), 7.68 (br. s., 1 H), 7.65 (s, 1 H), 7.38 (d, 1 H), 4.88 (quin, 1 H), 4.53 (dd, 1 H), 4.18 (dd, 1 H), 3.88 - 3.99 (m, 1 H), 2.32 - 2.49 (m, 2 H), 1.39 -1.49 (m, 1 H), 1.31-1.39 (m, 6 H), 1.08 (d, 3 H) | |
126 | ο Chiral y—\ HY Y °J 0 | P2 | L102 | Ref. 22 | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 7.55 - 8.12 (m, 5 H), 7.42 (d, 1 H), 4.91 (dt, 1 H), 4.24 - 4.42 (m, 2 H), 2.35 - 2.47 (m, 1 H), 2.23-2.35 (m, 1 H), 2.10-2.23 (m, 1 H), 1.83-1.97 (m, 1 H) |
127 | °Y HN 5 Y Y VvA HzNxJLyyA 0 | P2 | L5 | 1,7 | 388 | See Ref. 36. |
221
128 | °KF Chira! HN \ Y ό °υ^Λν 0 | P2 | L6 | 1,7 | 380 | 1H NMR (400 MHz, dmso-de) δ 9.28 (br. s., 1 H), 8.19 (s, 1 H), 7.89 (d, 1 H), 7.72 (br. s., 1 H), 7.70 (br. s., 1 H), 7.62 (s, 1 H), 7.44 (d, 1 H), 4.83 (dt, 1 H), 4.57 (dd, 1 H), 4.35 (dd, 1 H), 4.15 -4.26 (m, 1 H), 2.76-2.96 (m, 1 H), 2.54-2.71 (m, 1 H), 1.39 (t, 6 H) | |
129 | 0 Chiral ΥΛ HN ) FYF cj °Y^^N h2nYLYY 0 | P18 | 17342- 08-4 | commercial | 1,7 | 352 | 1H NMR (400 MHz, dmso-de) δ 8.10 (s, 1 H), 8.07 (br. s, 1 H), 8.04 (d, 1 H), 7.96 (s, 2 H), 7.75 (br. s., 1 H), 7.50 (d, 1 H), 7.31 (t, 1 H), 4.52 (dd, 1 H), 4.30 (dd, 1 H), 4.00-4.08 (m, 1 H), 2.14 -2.34 (m, 3 H), 1.85- 1.96 (m, 1 H) |
130 | 0 HN / U HY> Y 0^^ Vvk Η2ΝγγΥ 0 | P2 | 1192180- 58-7 | Ref. 23 | 1,7,17 | 370 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.81 - 7.98 (m, 2 H), 7.72 (d, 2 H), 7.41 (d, 1 H), 5.34 (br. s., 1 H), 4.85 (dt, 1 H), 4.05 (d, 1 H), 2.95 - 3.09 (m, 1 H), 2.43 - 2.53 (m, 1 H), 2.01 2.25 (m, 2 H), 1.82 - 2.03 (m, 2 H), 1.49 - 1.68 (m, 1 H), 1.39 (d, 6 H) |
131 | Chiral Y CL Η2Ν^Α 0 | Vf hn) | P2 | L7 | 1,7 | 390 | 1H NMR (400 MHz, dmso-de) δ 8.77 (s, 1 H), 8.19 (s, 1 H), 7.88 (d, 1 H), 7.64 - 7.79 (m, 3 H), 4.89 (dt, 1 H), 4.58 (dd, 1 H), 4.26 (dd, 1 H), 3.93 - 4.05 (m, 1 H), 2.10 - 2.26 (m, 1 H), 1.82-1.99 (m, 1 H), 1.61 -1.80 (m, 1 H), 1.32-1.44 (m, 6 H), 0.89 -1.01 (m, 3 H) | ||
Y χ^Υ | Y An | ||||||||
Chiral | Y HN. | 1H NMR (400 MHz, dmso-de) δ 8.87 (s, 1 H), 8.19 (s, 1 H), 7.89 | |||||||
( | (d, 1 H), 7.72 (d, 2 H), 7.66 (s, 1 H), 7.43 (d, 1 H), 4.81 - 5.02 | ||||||||
132 | Y | 0 | P2 | L8 | 1,7 | 390 | (m, 1 H), 4.59 (dd, 1 H), 4.26 (dd, 1 H), 4.10 - 4.21 (m, 1 H), | ||
CL | an | 2.31 - 2.54 (m, 1 H), 2.05 - 2.27 (m, 1 H), 1.86 - 2.03 (m, 1 H), | |||||||
0 | A | xy | 1.58 - 1.83 (m, 1 H), 1.24 -1.44 (m, 6 H), 0.96 (s, 3 H) | ||||||
Chiral | y HN | A | 1H NMR (500 MHz, dmso-de) δ 8.85 (s, 1 H), 8.20 (s, 1 H), 7.58 | ||||||
133 | Y CL | l | Y | P2 | L9 | 1,7 | 376 | - 7.81 (m, 3 H), 7.43 (d, 1 H), 4.92 (quin, 1 H), 4.57 (dd, 1 H), 4.29 (dd, 1 H), 4.15 (dd, 1 H), 2.38-2.68 (m, 1 H), 1.96-2.28 | |
HzNY O | 0 | Y X^V | (m, 1 H), 1.54 (s, 3 H), 1.39 (d, 6 H) |
134 | Chiral Y 0 H2NxJ 0 | y HN. □ | r Y Yn | P2 | L10 | 1,7 | 376 | 1H NMR (500 MHz, dmso-de) δ 8.75 (s, 1 H), 8.20 (s, 1 H), 7.61 - 7.82 (m, 3 H), 7.43 (d, 1 H), 4.90 (dt, 1 H), 4.57 (dd, 1 H), 4.28 (dd, 1 H), 3.95 - 4.09 (m, 1 H), 2.47 - 2.55 (m, 1 H), 2.19 - 2.37 (m, 1 H), 1.44 - 1.56 (m, 3 H), 1.39 (t, 6 H) | |
Chiral | y HN | Γ | 1,7, chiral HPLC | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 8.08 (s, 1 H), 7.88 (d, 1 H), 7.72 (d, 2 H), 7.61 (s, 1 H), 7.42 (d, 1 H), 4.80 - 5.00 | |||||
135 | Y 0. H2N^ 0 | l 0 | Y -^N | P2 | L4 | 372 | (m, 1 H), 4.46 (dd, 1 H), 4.32 (dd, 1 H), 3.82 - 4.03 (m, 1 H), 2.33-2.56 (m, 2H), 1.96-2.21 (m, 1 H), 1.94 (d, 1 H), 1.19- 1.35 (m, 1 H), 1.38 -1.41 (m, 3 H), 1.51 -1.82 (m, 1 H), 1.38 - 1.41 (m, 6H), 0.91 (t, 3 H) | ||
.$· | |||||||||
Chiral | ) | 1,7, | 1H NMR (400 MHz, dmso-de) δ 8.12 - 8.28 (m, 2 H), 7.89 (d, 1 H), 7.63 - 7.80 (m, 3 H), 7.42 (d, 1 H), 4.91 (dt, 1 H), 4.58 (dd, 1 | ||||||
136 | Y | Y | P2 | L4 | chiral | 372 | H), 4.20 (dd, 1 H), 3.98 (dd, 1 H), 2.26 - 2.46 (m, 2 H), 1.75 | ||
CL [i | Υγ | HPLC | (ddd, 1 H), 1.47-1.60 (m, 1 H), 1.19-1.35 (m, 1 H), 1.38- | ||||||
Η2Ν^Υ 0 | Y | 1.41 (m, 6H), 0.87-0.99 (m, 3 H) |
224
137 | Chiral ΗΝ^> Y Y 0 | P2 | L11 | 1,7 | 402 | 1H NMR (400 MHz, dmso-de) δ 8.24 (s, 1 H), 8.20 (s, 1 H), 7.89 (d, 1 H), 7.73 (d, 2 H), 7.61 (s, 1 H), 7.42 (d, 1 H), 4.84 - 4.97 (m, 1 H), 4.41 - 4.54 (m, 1 H), 4.32 (dd, 1 H), 3.90 - 4.01 (m, 1 H), 2.18 - 2.30 (m, 1 H), 1.92-2.10 (m, 1 H), 1.32 -1.48 (m, 6 H), 1.23 (s, 3 H), 1.13 (s, 3 H) | |
138 | â” Y ^0 °Y>An 0 | P2 | 53611-47- 5 | commercial | 1,7 | 358 | 1H NMR (500 MHz, dmso-d6) δ 8.20 (s, 1 H), 7.73 (d, 2 H), 7.52 (br. s., 1 H), 7.41 (d, 1 H), 4.87 (dt, 1 H), 4.40 (d, 2 H), 3.14 - 3.30 (m, 2 H), 2.34 - 2.48 (m, 2 H), 2.07 - 2.20 (m, 1 H), 1.92 - 2.03 (m, 1 H), 1.51 -1.65 (m, 1 H), 1.31 -1.45 (m, 6 H) |
139 | H HNq> / YyS ΗζΝγΐΥΥ 0 | P2 | 161152- 76-7 | Ref. 7 | 1,7, 10 | 342 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.88 (d, 1 H), 7.74 (d, 2 H), 7.58 (s, 1 H), 7.42 (d, 1 H), 4.79 - 4.95 (m, 1 H), 4.52 4.76 (m, 2 H), 3.56 (br. s., 1 H), 3.20 - 3.38 (m, 2 H), 2.51 (s, 1 H), 1.75 -1.94 (m, 1 H), 1.40 (d, 6 H), 1.04 (dd, 1 H), 0.86 (t, 1 H) |
140 | H ™d> . ? / °YV^n 0 | P2 | 161152- 76-7 | Ref. 7 | 1,7, 10 | 342 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.88 (d, 1 H), 7.74 (d, 2 H), 7.58 (s, 1 H), 7.42 (d, 1 H), 4.79 - 4.92 (m, 1 H), 4.55 4.74 (m, 2 H), 3.56 (br. s., 2 H), 3.23 - 3.36 (m, 2 H), 2.48 - 2.53 (m, 1 H), 1.79 -1.91 (m, 1 H), 1.40 (d, 6 H), 1.03 (dd, 1 H), 0.86 (t, 1 H) |
141 | 0 Chiral /—\ HN k,„ V cY °γγ^Ν 0 | P2 | L35 | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 8.07 (s, 1 H), 7.90 (s, 1 H), 7.73 (d, 2 H), 7.65 (s, 1 H), 7.42 (d, 1 H), 4.91 (dt, 1 H), 4.50 (dd, 1 H), 4.36 (dd, 1 H), 3.53 - 3.66 (m, 1 H), 2.47 2.52 (m, 1 H), 2.26 - 2.37 (m, 1 H), 1.88 (dd, 1 H), 1.31 -1.48 (m, 6 H), 1.17 (s, 3 H) | |
142 | Ô Y Y pyUA O | P2 | 146059- 77-0 | commercial | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.90 (d, 1 H), 7.72 (d, 2 H), 7.57 (s, 1 H), 7.48 (br. s., 1 H), 7.41 (d, 1 H), 4.87 (dt, 1 H), 4.45 - 4.55 (m, 1 H), 4.40 (dd, 1 H), 3.11 (t, 1 H), 2.51 (d, 1 H), 2.37 (br. s., 1 H), 2.25 (dd, 2 H), 1.84 - 2.04 (m, 1 H), 1.57 -1.73 (m, 1 H), 1.40 (d, 6 H) |
226
143 | 0 Ο «Λ A Y '° °>^Y^N 0 | P2 | □7838-56- 6 | Ref. 24 | 1,7 | 380 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 7.89 (d, 1 H), 7.74 (br. s., 1 H), 7.73 (s, 1 H), 7.71 (br. s., 1 H), 7.34 - 7.50 (m, 2 H), 4.92 (dt, 1 H), 4.46 (dd, 1 H), 4.39 (dd, 1 H), 4.00 - 4.09 (m, 1 H), 3.28 (ddd, 1 H), 3.10 (dt, 1 H), 2.50 - 2.59 (m, 1 H), 2.17 - 2.27 (m, 1 H), 1.40 (t, 6 H) |
144 | v_/ Chiral /—\ HN ) Y cY °γ^^Ν HaN^JÎ^À^ 0 | P2 | L2 | 1,7, chiral HPLC | 1,7 | 362 | 1H NMR (500 MHz, dmso-de) δ 8.74 (s, 1 H), 8.21 (s, 1 H), 7.89 (d, 1 H), 7.73 (d, 2 H), 7.59 (s, 1 H), 7.44 (d, 1 H), 5.15 - 5.43 (m, 1 H), 4.92 (dt, 1 H), 4.49 (dd, 1 H), 4.35 (dd, 1 H), 4.15 (d, 1 H), 2.48 - 2.64 (m, 1 H), 2.23 - 2.46 (m, 1 H), 1.30 - 1.58 (m, 6 H) |
145 | w Chiral / \ HN y> Y cY 0 | P2 | L2 | 1,7, chiral HPLC | 1,7 | 362 | 1H NMR (500 MHz, dmso-de) δ 8.71 (s, 1 H), 8.20 (s, 1 H), 7.89 (d, 1 H), 7.74 (br. s., 3 H), 7.43 (d, 1 H), 5.01 - 5.27 (m, 1 H), 4.88 (dt, 1 H), 4.59 (dd, 1 H), 4.29 (dd, 1 H), 4.04 (br. s., 1 H), 2.62 - 2.84 (m, 1 H), 1.97 - 2.21 (m, 1 H), 1.39 (t, 6 H) |
146 | Chiral I HzNxJt 0 | 0 F HF HN 5 (j | P1 | L6 | Ref. 25 | 2,7 | 352 | 1H NMR (500 MHz, dmso-de) δ 9.29 (br. s., 1 H), 8.12 (s, 1 H), 7.85 (d, 1 H), 7.82 (br. s., 1 H), 7.60 - 7.71 (m, 1 H), 7.56 (s, 1 H), 7.39 (d, 1 H), 4.55 (dd, 1 H), 4.29 (dd, 1 H), 4.10 - 4.22 (m, 1 H), 3.91 (s, 3 H), 2.75 - 2.95 (m, 1 H), 2.51 - 2.66 (m, 1 H) | |
ύ | Y | ||||||||
V HN. | Y >0H | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.97 (s, 1 H), 7.88 | |||||||
147 | Y | Ί | Γ 0 | P2 | 39531-65- 7 | Ref. 26 | 1,7 | 374 | (d, 1 H), 7.72 (d, 2 H), 7.64 (s, 1 H), 7.41 (d, 1 H), 5.03 (t, 1 H), 4.91 (dt, 1 H), 4.38 - 4.49 (m, 1 H), 4.28 - 4.38 (m, 1 H), 3.54 - |
0. | y | Y^N | 3.66 (m, 1 H), 3.43 - 3.53 (m, 1 H), 2.21 - 2.38 (m, 2 H), 1.85 - | ||||||
0 | V | kk | 2.12 (m, 2 H), 1.33-1.50 (m, 6 H) | ||||||
0 | /—OH | ||||||||
Y | ) | 1H NMR (500 MHz, dmso-de) δ 8.18 (s, 1 H), 8.10 (br. s, 1 H), | |||||||
7.87 (d, 1 H), 7.75 (br. s., 1 H), 7.70 (s, 1 H), 7.61 (br. s, 1 H), | |||||||||
148 | Y | Y | P2 | L12 | 2, 7, 9 | 374 | 7.40 (d, 1 H), 4.90 - 4.98 (m, 1 H), 4.43 - 4.48 (m, 2 H), 4.29 - | ||
0. | 4.36 (m, 1 H), 4.23 (dd, 1 H), 3.96 - 4.02 (m, 1 H), 2.52 - 2.63 | ||||||||
Η2ΝχΥ 0 | (m, 1 H), 2.15-2.29 (m, 1 H), 1.95-2.08 (m, 1 H), 1.39 (t, 6 H) |
149 | °·κ Chiral HNxr/”'NH2 Y °ysAn 0 | P2 | 203982- 57-4 | Ref. 27 | 2, 7,9 | 359 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 8.05 (s, 1 H), 7.89 (d, 1 H), 7.74 (br. s., 1 H), 7.72 (br. s., 1 H), 7.65 (s, 1 H), 7.42 (d, 1 H), 4.92 (dt, 1 H), 4.58 (dd, 1 H), 4.32 (dd, 1 H), 3.58 - 3.65 (m, 1 H), 3.44 - 3.50 (m, 1 H), 1.97 (dd, 1 H), 1.36 - 1.44 (m, 7 H) |
150 | 0 OH Chiral Y\ HN 3 Y 0^ °γγ^Ν 0 | P2 | L13 | 1,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.28 (s, 1 H), 8.12 - 8.24 (m, 1 H), 7.88 (d, 1 H), 7.64 - 7.82 (m, 3 H), 7.41 (d, 1 H), 5.55 (d, 1 H), 4.95 (quin, 1 H), 4.56 (dd, 1 H), 4.22 (dd, 1 H), 4.13 (td, 1 H), 3.90 (qd, 1 H), 2.52 - 2.57 (m, 1 H), 1.67 (dt, 1 H), 1.29 1.47 (m,6H) | |
151 | S 0 i F Chiral —i, HN 5 Y ΟγΥΝ ΗζΝ.γΑΥ 0 | P2 | L15 | 2, 7, HPLC | 426 | 1H NMR (400 MHz, dmso-de) δ 8.30 (s, 1 H), 8.11 (s, 1 H), 7.80 - 7.82 (d, 2 H), 7.47 (s, 1 H), 7.34 - 7.36 (d, 1 H), 4.74 - 4.77 (m, 1 H), 4.39 - 4.40 (m, 1 H), 4.32 - 4.34 (m, 1 H), 3.93 - 3.98 (m, 1 H), 2.59 - 2.75 (m, 3 H), 2.18 - 2.31 (m, 3 H), 1.29 -1.33 (m, 6 H). |
229
152 | Chiral Y <V« h2nX 0 | °> HN, 0' γχ | r N | P2 | L16 | 2, 7, HPLC | 426 | 1H NMR (400 MHz, dmso-de) δ 8.44 (s, 1 H), 8.11 (s, 1 H), 7.80 - 7.81 (d, 1 H), 7.61 - 7.66 (m, 3 H), 7.33 - 7.35 (d, 1 H), 4.83 4.86 (m, 1 H), 4.49 - 4.52 (m, 1 H), 4.14 - 4.18 (m, 1 H), 3.96 (s, 1 H), 2.59 - 2.66 (m, 3 H), 2.25 - 2.28 (m, 1 H), 1.61 -1.64 (m, 1 H), 1.29-1.33 (m, 6H). | |
Chiral | y | > .OH | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.97 (s, 1 H), 7.88 | ||||||
153 | Y CL | Ύ | P2 | 39531-65- 7 | Ref. 26 | 1,7, HPLC | 374 | (d, 1 H), 7.68 - 7.79 (m, 2 H), 7.63 (s, 1 H), 7.41 (d, 1 H), 5.11 (t, 1 H), 4.91 (dt, 1 H), 4.40 - 4.49 (m, 1 H), 4.30 - 4.39 (m, 1 H), 3.49 - 3.62 (m, 2 H), 2.23 - 2.39 (m, 2 H), 2.01 - 2.13 (m, 1 H), | |
hX 0 | 1.90 - 2.01 (m, 1 H), 1.33 - 1.44 (m, 6 H) | ||||||||
154 | Chiral Y 0 | y HN i Y | /OH O// Y -^N | P2 | 39531-65- 7 | Ref. 26 | 1,7, HPLC | 374 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.97 (s, 1 H), 7.88 (d, 1 H), 7.70 - 7.80 (m, 2 H), 7.41 (d, 1 H), 5.11 (t, 1 H), 4.91 (dt, 1 H), 4.40 - 4.47 (m, 1 H), 4.32 - 4.40 (m, 1 H), 3.49 - 3.63 (m, 2 H), 2.24 - 2.41 (m, 2 H), 2.02 - 2.13 (m, 1 H), 1.90 - 2.02 |
H2NXJ 0 | X | (m, 1 H), 1.32 -1.44 (m, 6 H) |
230
155 | 0 Chiral HN Y Y cY F θγγ^Ν HaNxJtYY 0 | P2 | L104 | 1,7, HPLC | 412 | 1H NMR (500 MHz, dmso-dB) δ 8.40 (s, 1 H), 8.21 (s, 1 H), 7.90 (d, 1 H), 7.73 (d, 2 H), 7.61 (s, 1 H), 7.45 (d, 1 H), 4.87 (dt, 1 H), 4.48 (dd, 2 H), 4.07 - 4.20 (m, 2 H), 2.79 (dd, 1 H), 2.34 (dd, 1 H), 1.42 (d, 6 H) | |
156 | 0 Chiral / \ hnY Y oY ουυΛν 0 | P2 | 1315057- 77-2 | Ref. 28 | 1,7, HPLC | 358 | 1H NMR (500 MHz, dmso-de) δ 8.08 - 8.24 (m, 2 H), 7.88 (d, 1 H), 7.64 - 7.78 (m, 2 H), 7.55 (s, 1 H), 7.39 (d, 1 H), 5.29 (dd, 1 H), 4.83 (dt, 1 H), 4.14 (t, 1 H), 3.73 - 3.93 (m, 1 H), 1.95 - 2.30 (m, 3 H), 1.74-1.93 (m, 1 H), 1.31 -1.46 (m, 9 H) |
157 | 0 Chiral HY Y o^·' °Y^N h2nY/J 0 | P2 | 1315057- 77-2 | Ref. 28 | 1,7, HPLC | 358 | 1H NMR (500 MHz, dmso-de) δ 8.18 (s, 1 H), 7.93 - 8.03 (m, 1 H), 7.89 (d, 1 H), 7.60 (s, 1 H), 7.39 (d, 1 H), 5.38 (dd, 1 H), 4.90 (dt, 1 H), 3.81 - 3.95 (m, 1 H), 3.42 - 3.54 (m, 1 H), 2.04 - 2.38 (m, 4 H), 1.30-1.48 (m, 9 H) |
158 | Chiral Y C'A γΥ V h2NsJ\Ay 0 | P2 | 714971- 28-5 | commercial | 346 | Rt= min2.159; method PF-AB01 | |
159 | Y ?Y$ γΥ ΗζΝγΧγΜ O | P2 | 170491- 63-1 | commercial | 330 | Rt = min 2.200; method PF-AB01 | |
160 | Chiral Y ΥΫ °Ύ^ι N ΗζΝγΑγΜ 0 | P2 | 215917- 99-0 | commercial | 346 | Rt = min 2.160; method PF-AB01 | |
161 | Chiral HN^ \^H Y (Y YV^n 0 | P2 | L105 | 1,7, 9, 18, HPLC, 10 | 356 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.87 (d, 1 H), 7.74 (br. s., 1 H), 7.72 (br. s„ 1 H), 7.61 (s, 1 H), 7.41 (d, 1 H), 4.88 (dt, 1 H), 4.48 (d, 1 H), 4.23 (d, 1 H), 3.64 (d, 1 H), 3.31 (d, 1 H), 2.90 - 3.00 (m, 1 H), 2.73 - 2.86 (m, 1 H), 2.12 - 2.22 (m, 1 H), 1.79 -1.90 (m, 1 H), 1.40 (d, 6 H), 1.30 - 1.38 (m, 2 H), 0.99 (dd, 1 H), 0.86 (t, 1 H) |
162 | Chiral Y Cl 0 | -CA- | P2 | L105 | 1,7, 9, 18, HPLC, 10 | 356 | 1H NMR (500 MHz, dmso-de) δ 8.54 (br. s, 1 H), 8.20 (s, 1 H), 7.87 (d, 1 H), 7.74 (br. s., 1 H), 7.72 (br. s., 1 H), 7.61 (s, 1 H), 7.41 (d, 1 H), 4.88 (dt, 1 H), 4.49 (d, 1 H), 4.23 (d, 1 H), 3.64 (d, 1 H), 3.31 (d, 1 H), 2.90 - 3.03 (m, 1 H), 2.72 - 2.85 (m, 1 H), 2.07-2.25 (m, 1 H), 1.78-1.93 (m, 1 H), 1.40 (d, 6 H), 1.30- 1.38 (m, 1 H), 0.99 (dd, 1 H), 0.85 (t, 1 H) | ||
-Y' | .....MA | ||||||||
A | /—OH | ||||||||
Chiral | HX | Y F | 1H NMR (500 MHz, dmso-de) δ 8.90 (s, 1 H), 8.20 (s, 1 H), 7.89 | ||||||
163 | Y 0 HzNxJ- 0 | l 0 | c YN Xy | P2 | L17 | 2, 7,9 | 392 | (d, 1 H), 7.59 - 7.80 (m, 3 H), 7.43 (d, 1 H), 4.95 (dt, 1 H), 4.57 (dd, 1 H), 4.27 (dd, 1 H), 4.07 - 4.22 (m, 1 H), 3.69 - 3.72 (m, 1 H), 3.35 (d, 1 H), 2.29 - 2.54 (m, 3 H), 1.26-1.48 (m, 6 H) | |
Chiral | Ύ ΗΝχ | î·—OH X | 1H NMR (500 MHz, dmso-de) δ 8.75 (s, 1 H), 8.20 (s, 1 H), 7.89 | ||||||
164 | Y CL | lo | P2 | L18 | 2, 7,9 | 392 | (d, 1 H), 7.74 (br. s., 3 H), 7.43 (d, 1 H), 4.88 (dt, 1 H), 4.59 (dd, 1 H), 4.29 (dd, 1 H), 4.00 (br. s., 1 H), 3.57 - 3.73 (m, 2 H), 2.77 | ||
HZNY 0 | 3 | < N yy | (ddd, 1 H), 2.05 - 2.31 (m, 1 H), 1.39 (t, 6 H) |
233
165 | VY0H Chiral 7—\ HN ) γ ό %αΛν 0 | P2 | L12 | 2, 7, 9, HPLC | 374 | 1H NMR (400 MHz, dmso-de) δ 8.22 (s, 1 H), 8.19 (s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 1 H), 7.71 (s, 1 H), 7.70 (br. s., 1 H), 7.41 (d, 1 H), 4.95 (dt, 1 H), 4.71 (t, 1 H), 4.54 (dd, 1 H), 4.23 (dd, 1 H), 3.95 - 4.04 (m, 1 H), 3.55 - 3.63 (m, 2 H), 2.27 - 2.38 (m, 1 H), 1.78 - 1.89 (m, 1 H), 1.39 (dd, 6 H) | |
166 | 0 ~°H Chiral / \ HN 3 Y °Y^Yn 0 | P2 | L12 | 2, 7, 9, HPLC | 374 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 8.11 (s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 1 H), 7.71 (br. s., 1 H), 7.62 (s, 1 H), 7.42 (d, 1 H), 4.90 (dt, 1 H), 4.70 (t, 1 H), 4.46 (dd, 1 H), 4.32 (dd, 1 H), 3.91 - 4.01 (m, 1 H), 3.59 (t, 2 H), 2.24 (dt, 1 H), 1.96 - 2.10 (m, 1 H), 1.39 (t, 6 H) | |
167 | . °h'Y Chiral HN^J.....0 Y 0^ °YY^n nh2 | P2 | 254441- 91-3 | Ref. 29 | 1,7 | 416 | 1H NMR (500 MHz, dmso-de) δ 8.30 (s, 1 H), 7.90 (d, 1 H), 7.73 (d, 2 H), 7.39 - 7.59 (m, 2 H), 4.88 (dt, 1 H), 4.80 (d, 1 H), 4.68 (d, 1 H), 4.50 - 4.59 (m, 1 H), 4.37 - 4.50 (m, 1 H), 4.00 (t, 1 H), 1.24-1.51 (m, 12 H) |
168 | Chiral Y 0 °A nh2 | Y γγ | ) Y yVn γγ F | spécial case | 17342- 08-4 | commercial | 1,7,12, HPLC | 362 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 8.11 (s, 1 H), 7.75 - 7.92 (m, 3 H), 7.63 - 7.72 (m, 1 H), 4.96 (dt, 1 H), 4.46 (dd, 1 H), 4.28 (dd, 1 H), 3.96 - 4.12 (m, 1 H), 2.14 - 2.36 (m, 3 H), 1.85-1.97 (m, 1 H,), 1.34 -1.47 (m, 6 H) |
v | |||||||||
Chiral | hnt | ) | 1H NMR (400 MHz, dmso-de) δ 13.10 (br. s, 1 H), 8.00 - 8.21 | ||||||
169 | Y CL OJ | t y | Y an | P2 | 17342- 08-4 | commercial | 1,7,19, HPLC | 345 | (m, 2 H), 7.89 (d, 1 H), 7.65 (s, 1 H), 7.40 (d, 1 H), 4.85 (dt, 1 H), 4.47 (dd, 1 H), 4.30 (dd, 1 H), 3.89 - 4.14 (m, 1 H), 2.11 - 2.37 (m, 3 H), 1.79-2.01 m, 1 H), 1.20-1.47 (m, 6 H) |
OH | |||||||||
0 | / | ||||||||
Chiral | HN | 1H NMR (500 MHz, dmso-de) δ 8.60 (br. s, 1 H), 8.21 (s, 1 H), | |||||||
170 | Y 0 H2N.J· 0 | Y yVn xY | P2 | L37 | 2, 7, HPLC | 376 | 7.91 (d, 1 H), 7.73 (d, 2 H), 7.39 - 7.53 (m, 2 H), 4.93 - 5.14 (m, 1 H), 4.79 - 4.92 (m, 1 H), 4.41 - 4.57 (m, 2 H), 4.00 (br. s, 1 H), 2.68 - 2.86 (m, 1 H), 1.41 (dd, 6 H), 1.21 (d, 3 H) |
235
171 | \1χΟΗ Ο ξ ρ Chiral ΗΝΥ Y Y θγΥΥ^Ν Η2ΝγΥΥ^ 0 | P2 | L19 | 1,7, HPLC | 420 | 1H NMR (400 MHz, dmso-de) δ 8.70 (br. s., 1 H), 8.17 (s, 1 H), 7.88 (d, 1 H), 7.72 (m, 3 H), 7.41 (d, 1 H), 4.98 (s, 1 H), 4.87 - 4.91 (m, 1 H), 4.55 (d, 1 H), 4.23 (dd, 1 H), 3.92 - 3.95 (m, 1 H), 2.82-2.93 (m, 1 H), 1.88-2.05 (m, 1 H), 1.38 (m, 6 H), 1.02 (s, 3 H), 0.93 (s, 3 H) | |
173 | 0 Chiral ΗΝ,Υ 0 | P5 | 17342- 08-4 | commercial | 5, 13, 14 | 315 | 1H NMR (500 MHz, dmso-de) δ 8.29 (s, 1 H), 8.07 (s, 1 H), 7.80 (br. s, 1 H), 7.57 - 7.70 (m, 2 H), 7.53 (d, 1 H), 7.32 (t, 1 H), 7.01 (d, 1 H), 4.02 - 4.20 (m, 2 H), 4.00 (s, 3 H), 3.92 - 4.02 (m, 1 H), 2.12-2.46 (m, 3 H, ),1.86-2.06 (m, 1 H) |
174 | Chiral ΗΝΠζ Y cY °^An HzN^JYk^ 0 | P2 | L72 | 3,7 | 356 | 1H NMR (400 MHz, dmso-de) δ 8.21 (s, 1 H), 7.90 (d, 1 H), 7.73 (d, 2 H), 7.65 (s, 1 H), 7.59 (s, 1 H), 7.43 (d, 1 H), 4.92 (dt, 1 H), 4.45 - 4.60 (m, 1 H), 4.33 - 4.45 (m, 1 H), 3.88 (t, 1 H), 1.92 -2.12(m, 1 H), 1.76 (br. s, 1 H), 1.42 (t, 6 H), 1.10 (td, 1 H), 0.60 (q, 1 H) |
175 | .0 ΗΝ-γ Μ'Η Y c/ ογΥ^Ν 0 | Ρ2 | L100 | Ref. 7 | 1,7 | 356 | 1Η NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.88 (d, 1 H), 7.72 (br. s„ 1 H), 7.70 (br. s., 1 H), 7.56 (s, 1 H), 7.41 (d, 1 H), 7.20 (br. s, 1 H), 4.84 (dt, 1 H), 4.67 (d, 1 H), 4.60 (d, 1 H), 3.54 (d, 1 H), 3.39 (d, 1 H), 1.77 -1.89 (m, 1 H), 1.40 (d, 6 H), 1.36 (dd, 1 H), 0.84 (t, 1 H) |
176 | A Chiral ΗΝ.> Υ^ F Ό °Υ^ΛΝ νη2 | Ρ2 | 17342- 08-4 | commercial | 1,7,12, HPLC | 362 | 1H NMR (500 MHz, dmso-de) δ 7.98 (d, 1 H), 7.81 - 7.93 (m, 2 H), 7.77 (s, 2 H), 7.47 (dd, 1 H), 4.32 - 4.56 (m, 3 H), 3.90 4.08 (m, 1 H), 2.09 - 2.44 (m, 3 H), 1.91 - 2.05 (m, 1 H), 1.30 (dd, 6 H) |
177 | Μ- Chiral ΗΝ ) I °Υ^ί Ν 0 | Ρ1 | L10 | 2,7 | 348 | 1H NMR (400 MHz, dmso-de) δ 9.00 (s, 1 H), 8.35 (s, 1 H), 8.04 - 8.10 (m, 3 H), 7.89 (s, 2 H), 7.62 - 7.63 (d, 1 H), 4.76 - 4.790 (m, 1 H), 4.43 - 4.47 (m, 1 H), 4.18 - 4.26 (m, 1 H), 4.17 (s, 3 H), 2.64 - 2.75 (m, 1 H), 2.42-2.52 (m, 1 H), 1.65-1.71 (m, 3 H) |
178 | 0 Chiral ?—\ HN 5 FfF (Z 0 | P19 | 17342- 08-4 | commercial | 1,20,7 | 370 | 1H NMR (500 MHz, dmso-de) δ 8.24 (s, 1 H), 8.16 - 8.21 (m, 2 H), 8.12 (d, 2 H), 7.79 (s, 1 H), 7.55 (d, 1 H), 4.54 (dd, 1 H), 4.30 (dd, 1 H), 3.94-4.12 (m, 1 H), 2.13-2.34 (m, 3 H), 1.81 - 1.99 (m, 1 H) |
179 | 0 OH Chiral /Λ HN y> Y 0^ °γγ^Ν 0 | P2 | L14 | 1,7, HPLC | 360 | 1H NMR (500 MHz, dmso-de) δ 8.21 (br. s, 1 H), 8.19 (s, 1 H), 7.88 (d, 1 H), 7.73 (br. s., 1 H), 7.70 (br. s., 1 H), 7.60 (s, 1 H), 7.41 (d, 1 H), 4.89 (dt, 1 H), 4.45 (dd, 1 H), 4.31 (dd, 1 H), 4.27 (t, 1 H), 3.94 - 4.04 (m, 1 H), 2.30 (ddd, 1 H), 2.04 (dt, 1 H), 1.40 (dd, 7H) | |
180 | Y Chiral γ % °Ύ^Ύ^Ν Η2ΝγΑΑΑ 0 | P2 | 122663- 19-8 | Ref. 30 | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.90 (d, 1 H), 7.72 (br. s, 2 H), 7.46 (s, 1 H), 7.43 (d, 1 H), 4.80 (dt, 1 H), 4.72 (dd, 1 H), 4.49 (dd, 1 H), 3.88 - 4.14 (m, 1 H), 2.81 (s, 3 H), 2.35 2.47 (m, 1 H), 2.18-2.35 (m, 2 H), 1.86-2.10 (m, 1 H), 1.41 (d, 6 H) |
181 | o^-Àh hn~) Y % °γγ^Ν 0 | P2 | L20 | 1,7 | 444 | 1H NMR (400 400 MHz, dmso-de) δ 8.13 - 8.25 (m, 2 H), 7.83 - 7.97 (m, 1 H), 7.67 - 7.77 (m, 2 H), 7.56 - 7.68 (m, 1 H), 7.42 (dd, 1 H), 4.78 - 5.02 (m, 1 H), 4.40 - 4.52 (m, 1 H), 4.26 - 4.40 (m, 1 H), 3.94 (d, 1 H), 3.65 (d, 3 H), 2.53 - 2.64 (m, 1 H), 2.10 2.42 (m, 2 H), 1.84 - 2.10 (m, 2 H), 1.58 - 1.83 (m, 2 H), 1.33 - 1.46 (m, 6 H), 1.17-1.33 (m, 1 H) | |
182 | . Y Chiral χ—r*0H HN J y r °Υί N Η2ΝγΑΛ^ 0 | P2 | L21 | 2, 7, HPLC | 442 | 1H NMR (400 MHz, CDaOD) δ 8.35 (s, 1 H), 7.86-7.88 (m, 2 H), 7.34 - 7.35 (d, 1 H), 5.00 - 5.06 (m, 1 H), 4.63 - 4.67 (m, 1 H), 4.46-4.50 (m, 1 H), 4.12-4.16 (m, 1 H), 3.66-3.67 (m, 1 H), 2.69 - 2.78 (m, 2 H), 2.57 - 2.63 (m, 1 H), 2.22 - 2.27 (m, 1 H), 1.41-1.50 (m, 6H) | |
183 | VP Chiral ΗΝγΥ Y Y °ΥΥ^Ν Η2Νγ1^ΐΥ 0 | P2 | L39 | 2,7 | 394 | 1H NMR (400 MHz, dmso-de) δ 9.32 (s, 1 H), 8.24 (s, 1 H), 7.95 - 7.94 (d, 1 H), 7.77 (s, 2 H), 7.66 (s, 1 H), 7.50 - 7.48 (d, 1 H), 4.87 - 4.85 (m, 1 H), 4.61 - 4.58 (m, 1 H), 4.42 - 4.41 (m, 1 H), 4.20 (s, 1 H), 3.09 - 3.04 (m, 1 H), 1.44 - 1.43 (d, 6 H), 1.23 1.21 (d, 3H). |
239
184 | Y Chiral y—v««OH HN 5 cY °YY^N 0 | P2 | L21 | 2, 7, HPLC | 442 | 1H NMR (400 MHz, CDsOD) δ 8.24 (s, 1 H), 7.78 - 7.80 (d, 1 H), 7.67 (s, 1 H), 7.24 - 7.26 (d, 1 H), 4.86 - 4.91 (m, 1 H), 4.57 - 4.6 (m, 1 H), 4.29 - 4.33 (m, 2 H), 2.67 - 2.73 (m, 1 H), 2.33 2.47 (m, 2 H), 2.13-2.19 (m, 1 H), 1.37-1.39 (m, 6 H). | |
185 | \νζ Chiral HN Z λ Y cY 0 | P2 | L106 | 7,2 | 359 | 1H NMR (500 MHz, dmso-d6) δ 8.18 (s, 1 H), 7.87 (d, 1 H), 7.76 (br. s, 1 H), 7.68 (br. s, 1 H), 7.62 (s, 1 H), 7.41 (d, 1 H), 4.91 (dt, 1 H), 4.45 (dd, 1 H), 4.32 (dd, 1 H), 4.03 (dd, 1 H), 3.47 - 3.58 (m, 1 H), 3.28 (dd, 1 H), 2.68 (s, 3 H), 1.31 - 1.45 (m, 6 H) | |
186 | Ÿ> Y οχ7 °Ύ^Αν 0 | P2 | L107 | 7, 2,9 | 384 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.86 - 7.91 (m, 2 H), 7.71 (br. s., 2 H), 7.49 (s, 1 H), 7.40 (d, 1 H), 5.29 (t, 1 H), 4.80 (quin, 1 H), 2.52 - 2.60 (m, 1 H), 2.22 - 2.38 (m, 3 H), 1.79 -1.96 (m, 3 H), 1.70 -1.79 (m, 2 H), 1.60 -1.71 (m, 1 H), 1.40 (dd, 6 H) |
187 | Chiral Y 0 H2N J 0 | y HNV Q | F y Y •Ά y | P2 | L38 | 2,7 | 376 | 1H NMR (400 MHz, dmso-de) δ 8.72 (s, 1 H), 8.18 (s, 1 H), 7.84 - 8.01 (m, 1 H), 7.63 - 7.84 (m, 3 H), 7.42 (d, 1 H), 4.80 - 5.10 (m, 2 H), 4.55 (dd, 1 H), 4.30 (dd, 1 H), 4.04 (m, 1 H), 1.31 - 1.44 (m, 6 H), 1.09 (d, 3 H) | |
y | |||||||||
188 | Chiral | HN I | k Y | P1 | L37 | 2,7 | 348 | 1H NMR (400 MHz, dmso-de) δ 8.65 (s, 1 H), 8.12 - 8.23 (m, 1 H), 7.92 (d, 1 H), 7.84 (s, 1 H), 7.71 (br. s, 1 H), 7.29 - 7.53 (m, | |
I CL | 2 H), 4.91 - 5.21 (m, 1 H), 4.47 (s, 2 H), 3.89 - 4.11 (m, 4 H), | ||||||||
ΗζΝυΥ 0 | 0 | 2.65 - 2.86 (m, 1 H), 1.03 - 1.28 (m, 3 H) | |||||||
Y | F / | ||||||||
Chiral | HN | X | 1H NMR (400 MHz, dmso-de) δ 8.78 (s, 1 H), 8.61 - 8.90 (m, 1 | ||||||
H), 8.12 - 8.13 (m, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.71 | |||||||||
189 | I | Y | P1 | L38 | 3,7 | 348 | (br. s., 2 H), 7.45 (d, 1 H), 4.78 - 5.13 (m, 1 H), 4.58 (dd, 1 H), | ||
CL | Ύ | 4.30 (dd, 1 H), 4.03 - 4.11 (m, 1 H), 3.99 (s, 3 H), 2.75 - 3.03 | |||||||
ΗζΝΆ 0 | M | Y | (m, 1 H), 1.11 (dd, 3H) |
190 | 0 Chiral HnO Y Y °γ^ΑΝ NH2 h N | P2 | 17342- 08-4 | commercial | 1,7,15, 20 | 369 | 1H NMR (500 MHz, dmso-de) δ 8.56 (s, 1 H), 8.13 - 8.25 (m, 2 H), 7.80 - 7.98 (m, 2 H), 7.76 (s, 1 H), 4.99 (dt, 1 H), 4.59 (dd, 1 H), 4.41 (dd, 1 H), 4.07 (d, 1 H), 2.14 - 2.39 (m, 4 H), 1.79 2.00 (m, 1 H), 1.42 (dd, 6 H) |
191 | Y ?'Ynh Y-Y 0 | P2 | 644971- 22-2 | commercial | 1,7, 10 | 330 | Rt = 2.175 min; method PF-AB01 |
192 | °~7 Chiral °γΛ0Η hnT) V Y 0YV^N HaN^JU^Y^ 0 | P2 | L22 | 2,7 | 416 | 1H NMR (500 MHz, dmso-de) δ 8.31 (s, 1 H), 8.14 - 8.22 (m, 1 H), 7.88 (d, 1 H), 7.66 - 7.79 (m, 3 H), 7.41 (d, 1 H), 5.96 (s, 1 H), 4.98 (dt, 1 H), 4.84 (d, 1 H), 4.40 - 4.62 (m, 4 H), 4.25 (dd, 1 H), 4.00 (dd, 1 H), 2.96 - 3.11 (m, 1 H), 2.29 - 2.43 (m, 1 H), 1.65-1.83 (m, 1 H), 1.31 -1.46 (m, 6 H) |
242
193 | °~7 0 YoH Chiral y—C HN 5 Y °YY^N 0 | P2 | L22 | 2,7 | 416 | 1H NMR (500 MHz, dmso-de) δ 8.21 (s, 1 H), 8.15 (s, 1 H), 7.90 (d, 1 H), 7.73 (d, 2 H), 7.65 (s, 1 H), 7.43 (d, 1 H), 5.96 (s, 1 H), 4.93 (dt, 1 H), 4.83 (d, 1 H), 4.54 (d, 1 H), 4.40 - 4.52 (m, 3 H), 4.32 (dd, 1 H), 3.96 (d, 1 H), 3.11 (t, 1 H), 2.01 -2.24 (m, 2 H), 1.40 (dd, 6H) | |
194 | M- Chiral HN 3 h2nYLY^J 0 | P5 | L10 | 5,13, 14 | 347 | 1H NMR (500 MHz, dmso-de) δ 8.75 (s, 1 H), 8.29 (s, 1 H), 7.79 (br. s., 1 H), 7.69 (s, 1 H), 7.62 (br. s., 1 H), 7.54 (d, 1 H), 7.31 (t, 1 H), 7.01 (d, 1 H), 4.16 - 4.31 (m, 1 H), 3.93 - 4.09 (m, 5 H), 2.23 - 2.40 (m, 1 H), 1.36- 1.59 (m, 3 H) | |
195 | 0 chiral ηνΠ Y O °Yy^n NH* Y2 | P2 | 17342- 08-4 | commercial | 1,7,15, 20, 9 | 373 | 1H NMR (500 MHz, dmso-de) δ 8.35 (s, 1 H), 8.11 (s, 1 H), 7.92 (s, 1 H), 7.63 - 7.83 (m, 3 H), 4.93 (dt, 1 H), 4.48 (dd, 1 H), 4.33 (dd, 1 H), 4.22 (br. s., 2 H), 4.04 (br. s., 2 H), 2.17 - 2.35 (m, 3 H), 1.85 - 1.99 (m, 1 H), 1.33 -1.48 (m, 6 H) |
196 | 0 F Chiral y—ç hn.54^/ I i °Ύ^ί N 0 | 378 | 1H NMR (600 MHz, dmso-d6) δ 8.85 (s, 1H), 8.17 (s, 1H), 7.91 (d, 1H), 7.85 (br. s, 1H), 7.71 (s, 2H), 7.45 (d, 1H), 4.58 (dd, 1H), 4.48 (d, 1H), 4.30 (dd, 1H), 3.98 (s, 3H), 3.87 (dd, 1H), 1.72 (q, 2H), 1.01 (t, 3H). | ||||
197 | <λ >F Chiral \—( HN^V JSdh I ? °Ύ^ι N 0 | 378 | Major Diastereomer: 1H NMR (600 MHz, dmso-d6) δ 9.25 (s, 1H), 8.18 (s, 1H), 7.92 (d, 1H), 7.6 (s, 1 H), 7.72 (s, 1H), 7.6 (s, 1H), 7.54 (s, 1H), 4.96 (dd, 1H ), 4.5 (dd, 2H), 3.98 (s, 3H), 2.47 (m, 1H), 1.67 (m, 1H), 0.99 (t, 3H). Minor Diastereomer: 1H NMR (600 MHz, dmso-d6) δ 9.18 (s, 1H), 8.16 (s, 1H), 7.91 (d, 1H), 7.83 (s, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.44 (s, 1H), 5.14 (dd, 1H ), 4.5 (dd, 2H), 3.92 (s, 3H), 2.39 (m, 1H), 1.58 (m, 1H), 0.99 (t, 3H). | ||||
198 | °k >F Chiral \( ΗΝγΎ I OH I ? °y^i n 0 | 378 | 1H NMR (600 MHz, dmso-d6) δ 9.0 (s, 1H), 8.17 (s, 1H), 7.91 (d, J 1H), 7.86 (br s, 1H), 7.76 (s, 1H), 7.71 (bs, 1H), 7.44 (d, 1H), 4.94 (d, 1H), 4.83 (dd, 1H), 4.60 (dd, 1 H), 4.26 (dd, 1H), 4.07 (m, 1H), 3.99 (m, 1H), 3.916 (m, 1H), 2.56 (m, 1H), 1.23 (d, 3H). |
199 | Chiral | H°b YY | P14 | 17342- 08-4 | commercial | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.01 - 8.25 (m, 2 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.74 (br. s„ 1 H), 7.44 (d, 1 H), 7.14 (s, 1 H), 5.52 (quin, 1 H), 4.91 - 5.18 (m, 2 H), 4.72 (dd, 1 H), 4.65 (dd, 1 H), 4.38 - 4.48 (m, 1 H), 4.34 (dd, 1 H), 3.94 - 4.13 (m, 1 H), 2.10 - 2.41 (m, 3 H), 1.84 - 2.00 (m, 1 H) | |
CL Η2Ν.Χ· 0 | Y -xY | ||||||||
Chiral | °Y | ||||||||
HN 5 | 1H NMR (500 MHz, dmso-de) δ 8.15 (s, 1 H), 8.01 (s, 1 H), 7.93 | ||||||||
200 | \Y | P12 | 17342- | commercial | 1.7 | 358 | (d, 1 H), 7.79 (s, 1 H), 7.71 (br. s., 2 H), 7.44 (d, 1 H), 4.32 - | ||
ο | 08-4 | 4.47 (m, 2 H), 3.95 - 4.10 (m, 1 H), 2.11 - 2.39 (m, 3 H), 1.89 - | |||||||
Y | Ύ | ||||||||
2.05 (m, 1 H), 1.44 (s, 9 H) | |||||||||
Η2ΝχΥ· 0 | ΥΥ | ||||||||
jJf | |||||||||
Chiral | H A | 1H NMR (400 MHz, dmso-de) δ 9.32 (s, 1 H), 8.24 (s, 1 H), 7.94 | |||||||
Ί | L | - 7.96 (d, 1 H), 7.77 (s, 2 H), 7.66 (s, 1 H),7.49 - 7.50 (d, 1 H), | |||||||
201 | Y | Ό | P2 | L40 | 2,7 | 408 | 4.85 - 4.87 (m, 1 H), 4.59 - 4.61 (m, 1 H), 4.40 - 4.43 (m, 1 H), | ||
CL | X | Λν | 4.20 (s, 1 H), 3.04 - 3.09 (m, 1 H), 1.43 - 1.44 (d, 6 H), 1.22 - | ||||||
h2nY 0 | XY | 1.23 (m, 3H) |
245
202 | Chiral Y °v 0 | ^y | o y-NH hnY Q> Ύ | P2 | L108 | 7,1 | 345 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.88 (d, 1 H), 7.63 - 7.82 (m, 3 H), 7.41 (d, 1 H), 6.76 (s, 1 H), 6.26 (s, 1 H), 4.95 (dt, 1 H), 4.45 (dd, 1 H), 4.33 (dd, 1 H), 4.11 (dq, 1 H), 3.56 (t, 1 H), 3.25 (dd, 1 H), 1.32-1.44 (m, 6 H) | |
% | / | ||||||||
Chiral | 4 | ?..... | 1H NMR (400 MHz, dmso-de) δ 8.71 (s, 1 H), 8.17 (s, 1 H), 7.91 | ||||||
203 | 1 Οχ | *-o | P1 | L90 | 2, 7 | 348 | (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.65 (s, 1 H), 7.45 (d, 1 H), 4.75 - 4.99 (m, 1 H), 4.66 (dd, 1 H), 4.35 (dd, 1 H), | ||
h2n^ 0 | Y N Ay | 3.97 (s, 3 H), 3.62 (dt, 1 H), 2.27 - 2.46 (m, 1 H), 1.28 (d, 3 H) | |||||||
Chiral A | °b | 17^49. | 1H NMR (500 MHz, dmso-de) δ 8.08 - 8.29 (m, 2 H), 7.80 - 7.95 (m, 2 H), 7.77 (br. s., 1 H), 7.62 (s, 1 H), 7.43 (d, 1 H), 4.49 (dd, | ||||||
204 | Y | Q> | P11 | 08-4 | commercial | 1,7 | 356 | 1 H), 4.28 (dd, 1 H), 4.09 - 4.21 (m, 1 H), 3.92 - 4.09 (m, 2 H), | |
CL | /Y | An | 2.10-2.40 (m, 3H), 1.81-1.97 (m, 1 H), 1.27-1.45 (m, 1 H), | ||||||
0 | Ay | 0.58 - 0.70 (m, 2 H), 0.34 - 0.49 (m, 2 H) |
205 | °H70H Chiral ΗΝ 3 1 I 0 | Ρ1 | L18 | 3, 7,9 | 364 | 1Η NMR (400 MHz, dmso-de) δ 8.79 (br. s, 1 Η), 8.16 (s, 1 Η), 7.90 (d, 1 Η), 7.84 (br. s., 1 H), 7.70 (s, 2 H), 7.44 (d, 1 H), 5.31 (t, 1 H), 4.60 (dd, 1 H), 4.27 (dd, 1 H), 3.98-4.10 (m, 1 H), 3.97 (s, 3 H), 3.56 - 3.72 (m, 1 H), 2.69 - 2.85 (m, 1 H), 2.06 - 2.21 (m, 1 H) | |
206 | ο Chiral ΗΝ 5 1 1 Η2ΝγΜΥΝ Ο | Ρ24 | 17342- 08-4 | commercial | 6,7 | 316 | 1H NMR (400 MHz, dmso-de) δ 8.91 (s, 1 H), 8.41 (s, 1 H), 8.14 (br. s„ 2 H), 7.83 (br. s., 1 H), 7.70 (br. s„ 1 H), 7.53 (s, 1 H), 4.21 -4.24(m, 1 H), 4.11-4.15 (m, 1 H), 4.04-4.06 (m 1 H), 4.02 (s, 3 H), 2.20 - 2.35 (m, 3 H), 1.0 - 1.93 (m, 1 H) |
207 | 0 F Chiral —V AdH ΗΝ γ> 1 1 0 | Ρ5 | L18 | 5,9 | 363 | 1H NMR (400 MHz, dmso-de) δ 8.75 (br. s, 1 H), 8.48 (br. s, 1 H), 8.28 (s, 1 H), 7.78 (br. s, 1 H), 7.68 (s, 1 H), 7.62 (br. s., 1 H), 7.54 (d, 1 H), 7.32 (t, 1 H), 7.02 (d, 1 H), 4.23 (dd, 1 H), 3.99 - 4.11 (m, 2 H), 3.97 (s, 3 H), 3.59 - 3.71 (m, 2 H), 2.72 - 2.88 (m, 1 H), 2.07-2.28 (m, 1 H) |
247
208 | οχ Γ0Η H~F Chiral Η N./-'*· I I °ΊΎι μ Η2Ν χγγΥΥ Ο | P1 | L41 | 2,7, 9 | 378 | 1H NMR (400 MHz, dmso-de) δ 8.85 (s, 1 H), 8.15 (s, 1 H), 7.79 - 7.97 (m, 1 H), 7.61 - 7.77 (m, 2 H), 7.43 (d, 1 H), 5.25 (br. s., 1 H), 4.57 (dd, 1 H), 4.27 (dd, 1 H), 3.97 (s, 3 H), 3.49 - 3.80 (m, 2 H), 2.80 - 3.04 (m, 1 H), 1.13 (s, 3 H) | |
209 | 0 Chiral ΗνΟ I l °ΊΥι Ν Η2ΝγΜΥ 0 | P3 | 17342- 08-4 | commercial | 2,7 | 317 | 1H NMR (400 MHz, dmso-de) δ 8.71 (s, 1 H), 8.22 (br. s, 1 H), 8.03 (s, 1 H), 7.91 (br. s., 1 H), 7.76 (br. s., 1 H), 7.62 (s, 1 H), 4.62 (dd, 1 H), 4.31 - 4.42 (m, 1 H), 4.03 - 4.12 (m, 1 H), 4.00 (s, 3 H), 2.14 - 2.37 (m, 3 H), 1.85 -1.94 (m, 1 H) |
210 | ο Γ°Η y--Al F Chiral I i °Ύ^ι N ΗζΝχΥΥΥ 0 | P1 | L42 | 2, 7,9 | 378 | 1H NMR (400 MHz, dmso-de) δ 9.01 (s, 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.71 (s, 2 H), 7.43 (d, 1 H), 5.36 (br. s., 1 H), 4.63 (dd, 1 H), 4.34 - 4.50 (m, 1 H), 4.07 - 4.24 (m, 1 H), 4.02 (s, 3 H), 3.68 (d, 2 H), 2.77 - 3.04 (m, 1 H), 1.21 (d, 3H) |
211 | 0 Chiral HnC, I I 0 | P1 | L36 | 2,7 | 330 | 1H NMR (400 MHz, dmso-dB) δ 8.15 (s, 1 H), 8.03 (s, 1 H), 7.90-7.94 (m, 1 H), 7.85 (s, 1 H), 7.71 (s, 1 H), 7.57 (s, 1 H), 7.42 - 7.44 (m, 1 H), 4.40 - 4.49 (m, 2 H), 3.97 (s, 3 H), 3.91 - 3.94 (m, 1 H), 2.66 - 2.72 (m, 1 H), 2.28 - 2.34 (m, 1 H), 2.06 - 2.12 (m, 1 H), 1.07-1.08 (m, 3 H). | |
212 | chirai hb).....zoh Y cY °ΊίΑ^Ν nh2 | P2 | L43 | 1,7,9 | 374 | 1H NMR (500 MHz, dmso-de) δ 8.14 - 8.31 (m, 1 H), 8.06 (s, 1 H), 7.83 - 7.98 (m, 1 H), 7.63 - 7.82 (m, 3 H), 7.42 (d, 1 H), 4.83 - 5.02 (m, 1 H), 4.50 (dd, 1 H), 4.34 (dd, 1 H), 3.82 (br. s., 1 H), 3.47 (br. s., 2 H), 2.32 - 2.47 (m, 2 H), 2.03 (dd, 1 H), 1.35 - 1.46 (m, 6H) | |
213 | cMral °HY γ ό AvA HznAAA 0 | P2 | L109 | 1,7, 9, 21 | 399 | 1H NMR (400 MHz, dmso-de) δ 9.73 (s, 1H), 8.18 - 8.19 (d, 1 H), 8.13 (s, 1 H), 7.87 - 7.90 (m, 2 H), 7.57 - 7.59 (d, 1H), 7.41 7.44 (m, 1 H), 4.85 - 4.90 (m, 1 H), 4.37 - 4.47 (m, 2 H), 3.80 3.91 (m, 1 H), 3.49 - 3.52 (m, 1 H), 3.03 - 3.16 (m, 3 H), 2.73 - 2.87 (m, 2 H), 2.32 - 2.49 (m, 3 H), 1.37 -1.41 (m, 6 H) |
249
214 | Chiral I °ϊΊ νη2 | H°b CF Y | ...z0H | P1 | L43 | 1,7,9 | 346 | 1H NMR (500 MHz, dmso-de) δ 8.17 (s, 1 H), 8.10 (s, 1 H), 7.83 - 7.98 (m, 2 H), 7.60 - 7.76 (m, 2 H), 7.43 (d, 1 H), 4.52 (dd, 1 H), 4.33 (dd, 1 H), 4.00 (s, 3 H), 3.78 - 3.87 (m, 1 H), 3.48 (d, 2 H), 2.30 - 2.49 (m, 2 H), 2.02 (dd, 1 H) | |
Chiral | «b | Π / T| | 1H NMR (400 MHz, CDeOD) δ 8.35 (s, 1 H), 7.91 - 7.92 (d, 1 | ||||||
215 | CK η2ν 0 | L €C | 0 Y | P1 | L23 | 2,7 | 366 | H), 7.82 (s, 1 H), 7.37 - 7.39 (d, 1 H), 4.63 - 4.86 (m, 3 H), 4.44 - 4.48 (m, 1 H), 4.22 - 4.24 (m, 1 H), 4.08 (s, 3 H), 2.89 - 3.00 (m, 1 H), 2.40 - 2.58 (m, 1 H). | |
Chiral | °> | ||||||||
HNX | f | 1H NMR (400 MHz, CDCb) δ 8.61 (s, 1 H), 7.38 - 7.51 (m, 2 H), | |||||||
216 | Ox | J | P5 | L36 | 5 | 329 | 7.23 (t, 3 H), 6.82 (d, 1 H), 4.16 - 4.26 (m, 1 H), 4.04 (dd, 4 H), | ||
I ι ΟγΥ 0 | 2.73-2.94 (m, 1 H), 2.51 (dd, 1 H), 2.27 (dd, 1 H), 1.08-1.16 (m, 3 H) |
218 | W Chiral ΗΝ.Ύ, i Η2ΝχΑγίγ 0 | P5 | L38 | 5 | 347 | 1H NMR (500 MHz, dmso-de) δ 8.56 (s, 1 H), 8.30 (s, 1 H), 7.79 (br. s., 1 H), 7.63 (br. s., 1 H), 7.56 (d, 1 H), 7.43 (s, 1 H), 7.33 (t, 1 H), 7.07 (d, 1 H), 5.01 - 5.23 (m, 1 H), 4.30 (dd, 1 H), 4.01 (d, 4 H), 2.68 - 2.88 (m, 1 H), 1.22 (d, 3 H) | |
219 | Chiral ΗΚ~Χ Y cY θγΥ^Ν 0 | P2 | L36 | 1,7 | 358 | 1H NMR (500 MHz, dmso-de) δ 8.20 (s, 1 H), 7.97 (s, 1 H), 7.90 (d, 1 H), 7.73 (d, 2 H), 7.58 (s, 1 H), 7.43 (d, 1 H), 4.87 (dt, 1 H), 4.44 - 4.55 (m, 2 H), 3.80 - 3.99 (m, 1 H), 2.66 - 2.80 (m, 1 H), 2.33 (dd, 1 H), 2.09 (dd, 1 H), 1.31 - 1.47 (m, 6 H), 1.09 (d, 3 H) | |
220 | 0 / chiral Æ i \ 0 F | P25 | L37 | 5 | 365 | 1H NMR (400 MHz, dmso-de) δ 8.57 (s, 1 H), 8.35 (s, 1 H), 7.84 (br. s., 1 H), 7.72 (br. s., 1 H), 7.44 (s, 1 H), 7.13 (dd, 1 H), 7.01 (dd, 1 H), 5.08 (dd, 1 H), 4.28 (dd, 1 H), 3.99 (s, 3 H), 3.92 - 4.08 (m, 2 H), 2.66 - 2.83 (m, 1 H), 1.21 (d, 3 H) |
251
221 | 0 chiral I i ° ïTN ΗζΝγΑΑγ 0 | P1 | 194421- 58-4 | Ref. 31 | 1,7, HPLC | 344 | 1H NMR (500 MHz, dmso-de) δ 8.17 (s, 1 H), 8.06 (s, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.61 (s, 1 H), 7.44 (d, 1 H), 4.47-4.55 (m, 1 H), 4.42 (dd, 1 H), 3.61 (t, 1 H), 2.27 (d, 1 H), 2.04 (d, 1 H), 1.22 (s, 3 H), 1.12 (s, 3 H) |
222 | 0 Chiral hn3^ i q/ ογΥγΑΝ Η2Νγ^Υ^ΥΥ 0 | P1 | 194421- 58-4 | Ref. 31 | 1,7, HPLC | 344 | 1H NMR (500 MHz, dmso-de) δ 8.17 (s, 1 H), 8.06 (s, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.61 (s, 1 H), 7.44 (d, 1 H), 4.47 - 4.55 (m, 1 H), 4.42 (dd, 1 H), 3.61 (t, 1 H), 2.27 (d, 1 H), 2.04 (d, 1 H), 1.22 (s, 3 H), 1.12 (s, 3 H) |
223 | 0 Chiral HN^Y v °/= h2n^JAAyA 0 | P2 | 194421- 58-4 | Ref. 31 | 1,7, HPLC | 372 | 1H NMR (500 MHz, dmso-de) δ 8.19 (s, 1 H), 7.99 (s, 1 H), 7.89 (d, 1 H), 7.70 (s, 1 H), 7.73 (s, 1 H), 7.60 (s, 1 H), 7.41 (d, 1 H), 4.77 - 4.94 (m, 1 H), 4.34 - 4.54 (m, 2 H), 3.52 - 3.64 (m, 1 H), 2.24 (d, 1 H), 2.03 (d, 1 H), 1.38 (d, 3 H), 1.40 (d, 3 H), 1.21 (s, 3 H), 1.10 (s, 3 H) |
252
224 | Ύ Chiral 1 ? ογΛΝ 0 | P1 | L110 | 7,2, HPLC | 355 | 1H NMR (500 MHz, dmso-de) δ 8.50 (s, 1 H), 8.17 (s, 1 H), 7.91 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.67 (s, 1 H), 7.44 (d, 1 H), 4.63 (dd, 1 H), 4.24 (dd, 1 H), 4.05 (m, 1 H), 3.99 (s, 3 H), 2.67 - 2.84 (m, 3 H), 1.66 -1.74 (m, 1 H) | |
225 | 0 / -Ν Chiral ηνΠ ι °Ύ^Αν 0 | P1 | L110 | 7,2, HPLC | 355 | 1H NMR (500 MHz, dmso-de) δ 8.46 (s, 1 H), 8.17 (s, 1 H), 7.91 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.60 (s, 1 H), 7.44 (d, 1 H), 4.49 (dd, 1 H), 4.37 (dd, 1 H), 4.05 (m, 1 H), 3.99 (s, 3 H), 2.96 (m, 1 H), 2.73 - 2.80 (m, 2 H), 2.29 (m, 1 H), 2.12 (m, 1 H) | |
226 | Chiral 'W'^n Y Y °ΥυΛν 0 | P2 | L111 | 2, 7, 10 | 385 | 1H NMR (400 MHz, dmso-de) δ 9.51 (s, 1 H), 59.24 (s, 1 H), 58.44 (s, 1 H), 58.20 (s, 1 H), 7.90-7.88 (d, 1 H), 7.72 (s, 2 H), 57.57 (s, 1 H), 7.44-7.43 (d, 1 H), 4.91 -4.81 (m, 1 H), 4.48 - 4.47 (m, 2 H), 3.98 - 3.92 (m, 1 H), 3.55 - 3.47 (m, 1 H), 3.37 - 3.25 (m, 3 H), 3.20 - 3.16 (m, 1 H), 3.08 - 3.02 (m, 1 H), 1.41 -1.35 (m, 6 H) |
253
227 | Vo Chiral / \ Ηγ,,„ 1 0 | P1 | 127913- 30-8 | Ref. 32 | 2,7 | 332 | 1H NMR (400 MHz, dmso-de) δ 8.07 (s, 1 H), 7.93 (s, 1 H), 7.77 - 7.81 (m, 2 H), 7.61 (s, 1 H), 7.51 (s, 1 H), 7.34 - 7.35 (d, 1 H), 4.49 - 4.52 (m, 1 H), 4.38 - 4.41 (m, 1 H), 4.30 - 4.34 (m, 1 H), 3.87 (s, 3 H), 3.74 - 3.75 (m, 1 H), 1.29 - 1.30 (d, 3 H) |
228 | y° Chiral HN^X,,, 1 1 θγ%Α η2νΥΑΑΑ 0 | P5 | 127913- 30-8 | Ref. 32 | 6 | 331 | 1H NMR (400 MHz, dmso-de) δ 8.29 (s, 1 H), 7.99 (s, 1 H), 7.79 (br. s, 1 H), 7.64 (br. s, 1 H), 7.61 (s, 1 H), 7.54 (d, 1 H), 7.32 (t, 1 H), 7.01 (d, 1 H), 4.63 (quin, 1 H), 4.19 (d, 2 H), 3.85 (m, 1 H), 1.43 (d, 1 H) |
229 | 0 Chiral Γ°\ HNY i q/ °υ%Λν O | P1 | 15546- 08-4 | Ref. 17 | 2,7 | 318 | 1H NMR (400 MHz, dmso-de) δ 8.18 (m, 1 H), 8.08 (m, 1 H), 7.87 - 7.92 (m, 2 H), 7.73 (m, 1 H), 7.63 (m, 1 H), 7.45 - 7.46 (m, 2 H), 4.49 - 4.52 (m, 2 H), 4.38 - 4.417 (m, 1 H), 4.28 - 4.32 (m, 2 H), 3.98 1 (s, 3 H) |
254
230 | Chiral | V° HNy> <y Y^N x^Y | P1 | 15546- 08-4 | Ref. 17 | 6 | 318 | 1H NMR (400 MHz, dmso-de) δ 8.18 (m, 1 H), 8.08 (m, 1 H), 7.87 - 7.92 (m, 2 H), 7.73 (m, 1 H), 7.63 (m, 1 H), 7.45 - 7.46 (m, 2 H), 4.49-4.52 (m, 2 H), 4.38-4.417 (m, 1 H), 4.28 - 4.32 (m, 2 H), 3.98 1 (s, 3 H) | |
I °x HzN^Y 0 | c | ||||||||
\ 0 o | |||||||||
Chiral | hH | 1H NMR (400 MHz, dmso-de) δ 8.44 (s, 1 H), 68.28 (s, 1 H), | |||||||
npixY | 6 | 7.80 (s, 1 H), 7.67 - 7.65 (m, 2 H), 7.54 - 7.52 (m, 1 H), 7.33 - | |||||||
231 | | | cr | P5 | L25 | u> HPLC | 345 | 7.29 (m, 1 H), 7.01-7.00 (m, 1 H),4.20 - 4.19 (m, 1 H), 4.03- | ||
0 | Y | 3.94 (m, 6 H), 3.44 (s, 3 H), 2.61 - 2.58 (m, 1 H), 1.85 - 1.84 | |||||||
H2N^J 0 | U | γ | (m, 1 H) | ||||||
D 0— | |||||||||
Chiral | hnD | 1H NMR (400 MHz, dmso-de) δ 8.35 (s, 1 H), 68.29 (s, 1 H), | |||||||
6 | 7.80 (s, 1 H), 7.65 (s, 1 H), 7.55 - 7.54 (m, 2 H), 7.34 - 7.30 | ||||||||
232 | I A | CT | P5 | L25 | Ul HPLC | 345 | (m, 1 H), 7.02-7.00 (m, 1 H), 4.19-4.15 (m, 1 H), 4.12-4.10 | ||
(J.___ . | Y/ | Ί | (m, 2 H), 4.01 (s, 3 H), 3.46 (s, 3 H), 2.41 -2.33 (m, 1 H), 2.17 | ||||||
H2NxJt 0 | Y | sY | -2.13 (m, 1 H) |
255
233 | v° Chiral HN\) 1 l ΟγγΙ 0 | P5 | 15546- 08-4 | Ref. 17 | 6 | 317 | 1H NMR (400 MHz, dmso-de) δ 8.29 (m, 1 H), 8.01 (m, 1 H), 7.80 (m, 1 H), 7.62-7.65 (m,2H), 7.53-7.55 (m, 1 H), 7.007.02 (m, 1 H), 4.50-4.52(s, 1 H), 4.36-4.37 (s, 1 H), 4.34 (m, 1 H), 4.17-4.18 (m, 2 H), 3.98 (s, 3 H) |
234 | v° chiral hnAX Ô-yyA 0 | P5 | L112 | 5 | 331 | 1H NMR (400 MHz, CDsOD) δ 8.45 (s, 1 H), 7.72 (s, 1 H), 7.49 (d, 1 H), 7.32 (t, 1 H), 7.00 (d, 1 H), 4.97 - 5.07 (m, 1 H), 4.32 (dd, 1 H), 4.23 (dd, 1 H), 4.14 - 4.20 (m, 1 H), 4.08 (s, 3 H), 1.51 (d, 3H) | |
235 | oK V-nh Chiral θχ/' 1 f HaN^JÎ^A^ 0 | P1 | 97859- 49-9 | Ref. 11 | 3,7 | 318 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 7.91 (d, 1 H), 7.84 (bs, 1 H), 7.70 (bs, 1 H), 7.67 (bs, 1 H), 7.53 (s, 1 H), 7.46 (d, 1 H), 5.06 (m, 1 H), 4.62 (m, 2 H), 3.96 (s, 3 H), 3.70 (m, 1 H) ,3.45 (m, 1 H) |
236 | Vo Chiral 1 l °ΊΥι N 0 | P1 | L112 | 3,7 | 332 | 1H NMR (400 MHz, dmso-de) δ 8.16 (s, 1 H), 7.91 (d, 1 H), 7.89 (s, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.62 (s, 1 H), 7.44 (d, 1 H), 4.87 (quin, 1 H), 4.42 - 4.53 (m, 2 H), 4.10 - 4.18 (m, 1 H), 3.97 (s, 3 H), 1.37 (d, 3 H) | |
237 | HF Chiral HNyO>, 1 1 °γγΝ η 2ΝχΛΑΑ 0 | P1 | L44 | 4,7 | 362 | 1H NMR (400 MHz, dmso-cfe) δ 8.83 (s, 1 H), 8.17 (s, 1 H), 7.85 - 7.93 (m, 2 H), 7.63 - 7.70 (m, 2 H), 7.45 - 7.46 (m, 1 H), 4.55-4.59 (m, 1 H), 4.32-4.37 (m, 1 H), 4.01 -4.16 (m, 1 H), 4.00 (s, 3 H), 2.51 (m, 1 H), 1.40 -1.46 (m, 3 H), 1.09 - 1.11 (m, 3 H) | |
238 | chirai hAC. 1 1 °γγο 0 | P1 | L45 | 4,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.95 (s, 1 H), 8.16 (s, 1 H), 7.85 - 7.92 (m, 2 H), 7.69 - 7.74 (m, 2 H), 7.43 - 7.44 (m, 1 H), 4.56 - 4.59 (m, 1 H), 4.24 - 4.28 (m, 1 H), 4.00 - 4.06 (m, 1 H), 3.99 (s, 3 H), 2.51 (m, 1 H), 1.40-1.46 (m, 3 H), 1.13 - 1.15 (m, 3 H) |
257
239 | VnZ Chiral I ογΥΝ 0 | P1 | 1315020- 11-1 | commercial | 2,7 | 332 | 1H NMR (400 MHz, dmso-de) δ 8.19 (m, 1 H), 7.87-7.93 (m, 2 H), 7.73 (s, 1 H), 7.46 - 7.48 (m, 2 H), 5.00 - 5.02 (m,1 H), 4.58 - 4.68 (m, 2 H), 4.00 (s, 3 H), 3.77 - 3.81 (m, 1 H), 3.52 - 3.54 (m, 1 H), 2.83 (s,3 H) |
240 | 0 ri; Chirai Y i .γ η 2νΥ\Υ^ 0 | P5 | L26 | 6 | 415 | 1H NMR (400 MHz, CDCb) δ 8.62 (s, 1 H), 7.81 -7.82 (m, 1 H), 7.44 - 7.50 (m, 2 H), 7.22 - 7.24 (m, 1 H), 6.78 - 6.80 (m, 1 H), 6.55 (s, 1 H), 5.87 (s, 1 H), 4.03-4.22 (m, 3 H), 4.00 (s, 3 H), 2.70 - 3.07 (m, 2 H), 2.41 - 2.63 (m, 2 H) | |
241 | Y Chiral y-kF HN 5 i .γ h2nYLY^ 0 | P5 | L26 | 6 | 415 | 1H NMR (400 MHz, CDeOD) δ 8.34 (s, 1 H), 7.61 (s, 1 H), 7.40 - 7.42 (m, 1 H), 7.21 - 7.25 (m, 1 H), 6.93 - 6.95 (m, 1 H), 4.09 -4.21 (m, 3 H), 3.97 (s, 3 H), 2.23-3.03 (m, 4 H) |
242 | ChÎral Hil·^ 1 1 °Ύ^ί N 0 | P1 | L1 | 2,7, HPLC | 330 | 1H NMR (400 MHz, dmso-de) δ 8.17 - 8.21 (m, 2 H) 7.90 - 7.91 (m, 2 H), 7.68 - 7.72 (m, 2 H), 7.43 - 7.44 (m, 1 H), 4.58 - 4.60 (m, 1 H), 4.18-4.22 (m, 1 H), 4.00 (s, 4 H), 2.68 (m, 1 H), 2.34 (m, 1 H), 1.47-1.48 (m, 1 H), 1.11 - 1.13 (d, 3 H) | |
243 | ο $> Chiral / \ HN 5 l °vyan H2Nxk\Y\k 0 | P1 | L1 | 2, 7, HPLC | 330 | 1H NMR (400 MHz, CDsOD) δ 8.23 (m, 2 H), 7.78 - 7.80 (m, 1 H), 7.61 (m, 1 H), 7.25 - 7.26 (m, 1 H), 4.39 - 4.47 (m, 2 H), 4.04 - 4.05 (m, 1 H), 3.98 (s, 3 H), 2.63 - 2.65 (m, 1 H), 2.27 (m, 1 H), 1.94-1.98 (m, 1 H), 1.12-1.14 (d, 3 H) | |
244 | 0 Chiral / \ . 1 0 | P1 | L46 | 2,7 | 344 | 1H NMR (400 MHz, dmso-de) δ 8.04 (s, 1 H), 8.01 (s, 1 H), 7.75 -7.79 (m, 2 H), 7.60 (s, 1 H), 7.52 (s, 1 H), 7.31 -7.32 (m, 1 H), 4.37 - 4.48 (m, 1 H), 4.17 - 4.22 (m, 1 H), 3.87 (s, 3 H), 3.55-3.58 (m, 1 H), 2.52-2.55 (m, 1 H), 1.97-2.03 (m, 1 H), 1.77-1.82 (m, 1 H), 1.46-1.50 (m, 1 H), 1.34-1.35 (m, 1 H), 0.79-0.83 (m, 3H) |
245 | Chiral | H HN 5 CL ïl N | P1 | L27 | 2,7 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.22 (s, 1 H), 8.15 (s, 1 H), 7.90 (d, 1 H), 7.85 (br. s, 1 H), 7.70 (br. s, 1 H), 7.65 (s, 1 H), 7.42 (d, 1 H), 4.52-4.55 (m, 1 H), 4.29-4.33 (m, 1 H), 4.12 (m, 1 H), 3.99 (s, 3 H), 2.38 - 2.41 (m, 1 H), 1.97 - 2.01 (m, 1 H), 0.86 (m, 2 H), 0.75 (m, 2 H) | ||
1 °x Η2ΝΎ 0 | Y Y | ||||||||
Chiral | HN 3--/ | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 8.06 (s, 1 H), 7.86 | |||||||
-7.92 (m, 2 H), 7.73 (s, 1 H), 7.57 (s, 1 H), 7.43-7.45 (m, 1 | |||||||||
246 | | | (Y | P1 | L47 | 3,7 | 344 | H), 4.45 (d, 2 H), 3.99 (s, 3 H), 3.96 - 3.98 (m, 1 H), 2.34 - | ||
0^. || | Y | an | 2.12 (m, 3 H), 1.55-1.64 (m, 1 H), 1.35-1.45 (m, 1 H), 0.92- | ||||||
h2NxJx 0 | 0.95 (m, 3 H) | ||||||||
Chiral | H | ||||||||
ΗΝγΑ | 1H NMR (400 MHz, CDsOD) δ 8.22 (s, 1 H), 7.79 - 7.80 (m, 1 | ||||||||
247 | 1 CL Η2ΝΎ 0 | fY | c> An | P1 | L48 | 2,7, HPLC | 344 | H), 7.64 (s, 1 H), 7.24-7.25 (m, 1 H), 4.53-4.54 (m, 1 H), 4.39 - 4.41 (m, 1 H), 4.09 - 4.11 (m, 1 H), 3.99 (s, 3 H), 2.59 - 2.78 (m, 2 H), 1.05 -1.07 (m, 3 H), 0.93 - 0.95 (m, 3 H) |
248 | Chiral À | K HN CT YY | P1 | L48 | 2,7, HPLC | 344 | 1H NMR (400 MHz, CDsOD) δ 8.24 (s, 1 H), 7.79-7.81 (m, 1 H), 7.53 (s, 1 H), 7.25 - 7.27 (m, 1 H), 4.46 - 4.53 (m, 2 H), 3.96 (s, 3 H), 3.89 -3.91 (m, 1 H), 2.29-2.33 (m, 2 H), 1 .ΙΟΙ.13 (m, 6 H) | ||
HzNxY 0 | U | ||||||||
Chiral | D | ||||||||
HN | 1H NMR (400 MHz, CD3OD) δ | ||||||||
8.38 (s, 1 H), 7.91 (d, 1 H), 7.78 (s, 1 H), 7.48 (d, 1 H), 4.62 - | |||||||||
249 | 1 | cr | P1 | L49 | 2,7 | 348 | 4.66 (m, 3 H), 4.51 -4.55 (m, 1 H), 4.13-4.15 (m, 1 H), 4.11 | ||
0. Ύ | ^N | (s, 3 H), 2.83 - 2.96 (m, 1 H), 2.68 - 2.78 (m, 1 H), 2.27 - 2.32 | |||||||
Η2ΝχΑ O | Y | (m, 1 H). | |||||||
V | |||||||||
Chiral | 1H NMR (400 MHz, dmso-de) δ 10.18 (s, 1 H), 8.76 (s, 1 H), | ||||||||
250 | ! | cr | P16 | L38 | 3,7 | 348 | 8.63 (d, 1 H), 7.81 (br. s., 1 H), 7.60 - 7.71 (m, 2 H), 7.09 (d, 1 | ||
/xs | H), 4.99 (d, 1 H), 4.86 (d, 1 H), 4.30 (dd, 1 H), 4.02 - 4.19 (m, 2 | ||||||||
H2NxY 0 | c | N | H), 3.96 (s, 3 H), 2.76 - 2.99 (m, 1 H), 1.09 (d, 3 H) |
251 | Chiral I °Ύ 0 | hnT\ Vy ^Y-xY | P1 | L50 | 3,7 | 342 | 1H NMR (600 MHz, dmso-de) δ 8.16 (s, 1 H) 8.13 (s, 1 H) 7.90 (d, 1 H) 7.83 (br. s., 1 H) 7.67 - 7.71 (m, 1 H) 7.58 (s, 1 H) 7.42 (d, 1 H) 5.94 (ddd, 1 H) 5.20 (d, 1 H) 5.11 (d, 1 H) 4.40 - 4.46 (m, 1 H) 4.30 - 4.38 (m, 1 H) 4.01 - 4.09 (m, 1 H) 3.32 - 3.41 (m, 1 H) 2.37 - 2.47 (m, 1 H) 2.27 - 2.36 (m, 1 H) | ||
Z | |||||||||
Chiral | HN | 1H NMR (400 MHz, dmso-de) δ 8.90 (s, 1 H), 8.35 (s, 1 H), 8.09 | |||||||
ï | 2, 7, | (d, 1 H), 8.05 (br, s, 1 H), 7.90 (br. s, 1 H), 7.81 (s, 1 H), 7.63 | |||||||
252 | I π | 0 | P1 | L2 | HPLC | 334 | (d, 1 H), 5.25 - 5.42 (m, 1 H), 4.77 (dd, 1 H), 4.43 - 4.48 (m, 1 | ||
H), 4.23 (m, 1 H), 4.16 (s, 3 H), 2.85 - 3.00 (m, 1 H), 2.19 - | |||||||||
H2nX 0 | 2.32 (m, 1 H) | ||||||||
v | F | ||||||||
Chiral | HN | 1H NMR (400 MHz, dmso-de) δ 9.01 (s, 1 H), 8.36 - 8.38 (m, 1 | |||||||
T | 2, 7, | H), 8.06 - 8.12 (m, 2 H), 7.92 (br. s, 1 H), 7.77 - 7.79 (m, 1 H), | |||||||
253 | I H | 0 | P1 | L2 | HPLC | 334 | 7.65-7.66 (m, 1 H), 5.42-5.57 (m, 1 H), 4.69-4.71 (m, 1 H), | ||
[ΑΥΝ | 4.50-4.55 (m, 1 H), 4.35 (m, 1 H), 4.18-4.20 (m, 3 H), 2.53- | ||||||||
HZNXY 0 | uu | 2.62 (m, 2 H) |
262
254 | Chiral Ρ ΗΝ^Χ,,Ζ 1 ι °Ύ^ι Ν 0 | Ρ1 | L52 | 2, 7, HPLC | 362 | 1Η NMR (400 MHz, CD3OD) δ 8.32 (s, 1 Η), 7.89 (d, 1 Η), 7.73 (s, 1 Η), 7.36 (d, 1 Η), 4.66 4.73 (m, 2 Η), 4.58 - 4.62 (m, 1 Η), 4.45 - 4.49 (m, 1 Η), 4.08 (s, 3 Η), 4.01 - 4.07 (m, 1 Η), 2.43 - 2.49 (m, 1 Η), 2.32 - 2.40 (m, 1 Η), 1.29 (d, 3 Η) | |
255 | 0 Chiral Γ\ ΗΝχ> I ?' °'^Ί Ν 0 | Ρ1 | 66673- 40-3 | commercial | 3,7 | 316 | 1Η NMR (400 MHz, CD3OD) δ 8.36 (s, 1 Η), 7.92 (d, 1 Η), 7.74 (s, 1 Η), 7.38 (d, 1 Η), 4.55 - 4.66 (m, 1 Η), 4.49 (dd, 1 Η), 4.20 - 4.31 (m, 1 Η), 4.11 (s, 3 Η), 2.36 - 2.63 (m, 3 Η), 2.05 - 2.19 (m, 1 Η) |
256 | Chiral (F ΗΝ γ> 1 0 | Ρ1 | L8 | 3,7 | 362 | 1Η NMR (400 MHz, dmso-de) δ 8.92 (s, 1 H), 8.18 (s, 1 H), 7.92 (d, 1 H), 7.87 (br. s., 1 H), 7.73 (br. s„ 1 H), 7.66 (s, 1 H), 7.46 (d, 1 H), 4.63 (dd, 1 H), 4.22 - 4.30 (m, 1 H), 4.12 - 4.22 (m, 1 H), 2.39 - 2.50 (m, 1 H), 2.09 - 2.26 (m, 1 H), 1.95 (ddd, 1 H), 1.62- 1.82 (m, 1 H), 0.98 (t, 3 H) |
257 | ο £ / Chiral /—V7 HN 5 1 i °Ύ^ι N 0 | P1 | L7 | 3,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.82 (s, 1 H), 8.18 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.72 (s, 2 H), 7.45 (d, 1 H), 4.60 (dd, 1 H), 4.27 (dd, 1 H), 3.90 - 4.09 (m, 4 H), 2.59 (td, 1 H), 2.12 2.27 (m, 1 H), 1.92 (td, 1 H), 1.66 -1.81 (m, 1 H), 0.97 (t, 3 H) | |
258 | °γθ HN 3 l °YY^N Η2Νγ1γΑ 0 | P1 | L28 | 3,7 | 406 | 1H NMR (600 MHz, dmso-de) δ 8.11 - 8.22 (m, 2 H), 7.87 (d, 1 H), 7.81 (br. s., 1 H), 7.65 (br. s., 1 H), 7.58 (s, 1 H), 7.41 (d, 1 H), 7.16 - 7.32 (m, 5 H), 4.46 (dd, 1 H), 4.28 (dd, 1 H), 3.93 4.01 (m, 3 H), 3.86 - 3.93 (m, 1 H), 3.07 (dd, 1 H), 2.83 (dd, 1 H), 2.61 (dd, 1 H), 1.99 (dd, 2 H) | |
259 | 0 F Z Chiral y_£,,„/ ΗΝγ> 1 l °y^vS 0 | P16 | L7 | 3,7 | 362 | 1H NMR (500 MHz, CDeOD) δ 8.63 (d, 1 H), 8.50 (s, 1 H), 7.80 (s, 1 H), 7.05 (d, 1 H), 4.42 (dd, 1 H), 4.28 (dd, 1 H), 4.19 (dt, 1 H), 4.08 (s, 3 H), 2.68 - 2.82 (m, 1 H), 2.37 - 2.50 (m, 1 H), 2.00 -2.14(m, 1 H), 1.80-1.96 (m, 1 H), 1.09 (t, 3 H) |
260 | Chiral HN 5 0 A 0 | P16 | L8 | 3,7 | 362 | 1H NMR (500 MHz, CDeOD) δ 8.62 (d, 1 H), 8.48 (s, 1 H), 7.68 (s, 1 H), 7.06 (d, 1 H), 4.32 - 4.46 (m, 2 H), 4.24 (dd, 1 H), 4.08 (s, 3 H), 2.53 - 2.68 (m, 1 H), 2.21 - 2.36 (m, 1 H), 2.09 (ddd, 1 H), 1.74-1.90 (m, 1 H), 1.07 (t, 3 H) | |
261 | °x\ »F Chiral y—CT HN 5 I I °Ύ^ι N 0 | P1 | L24 | 3,7 | 366 | 1H NMR (400 MHz, dmso-de) δ 9.16 (s, 1 H), 8.19 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.71 (br. s„ 1 H), 7.66 (s, 1 H), 7.46 (d, 1 H), 4.78 - 4.90 (m, 1 H), 4.61 - 4.77 (m, 2 H), 4.20 - 4.36 (m, 2 H), 4.00 (s, 3 H), 2.55 - 2.67 (m, 1 H), 2.35 - 2.49 (m, 1 H) | |
262 | 0 Chiral y—y HN ) A A ΗγΑ 0 | P16 | 17342- 08-4 | commercial | 3,7 | 316 | 1H NMR (500 MHz, dmso-de) δ 8.64 (d, 1 H), 8.20 (s, 1 H), 8.16 (s, 1 H), 7.84 (br. s., 1 H), 7.68 (br. s., 1 H), 7.58 (s, 1 H), 7.04 (d, 1 H), 4.26 (dd, 1 H), 4.15 (dd, 1 H), 4.05 - 4.12 (m, 1 H), 4.00 (s, 3 H), 2.17 - 2.40 (m, 3 H), 1.89 - 1.97 (m, 1 H) |
263 | O fi Chiral %—L/^ V„' 1 T °Y^i N Η2ΝχΥΥΎ 0 | P1 | L73 | 3,7 | 356 | 1H NMR (500 MHz, CDsOD) δ 8.35 (s, 1 H), 7.91 (d, 1 H), 7.76 (s, 1 H), 7.37 (d, 1 H), 4.61 (dd, 1 H), 4.55 (dd, 1 H), 4.11 (s, 3 H), 3.94 (s, 1 H), 2.68 (s, 1 H), 1.91 (d, 1 H), 1.86 (dd, 1 H), 1.24 (s, 3 H), 1.21 (s, 3 H) | |
264 | 0 H Chiral / HNYh 1 1 °ΊΥι N h 2nYLYY 0 | P1 | L72 | 3,7 | 328 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.71 (br. s., 1 H), 7.64 (s, 2 H), 7.45 (d, 1 H), 4.49 (dd, 1 H), 4.41 (dd, 1 H), 4.01 (s, 3 H), 3.90 (t, 1 H), 1.92-2.05 (m, 1 H), 1.78 (br. s„ 1 H), 1.10 (td, 1 H), 0.60 (q, 1 H) | |
265 | A y I ? °Y^i N h2n^XAJ 0 | P1 | 1004-59- | Ref. 33 | 1,7 | 346 | Rt = 2.037 min; method PF-AB01 |
266 | 0. yo HV | P1 | 29-8-2 | Ref. 34 | 1,7 | 332 | Rt = 2.043 min; method PF-AB01 | |||
I °v | A γ- | Q> Ύ | ||||||||
h2n | Il 0 | |||||||||
Chiral | °1 HN | F ? | 1H NMR (400 MHz, dmso-d6) δ 8.50 (br. s., 1 H), 8.23 (s, 1 H), 7.97 (d, 1 H), 7.90 (br. s., 1 H), 7.76 (br. s., 1 H), 7.63 (s, 1 H), | |||||||
267 | I | 0 | P1 | L15 | 3,7 | 398 | 7.50 (d, 1 H), 4.60 (d, 1 H), 4.45 (d, 1 H), 4.08 (br. s., 1 H), 4.03 | |||
0. | ------- | 'N | (s, 3 H), 2.93 (d, 1 H), 2.75 (br. s„ 1 H), 2.37 (d, 2 H), 2.25 (br. | |||||||
Y | Ay | s., 1 H) | ||||||||
0 | ||||||||||
Chiral | 0 F y---l· mi | |||||||||
HN 3 | 1H NMR (400 MHz, dmso-de) δ 8.83 (s, 1 H), 8.65 (d, 1 H), 8.20 | |||||||||
268 | I 0. x | o> | P16 | L10 | 3,7 | 348 | (s, 1 H), 7.85 (br. s., 1 H), 7.69 (br. s., 1 H), 7.67 (s, 1 H), 7.05 (d, 1 H), 4.35 (dd, 1 H), 4.03 - 4.17 (m, 2 H), 3.99 (s, 3 H), 2.54 | |||
H2N. | Ύ 0 | Ί | N | - 2.63 (m, 1 H), 2.23 - 2.38 (m, 1 H), 1.52 (d, 3 H) |
269 | 0 F Chiral y—Ç..n HN 5 Y c> HzNyC0 0 | P15 | L10 | 3,7 | 376 | 1H NMR (400 MHz, dmso-de) δ 8.78 (s, 1 H), 8.64 (d, 1 H), 8.24 (s, 1 H), 7.63 - 7.79 (m, 3 H), 7.04 (d, 1 H), 4.90 (dt, 1 H), 4.34 (dd, 1 H), 3.99 - 4.20 (m, 3 H), 3.18 (d, 1 H), 2.54 - 2.62 (m, 1 H), 2.23 - 2.38 (m, 1 H), 1.52 (d, 1 H), 1.39 (d, 3 H), 1.41 (d, 3 H) | |
270 | F Chiral / ^F hnÇ) F l l VVy Η2Νγ^ν9 0 | P1 | L16 | 3.7 | 398 | 1H NMR (400 MHz, CDCh) δ 8.68 (s, 1 H), 7.93 (d, 1 H), 7.80 (br. s., 1 H), 7.56 (s, 1 H), 7.33 (d, 1 H), 6.39 (br. s., 1 H), 5.94 (br. s., 1 H), 4.78 (dd, 1 H), 4.39 (dd, 1 H), 4.20 (d, 1 H), 4.11 (s, 3 H), 2.76 - 3.01 (m, 2 H), 2.66 - 2.76 (m, 1 H), 2.10 (dt, 1 H), 1.69- 1.82 (m, 1 H) | |
271 | 0 H chiral ΗΝγ\ I I °TY^N 0 | P1 | L74 | 3,7 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.71 (s, 1 H), 7.64 (s, 1 H), 7.62 (s, 1 H), 7.45 (d, 1 H), 4.47 (dd, 1 H), 4.36 (dd, 1 H), 4.01 (s, 3 H), 3.87 - 3.94 (m, 1 H), 1.73-1.82 (m, 1 H), 1.59 (d, 1 H), 1.10 (d, 3 H), 0.98- 1.06 (m, 1 H) |
272 | 0 F Chiral ?—\ HNyA 1 i °Ύ^ι N JVU | P1 | L38 | 3 | 330 | 1H NMR (600 MHz, dmso-de) δ 8.72 (s, 1 H), 8.49 (s, 1 H), 7.98 (d, 1 H), 7.78 (s, 1 H), 7.41 (d, 1 H), 4.92 (dd, 1 H), 4.58 (dd, 1 H), 4.28 (dd, 1 H), 3.99 - 4.08 (m, 4 H), 2.79 - 2.92 (m, 1 H), 1.08 (dd, 3H) | |
273 | θ 0 | P1 | 3637-61- 4 | commercial | 3,7 | 301 | 1H NMR (400 MHz, dmso-de) δ 8.16 (s, 1 H), 7.89 (d, 1 H), 7.82 (br. s., 1 H), 7.68 (br. s., 1 H), 7.53 (s, 1 H), 7.39 (d, 1 H), 4.37 (d, 2 H), 3.97 (s, 3 H), 2.42 - 2.50 (m, 1 H), 1.80 - 1.85 (m, 2 H), 1.58-1.66 (m,4H), 1.40-1.46 (m, 2 H) |
274 | VX/^ Chiral / \ HN ) A Jk haLA 0 | P16 | L29 | 3,7 | 380 | 1H NMR (600 MHz, dmso-de) δ 8.88 (s, 1 H), 8.59 - 8.65 (m, 1 H), 8.17 - 8.22 (m, 1 H), 7.79 (br. s., 1 H), 7.65 (s, 1 H), 7.61 (br. s., 1 H), 7.00 - 7.05 (m, 1 H), 4.60 - 4.76 (m, 2 H), 4.30 - 4.39 (m, 1 H), 4.04 - 4.20 (m, 3 H), 3.94 - 4.00 (m, 3 H), 2.61 - 2.73 (m, 1 H), 2.13-2.36 (m, 3 H) |
275 | Chira 1 Οχ Η2ΝΥ 0 | ¥ HN^ 0^ Ιγγ | / | P1 | L3 | 3,7 | 334 | 1H NMR (400 MHz, dmso-de) δ 8.77 (s, 1 H), 8.18 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.70 (s, 2 H), 7.45 (d, 1 H), 5.16 (ddd, 1 H), 4.61 (dd, 1 H), 4.28 (dd, 1 H), 4.04 (br. s., 1 H), 3.98 (s, 3 H), 2.65 - 2.84 (m, 1 H), 1.98 - 2.18 (m, 1 H) | |
Chiral | F Y' | z^F | |||||||
HN 5 | 1H NMR (400 MHz, dmso-de) δ 8.95 (s, 1 H), 8.18 (s, 1 H), 7.92 | ||||||||
276 | 1 h2n JL o | o> YY | P1 | L29 | 3,7 | 380 | (d, 1 H), 7.86 (br. s., 1 H), 7.72 (s, 2 H), 7.45 (d, 1 H), 4.70 - 4.85 (m, 1 H), 4.54 - 4.70 (m, 2 H), 4.28 (dd, 1 H), 4.02 - 4.13 (m, 1 H), 3.99 (s, 3 H), 2.58 - 2.75 (m, 1 H), 2.12 - 2.41 (m, 3 H) | ||
Chiral | V | ||||||||
HN^ | \’// | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 8.03 (s, 1 H), 7.93 | |||||||
277 | 1 °x | 0^ | P1 | L35 | 3,7 | 330 | (d, 1 H), 7.85 (br. s., 1 H), 7.71 (br. s., 1 H), 7.60 (s, 1 H), 7.45 (d, 1 H), 4.39 - 4.55 (m, 2 H), 3.99 (s, 3 H), 3.91 - 3.97 (m, 1 H), | ||
H2NY 0 | Ί ίΓ N | 2.65 - 2.78 (m, 1 H), 2.34 (dd, 1 H), 2.11 (dd, 1 H), 1.10 (d, 3 H) |
278 | O F Chiral y—G.,,, HN 5 ï N 0 | P7 | L10 | 3,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.79 (s, 1 H), 8.17 (s, 1 H), 7.89 (d, 1 H), 7.78 (br. s., 1 H), 7.69 (s, 2 H), 7.43 (d, 1 H), 4.60 (dd, 1 H), 4.21 - 4.31 (m, 3 H), 3.99 - 4.00 (m, 1 H), 2.21 - 2.33 (m, 2 H), 1.43-1.52 (m, 6 H) | |
279 | 0 F Chiral J—( HNY 0 | P17 | L38 | 3,7 | 362 | 1H NMR (600 MHz, dmso-de) δ 8.96 (d, 1 H) 8.78 (s, 1 H) 8.30 (s, 1 H) 7.84 (br. s., 1 H) 7.82 (br. s., 1 H) 7.76 (s, 1 H) 7.48 (d, 1 H) 4.92 (dd, 1 H) 4.51 (dd, 1 H) 4.29 - 4.36 (m, 2 H) 4.23 - 4.29 (m, 1 H) 4.10-4.15 (m, 1 H) 2.85-2.95 (m, 1 H) 1.45 (t, 3 H) 1.10 (dd, 3 H) | |
280 | o. y Chiral k__F “Oh > ï OyyA, iyyUy 0 | P17 | L72 | 3,7, HPLC | 342 | 1H NMR (600 MHz, dmso-de) δ 8.98 (br. s., 1 H), 8.47 (d, 1 H), 8.32 (s, 1 H), 8.16 (s, 1 H), 6.79 (d, 1 H), 5.08 (br. s., 2 H), 4.37 (q, 2 H), 4.10 (br. s„ 1 H), 3.83 (dd, 1 H), 3.69 (dd, 1 H), 1.80 - 1.88 (m, 1 H), 1.74-1.79 (m, 1 H), 1.48 (t, 3 H), 1.26 (td, 1 H), 1.05-1.11 (m, 1 H) |
281 | Οχ >F Chiral y—< ΗΝγΑ Y °Y*An h2nA\Y\A 0 | P21 | L38 | 3,7 | 374 | 1H NMR (400 MHz, dmso-de) δ 8.67 (s, 1 H), 8.12 (s, 1 H), 8.06 (s, 1 H), 7.93 (d, 1 H), 7.66 (br. s., 2 H), 7.44 (d, 1 H), 4.99 (dd, 1 H), 4.50 (dd, 1 H), 4.42 (dd, 1 H), 3.96 - 4.12 (m, 2 H), 2.78 2.98 (m, 1 H), 1.11 (dd, 3 H), 0.89 - 1.02 (m, 2 H), 0.80 - 0.89 (m, 1 H), 0.69-0.80 (m, 1 H) | |
282 | o Chiral /Π HN > Ί i °Ύ^ι N Η2ΝχΑ^χΑ 0 | P7 | L72 | 3,7 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.91 (d, 1 H), 7.80 (br. s., 1 H), 7.73 (br. s., 1 H), 7.63 (s, 2 H), 7.44 (d, 1 H), 4.49 (dd, 1 H), 4.39 (dd, 1 H), 4.18-4.35 (m, 2 H), 3.89 (t, 1 H), 1.94-2.05 (m, 1 H), 1.77 (br. s., 1 H), 1.47 (t, 3 H), 1.10 (td, 1 H), 0.60 (q, 1 H) | |
283 | 0 F Chiral y—y HNyA A ï ΗζΝχΑγ-χΑ 0 | P7 | L38 | 3,7 | 361 | 1H NMR (400 MHz, dmso-de) δ 8.77 (s, 1 H), 8.18 (s, 1 H), 7.91 (d, 1 H), 7.79 (br. s., 1 H), 7.72 (s, 2 H), 7.44 (d, 1 H), 4.95 (dd, 1 H), 4.58 (dd, 1 H), 4.18 - 4.37 (m, 3 H), 4.05 (br. s., 1 H), 2.78 - 2.98 (m, 1 H), 1.46 (t, 3 H), 1.05-1.16 (m, 3 H) |
284 | Chiral | V HN CT Y^N \Y | 0 | P1 | L31 | 3,7 | 417 | 1H NMR (400 MHz, dmso-de) δ 8.88 (s, 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (s, 2 H), 7.43 (d, 1 H), 4.57 (dd, 1 H), 4.25 (dd, 1 H), 3.87 - 3.96 (m, 6 H), 2.62 - 2.68 (m, 1 H), 2.07-2.19 (m, 2 H), 1.70 (d, 1 H), 1.33-1.43 (m, 3 H) | ||
1 0 0 | ^γ | |||||||||
CL | H r | |||||||||
Chiral | k | K | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.92 (d, 1 H), 7.86 | |||||||
285 | 1 CL | P1 | L75 | 3,7 | 341 | (br. s., 1 H), 7.83 (s, 1 H), 7.71 (br. s., 1 H), 7.66 (s, 1 H), 7.45 (d, 1 H), 4.56 (dd, 1 H), 4.40 (dd, 1 H), 4.01 (s, 3 H), 3.74 (br. | ||||
H2N./ 0 | C | Y^N kY | s., 1 H), 1.83 - 1.98 (m, 2 H), 1.31-1.42 (m, 1 H), 1.06 (d, 3 H) | |||||||
Chiral | v | 0 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 8.16 (s, 1 H), 7.89 | |||||||
Y | (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.62 (s, 1 H), 7.42 | |||||||||
286 | Xz (y | P1 | L30 | 3,7 | 399 | (d, 1 H), 4.47 (dd, 1 H), 4.28 (dd, 1 H), 3.95 - 3.99 (m, 4 H), 3.85 (dd, 2H) 3.24-3.29 (m, 2 H), 2.02 - 2.14 (m, 1 H) 1.93- | ||||
0 | 2.02 (m, 1 H), 1.82-1.93 (m, 1 H), 1.72 (d, 1 H), 1.45 (dq, 1 | |||||||||
HaN^J- 0 | Y | XY | H), 1.20-1.38 (m, 3H) |
273
287 | Chiral | H HN 5 Q> . Λ N | P17 | L10 | 3,7 | 361 | 1H NMR (400 MHz, dmso-de) δ 8.82 (s, 1 H), 8.63 (d, 1 H), 8.20 (s, 1 H), 7.78 (br. s., 1 H), 7.70 (br. s., 1 H), 7.64 (s, 1 H), 7.03 (d, 1 H), 4.29-4.19 (m, 3 H), 4.11 - 4.05 (m, 2 H), 2.59- 2.50 (m, 1 H), 2.29 - 2.22 (m, 1 H), 1.53 -1.43 (m, 6 H) | ||
ox H2N^. 0 | O | ||||||||
Chiral | w | ||||||||
hnY„, | 1H NMR (400 MHz, dmso-de) δ 8.78 (s, 1 H), 8.17 (s, 1 H), 7.92 | ||||||||
288 | 1 Os | cY | P1 | L53 | 3,7 | 347 | (d, 1 H), 7.85 (br. s„ 1 H), 7.73 (s, 1 H), 7.71 (br. s., 1 H), 7.45 (d, 1 H), 4.95 (dd, 1 H), 4.58 (dd, 1 H), 4.30 (dd, 1 H), 4.03 - | ||
η2ν^, 0 | O | N | 4.11 (m, 1 H), 3.99 (s, 3 H), 2.79 - 2.98 (m, 1 H), 1.10 (d, 3 H) | ||||||
Chiral | Y? | 1H NMR (400 MHz, dmso-de) δ 8.26 (s, 1 H), 8.18 (s, 1 H), 7.92 | |||||||
HN | □ | (d, 1 H), 7.86 (br. s., 1 H), 7.72 (br. s., 1 H), 7.63 (s, 1 H), 7.45 | |||||||
289 | 0 | J | P1 | L20 | 3,7 | 415 | (d, 1 H), 4.66 (s, 1 H), 4.48 (dd, 1 H), 4.32 (dd, 1 H), 4.01 (s, 3 H), 3.97 (br. s., 1 H), 3.59 - 3.69 (m, 4 H), 2.61 (t, 1 H), 2.33 (dt, | ||
H | 1 H), 1.93 - 2.04 (m, 2 H), 1.71 -1.78 (m, 1 H), 1.56 -1.68 (m, | ||||||||
0 | 1 H), 1.29 (d, 1 H) |
274
290 | Γ° Chiral # ηνΓ) I ι ογνΑ υνΑΑΑΑ 0 | Ρ1 | L32 | 3,7 | 369 | 1Η NMR (400 MHz, dmso-de) δ 8.54 (s, 1 Η), 8.18 (s, 1 Η), 7.91 (d, 1 Η), 7.86 (br. s., 1 Η), 7.71 (s, 1 Η), 7.64 (s, 1 Η), 7.45 (d, 1 Η), 5.31 - 5.46 (m, 2 Η), 5.15 - 5.27 (m, 2 Η), 4.54 (dd, 1 Η), 4.27 (dd, 1 Η), 4.15 (d, 1 Η), 4.02 (s, 3 Η), 2.77 - 2.91 (m, 1 Η) | |
291 | ο Chiral / \ ΗΝγ> Η2ΝγΧΛΝ^ 0 | Ρ17 | 17342- 08-4 | commercial | 3, 7 | 329 | 1Η NMR (400 MHz, dmso-de) δ 8.63 (d, 1 H), 8.20 (s, 1 H), 8.15 (s, 1 H), 7.77 (br. s., 1 H), 7.70 (br. s., 1 H), 7.57 (s, 1 H), 7.02 (d, 1 H), 4.28-4.37 (m, 1 H), 4.18-4.28 (m, 2 H), 4.10-4.17 (m, 1 H), 4.03-4.10 (m, 1 H), 2.17-2.40 (m, 3 H), 1.87-1.97 (m, 1 H), 1.45 (t, 3 H) |
292 | Chiral /~~~° Y I ι ογγΑ 0 | Ρ1 | L33 | 3,7 | 377 | 1H NMR (600 MHz, dmso-de) δ 8.80 (s, 1 H), 8.17 (s, 1 H), 7.90 (d, 1 H), 7.80 (br. s., 1 H), 7.69 (s, 1 H), 7.63 (br. s., 1 H), 7.43 (d, 1 H), 4.59 (dd, 1 H), 4.29 (dd, 1 H), 4.03 (d, 1 H), 3.97 (s, 3 H), 3.63 (s, 1 H), 3.61 (d, 1 H), 3.35 (s, 3 H), 2.68 - 2.77 (m, 1 H), 2.14-2.25 (m, 1 H) |
293 | °\ r F Chiral y—?«,/ HN 5 A i 0 | P17 | L23 | 3,7 | 379 | 1H NMR (400 MHz, dmso-de) δ 9.04 (s, 1 H), 8.64 (d, 1 H), 8.20 (s, 1 H), 7.77 (s, 1 H), 7.70 (s, 1 H), 7.63 (s,1 H), 7.04 (d,1 H), 4.63 - 4.82 (m, 2 H), 4.35 - 4.37 (m, 1 H), 4.14 - 4.27 (m, 4 H), 2.72 - 2.85 (m, 1 H), 2.20 - 2.35 (m, 1 H), 1.44 (t, 3 H) | |
294 | o F F Chiral y-L,/ HN ) > T °yVn ΗζΝ^ΛγΑγΙ 0 | P7 | L23 | 3,7 | 379 | 1H NMR (400 MHz, dmso-de) δ 9.02 (s, 1 H), 8.17 (s, 1 H), 7.90 (d, 1 H), 7.78 (br. s., 1 H), 7.71 (br. s., 1 H), 7.68 (s, 1 H), 7.44 (d, 1 H), 4.69 - 4.80 (m, 2 H), 4.59 - 4.65 (m, 2 H), 4.19 - 4.31 (m, 3 H), 4.10 (br. s., 1 H), 2.70 - 2.81 (m, 1 H), 2.21 - 2.28 (m, 1 H), 1.44 (t, 3 H) | |
295 | 0 Chiral 7 V;< HN\/> 1 \ 0 | P1 | L94 | 3,7 | 341 | 1H NMR (400 MHz, dmso-de) δ 8.23 (s, 1 H), 7.98 (d, 1 H), 7.90 (br. s., 1 H), 7.75 (br. s., 1 H), 7.66 (s, 1 H), 7.47 - 7.54 (m, 2 H), 4.56 (dd, 2 H), 4.05 (s, 3 H), 3.93 (br. s., 1 H), 1.69 (dd, 1 H), 1.35 (s, 3 H), 1.05 (dd, 1 H), 0.84 (t, 1 H) |
296 | Chiral 1 °v h2n^JI 0 | «b | F | P1 | L54 | 3,8 | 361 | 1H NMR (400 MHz, dmso-de) δ 8.87 (s, 1 H), 8.17 (s, 1 H), 7.91 (d, 1 H), 7.85 (br. s., 1 H), 7.75 (s, 1 H), 7.70 (br. s., 1 H), 7.44 (d, 1 H), 4.92 (dd, 1 H), 4.55 (dd, 1 H), 4.27 (dd, 1 H), 4.10 (br. s., 1 H), 3.98 (s, 3 H), 2.55 - 2.73 (m, 1 H), 1.52 -1.72 (m, 2 H), 1.03 (t, 3 H) | ||
A | 0 y | |||||||||
Chiral | V HN | 1H NMR (600 MHz, dmso-de) δ 8.17 (s, 1 H), 7.90 (d, 1 H), 7.81 | ||||||||
297 | 1 Os | o-J | P1 | L91 | 3,7 | 341 | (br. s., 1 H), 7.64 (br. s., 1 H), 7.61 (s, 1 H), 7.55 (s, 1 H), 7.42 (d, 1 H), 4.43 (d, 2 H), 3.99 (s, 3 H), 3.79 (t, 1 H), 1.82 (dd, 1 | |||
κ2γ 0 | γ N | H), 1.23 (s, 3 H), 0.94 (dd, 1 H), 0.66 (t, 1 H) | ||||||||
o. | d ¢. | Mixture of rotamers (major/minor): 1H NMR (400 MHz, 27 °C, | ||||||||
Chiral | HN^ | dmso-de) δ 8.30/8.24 (s, 1 H), 8.16/8.17 (s, 1 H), 7.90 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (br. s., 1 H), 7.66/7.63 (s, 1 H), 7.43 (d, 1 | ||||||||
298 | 0 | χΥ-Ν YY | P1 | L34 | 3,7 | 371 | H), 4.30 - 4.73 (m, 6 H), 4.21 (dd, 1 H), 3.95 - 4.07 (m, 4 H), 3.09 - 3.20 (m, 1 H), 2.95 - 3.05 (m, 1 H), 2.82 - 2.92 (m, 1 H), | |||
HzN^J 0 | 3 | 2.45 (~ 1 H), 2.29 - 3.35 (m, < 1 H), 2.17 - 2.25 (m, < 1 H), 1.93-2.03 (m, <1 H), 1.02 -1.13 (m , 1 H). |
Chiral | 0 HN | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 7.93 (d, 1 H), 7.85 (br. s., 1 H), 7.71 (br. s., 1 H), 7.60 (s, 1 H), 7.49 (s, 1 H), 7.45 | |||||||
299 | | | P1 | L95 | 3,7 | 355 | (d, 1 H), 4.46-4.59 (m, 2 H), 4.00 (s, 3 H), 3.95 (d, 1 H), 1.97 | |||
°x | (dd, 1 H), 1.70 (d, 1 H), 1.15-1.28 (m, 1 H), 0.94- 1.05 (m, 4 | ||||||||
Η2ΝΎ 0 | uj | H), 0.72 (br. s., 1 H) | |||||||
Chiral | M | 7^\ | 1H NMR (400 MHz, CDCIe) δ 8.66 (s, 1 H), 7.93 (d, 1 H), 7.82 (br. s., 1 H), 7.60 (s, 1 H), 7.31 (d, 1 H), 5.96 (br. s., 1 H), 5.54 | ||||||
300 | I | (J | P1 | L76 | 3,7 | 355 | (br. s„ 1 H), 4.62 (dd, 1 H), 4.50 (dd, 1 H), 4.12 (s, 3 H), 4.09 | ||
0., II | (d, 1 H), 1.69 - 1.78 (m, 2 H), 1.40 (dd, 2 H), 1.22 (t, 1 H), 1.05 | ||||||||
0 | (t, 3 H) | ||||||||
9x V | |||||||||
Chiral | hH | 7-\ | 1H NMR (400 MHz, CDCIe) δ 8.65 (s, 1 H), 7.94 (d, 1 H), 7.80 | ||||||
t | VH | (br. s., 1 H), 7.62 (s, 1 H), 7.32 (d, 1 H), 6.20 (s, 1 H), 6.12 (br. | |||||||
301 | I | Q> | P1 | L77 | 3,7 | 355 | s., 1 H), 4.69 (dd, 1 H), 4.55 (dd, 1 H), 4.12 (s, 3 H), 3.96 (d, 1 | ||
CL II | AY | H), 2.04 - 2.11 (m, 1 H), 1.95 - 2.02 (m, 1 H), 1.49 -1.60 (m, 2 | |||||||
0 | H), 1.33-1.43 (m, 1 H), 1.13 (t, 3 H) |
278
302 | °ΥΊ Chiral HN^J 1 l °YY^N h2nXxXX 0 | P1 | 128726- 47-6 | commercial | 3, 7 | 329 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.66 - 7.75 (m, 2 H), 7.64 (s, 1 H), 7.43 (d, 1 H), 4.41 (d, 2 H), 3.99 (s, 3 H), 3.79 - 3.89 (m, 1 H), 2.19 (t, 2 H), 1.81 - 2.04 (m, 2 H), 1.61 -1.76 (m, 2 H) |
303 | o U Chiral %αΑν H2nXL^Jx^ 0 | P1 | L78 | 3,7 | 359 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.78 (s, 1 H), 7.72 (br. s., 1 H), 7.62 (s, 1 H), 7.45 (d, 1 H), 4.38 - 4.52 (m, 3 H), 4.31 (ddd, 1 H), 4.01 (s, 3 H), 3.97 (br. s., 1 H), 2.10 (br. s., 1 H), 1.95 (d, 1 H), 1.49 (d, 1 H) | |
304 | Chlral 1 i °ΊΧι N 0 | P1 | L79 | 3,7 | 359 | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.77 (s, 1 H), 7.71 (br. s., 1 H), 7.62 (s, 1 H), 7.45 (d, 1 H), 4.38 - 4.53 (m, 3 H), 4.31 (ddd, 1 H), 4.01 (s, 3 H), 3.94 - 3.99 (m, 1 H), 2.08 - 2.12 (m, 1 H), 1.92 - 1.97 (m, 1 H), 1.50 (td, 1 H) |
279
305 | Chiral X hV^7 1 i N 0 | P1 | L58 | 3,7 | 355 | 1H NMR (400 MHz, dmso-de) δ 8.14 (s, 1 H), 8.04 (s, 1 H), 7.89 (d, 1 H), 7.82 (br. s., 1 H), 7.68 (br. s., 1 H), 7.59 (s, 1 H), 7.41 (d, 1 H), 4.52 - 4.64 (m, 2 H), 3.94 - 3.99 (m, 4 H), 2.19 - 2.34 (m, 2 H), 1.85 -1.97 (m, 1 H), 0.70 - 0.83 (m, 1 H), 0.36 - 0.50 (m, 2 H), 0.09 - 0.25 (m, 2 H) | |
306 | 0 H h%V^F 1 0 | P1 | L80 | 3,7 | 373 | 1H NMR (400 MHz, dmso-de) δ 8.10 (s, 1 H), 7.84 (d, 1 H), 7.81 (s, 1 H), 7.78 (br. s., 1 H), 7.63 (br. s., 1 H), 7.57 (s, 1 H), 7.37 (d, 1 H), 4.52 - 4.58 (m, 1 H), 4.48 (dd, 1 H), 4.40 - 4.45 (m, 1 H), 4.32 (dd, 1 H), 3.93 (s, 3 H), 3.72 (t, 1 H), 1.87 - 1.97 (m, 2 H), 1.54 - 1.81 (m, 2 H), 1.27 -1.39 (m, 1 H) | |
307 | o__ chirai Htry 1 °ΊΧ5>ιν 0 | P1 | L113 | 3,7 | 327 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 7.92 (d, 1 H), 7.86 (br. s., 1 H), 7.79 (s, 1 H), 7.71 (s, 2 H), 7.44 (d, 1 H), 4.63 - 4.72 (m, 1 H), 4.18 - 4.29 (m, 2 H), 4.02 (s, 3 H), 2.08 - 2.15 (m, 1 H), 1.75 -1.82 (m, 1 H), 0.97 (td, 1 H), 0.85 - 0.90 (m, 1 H) |
308 | Chiral | A CT yA Ay | '3 | P1 | L97 | 3,7 | 341 | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 2 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.55 (s, 1 H), 7.43 (d, 1 H), 4.36 (dd, 1 H), 4.29 (dd, 1 H), 3.99 (s, 3 H), 3.78 (t, 1 H), 2.94 - 3.02 (m, 1 H), 2.87 - 2.94 (m, 1 H), 2.27 - 2.46 (m, 2 H), 2.00 - 2.11 (m, 1 H), 1.87-1.97 (m, 1 H) | ||
I 0 HaN^J 0 | Y Ύ | |||||||||
Chiral | «H | r | 1H NMR (400 MHz, dmso-de) δ 8.18 (s, 1 H), 8.01 (br. s., 1 H), 7.92 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.61 (s, 1 H), | |||||||
309 | I | (j | P1 | L92 | 3,7 | 359 | 7.45 (d, 1 H), 4.53 (dd, 1 H), 4.40 (dd, 1 H), 3.98 (s, 3 H), 3.73 - | |||
II | Y | Y>N | 3.82 (m, 1 H), 2.19-2.28 (m, 1 H), 1.27- 1.35 (m, 1 H), 1.21 - | |||||||
0 | ^γ | Y | 1.26 (m, 3H) | |||||||
Chiral | u HNY | •y >·**' | 1H NMR (600 MHz, dmso-de) δ 8.17 (s, 1 H), 8.15 (br. s., 1 H), | |||||||
J | *H | 7.91 (d, 1 H), 7.80 (br. s., 1 H), 7.64 (br. s., 1 H), 7.61 (s, 1 H), | ||||||||
310 | I | O> | P1 | L93 | 3,7 | 359 | 7.43 (d, 1 H), 4.62 (dd, 1 H), 4.42 (dd, 1 H), 3.95 (s, 3 H), 3.64 | |||
ov | Yr | Y>N | (dd, 1 H), 2.53-2.59 (m, 1 H), 1.98 - 2.09 (m, 1 H), 1.01 (dd, 3 | |||||||
HaN^Jt 0 | γ | Y | H) |
311 | Chiral | ηΗυ. (T | P1 | L114 | 3,7 | 396 | 1H NMR (400 MHz, dmso-de) δ 8.49 (s, 1 H), 8.19 (s, 1 H), 7.93 (d, 1 H), 7.85 (br. s., 1 H), 7.68 - 7.74 (br. s., 1 H), 7.62 (s, 1 H), 7.47 (d, 1 H), 4.65 (dd, 1 H), 4.49 (dd, 1 H), 4.02 - 4.08 (m, 1 H), 4.01 (s, 3 H), 3.01 - 3.11 (m, 2 H) | ||
I 0 HzN>Y 0 | 0 | ||||||||
Chiral | H°b^ | 1H NMR (400 MHz, dmso-de) δ 8.16 (s, 1 H), 8.03 (br. s., 1 H), | |||||||
7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.59 (s, 1 H), | |||||||||
312 | I | o> | P1 | L59 | 3,7 | 358 | 7.43 (d, 1 H), 4.44 (d, 2 H), 3.93 - 3.98 (m, 4 H), 2.56 - 2.65 | ||
0. | (m, 1 H),2.27(dd, 1 H), 2.15 (dd, 1 H), 1.48-1.58 (m , 1 H), | ||||||||
0 | 1.27-1.44 (m, 3 H), 0.88 (t, 3 H) | ||||||||
°Yl r° | |||||||||
Chiral | ntX | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.64 - 7.73 (m, 2 H), 7.61 (s, 1 H), 7.43 (d, 1 H), | |||||||
313 | I °\ h2n^ 0 | Y | 0> | P1 | L81 | 3,7 | 372 | 4.46 (dd, 1 H), 4.38 (dd, 1 H), 3.99 (s, 3 H), 3.89 - 3.95 (m, 1 H), 3.25 (s, 3 H), 1.90 -1.96 (m, 1 H), 1.85 (s, 1 H), 1.73 -1.78 (m, 1 H), 1.21-1.31 (m, 2 H) | |
314 | 0 Η θ Chiral I c» °AY^N 0 | P1 | L82 | 3,7 | 372 | 1H NMR (400 MHz, dmso-d6) δ 8.17 (s, 1 H), 7.91 (d, 2 H), 7.85 (br. s., 1 H), 7.71 (br. s., 1 H), 7.63 (s, 1 H), 7.44 (d, 1 H), 4.53 (dd, 1 H), 4.37 (dd, 1 H), 3.99 (s, 3 H), 3.77 - 3.85 (m, 1 H), 3.44 (d, 2 H), 3.27 (s, 3 H), 2.05 - 2.11 (m, 1 H), 1.97 - 2.04 (m, 1 H), 1.58 (quin, 1 H) | |
315 | 0 H chiral ΗΝγ% I i °ΊΓί N 0 | P1 | L83 | 3,7 | 346 | 1H NMR (400 MHz, dmso-d6) δ 8.19 (s, 1 H), 7.94 (br. s., 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.71 (br. s., 1 H), 7.63 (s, 1 H), 7.46 (d, 1 H), 4.81 (d, 1 H), 4.38 - 4.51 (m, 2 H), 3.99 - 4.06 (m, 4 H), 2.34 - 2.50 (m, 2 H) | |
316 | 0 F Chiral /“f HN.)^ i A HzNUUy 0 | P16 | L54 | 3,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.87 (s, 1 H), 8.62 (d, 1 H), 8.18 (s, 1 H), 7.83 (br. s„ 1 H), 7.69 (s, 1 H), 7.67 (br. s., 1 H), 7.08 (d, 1 H), 4.92 (dd, 1 H), 4.22 - 4.32 (m, 1 H), 4.06 - 4.16 (m, 2 H), 3.96 (s, 3 H), 2.55 - 2.74 (m, 1 H), 1.52 - 1.69 (m, 2 H), 1.01 (t, 3 H) |
283
317 | Chiral °V H2N_Jl 0 | °\_J | P1 | L96 | 3,7 | 346 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 8.00 (br. s., 1 H), 7.91 (d, 1 H), 7.83 (br. s., 1 H), 7.68 (br. s., 1 H), 7.59 (s, 1 H), 7.44 (d, 1 H), 4.54 (dd, 1 H), 4.42 (dd, 1 H), 3.95 (s, 3 H), 3.66 - 3.77 (m, 1 H), 2.56 - 2.70 (m, 1 H), 1.68 -1.86 (m, 1 H), 0.98 - 1.12 (m, 1 H) | ||
h ύ^· | FH CT Yn | ||||||||
Chiral | |||||||||
h,O | 1H NMR (400 MHz, dmso-de) δ 8.14 (s, 1 H), 8.06 (br. s, 1 H), | ||||||||
318 | Y | 0A | P8 | 17342- 08-4 | commercial | 3,7 | 340 | 7.92 (d, 1 H), 7.83 (br. s., 1 H), 7.76 (s, 1 H), 7.73 (br. s„ 1 H), 7.44 (d, 1 H), 5.05 (s, 2 H), 4.50 (dd, 1 H), 4.28 (dd, 1 H), 3.96 - | |
4.07 (m, 1 H), 3.67 (s, 1 H), 2.34 (s, 1 H), 2.10 - 2.29 (m, 2 H), | |||||||||
HzN>Y 0 | M | XY | 1.90- 1.99 (m, 1 H) | ||||||
Chiral | F | ||||||||
hnQ | 1H NMR (400 MHz, dmso-de) δ 8.15 (s, 1 H), 8.06 (s, 1 H), 7.95 | ||||||||
Y | J | 17342- | (d, 1 H), 7.88 (s, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.45 | ||||||
319 | 0 | P8 | 08-4 | commercial | 3,7 | 340 | (d, 1 H), 7.39 (t, 1 H), 5.68 (dd, 2 H), 4.49 (dd, 1 H), 4.29 (dd, 1 | ||
LF | p^N | H), 4.00 - 4.07 (m, 1 H), 2.15 - 2.34 (m, 3 H), 1.88 - 1.94 (m, 1 | |||||||
H2N>Y 0 | XY | H) |
284
320 | 0 H F Chiral /V/'f hby\ I T °ΊΥι N 0 | P1 | L84 | 3,7 | 378 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 7.91 (d, 1 H), 7.88 (s, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.59 (s, 1 H), 7.44 (d, 1 H), 5.90 (td, 1 H), 4.47 - 4.58 (m, 1 H), 4.38 - 4.48 (m, 1 H), 4.02 - 4.10 (m, 1 H), 3.99 (s, 3 H), 2.25 - 2.33 (m, 1 H), 2.09 -2.17(m, 1 H), 1.62-1.74 (m, 1 H) | |
321 | 0 H Chiral i i <γγγ' 0 | P22 | L74 | 4,7 | 376 | 1H NMR (600 MHz, dmso-de) δ 8.84 (s, 1 H), 8.22 (s, 1 H), 7.86 (br. s„ 1 H), 7.69 (br. s„ 1 H), 7.58 (s, 1 H), 5.10 (br. s., 1 H), 4.05 - 4.13 (m, 1 H), 3.97 - 4.05 (m, 1 H), 3.93 (s, 3 H), 3.39 3.53 (m, 2H), 1.94 (d, 1 H), 1.47-1.59 (m, 1 H), 1.18 (d, 3 H) | |
322 | 0 F Chiral Y\\ HNYh I l °γγ*Ν 0 | P1 | L98 | 3,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.61 (br. s, 1 H), 8.15 (s, 1 H), 7.89 (d, 1 H), 7.81 (br. s., 1 H), 7.67 (br. s, 2 H), 7.42 (d, 1 H), 4.46 (dd, 1 H), 4.29 (dd, 1 H), 3.91 (s, 3 H), 3.71 - 3.87 (m, 1 H), 3.14 - 3.27 (m, 1 H), 2.36 - 2.50 (m, 1 H), 2.19 - 2.36 (m, 2 H), 1.29- 1.49 (m, 1 H) |
285
323 | Chiral | °ô Q> rr | P16 | L92 | 3,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.64 (d, 1 H), 8.19 (s, 1 H), 7.99 (br. s., 1 H), 7.82 (br. s., 1 H), 7.66 (br. s., 1 H), 7.53 (s, 1 H), 7.03 (d, 1 H), 4.27 (d, 2 H), 3.96 (s, 3 H), 3.79 (d, 1 H), 2.22 (m, 1 H), 1.27 - 1.36 (m, 1 H), 1.23 (s, 3 H) | ||
1 0 Η2Νχ^ 0 | |||||||||
Vl F | |||||||||
Chiral | AV | 1H NMR (400 MHz, dmso-de) δ 8.64 (d, 1 H), 8.20 (s, 1 H), 7.92 | |||||||
324 | 0. | P16 | L83 | 3,7 | 346 | (br. s., 1 H), 7.83 (br. s., 1 H), 7.67 (br. s., 1 H), 7.54 (s, 1 H), 7.03 (d, 1 H), 4.82 (d, 1 H), 4.25 (d, 2 H), 4.05 (t, 1 H), 4.00 (s, | |||
h2n 1 0 | Y | 3 H), 2.37 - 2.48 (m, 2 H) | |||||||
Chiral | 1H NMR (400 MHz, dmso-de) δ 8.65 (d, 1 H), 8.19 (s, 1 H), | ||||||||
325 | S | P16 | L96 | 3,7 | 346 | 8.01 (br. s., 1 H), 7.82 (br. s., 1 H), 7.66 (br. s., 1 H), 7.53 (s, 1 H), 7.04 (d, 1 H), 4.30 (d, 2 H), 3.95 (s, 3 H), 3.76 (d, 1 H), 2.56 | |||
H2N^ 0 | E 1 J W | -2.65 (m, 1 H), 1.80 (ddd, 1 H), 1.09 (dt, 1 H) |
286
326 | γϊ Chiral !\7 ηνΑ 1 c» Η2ΝγΑθ 0 | Ρ16 | L72 | 3,7 | 328 | 1Η NMR (400 MHz, dmso-de) δ 8.64 (d, 1 Η), 8.19 (s, 1 Η), 7.83 (br. s., 1 Η), 7.67 (br. s., 1 H), 7.61 (s, 1 H), 7.57 (s, 1 H), 7.05 (d, 1 H), 4.25 - 4.33 (m, 1 H), 4.16 - 4.24 (m, 1 H), 4.00 (s, 3 H), 3.88 - 3.95 (m, 1 H), 1.91 - 2.04 (m, 1 H), 1.72 -1.86 (m, 1 H), 1.11 (td, 1 H), 0.62 (q, 1 H) | |
327 | μτ Chiral l\7 ηνΑ 1 \ 0 | Ρ1 | L85 | 3, 7,9 | 358 | 1H NMR (400 MHz, CDeOD) δ 8.33 (s, 1 H), 7.89 (d, 1 H), 7.72 (s, 1 H), 7.35 (d, 1 H), 4.47 - 4.63 (m, 2 H), 4.10 (s, 3 H), 4.04 - 4.08 (m, 1 H), 3.54 (d, 1 H), 3.44-3.50 (m, 1 H), 3.12 (d, 1 H), 2.04-2.10 (m, 1 H), 1.93 (br. s„ 1 H), 1.33-1.41 (m, 1 H) | |
328 | 0 ” Chiral / \7</ζ/θ^ ηνΑ 1 ι °Ύ^ι Ν ΗζΝχΑχγΑΑ 0 | Ρ1 | L86 | 3,7,9 | 358 | 1H NMR (400 MHz, CDeOD) δ 8.33 (s, 1 H), 7.90 (d, 1 H), 7.74 (s, 1 H), 7.36 (d, 1 H), 4.52 - 4.66 (m, 2 H), 4.09 (s, 3 H), 3.99 - 4.08 (m, 1 H), 3.82 (dd, 1 H), 3.61 (dd, 1 H), 2.20-2.30 (m, 1 H), 2.18 (d, 1 H), 1.66-1.78 (m, 1 H) |
329 | 0 Chiral / \ /, hnY-.,/ 1 ι °Ύ^Ι Μ 0 | P1 | L51 | 3,7 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.21 (s, 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.84 (br. s., 1 H), 7.69 (br. s., 1 H), 7.64 (s, 1 H), 7.43 (d, 1 H), 5.98 (ddd, 1 H), 5.19 (d, 1 H), 5.08 (d, 1 H), 4.55 (dd, 1 H), 4.35 (dd, 1 H), 3.99 (s, 3 H), 3.80 (td, 1 H), 2.93 (dt, 1 H), 2.47 (d, 1 H), 2.18 (dd, 1 H) | |
330 | 0 Chiral ΗνΟ^ 1 ι °Ύ^ι N 0 | P1 | L125 | 3,7 | 342 | 1H NMR (400 MHz, dmso-de) δ 8.24 (br. s„ 1 H), 8.17 (s, 1 H), 7.90 (d, 1 H), 7.83 (br. s., 1 H), 7.69 (br. s., 1 H), 7.59 (s, 1 H), 7.42 (d, 1 H), 4.33 - 4.43 (m, 2 H), 3.98 (s, 3 H), 3.58 (t, 1 H), 2.65 (d, 1 H), 2.03 (d, 1 H), 0.79 - 0.90 (m, 1 H), 0.70 - 0.79 (m, 1 H), 0.54 - 0.70 (m, 2 H) | |
333 | ° H Chiral ?— ηνύ\ 1 i HaNyVk/ 0 | P16 | L79 | 3,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.64 (d, 1 H), 8.20 (s, 1 H), 7.84 (br. s., 1 H), 7.76 (s, 1 H), 7.68 (br. s., 1 H), 7.54 (s, 1 H), 7.03 (d, 1 H), 4.29 - 4.52 (m, 2 H), 4.22 - 4.29 (m, 2 H), 4.00 (s, 3 H), 3.95 - 3.99 (m, 1 H), 2.05 - 2.11 (m, 1 H), 1.94 - 2.03 (m, 1 H), 1.47-1.56 (m, 1 H) |
288
334 | Chiral | hH <y | F kH | P1 | L87 | 3,7 | 346 | 1H NMR (600 MHz, dmso-de) δ 8.17 (s, 1 H), 8.04 (s, 1 H), 7.90 (d, 1 H), 7.80 (br. s., 1 H), 7.63 (br. s., 2 H), 7.42 (d, 1 H), 5.15 (ddd, 1 H), 4.59 (dd, 1 H), 4.47 (dd, 1 H), 4.00 - 4.03 (m, 1 H), 3.96 - 4.00 (m, 3 H), 2.49 (dt, 2 H), 2.19 - 2.26 (m, 2 H) | ||
I CK H2NxT 0 | ||||||||||
Chiral | H | Z | ||||||||
HN λ | VH | 1H NMR (600 MHz, dmso-de) δ 8.17 (s, 1 H), 7.96 (d, 1 H), 7.90 | ||||||||
335 | (L h2n^Z 0 | 0 | J | P1 | L88 | 3,7 | 360 | (d, 1 H), 7.80 (br. s., 1 H), 7.60 - 7.66 (m, 2 H), 7.43 (d, 1 H), 4.54 (dd, 1 H), 4.41 (dd, 1 H), 3.99 (s, 3 H), 3.91 (t, 1 H), 2.39 (dd, 1 H), 2.33 (dd, 1 H), 1.61 (d, 3 H) | ||
Chiral | H | 7^F | 1H NMR (600 MHz, dmso-de) δ 8.21 (s, 1 H), 8.14 (s, 1 H), 7.88 | |||||||
Ji | *H | (d, 1 H), 7.83 (br. s., 1 H), 7.61 (br. s., 1 H), 7.59 (s, 1 H), 7.41 | ||||||||
336 | I | Q> | P1 | L89 | 3,7 | 360 | (d, 1 H), 4.70 (s, 1 H), 4.64 (dd, 1 H), 4.51 (dd, 1 H), 4.44 (dd, 1 | |||
CK | Y^N | H), 3.99 - 4.02 (m, 1 H), 3.96 (s, 3 H), 3.22 - 3.31 (m, 1 H), 2.62 | ||||||||
H2NsJ·- 0 | (dd, 1 H), 2.30 (dd, 1 H) |
289
337 | Chiral 1 °Ύ 0 | y HN | F Y | P1 | L55 | 3,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.65 (br. s, 1 H), 8.17 (s, 1 H), 7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.71 (br. s., 1 H), 7.48 (s, 1 H), 7.45 (d, 1 H), 5.13 (dd, 1 H), 4.38 - 4.47 (m, 2 H), 4.01 - 4.09 (m, 1 H), 3.97 (s, 3 H), 2.52 - 2.64 (m, 1 H), 1.49 -1.69 (m, 2 H), 1.01 (t, 3 H) | ||
Y | 0 Ά | |||||||||
Chiral | y HN | F L· | 1H NMR (400 MHz, dmso-de) δ | |||||||
? D | J | 8.15 (s, 1 H), 7.89 (d, 1 H), 7.83 (br. s, 1 H), 7.73 (s, 1 H), 7.68 | ||||||||
338 | D—l·0 | Q> | P9 | L54 | 3,7 | 365 | (br. s, 1 H), 7.42 (d, 1 H), 4.89 (dd, 1 H), 4.55 (dd, 1 H), 4.23 - | |||
J) | Y1 | Yn | 4.26 (m, 1 H), 4.06-4.09 (m, 1 H), 1.57-1.63 (m, 2 H), 1.02 | |||||||
H2N^A. 0 | ^Y | yA | (t, 3 H) | |||||||
Chiral | °y_ | / | ||||||||
HN | 1H NMR (400 MHz, dmso-de) δ 8.87 (br. s, 1 H), 8.27 (s, 1 H), | |||||||||
0 L | J | 7.91 (d, 1 H), 7.83 (br. s., 1 H), 7.77 (s, 2 H), 7.45 (d, 1 H), 4.90 | ||||||||
339 | 1 | P10 | L54 | 3.7 | 406 | (dd, 1 H), 4.55 (dd, 1 H), 4.35 - 4.43 (m, 1 H), 4.30 (s, 1 H), | ||||
II | Y, | YN | 4.23 (dd, 1 H), 4.04 - 4.14 (m, 1 H), 3.80 (t, 2 H), 3.36 (s, 3 H), | |||||||
h2n^A 0 | ^y | yA | 2.61 - 2.69 (m, 1 H), 1.53 - 1.66 (m, 2 H), 1.02 (t, 3 H) |
340 | Chiral Υ-Λ HN I 0YyA 0 | P1 | L60 | 3, 7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 8.11 (s, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.71 (br. s., 1 H), 7.58 (s, 1 H), 7.44 (d, 1 H), 4.39 - 4.54 (m, 2 H), 4.00 - 4.08 (m, 1 H), 3.98 (s, 3 H), 3.41 - 3.56 (m, 2 H), 3.24 (s, 3 H), 2.84 - 2.98 (m, 1 H), 2.23 (m, 2 H) | |
341 | 0 F Chiral Y—f HN I I °Ίί^ι N 0 | P3 | L54 | 3,7 | 363 | 1H NMR (400 MHz, dmso-de) δ 8.90 (s, 1 H), 8.71 (s, 1 H), 8.03 (s, 1 H), 7.89 (br. s., 1 H), 7.74 (br. s., 1 H), 7.68 (s, 1 H), 4.90 (dd, 1 H), 4.66 (dd, 1 H), 4.32 (dd, 1 H), 4.04 - 4.19 (m, 1 H), 3.97 (s, 3 H), 2.53 - 2.72 (m, 1 H), 1.50 - 1.68 (m, 2 H), 1.02 (t, 3 H) | |
342 | Chiral hnMv I i ογγΑΝ 0 | P1 | L66 | 3,7 | 374 | 1H NMR (400 MHz, CDsOD) δ 8.31 (s, 1 H), 7.88 (d, 1 H), 7.82 (s, 1 H), 7.34 (d, 1 H), 4.68 (dd, 1 H), 4.35-4.48 (m, 1 H), 4.12 - 4.19 (m, 1 H), 4.10 (s, 3 H), 3.66 (d, 1 H), 3.57 (s, 3 H), 2.45 2.59 (m, 1 H), 1.70 - 1.82 (m, 1 H), 1.53 - 1.70 (m, 1 H), 1.06 (t, 3 H) |
343 | Chiral | A an \A | P1 | L67 | 3,7 | 374 | 1H NMR (400 MHz, dmso-de) δ 8.23 (s, 1 H), 8.18 (s, 1 H), 7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.51 (s, 1 H), 7.45 (d, 1 H), 4.32 - 4.52 (m, 2 H), 3.99 (s, 3 H), 3.95 (br. s., 1 H), 3.86 (d, 1 H), 3.55 (s, 3 H), 2.22 - 2.37 (m, 1 H), 1.47 -1.65 (m, 2 H), 0.98 (t, 3 H) | ||
A H2nAI 0 | Y A | ||||||||
Chiral | 0 F | ||||||||
hnytd | 1H NMR (400 MHz, dmso-de) δ 8.85 (s, 1 H), 8.15 (s, 1 H), 7.90 | ||||||||
344 | 1 °° | P1 | L56 | 3,7 | 367 | (d, 1 H), 7.83 (br. s., 1 H), 7.73 (s, 1 H), 7.69 (br. s., 1 H), 7.43 (d, 1 H), 4.90 (dd, 1 H), 4.54 (dd, 1 H), 4.25 (dd, 1 H), 4.04 - | |||
h2n AL 0 | A' | N | 4.13 (m, 1 H), 3.97 (s, 3 H), 2.59 (ddd, 1 H) | ||||||
0. î | |||||||||
Chirai | A | 1H NMR (400 MHz, dmso-de) δ 9.33 (br. s., 1 H), 8.16 (s, 1 H), 7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.60 (s, 1 H), | |||||||
345 | | | cr | P1 | L40 | 3,7 | 380 | 7.45 (d, 1 H), 4.53 (d, 1 H), 4.33 (d, 1 H), 4.09 - 4.26 (m, 1 H), | ||
0. II | Y | An | 3.94 (s, 3 H), 2.74 - 2.98 (m, 1 H), 1.53 -1.79 (m, 2 H), 1.04 (t, | ||||||
0 | xY | CA | 3 H) |
346 | θχ ,F Chiral γ—( ηνΥΆ 1 ι °ΊΥι Ν Η2ΝχΥΥΎ 0 | Ρ1 | L57 | 3,7 | 362 | 1Η NMR (400 MHz, dmso-de) δ 8.78 (br. s, 1 Η), 8.17 (s, 1 Η), 7.90 (d, 1 Η), 7.84 (br. s., 1 H), 7.69 (br. s., 1 H), 7.63 (s, 1 H), 7.44 (d, 1 H), 5.17 (dd, 1 H), 4.57 (dd, 1 H), 4.34 (dd, 1 H), 3.99 (s, 3 H), 3.75 - 3.84 (m, 1 H), 1.59 -1.71 (m, 2 H), 1.46 -1.59 (m, 1 H), 1.00 (t, 3 H) | |
347 | 0 Î Chiral j-U HN 1 1 °ΊΎι Ν ΡγΥΜ 0 | Ρ1 | L63 | 3,7 | 396 | 1H NMR (400 MHz, dmso-de) δ 9.33 (br. s., 1 H), 8.17 (s, 1 H), 7.92 (d, 1 H), 7.83 (br. s., 1 H), 7.70 (br. s„ 1 H), 7.59 (s, 1 H), 7.46 (d, 1 H), 4.51 - 4.59 (m, 1 H), 4.31 - 4.40 (m, 1 H), 4.19 - 4.29 (m, 1 H), 3.94 (s, 3 H), 3.71 - 3.80 (m, 1 H), 3.59 - 3.71 (m, 1 H), 3.28 (s, 3 H), 3.17 - 3.26 (m, 1 H) | |
348 | 0 F Chira! W ο ΗΝ 1 ι °YPN Η2ΝγΥΥ 0 | Ρ1 | L61 | 3,7 | 378 | 1H NMR (400 MHz, dmso-de) δ 8.86 (s, 1 H), 8.16 (s, 1 H), 7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.72 (s, 1 H), 7.70 (br. s., 1 H), 7.44 (d, 1 H), 4.95 (dd, 1 H), 4.55 (dd, 1 H), 4.25 - 4.35 (m, 1 H), 4.07 - 4.18 (m, 1 H), 3.96 (s, 3 H), 3.62 - 3.73 (m, 1 H), 3.51 - 3.62 (m, 1 H), 3.27 (s, 3 H), 3.00 - 3.14 (m, 1 H) |
293
349 | Chiral ηγΜ^ I i ογνΧ 0 | P1 | L64 | 3,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.47 (s, 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.85 (br. s., 1 H), 7.70 (s, 2 H), 7.43 (d, 1 H), 4.56 (dd, 1 H), 4.21 - 4.32 (m, 1 H), 4.00 (s, 3 H), 3.88 - 3.98 (m, 1 H), 3.70 (d, 1 H), 3.45 (s, 3 H), 2.69 - 2.81 (m, 1 H), 0.98 (d, 3 H) | |
350 | VJ3 Chiral / \ HN J> I i ογγΧ h2nJUJ 0 | P1 | L65 | 3,7 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.23 (s, 1 H), 8.17 (s, 1 H), 7.92 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.52 (s, 1 H), 7.45 (d, 1 H), 4.39 - 4.50 (m, 2 H), 3.99 (s, 3 H), 3.85 - 3.91 (m, 1 H), 3.83 (d, 1 H), 3.55 (s, 3 H), 2.55 - 2.64 (m, 1 H), 1.15 (d, 3 H) | |
351 | 0 / Chiral / \ r, HNyW I l °ïYN HzN^JkJxJ 0 | P1 | L61 | 3,7 | 378 | 1H NMR (400 MHz, dmso-de) δ 8.74 (s, 1 H), 8.18 (s, 1 H), 7.92 (d, 1 H), 7.84 (br. s., 1 H), 7.71 (br. s., 1 H), 7.51 (s, 1 H), 7.46 (d, 1 H), 5.19 (dd, 1 H), 4.39 - 4.50 (m, 2 H), 4.05 - 4.15 (m, 1 H), 3.98 (s, 3 H), 3.57 - 3.67 (m, 2 H), 3.27 (s, 3 H), 2.86 - 3.07 (m, 1 H) |
352 | 0. OH Chiral \—( HN^Y/ 1 ΗζΝγΑΑΑ 0 | P1 | L68 | 3, 7, 9, 9 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.47 (s, 1 H), 8.14 (s, 1 H), 7.89 (d, 1 H), 7.84 (br. s„ 1 H), 7.80 (s, 1 H), 7.68 (br. s., 1 H), 7.41 (d, 1 H), 5.71 (d, 1 H), 4.55 (dd, 1 H), 4.23 - 4.36 (m, 1 H), 4.00 (s, 3 H), 3.91 - 3.99 (m, 1 H), 3.87 (t, 1 H), 1.56 - 1.69 (m, 1 H), 1.40-1.55 (m, 1 H), 0.97 (t, 3 H) | |
353 | OK OH Chiral —Λ hn^a^/ 1 \ ογγΑΝ 0 | P1 | L68 | 3, 7, 9, 9 | 360 | 1H NMR (400 MHz, dmso-de) δ 8.16 (br. s., 2 H), 7.91 (d, 1 H), 7.84 (br. s., 1 H), 7.70 (br. s., 1 H), 7.52 (s, 1 H), 7.43 (d, 1 H), 5.48 (d, 1 H), 4.34 - 4.51 (m, 2 H), 4.00 - 4.09 (m, 1 H), 3.97 (s, 3 H), 3.86-3.94 (m, 1 H), 2.09-2.23 (m, 1 H), 1.56-1.68 (m, 1 H), 1.43-1.56 (m, 1 H), 1.01 (t, 3 H) | |
354 | Chiral HN \ Y H 1 y 0 | P1 | L115 | 3,7 | 330 | 1H NMR (400 MHz, dmso-de) δ 8.16 (s, 1 H), 8.14 (s, 1 H), 7.89 (d, 1 H), 7.83 (br. s., 1 H), 7.70 (br. s., 1 H), 7.54 (s, 1 H), 7.40 (d, 1 H), 5.27 (quin, 1 H), 3.96 (s, 3 H), 3.79 - 3.88 (m, 1 H), 2.09 - 2.27 (m, 3 H), 1.76- 1.88 (m, 1 H), 1.35 (d, 3 H) |
295
355 | ox Chiral . hnLaf 1 i °Ύ^ι N O | P1 | L116 | 3,7 | 362 | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 1 H), 8.02 (s, 1 H), 7.91 (d, 1 H), 7.83 (br. s., 1 H), 7.69 (br. s., 1 H), 7.55 (s, 1 H), 7.44 (d, 1 H), 4.53 - 4.65 (m, 1 H), 4.42 - 4.53 (m, 3 H), 3.97 - 4.04 (m, 1 H), 3.97 (s, 3 H), 2.68 - 2.81 (m, 1 H), 2.20 - 2.36 (m, 2 H), 1.95-2.12 (m, 1 H), 1.66-1.84 (m, 1 H) | |
356 | 0 nh2 Chiral V—f 1 l ο-γΥχΧ'Ν Ο | P1 | L70 | 3, 7, 10 | 359 | 1H NMR (400 MHz, dmso-de) δ 8.99 (br. s, 1 H), 8.48 (br. s„ 3 H), 8.18 (s, 1 H), 7.93 (d, 1 H), 7.85 (br. s., 1 H), 7.72 (br. s., 1 H), 7.69 (s, 1 H), 7.46 (d, 1 H), 4.68 - 4.76 (m, 1 H), 4.42 - 4.51 (m, 1 H), 4.16 - 4.24 (m, 1 H), 4.00 (s, 3 H), 2.71 - 2.80 (m, 1 H), 1.47-1.58 (m, 2 H), 1.01 (t, 3 H) | |
357 | 0, nh2 Chiral —A 1 i θΥγγ h 2nXxXX 0 | P1 | L71 | 3, 7, 10 | 359 | 1H NMR (400 MHz, dmso-de) δ 8.93 (s, 1 H), 8.45 (br. s., 2 H), 8.19 (s, 1 H), 7.92 (d, 1 H), 7.85 (br. s., 1 H), 7.73 (br. s., 1 H), 7.49 (s, 1 H), 7.47 (d, 1 H), 4.46 - 4.58 (m, 2 H), 4.11 - 4.22 (m, 1 H), 3.99 (s, 3 H), 3.86 - 3.95 (m, 1 H), 2.38 - 2.47 (m, 1 H), 1.80 - 1.95 (m, 1 H), 1.40 - 1.54 (m, 1 H), 1.02 (t, 3 H) |
358 | °v >F Chiral V-Z Y cY °>yAn HaN γΑΑ\Α 0 | P2 | L54 | 3,7 | 390 | 1H NMR (400 MHz, dmso-de) δ 8.79 (s, 1 H), 8.17 (s, 1 H), 7.88 (d, 1 H), 7.74 (s, 1 H), 7.72 (br. s., 1 H), 7.70 (br. s., 1 H), 7.41 (d, 1 H), 4.88 (dt, 1 H), 4.90 (dd, 1 H), 4.52 (dd, 1 H), 4.27 (dd, 1 H), 4.01-4.11 (m, 1 H), 2.53-2.69 (m, 1 H), 1.51-1.68 (m, 2H), 1.38 (t, 6 H), 1.01 (t, 3 H) | |
359 | 0 F Chiral \—f HN A/ > 1 θΥΥ^Ν HaN γ\Α\Α 0 | P7 | L54 | 3,7 | 376 | 1H NMR (400 MHz, dmso-de) δ 8.85 (s, 1 H), 8.16 (s, 1 H), 7.89 (d, 1 H), 7.77 (br. s., 1 H), 7.72 (s, 1 H), 7.70 (br. s., 1 H), 7.42 (d, 1 H), 4.90 (dd, 1 H), 4.54 (dd, 1 H), 4.15 - 4.33 (m, 3 H), 4.02 - 4.13 (m, 1 H), 2.54 - 2.71 (m, 1 H), 1.52 - 1.68 (m, 2 H), 1.44 (t, 3 H), 1.02 (t, 3 H) | |
360 | 0 F Chiral y—\ HnJ—/ 1 \ °Ύ^ι N HaN^Jx^AA 0 F | P1 | L54 | 3, 7,12, HPLC | 380 | 1H NMR (400 MHz, dmso-de) δ 8.86 (s, 1 H), 8.20 (s, 1 H), 7.92 (br. s., 1 H), 7.90 (d, 1 H), 7.80 (br. s., 1 H), 7.78 (d, 1 H), 4.92 (dd, 1 H), 4.54 (dd, 1 H), 4.25 (dd, 1 H), 4.15 (dd, 1 H), 4.01 (s, 3 H), 2.54 - 2.72 (m, 1 H), 1.54 -1.69 (m, 2 H), 1.03 (t, 3 H) |
297
361 | Chiral | VA hnV/ CL yY | P1 | L54 | 3, 7,12, HPLC | 380 | 1H NMR (400 MHz, dmso-de) δ 8.65 (s, 1 H), 7.98 (d, 1 H), 7.93 (br. s., 1 H), 7.89 (s, 1 H), 7.76 (br. s., 1 H), 7.47 (dd, 1 H), 4.85 (dd, 1 H), 4.53 (dd, 1 H), 4.42 (dd, 1 H), 4.03 - 4.12 (m, 1 H), 3.97 (s, 3 H), 2.54 - 2.68 (m, 1 H), 1.53 -1.68 (m, 2 H), 1.00 (t, 3 H) | ||
I CL Η2ΝχΑ 0 | F A, | ||||||||
Chiral | A HnA^A | 1H NMR (400 MHz, dmso-de) δ 8.19 (s, 1 H), 8.05 (br. s, 1 H), | |||||||
362 | I CL |ί | •Y | J an | P1 | L47 | 3, 7, 12, HPLC | 362 | 7.90 (m, 2 H), 7.80 (br. s, 1 H), 7.60 (s, 1 H), 4.38-4.45 (m, 2 H), 4.00 (s, 3 H), 3.94 - 3.96 (m, 1 H), 2.43 - 2.45 (m, 1 H), 2.24-2.33 (m 1 H), 2.09-2.16 (m 1 H), 1.55-1.60 (m, 1 H), | |
H2N^A | γγ | 1.33-1.41 (m, 1 H), 0.93 (t, 3 H). | |||||||
0 | F | ||||||||
Chiral | A HN ΑΆ | 1H NMR (400 MHz, dmso-de) δ 7.98 (d, 1 H), 7.94 (br. s, 1 H), | |||||||
363 | I 0 |i | F Y | ok An | P1 | L47 | 3,7,12, HPLC | 362 | 7.89 (s, 1 H), 7.77 (br. s, 1 H), 7.70 (s, 1 H), 7.46 (d, 1 H), 4.51 - 4.55 (dd, 1 H), 4.41 - 4.45 (dd, 1 H), 3.94 (s, 3 H), 3.89 - 3.92 (m, 1 H), 2.43-2.45 (m 1 H), 2.17-2.21 (m 2 H), 1.59-1.64 | |
H2NsJ 0 | χΑ | yA | (m 1 H), 1.38-1.44 (m, 1 H), 0.91 (t, 3 H). |
364 | A F Z | P1 | L74 | 3, 7, 12, HPLC | 360 | 1H NMR (400 MHz, CDsOD) δ 8.47 (s, 1 H), 7.76 (d, 1 H), 7.71 (d, 1 H), 4.43 - 4.58 (m, 2 H), 4.11 (s, 3 H), 4.04 (t, 1 H), 1.87 (dd, 1 H), 1.71 (d, 1 H), 1.17 (d, 3 H), 1.07-1.15 (m, 1 H) | |||
Chiral 1 0. HzN>O 0 | Y (Y | ||||||||
Q | ^^N AA F | ||||||||
°vb | |||||||||
Chiral | HN'A | 1H NMR (400 MHz, CDaOD) δ | |||||||
365 | F | J (Ύ | P1 | L74 | 3, 7, 12, | 360 | 8.02 (s, 1 H), 7.95 (d, 1 H), 7.36 (dd, 1 H), 4.45 - 4.57 (m, 2 H), | ||
1 °x H2N^ 0 | AA | HPLC | 4.09 (s, 3 H), 4.02 (t, 1 H), 1.91 (dd, 1 H), 1.68 - 1.76 (m, 1 H), 1.18 (d, 3 H), 1.08-1.16 (m, 1 H) | ||||||
Chiral | Y hn.?^ | 1H NMR (400 MHz, dmso-de) δ 8.17 (s, 2 H), 7.91 (d, 1 H), 7.83 | |||||||
366 | 1 0. H2Nyjl 0 | 0^ •^N | P1 | L117 | 3,7 | 348 | (br. s., 1 H), 7.69 (br. s., 1 H), 7.60 (s, 1 H), 7.44 (d, 1 H), 4.70 (d, 1 H), 4.50 - 4.61 (m, 2 H), 4.41 - 4.49 (m, 1 H), 4.04 - 4.15 (m, 1 H), 3.98 (s, 3 H), 2.97 - 3.13 (m, 1 H), 2.20 - 2.36 (m, 2 H) |
367 | Chiral | ¥ HN CT Y | 0 | P1 | L118 | 3,7 | 366 | 1H NMR (400 MHz, dmso-de) δ 8.85 (s, 1 H), 8.16 (s, 1 H), 7.91 (d, 1 H), 7.83 (br. s., 1 H), 7.70 (s, 1 H), 7.68 (br. s., 1 H), 7.45 (d, 1 H), 5.09 (dd, 1 H), 4.81 - 4.93 (m, 1 H), 4.68 - 4.81 (m, 1 H), 4.59 (dd, 1 H), 4.36 (dd, 1 H), 4.16 - 4.25 (m, 1 H), 3.96 (s, 3 H), 3.16-3.28 (m, 1 H) | ||
I 0 H2NxJ 0 | 'Y | |||||||||
V- | F | |||||||||
Chiral | Γ- ΗΝ | 1H NMR (400 MHz, dmso-de) δ 8.81 (s, 1 H), 8.16 (s, 1 H), 7.91 | ||||||||
J | V | (d, 1 H), 7.83 (br. s., 1 H), 7.76 (s, 1 H), 7.68 (br. s., 1 H), 7.42 | ||||||||
368 | I | çy | P1 | L119 | 3,7 | 374 | (d, 1 H), 4.90 (dd, 1 H), 4.71 (dd, 1 H), 4.43 (dd, 1 H), 4.04 - | |||
0. | Y | 4.14 (m, 1 H), 3.98 (s, 3 H), 1.89 - 2.09 (m, 1 H), 0.80 - 0.93 (m, | ||||||||
0 | xY | Y | 1 H), 0.49 - 0.59 (m, 2 H), 0.24 - 0.37 (m, 2 H) | |||||||
v | ||||||||||
Chiral | Y HN | ¥7 | 1H NMR (400 MHz, dmso-de) δ 8.66 (s, 1 H), 8.18 (s, 1 H), 7.92 | |||||||
J | V | (d, 1 H), 7.83 (br. s., 1 H), 7.70 (br. s., 1 H), 7.52 (s, 1 H), 7.45 | ||||||||
369 | I | (F | P1 | L120 | 3,7 | 374 | (d, 1 H), 5.23 (dd, 1 H), 4.51 - 4.66 (m, 2 H), 4.06 (dt, 1 H), 3.98 | |||
0. | Ύ] | (s, 3 H), 1.96 - 2.14 (m, 1 H), 0.81 - 0.95 (m, 1 H), 0.46 - 0.57 | ||||||||
h2n,JL 0 | xY | XY | (m, 2H), 0.21-0.34 (m, 2 H) |
370 | Chiral I °γγ 0 | 0 | F | P1 | L121 | 3,7 | 380 | 1H NMR (400 MHz, dmso-de) δ 8.85 (br. s., 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.83 (br. s., 1 H), 7.73 (s, 1 H), 7.68 (br. s., 1 H), 7.43 (d, 1 H), 4.92 (dd, 1 H), 4.62 - 4.71 (m, 1 H), 4.49 - 4.60 (m, 2 H), 4.32 (dd, 1 H), 4.09-4.18 (m, 1 H), 3.96 (s, 3 H), 2.77 - 2.96 (m, 1 H), 1.92 - 2.08 (m, 2 H). | ||
Y 'N | ~F | |||||||||
Chiral | °b | |||||||||
371 | Y CL | Y^ | J ib | P23 | 17342- 08-4 | commercial | 3, 22, 16 (Ref. 37) | 424 | 1H NMR (400 MHz, CDeOD) δ 8.78 (s, 1 H), 8.00 (s, 1 H), 7.79 (s, 1 H), 7.77 (s, 1 H), 7.39 (s, 1 H), 4.99 (dt, 1 H), 4.59 (dd, 1 H), 4.52 (dd, 1 H), 4.19 - 4.27 (m, 1 H), 3.85 (s, 3 H), 2.36 - | |
H2N\Y | γ | Λγ | 2.58 (m, 3 H), 2.06 - 2.17 (m, 1 H), 1.50 (t, 6 H) | |||||||
0 | N'Y Μ \ | |||||||||
θ\ | ||||||||||
Chiral | ΗνΓ) | |||||||||
372 | Y 0 | γ- | J Ίι N | P23 | 17342- 08-4 | commercial | 3, 22, 16 (Ref. 38) | 438 | 1H NMR (400 MHz, CDeOD) δ 8.76 (s, 1 H), 7.98 (s, 1 H), 7.77 (s, 1 H), 7.28 (s, 1 H), 4.99 (dt, 1 H), 4.59 (dd, 1 H), 4.52 (dd, 1 H), 4.19 - 4.27 (m, 1 H), 3.73 (s, 3 H), 2.47 (s, 3 H), 2.37 - 2.58 | |
H2N.J· | γ | YY | (m, 3 H), 2.07 - 2.18 (m, 2 H), 1.50 (t,6 H). | |||||||
0 | N'Y Λ\ |
373 | 0 chiral ηνΠ Y cY ° ^-NH | P23 | 17342- 08-4 | commercial | 3, 22, 16 (Ref. 39) | 424 | 1H NMR (400 MHz, CDeOD) δ 8.70 (s, 1 H), 7.99 (s, 1 H), 7.78 (s, 1 H), 7.27 (s, 1 H), 5.00 (dt, 1 H), 4.61 (m, 1 H), 4.52 (dd, 1 H), 4.18 - 4.28 (m, 1 H), 2.51 (s, 3 H), 2.36 - 2.60 (m, 3 H), 2.06 -2.17(m, 1 H), 1.50 (t, 6 H) |
374 | chiral hnY I l YaAn Η2ΝγΙγΥ 0 | P1 | L123 | 3,7 | 364 | 1H NMR (600 MHz, dmso-de) δ 8.79 (br. s., 1 H), 8.16 (s, 1 H), 7.90 (d, 1 H), 7.80 (br. s., 1 H), 7.74 (s, 1 H), 7.63 (br. s., 1 H), 7.42 (d, 1 H), 4.55 (dd, 1 H), 4.27 (dd, 1 H), 4.04 - 4.12 (m, 1 H), 3.97 (s, 3 H), 1.54-1.66 (m, 2 H), 1.02 (t, 3 H) | |
375 | w chÎral hnO I i θγγ^Ν Η2ΝγΤΑ^ 0 | P1 | L124 | 3,7 | 366 | 1H NMR (400 MHz, dmso-de) δ 8.81 (s, 1 H), 8.65 (d, 1 H), 8.20 (s, 1 H), 7.83 (br. s., 1 H), 7.68 (br. s„ 1 H), 7.46 (s, 1 H), 7.05 (d, 1 H), 5.33 (dd, 1 H) 4.86 (dd, 1 H), 4.74 (dd, 1 H), 4.39 - 4.27 (m, 1 H), 4.24 (d, 2 H), 3.99 (s, 3 H), 3.26 - 3.06 (m, 1 H) |
302
376 | 0 Chiral hÇ Y cZ 0 | P23 | 17342- 08-4 | commercial | 3, 22, 16 (Ref 40) | 1H NMR (400 MHz, CDaOD) δ 9.27 (s, 1 H), 8.79 (d, 1 H), 8.49 (s, 1 H), 7.80 (s, 1 H), 7.38 (d, 1 H), 5.00 (dt, 1 H), 4.62 - 4.69 (m, 1 H), 4.53 - 4.62 (m, 1 H), 4.20 - 4.31 (m, 1 H), 2.65 (s, 3 H), 2.38 - 2.58 (m, 3 H), 2.07 - 2.19 (m, 1 H), 1.51 (t, 6 H) | |
377 | O Chiral HN^X Y cZ °Y^An ° N^N V Cl | P23 | 17342- 08-4 | commercial | 3,22, 16 (Ref 41) | 1H NMR (400 MHz, CDsOD) δ 9.46 (s, 1 H), 8.97 (s, 2 H), 8.67 (s, 1 H), 7.81 (s, 1 H), 5.00 (dt, 1 H), 4.62-4.72 (m, 1 H), 4.51 4.62 (m, 1 H), 4.18 - 4.32 (m, 1 H), 2.36 - 2.62 (m, 3 H), 2.04 - 2.21 (m, 1 H), 1.51 (t, 6 H) |
303
378 | Chiral HfÇ) °ΆίΑν ° HN^Y | P23 | 17342- 08-4 | commercial | 3, 22, 16 Ref. 42) | 1H NMR (400 MHz, CDeOD) δ 8.36 (s, 1 H), 7.99 (s, 1 H), 7.82 (s, 1 H), 7.72 (dd, 1 H), 6.62 (d, 1 H), 6.53 (d, 1 H), 5.01 (dt, 1 H), 4.61 - 4.70 (m, 1 H), 4.50 - 4.60 (m, 1 H), 4.18 - 4.30 (m, 1 H), 2.36 - 2.59 (m, 3 H), 2.06 - 2.20 (m, 1 H), 1.50 (t, 6 H) | |
379 | 0 Chiral / \ HN ) H2NxA^AA 0 n\ A | P23 | 17342- 08-4 | commercial | 3, 22, 16 (Ref 43) | 1H NMR (400 MHz, CDeOD) δ 8.85 (s, 1 H), 8.79 (d, 1 H), 8.17 (s, 1 H), 7.83 (s, 1 H), 7.63 (d, 1 H), 5.02 (dt, 1 H), 4.62 - 4.71 (m, 1 H), 4.53 - 4.62 (m, 1 H), 4.21 - 4.31 (m, 1 H), 2.80 (s, 3 H), 2.37 - 2.59 (m, 3 H), 2.05 - 2.18 (m, 1 H), 1.51 (t, 6 H) |
304
Table 1 References and Notes
1. Organic Process Research and Development, 2011, 15,1052 -1062.
2. European Journal of Organic Chemistry 2005, 1354 -1366.
3. Prepared as described in US patent application US 2012/95040 A1.
4. Organic & Biomolecular Chemistry, 2005, 3, 603 -611.
5. Prepared as described in WPO patent application WO 2007125405 A2
6. Prepared as described in US patent application US 2013/79324 A1.
7. Korean Journal of Médicinal Chemistry, 1994, 4, 119-125.
8. Organic Process Research and Development, 2011, 15, 1052 - 1062.
9. Journal of Organic Chemistry, 1987, 52, 5247 - 5254.
10. Prepared as described in US patent application US 2007/0265272 A1.
11. Tetrahedron: Asymmetry 1995, 6, 1181 -1190.
12. Bioorganic and Médicinal Chemistry Letters 2010, 20, 4749-4752.
13. Prepared as described in US patent application US 2012/95040 A1.
14. Bioorganic and Médicinal Chemistry Letters 2011, 21, 3290 - 3296.
15. Tetrahedron 2012, 68, 1286- 1298.
16. Prepared as described in World patent application WO 2013/042006 A1.
17. Tetrahedron: Asymmetry 2004, 15, 1659 - 1665.
18. Tetrahedron: Asymmetry, 2002, 13, 647 - 658.
19. Prepared as described in World patent application WO 2008/128919 A2.
20. Journal of Médicinal Chemistry 1987, 30, 992 - 998.
21. Journal of the Chemical Society, Perkin Transactions 1, 2002, 1076 - 1082.
22. Prepared as described in US patent application US 2010/197654 A1.
23. Journal of the American Chemical Society 2010, 732,1188-1189.
24. Prostaglandins 1979, 17, 223 - 226.
25. Organic Letters, 1999, 7, 2105-2107.
26. Tetrahedron, 2007, 63, 10587- 10595.
27. Tetrahedron Letters, 1998, 39, 857 - 860.
28. Prepared as described in European patent application EP 438311 A2.
29. Journal of the American Chemical Society 1999, 727,10478- 10486.
30. Journal of Médicinal Chemistry 1991, 34, 887 - 900.
31. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry 1997, 2111 -2122.
32. Tetrahedron Letters 1989, 30, 6637 - 6640.
33. Archiv der Pharmazie 1964, 297, 632 - 638.
34. Canadian Journal of Chemistry 1956, 34, 815 - 820.
305
35. Journal of Organic Chemistry, 1997, 62, 4770-4779.
36.1H NMR (500 MHz, dmso-d6) δ 8.28 (s, 1 H, diastereomer 1), 8.18 - 8.22 (m, 1 H, both diastereomers), 8.16 (s, 1 H, diastereomer 2), 7.87 - 7.91 (d, 1 H, both diastereomers), 7.74 (br. s., 1 H, both diastereomers), 7.71 (s, 1 H, both diastereomers), 7.62 (br. s, 1 H, both diastereomers), 7.42 (d, 1 H, both diastereomers), 4.92 - 5.01 (m, 1 H, diastereomer 1), 4.86 - 4.93 (m, 1 H, diastereomer 2), 4.56 (dd, 1 H, diastereomer 1), 4.44 - 4.51 (m, 1 H, diastereomer 2), 4.31 - 4.38 (m, 1 H, diastereomer 1), 4.22 (dd, 1 H, diastereomer 2), 3.93 4.05 (m, 1 H, both diastereomers), 3.48 - 3.54 (m, 2 H, both diastereomers), 3.27 (s, 3 H, diastereomer 1), 3.26 (s, 3 H, diastereomer 2), 2.69 - 2.80 (m, 1 H, diastereomer 1), 2.61 2.68 (m, 1 H, diastereomer 2), 2.33 - 2.43 (m, 1 H, diastereomer 1), 2.21 (dt, 1 H, diastereomer 2), 2.06 - 2.15 (m, 1 H, diastereomer 1), 1.76 (dt, 1 H, diastereomer 2), 1.35 1.45 (m, 6 H, both diastereomers)
37.4-Bromo-1-methyl-1H-imidazole was used as the Suzuki coupling partner in the step of Method 16.
38. 4-Bromo-1,2-dimethyl-1H-imidazole was used as the Suzuki coupling partner in the step of Method 16.
39. Tert-butyl 4-bromo-2-methyl-1H-imidazole-1-carboxylate was used as the Suzuki coupling partner in the step of Method 16.
40.2- Bromo-4-methylpyrimidine was used as the Suzuki coupling partner in the step of Method 16.
41.2- Bromo-5-chloropyrimidine was used as the Suzuki coupling partner in the step of Method 16.
42. 6-Bromopyridin-2(1 H)-one was used as the Suzuki coupling partner in the step of Method 16.
43. 4-Bromo-2-methylpyrimidine was used as the Suzuki coupling partner in the step of Method 16.
Table 2 names some of the spécifie intermediates unique to this work. As described in
Scheme 1, compounds such as P1, P16 or P3, P5, or P25, which may be prepared, respectively, from C5, C29 and C17, C25 and C179 may undergo nucleophilic aromatic substitution reactions with alcohols to afford products of the general structure la (See Scheme 1). As described in Scheme 2, compounds such as P5 or P25, which may be prepared, respectively, from C25 and C179, may undergo reactions such as alkylation or Mitsunobu reaction to afford products of the general structure la (See Scheme 2). As described in Scheme 10, α,β-unsaturated lactams such as (S)-3,3-dimethyl-1,7a-dihydropyrrolo[1,2-c]oxazol-5(3H)-one (P20) may be treated with an organometallic reagent such as an alkyllithium or alkyl Grignard reagent in the presence of
306
chlorotrimethylsilane and a copper compound. Some examples in the literature include reaction of benzylidene-protected lactams with alkyl or vinyl cuprate reagents to afford addition of an alkyl or vinyl group anti to the existing stereocenter. For example, see: N. Okamoto et al., Tetrahedron
Asymmetry 2001, 12(9), 1353-1358; S. Hara et al., Tetrahedron 2004, 60(37), 8031-8035; A. Endo and S. Danishefsky, J. Am. Chem. Soc. 2005, 127 (23), 8298-8299. In the chemistry described herein using the acetonide dérivative P20, conjugate addition generally occurs in an unprecedented manner to afford a product with the new substituent syn to the existing stereocenter.
Représentative conjugate addition products include C53, C54, C55, and C56. Such lactams may undergo further élaboration, for example, to provide fluoro dérivatives such as C53, C59, C61, and
C62, or oxygenated dérivatives such as C54.
Table 2
Intermediate | Structure | Name |
C5 | I | 7-methoxyisoquinoline-6-carbonitriIe |
C28 | Cl ho^±n IY | 1-chloro-7-hydroxyisoquinoline-6- carbonitrile |
P1 | i i' | 1-chloro-7-methoxyisoquinoline-6- carbonitrile |
C29 | Cl noyyl | 4-chloro-6-hydrQxyquinoline-7carbonitrile |
307
P16 | 4-chloro-6-methoxyquinoline-7carbonitrile | |
C17 | 1 I ïr-NH AA | 6-methoxy-4-oxo-3,4- dihydroquinazoline-7-carbonitrile |
P3 | 1 î1 °Ybi N IA | 4-chloro-6-methoxyquinazoline-7- carbonitrile |
C25 | OTBDPS HCApA /ογΑγΥ 0 | methyl 5-((tert-butyldiphenylsiIyl)oxy)- 3-hydroxy-2-naphthoate |
P5 | 1 OH H2N^POC^ O | 5-hydroxy-3-methoxy-2-naphthamide |
C179 | | OH O F | methyl 8-fluoro-5-hydroxy-3-methoxy- 2-naphthoate |
P25 | | OH AN^pC^C^ 0 F | 8-fluoro-5-hydroxy-3-methoxy-2- naphthamide |
308
C53 | / ο | (7R,7aS)-3,3,7- trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
C54 | / ο yÿ | (7R,7aS)-7-ethyl-3,3- dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
C55 | / ο yy | (7S,7aS)-3,3-dimethyl-7- vinyltetrahydropyrrolo[1,2-c]oxazol-5(3H)-one |
C56 | / ° < | (7S,7aS)-7-cyclopropyl-3,3- dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
C58 | ...... | (6R,7S,7aS)-6-fluoro-3,3,7- trimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
C59 | (6S,7S,7aS)-6-fIuoro-3,3,7- trimethyltetrahydropyrroIo[1,2-c]oxazol-5(3H)one | |
C61 | (6S,7S,7aS)-7-ethyl-6-fluoro-3,3- dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
309
C62 | <a>...... | (6R,7S,7aS)-7-ethyl-6-fluoro-3,3- dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one |
C54 | (7S,7aS)-7-ethyl-6-hydroxy-3,3- dimethyltetrahydropyrrolo[1,2-c]oxazol-5(3H)one | |
L38 | 0 hnA-f hoJA | (3S,4S,5S)-3-fluoro-5-(hydroxymethyl)- 4-methylpyrrolidin-2-one |
L47 | Ÿ HO—*'— | (4R,5S)-4-ethyl-5- (hydroxymethyl)pyrrolidin-2-one |
L74 | HO-<ft | (1R,4S,5S,6S)-4-(hydroxymethyl)-6- methyl-3-azabicyclo[3.1.0]hexan-2-one |
L54 | 0 HN^Y HO—< V-- | (3S,4S,5S)-4-ethyl-3-fluoro-5- (hydroxymethyl)pyrrolidin-2-one |
L61 | O hn^V'f HO—» '‘-O | (4R,5S)-3-fluoro-5-(hydroxymethyl)-4- (methoxymethyl)pyrrolidin-2-one |
310
L68 | A HN'jr''0 HO—'— | (4S,5S)-3-(benzyloxy)-4-ethyl-5- (hydroxymethyl)pyrrolidin-2-one |
L116 | Y HO—f \—/ | (4S,5S)-4-(2-fluoroethyl)-5- (hydroxymethyl)pyrrolidin-2-one |
L118 | O hnA-f HO—f V-F | (3S,4R,5S)-3-fluoro-4-(fluoromethyl)-5- (hydroxymethyl)pyrrolidin-2-one |
L121 | O hnA^f ΗΟ-Ά \—/ | (3S,4S,5S)-3-fluoro-4-(2-fluoroethyI)-5- (hydroxymethyl)pyrrolidin-2-one |
L124 | O ΗνΆ··'Ρ HO—Z F | (3 R,4R, 5S)-3-f I uoro-4-(fluorom ethyI)-5- (hydroxymethyl)pyrrolidin-2-one |
Biological Activity:
IRAK4 enzymatic DELFIA assay, Protocol A. This is an in vitro assay to measure IRAK4 enzymatic activity utiJizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent 5 Immunoassay, Perkin-Elmer) platform, with the human IRAK4 FL (Full Length) construct to characterize IRAK4 inhibitor and control compounds at 0.6 mM ATP (Km). The final amount of enzyme in the assay is 0.1 nM IRAK4 FL, final concentration of substrate is 50 nM, and final concentration of DMSO is 2.5%.
The test compound was solubilized in DMSO to a stock concentration of 30 mM. The dose 10 response plates were prepared with a 4 mM primary compound concentration, and then diluted in
311
DMSO in a four-fold sériés for a total of 11 data points. Compounds were prepared as a 40-fold multiple of the final in-assay concentration.
To begin the assay, 19 pL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCI2, 0.0025% Brij-35, 600 μΜ ATP, 0.21 nM Full-length phosphorylated recombinant human 5 IRAK4 (GenBank ID AF445802) were aliquoted into Ultra-Clear Polypropylene, 384-well, U-Bottom Plates (Corning Life Sciences). 1 pL of test compound from the dose-response plate was added to the reaction mixture and incubated for 20 minutes at room température. Then 20 pL of 20 mM HEPES pH=7.5, 5 mM MgCI2, 0.0025% Brij-35, 600 pM ATP, and 100 nM ERM-biotinylated peptide (AGAGRDKYKTLRQIR) was added to start the reaction. The reaction was incubated for 60 minutes 10 at room température and stopped by the addition of 20 pL 0.3M EDTA.
pL of the reaction mixture was transferred to a streptavidin coated détection plate (DELFIA streptavidin coated plates, 384-well, white plates, Perkin-Elmer Life Sciences) and incubated for 30 minutes at room température. The plates were washed 4x with 75 pL per well of PBS containing 0.05%Tween-20. Plates were then incubated with 50 pL per well of antibody 15 cocktail of Anti-pERM antibody at 0.125 pg/mL (Cell Signaling Technology), plus Anti-Rabbit IgG EuN1 at 0.25 ug/ml (Perkin-Elmer Life Sciences) in a solution of 10 mM MOPS pH=7.5, 150 mM NaCI, 0.05% Tween-20, 0.02% NaN3, 1% BSA, 0.1% Gelatin for 45 minutes. The plates were washed 4x with 50 pL per well of PBS containing 0.05%Tween-20. Then 50 pL per well of DELFIA Enhancement Solution (Perkin-Elmer Life Sciences) were added to the plate and then read on an 20 EnVision Model 2103 using a 340 nm excitation wavelength and a 665 nm émission wavelength for détection.
IRAK4 enzymatic DELFIA assay, Protocol B, This is an in vitro assay to measure IRAK4 enzymatic activity utilizing the DELFIA (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay, Perkin-Elmer) platform, with the human IRAK4 kinase domain (aa 154-460) 25 construct to characterize IRAK4 inhibitor and control compounds at 0.6 mM ATP (Km). The final amount of enzyme in the assay is 114 pM IRAK4 kinase domain, final concentration of substrate is 200 nM, and final concentration of DMSO is 5%.
The test compound was solubilized in DMSO to a stock concentration of 30 mM. The dose response plates were prepared with a 2 mM primary compound concentration, and then diluted in 30 DMSO in a four-fold sériés for a total of 10 data points. Compounds were prepared as a 20-fold multiple of the final in-assay concentration
To begin the assay, 45 pL of reaction mixture containing 20 mM HEPES pH=7.5, 5 mM MgCI2, 0.0025% Brij-35, 600 pM ATP, 228 pM phosphorylated recombinant human IRAK4 kinase domain (aa 154-460; GenBank ID AF445802) were aliquoted into Ultra-Clear Polypropylene, 9635 well, U-Bottom Plates (Corning Life Sciences). 5 pL of test compound from the dose-response plate was added to the reaction mixture and incubated for 15 minutes at room température. Then 50 pL of 20 mM HEPES pH=7.5, 5 mM MgCI2, 0.0025% Brij-35, 600 pM ATP, and 400 nM ERM18098
312 biotinylated peptide (AGAGRDKYKTLRQIR) were added to start the reaction. The reaction was incubated for 90 minutes at room température and stopped by the addition of 25 pL 0.5M EDTA.
100 μΙ_ of the reaction mixture was transferred to a streptavidin coated détection plate (EvenCoat Streptavidin Coated Plates, 96-Well, R&D Systems) and incubated for 30 minutes at room température. The plates were washed 4 times with 100 pL per well of PBS containing 0.05%Tween-20. Plates were then incubated with 50 pL per well of antibody cocktail of Anti-pERM antibody (Cell Signaling Technology) diluted 1:5000, plus Anti-Rabbit IgG EuN1 at 0.242 pg/ml (Perkin-Elmer Life Sciences) in a solution of 10 mM MOPS pH=7.5, 150 mM NaCI, 0.05% Tween20, 0.02% NaN3, 1% BSA, 0.1% Gelatin for 45 minutes. The plates were washed 4x with 100 pL per well of PBS containing 0.05%Tween-20. Then 100 pL per well of DELFIA Enhancement Solution were added to the plate and then read on an EnVision Model 2103 using a 340 nm excitation wavelength and a 665 nm émission détection.
R848 induced TNFa in human PBMC assay. This protocol is for R848-induced TNFa production by human peripheral blood mononuclear cells (PBMCs). R848 is a synthetic agonist for 15 the endosomal Toll-like receptors TLR7 and TLR8, which signal through interleukin-1 receptorassociated kinase 4 (IRAK4). The assay is used to assess cell-based potency of small molécule inhibitors of IRAK4 in the absence of sérum.
Peripheral blood mononuclear cells (PBMC) were purified from fresh human blood by séparation on a Histopaque-1077 cushion using ACCUSPIN-System-Histopaque -1077 System 20 (Sigma Aldrich). Briefly, 30 mL of human blood were added to an ACCUSPIN tube containing 15 mL of Histopaque-1077 and spun for 20 minutes at 1200xg at room température in an Eppendorf 5804R swinging-bucket centrifuge with low brake. The PBMCs in the interphase layer were collected and washed with PBS via centrifugation multiple times until the supernatant is clear. The purified PBMCs were re-suspended in RPMI (Roswell Park Memorial Institute) media (Sigma25 Aldrich).
For the assay, a compound dilution plate containing a top concentration of 4 mM compound in DMSO was serially diluted 4-fold for 11 times. 250 nL of the compound dilution plate was spotted into a 384-well, fiat bottom with lid, TC-treated, black with clear bottom, stérile, polystyrène plate (Corning Life Sciences). 100,000 PBMCs in 50 pL of RPMI containing 5.5 μΜ R848 are added to 30 each well of the 384 well plate and allowed to incubate for 3 hours at 37° C.
Plates were briefly spun at 1200xg Eppendorf 5804R swinging-bucket centrifuge for 5 minutes and 15 pL of the supernatant from each well is transferred to the corresponding well of a Human TNFa 384-Well Tissue Culture MSD Kit (Mesoscale Discovery). 10 pL of anti-TNFa antibody labeled with MSD SULFO-TAG at 50 pg/mL was added to each well and allowed to 35 incubate overnight at 4°C. The plates were then washed with 1xPBS containing 0.05% Tween 20 after which 35 pL of MSD read buffer T (Mesoscale Discovery) was added to each well. The plates were then imaged on an MSD Sector Imager 6000.
313
TABLE 3. Bioloqical Activity
Ex.# | IRAK4 DELFIA Protocol A IC50 (nM) | 1RAK4 DELFIA Protocol B IC50 (nM) | R848induced TNFa PBMC IC50 (nM) | ÎUPAC NAME |
1 | 2913 | 4-(azetidin-3-ylmethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
2 | 4497 | 4-[(3S)-piperidin-3-ylmethoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
3 | 2239 | 4-[(3R)-piperidin-3-ylmethoxy]-6-(propan-2- yloxy)quinoIine-7-carboxamide | ||
4 | 913 | 4-(piperidin-4-ylmethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
5 | 323 | 4-[(1 R,5S,6r)-3-azabicyclo[3.1.0]hex-6-ylmethoxy]-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
6 | 618 | 4-(oxetan-3-ylmethoxy)-6-(propan-2-yloxy)quinoIine-7- carboxamide | ||
7 | 170 | 4-(cyclopentylmethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
8 | 834 | 4-(1-cyclobutylethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
9 | 598 | 4-(cyclobutylmethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
10 | 752 | 6-(propan-2-yloxy)-4-(tetrahydrofuran-3- ylmethoxy)quinoline-7-carboxamide | ||
11 | 3234 | 6-(propan-2-yloxy)-4-(tetrahydrofuran-2- ylmethoxy)quinoHne-7-carboxamide |
314
12 | 1042 | 4-[(3-methyloxetan-3-yl)methoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
13 | 383 | 4-[(1-methylcyclobutyl)methoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
14 | 231 | 4-[(2R)-bicyclo[2.2.1]hept-2-yloxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
15 | 2969 | 6-(propan-2-yloxy)-4-[(2R)-tetrahydrofuran-2- ylmethoxy]quinoline-7-carboxamide | ||
16 | 386 | 4-(bicyclo[2.2.1]hept-2-yIoxy)-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
17 | 476 | 6-(propan-2-yloxy)-4-(tricyclo[2.2.1.0~2,6~]hept-3- yIoxy)quinoline-7-carboxamide | ||
18 | 507 | 4-(1,3-dioxolan-4-ylmethoxy)-6-(propan-2- yIoxy)quinoline-7-carboxamide | ||
19 | 354 | 4-[(1S,2R)-bicycIo[2.2.1]hept-2-yloxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
20 | 102 | 1-[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-4-yloxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
21 | 83 | 4-[(3aR,6aS)-octahydrocyclopenta[c]pyrrol-4-yloxy]-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
22 | 45 | 4-{[(3S)-1-(cyanoacetyl)pyrrolidin-3-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
23 | 656 | 4-{[(3R)-1-(cyanoacetyl)pyrrolidin-3-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
24 | 492 | 7-(propan-2-yloxy)-1-(tetrahydrofuran-3- yImethoxy)isoquinoline-6-carboxamide | ||
25 | 1130 | 7-(propan-2-yloxy)-1-(tetrahydro-2H-pyran-2- ylmethoxy)isoquinoline-6-carboxamide | ||
26 | 4.6 | 133 | 1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | |
27 | 2483 | 1-[(1,1-dioxido-1,2-thiazinan-3-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
28 | 1320 | 1-[(3S)-piperidin-3-ylmethoxy]-7-(propan-2- yloxy)isoquinonne-6-carboxamide | ||
29 | 76 | 1-[(3-methyl-2-oxo-1,3-oxazolidin-4-yl)methoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
30 | 2445 | 7-(propan-2-yloxy)-1-[(2R)-tetrahydrofuran-2- ylmethoxy]isoquinoline-6-carboxamide | ||
31 | 2616 | 1-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-7-(propan-2- yIoxy)isoquinoline-6-carboxamide |
315
32 | 840 | 1-{[(2R)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2- yloxy)isoquino(ine-6-carboxamide | ||
33 | 2862 | 1-[(1-acetylpiperidin-4-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
34 | 483 | 1-{[(3R,4R)-4-methoxypyrrolidin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
35 | 16 | 1-[(2-oxo-1,3-oxazoIidin-5-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
36 | 735 | 7-(propan-2-yloxy)-1-(tetrahydro-2H-pyran-4- ylmethoxy)isoquinoIine-6-carboxamide | ||
37 | 3516 | 1-[(2S)-morpholin-2-ylmethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
38 | 4640 | 1-[(4-fluoropiperidin-4-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
39 | 386 | 1-(morpholin-2-ylmethoxy)-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
40 | 109 | 1-[(1 S,5S)-3-azabicyclo[3.1.0]hex-1-ylmethoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
41 | 2351 | 7-(propan-2-yIoxy)-1-[(2R)-pyrrolidin-2- ylmethoxy]isoquinoline-6-carboxamide | ||
42 | 219 | 1-[(1 R,5S,6r)-3-azabicycIo[3.1.0]hex-6-ylmethoxy]-7(propan-2-yloxy)isoquinoline-6-carboxamide | ||
43 | 3323 | 1-(piperidin-2-ylmethoxy)-7-(propan-2- yIoxy)isoquinoline-6-carboxamide | ||
44 | 4265 | 1-[(4-methylmorpholin-2-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
45 | 1922 | 1-[(1-methylpiperidin-3-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
46 | 237 | 7-(propan-2-yloxy)-1-{[(3R,4R)-4- (trifluoromethyl)pyrrolidin-3-yl]methoxy}isoquinoline-6carboxamide | ||
47 | 2786 | 1-[(2R)-morpholin-2-ylmethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
48 | 366 | 1-[(3R)-piperidin-3-ylmethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
49 | 451 | 7-(propan-2-yloxy)-1-[(3S)-pyrrolidin-3- ylmethoxy]isoquinoline-6-carboxamide | ||
50 | 701 | 6-(propan-2-yloxy)-4-[(3S)-pyrrolidin-3- ylmethoxy]quinoline-7-carboxamide |
316
51 | 2412 | 4-[(2S)-morpholin-2-ylmethoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
52 | 4236 | 4-(7-azaspiro[3.5]non-1-yloxy)-6-(propan-2- yloxy)quinoIine-7-carboxamide | ||
53 | 2380 | 4-[(2R)-morpholin-2-ylmethoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
54 | 2435 | 4-[(4-fluoropiperidin-4-yl)methoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
55 | 264 | 4-{[(3R,4R)-3,4-dimethylpyrrolidin-3-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
56 | 1489 | 4-[(4-methylpiperidin-4-yl)methoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
57 | 5.8 | 4-{[(5R)-2-oxo-1,3-oxazolidin-5-yl]methoxy}-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
58 | 144 | 4-[(3-methylpiperidin-3-yl)methoxy]-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
59 | 243 | 4-(piperidin-3-ylmethoxy)-6-(propan-2-yloxy)quinoline-7- carboxamide | ||
60 | 8.9 | 4-{[1-(cyanoacetyl)azetidin-3-yl]methoxy}-6-(propan-2- yloxy)quinoIine-7-carboxamide | ||
61 | 249 | 1-{[(2R)-1-(cyanoacetyl)pyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
62 | 1286 | 1-{[1-(cyanoacetyl)piperidin-4-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
63 | 252 | 1-{[(2S)-1-(cyanoacetyl)pyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
64 | 641 | 1-{[(3R)-4-(cyanoacetyI)morpholin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
65 | 563 | 1-({1-[(cyanoacetyl)amino]cyclopentyl}methoxy)-7- (propan-2-yIoxy)isoquinoline-6-carboxamide | ||
66 | 255 | 1-{[(3S)-1-(cyanoacetyl)pyrrolidin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | ||
67 | 1730 | 1-{[(3R)-1-(cyanoacetyl)piperidin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
68 | 320 | 1-{[(1R,5R,6R)-3-(cyanoacetyl)-3-azabicyclo[3.2.1]oct-6- yl]oxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
69 | 29 | 1-{[1-(cyanoacetyl)azetidin-3-yl]methoxy}-7-(propan-2- yIoxy)isoquinoline-6-carboxamide | ||
70 | 423 | 1-{[(3R)-1-(cyanoacetyl)pyrrolidin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide |
317
71 | 153 | 4-{[(3aR,6aS)-2- (cyanoacetyl)octahydrocyclopenta[c]pyrrol-4-yl]oxy}-6-(propan- 2-yloxy)quinoline-7-carboxamide | ||
72 | 2625 | 1-[(1S,4R)-2-azabicyclo[2.2.1]hept-6-yloxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
73 | 1161 | 1-{[(2S)-1-(cyanoacetyl)azetidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
74 | 43 | 1-{[(1S,4S,5S)-2-(cyanoacetyl)-2-azabicyclo[2.2.1]hept- 5-yl]oxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
75 | 4039 | 1-{[(2S)-4-(cyanoacetyl)morpholin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
76 | 1721 | 1-{[1-(cyanoacetyl)-4-fluoropiperidin-4-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
77 | 468 | 1-{[(1S,5S)-3-(cyanoacetyl)-3-azabicyclo[3.1.0]hex-1- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
78 | 4743 | 1-{[(2R)-4-(cyanoacetyl)morpholin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | ||
79 | 457 | 1-{[(3aR,4S,6aS)-2- (cyanoacetyl)octahydrocyclopenta[c]pyrrol-4-yl]oxy}-7-(propan- 2-yloxy)isoquinoline-6-carboxamide | ||
80 | 333 | 1-{[(3R,4R)-1-(cyanoacetyi)-4-ethylpyrroiidin-3- yl]methoxy}-7-(propan-2-yloxy)isoquinoIine-6-carboxamide | ||
81 | 479 | 1-{[(1S,5S,6S)-3-(cyanoacetyl)-3-azabicyclo[3.2.1]oct-6- yl]oxy}-7-(propan-2-yloxy)isoquinoIine-6-carboxamide | ||
82 | 969 | 1-{[1-(cyanoacetyl)-3-methylpyrrolidin-3-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
83 | 175 | 1-{[(3S)-4-(cyanoacetyl)morpholin-3-yl]methoxy}-7- (propan-2-yIoxy)isoquinoline-6-carboxamide | ||
84 | 534 | 1 -{[(3R,4R)-1 -(cyanoacetyl)-4-methoxypyrroIidin-3- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
85 | 610 | 1-{[(3R,4R)-1-(cyanoacetyl)-4-methylpyrrolidin-3- yl]methoxy}-7-(propan-2-yloxy)isoquinoIine-6-carboxamide | ||
86 | 216 | 1-{[1-(cyanoacetyl)-4-methylpiperidin-4-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
87 | 2621 | 4-{[(1 R,5S,6r)-3-(cyanoacetyl)-3-azabicyclo[3.1.0]hex-6- yl]methoxy}-6-(propan-2-yioxy)quinoline-7-carboxamide | ||
88 | 292 | 4-{[(3R,4R)-1-(cyanoacetyl)-4-methylpyrrolidin-3- yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | ||
89 | 395 | 4-{[(1R,5R,6R)-3-(cyanoacetyl)-3-azabicyclo[3.2.1]oct-6- yl]oxy}-6-(propan-2-yIoxy)quinoline-7-carboxamide |
318
90 | 438 | 4-{[(1 S,5S)-3-(cyanoacetyl)-3-azabicyclo[3.1,0]hex-1- yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | ||
91 | 489 | 4-{[1-(cyanoacetyl)-4-methyIpiperidin-4-yl]methoxy}-6- (propan-2-yloxy)quino)ine-7-carboxamide | ||
92 | 473 | 4-{[(1S,5S,6S)-3-(cyanoacetyl)-3-azabicyclo[3.2.1]oct-6- yl]oxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | ||
93 | 1520 | 4-{[(3S)-1-(cyanoacetyl)piperidin-3-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
94 | 526 | 4-{[(1 S,5S)-3-(cyanoacetyl)-3-azabicyclo[3.1,0]hex-1- yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | ||
95 | 3167 | 4-{[1-(cyanoacetyl)-4-fluoropiperidin-4-yl]methoxy}-6- (propan-2-yloxy)quino!ine-7-carboxamide | ||
96 | 301 | 4-{[(3R,4R)-1-(cyanoacetyl)-4-methoxypyrrolidin-3- yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | ||
97 | 2741 | 4-{[(3R)-1-(cyanoacetyl)piperidin-3-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
98 | 575 | 4-{[(2S)-4-(cyanoacetyl)morpholin-2-yl]methoxy}-6- (propan-2-yloxy)quinoline-7-carboxamide | ||
99 | 524 | 4-{[1-(cyanoacety[)piperidin-2-ylJmethoxy}-6-(propan-2- yloxy)quinoline-7-carboxamide | ||
100 | 482 | 4-{[1-(cyanoacetyl)piperidin-4-yl]methoxy}-6-(propan-2- yloxy)quino!ine-7-carboxamide | ||
101 | 1177 | 1-[(1S,4S,5S)-2-azabicyclo[2.2.1]hept-5-yloxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
02 | 217 | 1 -[(1 R,4R, 5R)-2-azabicyclo[2.2.1 ]hept-5-yIoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
03 | 575 | 2741 | 1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carbonitrile | |
04 | 6.6 | 1796 | 1-{[(4R)-2-°xo-1,3-oxazolidin-4-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | |
05 | 84 | 4-methyl-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
06 | 51 | 472 | 1-{[(2S)-6-oxopiperidin-2-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | |
107 | 16 | 1-{[(2S)-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
108 | 1867 | 1-[(1S,4R,6R)-2-azabicyclo[2.2.1]hept-6-yloxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide |
319
109 | 1909 | 1-[(1S,4R,6S)-2-azabicyclo[2.2.1]hept-6-yloxy]-7- (propan-2-y!oxy)isoquinoline-6-carboxamide | ||
110 | 418 | 1167 | 1-{[(2S)-4,4-dimethyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
111 | 196 | 1-[(5-oxopyrrolidin-3-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
112 | 1 | 50 | 1-{[(2S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
113 | 53 | 1-{[(2S)-4-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan- 2-yloxy)isoquinoline-6-carboxamide | ||
114 | 0.7 | 33 | 5-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-3-(propan-2- yloxy)naphthalene-2-carboxamide | |
115 | 61 | 3-(propan-2-yloxy)-5-[(3R)-pyrrolidin-3- ylmethoxy]naphthalene-2-carboxamide | ||
116 | 146 | 1-[(5-oxomorpholin-3-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
117 | 136 | 7-(propan-2-yloxy)-1-[(3R)-pyrrolidin-3- ylmethoxy]isoquinoline-6-carboxamide | ||
118 | 162 | 1-[(3-oxooctahydro-1H-isoindol-1-yl)methoxy]-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | ||
119 | 1429 | 1-[(2S)-azetidin-2-yImethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
120 | 1141 | 7-(cyclobutyloxy)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | ||
121 | 7.6 | 347 | 7-methoxy-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
122 | 24 | 672 | 7-ethoxy-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
123 | 747 | 1-[(3aR,6aR)-hexahydrocyclopenta[c]pyrrol-3a(1H)- ylmethoxy]-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
124 | 7.8 | 175 | 1-{[(2S,4R)-4-methyI-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
125 | 40 | 685 | 1-{[(2S,4S)-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
126 | 42 | 1-{[(2S)-2-methyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
127 | 65 | 682 | 1-{[(2S)-4-(methoxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide |
320
128 | 0.3 | 27 | 1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | |
129 | 231 | 7-(difluoromethoxy)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoIine-6-carboxamide | ||
130 | 417 | 1-{[(3aS,6R,6aR)-2-oxooctahydrocyclopenta[b]pyrrol-6- yl]oxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
131 | 0.6 | 29 | 1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
132 | 188 | 1180 | 1-{[(2S,4R)-4-ethyl-4-fluoro-5-oxopyrroIidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
133 | 175 | 1-{[(2S,4R)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
134 | 1 | 36 | 1-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yIoxy)isoquinoline-6-carboxamide | |
135 | 1.2 | 32 | 1-{[(2S,4S)-4-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)îsoquinoline-6-carboxamide | |
136 | 7.8 | 184 | 1-{[(2S,4R)-4-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
137 | 98 | 1-{[(2S,4R)-4-(2-hydroxypropan-2-yl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
138 | 1037 | 1-[(2-oxopiperidin-4-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
139 | 256 | 1-[(1S,5S)-3-azabicyclo[3.1.0]hex-1-yImethoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
140 | 84 | 1-[(1 R,5R)-3-azabicyclo[3.1,0]hex-1-ylmethoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
141 | 70 | 294 | 1-{[(2S,3S)-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | |
142 | 1222 | 1-[(6-oxopiperidin-3-yl)methoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
143 | 2542 | 1-[(1,1-dioxido-1,2-thiazolidin-3-yl)methoxy]-7-(propan- 2-yloxy)isoquinoline-6-carboxamide | ||
144 | 1.4 | 141 | 1-{[(2S,4R)-4-fluoro-5-oxopyrrolidin-2-yI]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
145 | 0.4 | 41 | 1-{[(2S,4S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
146 | 0.2 | 15 | 1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide |
321
147 | 59 | 1161 | 1-{[2-(hydroxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yioxy)isoquinofine-6-carboxamide | |
148 | 24 | 1-{[(2S)-4-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
149 | 105 | 1-{[(2S,3S)-3-amino-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
150 | 41 | 864 | 1-{[(2S,4S)-4-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
151 | 1.2 | 25 | 1-{[(2S,4S)-5-oxo-4-(2,2,2-trifluoroethyl)pyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
152 | 6.7 | 139 | 1-{[(2S,4R)-5-oxo-4-(2,2,2-trifluoroethyl)pyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
153 | 1480 | 1-{[(2S)-2-(hydroxymethyl)-5-oxopyrroIidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
154 | 17 | 1-{[(2R)-2-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
155 | 267 | 1-{[(2S,3S)-5-oxo-3-(trifluoromethyl)pyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
156 | 4097 | 1-{(1R)-1-[(2S)-5-oxopyrrolidin-2-yl]ethoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
157 | 152 | 1 -{(1 S)-1 -[(2S)-5-oxopyrrolidin-2-yl]ethoxy}-7-(propan-2yloxy)isoquino!ine-6-carboxamide | ||
158 | 1443 | 1-[(3R)-morpholin-3-ylmethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
159 | 3377 | 7-(propan-2-yloxy)-1-(pyrrolidin-2- ylmethoxy)isoquinoIine-6-carboxamide | ||
160 | 151 | 1-[(3S)-morpholin-3-ylmethoxy]-7-(propan-2- yloxy)isoquinoline-6-carboxamide | ||
161 | 88 | 1-[(1 R,6S)-3-azabicyclo[4.1.0]hept-1-ylmethoxy]-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
162 | 35 | 1-[(1 S,6R)-3-azabicycIo[4.1,0]hept-1-ylmethoxy]-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | ||
163 | 1396 | 7449 | 1-{[(2S,4S)-4-fluoro-4-(hydroxymethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
164 | 1.7 | 116 | 1-{[(2S,4R)-4-fluoro-4-(hydroxymethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-(propan-2-yIoxy)isoquinoline-6-carboxamide | |
165 | 541 | 1-{[(2S,4R)-4-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide |
322
166 | 4.3 | 389 | 1-{[(2S,4S)-4-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
167 | 19 | 1-{[(3aR,4R,6aR)-2,2-dimethyl-6-oxotetrahydro-3aH[1,3]dioxolo[4,5-c]pyrrol-4-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide | ||
168 | 6.6 | 1456 | 4-fluoro-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yIoxy)isoquinoIine-6-carboxamide | |
169 | 890 | 1-{[(2S)-5-oxopyrrolidin-2-y!]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxylic acid | ||
170 | 0.8 | 41 | 1-{[(2S,3S,4R)-4-fluoro-3-methyl-5-oxopyrroIidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
171 | 101 | 1-{[(2S,4R)-4-fluoro-4-(2-hydroxypropan-2-yl)-5- oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6carboxamide | ||
173 | 1.3 | 37 | 3-methoxy-5-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}naphthalene-2-carboxamide | |
174 | 3.1 | 126 | 1-{[(1S,2S,5R)-4-oxo-3-azabicyc!o[3.1.0]hex-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
175 | 101 | 1-{[(1S,5S)-4-oxo-3-azabicyclo[3.1.0]hex-1-yl]methoxy}- 7-(propan-2-yIoxy)isoquinoline-6-carboxamide | ||
176 | 695 | 8-fluoro-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
177 | 3.8 | 43 | 1-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
178 | 1689 | 1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7- (trifluoromethoxy)isoquinoline-6-carboxamide | ||
179 | 1.2 | 199 | 1-{[(2S,4R)-4-hydroxy-5-oxopyrro!idin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
180 | 1786 | 2555 | 1-{[(2S)-1-methyl-5-oxopyrroIidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | |
181 | 5.7 | 503 | 1-{[(2S)-4-(4-hydroxytetrahydro-2H-pyran-4-yl)-5- oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6carboxamide | |
182 | 1048 | 1-{[(2S,4R)-4-hydroxy-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yI]methoxy}-7-(propan-2yIoxy)isoquinoline-6-carboxamide | ||
183 | 0.2 | 10 | 1-{[(2S,3S)-4,4-difluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yIoxy)isoquinoline-6-carboxamide |
323
184 | 60 | 1-{[(2S,4S)-4-hydroxy-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide | ||
185 | 116 | 1-{[(4S)-1-methyl-2-oxoimidazolidin-4-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
186 | 303 | 1-{[(5S,6R)-2-oxo-1-azaspiro[4.4]non-6-yl]oxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
187 | 1.1 | 40 | 1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
188 | 1.9 | 30 | 1-{[(2S,3S,4R)-4-fluoro-3-methyI-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
189 | 0.3 | 12 | 1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
190 | 294 | 4-cyano-1-{[(2S)-5-oxopyrrolidin-2-yI]methoxy}-7- (propan-2-yloxy)isoquinoIine-6-carboxamide | ||
191 | 252 | 7-(propan-2-yloxy)-1-(pyrrolidin-3- ylmethoxy)isoquinoline-6-carboxamide | ||
192 | 284 | 1-{[(2S,4R)-4-(3-hydroxyoxetan-3-yl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
193 | 238 | 1-{[(2S,4S)-4-(3-hydroxyoxetan-3-yl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
194 | 1 | 5.2 | 5-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-3-methoxynaphthalene-2-carboxamide | |
195 | 3402 | 4-(aminomethyl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}- 7-(propan-2-yloxy)isoquinoIine-6-carboxamide | ||
196 | 11 | 1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | ||
197 | 71 | 1-{[(3S,4S)-3-ethyl-4-fluoro-2-hydroxy-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | ||
198 | 715 | 1-{[(2S,3R,4S)-4-fIuoro-3-(1-hydroxyethyl)-5~ oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoIine-6carboxamide | ||
199 | 2904 | 7-(oxetan-3-yIoxy)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoIine-6-carboxamide | ||
200 | 697 | 7-tert-butoxy-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide |
324
201 | 0.4 | 1 | 1-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
202 | 85 | 922 | 1-{[(4S)-2-oxoimidazolidin-4-yl]methoxy}-7-(propan-2- yloxy)isoquinoline-6-carboxamide | |
203 | 3.5 | 47 | 1-{[(2S,3R,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
204 | 2064 | 7-(cyclopropylmethoxy)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | ||
205 | 3.6 | 380 | 1-{[(2S,4R)-4-fluoro-4-(hydroxymethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
206 | 216 | 4570 | 6-methoxy-4-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}isoquinoIine-7-carboxamide | |
207 | 41 | 5-{[(2S,4R)-4-fluoro-4-(hydroxymethyl)-5-oxopyrrolidin- 2-yl]methoxy}-3-methoxynaphthalene-2-carboxamide | ||
208 | 1.1 | 87 | 1-{[(2S,3S,4R)-4-fluoro-4-(hydroxymethyl)-3-methyl-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoIine-6carboxamide | |
209 | 251 | 9309 | 6-methoxy-4-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}quinazoIine-7-carboxamide | |
210 | 3467 | 1-{[(2S,3S,4S)-4-fluoro-4-(hydroxymethyl)-3-methyl-5oxopyrroIidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | ||
211 | 2.7 | 52 | 7-methoxy-1-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2- yI]methoxy}isoquinoline-6-carboxamide | |
212 | 150 | 1-{[(2S,3S)-3-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
213 | 1416 | 1-{[(1S,3aS,6aR)-5-methyl-3-oxooctahydropyrrolo[3,4c]pyrrol-1-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6carboxamide | ||
214 | 215 | 1-{[(2S,3S)-3-(hydroxymethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | ||
215 | 1.7 | 35 | 1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
216 | 0.4 | 27 | 3-methoxy-5-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2- yl]methoxy}naphthalene-2-carboxamide | |
218 | 0.3 | 11 | 5-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-3-methoxynaphthalene-2-carboxamide | |
219 | 1.7 | 65 | 1-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide |
325
220 | 0.9 | 14 | 8-fluoro-5-{[(2S,3S,4S)-4-fluoro-3-methyl-5oxopyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2carboxamide | |
221 | 54 | 1-{[(2S)-3,3-dimethyl-5-oxopyrroIidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | ||
222 | 1870 | 1-{[(2R)-3,3-dimethyl-5-oxopyrroIidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | ||
223 | 15 | 1-{[(2R)-3,3-dimethyl-5-oxopyrrolidin-2-yl]methoxy}-7- (propan-2-yloxy)isoquinoline-6-carboxamide | ||
224 | 1173 | 1-{[(2S,4R)-4-(cyanomethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | ||
225 | 3.4 | 155 | 1-{[(2S,4S)-4-(cyanQmethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
226 | 222 | 1-{[(1S,3aS,6aR)-3-oxooctahydropyrrolo[3,4-c]pyrrol-1- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
227 | 19 | 749 | 7-methoxy-1 -{[(4R,5R)-5-methyl-2-oxo-1,3-oxazolidin-4yl]methoxy}isoquinoline-6-carboxamide | |
228 | 4.2 | 118 | 3-methoxy-5-{[(4R,5R)-5-methyl-2-oxo-1,3-oxazolidin-4- yl]methoxy}naphthalene-2-carboxamide | |
229 | 3514 | 6298 | 7-methoxy-1-{[(4S)-2-oxo-1,3-oxazolidin-4- yl]methoxy}isoquinoline-6-carboxamide | |
230 | 7 | 199 | 7-methoxy-1-{[(4R)-2-oxo-1,3-oxazolidin-4- yl]methoxy}isoquinoline-6-carboxamide | |
231 | 67 | 509 | 3-methoxy-5-{[(2S,4S)-4-methoxy-5-oxopyrrolidin-2- yl]methoxy}naphthalene-2-carboxamide | |
232 | 20 | 261 | 3-methoxy-5-{[(2S,4R)-4-methoxy-5-oxopyrrolidin-2- yl]methoxy}naphthalene-2-carboxamide | |
233 | 0.3 | 47 | 3-methoxy-5-{[(4R)-2-oxo-1,3-oxazolidin-4- yl]methoxy}naphthalene-2-carboxamide | |
234 | 1.9 | 45 | 3-methoxy-5-{[(4R,5S)-5-methyl-2-oxo-1,3-oxazolidin-4- yl]methoxy}naphthalene-2-carboxamide | |
235 | 97 | 1092 | 7-methoxy-1-{[(5R)-2-oxo-1,3-oxazolidin-5- yl]methoxy]isoquinoline-6-carboxamide | |
236 | 8.4 | 125 | 7-methoxy-1-{[(4R,5S)-5-methyl-2-oxo-1,3-oxazolidin-4- yl]methoxy}isoquinoline-6-carboxamide | |
237 | 295 | 1076 | 1-{[(2S,3S,4R)-4-fluoro-3,4-dimethyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide |
326
238 | 3.7 | 45 | 1-{[(2S,3S,4S)-4-fluoro-3,4-dimethyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
239 | 1182 | 7-methoxy-1-{[(5R)-3-methyI-2-oxo-1,3-oxazolidin-5- yl]methoxy}isoquinoline-6-carboxamide | ||
240 | 2.3 | 24 | 5-{[(2S,4R)-4-fluoro-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2carboxamide | |
241 | 161 | 5765 | 5-{[(2S,4S)-4-fluoro-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yl]methoxy}-3-methoxynaphthalene-2carboxamide | |
242 | 263 | 7248 | 7-methoxy-1-{[(2S,4S)-4-methyI-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
243 | 205 | 713 | 7-methoxy-1-{[(2S,4R)-4-methyl-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
244 | 4.7 | 64 | 1-{[(2S,3S)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
245 | 29 | 529 | 7-methoxy-1-{[(6S)-4-oxo-5-azaspiro[2.4]hept-6- yI]methoxy}isoquinoline-6-carboxamide | |
246 | 0.5 | 9 | 1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
247 | 29 | 2836 | 1-{[(2S,3R,4S)-3,4-dimethyl-5-oxopyrroIidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
248 | 3.7 | 87 | 1-{[(2S,3R,4R)-3,4-dimethyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
249 | 20 | 764 | 1-{[(2S,3S)-3-(fluoromethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
250 | 0.6 | 144 | 4-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
251 | 3.4 | 72 | 1-{[(2S,3S)-3-ethenyl-5-oxopyrroIidin-2-yl]methoxy}-7- methoxyisoquinoIine-6-carboxamide | |
252 | 0.9 | 40 | 1-{[(2S,4S)-4-fIuoro-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
253 | 2.6 | 122 | 1-{[(2S,4R)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
254 | 2951 | 1-{[(2S,3S,4S)-3-(fluoromethyI)-4-methyI-5- oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | ||
255 | 1683 | 11527 | 7-methoxy-1-{[(2R)-5-oxopyrrolidin-2- yI]methoxy}isoquinoline-6-carboxamide |
327
256 | 2000 | 5617 | 1-{[(2S,4R)-4-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
257 | 6.8 | 60 | 1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
258 | 141 | 2933 | 1-{[(2S)-4-benzyl-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
259 | 3.1 | 120 | 4-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
260 | 202 | 6275 | 4-{[(2S,4R)-4-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
261 | 671 | 1-{[(2S,4R)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | ||
262 | 4.7 | 1604 | 6-methoxy-4-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}quinoline-7-carboxamide | |
263 | 80 | 496 | 1 -{[(1 R,2S, 5S)-6,6-dimethyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6- carboxamide | |
264 | 4.8 | 115 | 7-methoxy-1-{[(1 S,2S,5R)-4-oxo-3-azabicyclo[3.1,0]hex- 2-yl]methoxy}isoquinoIine-6-carboxamide | |
265 | 1539 | 7-methoxy-1-[(3-methyl-5-oxomorpholin-3yl)methoxy]isoquinoline-6-carboxamide | ||
266 | 74 | 394 | 7-methoxy-1-[(4-methyl-2-oxo-1,3-oxazolidin-4- yl)methoxy]isoquinoline-6-carboxamide | |
267 | 15 | 158 | 7-methoxy-1-{[(2S,4S)-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
268 | 1.4 | 175 | 4-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
269 | 0.6 | 104 | 4-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2- yl]methoxy}-6-(propan-2-yloxy)quinoline-7-carboxamide | |
270 | 290 | 7-methoxy-1-{[(2S,4R)-5-oxo-4-(2,2,2- trifluoroethyl)pyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | ||
271 | 2.4 | 52 | 7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide | |
272 | 432 | 2470 | 1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carbonitrile | |
73 | 4365 | 1586 | 1-(cyclopentylmethoxy)-7-methoxyisoquinoline-6- carboxamide |
328
274 | 2.2 | 748 | 4-{[(2S,4R)-4-fluoro-4-(2-fluoroethyl)-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
275 | 119 | 5137 | 1-{[(2R,4R)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7- methoxyisoquinoline-6-carboxamide | |
276 | 4.1 | 107 | 1-{[(2S,4R)-4-fluoro-4-(2-fluoroethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
277 | 289 | 4420 | 7-methoxy-1-{[(2R,3S)-3-methyl-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
278 | 8.5 | 299 | 7-ethoxy-1-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin- 2-yl]methoxy}isoquinoline-6-carboxamide | |
279 | 1.2 | 212 | 6-ethoxy-4-{[(2S,3S,4S)-4-fluora-3-methyl-5- oxopyrrolidin-2-yI]methoxy}quinoline-7-carboxamide | |
280 | 3789 | 6-ethoxy-4-{[(1 S,2S,5R)-4-oxo-3-azabicyclo[3.1.0]hex-2- yl]rnethoxy}quinoline-7-carboxamide | ||
281 | 11 | 127 | 7-(cyclopropyloxy)-1-{[(2S,3S,4S)-4-fluoro-3-methyl-5- oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
282 | 11 | 191 | 7-ethoxy-1-{[(1S,2S,5R)-4-oxo-3-azabicyclo[3.1.0]hex-2- yl]methoxy}isoquinoline-6-carboxamide | |
283 | 1 | 27 | 7-ethoxy-1-{[(2S,3S,4S)-4-fluoro-3-methyl-5- oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
284 | 18 | 320 | 1-{[(2S,4R)-4-fluoro-5-oxo-4-(tetrahydro-2H-pyran-4yl)pyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
285 | 153 | 1056 | 7-methoxy-1 -(((1 R,2S,5R,6R)-6-methyl-4-oxo-3azabicyclo[3.1.0]hexan-2-yl)methoxy)isoquinoline-6carboxamide | |
286 | 137 | 7025 | 7-methoxy-1-{[(2S,4S)-5-oxo-4-(tetrahydro-2H-pyran-4- yl)pyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
287 | 7.7 | 2302 | 6-ethoxy-4-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin- 2-yI]methoxy}quinoline-7-carboxamide | |
288 | 34 | 1809 | 1-{[(2R,3R,4R)-4-fluoro-3-methyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
289 | 562 | 6271 | 1-{[(2S,4S)-4-(4-hydroxytetrahydro-2H-pyran-4-yl)-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
290 | 1200 | 7-methoxy-1-{[(2S)-4-(oxetan-3-ylidene)-5-oxopyrrolidin- 2-yl]methoxy}isoquinoline-6-carboxamide | ||
291 | 32 | 6-ethoxy-4-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}quinoline-7-carboxamide |
329
292 | 78 | 3136 | 1-{[(2S,4R)-4-fluoro-4-(methoxymethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
293 | 1.1 | 462 | 6-ethoxy-4-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5- oxopyrrolidin-2-yl]methoxy}quinoiine-7-carboxamide | |
294 | 3.3 | 24 | 7-ethoxy-1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5- oxopyrroIidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
295 | 7.3 | 67 | 7-methoxy-1-{[(1 S,2S,5R)-1-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide | |
296 | 0.2 | 2.4 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
297 | 365 | 7125 | 7-methoxy-1-{[(1 S,2S,5R)-5-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide | |
298 | 1243 | 7-methoxy-1-{[(2S,4S)-4-(oxetan-3-yl)-5-oxopyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | ||
299 | 4.3 | 49 | 1-{[(1S,2S,5R)-1-ethyl-4-oxo-3-azabicycio[3.1.0]hex-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
300 | 75 | 931 | 1 -{[(1 S,2S,5R)-6-ethyI-4-oxo-3-azabicyclo[3.1.0]hex-2yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
301 | 338 | 4047 | 1-(((1 R,2S.5R,6R)-6-ethyl-4-oxo-3azabicyclo[3.1.0]hexan-2-yl)methoxy)-7-methoxyisoquinoline-6carboxamide | |
302 | 28 | 1275 | 7-methoxy-1-{[(2S)-6-oxopiperidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
303 | 127 | 6047 | 1-(((1S,2S,5S,6R)-6-(fluoromethyl)-4-oxo-3- azabicycIo[3.1.0]hexan-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide | |
304 | 1.3 | 35 | 1-{[(1R,2S,5S)-6-(fluoromethyl)-4-oxo-3- azabicycIo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6- carboxamide | |
305 | 2 | 57 | 1-{[(2S,3S)-3-cyclopropyl-5-oxopyrrolidin-2-yl]methoxy}- 7-methoxyisoquinoline-6-carboxamide | |
306 | 155 | 4058 | 1-(((1 R, 2S,5R, 6R)-6-(2-fluoroethyl)-4-oxo-3- azabicyclo[3.1.0]hexan-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide | |
307 | 2060 | 7-methoxy-1-{[(1 R,2S,5S)-4-oxo-3-azabicyclo[3.1.0]hex- 2-yl]methoxy}isoquinoline-6-carboxamide | ||
308 | 9.8 | 134 | 7-methoxy-1-{[(1S,2S,5R)-4-oxo-3- azabicyclo[3.2.0]hept-2-yl]methoxy}isoquinoIine-6-carboxamide |
330
309 | 0.6 | 17 | 1-{[(1R,2S,5S)-5-fluoro-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
310 | 10 | 380 | 1-(((1 S, 2S.5S, 6R)-5-fIuoro-6-methyl-4-oxo-3azabicycIo[3.1.0]hexan-2-yl)methoxy)-7-methoxyisoquinoline-6carboxamide | |
311 | 229 | 1083 | 1-{[(1S,2S,5R)-6,6-dichloro-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
312 | 1.3 | 26 | 7-methoxy-1-{[(2S,3R)-5-oxo-3-propylpyrrolidin-2- yl]methoxy}isoquinoline-6-carboxamide | |
313 | 210 | 1593 | 7-methoxy-1-{[(1S,2S,5S)-6-(methoxymethyl)-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoIine-6-carboxamide | |
314 | 1980 | 8356 | 7-methoxy-1-{[(1S,2S,5S)-6-(methoxymethyl)-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide | |
315 | 1.5 | 45 | 1-{[(1S,2S,5R)-6-fluoro-4-oxo-3-azabicyclo[3.1.0]hex-2- yl]methoxy}-7-methoxyisoquinoIine-6-carboxamide | |
316 | 129 | 464 | 4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide | |
317 | 0.6 | 22 | 1 -{[(1 R,2S,5S)-5-fluoro-4-oxo-3-azabicyclo[3.1,0]hex-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
318 | 1938 | 17188 | 1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(prop-2-yn-1- yloxy)isoquinoline-6-carboxamide | |
319 | 1948 | 10990 | 1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7- (propadienyloxy)isoquinoIine-6-carboxamide | |
320 | 0.8 | 11 | 1-{[(1R,2S,5S)-6-(difIuoromethyl)-4-oxo-3- azabicycfo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
321 | 4188 | 3-chloro-6-methoxy-4-{[(1 S,2S, 5R)-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}quinoline-7-carboxamide | ||
322 | 6.1 | 26 | 1-{[(1R,2S,5S)-5-fluoro-4-oxo-3-azabicyclo[3.2.0]hept-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
323 | 0.2 | 30 | 4-{[(1R,2S,5S)-5-fluoro-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-6-methoxyquinoline-7- carboxamide | |
324 | 0.6 | 277 | 4-{[(1S,2S,5R)-6-fluoro-4-oxo-3-azabicyclo[3.1.0]hex-2- yl]methoxy}-6-methoxyquinoIine-7-carboxamide | |
325 | 0.4 | 87 | 4-{[(1 R,2S,5S)-5-fluoro-4-oxo-3-azabicyclo[3.1,0]hex-2- yl]methoxy}-6-methoxyquinoline-7-carboxamide |
331
326 | 1.2 | 1196 | 6-methoxy-4-{[(1 S,2S,5R)-4-oxo-3-azabicycIo[3.1.0]hex- 2-yl]methoxy}quino!ine-7-carboxamide | |
327 | 20 | 3307 | 1-{[(1S,2S,5S)-6-(hydroxymethyl)-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
328 | 93 | 1-{[(1S,2S,5S)-6-(hydroxymethyl)-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | ||
329 | 13 | 252 | 1-{[(2S,3R)-3-ethenyl-5-oxopyrroIidin-2-yl]methoxy}-7- methoxyisoquinoIine-6-carboxamide | |
330 | 14 | 134 | 7-methoxy-1-{[(4S)-6-oxo-5-azaspiro[2.4]hept-4- yl]methoxy}isoquinoline-6-carboxamide | |
333 | 0.3 | 182 | 4-{[(1R,2S,5S)-6-(fluoromethyl)-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-6-methoxyquinoline-7carboxamide | |
334 | 4.2 | 1771 | 1-(((1R,2S,5R,6R)-6-fluoro-4-oxo-3- azabicyclo[3.1.0]hexan-2-yl)methoxy)-7-methoxyisoquinoline-6- carboxamide | |
335 | 4 | 746 | 1-{[(1S,2S,5R)-6-fluoro-6-methyl-4-oxo-3azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
336 | 0.3 | 674 | 1-{[(1S,2S,5R)-6-fluoro-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}-7-methoxyisoquinoline-6- carboxamide | |
337 | 0.1 | 6.5 | 1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
338 | 0.2 | 3 | 1-{[(2S,3S,4S)-3-ethyI-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-[(trideutero)methyloxy]isoquinoIine-6-carboxamide | |
339 | 90 | 269 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-(2-methoxyethoxy)isoquinoline-6-carboxamide | |
340 | 12 | 456 | 7-methoxy-1-{[(2S,3R)-3-(methoxymethyl)-5- oxopyrrolidin-2-yI]methoxy}isoquinoline-6-carboxamide | |
341 | 0.3 | 16 | 4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-6-methoxyquinazoline-7-carboxamide | |
342 | 1003 | 2382 | 1-{[(2S,3S,4S)-3-ethyI-4-methoxy-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoIine-6-carboxamide | |
343 | 41 | 408 | 1-{[(2S,3S,4R)-3-ethyl-4-methoxy-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide |
332
344 | 0.2 | 0.5 | 1-{[(2S,3S,4S)-3-(pentadeutero)ethyl-4-fluoro-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
345 | 0.2 | 1.6 | 1-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
346 | 6.1 | 150 | 1-{[(2S,3R,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
347 | 0.6 | 27 | 1-{[(2S,3R)-4,4-difluoro-3-(methoxymethyl)-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
348 | 0.7 | 42 | 1-{[(2S,3R,4S)-4-fluoro-3-(methoxymethyl)-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoIine-6carboxamide | |
349 | 2962 | 9461 | 7-methoxy-1-{[(2S,3S,4S)-4-methoxy-3-methyl-5- oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
350 | 58 | 568 | 7-methoxy-1-{[(2S,3S,4R)-4-methoxy-3-methyI-5- oxopyrrolidin-2-yl]methoxy}isoquinoline-6-carboxamide | |
351 | 6.3 | 213 | 1-{[(2S,3R,4R)-4-fluoro-3-(methoxymethyl)-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
352 | 3.3 | 557 | 1-{[(2S,3S,4S)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
353 | 0.5 | 20 | 1-{[(2S,3S,4R)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
354 | 2887 | 7-methoxy-1-{(1 S)-1-[(2S)-5-oxopyrrolidin-2- yl]ethoxy}isoquinoline-6-carboxamide | ||
355 | 1.7 | 33 | 1-{[(2S,3S)-3-(2-fluoroethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
356 | 115 | 594 | 1-{[(2S,3R,4S)-4-amino-3-ethyl-5-oxopyrroIidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
357 | 30 | 588 | 1-{[(2S,3R,4R)-4-amino-3-ethyl-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
358 | 0.4 | 1.3 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yIoxy)isoquinoline-6-carboxamide | |
359 | 0.4 | 3.9 | 7-ethoxy-1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin- 2-yl]methoxy}isoquinoline-6-carboxamide | |
360 | 0.1 | 3.9 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-4-fIuoro-7-methoxyisoquinoline-6-carboxamide |
333
361 | 4.8 | 27 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrroJidin-2- yl]methoxy}-8-fluoro-7-methoxyisoquinoline-6-carboxamide | |
362 | 1.1 | 28 | 1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-4- fluoro-7-methoxyisoquinoline-6-carboxamide | |
363 | 11 | 110 | 1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-8- fIuoro-7-methoxyisoquinoline-6-carboxamide | |
364 | 16 | 145 | 4-fluoro-7-methoxy-1 -{[(1 S,2S,5R)-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide | |
365 | 187 | 724 | 8-fluoro-7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3- azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoIine-6-carboxamide | |
366 | 6.1 | 91 | 1-{[(2S,3R)-3-(fluoromethyl)-5-oxopyrrolidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
367 | 0.4 | 14 | 1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrroIidin- 2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
368 | 0.3 | 10 | 1-{[(2S,3S,4S)-3-cycIopropyl-4-fluoro-5-oxopyrroIidin-2- yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
369 | 3.7 | 45 | 1-{[(2S,3S,4R)-3-cyclopropyl-4-fluoro-5-oxopyrrolidin-2- yl]methoxy}-7-meihoxyisoquinoline-6-carboxamide | |
370 | 0.1 | 3.7 | 1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | |
371 | 7 | 604 | 4-(1 -methyl-1 H-imidazol-4-yl)-1 -{[(2S)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
372 | 11 | 649 | 4-(1,2-dimethyl-1 H-imidazol-4-yl)-1-{[(2S)-5- oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6carboxamide | |
373 | 35 | 6162 | 4-(2-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | |
374 | 0.1 | 1.2 | 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo(3,4- bisdeutero)pyrroIidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide | |
375 | 0.3 | 1-{[(2S,3R,4R)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin- 2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide | ||
376 | 740 | 4-(4-methylpyrimidin-2-yl)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide | ||
377 | 72 | 4-(5-chloropyrimidin-2-yl)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yIoxy)isoquinoline-6-carboxamide | ||
378 | 59 | 4-(6-oxo-1,6-dihydropyridin-2-yl)-1-{[(2S)-5- oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6carboxamide |
334
379 | 503 | 4-(2-methylpyrimidin-4-yI)-1-{[(2S)-5-oxopyrrolidin-2- yl]methoxy}-7-(propan-2-yloxy)isoquinoline-6-carboxamide |
In vivo mouse LPS/D-qal Challenge Model.
Efficacy of IRAK4 compounds of the présent invention was also evaluated in an in vivo mouse model of endotoxin induced (Lipopolysaccharide(LPS)) inflammation. See: S. Copeland, H.W. Warren, S.F. Lowry, S.E. Calvano, and D. Remick, Clin. Diagn. Lab. Immnol. 2005, 12(1), 6067. An exemplary protocol for this in vivo model follows.
Female C57/BL6 mice, 8 to 10 weeks old, are orally administered either vehicle or formulated IRAK-4 compound 1 hour prior to the challenge. Vehicle or IRAK4 compound is 10 administered by oral gavage at a volume of 10 mL/kg. One hour post oral delivery of vehicle or compound, the animais are challenged with an intraperitoneal injection (IP) of a solution containing 1 pg/mL LPS and 80 mg/mL D-gal. Each mouse is injected with 200 pL of the solution, for a final challenge dose of 100 ng LPS and 8 mg D-gal. Ninety minutes post LPS/D-gal challenge, animais are euthanized and blood collected. Blood is allowed to clôt at room température and sérum is 15 separated by centrifugation and stored at -80 °C for analysis. Sérum TNF and IL-6 are measured by Meso Scale Discovery (MSD) multiplex platform.
The groups consisted of N=10 animals/group. Naïve animais and vehicle control groups were run with each study. Mean cytokine data was plotted and students T-test was performed to calculate significance (t-test, p<0.05 vs. vehicle) of IRAK4 treated group vs. vehicle treated group. 20 Percent inhibition of cytokine induction was calculated for IRAK4 treated group vs. vehicle treated group.
Table 4 contains data from multiple studies with columns for Compound, Dose in mg/kg (mpk) and % inhibition of sérum TNF. In cases where doses of certain compounds were repeated in multiple experiments, the average percent inhibition of TNF and standard déviation is shown in 25 the table.
Table 4 % Inhibition of TNF in mouse LPS model with various IRAK4 inhibitors.
Compound | Dose (mpk) | % inhib TNF |
Example 26 | 100 | 78 (+ 23) |
30 | 41 (+17) | |
10 | 27(+19) | |
Example 173 | 100 | 98 |
30 | 55 | |
Example 189 | 30 | 40 |
Example 194 | 30 | 76 |
335
Imiquimod Induced Mouse Model of Skin Inflammation.
Efficacy of IRAK4 inhibitors ofthe présent invention was also evaluated in an in vivo mouse model imiquimod induced skin inflammation inflammation (L. van der Fits, S. Mourits, J. S.A. Voerman, M. Kant, L. Boon, J.D. Laman, F. Cornelissen, A.-M. Mus, E. Florencia, E.P. Prens, and E. Luberts, J. Immunol. 2009, 182, 5836-5845). An exemplary protocol for this in vivo model follows.
Female Balb/C mice, 12-14 weeks old, received a daily topical dose of commercially available imiquimod cream (5%) on the shaved back and the left ear for 3 consecutive days. This translated into a daily dose of 1.56 mg ofthe active compound. This dosing regimen was optimized to achieve robust skin inflammation in mice as measured by increased ear thickness. Vehicle or IRAK4 compounds are administered by oral gavage, twice daily (AM and PM) for 5 consecutive days. Ear thickness were measured daily, 1 hour post AM oral administration of compound or vehicle and prior to application of imiquimod. An exemplary protocol for this in vivo model follows.
• On Day 1, mice were pre-treated with vehicle or IRAK4 inhibitor by oral gavage at a volume of 10 mL/kg. Oral dosing of compound or vehicle continued twice daily (BID) for 5 consecutive days.
• One hour post vehicle or compound delivery, baseline ear thickness was measured in triplicate using a micrometer (Mitutoyo) prior to the application of imiquimod. Ear thickness was measured each day in this manner and then the imiquimod cream was applied to back skin and left ear on Days 1, 2 and 3.
• On Day 5 ofthe study, mice were given the AM dose of vehicle or IRAK4 inhibitor. One hour after oral delivery, ears were measured and animais were euthanized. The left ear was collected; snap frozen and stored at -80 °C for analysis.
• Data were presented as mean change in ear thickness (microns) from baseline measu rement.
• Positive contrai compound for the model was two IP injections of anti-P40 antibody at a dose of 400 pg/mouse given on Days 1 and 4.
In vivo rat collaqen-induced arthritis model. Efficacy of IRAK4 compounds of the présent invention was also evaluated in a rat in vivo model of rheumatoid arthritis (M. Hegen, J.C. Keith, Jr, M. Collins, C. L. Nickerson-Nutter, Ann. Rheum. Dis. 2008, 67, 1505-1515). An exemplary protocol for this in vivo model follows.
Female Lewis rats, approximately 7 weeks old, were immunized with an émulsion of type II collagen (Cil) and incomplète Freund’s adjuvant (IFA) on day 0 and received a boost of Cll/IFA on day 7. Hind paw volume increase was taken by plethysmograph. Animais were randomly enrolled into treatment groups based on the development of disease. Beginning on day 11 post
336
immunization, rats were enrolled into random treatment groups based on an increase in a single hind paw volume compared to day 7 post immunization baseline measurements.
The groups consisted of: (1) a naïve control group, (2) a vehicle control group, (3) a group dosed orally with a p38 inhibitor, (4) a positive control, at 30 mg/kg once a day, (5) a group dosed 5 orally with Example 26 at 100 mg/kg twice a day, (6) a group dosed orally with Example 26 at 30 mg/kg twice a day, and (7) a group dosed orally with Example 26 at 10 mg/kg twice a day.
Ten rats were enrolled per treatment group with the exception of the naïve control group, which contained two rats. Day 0 was designated as the first treatment day, and paw measurements are taken daily by plethysmograph. The rats were weighed on a daily basis.
IRAK4 inhibitors are efficacious in the Lewis rat model of collagen-induced arthritis. Results of the study are presented in Figure 2 which demonstrates the average paw volume increase of the groups dosed orally. In particular, therapeutic treatment BID daily with Example 26 for 8 days reduced the hind paw swelling in CIA rats significantly (t-test, p<0.05 vs. vehicle) in the following groups:
Example 26 100 mg/kg PO, BID
Example 26 30 mg/kg PO, BID
BIRB796 30 mg/kg PO, QD
Day 1 - Day 8 (end)
Day 2 - Day 8
Day 1 - Day 8
Animais treated with
Example 26 at 10 mg/kg PO, BID showed a transiently significant réduction in hind paw swelling only on Day 5 and Day 6 post treatment.
337
Claims (41)
- We claim:1. A compound of Formula la,R8 la whereinX and X’ are each CR8; Y is N, or -N+-0‘ ;R1 is Ci-C6alkyl; C2-C6alkenyl; or C2-C6alkynyl; wherein said alkyl, alkenyl, or alkynyl, is optionally substituted with one to five halogen, deuterium, -OR5, -SR5, NR11aR11b, cyano, CrCealkyl, C3-C6cycloalkyl or-C-|-C6alkoxy;R2 is -(CR3aR3b)m-(3- to 10-membered cycloalkyl); -(CR3aR3b)m-(3- to 10membered heterocycloalkyl) having one to three heteroatoms; -(CR3aR3b)m-(5- to 10 membered heteroaryl) having one to three heteroatoms; or -(CR3aR3b)m-C6-C12aryl; wherein said cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to five R4; and wherein, if the heteroatom on said heterocycloalkyl and heteroaryl is N, said N is optionally substituted with R4; or R2 is CrCgalkyl, wherein said alkyl is optionally substituted with NH2, OH or cyano;R3a and R3b for each occurrence are independently hydrogen or Ci-C3alkyl;R4 for each occurrence is independently a bond, deuterium halogen, cyano, CiC6alkyl, C2-C6alkenyl, oxo, -OR5, -SR5, -S(O)R9, -S(O)2R9, -NR11aR11b, -C(O)R10, (CR3aR3b)n-(3- to 7- membered cycloalkyl), -(CR3aR3b)n-(4- to 10- membered heterocycloalkyl), having one to three heteroatoms, -(CR3aR3b)n-(5- to 10 membered heteroaryl), having one to three heteroatoms, or ~(CR3aR3b)n- C6-C12aryl wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is each optionally and independently substituted with one tofive deuterium, halogen, OR5, -SR5, -NR11aR11b, cyano, C-pCealkyl, C3-C6cycloalkyl or - CrCealkoxy; or two R4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano or Ci-C6alkyl or C-r C6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen,338 deuterium, -OR5, -SR5, -NR11aR11b or cyano; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with R4’;R4’ is independently C-|-C6alkyl, C2-C6alkenyl, -C(O)R10, -S(O)2R9, -(CR3aR3b)n(3- to 7- membered cycloalkyl), -(CR3aR3b)n-(4- to 10- membered heterocycloalkyl) or C(O)(CH2)tCN; wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano or Ct-C6alkoxy; or R4 and R4 taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, C-|-C6alkyl or C-|-C6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, -OR5, -SR5, NR11aR11b, or cyano;R5 is independently hydrogen or CrCgalkyl, wherein said alkyl is optionally substituted with halogen, deuterium, Ci-C6alkoxy, C-i-Cgalkylthiolyl, -NR11aR11b, cyano, Ci-C6alkyl or C3-C6cycloalkyl; or two R5 taken together with the oxygen atoms to which they are bonded form a 5- or 6-membered heterocycloalkyl;R6 is -C(O)NHR7, CO2R7 or cyano;R7 is hydrogen or C^Cealkyl;each R8 is independently hydrogen, halogen, cyano, -OR5, -SR5, -NR11aR11b, C-|-C6alkyl, C3-C6cycloalkyl, 3- to 10-membered heterocycloalkyl or 5- to 6-membered heteroaryl or aryl, wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl is optionally substituted with one to three halogen, -NR11aR11b, -OR5, -SR5, cyano, C1-C3 alkyl, -C(O)R10 or oxo;R8’ is hydrogen, deuterium, halogen, cyano, -OR5, -SR5 or NR11aNR11b;R9 is -(CR^R^p-iCrCgalkyl), -(CR3aR3b)p-(4- to 6- membered cycloalkyl), -(CR3aR3b)p-(4- to 6- membered heterocycloalkyl) or -(CR3aR3b)p-( C5-C9aryl), wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl are each optionally substituted with fluoro or C^Csalkyl;R10 is C-i-Cealkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, Ci-C6alkoxy or cyano;R11a and R11b are each independently hydrogen or Cj-Cealkyl, wherein said alkyl is optionally substituted with deuterium, Ci-C6alkoxy or cyano; and if C2-C6alkyl, said alkyl is optionally substituted with deuterium, Ci-C6alkoxy, cyano, halogen or OH;m is independently 0, 1, 2 or 3;n is independently 0, 1,2 or 3;p is independently 0 or 1; and tis 1, 2 or 3;339 or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 2. The compound of claim 1 wherein R6 is -C(O)NHR7, -CO2R7 or cyano; and R7 is hydrogen; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 3. The compound of claim 1 or 2 wherein X is N, X’ is CR8 and Y is CR8 ; X is N, X’ is N and Y is CR8 ; X is N, X’ is CR8 and Y is N; X is CR8, X’ and Y are N; X and X’ are CR8 and Y is N; X is CR8 and Y is CR8' and X’ is N; X and X’ are CR8 and Y is CR8'; or a pharmaceutically acceptable sait of said compound or a tautomer of said sait.
- 4. A compound of Formula llb,Ib whereinR1 is C^Cealkyl; C2-C6alkenyl; or C2-C6alkynyl; wherein said alkyl, alkenyl, or alkynyl, is optionally substituted with one to five halogen, deuterium, -OR5, -SR5, NR11aR11b, cyano, CrC6alkyl, C3-C6cycloalkyl or -C-|-C6alkoxy;R2 is ~(CR3aR3b)m-(3- to 7-membered cycloalkyl), wherein said cycloalkyl is optionally substituted with one to four R4; -(CR3aR3b)m-(3- to 7-membered heterocycloalkyl) having one to three heteroatoms, wherein said heterocycloalkyl is optionally substituted at a carbon atom with one to five R4 and wherein, if the heteroatom is N, said N is optionally substituted with R4; or R2 is CrCealkyl, wherein said alkyl is optionally substituted with NH2, cyano or halogen;R3a and R3b are each independently hydrogen or C-rC3alkyl;R4 for each occurrence is independently and optionally halogen, cyano, Cr C6alkyl, C2-C6alkenyl, oxo, -OR5, -SR5,-S(O)R9, -S(O)2R9, -C(O)R10, -(CR3aR3b)n-(3- to 7membered cycloalkyl) or -(CR3aR3b)n-(4- to 7- membered heterocycloalkyl) wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally and independently substituted with one to five deuterium, halogen, -OR5, -SR5, -NR11aR11b, cyano, Ci-C6alkyl,340C3-C6cycloalkyl C-j-Cealkoxy or NR11aR11b; or two R4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano or C-j-Cealkyl or C-|-C6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, -OR5, -NR11aR11b, or cyano ; and wherein, if a heteroatom on said heterocycloalkyl is N, said N is optionally substituted with R4’;R4’ is independently Ci-C6alkyl, C2-C6alkenyl, -S(O)R9, -S(O)2R9, -C(O)R10, C(O)(CH2)tCN; wherein said alkyl is optionally substituted with NH2, cyano or halogen (CR3aR3b)n-(3- to 7- membered cycloalkyl), -(CR3aR3b)n-(4- to 10- membered heterocycloalkyl), wherein said alkyl, alkenyl, cycloalkyl, or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano or C-|-C6alkoxy; or R4 and R4’ taken together with the respective atoms to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three halogen, deuterium, -OR5, -SR5, -NR11aR11b, cyano, C-|-C6alkyl or C-|-C6alkoxy, wherein the alkyl or alkoxy is optionally substituted with halogen, deuterium, -OR5, -SR5, NR11aR11bor cyano;R5 is hydrogen or Ci-C6alkyl, wherein said alkyl is optionally substituted with halogen;R6 is -C(O)NHR7 or cyano;R7 is hydrogen or Ci-C6alkyl;R8 is independently hydrogen, halogen, cyano,,-NR11aR11b, Ci-C6alkyl, 5- to 6membered heteroaryl or 5- to 6- membered aryl, wherein said alkyl or heteroaryl or aryl is optionally substituted with one to three halogen, -NR11aR11b, CrC3 alkyl or oxo;R8’ is hydrogen, deuterium, halogen, cyano, -OR5, or NR11aNR11b;R9 is -(CR3aR3b)p-(C1-C3alkyl), -(CR3aR3b)p-(4- to 6- membered cycloalkyl), -(CR3aR3b)p-(4- to 6- membered heterocycloalkyl) or -(CR3aR3b)p-(C5-C9aryl), wherein said alkyl, cycloalkyl, heterocycloalkyl or aryl is each optionally substituted with fluoro or C-pCsalkyl;R10 is C-|-C6alkyl, wherein said alkyl is optionally substituted with fluoro or cyano;R11a and R11b are each independently hydrogen or CrCealkyl, wherein said alkyl is optionally substituted with OH;m is independently 0, 1 or 2;n is independently 0 or 1;p is independently 0 or 1; and t is 0, 1, 2 or 3;341 or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 5. The compound of Claim 4 whereinR1 is C1-C4alkyl;R3a and R3b are each independently hydrogen or C-|-C3alkyl;R6 is -C(O)NHR7 or cyano;R7 is hydrogen; and m is independently 0 or 1;or a pharmaceutically acceptable sait of said compound or a tautomer of said compound.
- 6. The compound of Claim 5 wherein R1 is fluoromethyl; difluoromethyl; trifluoromethyl; methyl, ethyl, propyl or isopropyl, each optionally substituted with one to three fluoro or deuterium; aliéné, propargyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, oxetane or tetrahydrofuran, each of which is optionally substituted with fluoro or ^-Ό3 alkyl; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 7. The compound of Claim 6 wherein the cycloalkyl, heterocycloalkyl and Cr C6alkyl of R2 is selected from pyrrolidinyl, pyrrolidin-2-onyl, piperidinyl, piperidin-2-onyl, octahydro-1H-pyrrolo[3,4-c]pyridinyl, oxazolidinyl, oxazolidin-2-onyl, 1,3-oxazinan-2-onyl, imidazolidinyl, imidazolidin-2-onyl, morpholinyl, morpholin-3-onyl, thiazyl, isothiazyl, isothiazolidine-1,1-dioxidyl, 1,2-thiazinane 1,1-dioxidyl, hexahydrocyclopenta/jbjpyrrol2(1H)-onyl, octahydrocyclopenta[c]pyrrolyl, azetidinyl, hexahydro-1/-/-indol-2(3H)-onyl, octahydro-1/7-isoindolyl, azepanyl, tetrahydrofuranyl, 1,3-dioxolanyl, oxetanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-azepanyl, 1,4-oxazepanyl, tetrahydro2H-pyranyl, 6,7-dihydro-5H-pyrrolo[1,2-a]imidazolyl, cyclohex-2-enyl, or 1,2,3,4tetrahydroisoquinolinyl; wherein said alkyl, cycloalkyl or heterocycloalkyl is optionally substituted with one to four R4; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.342
- 8. The compound of Claim 7 wherein the cycloalkyl or heterocycloalkyl of R25 wherein said cycloalkyl and heterocycloalkyl is optionally substituted with one to four R4; or two R4 taken together with the respective carbons to which each are bonded form a 3- to 6-membered cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three F, Cl, OH, cyano, C-|-C3alkyl (optionally substituted with OH, F or Cl), C^Csfluoroalkyl or 10 C-i-C6alkoxy;Rq is independently hydrogen, deuterium or C-|-C3alkyl, wherein said alkyl is optionally substituted with halogen; and343R3a and R3b for each occurrence are independently hydrogen or C-|-C3alkyl;R4 for each occurrence is independently and optionally halogen; C^C^kyl; C2-C4alkenyl; oxo; -OR5; -C(O)R10; -(CR3aR3b)n-(3- to 5-membered cycloalkyl); or (CR3aR3b)n-(4- to 7- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, cyano, C-|-C6alkoxy or -NR11aR11b; or two R4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three halogen, OH, methyl, ethyl, propyl, CfCsfluoroalkyl, C-i-Cshydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the respective carbons to which each are bonded form a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one to three fluoro, CrCsalkyl, or CrCsfluoroalkyl;R5 is hydrogen, methyl or ethyl;R9 is phenyl;R10 is CrCealkyl, wherein said alkyl is optionally substituted with fluoro or cyano; andR11a and R11b are each independently H or Ci-C6alkyl;or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait.
- 9. The compound of Claim 8 wherein R4 is selected from F, Cl, OH; Ci-C3alkyl, optionally substituted with one to five deuterium, Cl, F, OH, CrC3alkyl, C-i-Csalkoxy; or two R4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three Cl, F, OH, methyl, ethyl, propyl, C^Cafluoroalkyl, CrCshydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the respective carbons to which each are bonded form a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one to three fluoro, C1-C3alkyl, C-i-Csfluoroalkyl, -C(O)(CH2)tCN; or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait.344
- 10. A compound of Formula III,III whereinX and X’ are each CR8; Y is N ;R1 is CrCealkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, cyano, ^-C^lkyl, C3-C6cycloalkyl, Ci-C6alkoxy or CrCealkylthiolyl;R3a and R3b are each independently hydrogen or Cf-Csalkyl;R4 for each occurrence (one, two, three, four or five) is independently and optionally halogen, CrCealkyl, C2-C6alkenyl -OR5, -(CR3aR3b)n-(3- to 6- membered cycloalkyl), -(CR3aR3b)n-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl or heterocycloalkyl is each optionally and independently substituted with one to five deuterium, halogen, OH, CN, -C(O)(CH2)tCN or -CrC6alkoxy; -NR11aR11b; two R4 taken together with the respective carbons to which each are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three F, Cl, OH, methyl, ethyl, propyl, Ci-C3fluoroalkyl, CrC3difluoroalkyl, CrC3trifluoroalkyl, CrC3hydroxyalkyl, methoxy or ethoxy;R5 is hydrogen or C-t-C6alkyl, wherein said alkyl is optionally substituted with fluoro;R8 is independently hydrogen, halogen, cyano, -NR11aR11b, C1-Cealkyl, 5- to 6membered heteroaryl or aryl, wherein said alkyl or heteroaryl or aryl is optionally substituted with one, two or three halogen, -NR11aR11b, Ο4-Ο3 alkyl or oxo;R8' is hydrogen, deuterium, halogen or cyano;R10 is CrCealkyl, wherein said alkyl is optionally substituted with fluoro or cyano;R11a and R11b are each independently hydrogen or CrCealkyl, wherein said alkyl is optionally substituted with OH;n is independently 0 or 1; and t is 1, 2 or 3;or a pharmaceutically acceptable sait of said compound or a tautomer of said compound.345
- 11. The compound of Claim 10 wherein R1 is C-|-C3alkyl, wherein said alkyl is optionally substituted with one to three deuterium, F, Cl or C-i-Csalkoxy; and R3a and R3b are each independently hydrogen or methyl; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound.
- 12. The compound of Claim 11 wherein R4 for each occurrence is independently and optionally F; Cl; OH; or C-|-C3alkyl, optionally substituted with one to five deuterium, Cl, F, OH, Cj-Csalkyl, or Ci-C3alkoxy; or two R4 taken together with the carbons to which they are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl is optionally substituted with one to three Cl, F, OH, methyl, ethyl, propyl, CrCshaloalkyl, C^Csdihaloalkyl, C-|-C3trihaloalkyl, C-i-Cshydroxyalkyl, methoxy or ethoxy; or two R4 taken together with the carbons to which they are bonded form a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with one to three fluoro, CrCsalkyl, C-i-Csfluoroalkyl or -C(O)(CH2)tCN; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or sait.
- 13. The compound of claim 12 wherein R1 is methyl, ethyl, propyl or isopropyl wherein each of said R1 moieties are optionally substituted with deuterium, fluoro or methoxy; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound.
- 14. The compound of claim 13 wherein each R4 is independently and optionally selected from fluoro, OH, methyl, ethyl, vinyl, propyl, wherein said methyl, ethyl, vinyl or propyl are optionally substituted with one, two or three fluoro, OH or methoxy; or two R4 taken together with the carbons to which they are bonded form a cyclopropyl, cyclobutyl or cyclopentyl, wherein said cyclopropyl, cyclobutyl or cyclopentyl are optionally substituted with one to three Cl, F, OH, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethyl, methoxymethyl, propyl, CrCshaloalkyl, C-|-C3dihaloalkyl, C-|-C3trihaloalkyl, CrCshydroxyalkyl, methoxy, or ethoxy; andR8 is independently hydrogen, halogen or Cj-Cealkyl, wherein said alkyl is optionally substituted with fluoro;or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.346
- 15. A compound of Formula Ilia,Ilia whereinX and X’ are CR8 or N; Y is N;R1 is Cf-Cealkyl, wherein said alkyl is optionally substituted with deuterium, halogen, OH, Ci-C3alkyl, C3-C6cycloalkyl or Ci-C6alkoxy;R3a and R3b are each independently hydrogen or C-|-C3alkyl;R4a and R4b are each independently hydrogen, deuterium, fluoro, OH, -OR5, methyl, ethyl, vinyl, cyclopropyl or propyl, optionally substituted with one to five deuterium, fluoro, methoxy or OH;R4c and R4d for each occurrence are independently and optionally halogen, OH, deuterium, C^Cealkyl, C2-C6alkenyl, -OR5, -(CR3aR3b)n-(3- to 6- membered cycloalkyl), or -(CR3aR3b)n-(4- to 6- membered heterocycloalkyl) wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally and independently substituted with one to five deuterium, halogen, OH, cyano, or CrC6alkoxy; NH2; or R4c and R4d taken together with the carbons to which they are bonded form a 4- to 7-membered heterocycloalkyl or a 3to 7-membered cycloalkyl, wherein said heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, C^C^kyl or C-j-Cafluoroalkyl; orR4a and R40 taken together with the carbon to which they are bonded form a 4- to 7-membered heterocycloalkyl or a 3- to 7-membered cycloalkyl, wherein said heterocycloalkyl or cycloalkyl is optionally substituted with one to three fluoro, C-|-C3alkyl or CfCsfluoroalkyl;R5 is hydrogen or Ci-C6alkyl, wherein said alkyl is optionally substituted with fluoro;R8 is hydrogen, halogen or CrCgalkyl, wherein said alkyl is optionally substituted with halogen;R8’ is hydrogen, deuterium, halogen or cyano; and n is independently 0 or 1;347 or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 16. The compound of Claim 15 wherein R8 is hydrogen, methyl or fluoro; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 17. The compound of Claim 16 wherein R1 is methyl, ethyl, isopropyl or propyl, optionally substituted with deuterium; or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 18. The compound of Claim 17 whereinR4a is hydrogen; methyl, ethyl or propyl, optionally substituted with deuterium, fluoro, methoxy;R4b is hydrogen or fluoro;R4c is hydrogen or OH;R4d is hydrogen, fluoro, methoxy or OH; or methyl, optionally substituted with 1, 2 or 3 fluoro; or ethyl, optionally substituted with 1, 2, or 3 fluoro; orR4c and R4d or altematively R4a and R4c taken together with the carbons to which they are bonded form a cyclopropyl, optionally substituted with one to three fluoro, Ci-C3alkyl or CrCsfluoroalkyl;or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or said sait.
- 19. A compound of Claim 4 selected from:1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline6-carboxamide;1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;1-{[(2S,4S)-4-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline6-carboxamide;1-{[(2S,4S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2-yloxy)isoquinoline6-carboxamide;1-{[(2S)-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,4S)-5-oxo-4-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;3481-{[(2S,3S,4R)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;1-{[(2S,4S)-4-fluoro-4-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3S)-4l4-difluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;1-{[(2S,3S,4R)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;7-methoxy-1-{[(2S,3R)-3-methyl-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6carboxamide;1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;4-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-6-methoxyquinoline-7carboxamide;1-{[(2S,3S)-3-ethenyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,4S)-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,4S)-4-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;7-methoxy-1-{[(1S,2S,5R)-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6carboxamide;7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2yl]methoxy}isoquinoline-6-carboxamide;3497-ethoxy-1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}isoquinoline6-carboxamide;7-ethoxy-1-{[(2S,4S)-4-fluoro-4-(fluoromethyl)-5-oxopyrrolidin-2yl]methoxy}isoquinoline-6-carboxamide;7-methoxy-1-{[(1S,2S,5R)-1-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2yl]methoxy}isoquinoline-6-carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline6-carboxamide;1-{[(1S,2S,5R)-1-ethyl-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1 -{[(1 R,2S,5S)-6-(fluoromethyl)-4-oxo-3-azabicyclo[3.1,0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S)-3-cyclopropyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1 -{[(1 R,2S,5S)-5-fluoro-6-methyl-4-oxo-3-azabicyclo[3.1,0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;7-methoxy-1-{[(2S,3R)-5-oxo-3-propylpyrrolidin-2-yl]methoxy}isoquinoline-6carboxamide;1 -{[(1 S,2S,5R)-6-fluoro-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(1R,2S,5S)-5-fluoro-4-oxo-3-azabicyclo[3.1.0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1 -{[(1 R,2S,5S)-6-(difluoromethyl)-4-oxo-3-azabicyclo[3.1,0]hex-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(1R,2S,5S)-5-fluoro-4-oxo-3-azabicyclo[3.2.0]hept-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;7-methoxy-1-{[(4S)-6-oxo-5-azaspiro[2.4]hept-4-yl]methoxy}isoquinoline-6carboxamide;1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline6-carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7[(trideuterium)methyloxy]isoquinoline-6-carboxamide;1-{[(2S,3S,4R)-3-ethyl-4-methoxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4S)-3-(pentadeuterium)ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;3501-{[(2S,3S)-3-ethyl-4,4-difluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline6-carboxamide;1-{[(2S,3R,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-nnethoxyisoquinoline6-carboxamide;1-{[(2S,3R)-4,4-difluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3R,4S)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;7-methoxy-1-{[(2S,3S,4R)-4-methoxy-3-methyl-5-oxopyrrolidin-2yl]methoxy}isoquinoline-6-carboxamide;1-{[(2S,3R,4R)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4R)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S)-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;7- ethoxy-1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}isoquinoline-6carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-4-fluoro-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-8-fluoro-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-4-fluoro-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-8-fluoro-7-methoxyisoquinoline-6carboxamide;4-fluoro-7-methoxy-1 -{[(1 S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1,0]hex-2yl]methoxy}isoquinoline-6-carboxamide;8- fluoro-7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2yl]methoxy}isoquinoline-6-carboxamide;1-{[(2S,3R)-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6~carboxamide;3511-{[(2S,3S,4S)-3-cyclopropyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4R)-3-cyclopropyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;4-(1 -methyl-1 H-imidazol-4-yl)-1 -{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;4-(1,2-dimethyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrro)idin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;4-(2-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;4-(2-methyl-1H-imidazol-4-yl)-1-{[(2S)-5-oxopyrrolidin-2-yl]methoxy}-7-(propan-2yloxy)isoquinoline-6-carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxo(3,4-bisdeuterium)pyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide; and1-{[(2S,3R,4R)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;or a pharmaceutically acceptable sait of said compound or a tautomer of said compound or sait.
- 20. The compound of Claim 19 selected from,1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;7-methoxy-1-{[(1S,2S,5R)-6-methyl-4-oxo-3-azabicyclo[3.1.0]hex-2yl]methoxy}isoquinoline-6-carboxamide;1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline6-carboxamide;1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline6-carboxamide;1-{[(2S,3R,4S)-4-fluoro-3-(methoxymethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;3521-{[(2S,3S,4R)-3-ethyl-4-hydroxy-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S)-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6carboxamide;1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide; and1-{[(2S,3R,4R)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide;or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait.
- 21. A compound according to any of the preceding daims for use in a method of treating a mammal, including a human, having a disease or condition selected from the group consisting of autoimmune diseases; inflammatory diseases; autoinflammatory conditions; pain conditions; respiraratory; airway and pulmonary conditions; gastrointestinal (Gl) disorders; allergie diseases; infection-based diseases; trauma and tissue injury-based conditions; fibrotic diseases; diseases driven by over-activity of IL1 pathways; ophthalmic/ocular diseases; joint, muscle and bone disorders; skin/dermatological diseases; rénal diseases; genetic diseases; hematopoietic diseases; liver diseases; oral diseases; metabolic diseases, including diabètes (e.g. Type II) and complications thereof; proliférative diseases; cardiovascular conditions; vascular conditions; neuroinflammatory conditions; neurodegenerative conditions; cancer; sepsis; pulmonary inflammation and injury; or pulmonary hypertension.
- 22. The compound for use according to Claim 21 wherein the disease or condition is systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopie dermatitis, goût, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm.
- 23. A compound according to any of Claims 1 to 20 for use in a method for treating a disease or condition mediated by or otherwise associated with an IRAK receptor.353
- 24. A pharmaceutical composition comprising a compound of any of Claims 1 to 20 or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait and a pharmaceutically acceptable vehicle, diluents or carrier.
- 25. A pharmaceutical combination comprising a therapeutically effective amount of a composition comprising:a first compound, the first compound being a compound of any of Claims 1 to 20 or a pharmaceutically acceptable sait thereof or a tautomer of said compound or said sait;a second compound, the second compound being selected from an approved drug or a clinical candidate useful for the treatment of systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopie dermatitis, goût, cryopyrinassociated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm; and an optional pharmaceutically acceptable carrier, vehicle or diluent.
- 26. A pharmaceutical combination comprising a therapeutically effective amount of a composition comprising:a first compound, the first compound being a compound of any of Claims 1 to 20 or a pharmaceutically acceptable sait thereof;a second compound, the second compound being selected from the group consisting of a non-steroidal anti-inflammatory drugs, immunomodulatory and/or antiinflammatory agents, antimalarials, antibiotics, Anti-TNFa agents, Anti-CD20 agents, Antidiarrheals, Bile acid binding agents, laxatives, T lymphocyte activation, Anti-IL1 treatments, Glucocorticoid receptor modulators, Aminosalicyic acid dérivatives including but not limited to: sulfasalazine and mesalazine, Anti-a4 integrin agents, cc1- or a2adrenergic agonist agents, β-adrenergic agonists, Anticholinergic agents, inhaled long acting beta-agonists, long acting muscarinic antagonists, long acting corticosteroids, leukotriene pathway modulators, H1 receptor antagonists, PDE4 inhibitors, Vitamin D receptor modulators, Nrf2 pathway activators, Modulators of the RAR-related orphan receptor (ROR) family, Modulator and/ or antagonists of the chemokine receptors, Prostaglandins, PDE5 inhibitors, Endothelin receptor antagonists, Soluble guanylate cyclase activators, Interferons, Sphingosine 1-phosphate receptor modulators, Inhibitors of the complément pathway, Inhibitors of Janus kinases (one of more of JAK1, JAK2, JAK3, TYK2), Inhibitors of other anti-inflammatory or immunomodulatory kinases,354Antioxidants, Inhibitors of IL5, Inhibitors of IL4, Inhibitors of IL13, Anti-IL6 agents, Inhibitors/Antagonists of IL17/IL17R, Antagonists of IL12 and/or IL23, Inhibitors of IL33, Inhibitors of IL9, Inhibitors of GM-CSF, Anti CD4 agents, CRTH2 antagonists, Inhibitors of B lymphocyte stimulator, CD22-specific monoclonal antibodies, Inhibitors of interferona, Inhibitor of type I interferon receptors, FcyRIIB agonists, Modified and/or recombinant versions of Heat Shock Protein 10, Inhibitors of the TNF superfamily receptor 12A, Inhibitors of xanthine, Inhibitors of URAT1, agents for the treatment of goût and/ or lowering of uric acid levels, Inhibitors of toll-like receptors, Agonists of TLRs, Activators SIRT1, A3 receptor agonists, agents for the treatment of psoriasis, Antifibrotic agents, Prolyl hydroxylase inhibitors, Inhibitors of granulocyte macrophage colony-stimulating factor, Inhibitors of MAdCAM, inhibitors of connective tissue growth factor (CTGF), inhibitors of cathepsin C, inhibitors of soluble epoxide hydrolase, inhibitors of the TNFR1 associated dath domain protein, anti-CD19 agents, anti-B7RP1 agents, inhibitors of ICOS ligand, inhibitors of thymie stromal lymphoprotein, inhibitors of IL2, inhibitors of leucine rich repeat neuronal protein 6A, inhibitors of integrins, anti-CD40L agents, modulators of the dopamine D3 receptor, inhibitors/modulators of galectin-3, agents for treating diabetic nephropathy, agents for treating acute kidney injury, modulators of inflammasomes, modulators of bromodomains, modulators of GPR43, BTK inhibitors or inhibitors of TRP channels and an optional pharmaceutically acceptable carrier, vehicle or diluent
- 27. The pharmaceutical combination of Claim 26 wherein the second compound is selected from the group consisting of a corticosteroid, hydroxychloroquine, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, janus kinase inhibitor, statin, calcipotriene, infliximab, adalimumab, certolizumab pegol, golimumab and etanercept, cetirizine, loratidine, desloratidine, fexofenadine, astemizole, azelastine, chlorpheniramine, seeukinumab, RG-7624, brodalumab, ixekizumab, angiotensinconverting enzyme inhibitor and angiotensin receptor blocker; and an optional pharmaceutically acceptable carrier, excipient or diluents.
- 28. The pharmaceutical combination of Claim 27 wherein the second compound is a janus kinase inhibitor.
- 29. The pharmaceutical combination of Claim 28 wherein the janus kinase inhibitor is selected from ruxolitinib, baricitinib, tofacitinib, Decernotinib, Cerdulatinib, JTE-052, Peficitinib, GLPG-0634, INCB-47986, INCB-039110, PF-04965842, XL-019, ABT-494, R-348, GSK-2586184, AC-410, BMS-911543 and PF-06263276.355
- 30. The compound, 1-{[(2S,3S,4S)-4-fluoro-3-(2-fluoroethyl)-5-oxopyrrolidin2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 31. The compound, 1-{[(2S,3R)-3-ethyl-5-oxopyrrolidin-2-yl]methoxy}-7methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 32. The compound, 1-{[(2S,3S,4S)-4-fluoro-3-methyl-5-oxopyrrolidin-2yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 33. The compound, 1-{[(2S,3R,4S)-4-fluoro-3-(fluoromethyl)-5-oxopyrrolidin2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 34. The compound, 4-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2yl]methoxy}-6-methoxyquinazoline-7-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 35. The compound, 7-methoxy-1-[[(1S,2S,5R)-6-methyl-4-oxo-3azabicyclo[3.1.0]hex-2-yl]methoxy}isoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 36. The compound, 1-{[(2S,3S,4R)-3-ethyl-4-fluoro-5-oxopyrrolidin-2yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 37. The compound, 1-{[(2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, having the following structure356 said compound or sait.or a pharmaceutically acceptable sait thereof or tautomer of
- 38. The compound, 1-{[(2R,3R,4S)-3-ethyl-4-fluoro-3-hydroxy-5oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide, or a pharmaceutically acceptable sait thereof or tautomer of said compound or sait.
- 39. Us of a compound according to any of Claims 1 to 20 or 30 to 38 in the manufacture of a médicament for treating a mammal, including a human, having a disease or condition selected from the group consisting of autoimmune diseases; inflammatory diseases; autoinflammatory conditions; pain conditions; respiraratory; airway and pulmonary conditions; gastrointestinal (Gl) disorders; allergie diseases; infection-based diseases; trauma and tissue injury-based conditions; fibrotic diseases; diseases driven by over-activity of IL1 pathways; ophthalmic/ocular diseases; joint, muscle and bone disorders; skin/dermatological diseases; rénal diseases; genetic diseases; hematopoietic diseases; liver diseases; oral diseases; metabolic diseases, including diabètes (e.g. Type II) and complications thereof; proliférative diseases; cardiovascular conditions; vascular conditions; neuroinflammatory conditions; neurodegenerative conditions; cancer; sepsis; pulmonary inflammation and injury; or pulmonary hypertension.
- 40. The use according to Claim 39 wherein the disease or condition is systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopie dermatitis, goût, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm
- 41. Use of a compound according to any of Claims 1 to 20 or 30 to 38 in the manufacture of a médicament for treating a disease or condition mediated by or otherwise associated with an IRAK receptor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/975,473 | 2014-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA18098A true OA18098A (en) | 2018-06-14 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11702424B2 (en) | Bicyclic-fused heteroaryl or aryl compounds | |
US10316018B2 (en) | Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators | |
OA18098A (en) | Bicyclic-Fused Heteroaryl or Aryl Compounds and their use as IRAK4 Inhibitors | |
OA19977A (en) | Bicyclic-fused heteroaryl or aryl compounds. |